
<html lang="en"     class="pb-page"  data-request-id="38f79d52-471a-415b-ba8c-539594026d1e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2020.63.issue-17;article:article:10.1021/acs.jmedchem.0c00491;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy" /></meta><meta name="dc.Creator" content="Tingting  Liu" /></meta><meta name="dc.Creator" content="Yichao  Wan" /></meta><meta name="dc.Creator" content="Yuliang  Xiao" /></meta><meta name="dc.Creator" content="Chengcai  Xia" /></meta><meta name="dc.Creator" content="Guiyun  Duan" /></meta><meta name="dc.Description" content="Histone deacetylases (HDACs) play an important role in regulating target gene expression. They have been highlighted as a novel category of anticancer targets, and their inhibition can induce apopt..." /></meta><meta name="Description" content="Histone deacetylases (HDACs) play an important role in regulating target gene expression. They have been highlighted as a novel category of anticancer targets, and their inhibition can induce apopt..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 22, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00491" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00491" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00491" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00491" /></link>
        
    
    

<title>Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00491" /></meta><meta property="og:title" content="Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0028.jpeg" /></meta><meta property="og:description" content="Histone deacetylases (HDACs) play an important role in regulating target gene expression. They have been highlighted as a novel category of anticancer targets, and their inhibition can induce apoptosis, differentiation, and growth arrest in cancer cells. In view of the fact that HDAC inhibitors and other antitumor agents, such as BET inhibitors, topoisomerase inhibitors, and RTK pathway inhibitors, exert a synergistic effect on cellular processes in cancer cells, the combined inhibition of two targets is regarded as a rational strategy to improve the effectiveness of these single-target drugs for cancer treatment. In this review, we discuss the theoretical basis for designing HDAC-involved dual-target drugs and provide insight into the structure–activity relationships of these dual-target agents." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00491"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00491">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00491&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00491&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00491&amp;href=/doi/10.1021/acs.jmedchem.0c00491" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 17</span><span class="cit-fg-pageRange">, 8977-9002</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/17" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b02092" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.9b02101" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Tingting Liu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tingting Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian 271016, Shandong, China</div></div><span class="conrtib-corresp"><strong>*</strong>Tel/Fax: 86-538-6229751. E-mail: <a href="/cdn-cgi/l/email-protection#91fdf8e4e5f8fff6e5f8fff6d1e2f5f7fce4bff4f5e4bff2ff"><span class="__cf_email__" data-cfemail="24484d51504d4a43504d4a436457404249510a4140510a474a">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tingting++Liu">Tingting Liu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5144-5179" title="Orcid link">http://orcid.org/0000-0002-5144-5179</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yichao Wan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yichao Wan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Theoretical Organic Chemistry and Functional Molecule, Ministry of Education, School of Chemistry and Chemical Engineering, Hunan University of Science and Technology, Xiangtan 411201, Hunan, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yichao++Wan">Yichao Wan</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yuliang Xiao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuliang Xiao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian 271016, Shandong, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuliang++Xiao">Yuliang Xiao</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chengcai Xia</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chengcai Xia</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian 271016, Shandong, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chengcai++Xia">Chengcai Xia</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1943-5720" title="Orcid link">http://orcid.org/0000-0002-1943-5720</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Guiyun Duan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Guiyun Duan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian 271016, Shandong, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Guiyun++Duan">Guiyun Duan</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00491&amp;href=/doi/10.1021%2Facs.jmedchem.0c00491" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 17</span><span class="cit-pageRange">, 8977–9002</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 22, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>23 March 2020</li><li><span class="item_label"><b>Published</b> online</span>22 April 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 September 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00491" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00491</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8977%26pageCount%3D26%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DTingting%2BLiu%252C%2BYichao%2BWan%252C%2BYuliang%2BXiao%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D17%26contentID%3Dacs.jmedchem.0c00491%26title%3DDual-Target%2BInhibitors%2BBased%2Bon%2BHDACs%253A%2BNovel%2BAntitumor%2BAgents%2Bfor%2BCancer%2BTherapy%26numPages%3D26%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9002%26publicationDate%3DSeptember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00491"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2839</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">21</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00491" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Tingting&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Yichao&quot;,&quot;last_name&quot;:&quot;Wan&quot;},{&quot;first_name&quot;:&quot;Yuliang&quot;,&quot;last_name&quot;:&quot;Xiao&quot;},{&quot;first_name&quot;:&quot;Chengcai&quot;,&quot;last_name&quot;:&quot;Xia&quot;},{&quot;first_name&quot;:&quot;Guiyun&quot;,&quot;last_name&quot;:&quot;Duan&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;22&quot;,&quot;issue&quot;:&quot;17&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;8977-9002&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00491&quot;},&quot;abstract&quot;:&quot;Histone deacetylases (HDACs) play an important role in regulating target gene expression. They have been highlighted as a novel category of anticancer targets, and their inhibition can induce apoptosis, differentiation, and growth arrest in cancer cells. In view of the fact that HDAC inhibitors and other antitumor agents, such as BET inhibitors, topoisomerase inhibitors, and RTK pathway inhibitors, exert a synergistic effect on cellular processes in cancer cells, the combined inhibition of two targets is regarded as a rational strategy to improve the effectiveness of these single-target drugs for cancer treatment. In this review, we discuss the theoretical basis for designing HDAC-involved dual-target drugs and provide insight into the structure–activity relationships of these dual-target agents.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00491&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00491" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00491&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00491" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00491&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00491" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00491&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00491&amp;href=/doi/10.1021/acs.jmedchem.0c00491" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00491" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00491" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00491%26sid%3Dliteratum%253Aachs%26pmid%3D32320239%26genre%3Darticle%26aulast%3DLiu%26date%3D2020%26atitle%3DDual-Target%2BInhibitors%2BBased%2Bon%2BHDACs%253A%2BNovel%2BAntitumor%2BAgents%2Bfor%2BCancer%2BTherapy%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D17%26spage%3D8977%26epage%3D9002%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/17" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/jmcmar.2020.63.issue-17/20200910/jmcmar.2020.63.issue-17.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0028.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Histone deacetylases (HDACs) play an important role in regulating target gene expression. They have been highlighted as a novel category of anticancer targets, and their inhibition can induce apoptosis, differentiation, and growth arrest in cancer cells. In view of the fact that HDAC inhibitors and other antitumor agents, such as BET inhibitors, topoisomerase inhibitors, and RTK pathway inhibitors, exert a synergistic effect on cellular processes in cancer cells, the combined inhibition of two targets is regarded as a rational strategy to improve the effectiveness of these single-target drugs for cancer treatment. In this review, we discuss the theoretical basis for designing HDAC-involved dual-target drugs and provide insight into the structure–activity relationships of these dual-target agents.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60825" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60825" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3">1.1.  Dual-Target Therapies</h3><div class="NLM_p">Recently, dual-target therapies have attracted a great deal of attention from medical researchers. Even though current single-target drugs show significant treatment effects, to maximize their efficacy, drug combination has become a well-established approach. The combinational inhibition of two different pathways involved in disease progression often causes synergistic or additive effects and can lower the potential for developing drug resistance.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Moreover, dual-target therapies show high efficacy and can reduce the therapeutic doses and side effects compared to single-target drug treatments.<a onclick="showRef(event, 'ref1 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref3">(1,3)</a></div><div class="NLM_p last">Dual-target drugs have been used successfully since the beginning of modern pharmacology, and their dual-target nature has contributed to their clinical success.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Typical examples of such drugs include statins, metformin, paracetamol, and acetylsalicylic acid. Today, increasing number of medicinal chemists are interested in designing dual-target ligands that bind with prespecified targets. The main selection strategy is often based on the clinical data, phenotypic screening of drug combinations, or <i>in silico</i> approaches. It is currently well-known that most cancers can quickly develop resistance against any single protein or kinase inhibitor;<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> it seems that combination therapy is critical to enhance the effectiveness of these single-target inhibitors. Consequently, developing dual-target inhibitors as potential therapies should be the focus of study.</div></div><div id="sec1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">1.2.  HDAC</h3><div class="NLM_p">Histone deacetylases (HDACs), also referred to as lysine deacetylases (KDACs), are important for the removal of acetyl groups from acetylated lysine residues of diverse protein substrates, including non-histone and histone proteins. They play crucial roles in regulating gene expression and modulating various cellular processes. Histone tails with “naked” arginine or lysine residues (unmodified amine groups) are normally positively charged, which is beneficial to the interaction of histone tails with the negatively charged phosphate groups located on the DNA backbone.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Histone deacetylation involves increasing the binding affinity of histones and DNA, blocking gene transcription. Although it seems that acetylated lysine histone tails are the main targets of HDACs, in fact, these enzymes can also regulate the functions of many non-histone proteins, including nuclear transport proteins, α-tubulin in microtubules, and transcription factors, such as the tumor suppressor p53.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> Abnormal activity of HDAC is implicated in a range of human diseases, including some cancers and central nervous system (CNS) disorders. Thus, HDACs represent a potential target for disease treatment.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p">The HDAC superfamily comprises 11 components characterized into four classes: class I (HDACs 1, 2, 3, and 8), class II (HDACs 4, 5, 6, 7, 9, and 10), class III (sirtuin family, sirt1–sirt7), and class IV (HDAC11).<a onclick="showRef(event, 'ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13">(11−13)</a> Class I, II, and IV HDACs belong to the zinc-dependent Rpd3/Hda1 family and are referred to as “classical” HDACs. Class III HDACs are Sir2 proteins (SIRT1–7) or members of the NAD+-dependent sirtuin family.<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14−16)</a> Classes I, II, and IV require a zinc ion and hydrolyze acetyl-lysine by a similar catalytic core,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> while class III requires nicotinamide adenine dinucleotides for their enzyme activities. Among them, SIRT4 and -6 exhibit primarily NAD+-dependent mono-ADP-ribosyltransferase activity, while SIRT5 displays potent desuccinylase/demalonylase activity. Class II HDACs can be further subcategorized into two subgroups: class IIa, which includes subtypes 4, 5, 7, and 9 and has a large C-terminus; class IIb, which includes isoforms HDAC6 and HDAC10 and has two deacetylase domains. HDAC11 is classified as class IV because of its lower similarity to the others. In general, class I HDACs located in the nucleus are associated with cell proliferation and are considered as hallmarks of cancer.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> Class II HDACs can shuttle between the cytoplasm and nucleus in response to cellular signals, engaging in the functional regulation of neural and cardiac cells.<a onclick="showRef(event, 'ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22">(20−22)</a> However, sirtuins are structurally and mechanistically different from other HDACs and are also related to cancer and neurological diseases.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> Normally, SIRT1, -3, -6, and -7 can be found located in the nucleus, and SIRT7 preferentially localizes in the nucleolus. SIRT1 is also detected in the cytoplasm, where SIRT2 is also predominantly located. SIRT3 can also be found within mitochondria in which SIRT4 and -5 are also localized. The specific role of HDAC11, however, is still blurry.</div><div class="NLM_p">The key roles of HDACs in organisms have been verified in the studies using mice with knocked out HDAC subclass I members. HDAC1-null mice die prenatally with general growth retardation and bad proliferation defects; HDAC2-null mice die on the first day after birth due to cardiac malformations; and HDAC3-null mice die before birth due to gastrulation defects.<a onclick="showRef(event, 'ref12 ref25'); return false;" href="javascript:void(0);" class="ref ref12 ref25">(12,25)</a> In addition, HDACs appear to be crucial for gene expression.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> It has been demonstrated that the levels of HDACs vary considerably in cancer cells and differ based on the tumor type. HDAC1 is abundantly expressed in lung, prostate, gastric, colon, esophageal, and breast cancers.<a onclick="showRef(event, 'ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29">(27−29)</a> High expression of HDAC2 is found in cervical, gastric, and colorectal cancers.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a> Moreover, HDAC3 is highly expressed in breast and colon tumors,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> while HDAC6 is overexpressed in mammary tumors. HDAC8 shows rich expression in neuroblastoma cells, and HDAC11 is mainly expressed in rhabdomyosarcoma.<a onclick="showRef(event, 'ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35">(33−35)</a> The expression level of different HDACs and/or histone hyperacetylation results from different mechanisms, which may affect the functions of single-target HDAC inhibitors. The analysis of different HDAC isoforms using small interfering RNA against HDAC1, HDAC2, and HDAC3 in many types of ovarian carcinoma cells (SKOV3, IGROV-1, TOV112D, OVCAR3, ES-2, A2780, and A2780/CDDP) illustrated that knockdown of HDAC1 inhibits cell proliferation and tumorigenicity, whereas knockdown of HDAC3 decreases cell migration with upregulation of E-cadherin. However, knockdown of HDAC2 shows no effect on cell proliferation, migration, or tumorigenicity.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> All these phenomena show that HDACs are important to the physiological processes of cancer cells.</div><div class="NLM_p last">In view of the predominant roles of HDAC family members, HDACs have become a very promising therapeutic target for cancers.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> In the past, many HDAC inhibitors have been developed, including SAHA, belinostat, panabiostat, valproic acid, and so on. Today, exploring dual inhibitors with a synergistic antitumor mechanism has become a new cancer treatment trend.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> In this review, we discuss the application of dual-target inhibitors based on HDAC and different therapeutic targets.</div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">2.  Dual Inhibition of HDAC/BET Proteins</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17140" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17140" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">2.1.  Molecular Interplay between HDAC and BET Proteins</h3><div class="NLM_p">HDACs regulate the level of acetylation of ε-N-acetylated lysine residues on histone tails, so shaping the acetylation profile for the genome.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> BET proteins can read the histone acetylation code, making a response to facilitate the activation of target genes.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Thus, it is rational to inhibit HDAC and BET proteins because they may converge on the same targets and molecular pathways. Direct and indirect interplay between these two classes of proteins has been described.</div><div class="NLM_p">First, HDAC inhibition leads to great changes in the chromatin acetylation profile, leading to the upregulation of the overall acetylation level in low-density or generally deprived acetylated regions, such as intergenic and gene body regions.<a onclick="showRef(event, 'ref40 ref41 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref40 ref41 ref42 ref43">(40−43)</a> The recruitment of BET proteins is affected by the acetylation redistribution throughout the genome; the affected BET proteins will delocalize to new acetylated sites and alter the positive effect on gene transcription (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Scaffold for transcription factors binding. BRD4 can read acetylated histones and bind to other acetylated proteins like transcription factor (TF) or cofactors, hence functioning as a scaffold unit. HDACs can damage BRD4 functions by effectively removing acetylated residues from histones or other proteins.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Secondarily, it is verified that BET inhibitors influence the preferential transcription of oncogenes to which tumor cells are addicted. This phenomenon occurring may be because of superenhancers, which are specifically dependent on BRD4 activity and cardinal for cancer cells survival.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Additionally, HDAC inhibitors preferentially influence highly expressed oncogenic amplicons by inducing RNA Pol II elongation-pause at the genome-wide level.</div><div class="NLM_p">As a result, transcription is repressed; especially the transcripts that require an efficient transition from the initiation phase to the elongation phase are affected. Moreover, this event is strongly associated with the acetylation of histones or other transcription regulators.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Finally, BRD4 displays histone–chaperone activity. Exploiting the interaction between BRD4 and acetylated histones can assist RNA Pol II pass through hyperacetylated nucleosomes (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0012.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Model of histone–chaperone interaction. BRD4 has histone–chaperone activity: it can assist RNA Pol II to pass through acetylated nucleosomes. A change in the BRD4 presence on nucleosomes and on chromatin-associated protein complexes is caused by impaired BRD4 functions by HDACs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Another possible mechanism is related to the level of the N-CoR/HDAC3 complex. A report<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> demonstrated that the binding of HEXIM1 to N-CoR enables HDAC3 to deacetylate CDK9, which restrains the CDK9-dependent phosphorylation of the RNA Pol II CTD domain and counteracts the BRD4-mediated activation effect on pausing release of RNA Pol II at the level of TSS.</div><div class="NLM_p">An indirect functional interaction linked to STAT proteins is described; HDAC inhibitors inhibit STAT5 transcriptional activity by disturbing the function of BRD2,<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> leading to inhibition of the STAT5 gene expression. This inhibition is independent of the level of acetylated STAT5 and is not even related to the interruption of STAT5-containing protein complexes. Indeed, this effect is because of the delocalization of BRD2 from the soluble chromatin to the insoluble chromatin, thus limiting its availability to assist STAT5-mediated transcription.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Furthermore, Hu et al.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> demonstrated that PP1a dephosphorylates H3S10ph in response to stress stimuli, which enables HDAC1/2/3 to deacetylate the nucleosome. The decrease in histone acetylation results in the release of the chromatin-associated BRD4. Simultaneously, PP2B collaborates with PP1a to dephosphorylate CDK9, inducing P-TEFb to release from the inactive complex.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div><div class="NLM_p last">These and other studies provide evidence to support the rational idea of combined therapy; some researchers went further and attempted to develop a single molecule that is able to double-inhibit HDAC and BET protein.<a onclick="showRef(event, 'ref49 ref50 ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref49 ref50 ref51 ref52">(49−52)</a> Next, we summarize the development of HDAC/BET dual inhibitors.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">2.2.  Dual Targeting Inhibition Strategies</h3><div class="NLM_p">After a careful assessment of chemical tractability and a consideration of structural biology, Prinjha et al. focus on the tetrahydroquinoline (THQ) template of BET inhibitors.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> This chemical class, including I-BET726, shows excellent BET selectivity against the family of bromodomains. X-ray structures of these inhibitors with the N-terminal bromodomain of BRD4 showed that the THQ acetamide motif mimics the conserved interactions created by the natural lysine acetyl group.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> H-bonds are formed by the carbonyl group with the conserved asparagine (Asn140 in BRD4) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). The aliphatic substituent group of the THQ ring fills a lipophilic pocket generally occupied by the acetylated lysine side chain. Moreover, the aromatic part of the THQ lies between Leu92 and Pro82, and the methyl group of the THQ ring ((<i>S</i>)-configuration) occupies a pocket formed by the side chains of Leu92, Val87, Tyr139, Leu94, and Tyr97. The THQ scaffold thus demonstrates great complementarity in regard to its shape to BET proteins.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0021.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Overlay of I-BET726 bonds to BRD4<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> and the structure of I-BET295.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The known HDAC inhibitor SAHA first gained regulatory approval for the treatment of cutaneous T cell lymphomas. By recognizing the conserved structural features of HDAC family members, SAHA achieved broad HDAC inhibitor activity. The hydroxamic acid group anchors SAHA into the active site by chelating the important catalytic zinc ion. The alkyl chain, which mimics the side chain of acetylated lysine, exits the reaction center along a narrow pocket. As a result, the capping phenyl group is placed in a more open environment, reducing contact with the hydrophobic residues on the protein surface. In light of the binding modes of the THQ inhibitors with SAHA, it was imagined that combining their pharmacophores to single molecules, retaining both activities, would be a viable strategy. Then, researchers tried to combine the features of THQ inhibitors with SAHA without compromising binding at either target. The aryl group of SAHA can serve as the aryl at the 4- or 6-position of THQ, with these groups expected to place the hydroxamic acid fraction warhead to solvent, which is anticipated to have tolerance to BET activity.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Furthermore, when the THQ inhibitor binds to the HDAC enzymes, because the THQ extends from the 4-position of the capping phenyl to solvent, it was anticipated that the inhibitor would also retain HDAC activity. In combination, THQ derivatives (<b>1a</b>–<b>1d</b>) were designed as HDAC/BRD4 inhibitors (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0022.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Three series of dual BRD4/HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Among all the studied compounds, compound <b>1a</b> (R<sub>1</sub> = A, R<sub>2</sub> = CO<sub>2</sub><sup><i>i</i></sup>Pr) known as DUAL946 displayed the best dual-target inhibitory activity (IC<sub>50</sub> values of 0.25 μM for HDAC1 and 0.05 μM for BRD4).<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> The X-ray structures of these compounds with BRD4 revealed that the carbonyl group could interact with the conserved asparagine (Asn140 in BRD4-BD1) though H-bonds. The THQ scaffold of these compounds mimicked the conserved interactions created by the native lysine acetyl group. The R<sub>2</sub> group of the inhibitor with 4-isopropyl carbamate showed more potent activity for HDAC1 and -6 than inhibitors with a phenyl ring. The addition of the HDAC warhead to the 4-position of THQ increased the potency of HDAC1, -7, and -9 but reduced the potency of BRD4 and HDAC6. The cellular activity studies indicated that DUAL946 inhibited cell growth in NUT midline carcinoma and acute myeloid leukemia cells. However, in each cellular system studied, there was no marked increase in DUAL946 potency compared to I-BET295 and SAHA.</div><div class="NLM_p">Following a very similar trajectory, combining the binding properties of HDAC and BRD4 inhibitors with hydroxamic acid as the HDAC-binding moiety, a BRD4 pharmacophore, and a flexible alkyl linker, a series of <i>N</i><sup>6</sup>-benzoyladenine compounds (<b>2a</b>–<b>e</b>),<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> 3,5-dimethylisoxazole derivatives (<b>3a</b>–<b>i</b>),<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> indole-based compounds (<b>4a</b>–<b>q</b>),<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> 5,7-dimethoxyquinazoline derivatives (<b>5a</b>–<b>k</b>),<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> and JQ1-based compounds,<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> such as compounds <b>6a</b>–<b>h</b>, as dual HDAC/BRD4 inhibitors were synthesized (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>–<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). After biological evaluation of the <i>N</i><sup>6</sup>-benzoyladenine derivatives (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), compound <b>2d</b> (<i>n</i><sub>1</sub> = 3) showed the best dual-inhibitory activities with IC<sub>50</sub> values of 0.26 μM for HDAC and 2.7 μM for BRD4.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> The biological studies showed that the length of the alkyl linker was related to the inhibitory activities against BRD4 and HDAC protein. In general, the inhibitory activity increased as the alkyl chain length increased. Furthermore, compound <b>2d</b> possessed HL-60 cell growth-inhibitory activity, c-MYC production-inhibitory activity, and HL-60 cell differentiation-inducing activity. Moreover, it exhibited a significant growth-inhibitory effect on BRD4 inhibitor-resistant cells.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0023.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures of representative compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 3,5-dimethylisoxazole derivatives, the target compound <b>3h</b> (<i>n</i><sub>3</sub> = 4, L = -NHCO-) showed the most powerful inhibitory activity against HDAC1 and BRD4 (IC<sub>50</sub> = 0.15 μM and 0.67 μM, respectively) (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). It also displayed potent antiproliferative activities against the human myelogenous leukemia cell lines MV4-11 and K562 in cellular assays. The structure–activity relationship studies showed that the alkyl chains were important for HDAC1 inhibition; the best length was five or six carbon atoms. However, the length of the side chain slightly affected BRD4 inhibition. In addition, compounds with the amide group as the linker between the hydroxamic acid and the phenylisoxazole skeleton showed better HDAC1 and BRD4 inhibition than compounds with the ether linkage.</div><div class="NLM_p">On the basis of the results of indole-based compounds (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), compound <b>4f</b> (R<sub>3</sub> = -4-F, <i>n</i><sub>2</sub> = 6, <i>m</i> = 1) showed the best inhibitory activity against HDACs with an IC<sub>50</sub> value of 291 nM and against BRD4 (BRD4 inhibition rate (%) at 10 μM = 88%). It exhibited antiproliferative activity against human acute monocytic leukemia THP-1 with a GI<sub>50</sub> value of 15.5 μM. The binding mode of <b>3f</b> to BRD4 demonstrated that the 3,5-dimethylisoxazole group formed a hydrogen bond with the residue Asn140. The hydroxamic acid group can interact with the residue Pro86 via two hydrogen bonds. Moreover, the indole ring exhibited hydrophobic interactions with residue Pro82 and residue Trp81. Additionally, a π–π interaction occurred between the phenyl group and the residue Trp81. When the target compounds bound to HDAC3, the -NH of the hydroxamic acid group interacted with His134 and His135 through hydrogen bonds. Furthermore, van der Waals and hydrophobic interactions between the indole ring and residues Phe200 and Phe199 of HDAC were observed. For the R<sub>3</sub> group, the electron-withdrawing moieties of the inhibitors favored their inhibitory activities against HDAC.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0024.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Representatives of three series of dual BRD4/HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For the 5,7-dimethoxyquinazoline derivatives (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), Chen’s group reported that the target compound <b>5a</b> (R<sub>4</sub> = -CH<sub>3</sub>, X = -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-) showed the best inhibitory activities (IC<sub>50</sub> = 32 nM for HDAC and 225 nM for BRD4 (BD2 domain)). The binding study of RVX-OH with BRD4 indicated that the free hydroxyl group could form a hydrogen bond with Asn140. The compounds with alkanes as linkers displayed better biological activity than those with phenyl groups as linkers for HDAC1. In addition, the larger groups introduced to the hydroxyl group of the target compounds not only maintained their original activity but also enhanced their selectivity for BRD4/BD2. The above results demonstrate that it is rational to develop HDAC/BET inhibitors and that their inhibitory activities require improvement. The antiproliferative activities against the human leukemia cell lines OCI-AML2, OCI-AML3, and MV4-11 were evaluated by MTT. Compound <b>5a</b> exhibited remarkable antiproliferative activities with IC<sub>50</sub> values of 1.52 μM, 1.09 μM, and 1.67 μM, respectively. Among JQ1-based compounds, compound <b>6a</b> (linker = -NH-Ph-, ZBG = -CONHOH) was identified to show excellent and balanced activities against HDAC1 with an IC<sub>50</sub> value of 21 nM and BRD4 BD1 with an IC<sub>50</sub> value of 11 nM. It possessed the best antitumor potency against Capan-1 cells with an IC<sub>50</sub> value of 0.15 μM. In Capan-1 xenograft models, it also showed excellent in vivo antitumor efficacy. The SAR studies demonstrated that compounds with hydroxamic acid enhanced inhibitory activities toward HDAC1 with improved antitumor potency. For the position of the carbon chain, derivatives with substituents on para-position of the phenyl group were more potent than those with substituents on meta-position.</div><div class="NLM_p">By analysis of binding modes of BRD4 protein with its inhibitors and using docking studies, a series of thieno[2,3-<i>d</i>]pyrimidine based hydroxamic acid derivatives as BRD4/HDAC dual inhibitors were discovered (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> After biological evaluations, compound <b>7c</b> (-(CH<sub>2</sub>)<sub>5</sub>-) showed the most potent inhibitor for HDAC and BRD4 with IC<sub>50</sub> values at nanomolar levels (IC<sub>50</sub> of 58 nM for HDAC2, 73 nM for HDAC6, and 710 nM for BRD4). It showed potent antiproliferative activity in colorectal carcinoma cells by inducing autophagic cell death and displayed good inhibitory efficiency on tumor growth in the HCT-116 xenograft in vivo models.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0025.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Representatives of thieno[2,3-<i>d</i>]pyrimidine based hydroxamic acid derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In general, the Y group of alkyl chain is favored for the inhibitory activity against BRD4 and HDAC. The docking studies (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) of compound <b>7c</b> showed that the thieno[2,3-<i>d</i>]pyrimidine fragment occupied the cap region well. The hydroxylamine fragment interacted with His145 and His146 residues of HDAC2 via stable hydrogen bonds. Moreover, the phenyl substituted at 2-position of the thieno[2,3-<i>d</i>]pyrimidine scaffold could form a cation−π interaction with Arg275 residue of HDAC2. In addition, the 4-carbonyl group and 3-nitrogen atom of thieno[2,3-<i>d</i>]pyrimidine formed an H-bond with the Asn140 residue of BRD4. The <i>N</i>-methylpiperidine moiety was placed between the WPF stack formed by Trp81, Pro82, and Phe83 residues.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0026.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Binding modes of <b>7c</b> to BRD4 (A, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZW1">4ZW1</a>) and HDAC2 (B, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LXZ">4LXZ</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">3.  Combination of HDAC Inhibitors with RTK Pathway Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04476" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04476" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">3.1.  Molecular Interplay between HDAC and RTKs</h3><div class="NLM_p">Receptor tyrosine kinases (RTKs) are cell surface receptors for growth factors, cytokines, neurotrophic factors, hormones, and other extracellular signaling molecules that activate intracellular signaling pathways. RTKs can mediate the key signaling pathways involved in cell proliferation, differentiation, and cell migration and survival.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> The RTK family is divided into several subfamilies, which include fibroblast growth factor receptors (FGFRs), epidermal growth factor receptors (EGFRs), platelet-derived growth factor receptors (PDGFRs), insulin and insulin-like growth factor receptors (IR and IGFR), hepatocyte growth factor receptors (HGFRs), vascular endothelial growth factor receptors (VEGFRs), and proto-oncogene c-KIT.<a onclick="showRef(event, 'ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref61 ref62">(61,62)</a> RTK monomers are divided into transmembrane, extracellular (N-terminal), and cytoplasmic kinase domains. They can be activated through ligand-induced dimerization, which leads to receptor autophosphorylation and RTK substrate activation, including phosphatidylinositol 3-kinase, phospholipase C-γ, and mitogen-activated protein kinases.<a onclick="showRef(event, 'ref63 ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref63 ref64 ref65">(63−65)</a></div><div class="NLM_p">Both RTK and HDAC play crucial roles in various biological processes. HDAC inhibitors have been demonstrated to have a synergistic or an additive effect with different RTK inhibitors through their ability to downregulate the transcriptional and/or post-translational expression level of RTKs.<a onclick="showRef(event, 'ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref66 ref67">(66,67)</a> In addition, by downregulating the expression level of important proteins involved in alternative mitogenic pathways, including AKT and MET,<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> and downstream effectors of the RTK pathway, such as c-MYC and cyclin D1, HDAC inhibitors can restore sensitivity to RTK inhibitors.<a onclick="showRef(event, 'ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref69 ref70">(69,70)</a> Moreover, HDAC inhibitors can also sensitize tumor cells to treatment with RTK inhibitors by downregulating antiapoptotic proteins (like survivin and XIAP)<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> and/or upregulating proapoptotic proteins (e.g., BIM).<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a></div><div class="NLM_p">Starting from RTKs, two important signaling cascades transduce to the nucleus prosurvival and proproliferative signals: the PI3K/AKT/mTOR pathway and the RAS/RAF/MAPK/ERK pathway. As a consequence of activating mutations in RTKs or downstream members, such as the small GTPase RAS proteins, these pathways are generally aberrantly activated in cancer. The ability of HDAC inhibitors to attenuate the AKT and MAPK pathways<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> and to suppress prosurvival while activating proapoptotic signals<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> indicates a rationale for combining these drugs also with mammalian target of rapamycin (mTOR) inhibitors.</div><div class="NLM_p last">The clinical studies evaluating HDAC inhibitors in combination with PTK pathway inhibitors have shown good tolerability, and further studies are ongoing.<a onclick="showRef(event, 'ref75 ref76'); return false;" href="javascript:void(0);" class="ref ref75 ref76">(75,76)</a> All these studies illustrate the rationality, significance, and the promising clinical activities of combination treatment with HDAC inhibitors and PTK pathway inhibitors.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">3.2.  Combined Targeting Inhibition Strategies</h3><div class="NLM_p">Generally, an HDAC inhibitor consists of a zinc-binding group (ZBG), a capping group, and an appropriate linker. By introduction of the pharmacophore of an RTK inhibitor into the zinc-binding group, quinazoline derivatives (compounds <b>8a</b>–<b>l</b> and <b>9a</b>–<b>z</b>),<a onclick="showRef(event, 'ref77 ref78 ref79'); return false;" href="javascript:void(0);" class="ref ref77 ref78 ref79">(77−79)</a><i>N</i>-arylsalicylamides (compounds <b>10a</b>–<b>o</b>),<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> and osimertinib-based compounds <b>11a</b>–<b>l</b><a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> as HDAC/RTK pathway inhibitors were designed (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a> and <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). Among all these quinazoline compound derivatives (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>), compound <b>8g</b> (R<sub>5</sub> = morpholinylpropyl-, R<sub>6</sub> = methyl-, meta) showed the most potent anti-HDAC activity with IC<sub>50</sub> values of 0.16, 0.18, and 0.56 μM for HDAC1, HDAC3, and HDAC6, respectively. Compound <b>8f</b> (R<sub>5</sub> = R<sub>6</sub> = CH<sub>3</sub>OCH<sub>2</sub>CH<sub>2</sub>-, para-) exhibited the most potent anti-HER2 and anti-EGFR activities (inhibition at 10 μg/mL is 84% and 70%, respectively).<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> The SARs indicated that the inhibitors with metasubstitutions on the phenyl group showed more potent HDAC inhibition than inhibitors with parasubstitutions. Introducing polar groups such as hydroxamate into the phenyl group reduced RTK inhibition. However, introducing hydroxamate at the 6 and 7 positions of the quinazoline moiety retained their inhibition activity.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Moreover, introduction of hydroxamate at the para-position of the quinazoline core is more likely to inhibit HDAC and HER2 than HDAC and EGFR.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0027.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Quinazoline derivatives as HDAC/RTK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0002.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. HDAC/EGFR pathway inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Subsequently, compounds <b>9a</b>–<b>z</b> were investigated (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>); the results showed that compound <b>9d</b> (R<sub>7</sub> = R<sub>8</sub> = R<sub>10</sub> = H, R<sub>9</sub> = Br, <i>m</i> = 5) displayed improved anti-VEGFR-2 (IC<sub>50</sub> = 74 nM) and anti-HDAC activities (IC<sub>50</sub> = 2.2 nM) compared to <b>8f</b>. The SARs showed that inhibitors with different carbon chain length exhibited similar VEGFR-2 inhibition. On the contrary, increasing the chain length can increase the HDAC inhibitory activity. The addition of different halogen substituents to the different positions of the phenyl ring was important for VEGFR-2 inhibition. The biological results indicated that the bromo substituent introduced at the para-position on the phenyl group was favorable for VEGFR-2 inhibition. The anticancer activities of compounds <b>9a</b>–<b>z</b> against the human breast cancer cell line MCF-7 were evaluated by the MTT assay. Compound <b>9d</b> showed the most potent anticancer activities against MCF-7 (IC<sub>50</sub> = 0.85 μM); it exhibited greater potency than the positive compounds vorinostat (IC<sub>50</sub> = 4.2 μM) and vandetanib (IC<sub>50</sub> = 18.5 μM).</div><div class="NLM_p">It is worth mentioning that the quinazoline derivative CUDC-101 (<i>m</i> = 6, R<sub>10</sub> = R<sub>9</sub> = R<sub>7</sub> = H, R<sub>8</sub> = ethynyl group) is a potential HDAC/RTK inhibitor. The antiproliferative activity of CUDC-101 was tested. In all the cancer cell lines tested, CUDC-101 showed greater potency than erlotinib, SAHA, and the combination of SAHA/erlotinib. For example, CUDC-101 inhibited the breast cancer cell line MCF-7 with an IC<sub>50</sub> value of 0.55 μM, which is more potent than the combination of the parents SAHA + erlotinib (IC<sub>50</sub> = 2.7 μM).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Additionally, the studies of CUDC-101 in the clinical I trial have been completed (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Clinical Trials of CUDC-101</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="4" align="center">drug CUDC-101</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">phase</th><th class="colsep0 rowsep0" align="center">tumor type</th><th class="colsep0 rowsep0" align="center">status</th><th class="colsep0 rowsep0" align="center">number</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">Advanced solid tumors</td><td class="colsep0 rowsep0" rowspan="4" align="left">Completed</td><td class="colsep0 rowsep0" align="left">NCT00728793</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">Head and neck cancer, liver cancer, breast cancer, gastric cancer, non-small-cell lung cancer</td><td class="colsep0 rowsep0" align="left">NCT01171924</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">Diffuse intrinsic pontine glioma, recurrent anaplastic astrocytoma, recurrent glioblastoma, recurrent malignant glioma, recurrent medulloblastoma</td><td class="colsep0 rowsep0" align="left">NCT03893487</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">Head and neck cancer</td><td class="colsep0 rowsep0" align="left">NCT01384799</td></tr></tbody></table></div></div><div class="NLM_p">Atkinson’s team<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> studied the in vitro capacities of CUDC-101 and SAHA to increase the radiosensitivity of three human pancreatic cancer cell lines (Su.86.86, MIAPaca-2, and T3M-4 cells). According to their results, the dual-target inhibitor CUDC-101 is a more potent radiosensitizer than the HDAC inhibitor SAHA. Moreover, CUDC-101 has been recently identified to significantly repress leukemia development in vivo and can be used as a potential candidate drug for acute promyelocytic leukemia, particularly for arsenic trioxide-resistant acute promyelocytic leukemia.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Besides, in the first-in-human phase I study, CUDC-101 showed safety, good pharmacodynamic activity, and promising single-agent activity when it was administered to patients with advanced solid tumors, which supports the continued clinical development of CUDC-101.</div><div class="NLM_p">In <i>N</i>-arylsalicylamide compounds (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>), compound <b>10O</b> (R<sub>11</sub> = 2- alkynyl group, R<sub>12</sub> = H, <i>n</i> = 6), which has a hydroxyl group at the 2-position of the benzoic acid ring, showed comparable activity against HDACs (IC<sub>50</sub> = 1.21 μM) compared to SAHA (IC<sub>50</sub> = 0.98 μM); it showed the best anti-EGFR activity with an IC<sub>50</sub> value of 0.90 μM. By analysis of the activity of these compounds, the length of the side chain was found to be important for HDAC and EGFR inhibition. A methoxy group introduced at the 4-position of salicylic acid favored EGFR inhibition, but when it was introduced at the 2-position, it improved HDACs inhibition. Additionally, the R<sub>4</sub> group did not obviously affect HDACs and EGFR inhibitory activity. The antiproliferative activities against the A431, A549, and HL-60 cell lines were evaluated by the MTT method. The results indicated that compound <b>10O</b> displayed the most potent inhibitory activity against the A549 and A431 cell lines (IC<sub>50</sub> = 15.5 μM against A549 and IC<sub>50</sub> = 1.88 μM against A431) and comparable inhibitory activity to the positive drug erlotinib (IC<sub>50</sub> = 11.8 μM for A549 and IC<sub>50</sub> = 1.41 μM for A431). When tested against the HL-60 cell line, most compounds were less potent.</div><div class="NLM_p">For osimertinib-based compounds (<b>11a</b>–<b>l</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>), most of the compounds exhibited significant HDAC inhibition (IC<sub>50</sub> < 1 μM). Compound <b>11e</b> (R′ = MeO-, linker = -NHCO(CH<sub>2</sub>)<sub>6</sub>-, ZBG = CONHOH) showed the best inhibitory activity against EGFR with an IC<sub>50</sub> value of 5.7 μM (IC<sub>50</sub> = 85 nM for HDAC). The binding mode of the parent compound osimertinib in EGFR indicated that the 2-aminopyrimidine core and the indole group could fit into the ATP binding pocket of EGFR with two important hydrogen bonds between the 2-aminopyrimidine core and Met793. The results of the HDAC activity studies showed that the inhibitor with hydroxamate moiety was more potent than that with the 2-aminophenyl group (ZBG) for HDAC inhibition. The linker between the HDAC pharmacophore and the EGFR pharmacophore containing five or six carbons was more potent than the parent compound SAHA. The antiproliferative activities of all compounds were tested by the MTT assay. Compared with the positive controls SAHA and osimertinib, compound <b>11e</b> showed better antiproliferative activity against the human cancer cell lines MDA-MB-231, MDA-MB-468, HeLa, HT-29, and KG-1 with IC<sub>50</sub> values of 0.60, 0.23, 1.85, 0.79, and 0.24 μM, respectively.</div><div class="NLM_p">Following a similar design strategy, a series of pazopanid derivatives as VEGFR/HDAC dual inhibitors<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> and pyrimidinepyrazolyl analogues as dual mTOR and HDAC inhibitors<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> were rationally designed and synthesized (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). After biological evaluation of the HDAC/RTK pathway inhibitors, the best compound among them <b>12f</b> (R<sub>13</sub> = CONH(CH<sub>2</sub>)<sub>6</sub>CONHOH, R<sub>14</sub> = H) showed better HDACs inhibitory activity (IC<sub>50</sub> = 3.3 nM) than SAHA (IC<sub>50</sub> = 130 nM) and exhibited antiangiogenic potency comparable to pazopanib. On the basis of the binding modes and inhibitory activities of pazopanid derivatives with VEGFR and HDAC, we learned that the 2-aminopyrimidine moiety could form two hydrogen bonds with Cys917. Para-substituted entinostat-based inhibitors exhibited better VEGFR-2 and HDAC inhibitory activities than meta-substituted inhibitors. On the contrary, meta-substituted SAHA-based compounds showed inferior VEGFR-2 and HDAC inhibitory activities than those that were para-substituted. The introduction of a longer linker to the SAHA-based compounds benefitted HDAC inhibition, but was not detrimental to VEGFR inhibition. In addition, compound <b>12O</b> (R<sub>15</sub> = -CONH-Ph-2-NH<sub>2</sub>, R<sub>16</sub> = H) possessed desirable pharmacokinetic profiles and considerable in vivo antitumor effects in a HT-29 xenograft model.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0003.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Pazopanid derivatives as HDAC/VEGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Among the mTOR/HDAC dual inhibitors (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>),<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> compound <b>13l</b> (<i>i</i> = 5, R<sub>17</sub> = 3-methylmorpholino) was the optimal compound with potent inhibition for HDAC1 and mTOR with IC<sub>50</sub> values of 0.19 and 1.2 nM, respectively. It can induce apoptosis of MV4-11 and MM1S cells and stimulate cell cycle arrest in the G0/G1 phase. It also exhibited comparable antitumor activity in the MM1S xenograft model with a combination medication. These results indicated that compound <b>13l</b> could be a promising mTOR/HDAC dual inhibitor for treating hematologic malignancies. The docking and inhibitory activity studies on this series of compounds showed that the benzene ring as the linker could form π–π stacking interactions with the residue His28 and the residue Phe150. Their hydroxamic tails interacted with residues of Thr809, Ala812, and Ser906 through hydrogen bonds. In addition, the morpholinopyrimidine functional moiety is frequently used in PI3K inhibitors. Moreover, introduction of a urea linkage to target compounds increased the inhibition efficacy for mTOR kinase.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0004.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Pyrimidine-pyrazolyl-based compounds as HDAC/mTOR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">CUDC-907 is a first-in-class compound that has been widely studied as a dual inhibitor of the PI3K/AKT pathway and HDACs (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>).<a onclick="showRef(event, 'ref87 ref88 ref89'); return false;" href="javascript:void(0);" class="ref ref87 ref88 ref89">(87−89)</a> The clinical trials of CUDC-907 with several tumors are ongoing (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The in vivo study of CUDC-907 performed by Ge’s group illustrated that CUDC-907 as a dual inhibitor lends itself to potential combination therapies to further eliminate acute myeloid leukemia and prevent disease relapse.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Additionally, on the basis of the in vivo study of CUDC-907 on Philadelphia chromosome-positive leukemia cells, CUDC-907 administration may be an effective strategy against ABL tyrosine kinase inhibitors-resistant cells.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> The proapoptotic activity and antitumor growth of CUDC-907 has been shown to be more potent than those of single-target PI3K or HDAC inhibitors in a variety of implanted and cultured cancer cell lines representing T-cell lymphomas and leukemias. The phase 1 clinical study<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> showed that dual HDAC/PI3K inhibition with CUDC-907 is well tolerated, with a favorable toxicity profile slightly better than, or comparable to, that of FDA-approved PI3K and HDAC single-target agents.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Clinical Trials of CUDC-907</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="4" align="center">drug CUDC-907</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">phase</th><th class="colsep0 rowsep0" align="center">tumor type</th><th class="colsep0 rowsep0" align="center">status</th><th class="colsep0 rowsep0" align="center">number</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">Lymphoma, neuroblastoma, brain tumor, solid tumor</td><td class="colsep0 rowsep0" rowspan="4" align="left">Recruiting</td><td class="colsep0 rowsep0" align="left">NCT02909777</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">I, II</td><td class="colsep0 rowsep0" align="left">Relapsed and/or refractory lymphoma, relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBL)</td><td class="colsep0 rowsep0" align="left">NCT01742988</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">Diffuse intrinsic pontine glioma, recurrent anaplastic astrocytoma, recurrent glioblastoma, recurrent malignant glioma, recurrent medulloblastoma</td><td class="colsep0 rowsep0" align="left">NCT03893487</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">I, II</td><td class="colsep0 rowsep0" align="left">Prostate cancer</td><td class="colsep0 rowsep0" align="left">NCT02913131</td></tr></tbody></table></div></div><div class="NLM_p">Romidepsin (FK228, depsipeptide) (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>) and its analogs verified as HDAC/PI3K dual inhibitors can directly inhibit PI3K activity at μM concentrations.<a onclick="showRef(event, 'ref93 ref94'); return false;" href="javascript:void(0);" class="ref ref93 ref94">(93,94)</a> In addition, a series of novel 4-methylquinazoline derivatives <b>14a</b>–<b>z</b> (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) were discovered to be anticancer agents that simultaneously target PI3K and HDAC; some of them had nanomolar potencies and exhibited favorable antiproliferative activities.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> According to their report, quinazoline inhibitors can establish hydrogen bonds with Val851 and a conserved water molecule bridge with residues Asp810 and Tyr836. As the linker length increased, the HDAC1 activity was enhanced, but a similar PI3Kα potency was observed. Moreover, sulfonamide functionalities of R<sub>15</sub> can form a charge interaction with Lys802 in the ATP binding pocket of PI3Kα, further boosting the PI3Kα potency. Furthermore, compound <b>14w</b> (R<sub>19</sub> = F, <i>n</i> = 6) efficiently arrested the cell cycle and increased apoptosis in HCT116 cancer cells. In pharmacokinetic studies, compound <b>14w</b> showed significant in vivo anticancer efficacies in HGC-27 and HCT116 xenograft models, with tumor growth inhibition of 62.6% (ip, 30 mg/kg) and 45.8% (po, 150 mg/kg), respectively. These dual inhibitors show promise in discovering new antitumor therapeutics by simultaneously inhibiting PI3K and HDAC with a single molecule.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0005.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. 4-Methylquinazoline derivatives as HDAC/PI3K inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further, Zhang’s team reported that ((3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)benzamide analogues (<b>15a</b>–<b>j</b>) derived from farnesylthiosalicylic acid and hydroxamic acid displayed significant inhibitory activities on both HDAC and ras-related signaling (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>).<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Moreover, novel phenoxybenzamide derivatives were obtained as Raf/HDAC dual inhibitors.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> The selectivity assay of some target compounds showed that they had not only pan-Raf inhibition but also excellent selective inhibition of HDAC1.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0006.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. HDAC/RTK pathway inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">4.  Combination of HDAC Inhibitors with Topoisomerase Inhibitor</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02036" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02036" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">4.1.  Molecular Interplay between HDAC and Topoisomerases</h3><div class="NLM_p">Topoisomerases (Topo) are universal nuclear enzymes involved in modulating DNA supercoiling during DNA transcription, replication, and chromatin assembly.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Topo I and Topo II are two classes of DNA topoisomerases that can induce transient DNA single-strand or double-strand breaks by cleaving single or double DNA strands, respectively. Topo I and Topo II are validated targets for many inhibitors, including clinically useful anthracyclines, such as daunomycin (DAU) and doxorubicin (DOX), and camptothecins, such as topotecan and irinotecan.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></div><div class="NLM_p last">Topo inhibitors show anticancer activities primarily due to the stabilization of the DNA-enzyme cleavable complex by intercalation between DNA base pairs.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> However, DNA is not present in the nucleus as a naked structure. It is noncovalently associated with histones to form nucleosomes, which make up chromatin subunits. HDAC inhibitors can enhance the antitumor activity of Topo inhibitors because they can increase the accessibility of DNA within chromatin by inducing hyperacetylation of histone proteins complexed with DNA.<a onclick="showRef(event, 'ref101 ref102'); return false;" href="javascript:void(0);" class="ref ref101 ref102">(101,102)</a> Furthermore, recent observations have shown that the colocalization of Topo II with HDAC1 and HDAC2 in vivo is a part of functionally coupled complexes.<a onclick="showRef(event, 'ref103 ref104'); return false;" href="javascript:void(0);" class="ref ref103 ref104">(103,104)</a> Plenty of evidence indicates that cotreatment with HDAC inhibitors and Topo inhibitors, such as topotecan, synergistically blocks cell proliferation.<a onclick="showRef(event, 'ref105 ref106'); return false;" href="javascript:void(0);" class="ref ref105 ref106">(105,106)</a> All these evidences mentioned above suggest that simultaneously inhibiting Topo and HDAC may be a viable alternative approach for cancer treatment.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">4.2.  Dual Targeting Inhibition Strategies</h3><div class="NLM_p">By incorporation of an appropriate pharmacophore of Topo inhibitors and a prototypical pharmacophore of HDAC inhibitors into a SAHA-like template, four series of compounds were synthesized as dual Topo and HDAC inhibitors (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>). Among the camptothecin derivatives (<b>17a</b>–<b>g</b>),<a onclick="showRef(event, 'ref107 ref108'); return false;" href="javascript:void(0);" class="ref ref107 ref108">(107,108)</a> compound <b>17g</b> (<i>a</i> = 5, R<sub>20</sub> = OH) showed the most favorable interactions with both target proteins in the molecular modeling studies. This result of compound <b>17g</b> can be explained considering the simultaneous existence of the phenolic -OH of camptothecin (10-hydroxy) and a linker of the appropriate length. These structural features make compound <b>17g</b> a good ligand for both the HDAC-II active site and the DNA-Top I binary complex.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0007.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Camptothecin derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The molecular modeling studies showed that some compounds, including compound <b>17g</b>, exhibited a hydrogen-binding interaction between the R<sup>364</sup> NH<sub>2</sub> residue and the nitrogen atom of ring B or the OH group of the lactone ring. Compounds with a 5/6 carbon chain were able to form stable complexes with both Top1 and HDAC. Regarding its antiproliferative activity, compound <b>17g</b> exhibited a potent antiproliferative effect against human myeloma, lymphoma, and leukemia cell lines with IC<sub>50</sub> value ranging from 0.05 to 11 μM, which is higher than the antiproliferative effect of irinotecan (IC<sub>50</sub> > 7 μM) and SAHA (4 μM < IC<sub>50</sub> < 12 μM). Moreover, compound <b>17g</b> was found to be more effective than cisplatin (1.2 μM < IC<sub>50</sub> < 8.0 μM), 5-FU (18 μM < IC<sub>50</sub> < 200 μM), and gefitinib (14 μM < IC<sub>50</sub> < 38 μM). The efficacy of compound <b>17g</b> was tested on the human mesothelioma primary cell line MM473-Luc orthotopically xenografted in CD-1 nude mice. The results revealed that the positive control irinotecan showed only a marginal antitumor effect, but compound <b>17g</b> obviously reduced the progression of tumor growth.</div><div class="NLM_p">For podophyllotoxin derivatives (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>),<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> all the target compounds showed obvious anti-Topo II activity in the in vitro topoisomerase II relaxation assay; compound <b>18d</b> (<i>n</i> = 6, R<sub>22</sub> = -O(CH<sub>2</sub>)<sub>6</sub>CONHOH, meta-position) expressed the best HDAC inhibitory activity against HDAC1, HDAC3, and HDAC6 with IC<sub>50</sub> values of 11, 9.6, and 5.6 nM, respectively. Compound <b>18d</b> also showed powerful antiproliferative activity against HCT116 colon carcinoma cells with an IC<sub>50</sub> value of 3.33 μM. The HDAC inhibition activities of these compounds indicated that the meta- and para-substituted hybrids had similar anti-HDAC activities. A larger capping group, such as PPT, could promote the binding affinity between the compound and the HDAC enzymes. Moreover, the HDAC inhibition activity improved with increasing carbon chain length.</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0008.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Podophyllotoxin derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Of the acridine derivatives (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>),<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> compound <b>19c</b> (R<sub>23</sub> = R<sub>24</sub> = H, <i>m</i> = 2, para-) displayed the best HDAC1/6 inhibition activity and effective Topo II inhibition activity at 50 μM. It displayed potent activity against U937 with an IC<sub>50</sub> value of 0.90 μM. The binding models of compound <b>19c</b> with HDAC and Topo displayed that the hydroxamic acid moiety formed six hydrogen bonds with His145, His146, Tyr308, and Asp181. The 9-aminoacridine group of compound <b>19c</b> was parallel to DG13 and formed a hydrogen bond with DNA. A chain length of five carbons was the proper distance for the hydroxamic acid group to chelate with zinc. The biological activities showed that introducing the chlorine and methoxy groups into acridine greatly reduced HDAC1/6 inhibition.</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0009.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Acridine derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The <i>N</i>-benzyldoxorubicin derivatives (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>)<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> more potently inhibited Topo II and HDAC activities compared to daunomycin (a standard Topo II inhibitor) and SAHA. Among them, compound <b>20b</b> (<i>b</i> = 2) showed a rapid onset of Topo II and HDAC inhibition activities, which may rapidly disappear because of its diminished intracellular residency. Molecular docking studies showed that most target compounds, including <b>20b</b>, had a hydrogen bond between the hydroxyl group of the daunosamine sugar and the guanidinium group of Arg270. In addition, the hydroxyl groups of the anthracycline ring of most compounds can interact with the N–H group of Gly272 and the backbone carbonyl group of Arg270 via H-bonding interactions. Among all the <i>N</i>-benzyldoxorubicin derivatives, compound <b>20e</b> showed the best cytotoxicity across all cell lines (DU-145 prostate carcinoma, MCF-7, and SK-MES-1 non-small-cell lung carcinoma), possessing submicromolar activities.</div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0010.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. <i>N</i>-Benzyl doxorubicin derivatives as dual-acting Topo-HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">5.  Combination of HDAC Inhibitor with DNA Damaging Drugs and PARP Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45522" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45522" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">5.1.  Molecular Interplay between HDAC, DNA Damaging, and PARP</h3><div class="NLM_p">Genotoxic anticancer drugs play an important role in cancer treatment. Among them, nitrogen mustards represent a typical class. Chlorambucil as a representative is widely used clinically worldwide; it can attack cellular DNA and cause DNA damage.<a onclick="showRef(event, 'ref112 ref113'); return false;" href="javascript:void(0);" class="ref ref112 ref113">(112,113)</a> However, the DNA damage caused by chlorambucil can be repaired by the cellular DNA repair machinery; some tumor cells survive and eventually result in treatment failure.<a onclick="showRef(event, 'ref113 ref114 ref115'); return false;" href="javascript:void(0);" class="ref ref113 ref114 ref115">(113−115)</a> Consequently, nitrogen mustards elicit poor potency and limit treatment efficacy. Thus, inhibition of the DNA repair protein poly ADP-ribose polymerase (PARP) or other DNA repair pathways may be effective strategies to improve the efficacy of nitrogen mustards.</div><div class="NLM_p last">HDAC inhibitors have been proven to act synergistically with DNA-damaging agents and PARP inhibitors through multiple mechanisms, including the attenuation of HR protein ATM activity,<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> induction of DNA damage,<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> induction of p53 acetylation and activity,<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> inhibition of both HR and NHEJ systems,<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> downregulation of antiapoptotic proteins such as Bcl-2, and upregulation of proapoptotic proteins such as Bax.<a onclick="showRef(event, 'ref120 ref121'); return false;" href="javascript:void(0);" class="ref ref120 ref121">(120,121)</a> Many reports have provided preclinical evidence of the synergism between HDAC inhibitors and DNA-damaging agents in both solid cancer and hematological models.<a onclick="showRef(event, 'ref122 ref123'); return false;" href="javascript:void(0);" class="ref ref122 ref123">(122,123)</a> Furthermore, several papers have illustrated that the HDAC inhibitor’s ability to impair the DNA repair machinery sensitizes tumor cells to PARP inhibitor treatment.<a onclick="showRef(event, 'ref124 ref125'); return false;" href="javascript:void(0);" class="ref ref124 ref125">(124,125)</a> Additionally, an HDAC inhibitor can also sensitize tumor cells to radiation treatment in many solid tumors, including prostate carcinoma, glioblastoma multiforme, colorectal carcinoma, melanoma, non-small-cell lung cancer, and head and neck squamous cell carcinoma.<a onclick="showRef(event, 'ref126 ref127 ref128 ref129'); return false;" href="javascript:void(0);" class="ref ref126 ref127 ref128 ref129">(126−129)</a> In all these studies, the combination of HDAC inhibitors with DNA damaging agents or PARP inhibitors has been well-tolerated and presents encouraging efficacy.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">5.2.  Dual Targeting Inhibition Strategies</h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19">5.2.1.  DNA/HDAC Dual Inhibitors</h4><div class="NLM_p">Researchers derivatized HDAC inhibitors by adding a malonic acid substituent or pharmacophores from nitrogen mustard drugs to its phenyl ring or cap group to give compound <b>21</b>,<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> chlordinaline,<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> vorambucil,<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> and CY (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>).<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> CY, which is a bendamustine-derived, is the first-in-class example of such DNA/HDAC dual inhibitors exhibiting far-superior anticancer activity compared to bendamustine or HDAC.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> The aromatic rings of CY improve its interaction with the HDAC’s enzyme pocket. The seven-carbon side chain of CY enhanced the inhibitory activity against HDAC by mimicking the length of a lysine residue. The clinical efficacy of CY was evaluated. The results showed that CY could kill nearly all CLL cells at 5 μM. In contrast, its parent compound, bendamustine, at 100 μM can only kill approximately 80% CLL cells. In clinics, bendamustine is ineffective against chronic lymphocytic leukemia cells with 17p deletion. However, CY can kill 17p-retaining and 17p-deleted chronic lymphocytic leukemia cells with a similar efficacy, suggesting that it may represent a potential treatment strategy for 17p-deleted chronic lymphocytic leukemia. Regarding compound <b>21</b>, it showed poorer HDAC1 inhibitory activity compared to SAHA. However, it may play a role as a Trojan horse, delivering the HDAC inhibitor and the DNA binding agent Pt<sup>II</sup> to their target sites, thereby reducing nonspecific effects and showing a distinct advantage over treatments involving cisplatin alone.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> The inhibition mechanism of compound <b>21</b> is that it acts as carboplatin releasing the malSAHA derivative free to inhibit HDACs and the Pt moiety to bind DNA nucleobases.</div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0011.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Design strategies of DNA/HDAC dual-targeting drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">As for chlordinaline, it moderately inhibited HDACs and showed excellent selective inhibition against HDAC3. It also significantly increased the DNA damage. Further structural optimization of chlordinaline is ongoing.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> The phenyl group of chlordinaline can form three π–π stacking interactions with residues Tyr308, Phe200, and Phe144 in different active sites of HDAC. As expected, vorambucil exhibited potent inhibition against both HDACs and DNA. Notably, it showed slightly selective inhibitory activity against HDAC1 and HDAC2 over HDAC6. Moreover, it induced increased DNA damage compared to its parent compound chlorambucil and showed significantly enhanced anticancer potency in cell growth inhibition assays.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> Vorambucil can form several hydrogen bonds with different residues at different HDAC active sites; for example, it can form five hydrogen bonds with residues Ala136, Gly137, Arg34, and Trp135 at the HDAC1 active site. Vorambucil showed potent antiproliferative activity against HepG2, A549, HCT116, and A375 cancer cells with IC<sub>50</sub> values of 3.2–6.2 μM and displayed 5- to 18-fold enhanced antiproliferative activity compared to its parent compound chlorambucil. Further investigation demonstrated that vorambucil remarkably arrested the cell cycle and induced apoptosis of A375 cells at the G2/M phase.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20">5.2.2.  PARP/HDAC Dual Inhibitors</h4><div class="NLM_p">Jiang’s team constructed hydroxamic acid derivatives, such as compounds <b>22a</b> and <b>22b</b>, as PARP and HDAC dual-targeting inhibitors<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> utilizing structure-based and knowledge-based drug design approaches (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>). These two compounds showed potent inhibitory activities against HDAC1/6 and PARP1/2 with IC<sub>50</sub> values within 100 nM. Besides, compound <b>22a</b> also obviously increased the expression of γ-H2AX in MDA-MB-231 cells, indicating that compound <b>22a</b> treatment increased DNA damage. Compared with SAHA, compound <b>22a</b> displayed more potent activity than SAHA and olaparib in Raji, HCC1937, and MDA-MB-231 cancer cells and 4.1-fold less cytotoxicity to normal MCF-10A cells. These results demonstrated that structural modification of olaparib to a hydroxamate is a rational and feasible way to obtain PARP and HDAC dual-targeting drugs. The piperazine unit might be helpful for maintaining PARP1 inhibitory activity, but it is not important for suppressing PARP2. The linker length is closely related to the inhibitory potency of HDAC inhibitors by affecting the inhibitor to insert itself into the hydrophobic pocket of the HDAC enzyme.</div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0013.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Design strategy of PARP/HDAC dual inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">6.  Combination of HDAC with JAK Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05270" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05270" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">6.1.  Molecular Interplay between HDAC and JAKs</h3><div class="NLM_p">Janus kinases (JAKs), consisting of JAK1, JAK2, JAK3, and TYK2, play key roles in transducing cytokine-mediated signals.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> The phosphorylation and dimerization of the signal transducers and activators of transcription (STAT) proteins induced by the activation of JAKs allow STAT proteins to translocate to the nucleus, and then gene transcription is activated.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> The JAK/STAT pathway is tightly related to diverse biological functions, including hematopoiesis, inflammation, and immune function.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a></div><div class="NLM_p last">STAT1, a transcription factor, plays an important role in signaling by interferons (IFNs). A study reported that HDAC inhibitors could prevent IFNγ-induced JAK1 activation, STAT1 phosphorylation, and STAT1-dependent gene activation.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> The inhibition of JAKs directly downregulates the intracellular expression of STATs. Moreover, it has been reported that the inhibition of HDACs with the HDAC inhibitor pracinostat also can reduce the levels of STATs in a myelofibrosis clinical trial.<a onclick="showRef(event, 'ref139 ref140'); return false;" href="javascript:void(0);" class="ref ref139 ref140">(139,140)</a> Therefore, utilizing the synergistic effect of JAK and HDAC inhibitors for cancer therapy is promising.</div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">6.2.  Dual Targeting Inhibition Strategies</h3><div class="NLM_p">When considering to explore a dual JAK-HDAC inhibitor, HDAC inhibition is most easily achieved by adding a hydroxamate-bearing chain.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> It is critically important for a potent dual JAK-HDAC inhibitor to contain functional groups that can form strong hydrogen bonds with the hinge of the JAK kinase. In light of this principle, a series of JAK-HDAC dual-target inhibitors derived based on the structures of 4-amino-(1<i>H</i>)-pyrazole,<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> ruxolitinib,<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> CYT-387,<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> pacritinib,<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> and XL019<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> were designed and studied (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>).</div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0014.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Representative JAK/HDAC dual inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For 4-amino-(1<i>H</i>)-pyrazole-based derivatives, compound <b>23</b> as a representative possessed excellent and balanced activities against both HDAC6 and JAK2 with IC<sub>50</sub> values at the nanomolar level. Compared with its parent compound ruxolitinib and SAHA, compound <b>23</b> exhibited improved proapoptotic and antiproliferative activities in a range of hematological cell lines.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> Pharmacokinetic studies in mice identified that compound <b>23</b> showed good bioavailability after intraperitoneal administration. Furthermore, it exhibited antitumor efficacy in an HEL xenograft model without significant toxicity. The structure–activity relationships of these derivatives revealed that the aromatic terminal groups were better than the aliphatic terminal groups for their HDAC inhibitory activity. Para-substitution on the aromatic terminal group was beneficial for HDAC inhibition, and the structural modification of the aromatic terminal group was generally tolerated for HDAC and JAK2 inhibition.</div><div class="NLM_p">Considering ruxolitinib derivatives, the most potent compound <b>24</b> inhibited HDACs 1, 2, 3, 6, 10, and JAK1 with IC<sub>50</sub> values less than 20 nM and showed inhibitory activities against JAK2 and HDAC11 with IC<sub>50</sub> values less than 100 nM.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> The design strategies for dual inhibitors emphasize that the pyrrolopyrimidine nitrogens are critically important by providing a donor–acceptor interaction with the JAK2 kinase. The optimal alkyl chain length for both HDAC and JAK2 targets is six carbons. The antiproliferative potency of compound <b>24</b> showed that it is the most potent compound against solid tumors and hematological cancer cell lines with IC<sub>50</sub> values of 490–2000 nM. In a pharmacokinetic study in rats, compound <b>24</b> was rapidly cleared via renal clearance or other routes with a short terminal half-life. The oral bioavailability of compound <b>24</b> was measurable but poor at 1.4% possibly, which indicates its low permeability.</div><div class="NLM_p">As for CYT-387 derivatives, the best compound <b>25</b> exhibited high activity and remarkable selectivity against JAK2 and HDAC6 with IC<sub>50</sub> < 50 nM. More significantly, compound <b>25</b> showed potent in vivo antitumor efficacy in acute myeloid leukemia (AML) models.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> The therapeutic potential of compound <b>25</b> was validated in different in vivo models. In the AML model, compound <b>25</b> markedly prolonged the survival of leukemic mice. In the HEL xenograft model, compound <b>25</b> possessed potent in vivo antitumor efficacy. The SAR studies showed that the <i>N</i>-phenylmethanesulfonamide moiety improved HDAC1 inhibitory activity and retained the excellent JAK2 inhibitory activity. With the elongation of various linkers, the HDAC1 inhibitory activity increased.</div><div class="NLM_p">Compound <b>26</b>, a typical example of XL019 derivatives, exhibited nanomolar JAK2 and HDAC1/6 inhibition. The enzyme inhibition assay also showed that compound <b>26</b> had 16- to 25-fold selectivity for JAK2 against other JAK-family members JAK1, JAK3, and TYK2.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> Compound <b>26</b> showed potent antiproliferative activity against solid tumor cell lines, such as PC-3 with IC<sub>50</sub> values of 0.64–1.0 μM. The binding studies revealed that compounds with para-substituted piperidine or methylpiperazine were better than those with meta-substituted piperidine or methylpiperazine for JAK2 potency. Furthermore, a linker with six methylenes was generally optimal for HDAC inhibition. Methylation at the 5-position of pyrimidine maintained potency against HDAC6 and JAK2, while it reduced HDAC1 potency.</div><div class="NLM_p last">For pacritinib derivatives, compound <b>27</b>, which had single-digit nanomolar potency against HDAC6 and JAK2, was found to be optimal. It showed broad antiproliferative potency across several solid and hematological cell lines.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> All these studies lay structural foundation for the further exploration of JAK-HDAC dual-target drugs. The SARs showed that the 6-methylene group as the aliphatic linker was the optimal length for HDAC6 activity.</div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">7.  Combination of HDAC with BCL-2 Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50501" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50501" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25">7.1.  Molecular Interplay between HDAC and Bcl-2</h3><div class="NLM_p">Cell survival is tightly related to the suppression of the intrinsic pathway of cell apoptosis through complex interactions between Bcl-2 family proteins. Major antiapoptotic proteins of the Bcl-2 family include Bcl-2, Mcl-1, Bcl-xl, Bcl-w, and A1/BFL1. These members regulate cell apoptosis by interacting with proapoptotic proteins, including BH3 domain-only containing proteins and multidomain proteins, such as Bak and Bax. Abrogation of antiapoptotic Bcl-2 protein activity by BH3 mimetics has been confirmed as an effective anticancer therapeutic strategy in both solid and hematologic tumors.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a></div><div class="NLM_p">Studies have shown that the induction of the proapoptotic Bcl-2 family has a direct effect on chromatin.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> For example, a study demonstrated that p63, a lineage-specific transcription factor, can directly repress Noxa and Puma transcription in squamous cell carcinoma through recruitment of HDAC1/2. Thus, treatment with p63 inhibition or an HDAC inhibitor upregulates histone acetylation, resulting in cell death of squamous cell carcinoma.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Inspired by this finding, the Bcl-2 family was proposed as a therapeutic target for squamous cell carcinoma treatment. Subsequently, the synergistic effect of HDAC inhibition with a BH3-mimetic agent, a Bcl-2 inhibitor, in squamous cell carcinoma treatment was studied and described.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a></div><div class="NLM_p last">Additionally, HDAC inhibitors and Bcl-2 inhibitors were discovered to be cooperative in multiple myeloma cells, at least in part, by Bim upregulation.<a onclick="showRef(event, 'ref149 ref150'); return false;" href="javascript:void(0);" class="ref ref149 ref150">(149,150)</a> The synergistic interaction was further verified to overcome bortezomib resistance in vitro.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> All these studies demonstrate it is reasonable to use combination therapy with these two types of agents in cancer treatment.</div></div><div id="sec7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26">7.2.  Dual Targeting Inhibition Strategies</h3><div class="NLM_p">A series of Bcl-2/HDAC dual-target inhibitors were designed by changing the tetrahydropyranyl methyl group of venetoclax, a known Bcl-2 inhibitor, into a hydroxamic acid group with different linkers (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>).<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> Among them, compounds <b>28a</b>–<b>g</b> (<i>n</i> = 5–7) showed potent binding affinity to the Bcl-2 protein and good inhibitory activities against HDAC6 simultaneously. The inhibitory activities of these compounds are comparable to those of their parent compounds, venetoclax and SAHA, respectively. Nevertheless, these compounds displayed great growth inhibitory activities in the multiple myeloma cell line RPMI-8226, apparently better than that of SAHA and ABT-199. These results proved the potential possibilities of using Bcl-2/HDAC dual-target inhibitors for the development of novel therapeutic strategies for multiple myeloma and other cancers. The compounds with linkers containing 5–7 carbons displayed potent inhibitory activities against HDAC6 and obvious selectivity for HDAC6.</div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0015.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Bcl-2/HDAC dual inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">8.  Combination of HDAC Inhibitor with Phosphodiesterase Inhibitor</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55668" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55668" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28">8.1.  Molecular Interplay between HDAC and PDE5</h3><div class="NLM_p">Phosphodiesterases (PDEs) are metallohydrolases that modulate the intensity and duration of their intracellular response through catalyzing the breakdown of cGMP or cAMP into the inactive GMP or 5′-AMP. PDEs contain 11 families encoded by 21 different genes. PDE1–3, PDE10, and PDE 11 are dual-specificity esterases that hydrolyze both cAMP and cGMP; PDE5, PDE6, and PDE9 can hydrolyze cGMP and PDE4, PDE7; PDE8 degrades cAMP.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> The NH<sub>2</sub>-terminal portion of these enzymes may be phosphorylated/dephosphorylated, binding with Ca<sup>2+</sup>/calmodulin or cGMP and mediating interactions with other proteins.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> PDE5 contains allosteric binding sites for cGMP and phosphorylation sites. Phosphorylation of PDE5 by protein kinase G serves to enhance its cGMP affinity and shows an alternative process of regulatory feedback inhibition during the cGMP/PKG signaling cascade, thus normalizing levels of cGMP.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a></div><div class="NLM_p last">PDE5 is upregulated in Alzheimer’s disease patients’ brains, often with the down-regulation of cGMP in the cerebrospinal fluid of AD patients,<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> drawing attention to the application of PDE5 inhibitors in AD.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> It has been reported that the activation of the cAMP/cGMP response element-binding (CREB) pathway may improve AD symptoms, as observed with PDE5 inhibitors in animal models.<a onclick="showRef(event, 'ref158 ref159'); return false;" href="javascript:void(0);" class="ref ref158 ref159">(158,159)</a> Similarly, HDAC inhibitors are also considered as promising therapeutic agents for AD.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> Class I HDAC and HDAC6 are associated with AD memory-related dysfunction, and these enzymes can regulate memory consolidation.<a onclick="showRef(event, 'ref161 ref162'); return false;" href="javascript:void(0);" class="ref ref161 ref162">(161,162)</a> Among class I, HDAC2 and HDAC3 are important for controlling multiple memory-related genes, while HDAC6 can regulate microtubule stability and function through tubulin acetylation, and inhibiting HDAC6 activity can promote Aβ and tau clearance.<a onclick="showRef(event, 'ref163 ref164'); return false;" href="javascript:void(0);" class="ref ref163 ref164">(163,164)</a> On the basis of the fact that most of the HDAC inhibitors and PDE inhibitors are effective in AD models,<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> dual inhibition has emerged as a promising therapeutic approach for AD treatment.</div></div><div id="sec8_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29">8.2.  Dual Targeting Inhibition Strategies</h3><div class="NLM_p">According to the structural characteristics of HDAC inhibitors and PDE5 inhibitors, CM-414, the first-in-class small molecule, was identified as a dual inhibitor. Subsequently, its analogies were well developed and studied (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>).<a onclick="showRef(event, 'ref165 ref166 ref167'); return false;" href="javascript:void(0);" class="ref ref165 ref166 ref167">(165−167)</a> Among the target compounds, compounds A and B were found to be the best inhibitors and represent two series of derivatives. Compound <b>29a</b> showed inhibitory activity against class I HDACs in the midnanomolar range with moderate inhibitory activity against PDE5. Compared to its parent compound CM-414, compound <b>29a</b> elicited a 10 times longer residence time on HDAC1 and HDAC2.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> Among the other series of dual inhibitors, compound <b>29b</b> was the most potent and selective analogue against HDAC<sub>6</sub> (IC<sub>50</sub> = 15 nM); it exhibited potent activity toward PDE5A (IC<sub>50</sub> of 11 nM).<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> It showed adequate pharmacokinetic properties and was tested in a mouse model of AD in vivo. The results indicated that the mice treated with compound <b>29b</b> exhibited a partial restoration of the memory impairment.</div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0016.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Representatives of PDE-5/HDAC dual inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">9.  Dual Targeting Estrogen Receptor and HDAC</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04424" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04424" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec9_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31">9.1.  Molecular Interplay between HDAC and Estrogen Receptor</h3><div class="NLM_p">Breast cancer is a very common cancer among women. The estrogen receptor (ER), a ligand-regulated transcription factor, regulates many pathological and physiological processes and plays a critical role in breast cancer growth.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> Therefore, therapeutic strategies that inhibit estrogen signaling have proven efficacy in breast cancer and have entered clinical practice.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> In preclinical breast cancer models, HDAC inhibitors have been shown to induce the expression of aromatase and estrogen receptor α (ERα) in ERα-negative cells, resulting in increased sensitivity to aromatase inhibitors letrozole and tamoxifen.<a onclick="showRef(event, 'ref170 ref171 ref172'); return false;" href="javascript:void(0);" class="ref ref170 ref171 ref172">(170−172)</a></div><div class="NLM_p">Moreover, treatment with entinostat, an HDAC inhibitor, has been shown to counteract letrozole resistance by regulating HER2 expression and activity.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> In 2011, the combination treatment of the HDAC inhibitor vorinostat with tamoxifen for hormone-therapy-resistant breast cancer was evaluated in a phase II clinical trial.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> The results showed that the tamoxifen-vorinostat combination is well-tolerated and presents promising activity in reversing hormone resistance.</div><div class="NLM_p last">In addition, the direct interaction of HDACs with ER in the cell nucleus has been confirmed.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> In ER-positive cells, HDAC inhibition or the knockdown of HDAC1 can decrease ERα levels.<a onclick="showRef(event, 'ref176 ref177'); return false;" href="javascript:void(0);" class="ref ref176 ref177">(176,177)</a> Thus, because the combination of selective estrogen receptor modulators with HDAC inhibitors requires both agents in close proximity to the cell nucleus, the concept of a selective estrogen receptor modulator combined with an HDAC inhibitor in a single molecule is thus proposed.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a></div></div><div id="sec9_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32">9.2.  Dual Targeting Strategies</h3><div class="NLM_p">Zhou’s group attempted to incorporate SAHA into unique ER ligands to produce new bifunctional hybrid agents, which have improved selectivity and efficacy while retaining high affinity for ER.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> They expanded the diversity of an ER ligand OBHS by equipping it in two ways with SAHA to obtain dual-target agents (<b>30a</b>–<b>n</b>) (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>).</div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0017.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Design of OBHS-HDAC inhibitor conjugates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The evaluation results demonstrated that the hydroxamic acid compound <b>30f</b> (R<sub>25</sub> = 2-CH<sub>3</sub>), belonging to series II, showed the most potent anti-HDAC1 activity with an IC<sub>50</sub> value of 22 nM; it is more potent than SAHA’s inhibition of HDAC1. All these OBHS-HDAC inhibitor conjugates elicited good ER binding affinity and outstanding ERα antagonistic activity.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> It showed over 10-fold greater selectivity for MCF-7 cells (IC<sub>50</sub> = 7.9 μM) than DU-145 cells (IC<sub>50</sub> > 100 μM). The SARs demonstrated that the compounds that possessed a suberic acid moiety in the phenyl sulfonate group of series I had a better binding affinity for ERα than compounds with a suberic acid group attached to the phenol ring of OBHS of series II. The suberic acid at the paraposition of the phenyl sulfonate unit favored ER subtype selectivity and ERα binding affinity. Replacing the carboxylic acid with a hydroxamic acid or a methyl ester reduced the ERα binding affinity and subtype selectivity. In addition, the phenolic group is crucial to their ER binding affinity. Moreover, introduction of a methyl group to the target compounds increased their binding affinity for ERβ, and the position of the methyl group showed a slight effect on binding affinity for ERs.</div></div></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">10.  Combination of HDAC Inhibitor with MMP-2 Inhibitor</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08823" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08823" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec10_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34">10.1.  Molecular Interplay between HDAC and MMP-2</h3><div class="NLM_p">Both HDAC and matrix metalloproteinases (MMPs) are zinc-dependent metalloenzymes. MMPs are important for the degradation of extracellular matrix protein components<a onclick="showRef(event, 'ref179 ref180'); return false;" href="javascript:void(0);" class="ref ref179 ref180">(179,180)</a> and play critical roles in tissue remodeling under pathological and physiological conditions.<a onclick="showRef(event, 'ref181 ref182'); return false;" href="javascript:void(0);" class="ref ref181 ref182">(181,182)</a> Considering their cellular sources, substrate specificity, primary structure, and biological functions, 26 MMPs are divided into five groups: collagenases (MMP-1, -8, -13, and -18), gelatinases (MMP-2 and -9), stromelysins (MMP-3, -10, and -11), membrane-type MMPs (MMP-14, -15, -16, -17, -23, -24, and -25), (<i>E</i>) matrilysins (MMP-7 and -26), and others (MMP-12, -19, -20, -21, -22, -27, and -28).<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> Among them, MMP-2 has been widely studied and is tightly associated with tumor progression and pathogenesis because of its crucial role in cell proliferation, migration, adhesion, and angiogenesis.<a onclick="showRef(event, 'ref183 ref184'); return false;" href="javascript:void(0);" class="ref ref183 ref184">(183,184)</a></div><div class="NLM_p">It was reported that both HDAC8 and MMP-2 were overexpressed in the leukemia cells; their inhibition may potentially limit the leukemia cell growth, metastasis, invasion, and associated events.<a onclick="showRef(event, 'ref184 ref185 ref186 ref187'); return false;" href="javascript:void(0);" class="ref ref184 ref185 ref186 ref187">(184−187)</a> HDAC inhibitors could repress the HIF-1α-induced vascular endothelial growth factor (VEGF) expression. The antiangiogenic effects induced by HDAC inhibitors were noticed by direct/indirect inhibition of the VEGF. In addition, HDAC inhibition may restrict HDAC binding to the Sp1 site of the reversion-inducing-cysteine-rich protein with a kazal motif (RECK) promoter, which leads to the upregulation of RECK.<a onclick="showRef(event, 'ref188 ref189'); return false;" href="javascript:void(0);" class="ref ref188 ref189">(188,189)</a> Moreover, a significant inverse relation between MMPs and RECK expression in lung adenocarcinoma,<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> salivary adenoid cystic carcinoma,<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> and breast cancer<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> was reported. The upregulated RECK expression via HDAC inhibitors was found to negatively affect the enzymatic activity of MMP-2.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a></div><div class="NLM_p last">Park et al. suggested that spermidine prevented metastasis by inhibiting the activity and expression of MMP-2 in human dermal fibroblasts (HDFs) via regulating HDAC and HAT.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> Many reports have illustrated that HDAC inhibitors potentially upregulate RECK expression, which negatively modulates MMPs, resulting in an anticancer effect.<a onclick="showRef(event, 'ref194 ref195 ref196'); return false;" href="javascript:void(0);" class="ref ref194 ref195 ref196">(194−196)</a> On the basis of this solid evidence, dual acting HDAC/MMP-2 inhibitors may potentially block the metastasis, invasion, and angiogenesis in cancer cells like leukemic malignant cells.</div></div><div id="sec10_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35">10.2.  Dual Targeting Strategies</h3><div class="NLM_p">Zhang’s group investigated dual HDAC6/MMP-2 inhibitors via hierarchical virtual screening of natural products.<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> Four potential dual HDAC-6/MMP-2 inhibitors were found (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>). The binding modes showed that these compounds could simultaneously bind to the active sites of HDAC6 and MMP-2 via different interactions to inhibit HDAC6 and MMP-2 activities. These four compounds lay structural foundation for designing new dual HDAC6/MMP-2 inhibitors with higher biological activities.<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a></div><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0018.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Molecular structures of dual HDAC-6/MMP-2 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec11" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">11.  Combination of HDAC Inhibitor with MDM2 Inhibitor</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32836" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32836" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec11_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37">11.1.  Molecular Interplay between HDAC and MDM2</h3><div class="NLM_p">As is known, p53 is crucial for inhibiting tumor development. It interacts with murine double minute 2 protein (MDM2), and this interaction is important for its tumor suppressor function and the inactivation of transcriptional activity.<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a> Blocking the interaction between p53 and MDM2 can reactivate the tumor suppressor function of p53 and is considered as a potential strategy in cancer therapy.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> Recent studies revealed that HDAC inhibitors could synergize with MDM2 inhibitors to suppress tumor cell proliferation.<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a></div><div class="NLM_p last">Disrupting the p53-MDM2 interaction can release p53, thus restoring the tumor-suppressive activity of p53. Generally speaking, the functional inactivation of p53 is a fundamental step to inducing tumor.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> p53 acetylated at Lys382 possesses the tumor suppressor function, and the acetylation of p53 is regulated by HDAC inhibitors. Inhibition of MDM2 or/and HDACs may result in the accumulation of activated p53. Inhibition of HDAC can synergistically enhance the antitumor activity of MDM2 inhibitors via modification of the hyperacetylation of p53.<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> Therefore, developing inhibitors that simultaneously target HDAC and MDM2 may be a promising strategy in cancer therapy.</div></div><div id="sec11_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38">11.2.  Dual Targeting Strategies</h3><div class="NLM_p">By incorporation of the pharmacophore of the HDAC inhibitor SAHA into the structure of nutlin-3a, a series of dual MDM2/HDAC inhibitors were designed and synthesized<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>). The MDM2 and HDACs inhibitory activities were evaluated; the results showed that all the compounds had good inhibitory activity against MDM2 (<i>K</i><sub>i</sub> = 0.96–1.43 μM). Among them, compound <b>31e</b> (linker = -piperidine-) exhibited the best MDM2 binding affinity (<i>K</i><sub>i</sub> = 0.06 μM); however, its HDAC1 inhibitory activity was poor (IC<sub>50</sub> = 9.72 μM). Regarding its in vivo antitumor activity, compound <b>31d</b> (linker = -piperazine-(CH<sub>2</sub>)<sub>6</sub>-) with the best antitumor activity among all the compounds against A549 cell line (IC<sub>50</sub> = 0.91 μM) was evaluated in a xenograft nude mouse model (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>). The results showed that oral administration of 150 mg kg<sup>–1</sup> day<sup>–1</sup> of compound <b>31d</b> achieved a tumor growth inhibition of 74.5%. Compound <b>31d</b> showed better in vivo potency than SAHA (100 mg kg<sup>–1</sup> day<sup>–1</sup>, 57.3%). Additionally, it displayed reasonable PK properties in rats with oral bioavailability of 18%.</div><figure id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0019.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Structures of dual MDM2/HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0020.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Binding modes of compound <b>31d</b> enantiomers with MDM2 and HDAC1.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> (A) Compound <b>31d-2</b> with MDM2. (B) Compound <b>31d-2</b> with HDAC1. (C) Binding mode of compound <b>31d-1</b> with MDM2. (D) Proposed binding mode of <b>31d-1</b> with HDAC1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The structure–activity relationships of these compounds were studied.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> The studies indicated that the extension of the linker length enhanced the activity of these compounds against HDAC1 but showed little effect on their MDM2 inhibitory activity. Moreover, the incorporation of piperazine or piperidine into the linker improved the binding affinities of these compounds for both targets. Generally, compounds with a rigid aromatic-based chain showed decreased MDM2/HDAC1 inhibitory activity compared to compounds with a flexible alkyl linker. The computational docking studies of different enantiomers of compound <b>31d</b> (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>) revealed that three aromatic substituents of <b>31d-2</b> stretched into the cavities occupied by residues Phe19, Trp23, and Leu26 of p53. The two 4-chlorophenyl groups of <b>31d-2</b> stretched into the Trp23 and Leu26 pockets, respectively, and the ethyl ether side chain was directed toward the Phe19 pocket. Moreover, the 4-chlorophenyl moiety of <b>31d-2</b> formed a π–π stacking interaction with His92. In contrast, the hydrophobic interactions of <b>31d-1</b> were lost, and the ethyl ether side chain was located outside the Phe19 pocket. The fact that the MDM2 binding affinity of <b>31d-2</b> was better than that of <b>31d-1</b> demonstrated that the hydrophobic interactions and the three residues (Phe19, Trp23, and Leu26) are crucial for the inhibitory activities of these inhibitors.</div><div class="NLM_p last">The binding modes of compounds <b>31d-1</b> and <b>31d-2</b> with HDAC1 showed that the aliphatic linker was stretched into the hydrophobic pocket of HDAC1. The terminal hydroxamic acid moiety of <b>31d-2</b> can form two hydrogen bonds with His145 and Tyr308, respectively. Furthermore, the 4-chloropnenyl group formed π–π stacking interactions with Arg275. Similarly, the hydroxamic acid group of <b>31d-1</b> formed two hydrogen bonds with His145 and Gly143, respectively. Moreover, the carbonyl group of <b>31d-1</b> interacted with Phe210 by a hydrogen bonding. The docking result of <b>31d</b> was consistent with the result that <b>31d-1</b> and <b>31d-2</b> had similar HDAC1 inhibitory activity.</div></div></div><div id="sec12" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i39">12.  Others</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57777" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57777" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In addition to the targets mentioned above, Fang’s team discovered a series of HDAC and proteasome dual inhibitors, which are promising tools for overcoming bortezomib resistance of multiple myeloma.<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a> Furthermore, Valente’s group designed the first-in-class HDAC/EZH2 (Zeste homologue 2) dual inhibitor with (sub)micromolar inhibition against both targets.<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> In addition, HDAC inhibitors also can synergize with several other inhibitors, for example, tubulin inhibitors,<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> nicotinamide phosphoribosyltransferase (NAMPT) inhibitors,<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> ephrin type-A receptor 2 (EphA2) inhibitors,<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> and indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a> Besides, HDAC inhibitors have also been shown to cooperate with TNF-related apoptosis-inducing ligand (TRAIL) in inducing apoptosis in many different cancer types;<a onclick="showRef(event, 'ref207 ref208'); return false;" href="javascript:void(0);" class="ref ref207 ref208">(207,208)</a> however, there is a paucity of dual inhibitors that simultaneously target on these two targets. Thus, it is significant to study and exploit more HDAC-involved dual-target agents for cancer therapy.</div></div><div id="sec13" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i40">13.  Conclusion and Perspective</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50710" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50710" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cancer is a serious disease that threatens people’s health. It shows the characteristics of a long complex treatment. Although the diagnosis and treatment of cancer have shown significant advances, it is a great challenge to cure cancers successfully. Today, multitarget, especially dual-target, drug design has become a popular research field for cancer treatment. These drugs can bring synergistic anticancer effects and possess pharmacokinetic advantages compared to combination chemotherapy.<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a> In view of HDAC’s important roles in cancer cell physiological processes, dual-target drug design for HDAC is one of the research hotspots in this area. The proven efficacy of HDAC inhibitors in oncotherapy together with their simple SAR has attracted many researchers into the development of HDAC-involved multitarget agents, especially dual-target drugs.</div><div class="NLM_p">Generally speaking, this drug design strategy combines the active group of an HDAC inhibitor with the pharmacophore of another inhibitor, such as a BET inhibitor, into one molecule to explore new and more efficient drugs. In this review, we summarize HDAC-based dual-target agents, which provide a concrete foundation for future HDAC-involved dual-target drug design. Clinical studies have shown that HDAC inhibitors can synergize with various inhibitors; however, the dual-target drug design strategy has not been widely used for many targets, such as tubulin and IDO1, which have synergistic effects with HDAC inhibitors. What’s more, CUDC-101 and CUDC-907, which have entered clinical trials as potential HDAC-based dual-target drugs, show more potent antitumor activity than their parent compounds alone or combined and have better safety profiles, which eliminates the serious safety obstacle of HDAC inhibitors. The in vivo and in vitro studies of CUDC-101 and CUDC-907 manifested the possibility of them being significant agents against human pancreatic cancer and acute myeloid leukemia, which shows that the HDAC-based dual-target drug design strategy is feasible.</div><div class="NLM_p">Along with opportunities, there are challenges. Currently, the most frequently used design strategy is combing two or more pharmacophores. This strategy converts the parent compounds into dual-target inhibitors with a larger volume, which may affect the selectivity, membrane permeability, binding affinity, pharmacological properties, and safety profiles of these agents. Thus, the challenges for these dual-target agents are balancing the two activities by combining two pharmacophores with the desired pharmacological properties and safety profiles and developing potency scaffolds for these inhibitors. Therefore, more work needs to be done to develop effective dual target inhibitors for them.</div><div class="NLM_p last">This review concludes some important SARs and binding modes of these dual-target inhibitors as anticancer agents. On the basis of these results and the development of drug design approaches, more potent and higher selectivity dual-target inhibitors based on HDACs can be obtained, which will provide potential recipes for future tumor therapy.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00491" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51385" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51385" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tingting Liu</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Shandong First Medical University & Shandong Academy of Medical
Sciences, Taian 271016, Shandong, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5144-5179" title="Orcid link">http://orcid.org/0000-0002-5144-5179</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#264a4f53524f4841524f4841665542404b5308434253084548"><span class="__cf_email__" data-cfemail="472b2e32332e2920332e2920073423212a3269222332692429">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yichao Wan</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Theoretical Organic Chemistry and Functional Molecule,
Ministry of Education, School of Chemistry and Chemical Engineering, Hunan University of Science and Technology, Xiangtan 411201, Hunan, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuliang Xiao</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Shandong First Medical University & Shandong Academy of Medical
Sciences, Taian 271016, Shandong, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chengcai Xia</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Shandong First Medical University & Shandong Academy of Medical
Sciences, Taian 271016, Shandong, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1943-5720" title="Orcid link">http://orcid.org/0000-0002-1943-5720</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guiyun Duan</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Shandong First Medical University & Shandong Academy of Medical
Sciences, Taian 271016, Shandong, China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85340" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85340" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Tingting Liu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=BIO-d7e2449-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Tingting Liu</b> is an Associate Professor at the School of Pharmacy, Shandong First Medical University & Shandong Academy of Medical Sciences, China. She received her Ph.D. from Shandong University in 2018 and studied at UT Southwestern Medical Center for one year. Her research area involves design, synthesis, and bioactivity study of novel inhibitors and fluorescent probes for protein–protein interaction.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Yichao Wan</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=BIO-d7e2454-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yichao Wan</b> is a lecturer at Key Laboratory of Theoretical Organic Chemistry and Functional Molecule (Ministry of Education), Hunan University of Science and Technology, China. He received his Ph.D. from Shandong University in 2016. His research area involves design, synthesis, and bioactivity study of novel inhibitors as antitumor agents.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Yuliang Xiao</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=BIO-d7e2459-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yuliang Xiao</b> is a Professor at the School of Pharmacy, Shandong First Medical University & Shandong Academy of Medical Sciences, China. He received his Ph.D. degree from Shandong University. His research interests are mainly focused on rational design of medicinal molecules and mechanism studies for Alzheimer’s disease.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Chengcai Xia</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=BIO-d7e2464-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Chengcai Xia</b> is a Professor at the School of Pharmacy, Shandong First Medical University & Shandong Academy of Medical Sciences, China. He received his Ph.D. degree from Zhejiang University of Technology. He is interested in organic synthesis.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Guiyun Duan</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=BIO-d7e2469-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Guiyun Duan</b> is a Professor at the School of Pharmacy, Shandong First Medical University & Shandong Academy of Medical Sciences, China. He received his Ph.D. degree from Shandong University. He is interested in design, synthesis, and bioactivity study of novel kinases inhibitors.</p></figure></div><div class="ack" id="ACK-d7e2650-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i46">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35757" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35757" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the Natural Science Foundation of China (No. 81671395) and the university students’ innovation and entrepreneurship training programs of Shandong Province of China (No. S201910439052); Academic promotion programme of Shandong First Medical University (No. 2019LJ003, 2019QL011).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">BET</td><td class="NLM_def"><p class="first last">bromodomain and extraterminal</p></td></tr><tr><td class="NLM_term">BRD4</td><td class="NLM_def"><p class="first last">bromodomain containing protein 4</p></td></tr><tr><td class="NLM_term">THQ</td><td class="NLM_def"><p class="first last">tetrahydroquinoline</p></td></tr><tr><td class="NLM_term">TF</td><td class="NLM_def"><p class="first last">transcription factor</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">ZBG</td><td class="NLM_def"><p class="first last">zinc-binding group</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide-3-kinase</p></td></tr><tr><td class="NLM_term">MTOR</td><td class="NLM_def"><p class="first last">mechanistic target of rapamycin</p></td></tr><tr><td class="NLM_term">VEGFR</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">Topo</td><td class="NLM_def"><p class="first last">topoisomerase</p></td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">poly ADP-ribose polymerase</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">PDE</td><td class="NLM_def"><p class="first last">phosphodiesterase</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">estrogen receptor</p></td></tr><tr><td class="NLM_term">MMP</td><td class="NLM_def"><p class="first last">matrix metalloproteinase</p></td></tr><tr><td class="NLM_term">RECK</td><td class="NLM_def"><p class="first last">reversion-inducing-cysteine-rich protein with kazal motifs</p></td></tr><tr><td class="NLM_term">HDF</td><td class="NLM_def"><p class="first last">human dermal fibroblast</p></td></tr><tr><td class="NLM_term">EphA2</td><td class="NLM_def"><p class="first last">ephrin type-A receptor 2</p></td></tr><tr><td class="NLM_term">TRAIL</td><td class="NLM_def"><p class="first last">TNF-related apoptosis-inducing ligand</p></td></tr><tr><td class="NLM_term">BH3</td><td class="NLM_def"><p class="first last">Bcl-2 homology domains 3</p></td></tr><tr><td class="NLM_term">MDM2</td><td class="NLM_def"><p class="first last">murine double minute 2 protein</p></td></tr><tr><td class="NLM_term">CREB</td><td class="NLM_def"><p class="first last">cAMP/cGMP response element-binding</p></td></tr><tr><td class="NLM_term">EZH2</td><td class="NLM_def"><p class="first last">Zeste homologue 2</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24237" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24237" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 209 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mokhtari, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homayouni, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baluch, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgatskaya, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeger, H.</span></span> <span> </span><span class="NLM_article-title">Combination therapy in combating cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">38022</span>– <span class="NLM_lpage">38043</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.16723</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.18632%2Foncotarget.16723" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=28410237" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=38022-38043&author=R.+B.+Mokhtariauthor=T.+S.+Homayouniauthor=N.+Baluchauthor=E.+Morgatskayaauthor=S.+Kumarauthor=B.+Dasauthor=H.+Yeger&title=Combination+therapy+in+combating+cancer&doi=10.18632%2Foncotarget.16723"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.16723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.16723%26sid%3Dliteratum%253Aachs%26aulast%3DMokhtari%26aufirst%3DR.%2BB.%26aulast%3DHomayouni%26aufirst%3DT.%2BS.%26aulast%3DBaluch%26aufirst%3DN.%26aulast%3DMorgatskaya%26aufirst%3DE.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DDas%26aufirst%3DB.%26aulast%3DYeger%26aufirst%3DH.%26atitle%3DCombination%2520therapy%2520in%2520combating%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D38022%26epage%3D38043%26doi%3D10.18632%2Foncotarget.16723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blagosklonny, M. V.</span></span> <span> </span><span class="NLM_article-title">Overcoming limitations of natural anticancer drugs by combining with artificial agents</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2004.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.tips.2004.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15681024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2MXoslagsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=77-81&author=M.+V.+Blagosklonny&title=Overcoming+limitations+of+natural+anticancer+drugs+by+combining+with+artificial+agents&doi=10.1016%2Fj.tips.2004.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming limitations of natural anticancer drugs by combining with artificial agents</span></div><div class="casAuthors">Blagosklonny, Mikhail V.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">77-81</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  During a billion years of evolution, living creatures have perfected cytotoxic agents to kill other organisms without killing themselves, thus providing us with antibiotics to kill bacteria without killing eukaryotic (e.g. human) cells.  Some natural agents inhibit specifically most vital cellular structures and functions in cancer cells.  However, nature was not creating antibiotics for cancer, and natural agents kill cancer cells precisely because they share targets with normal cells.  To discriminate between particular cancer cells and normal cells, one can design or select artificial agents that are not necessarily lethal but are aimed either at cancer-specific targets or at dispensable and even unavailable (in cancer cells) targets.  Using rational drug combinations, such selective agents can assist natural agents to eradicate cancer cells selectively.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHEqPHb7M1qbVg90H21EOLACvtfcHk0lgyesndBPiDYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXoslagsg%253D%253D&md5=6160179fcd3935adebbab83716b470c5</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2004.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2004.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DBlagosklonny%26aufirst%3DM.%2BV.%26atitle%3DOvercoming%2520limitations%2520of%2520natural%2520anticancer%2520drugs%2520by%2520combining%2520with%2520artificial%2520agents%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2005%26volume%3D26%26spage%3D77%26epage%3D81%26doi%3D10.1016%2Fj.tips.2004.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinarivala, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span> <span> </span><span class="NLM_article-title">Multi-targeting anticancer agents: rational approaches, synthetic routes and structure activity relationship</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">842</span>– <span class="NLM_lpage">874</span>, <span class="refDoi"> DOI: 10.2174/1871520619666190118120708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.2174%2F1871520619666190118120708" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=30657048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFCisbnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=842-874&author=H.+Singhauthor=N.+Kinarivalaauthor=S.+Sharma&title=Multi-targeting+anticancer+agents%3A+rational+approaches%2C+synthetic+routes+and+structure+activity+relationship&doi=10.2174%2F1871520619666190118120708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-Targeting Anticancer Agents: Rational Approaches, Synthetic Routes and Structure Activity Relationship</span></div><div class="casAuthors">Singh, Harbinder; Kinarivala, Nihar; Sharma, Sahil</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">842-874</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  We live in a world with complex diseases such as cancer which cannot be cured with one-compd. one-target based therapeutic paradigm.  This could be due to the involvement of multiple pathogenic mechanisms.  One-compd.-various-targets stratagem has become a prevailing research topic in anti-cancer drug discovery.  The simultaneous interruption of two or more targets has improved the therapeutic efficacy as compared to the specific targeted based therapy.  In this review, six types of dual targeting agents along with some interesting strategies used for their design and synthesis are discussed.  Their pharmacol. with various types of the mol. interactions within their specific targets has also been described.  This assemblage will reveal the recent trends and insights in front of the scientific community working in dual inhibitors and help them in designing the next generation of multi-targeted anti-cancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojOVp3ZXdphrVg90H21EOLACvtfcHk0lhuNQKbM_F8-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFCisbnO&md5=c8cdf59ab0e86c63b7d1f4fd4bde682d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2174%2F1871520619666190118120708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520619666190118120708%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DH.%26aulast%3DKinarivala%26aufirst%3DN.%26aulast%3DSharma%26aufirst%3DS.%26atitle%3DMulti-targeting%2520anticancer%2520agents%253A%2520rational%2520approaches%252C%2520synthetic%2520routes%2520and%2520structure%2520activity%2520relationship%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2019%26volume%3D19%26spage%3D842%26epage%3D874%26doi%3D10.2174%2F1871520619666190118120708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hesham, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasheen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abouzid, K. A. M.</span></span> <span> </span><span class="NLM_article-title">Chimeric HDAC inhibitors: comprehensive review on the HDAC-based strategies developed to combat cancer</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">2058</span>– <span class="NLM_lpage">2109</span>, <span class="refDoi"> DOI: 10.1002/med.21505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1002%2Fmed.21505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=29733427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A280%3ADC%252BC1MfgsV2htQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=2058-2109&author=H.+M.+Heshamauthor=D.+S.+Lasheenauthor=K.+A.+M.+Abouzid&title=Chimeric+HDAC+inhibitors%3A+comprehensive+review+on+the+HDAC-based+strategies+developed+to+combat+cancer&doi=10.1002%2Fmed.21505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer</span></div><div class="casAuthors">Hesham Heba M; Lasheen Deena S; Abouzid Khaled A M</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2058-2109</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Recently, molecular hybridization paradigm became an interesting and smart way to defeat the multifaceted cancer disease by a single molecular entity that acts via several mechanisms just like a magic bullet.  Also, HDAC is an important epigenetic target in drug discovery, and the HDAC inhibitors showed successful pattern as cytotoxic agents.  Because of their flexible structure activity relationship, it was easy to link them to other anticancer scaffolds.  So, many dual action HDAC inhibitors have been developed and most of these hybrids have higher potency than the constituting parents in fighting of the cancer cells.  This review describes potential applications of chimeric HDAC inhibitors, which simultaneously modulate not only HDAC but also multiple targets, in treatment of relapsing and drug-resistant cancers.  We have nearly collected most of the reported dual action HDAC inhibitors yet to provide a comprehensive guide for the drug discovery process for developing more efficient anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7h5aD28C1RtbHMBt0mMIXfW6udTcc2eaOD6ANuy6kOLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MfgsV2htQ%253D%253D&md5=c935014e94bf04c21eafbcb2f8ef8218</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fmed.21505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21505%26sid%3Dliteratum%253Aachs%26aulast%3DHesham%26aufirst%3DH.%2BM.%26aulast%3DLasheen%26aufirst%3DD.%2BS.%26aulast%3DAbouzid%26aufirst%3DK.%2BA.%2BM.%26atitle%3DChimeric%2520HDAC%2520inhibitors%253A%2520comprehensive%2520review%2520on%2520the%2520HDAC-based%2520strategies%2520developed%2520to%2520combat%2520cancer%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26spage%3D2058%26epage%3D2109%26doi%3D10.1002%2Fmed.21505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Harbi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazumder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsi, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almasan, A.</span></span> <span> </span><span class="NLM_article-title">MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">e1593</span>, <span class="refDoi"> DOI: 10.1038/cddis.2014.525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fcddis.2014.525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25590803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=e1593&author=G.+S.+Choudharyauthor=S.+Al-Harbiauthor=S.+Mazumderauthor=B.+T.+Hillauthor=M.+R.+Smithauthor=J.+Bodoauthor=E.+D.+Hsiauthor=A.+Almasan&title=MCL-1+and+BCL-xL-dependent+resistance+to+the+BCL-2+inhibitor+ABT-199+can+be+overcome+by+preventing+PI3K%2FAKT%2FmTOR+activation+in+lymphoid+malignancies&doi=10.1038%2Fcddis.2014.525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies</span></div><div class="casAuthors">Choudhary, G. S.; Al-harbi, S.; Mazumder, S.; Hill, B. T.; Smith, M. R.; Bodo, J.; Hsi, E. D.; Almasan, A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e1593</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Overexpression of anti-apoptotic BCL-2 family members is a hallmark of many lymphoid malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) that can be targeted with small mol. inhibitors.  ABT-199 is a rationally designed BCL-2 homol. (BH)-3 mimetic that specifically binds to BCL-2, but not to MCL-1 and BCL-xL.  Although the thrombocytopenia that occurs with navitoclax treatment has not been a problem with ABT-199, clin. trials in CLL could benefit by lowering the ABT-199 concn. through targeting other survival pathways.  In this study, we investigated the mechanisms of resistance that develops to ABT-199 therapy by generating ABT-199-resistant (ABT199-R) cell lines via chronic exposure of NHL cell lines to ABT-199.  Acquired resistance resulted in substantial AKT activation and upregulation of MCL-1 and BCL-xL levels that sequestered BIM.  ABT199-R cells exhibited increased MCL-1 stability and failed to activate BAX in response to ABT-199.  The ABT-199 acquired and inherent resistant cells were sensitized to treatment with ABT-199 by inhibitors of the PI3K, AKT, and mTOR pathways, NVP-BEZ235 and GS-1101.  NVP-BEZ235, a dual inhibitor of p-AKT and mTOR, reduced MCL-1 levels causing BIM release from MCL-1 and BCL-xL, thus leading to cell death by BAX activation.  The PI3Kδ inhibitor GS-1101 (idelalisib) downregulated MCL-1 and sensitized ABT199-R cells through AKT-mediated BAX activation.  A genetic approach, through siRNA-mediated down-regulation of AKT, MCL-1, and BCL-xL, significantly decreased cell survival, demonstrating the importance of these cell survival factors for ABT-199 resistance.  Our findings suggest a novel mechanism that modulates the expression and activity of pro-survival proteins to confer treatment resistance that could be exploited by a rational combination therapeutic regimen that could be effective for treating lymphoid malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ3IPkt2N8BbVg90H21EOLACvtfcHk0lhnBQlaPBpHlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOitbY%253D&md5=bf94dc99ed80e1c7b5880b5dee25c522</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2014.525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2014.525%26sid%3Dliteratum%253Aachs%26aulast%3DChoudhary%26aufirst%3DG.%2BS.%26aulast%3DAl-Harbi%26aufirst%3DS.%26aulast%3DMazumder%26aufirst%3DS.%26aulast%3DHill%26aufirst%3DB.%2BT.%26aulast%3DSmith%26aufirst%3DM.%2BR.%26aulast%3DBodo%26aufirst%3DJ.%26aulast%3DHsi%26aufirst%3DE.%2BD.%26aulast%3DAlmasan%26aufirst%3DA.%26atitle%3DMCL-1%2520and%2520BCL-xL-dependent%2520resistance%2520to%2520the%2520BCL-2%2520inhibitor%2520ABT-199%2520can%2520be%2520overcome%2520by%2520preventing%2520PI3K%252FAKT%252FmTOR%2520activation%2520in%2520lymphoid%2520malignancies%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2015%26volume%3D6%26spage%3De1593%26doi%3D10.1038%2Fcddis.2014.525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bailly, C.</span></span> <span> </span><span class="NLM_article-title">Contemporary challenges in the design of topoisomerase II inhibitors for cancer chemotherapy</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">3611</span>– <span class="NLM_lpage">3640</span>, <span class="refDoi"> DOI: 10.1021/cr200325f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr200325f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsVChtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2012&pages=3611-3640&author=C.+Bailly&title=Contemporary+challenges+in+the+design+of+topoisomerase+II+inhibitors+for+cancer+chemotherapy&doi=10.1021%2Fcr200325f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Contemporary Challenges in the Design of Topoisomerase II Inhibitors for Cancer Chemotherapy</span></div><div class="casAuthors">Bailly, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3611-3640</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review reports the use of topoisomerase II modulators as anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozIpYLsh9eCLVg90H21EOLACvtfcHk0lhnBQlaPBpHlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsVChtbY%253D&md5=f5ba565e42cd9ff9a38e47ad7c1e77c0</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fcr200325f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr200325f%26sid%3Dliteratum%253Aachs%26aulast%3DBailly%26aufirst%3DC.%26atitle%3DContemporary%2520challenges%2520in%2520the%2520design%2520of%2520topoisomerase%2520II%2520inhibitors%2520for%2520cancer%2520chemotherapy%26jtitle%3DChem.%2520Rev.%26date%3D2012%26volume%3D112%26spage%3D3611%26epage%3D3640%26doi%3D10.1021%2Fcr200325f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jenuwein, T.</span></span> <span> </span><span class="NLM_article-title">Translating the histone code</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>293</i></span>,  <span class="NLM_fpage">1074</span>– <span class="NLM_lpage">1080</span>, <span class="refDoi"> DOI: 10.1126/science.1063127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1126%2Fscience.1063127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=11498575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmtVWltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2001&pages=1074-1080&author=T.+Jenuwein&title=Translating+the+histone+code&doi=10.1126%2Fscience.1063127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Translating the histone code</span></div><div class="casAuthors">Jenuwein, Thomas; Allis, C. David</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">293</span>
        (<span class="NLM_cas:issue">5532</span>),
    <span class="NLM_cas:pages">1074-1080</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The review.  Chromatin, the physiol. template of all eukaryotic genetic information, is subject to a diverse array of posttranslational modifications that largely impinge on histone amino termini, thereby regulating access to the underlying DNA.  Distinct histone amino-terminal modifications can generate synergistic or antagonistic interaction affinities for chromatin-assocd. proteins, which in turn dictate dynamic transitions between transcriptionally active or transcriptionally silent chromatin states.  The combinatorial nature of histone amino-terminal modifications thus reveals a "histone code" that considerably extends the information potential of the genetic code.  We propose that this epigenetic marking system represents a fundamental regulatory mechanism that has an impact on most, if not all; chromatin-templated processes, with far-reaching consequences for cell fate decisions and both normal and pathol. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUFyHNepKcUbVg90H21EOLACvtfcHk0lhnBQlaPBpHlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmtVWltro%253D&md5=021dcd98a5e5bf2ed7eedef1897b2269</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1126%2Fscience.1063127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1063127%26sid%3Dliteratum%253Aachs%26aulast%3DJenuwein%26aufirst%3DT.%26atitle%3DTranslating%2520the%2520histone%2520code%26jtitle%3DScience%26date%3D2001%26volume%3D293%26spage%3D1074%26epage%3D1080%26doi%3D10.1126%2Fscience.1063127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glozak, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sengupta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span> <span> </span><span class="NLM_article-title">Acetylation and deacetylation of non-histone proteins</span>. <i>Gene</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1016/j.gene.2005.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.gene.2005.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16289629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Klu7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2005&pages=15-23&author=M.+A.+Glozakauthor=N.+Senguptaauthor=X.+Zhangauthor=E.+Seto&title=Acetylation+and+deacetylation+of+non-histone+proteins&doi=10.1016%2Fj.gene.2005.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Acetylation and deacetylation of non-histone proteins</span></div><div class="casAuthors">Glozak, Michele A.; Sengupta, Nilanjan; Zhang, Xiaohong; Seto, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Gene</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15-23</span>CODEN:
                <span class="NLM_cas:coden">GENED6</span>;
        ISSN:<span class="NLM_cas:issn">0378-1119</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Since the first report of p53 as a non-histone target of a histone acetyltransferase (HAT), there has been a rapid proliferation in the description of new non-histone targets of HATs.  Of these, transcription factors comprise the largest class of new targets.  The substrates for HATs extend to cytoskeletal proteins, mol. chaperones and nuclear import factors.  Deacetylation of these non-histone proteins by histone deacetylases (HDACs) opens yet another exciting new field of discovery in the role of the dynamic acetylation and deacetylation on cellular function.  This review will focus on these non-histone targets of HATs and HDACs and the consequences of their modification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrghezJOUSImbVg90H21EOLACvtfcHk0ljx0CeKIrO2LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Klu7%252FN&md5=c6befd12e4556a9154628d9fe9ebe53a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.gene.2005.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gene.2005.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DGlozak%26aufirst%3DM.%2BA.%26aulast%3DSengupta%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSeto%26aufirst%3DE.%26atitle%3DAcetylation%2520and%2520deacetylation%2520of%2520non-histone%2520proteins%26jtitle%3DGene%26date%3D2005%26volume%3D363%26spage%3D15%26epage%3D23%26doi%3D10.1016%2Fj.gene.2005.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minucci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelicci, P. G.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1038/nrc1779</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnrc1779" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16397526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1GgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=38-51&author=S.+Minucciauthor=P.+G.+Pelicci&title=Histone+deacetylase+inhibitors+and+the+promise+of+epigenetic+%28and+more%29+treatments+for+cancer&doi=10.1038%2Fnrc1779"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer</span></div><div class="casAuthors">Minucci, Saverio; Pelicci, Pier Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-51</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are considered to be among the most promising targets in drug development for cancer therapy, and first-generation histone deacetylase inhibitors (HDACi) are currently being tested in phase I/II clin. trials.  A wide-ranging knowledge of the role of HDACs in tumorigenesis, and of the action of HDACi, has been achieved.  However, several basic aspects are not yet fully understood.  Investigating these aspects in the context of what we now understand about HDACi action both in vitro and in vivo will further improve the design of optimized clin. protocols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxXiACZV1sK7Vg90H21EOLACvtfcHk0ljx0CeKIrO2LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1GgsA%253D%253D&md5=384e1f8d676d61531e46843c060a9380</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrc1779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1779%26sid%3Dliteratum%253Aachs%26aulast%3DMinucci%26aufirst%3DS.%26aulast%3DPelicci%26aufirst%3DP.%2BG.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520and%2520the%2520promise%2520of%2520epigenetic%2520%2528and%2520more%2529%2520treatments%2520for%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D38%26epage%3D51%26doi%3D10.1038%2Fnrc1779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotili, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerbara, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valente, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeoni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragno, R.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylation in epigenetics: an attractive target for anticancer therapy</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1002/med.20024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1002%2Fmed.20024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15717297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslGit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=261-309&author=A.+Maiauthor=S.+Massaauthor=D.+Rotiliauthor=I.+Cerbaraauthor=S.+Valenteauthor=R.+Pezziauthor=S.+Simeoniauthor=R.+Ragno&title=Histone+deacetylation+in+epigenetics%3A+an+attractive+target+for+anticancer+therapy&doi=10.1002%2Fmed.20024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylation in epigenetics: An attractive target for anticancer therapy</span></div><div class="casAuthors">Mai, Antonello; Massa, Silvio; Rotili, Dante; Cerbara, Ilaria; Valente, Sergio; Pezzi, Riccardo; Simeoni, Silvia; Ragno, Rino</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">261-309</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The reversible histone acetylation and deacetylation are epigenetic phenomena that play crit. roles in the modulation of chromatin topol. and the regulation of gene expression.  Aberrant transcription due to altered expression or mutation of genes that encode histone acetyltransferase (HAT) or histone deacetylase (HDAC) enzymes or their binding partners, has been clearly linked to carcinogenesis.  The histone deacetylase inhibitors are a new promising class of anticancer agents (some of which in clin. trials), that inhibit the proliferation of tumor cells in culture and in vivo by inducing cell-cycle arrest, terminal differentiation, and/or apoptosis.  This report reviews the chem. and the biol. of HDACs and HDAC inhibitors, laying particular emphasis on agents actually in clin. trials for cancer therapy and on new potential anticancer lead compds. more selective and less toxic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDbzbbO5ZKrLVg90H21EOLACvtfcHk0ljx0CeKIrO2LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslGit7w%253D&md5=60112258470a6d520cbc0af24046e994</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fmed.20024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20024%26sid%3Dliteratum%253Aachs%26aulast%3DMai%26aufirst%3DA.%26aulast%3DMassa%26aufirst%3DS.%26aulast%3DRotili%26aufirst%3DD.%26aulast%3DCerbara%26aufirst%3DI.%26aulast%3DValente%26aufirst%3DS.%26aulast%3DPezzi%26aufirst%3DR.%26aulast%3DSimeoni%26aufirst%3DS.%26aulast%3DRagno%26aufirst%3DR.%26atitle%3DHistone%2520deacetylation%2520in%2520epigenetics%253A%2520an%2520attractive%2520target%2520for%2520anticancer%2520therapy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2005%26volume%3D25%26spage%3D261%26epage%3D309%26doi%3D10.1002%2Fmed.20024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dokmanovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: overview and perspectives</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">981</span>– <span class="NLM_lpage">989</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-07-0324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1541-7786.MCR-07-0324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=17951399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFygsLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2007&pages=981-989&author=M.+Dokmanovicauthor=C.+Clarkeauthor=P.+A.+Marks&title=Histone+deacetylase+inhibitors%3A+overview+and+perspectives&doi=10.1158%2F1541-7786.MCR-07-0324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitors: Overview and Perspectives</span></div><div class="casAuthors">Dokmanovic, Milos; Clarke, Cathy; Marks, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">981-989</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase inhibitors (HDACi) comprise structurally diverse compds. that are a group of targeted anticancer agents.  The first of these new HDACi, vorinostat (suberoylanilide hydroxamic acid), has received Food and Drug Administration approval for treating patients with cutaneous T-cell lymphoma.  This review focuses on the activities of the 11 zinc-contg. HDACs, their histone and nonhistone protein substrates, and the different pathways by which HDACi induce transformed cell death.  A hypothesis is presented to explain the relative resistance of normal cells to HDACi-induced cell death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_V1LFFdlQYbVg90H21EOLACvtfcHk0lgYb_Fqo_X2Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFygsLvN&md5=8696ff3e0f8e910fd6fc6a7e38579b95</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-07-0324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-07-0324%26sid%3Dliteratum%253Aachs%26aulast%3DDokmanovic%26aufirst%3DM.%26aulast%3DClarke%26aufirst%3DC.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520overview%2520and%2520perspectives%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2007%26volume%3D5%26spage%3D981%26epage%3D989%26doi%3D10.1158%2F1541-7786.MCR-07-0324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haberland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E. N.</span></span> <span> </span><span class="NLM_article-title">The many roles of histone deacetylases in development and physiology: implications for disease and therapy</span>. <i>Nat. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1038/nrg2485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnrg2485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=19065135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFWis7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=32-42&author=M.+Haberlandauthor=R.+L.+Montgomeryauthor=E.+N.+Olson&title=The+many+roles+of+histone+deacetylases+in+development+and+physiology%3A+implications+for+disease+and+therapy&doi=10.1038%2Fnrg2485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The many roles of histone deacetylases in development and physiology: implications for disease and therapy</span></div><div class="casAuthors">Haberland, Michael; Montgomery, Rusty L.; Olson, Eric N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-42</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The expression of many histone deacetylase (HDAC) isoforms in eukaryotic cells raises questions regarding their specificity and the programs of gene expression that they control.  HDAC knockout mice are a powerful tool for addressing these questions and have revealed that individual HDACs have specific functions in development and disease.  Histone deacetylases (HDACs) are part of a vast family of enzymes that have crucial roles in numerous biol. processes, largely through their repressive influence on transcription.  The expression of many HDAC isoforms in eukaryotic cells raises questions about their possible specificity or redundancy, and whether they control global or specific programs of gene expression.  Recent analyses of HDAC knockout mice have revealed highly specific functions of individual HDACs in development and disease.  Mutant mice lacking individual HDACs are a powerful tool for defining the functions of HDACs in vivo and the mol. targets of HDAC inhibitors in disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMWcIo3mrsM7Vg90H21EOLACvtfcHk0lgYb_Fqo_X2Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFWis7bI&md5=0678d8655e86994cd4f0174c1e9d0eb1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrg2485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg2485%26sid%3Dliteratum%253Aachs%26aulast%3DHaberland%26aufirst%3DM.%26aulast%3DMontgomery%26aufirst%3DR.%2BL.%26aulast%3DOlson%26aufirst%3DE.%2BN.%26atitle%3DThe%2520many%2520roles%2520of%2520histone%2520deacetylases%2520in%2520development%2520and%2520physiology%253A%2520implications%2520for%2520disease%2520and%2520therapy%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2009%26volume%3D10%26spage%3D32%26epage%3D42%26doi%3D10.1038%2Fnrg2485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, T. C.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases and mechanisms of regulation of gene expression</span>. <i>Crit. Rev. Oncog.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1615/CritRevOncog.2015012997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1615%2FCritRevOncog.2015012997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25746103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A280%3ADC%252BC2MnhslCgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=35-47&author=H.+P.+Chenauthor=Y.+T.+Zhaoauthor=T.+C.+Zhao&title=Histone+deacetylases+and+mechanisms+of+regulation+of+gene+expression&doi=10.1615%2FCritRevOncog.2015012997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases and mechanisms of regulation of gene expression</span></div><div class="casAuthors">Chen Hong Ping; Zhao Yu Tina; Zhao Ting C</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncogenesis</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">35-47</span>
        ISSN:<span class="NLM_cas:issn">0893-9675</span>.
    </div><div class="casAbstract">In recent years it has become widely recognized that histone modification plays a pivotal role in controlling gene expression and is involved in a wide spectrum of disease regulation.  Histone acetylation is a major modification that affects gene transcription and is controlled by histone acetyltransferases (HATs) and histone deacetylases (HDACs).  HATs acetylate lysines of histone proteins, resulting in the relaxation of chromatin structure, and they also facilitate gene activation.  Conversely, HDACs remove acetyl groups from hyperacetylated histones and suppress general gene transcription.  In addition to histones, numerous nonhistone proteins can be acetylated and deacetylated, and they also are involved in the regulation of a wide range of diseases.  To date there are 18 HDACs in mammals classified into 4 classes based on homology to yeast HDACs.  Accumulating evidence has revealed that HDACs play crucial roles in a variety of biological processes including inflammation, cell proliferation, apoptosis, and carcinogenesis.  In this review we summarize the current state of knowledge of HDACs in carcinogenesis and describe the involvement of HDACs in cancer-associated molecular processes.  It is hoped than an understanding of the role of HDACs in cancer will lead to the design of more potent and specific drugs targeting selective HDAC proteins for the treatment of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSe2viLetAEXjMsgLhIoICsfW6udTcc2eaYTD0lZQDBf7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnhslCgsg%253D%253D&md5=1ff0202b04c8b2280ae60d82ac81e8f8</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1615%2FCritRevOncog.2015012997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1615%252FCritRevOncog.2015012997%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%2BP.%26aulast%3DZhao%26aufirst%3DY.%2BT.%26aulast%3DZhao%26aufirst%3DT.%2BC.%26atitle%3DHistone%2520deacetylases%2520and%2520mechanisms%2520of%2520regulation%2520of%2520gene%2520expression%26jtitle%3DCrit.%2520Rev.%2520Oncog.%26date%3D2015%26volume%3D20%26spage%3D35%26epage%3D47%26doi%3D10.1615%2FCritRevOncog.2015012997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregoretti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodson, H. V.</span></span> <span> </span><span class="NLM_article-title">Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>338</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2004.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.jmb.2004.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15050820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisFyksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2004&pages=17-31&author=I.+Gregorettiauthor=Y.-M.+Leeauthor=H.+V.+Goodson&title=Molecular+evolution+of+the+histone+deacetylase+family%3A+functional+implications+of+phylogenetic+analysis&doi=10.1016%2Fj.jmb.2004.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Evolution of the Histone Deacetylase Family: Functional Implications of Phylogenetic Analysis</span></div><div class="casAuthors">Gregoretti, Ivan V.; Lee, Yun-Mi; Goodson, Holly V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-31</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) modify core histones and participate in large regulatory complexes that both suppress and enhance transcription.  Recent studies indicate that some HDACs can act on non-histone proteins as well.  Interest in these enzymes is growing because HDAC inhibitors appear to be promising therapeutic agents against cancer and a variety of other diseases.  Thus far, 11 members of the HDAC family have been identified in humans, but few have been characterized in detail.  To better define the biol. function of these proteins, make maximal use of studies performed in other systems, and assist in drug development efforts, we have performed a phylogenetic anal. of all HDAC-related proteins in all fully sequenced free-living organisms.  Previous analyses have divided non-sirtuin HDACs into two groups, classes 1 and 2.  We find that HDACs can be divided into three equally distinct groups: class 1, class 2, and a third class consisting of proteins related to the recently identified human HDAC11 gene.  We term this novel group "class 4" to distinguish it from the unrelated "class 3" sirtuin deacetylases.  Anal. of gene duplication events indicates that the common ancestor of metazoan organisms contained two class 1, two class 2, and a single class 4 HDAC.  Examn. of HDAC characteristics in light of these evolutionary relationships leads to functional predictions, among them that self-assocn. is common among HDAC proteins.  All three HDAC classes (including class 4) exist in eubacteria.  Phylogenetic anal. of bacterial HDAC relatives suggests that all three HDAC classes precede the evolution of histone proteins and raises the possibility that the primary activity of some "histone deacetylase" enzymes is directed against non-histone substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVqdtToKvZgLVg90H21EOLACvtfcHk0ljbgM5JVzL7YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisFyksro%253D&md5=1748e3b88d8f3b774db50eb19799f63c</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2004.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2004.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DGregoretti%26aufirst%3DI.%26aulast%3DLee%26aufirst%3DY.-M.%26aulast%3DGoodson%26aufirst%3DH.%2BV.%26atitle%3DMolecular%2520evolution%2520of%2520the%2520histone%2520deacetylase%2520family%253A%2520functional%2520implications%2520of%2520phylogenetic%2520analysis%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2004%26volume%3D338%26spage%3D17%26epage%3D31%26doi%3D10.1016%2Fj.jmb.2004.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blander, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guarente, L.</span></span> <span> </span><span class="NLM_article-title">The sir2 family of protein decetylases</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">417</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.73.011303.073651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1146%2Fannurev.biochem.73.011303.073651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15189148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslags7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2004&pages=417-435&author=G.+Blanderauthor=L.+Guarente&title=The+sir2+family+of+protein+decetylases&doi=10.1146%2Fannurev.biochem.73.011303.073651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The Sir2 family of protein deacetylases</span></div><div class="casAuthors">Blander, Gil; Guarente, Leonard</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">417-435</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The yeast SIR protein complex has been implicated in transcription silencing and suppression of recombination.  The Sir complex represses transcription at telomeres, mating-type loci, and ribosomal DNA.  Unlike SIR3 and SIR4, the SIR2 gene is highly conserved in organisms ranging from archaea to humans.  Interestingly, Sir2 is active as an NAD+-dependent deacetylase, which is broadly conserved from bacteria to higher eukaryotes.  In this review, we discuss the role of NAD+, the unusual products of the deacetylation reaction, the Sir2 structure, and the Sir2 chem. inhibitors and activators that were recently identified.  We summarize the current knowledge of the Sir2 homologs from different organisms, and finally we discuss the role of Sir2 in caloric restriction and aging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGOpp_Sk7r0rVg90H21EOLACvtfcHk0liOxJVcklmtYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslags7c%253D&md5=0ee832d37d4865477d458ea5ce579c6a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.73.011303.073651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.73.011303.073651%26sid%3Dliteratum%253Aachs%26aulast%3DBlander%26aufirst%3DG.%26aulast%3DGuarente%26aufirst%3DL.%26atitle%3DThe%2520sir2%2520family%2520of%2520protein%2520decetylases%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2004%26volume%3D73%26spage%3D417%26epage%3D435%26doi%3D10.1146%2Fannurev.biochem.73.011303.073651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Ruijter, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gennip, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kuilenburg, A. B.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases (HDACs): characterization of the classical HDAC family</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">737</span>– <span class="NLM_lpage">749</span>, <span class="refDoi"> DOI: 10.1042/bj20021321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1042%2Fbj20021321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=12429021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvFKiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2003&pages=737-749&author=A.+J.+de%0ARuijterauthor=A.+H.+van+Gennipauthor=H.+N.+Caronauthor=S.+Kempauthor=A.+B.+van+Kuilenburg&title=Histone+deacetylases+%28HDACs%29%3A+characterization+of+the+classical+HDAC+family&doi=10.1042%2Fbj20021321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases (HDACs): characterization of the classical HDAC family</span></div><div class="casAuthors">de Ruijter, Annemieke J. M.; van Gennip, Albert H.; Caron, Huib N.; Kemp, Stephan; van Kuilenburg, Andre B. P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">737-749</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review, with refs.  Transcriptional regulation in eukaryotes occurs within a chromatin setting, and is strongly influenced by the post-translational modification of histones, the building blocks of chromatin, such as methylation, phosphorylation and acetylation.  Acetylation is probably the best understood of these modifications: hyperacetylation leads to an increase in the expression of particular genes, and hypoacetylation has the opposite effect.  Many studies have identified several large, multisubunit enzyme complexes that are responsible for the targeted deacetylation of histones.  The aim of this review is to give a comprehensive overview of the structure, function and tissue distribution of members of the classical histone deacetylase (HDAC) family, in order to gain insight into the regulation of gene expression through HDAC activity.  SAGE (serial anal. of gene expression) data show that HDACs are generally expressed in almost all tissues investigated.  Surprisingly, no major differences were obsd. between the expression pattern in normal and malignant tissues.  However, significant variation in HDAC expression was obsd. within tissue types.  HDAC inhibitors have been shown to induce specific changes in gene expression and to influence a variety of other processes, including growth arrest, differentiation, cytotoxicity and induction of apoptosis.  This challenging field has generated many fascinating results which will ultimately lead to a better understanding of the mechanism of gene transcription as a whole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN1-6ct5EQtrVg90H21EOLACvtfcHk0liOxJVcklmtYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvFKiu7o%253D&md5=8a521cd3ddcf046b4b806ebf9f1476b4</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1042%2Fbj20021321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj20021321%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BRuijter%26aufirst%3DA.%2BJ.%26aulast%3Dvan%2BGennip%26aufirst%3DA.%2BH.%26aulast%3DCaron%26aufirst%3DH.%2BN.%26aulast%3DKemp%26aufirst%3DS.%26aulast%3Dvan%2BKuilenburg%26aufirst%3DA.%2BB.%26atitle%3DHistone%2520deacetylases%2520%2528HDACs%2529%253A%2520characterization%2520of%2520the%2520classical%2520HDAC%2520family%26jtitle%3DBiochem.%2520J.%26date%3D2003%26volume%3D370%26spage%3D737%26epage%3D749%26doi%3D10.1042%2Fbj20021321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holbert, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marmorstein, R.</span></span> <span> </span><span class="NLM_article-title">Structure and activity of enzymes that remove histone modifications</span>. <i>Curr. Opin. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">680</span>, <span class="refDoi"> DOI: 10.1016/j.sbi.2005.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.sbi.2005.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16263263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1GnsrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=673-680&author=M.+A.+Holbertauthor=R.+Marmorstein&title=Structure+and+activity+of+enzymes+that+remove+histone+modifications&doi=10.1016%2Fj.sbi.2005.10.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and activity of enzymes that remove histone modifications</span></div><div class="casAuthors">Holbert, Marc A.; Marmorstein, Ronen</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">673-680</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The post-translational modification of histones plays an important role in chromatin regulation, a process that insures the fidelity of gene expression and other DNA transactions.  Equally important as the enzymes that generate these modifications are the enzymes that remove them.  Recent studies have identified some of the enzymes that remove histone modifications and have characterized their activities.  In addn., structural and biochem. studies of these enzymes have focused on histone lysine deacetylase HDAC8, and sirtuin, and on arginine and lysine demethylases PAD and BHC110/LSD1, resp.  These new findings may be used as a context to present new information that contributes to an understanding of chromatin regulation, and to pose remaining questions pertaining to the activities of these enzymes and the roles they play in chromatin regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5ESHacfk8eLVg90H21EOLACvtfcHk0lhR_7OhdcGkTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1GnsrzN&md5=ab2aa48fa7d7f49f7a56e1c55a0cc413</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2005.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2005.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DHolbert%26aufirst%3DM.%2BA.%26aulast%3DMarmorstein%26aufirst%3DR.%26atitle%3DStructure%2520and%2520activity%2520of%2520enzymes%2520that%2520remove%2520histone%2520modifications%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2005%26volume%3D15%26spage%3D673%26epage%3D680%26doi%3D10.1016%2Fj.sbi.2005.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zupkovitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tischler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadzak, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grausenburger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweifer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiocca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiser, C.</span></span> <span> </span><span class="NLM_article-title">Negative and positive regulation of gene expression by mouse histone deacetylase 1</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">7913</span>– <span class="NLM_lpage">7928</span>, <span class="refDoi"> DOI: 10.1128/MCB.01220-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1128%2FMCB.01220-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16940178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFemur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2006&pages=7913-7928&author=G.+Zupkovitzauthor=J.+Tischlerauthor=M.+Poschauthor=I.+Sadzakauthor=K.+Ramsauerauthor=G.+Eggerauthor=R.+Grausenburgerauthor=N.+Schweiferauthor=S.+Chioccaauthor=T.+Deckerauthor=C.+Seiser&title=Negative+and+positive+regulation+of+gene+expression+by+mouse+histone+deacetylase+1&doi=10.1128%2FMCB.01220-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Negative and positive regulation of gene expression by mouse histone deacetylase 1</span></div><div class="casAuthors">Zupkovitz, Gordin; Tischler, Julia; Posch, Markus; Sadzak, Iwona; Ramsauer, Katrin; Egger, Gerda; Grausenburger, Reinhard; Schweifer, Norbert; Chiocca, Susanna; Decker, Thomas; Seiser, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7913-7928</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) catalyze the removal of acetyl groups from core histones.  Because of their capacity to induce local condensation of chromatin, HDACs are generally considered repressors of transcription.  In this report, we analyzed the role of the class I histone deacetylase HDAC1 as a transcriptional regulator by comparing the expression profiles of wild-type and HDAC1-deficient embryonic stem cells.  A specific subset of mouse genes (7%) was deregulated in the absence of HDAC1.  We identified several putative tumor suppressors (JunB, Prss11, and Plagl1) and imprinted genes (Igf2, H19, and p57) as novel HDAC1 targets.  The majority of HDAC1 target genes showed reduced expression accompanied by recruitment of HDAC1 and local redn. in histone acetylation at regulatory regions.  At some target genes, the related deacetylase HDAC2 partially masks the loss of HDAC1.  A second group of genes was found to be downregulated in HDAC1-deficient cells, predominantly by addnl. recruitment of HDAC2 in the absence of HDAC1.  Finally, a small set of genes (Gja1, Irf1, and Gbp2) was found to require HDAC activity and recruitment of HDAC1 for their transcriptional activation.  Our study reveals a regulatory cross talk between HDAC1 and HDAC2 and a novel function for HDAC1 as a transcriptional coactivator.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoizxopSxe3nLVg90H21EOLACvtfcHk0lik5LuO38rodQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFemur%252FJ&md5=4ec90ff6da2f26688f1c932dd8a27d93</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1128%2FMCB.01220-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.01220-06%26sid%3Dliteratum%253Aachs%26aulast%3DZupkovitz%26aufirst%3DG.%26aulast%3DTischler%26aufirst%3DJ.%26aulast%3DPosch%26aufirst%3DM.%26aulast%3DSadzak%26aufirst%3DI.%26aulast%3DRamsauer%26aufirst%3DK.%26aulast%3DEgger%26aufirst%3DG.%26aulast%3DGrausenburger%26aufirst%3DR.%26aulast%3DSchweifer%26aufirst%3DN.%26aulast%3DChiocca%26aufirst%3DS.%26aulast%3DDecker%26aufirst%3DT.%26aulast%3DSeiser%26aufirst%3DC.%26atitle%3DNegative%2520and%2520positive%2520regulation%2520of%2520gene%2520expression%2520by%2520mouse%2520histone%2520deacetylase%25201%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2006%26volume%3D26%26spage%3D7913%26epage%3D7928%26doi%3D10.1128%2FMCB.01220-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lagger, G.</span></span> <span> </span><span class="NLM_article-title">Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2672</span>– <span class="NLM_lpage">2681</span>, <span class="refDoi"> DOI: 10.1093/emboj/21.11.2672</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1093%2Femboj%2F21.11.2672" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=12032080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvV2is70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=2672-2681&author=G.+Lagger&title=Essential+function+of+histone+deacetylase+1+in+proliferation+control+and+CDK+inhibitor+repression&doi=10.1093%2Femboj%2F21.11.2672"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression</span></div><div class="casAuthors">Lagger, Gerda; O'Carroll, Donal; Rembold, Martina; Khier, Harald; Tischler, Julia; Weitzer, Georg; Schuettengruber, Bernd; Hauser, Christoph; Brunmeir, Reinhard; Jenuwein, Thomas; Seiser, Christian</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2672-2681</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) modulate chromatin structure and transcription, but little is known about their function in mammalian development.  HDAC1 was implicated previously in the repression of genes required for cell proliferation and differentiation.  Here we show that targeted disruption of both HDAC1 alleles results in embryonic lethality before E10.5 due to severe proliferation defects and retardation in development.  HDAC1-deficient embryonic stem cells show reduced proliferation rates, which correlate with decreased cyclin-assocd. kinase activities and elevated levels of the cyclin-dependent kinase inhibitors p21WAF1/CIP1 and p27KIP1.  Similarly, expression of p21 and p27 is up-regulated in HDAC1-null embryos.  In addn., loss of HDAC1 leads to significantly reduced overall deacetylase activity, hyperacetylation of a subset of histones H3 and H4 and concomitant changes in other histone modifications.  The expression of HDAC2 and HDAC3 is induced in HDAC1-deficient cells, but cannot compensate for loss of the enzyme, suggesting a unique function for HDAC1.  Our study provides the first evidence that a histone deacetylase is essential for unrestricted cell proliferation by repressing the expression of selective cell cycle inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK1zFkPbWlqbVg90H21EOLACvtfcHk0lhRQHBZx-3rKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvV2is70%253D&md5=371e6d091fde2eb4c5efd030bd34e7f6</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F21.11.2672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F21.11.2672%26sid%3Dliteratum%253Aachs%26aulast%3DLagger%26aufirst%3DG.%26atitle%3DEssential%2520function%2520of%2520histone%2520deacetylase%25201%2520in%2520proliferation%2520control%2520and%2520CDK%2520inhibitor%2520repression%26jtitle%3DEMBO%2520J.%26date%3D2002%26volume%3D21%26spage%3D2672%26epage%3D2681%26doi%3D10.1093%2Femboj%2F21.11.2672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potthoff, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fielitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E. N.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1790</span>– <span class="NLM_lpage">1802</span>, <span class="refDoi"> DOI: 10.1101/gad.1563807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1101%2Fgad.1563807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=17639084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2sXoslSisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=1790-1802&author=R.+L.+Montgomeryauthor=C.+A.+Davisauthor=M.+J.+Potthoffauthor=M.+Haberlandauthor=J.+Fielitzauthor=X.+Qiauthor=J.+A.+Hillauthor=J.+A.+Richardsonauthor=E.+N.+Olson&title=Histone+deacetylases+1+and+2+redundantly+regulate+cardiac+morphogenesis%2C+growth%2C+and+contractility&doi=10.1101%2Fgad.1563807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility</span></div><div class="casAuthors">Montgomery, Rusty L.; Davis, Christopher A.; Potthoff, Matthew J.; Haberland, Michael; Fielitz, Jens; Qi, Xiaoxia; Hill, Joseph A.; Richardson, James A.; Olson, Eric N.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1790-1802</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) tighten chromatin structure and repress gene expression through the removal of acetyl groups from histone tails.  The class I HDACs, HDAC1 and HDAC2, are expressed ubiquitously, but their potential roles in tissue-specific gene expression and organogenesis have not been defined.  To explore the functions of HDAC1 and HDAC2 in vivo, the authors generated mice with conditional null alleles of both genes.  Whereas global deletion of HDAC1 results in death by embryonic day 9.5, mice lacking HDAC2 survive until the perinatal period, when they succumb to a spectrum of cardiac defects, including obliteration of the lumen of the right ventricle, excessive hyperplasia and apoptosis of cardiomyocytes, and bradycardia.  Cardiac-specific deletion of either HDAC1 or HDAC2 does not evoke a phenotype, whereas cardiac-specific deletion of both genes results in neonatal lethality, accompanied by cardiac arrhythmias, dilated cardiomyopathy, and up-regulation of genes encoding skeletal muscle-specific contractile proteins and calcium channels.  These results reveal cell-autonomous and non-cell-autonomous functions for HDAC1 and HDAC2 in the control of myocardial growth, morphogenesis, and contractility, which reflect partially redundant roles of these enzymes in tissue-specific transcriptional repression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9hvzvEx0USbVg90H21EOLACvtfcHk0liABrmncs2AEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXoslSisb0%253D&md5=d650513a79a442a07af5a631a8d4c1a3</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1101%2Fgad.1563807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1563807%26sid%3Dliteratum%253Aachs%26aulast%3DMontgomery%26aufirst%3DR.%2BL.%26aulast%3DDavis%26aufirst%3DC.%2BA.%26aulast%3DPotthoff%26aufirst%3DM.%2BJ.%26aulast%3DHaberland%26aufirst%3DM.%26aulast%3DFielitz%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DX.%26aulast%3DHill%26aufirst%3DJ.%2BA.%26aulast%3DRichardson%26aufirst%3DJ.%2BA.%26aulast%3DOlson%26aufirst%3DE.%2BN.%26atitle%3DHistone%2520deacetylases%25201%2520and%25202%2520redundantly%2520regulate%2520cardiac%2520morphogenesis%252C%2520growth%252C%2520and%2520contractility%26jtitle%3DGenes%2520Dev.%26date%3D2007%26volume%3D21%26spage%3D1790%26epage%3D1802%26doi%3D10.1101%2Fgad.1563807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinsey, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antos, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E. N.</span></span> <span> </span><span class="NLM_article-title">Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">479</span>– <span class="NLM_lpage">488</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(02)00861-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2FS0092-8674%2802%2900861-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=12202037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD38Xmslyjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2002&pages=479-488&author=C.+L.+Zhangauthor=T.+A.+McKinseyauthor=S.+Changauthor=C.+L.+Antosauthor=J.+A.+Hillauthor=E.+N.+Olson&title=Class+II+histone+deacetylases+act+as+signal-responsive+repressors+of+cardiac+hypertrophy&doi=10.1016%2FS0092-8674%2802%2900861-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy</span></div><div class="casAuthors">Zhang, Chun Li; McKinsey, Timothy A.; Chang, Shurong; Antos, Christopher L.; Hill, Joseph A.; Olson, Eric N.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">479-488</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The heart responds to stress signals by hypertrophic growth, which is accompanied by activation of the MEF2 transcription factor and reprogramming of cardiac gene expression.  We show here that class II histone deacetylases (HDACs), which repress MEF2 activity, are substrates for a stress-responsive kinase specific for conserved serines that regulate MEF2-HDAC interactions.  Signal-resistant HDAC mutants lacking these phosphorylation sites are refractory to hypertrophic signaling and inhibit cardiomyocyte hypertrophy.  Conversely, mutant mice lacking the class II HDAC, HDAC9, are sensitized to hypertrophic signals and exhibit stress-dependent cardiomegaly.  Thus, class II HDACs act as signal-responsive suppressors of the transcriptional program governing cardiac hypertrophy and heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov5BKDzDFqOrVg90H21EOLACvtfcHk0lia1tnGdYY0-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xmslyjt7w%253D&md5=9eb74a943a5e10834d5fc343879737e2</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2802%2900861-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252802%252900861-9%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%2BL.%26aulast%3DMcKinsey%26aufirst%3DT.%2BA.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DAntos%26aufirst%3DC.%2BL.%26aulast%3DHill%26aufirst%3DJ.%2BA.%26aulast%3DOlson%26aufirst%3DE.%2BN.%26atitle%3DClass%2520II%2520histone%2520deacetylases%2520act%2520as%2520signal-responsive%2520repressors%2520of%2520cardiac%2520hypertrophy%26jtitle%3DCell%26date%3D2002%26volume%3D110%26spage%3D479%26epage%3D488%26doi%3D10.1016%2FS0092-8674%2802%2900861-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolger, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, T.-P.</span></span> <span> </span><span class="NLM_article-title">Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">9544</span>– <span class="NLM_lpage">9553</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.1826-05.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1523%2FJNEUROSCI.1826-05.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16221865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFGmu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=9544-9553&author=T.+A.+Bolgerauthor=T.-P.+Yao&title=Intracellular+trafficking+of+histone+deacetylase+4+regulates+neuronal+cell+death&doi=10.1523%2FJNEUROSCI.1826-05.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death</span></div><div class="casAuthors">Bolger, Timothy A.; Yao, Tso-Pang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">9544-9553</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Histone deacetylase 4 (HDAC4) undergoes signal-dependent shuttling between the cytoplasm and nucleus, which is regulated in part by Ca2+/calmodulin-dependent kinase (CaMK)-mediated phosphorylation.  Here, the authors report that HDAC4 intracellular trafficking is important in regulating neuronal cell death.  HDAC4 is normally localized to the cytoplasm in brain tissue and cultured cerebellar granule neurons (CGNs).  However, in response to low-K+ or excitotoxic glutamate conditions that induce neuronal cell death, HDAC4 rapidly translocates into the nucleus of cultured CGNs.  Treatment with neuronal survival factor BDNF suppressed HDAC4 nuclear translocation, whereas a pro-apoptotic CaMK inhibitor stimulated HDAC4 nuclear accumulation.  Moreover, ectopic expression of nuclear-localized HDAC4 promoted neuronal apoptosis and repressed the transcriptional activities of myocyte enhancer factor 2 and cAMP response element-binding protein, survival factors in neurons.  In contrast, inactivation of HDAC4 by small interfering RNA or HDAC inhibitors suppressed neuronal cell death.  Finally, an increase of nuclear HDAC4 in granule neurons was also obsd. in weaver mice, which harbored a mutation that promoted CGN apoptosis.  The data identified HDAC4 and its intracellular trafficking as key effectors of multiple pathways that regulate neuronal cell death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv9TwUmr7aY7Vg90H21EOLACvtfcHk0lia1tnGdYY0-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFGmu7jI&md5=c258df67be207d4af476d4f8ed6f4d40</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.1826-05.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.1826-05.2005%26sid%3Dliteratum%253Aachs%26aulast%3DBolger%26aufirst%3DT.%2BA.%26aulast%3DYao%26aufirst%3DT.-P.%26atitle%3DIntracellular%2520trafficking%2520of%2520histone%2520deacetylase%25204%2520regulates%2520neuronal%2520cell%2520death%26jtitle%3DJ.%2520Neurosci.%26date%3D2005%26volume%3D25%26spage%3D9544%26epage%3D9553%26doi%3D10.1523%2FJNEUROSCI.1826-05.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Outeiro, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontopoulos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kufareva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strathearn, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amore, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volk, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxwell, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochet, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abagyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feany, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazantsev, A. G.</span></span> <span> </span><span class="NLM_article-title">Sirtuin 2 inhibitors rescue α-synuclein-mediated toxicity in models of Parkinson’s disease</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>317</i></span>,  <span class="NLM_fpage">516</span>– <span class="NLM_lpage">519</span>, <span class="refDoi"> DOI: 10.1126/science.1143780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1126%2Fscience.1143780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=17588900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotFylurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=317&publication_year=2007&pages=516-519&author=T.+F.+Outeiroauthor=E.+Kontopoulosauthor=S.+M.+Altmannauthor=I.+Kufarevaauthor=K.+E.+Strathearnauthor=A.+M.+Amoreauthor=C.+B.+Volkauthor=M.+M.+Maxwellauthor=J.-C.+Rochetauthor=P.+J.+McLeanauthor=A.+B.+Youngauthor=R.+Abagyanauthor=M.+B.+Feanyauthor=B.+T.+Hymanauthor=A.+G.+Kazantsev&title=Sirtuin+2+inhibitors+rescue+%CE%B1-synuclein-mediated+toxicity+in+models+of+Parkinson%E2%80%99s+disease&doi=10.1126%2Fscience.1143780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Sirtuin 2 Inhibitors Rescue α-Synuclein-Mediated Toxicity in Models of Parkinson's Disease</span></div><div class="casAuthors">Outeiro, Tiago Fleming; Kontopoulos, Eirene; Altmann, Stephen M.; Kufareva, Irina; Strathearn, Katherine E.; Amore, Allison M.; Volk, Catherine B.; Maxwell, Michele M.; Rochet, Jean-Christophe; McLean, Pamela J.; Young, Anne B.; Abagyan, Ruben; Feany, Mel B.; Hyman, Bradley T.; Kazantsev, Aleksey G.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">317</span>
        (<span class="NLM_cas:issue">5837</span>),
    <span class="NLM_cas:pages">516-519</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The sirtuins are members of the histone deacetylase family of proteins that participate in a variety of cellular functions and play a role in aging.  We identified a potent inhibitor of sirtuin 2 (SIRT2) and found that inhibition of SIRT2 rescued α-synuclein toxicity and modified inclusion morphol. in a cellular model of Parkinson's disease.  Genetic inhibition of SIRT2 via small interfering RNA similarly rescued α-synuclein toxicity.  Furthermore, the inhibitors protected against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson's disease.  The results suggest a link between neurodegeneration and aging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm5psHCGzkkLVg90H21EOLACvtfcHk0lia1tnGdYY0-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotFylurs%253D&md5=4b8914c34ad0f45fb51b94701609bfa6</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1126%2Fscience.1143780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1143780%26sid%3Dliteratum%253Aachs%26aulast%3DOuteiro%26aufirst%3DT.%2BF.%26aulast%3DKontopoulos%26aufirst%3DE.%26aulast%3DAltmann%26aufirst%3DS.%2BM.%26aulast%3DKufareva%26aufirst%3DI.%26aulast%3DStrathearn%26aufirst%3DK.%2BE.%26aulast%3DAmore%26aufirst%3DA.%2BM.%26aulast%3DVolk%26aufirst%3DC.%2BB.%26aulast%3DMaxwell%26aufirst%3DM.%2BM.%26aulast%3DRochet%26aufirst%3DJ.-C.%26aulast%3DMcLean%26aufirst%3DP.%2BJ.%26aulast%3DYoung%26aufirst%3DA.%2BB.%26aulast%3DAbagyan%26aufirst%3DR.%26aulast%3DFeany%26aufirst%3DM.%2BB.%26aulast%3DHyman%26aufirst%3DB.%2BT.%26aulast%3DKazantsev%26aufirst%3DA.%2BG.%26atitle%3DSirtuin%25202%2520inhibitors%2520rescue%2520%25CE%25B1-synuclein-mediated%2520toxicity%2520in%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DScience%26date%3D2007%26volume%3D317%26spage%3D516%26epage%3D519%26doi%3D10.1126%2Fscience.1143780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ota, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokunaga, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hikasa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iijima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akishita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneki, M.</span></span> <span> </span><span class="NLM_article-title">Sirt1 inhibitor, sirtinol, induces senescence-like growth arrest with attenuated Ras–MAPK signaling in human cancer cells</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">176</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1209049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fsj.onc.1209049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16170353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtV2isA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=176-185&author=H.+Otaauthor=E.+Tokunagaauthor=K.+Changauthor=M.+Hikasaauthor=K.+Iijimaauthor=M.+Etoauthor=K.+Kozakiauthor=M.+Akishitaauthor=Y.+Ouchiauthor=M.+Kaneki&title=Sirt1+inhibitor%2C+sirtinol%2C+induces+senescence-like+growth+arrest+with+attenuated+Ras%E2%80%93MAPK+signaling+in+human+cancer+cells&doi=10.1038%2Fsj.onc.1209049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells</span></div><div class="casAuthors">Ota, H.; Tokunaga, E.; Chang, K.; Hikasa, M.; Iijima, K.; Eto, M.; Kozaki, K.; Akishita, M.; Ouchi, Y.; Kaneki, M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">176-185</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The induction of senescence-like growth arrest has emerged as a putative contributor to the anticancer effects of chemotherapeutic agents.  Clin. trials are underway to evaluate the efficacy of inhibitors for class I and II histone deacetylases to treat malignancies.  However, a potential antiproliferative effect of inhibitor for Sirt1, which is an NAD+-dependent deacetylase and belongs to class III histone deacetylases, has not yet been explored.  Here, we show that Sirt1 inhibitor, Sirtinol, induced senescence-like growth arrest characterized by induction of senescence-assocd. β-galactosidase activity and increased expression of plasminogen activator inhibitor 1 in human breast cancer MCF-7 cells and lung cancer H1299 cells.  Sirtinol-induced senescence-like growth arrest was accompanied by impaired activation of mitogen-activated protein kinase (MAPK) pathways, namely, extracellular-regulated protein kinase, c-jun N-terminal kinase and p38 MAPK, in response to epidermal growth factor (EGF) and insulin-like growth factor-I (IGF-I).  Active Ras was reduced in Sirtinol-treated senescent cells compared with untreated cells.  However, tyrosine phosphorylation of the receptors for EGF and IGF-I and Akt/PKB activation were unaltered by Sirtinol treatment.  These results suggest that inhibitors for Sirt1 may have anticancer potential, and that impaired activation of Ras-MAPK pathway might take part in a senescence-like growth arrest program induced by Sirtinol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA2FwjUcUUy7Vg90H21EOLACvtfcHk0liIP1lejwhemQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtV2isA%253D%253D&md5=f2ea6ec5fffad873813d6b7979deb8e3</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1209049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1209049%26sid%3Dliteratum%253Aachs%26aulast%3DOta%26aufirst%3DH.%26aulast%3DTokunaga%26aufirst%3DE.%26aulast%3DChang%26aufirst%3DK.%26aulast%3DHikasa%26aufirst%3DM.%26aulast%3DIijima%26aufirst%3DK.%26aulast%3DEto%26aufirst%3DM.%26aulast%3DKozaki%26aufirst%3DK.%26aulast%3DAkishita%26aufirst%3DM.%26aulast%3DOuchi%26aufirst%3DY.%26aulast%3DKaneki%26aufirst%3DM.%26atitle%3DSirt1%2520inhibitor%252C%2520sirtinol%252C%2520induces%2520senescence-like%2520growth%2520arrest%2520with%2520attenuated%2520Ras%25E2%2580%2593MAPK%2520signaling%2520in%2520human%2520cancer%2520cells%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26spage%3D176%26epage%3D185%26doi%3D10.1038%2Fsj.onc.1209049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span> <span> </span><span class="NLM_article-title">The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1038/nrm2346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnrm2346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=18292778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitlGnurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=206-218&author=X.-J.+Yangauthor=E.+Seto&title=The+Rpd3%2FHda1+family+of+lysine+deacetylases%3A+from+bacteria+and+yeast+to+mice+and+men&doi=10.1038%2Fnrm2346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men</span></div><div class="casAuthors">Yang, Xiang-Jiao; Seto, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">206-218</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein lysine deacetylases have a pivotal role in numerous biol. processes and can be divided into the Rpd3/Hda1 and sirtuin families, each having members in diverse organisms including prokaryotes.  In vertebrates, the Rpd3/Hda1 family contains 11 members, traditionally referred to as histone deacetylases (HDAC) 1-11, which are further grouped into classes I, II and IV.  Whereas most class I HDACs are subunits of multiprotein nuclear complexes that are crucial for transcriptional repression and epigenetic landscaping, class II members regulate cytoplasmic processes or function as signal transducers that shuttle between the cytoplasm and the nucleus.  Little is known about class IV HDAC11, although its evolutionary conservation implies a fundamental role in various organisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRiVyZexxGn7Vg90H21EOLACvtfcHk0liIP1lejwhemQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitlGnurk%253D&md5=f11f89567feadf9cd38b3852dc44c382</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrm2346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2346%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.-J.%26aulast%3DSeto%26aufirst%3DE.%26atitle%3DThe%2520Rpd3%252FHda1%2520family%2520of%2520lysine%2520deacetylases%253A%2520from%2520bacteria%2520and%2520yeast%2520to%2520mice%2520and%2520men%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2008%26volume%3D9%26spage%3D206%26epage%3D218%26doi%3D10.1038%2Fnrm2346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M.</span></span> <span> </span><span class="NLM_article-title">Epigenome-based personalized medicine in human cancer</span>. <i>Epigenomics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">133</span>, <span class="refDoi"> DOI: 10.2217/epi.15.84</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.2217%2Fepi.15.84" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=26344672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC28Xos1aqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=119-133&author=W.+Yanauthor=J.+G.+Hermanauthor=M.+Guo&title=Epigenome-based+personalized+medicine+in+human+cancer&doi=10.2217%2Fepi.15.84"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenome-based personalized medicine in human cancer</span></div><div class="casAuthors">Yan, Wenji; Herman, James G.; Guo, Mingzhou</div><div class="citationInfo"><span class="NLM_cas:title">Epigenomics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">119-133</span>CODEN:
                <span class="NLM_cas:coden">EPIGC7</span>;
        ISSN:<span class="NLM_cas:issn">1750-192X</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Cancer genome sequencing has created an opportunity for precision medicine.  Thus far, genetic alterations can only be used to guide treatment for small subsets of certain cancer types with these key alterations.  Similar to mutations, epigenetic events are equally suitable for personalized medicine.  DNA methylation alterations have been used to identify tumor-specific drug responsive markers.  Methylation of MGMT sensitizes gliomas to alkylating agents is an example of epigenetic personalized medicine.  Recent studies have revealed that 5-azacytidine and decitabine show activity in myelodysplasia, lung and other cancers.  There are currently at least 20 kinds of histone deacetylase inhibitors in clin. testing.  Inhibitors targeting other epigenetic regulators are being clin. tested, such as EZH2 inhibitor EPZ-6438.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_za-KvY9spLVg90H21EOLACvtfcHk0lhSX-eGJxN9jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xos1aqtA%253D%253D&md5=f872718075e1a9b7f7788965fe143c53</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2217%2Fepi.15.84&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fepi.15.84%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DW.%26aulast%3DHerman%26aufirst%3DJ.%2BG.%26aulast%3DGuo%26aufirst%3DM.%26atitle%3DEpigenome-based%2520personalized%2520medicine%2520in%2520human%2520cancer%26jtitle%3DEpigenomics%26date%3D2016%26volume%3D8%26spage%3D119%26epage%3D133%26doi%3D10.2217%2Fepi.15.84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halkidou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaughan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, C. N.</span></span> <span> </span><span class="NLM_article-title">Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer</span>. <i>Prostate</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1002/pros.20022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1002%2Fpros.20022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15042618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktl2lsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2004&pages=177-189&author=K.+Halkidouauthor=L.+Gaughanauthor=S.+Cookauthor=H.+Y.+Leungauthor=D.+E.+Nealauthor=C.+N.+Robson&title=Upregulation+and+nuclear+recruitment+of+HDAC1+in+hormone+refractory+prostate+cancer&doi=10.1002%2Fpros.20022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer</span></div><div class="casAuthors">Halkidou, Kalipso; Gaughan, Luke; Cook, Susan; Leung, Hing Y.; Neal, David E.; Robson, Craig N.</div><div class="citationInfo"><span class="NLM_cas:title">Prostate (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">177-189</span>CODEN:
                <span class="NLM_cas:coden">PRSTDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-4137</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Histone deacetylase 1(HDAC1) is a co-repressor involved in differentiation and proliferation control.  It is upregulated in malignant compared to benign tissue, and targets a no. of transcription factors including p53.  By immunohistochem., HDAC1 protein expression was investigated in human prostate specimens and the CWR22 mouse xenograft model.  Flow cytometry and deconvolution immunofluorescence were also performed.  HDAC1 was upregulated in pre-malignant and malignant lesions, with the highest increase in expression in hormone refractory (HR) cancer.  Using the CWR22 xenograft model the authors showed androgen dependent regulation of HDAC1.  HDAC1 overexpression led to a significant increase in proliferation and a shift towards the undifferentiated cytokeratin (CK) profile in a PC3M deriv. clone constitutively expressing HDAC1.  This study underlines the importance of HDAC1 in cell proliferation and the development of prostate cancer (CaP) and proposes a mechanism for HDAC1 nuclear recruitment.  HDAC1 may constitute a crucial therapeutic target particularly in the most lethal phase of androgen independence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos2Ok-5duE2bVg90H21EOLACvtfcHk0liHTeAWCkJmDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktl2lsLo%253D&md5=f5a4d076fdd9b3334cd756c1133c58f4</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fpros.20022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpros.20022%26sid%3Dliteratum%253Aachs%26aulast%3DHalkidou%26aufirst%3DK.%26aulast%3DGaughan%26aufirst%3DL.%26aulast%3DCook%26aufirst%3DS.%26aulast%3DLeung%26aufirst%3DH.%2BY.%26aulast%3DNeal%26aufirst%3DD.%2BE.%26aulast%3DRobson%26aufirst%3DC.%2BN.%26atitle%3DUpregulation%2520and%2520nuclear%2520recruitment%2520of%2520HDAC1%2520in%2520hormone%2520refractory%2520prostate%2520cancer%26jtitle%3DProstate%26date%3D2004%26volume%3D59%26spage%3D177%26epage%3D189%26doi%3D10.1002%2Fpros.20022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joo, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. Y.</span></span> <span> </span><span class="NLM_article-title">Expression profile of histone deacetylase 1 in gastric cancer tissues</span>. <i>Jpn. J. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">1300</span>– <span class="NLM_lpage">1304</span>, <span class="refDoi"> DOI: 10.1111/j.1349-7006.2001.tb02153.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1111%2Fj.1349-7006.2001.tb02153.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=11749695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtV2jt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2001&pages=1300-1304&author=J.+H.+Choiauthor=H.+J.+Kwonauthor=B.+I.+Yoonauthor=J.+H.+Kimauthor=S.+U.+Hanauthor=H.+J.+Jooauthor=D.+Y.+Kim&title=Expression+profile+of+histone+deacetylase+1+in+gastric+cancer+tissues&doi=10.1111%2Fj.1349-7006.2001.tb02153.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Expression profile of histone deacetylase 1 in gastric cancer tissues</span></div><div class="casAuthors">Choi, Jae-Hoon; Kwon, Ho Jeong; Yoon, Byung-Il; Kim, Jin-Hyun; Han, Sang Uk; Joo, Hee Jae; Kim, Dae-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Japanese Journal of Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1300-1304</span>CODEN:
                <span class="NLM_cas:coden">JJCREP</span>;
        ISSN:<span class="NLM_cas:issn">0910-5050</span>.
    
            (<span class="NLM_cas:orgname">Japanese Cancer Association</span>)
        </div><div class="casAbstract">Although histone deacetylases (HDACs) appear to play a crucial role in carcinogenesis, the expression status of HDACs in primary human cancer tissues has not yet been reported.  In this study, we investigated the expression level of HDAC1 in 25 paired primary human gastric cancer (GC) tissues and corresponding normal tissues through semi-quant. RT-PCR and immunoblot anal.  The HDAC1 expression pattern was also topol. examd. through immunohistochem.  Overexpression of HDAC1 mRNA was detected in 68% of GC tissues (17 of 25), and the relative d. of HDAC1 mRNA in GC tissue was increased 1.8-fold vs. the normal counterpart (P<0.01).  Elevated expression of HDAC1 protein was also detected in 61% of GC samples (11 of 18), which also showed an increased mRNA level of HDAC.  Immunohistochem., overexpression of HDAC1 was predominantly localized in the nuclei of most neoplastic cells, including embolic tumor cells, whereas normal glandular epithelial cells revealed only weak HDAC1 expression that was focal in distribution.  Thus, the present study clearly demonstrates that HDAC1 is overexpressed in GC and probably plays a significant role in gastric carcinogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8nWdwWipzTLVg90H21EOLACvtfcHk0lh6ewA15dXrSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtV2jt7c%253D&md5=acc60d0eaa2076c8aa7c5f6fef8c3c6d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2001.tb02153.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2001.tb02153.x%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DJ.%2BH.%26aulast%3DKwon%26aufirst%3DH.%2BJ.%26aulast%3DYoon%26aufirst%3DB.%2BI.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DHan%26aufirst%3DS.%2BU.%26aulast%3DJoo%26aufirst%3DH.%2BJ.%26aulast%3DKim%26aufirst%3DD.%2BY.%26atitle%3DExpression%2520profile%2520of%2520histone%2520deacetylase%25201%2520in%2520gastric%2520cancer%2520tissues%26jtitle%3DJpn.%2520J.%2520Cancer%2520Res.%26date%3D2001%26volume%3D92%26spage%3D1300%26epage%3D1304%26doi%3D10.1111%2Fj.1349-7006.2001.tb02153.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamaguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwase, H.</span></span> <span> </span><span class="NLM_article-title">Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1007/s10549-005-6001-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1007%2Fs10549-005-6001-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16172792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVyltbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2005&pages=11-16&author=Z.+Zhangauthor=H.+Yamashitaauthor=T.+Toyamaauthor=H.+Sugiuraauthor=Y.+Andoauthor=K.+Mitaauthor=M.+Hamaguchiauthor=Y.+Haraauthor=S.+Kobayashiauthor=H.+Iwase&title=Quantitation+of+HDAC1+mRNA+expression+in+invasive+carcinoma+of+the+breast&doi=10.1007%2Fs10549-005-6001-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast</span></div><div class="casAuthors">Zhang, Zhenhuan; Yamashita, Hiroko; Toyama, Tatsuya; Sugiura, Hiroshi; Ando, Yoshiaki; Mita, Keiko; Hamaguchi, Maho; Hara, Yasuo; Kobayashi, Shunzo; Iwase, Hirotaka</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-16</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Estrogen is well-established as a mitogenic factor implicated in the tumorigenesis and progression of breast cancer via its binding to the estrogen receptor α (ERα).  Recent data indicate that chromatin inactivation mediated by histone deacetylation (HDAC) and DNA methylation is a crit. component of ERα silencing in human breast cancer cells.  The aim of this study was to det. the expression of the HDAC1 gene in malignant human breast tissue and to correlate our observations with available clin. information.  In the present study, the level of expression of HDAC1 mRNA was assessed by LightCycler-based quant. real-time reverse transcriptase (RT)-PCR anal. in 162 cases of invasive carcinoma of the breast.  Assocns. between HDAC1 mRNA expression and different clinicopathol. factors were sought.  It was found that HDAC1 mRNA was expressed at significantly higher levels in tumors from patients over 50 years of age and in those tumors without axillary lymph node involvement, that are less than 2 cm, that are of a non-high histol. grade, that are HER2 neg. and that are ERα/PgR pos.  Patients with tumors displaying high levels of HDAC1 mRNA expression tended to have a better prognosis in terms of both disease-free and overall survival.  However, univariate and multivariate anal. did not show HDAC1 mRNA expression level to be an independent prognostic factor for either disease-free or overall survival.  These results imply that HDAC1 mRNA expression could have potential as an endocrine response marker and may have prognostic implications for breast cancer progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXQ0D466PdgrVg90H21EOLACvtfcHk0ljBXAO4vUBRJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVyltbjK&md5=2481b26970c84afab7b464d6769014da</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2Fs10549-005-6001-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-005-6001-1%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DYamashita%26aufirst%3DH.%26aulast%3DToyama%26aufirst%3DT.%26aulast%3DSugiura%26aufirst%3DH.%26aulast%3DAndo%26aufirst%3DY.%26aulast%3DMita%26aufirst%3DK.%26aulast%3DHamaguchi%26aufirst%3DM.%26aulast%3DHara%26aufirst%3DY.%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DIwase%26aufirst%3DH.%26atitle%3DQuantitation%2520of%2520HDAC1%2520mRNA%2520expression%2520in%2520invasive%2520carcinoma%2520of%2520the%2520breast%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2005%26volume%3D94%26spage%3D11%26epage%3D16%26doi%3D10.1007%2Fs10549-005-6001-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mengwasser, J. r.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlag, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, K.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Göttlicher, M.</span></span> <span> </span><span class="NLM_article-title">Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">463</span>, <span class="refDoi"> DOI: 10.1016/S1535-6108(04)00114-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2FS1535-6108%2804%2900114-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15144953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksFCmt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=455-463&author=P.+Zhuauthor=E.+Martinauthor=J.+r.+Mengwasserauthor=P.+Schlagauthor=K.-P.+Janssenauthor=M.+G%C3%B6ttlicher&title=Induction+of+HDAC2+expression+upon+loss+of+APC+in+colorectal+tumorigenesis&doi=10.1016%2FS1535-6108%2804%2900114-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis</span></div><div class="casAuthors">Zhu, Ping; Martin, Elke; Mengwasser, Joerg; Schlag, Peter; Janssen, Klaus-Peter; Goettlicher, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">455-463</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inappropriate transcriptional repression involving histone deacetylases (HDACs) is a prominent cause for the development of leukemia.  We now identify faulty expression of a specific mediator of transcriptional repression in a solid tumor.  Loss of the adenomatosis polyposis coli (APC) tumor suppressor induces HDAC2 expression depending on the Wnt pathway and c-Myc.  Increased HDAC2 expression is found in the majority of human colon cancer explants, as well as in intestinal mucosa and polyps of APC-deficient mice.  HDAC2 is required for, and sufficient on its own to prevent, apoptosis of colonic cancer cells.  Interference with HDAC2 by valproic acid largely diminishes adenoma formation in APCmin mice.  These findings point toward HDAC2 as a particularly relevant potential target in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP4i9iItBfArVg90H21EOLACvtfcHk0lhWGZtCIV5XgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksFCmt7c%253D&md5=bfd948db793310e303ad8d71d8cbf8b0</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS1535-6108%2804%2900114-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-6108%252804%252900114-X%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DE.%26aulast%3DMengwasser%26aufirst%3DJ.%2Br.%26aulast%3DSchlag%26aufirst%3DP.%26aulast%3DJanssen%26aufirst%3DK.-P.%26aulast%3DG%25C3%25B6ttlicher%26aufirst%3DM.%26atitle%3DInduction%2520of%2520HDAC2%2520expression%2520upon%2520loss%2520of%2520APC%2520in%2520colorectal%2520tumorigenesis%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D5%26spage%3D455%26epage%3D463%26doi%3D10.1016%2FS1535-6108%2804%2900114-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noh, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eun, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, S. W.</span></span> <span> </span><span class="NLM_article-title">Increased expression of histone deacetylase 2 is found in human gastric cancer</span>. <i>APMIS</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">264</span>– <span class="NLM_lpage">268</span>, <span class="refDoi"> DOI: 10.1111/j.1600-0463.2005.apm_04.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1111%2Fj.1600-0463.2005.apm_04.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15865607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltlOjtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2005&pages=264-268&author=J.+Songauthor=J.+H.+Nohauthor=J.+H.+Leeauthor=J.+W.+Eunauthor=Y.+M.+Ahnauthor=S.+Y.+Kimauthor=S.+H.+Leeauthor=W.+S.+Parkauthor=N.+J.+Yooauthor=J.+Y.+Leeauthor=S.+W.+Nam&title=Increased+expression+of+histone+deacetylase+2+is+found+in+human+gastric+cancer&doi=10.1111%2Fj.1600-0463.2005.apm_04.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Increased expression of histone deacetylase 2 is found in human gastric cancer</span></div><div class="casAuthors">Song, Jaehwi; Noh, Ji Heon; Lee, Jong Heun; Eun, Jung Woo; Ahn, Young Min; Kim, Su Young; Lee, Sug Hyung; Park, Won Sang; Yoo, Nam Jin; Lee, Jung Young; Nam, Suk Woo</div><div class="citationInfo"><span class="NLM_cas:title">APMIS</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">264-268</span>CODEN:
                <span class="NLM_cas:coden">APMSEL</span>;
        ISSN:<span class="NLM_cas:issn">0903-4641</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Accumulated evidence has established that aberrant regulation of histone deacetylases (HDACs) is one of the major causes of the development of human malignancies.  Among different isoenzymes of HDAC and sirtuins grouped as the HDAC super family, little is known as to how historic deacetylase 2 (HDAC2) causes carcinogenesis in solid tumors.  Here, in order to investigate the possible role of HDAC2 in gastric carcinogenesis, we analyzed the expression of HDAC2 in 71 gastric adenocarcinomas by immunohistochem.  Moderate to strong expression of HDAC2 was found in 44 (62%) out of a total of 71 tumors.  The majority of pos. tumors, which were detected in the nucleus but not in normal gastric epithelium, did not express HDAC2 or showed only weak pos. staining.  Interestingly, we also noted that HDAC2 expression appeared to be assocd. with tumor aggressiveness as HDAC2 expression was obsd. to be statistically significant in advanced gastric cancer (P=0.0023, Chi-square test) and in pos. lymph node metastasis (P=0.0713, Chi-square test).  Taken together, these results suggest that HDAC2 may play an important role in the aggressiveness of gastric cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyCR3h4ZoipLVg90H21EOLACvtfcHk0liXrzSPgRFiLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltlOjtb0%253D&md5=996e6dc8a3e52e1c12509e8c1f143663</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0463.2005.apm_04.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0463.2005.apm_04.x%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DNoh%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DEun%26aufirst%3DJ.%2BW.%26aulast%3DAhn%26aufirst%3DY.%2BM.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DPark%26aufirst%3DW.%2BS.%26aulast%3DYoo%26aufirst%3DN.%2BJ.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DNam%26aufirst%3DS.%2BW.%26atitle%3DIncreased%2520expression%2520of%2520histone%2520deacetylase%25202%2520is%2520found%2520in%2520human%2520gastric%2520cancer%26jtitle%3DAPMIS%26date%3D2005%26volume%3D113%26spage%3D264%26epage%3D268%26doi%3D10.1111%2Fj.1600-0463.2005.apm_04.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byun, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popova, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">L’Italien, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sowa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arango, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velcich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augenlicht, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariadason, J. M.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">13548</span>– <span class="NLM_lpage">13558</span>, <span class="refDoi"> DOI: 10.1074/jbc.M510023200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1074%2Fjbc.M510023200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16533812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD28Xkt1ymt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=13548-13558&author=A.+J.+Wilsonauthor=D.+S.+Byunauthor=N.+Popovaauthor=L.+B.+Murrayauthor=K.+L%E2%80%99Italienauthor=Y.+Sowaauthor=D.+Arangoauthor=A.+Velcichauthor=L.+H.+Augenlichtauthor=J.+M.+Mariadason&title=Histone+deacetylase+3+%28HDAC3%29+and+other+class+I+HDACs+regulate+colon+cell+maturation+and+p21+expression+and+are+deregulated+in+human+colon+cancer&doi=10.1074%2Fjbc.M510023200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer</span></div><div class="casAuthors">Wilson, Andrew J.; Byun, Do-Sun; Popova, Natalia; Murray, Lucas B.; L'Italien, Kaitlin; Sowa, Yoshihiro; Arango, Diego; Velcich, Anna; Augenlicht, Leonard H.; Mariadason, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">13548-13558</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Inhibitors of histone deacetylases (HDACs) induce growth arrest, differentiation, and apoptosis of colon cancer cell lines in vitro and have demonstrated anti-cancer efficacy in clin. trials.  Whereas a role for HDAC1 and -2 in mediating components of the HDAC inhibitor response has been reported, the role of HDAC3 is unknown.  Here we demonstrate increased protein expression of HDAC3 in human colon tumors and in duodenal adenomas from Apc1638N/+ mice.  HDAC3 was also maximally expressed in proliferating crypt cells in normal intestine.  Silencing of HDAC3 expression in colon cancer cell lines resulted in growth inhibition, a decrease in cell survival, and increased apoptosis.  Similar effects were obsd. for HDAC2 and, to a lesser extent, for HDAC1.  HDAC3 silencing also selectively induced expression of alk. phosphatase, a marker of colon cell maturation.  Concurrent with its effect on cell growth, overexpression of HDAC3 and other Class I HDACs inhibited basal and butyrate-induced p21 transcription in a Sp1/Sp3-dependent manner, whereas silencing of HDAC3 stimulated p21 promoter activity and expression.  However, the magnitude of the effects elicited by silencing of individual Class I HDACs was significantly less than that induced by HDAC inhibitors.  These findings identify HDAC3 as a gene deregulated in human colon cancer and as a novel regulator of colon cell maturation and p21 expression.  These findings also demonstrate that multiple Class I HDACs are involved in repressing p21 and suggest that the growth-inhibitory and apoptotic effects induced by HDAC inhibitors are probably mediated through the inhibition of multiple HDACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3RTpbaBl4gLVg90H21EOLACvtfcHk0liXrzSPgRFiLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xkt1ymt7Y%253D&md5=10da7c0a6ec5fa4fc494716323dece9d</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M510023200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M510023200%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DA.%2BJ.%26aulast%3DByun%26aufirst%3DD.%2BS.%26aulast%3DPopova%26aufirst%3DN.%26aulast%3DMurray%26aufirst%3DL.%2BB.%26aulast%3DL%25E2%2580%2599Italien%26aufirst%3DK.%26aulast%3DSowa%26aufirst%3DY.%26aulast%3DArango%26aufirst%3DD.%26aulast%3DVelcich%26aufirst%3DA.%26aulast%3DAugenlicht%26aufirst%3DL.%2BH.%26aulast%3DMariadason%26aufirst%3DJ.%2BM.%26atitle%3DHistone%2520deacetylase%25203%2520%2528HDAC3%2529%2520and%2520other%2520class%2520I%2520HDACs%2520regulate%2520colon%2520cell%2520maturation%2520and%2520p21%2520expression%2520and%2520are%2520deregulated%2520in%2520human%2520colon%2520cancer%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D13548%26epage%3D13558%26doi%3D10.1074%2Fjbc.M510023200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolden, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peart, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Anticancer activities of histone deacetylase inhibitors</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">769</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1038/nrd2133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnrd2133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16955068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=769-784&author=J.+E.+Boldenauthor=M.+J.+Peartauthor=R.+W.+Johnstone&title=Anticancer+activities+of+histone+deacetylase+inhibitors&doi=10.1038%2Fnrd2133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer activities of histone deacetylase inhibitors</span></div><div class="casAuthors">Bolden, Jessica E.; Peart, Melissa J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">769-784</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are enzymes involved in the remodelling of chromatin, and have a key role in the epigenetic regulation of gene expression.  In addn., the activity of non-histone proteins can be regulated through HDAC-mediated hypo-acetylation.  In recent years, inhibition of HDACs has emerged as a potential strategy to reverse aberrant epigenetic changes assocd. with cancer, and several classes of HDAC inhibitors have been found to have potent and specific anticancer activities in preclin. studies.  However, such studies have also indicated that the effects of HDAC inhibitors could be considerably broader and more complicated than originally understood.  Here we summarize recent advances in the understanding of the mol. events that underlie the anticancer effects of HDAC inhibitors, and discuss how such information could be used in optimizing the development and application of these agents in the clinic, either as monotherapies or in combination with other anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhfqS1awkOHbVg90H21EOLACvtfcHk0liP4SeCUt43Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltrY%253D&md5=91e55ee942fda3e4e2055ddf299fc866</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnrd2133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2133%26sid%3Dliteratum%253Aachs%26aulast%3DBolden%26aufirst%3DJ.%2BE.%26aulast%3DPeart%26aufirst%3DM.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DAnticancer%2520activities%2520of%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D769%26epage%3D784%26doi%3D10.1038%2Fnrd2133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aishima, S.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuneyoshi, M.</span></span> <span> </span><span class="NLM_article-title">Expression profile of class I histone deacetylases in human cancer tissues</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">769</span>– <span class="NLM_lpage">774</span>, <span class="refDoi"> DOI: 10.3892/or.18.4.769</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.3892%2For.18.4.769" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=17786334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFygu7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2007&pages=769-774&author=M.+Nakagawaauthor=Y.+Odaauthor=T.+Eguchiauthor=S.-I.+Aishimaauthor=T.+Yaoauthor=F.+Hosoiauthor=Y.+Basakiauthor=M.+Onoauthor=M.+Kuwanoauthor=M.+Tanakaauthor=M.+Tsuneyoshi&title=Expression+profile+of+class+I+histone+deacetylases+in+human+cancer+tissues&doi=10.3892%2For.18.4.769"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Expression profile of class I histone deacetylases in human cancer tissues</span></div><div class="casAuthors">Nakagawa, Masamune; Oda, Yoshinao; Eguchi, Takashi; Aishima, Shin-Ichi; Yao, Takashi; Hosoi, Fumihito; Basaki, Yuji; Ono, Mayumi; Kuwano, Michihiko; Tanaka, Masao; Tsuneyoshi, Masazumi</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">769-774</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Oncology Reports</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) activity is one of the widely used and well-established mechanisms for regulation of various genes in cancer.  To identify which subtype of class I HDACs are overexpressed in cancers, we analyzed the expression of class I HDAC isotypes composed of HDAC1, 2, 3 and 8 in several cell lines and human cancer tissues, including cancer of the stomach, esophagus, colon, prostate, breast, ovary, lung, pancreas and thyroid.  The results showed that >75% of human cancer tissues and their corresponding non-cancerous epithelium showed high expression of these class I HDACs.  However, the immunoreactivity of HDAC8 in both prostatic cancer tissue and non-cancerous prostate glands was lower than that in other cancer tissues.  Furthermore, 5-40% of cancer tissues overexpressed class I HDACs, when compared with normal epithelium.  The results suggest the potential usefulness of HDAC inhibitors for the treatment of a wide variety of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj0FRA62UIeLVg90H21EOLACvtfcHk0liP4SeCUt43Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFygu7vK&md5=d060cf1947074edc9ca3323e2490165e</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3892%2For.18.4.769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.18.4.769%26sid%3Dliteratum%253Aachs%26aulast%3DNakagawa%26aufirst%3DM.%26aulast%3DOda%26aufirst%3DY.%26aulast%3DEguchi%26aufirst%3DT.%26aulast%3DAishima%26aufirst%3DS.-I.%26aulast%3DYao%26aufirst%3DT.%26aulast%3DHosoi%26aufirst%3DF.%26aulast%3DBasaki%26aufirst%3DY.%26aulast%3DOno%26aufirst%3DM.%26aulast%3DKuwano%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DTsuneyoshi%26aufirst%3DM.%26atitle%3DExpression%2520profile%2520of%2520class%2520I%2520histone%2520deacetylases%2520in%2520human%2520cancer%2520tissues%26jtitle%3DOncol.%2520Rep.%26date%3D2007%26volume%3D18%26spage%3D769%26epage%3D774%26doi%3D10.3892%2For.18.4.769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oehme, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deubzer, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegener, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linke, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hero, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopp-Schneider, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westermann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Deimling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 8 in neuroblastoma tumorigenesis</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-0684</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1078-0432.CCR-08-0684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=19118036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Cjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=91-99&author=I.+Oehmeauthor=H.+E.+Deubzerauthor=D.+Wegenerauthor=D.+Pickertauthor=J.-P.+Linkeauthor=B.+Heroauthor=A.+Kopp-Schneiderauthor=F.+Westermannauthor=S.+M.+Ulrichauthor=A.+von+Deimlingauthor=M.+Fischerauthor=O.+Witt&title=Histone+deacetylase+8+in+neuroblastoma+tumorigenesis&doi=10.1158%2F1078-0432.CCR-08-0684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase 8 in Neuroblastoma Tumorigenesis</span></div><div class="casAuthors">Oehme, Ina; Deubzer, Hedwig E.; Wegener, Dennis; Pickert, Diana; Linke, Jan-Peter; Hero, Barbara; Kopp-Schneider, Annette; Westermann, Frank; Ulrich, Scott M.; von Deimling, Andreas; Fischer, Matthias; Witt, Olaf</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">91-99</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The effects of pan-histone deacetylase (HDAC) inhibitors on cancer cells have shown that HDACs are involved in fundamental tumor biol. processes such as cell cycle control, differentiation, and apoptosis.  However, because of the unselective nature of these compds., little is known about the contribution of individual HDAC family members to tumorigenesis and progression.  The purpose of this study was to evaluate the role of individual HDACs in neuroblastoma tumorigenesis.  Exptl. Design: We have investigated the mRNA expression of all HDAC1-11 family members in a large cohort of primary neuroblastoma samples covering the full spectrum of the disease.  HDACs assocd. with disease stage and survival were subsequently functionally evaluated in cell culture models.  RESULTS: Only HDAC8 expression was significantly correlated with advanced disease and metastasis and down-regulated in stage 4S neuroblastoma assocd. with spontaneous regression.  High HDAC8 expression was assocd. with poor prognostic markers and poor overall and event-free survival.  The knockdown of HDAC8 resulted in the inhibition of proliferation, reduced clonogenic growth, cell cycle arrest, and differentiation in cultured neuroblastoma cells.  The treatment of neuroblastoma cell lines as well as short-term-culture neuroblastoma cells with an HDAC8-selective small-mol. inhibitor inhibited cell proliferation and clone formation, induced differentiation, and thus reproduced the HDAC8 knockdown phenotype.  Global histone 4 acetylation was not affected by HDAC8 knockdown or by selective inhibitor treatment.  CONCLUSIONS: Our data point toward an important role of HDAC8 in neuroblastoma pathogenesis and identify this HDAC family member as a specific drug target for the differentiation therapy of neuroblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsN9HmNgpdA7Vg90H21EOLACvtfcHk0liP4SeCUt43Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Cjuw%253D%253D&md5=8c8e0b989c0036b233332a74a355dece</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0684%26sid%3Dliteratum%253Aachs%26aulast%3DOehme%26aufirst%3DI.%26aulast%3DDeubzer%26aufirst%3DH.%2BE.%26aulast%3DWegener%26aufirst%3DD.%26aulast%3DPickert%26aufirst%3DD.%26aulast%3DLinke%26aufirst%3DJ.-P.%26aulast%3DHero%26aufirst%3DB.%26aulast%3DKopp-Schneider%26aufirst%3DA.%26aulast%3DWestermann%26aufirst%3DF.%26aulast%3DUlrich%26aufirst%3DS.%2BM.%26aulast%3Dvon%2BDeimling%26aufirst%3DA.%26aulast%3DFischer%26aufirst%3DM.%26aulast%3DWitt%26aufirst%3DO.%26atitle%3DHistone%2520deacetylase%25208%2520in%2520neuroblastoma%2520tumorigenesis%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D91%26epage%3D99%26doi%3D10.1158%2F1078-0432.CCR-08-0684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Girija, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steven, G.</span></span> <span> </span><span class="NLM_article-title">Retraction: synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4959</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-1914</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1078-0432.CCR-16-1914" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=27697993" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=4959&author=D.+Girijaauthor=Y.+Nitinauthor=D.+Yunauthor=D.+Paulauthor=G.+Steven&title=Retraction%3A+synergistic+interactions+between+vorinostat+and+sorafenib+in+chronic+myelogenous+leukemia+cells+involve+Mcl-1+and+p21CIP1+down-regulation&doi=10.1158%2F1078-0432.CCR-16-1914"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-1914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-1914%26sid%3Dliteratum%253Aachs%26aulast%3DGirija%26aufirst%3DD.%26aulast%3DNitin%26aufirst%3DY.%26aulast%3DYun%26aufirst%3DD.%26aulast%3DPaul%26aufirst%3DD.%26aulast%3DSteven%26aufirst%3DG.%26atitle%3DRetraction%253A%2520synergistic%2520interactions%2520between%2520vorinostat%2520and%2520sorafenib%2520in%2520chronic%2520myelogenous%2520leukemia%2520cells%2520involve%2520Mcl-1%2520and%2520p21CIP1%2520down-regulation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D4959%26doi%3D10.1158%2F1078-0432.CCR-16-1914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernatchez, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span> <span> </span><span class="NLM_article-title">Kinase and histone deacetylase hybrid inhibitors for cancer therapy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3171</span>– <span class="NLM_lpage">3183</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00189</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00189" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFKntbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3171-3183&author=Y.+Luanauthor=J.+Liauthor=J.+A.+Bernatchezauthor=R.+Li&title=Kinase+and+histone+deacetylase+hybrid+inhibitors+for+cancer+therapy&doi=10.1021%2Facs.jmedchem.8b00189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy</span></div><div class="casAuthors">Luan, Yepeng; Li, Jerry; Bernatchez, Jean A.; Li, Rongshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3171-3183</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs), encompassing at least 18 members, are promising targets for anticancer drug discovery and development.  To date, five histone deacetylase inhibitors (HDACis) have been approved for cancer treatment, and numerous others are undergoing clin. trials.  It has been well validated that an agent that can simultaneously and effectively inhibit two or more targets may offer greater therapeutic benefits over single-acting agents in preventing resistance to treatment and in potentiating synergistic effects.  A prime example of a bifunctional agent is the hybrid HDAC inhibitor.  In this perspective, the authors review the majority of reported kinase/HDAC hybrid inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvS3FgFwT7r7Vg90H21EOLACvtfcHk0lg7fjXx2PkT-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFKntbnF&md5=a75c9578b68044a0f702bbf901c3cdcf</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00189%26sid%3Dliteratum%253Aachs%26aulast%3DLuan%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DBernatchez%26aufirst%3DJ.%2BA.%26aulast%3DLi%26aufirst%3DR.%26atitle%3DKinase%2520and%2520histone%2520deacetylase%2520hybrid%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3171%26epage%3D3183%26doi%3D10.1021%2Facs.jmedchem.8b00189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walther, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, C.</span></span> <span> </span><span class="NLM_article-title">Lysine acetylation targets protein complexes and co-regulates major cellular functions</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>325</i></span>,  <span class="NLM_fpage">834</span>– <span class="NLM_lpage">840</span>, <span class="refDoi"> DOI: 10.1126/science.1175371</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1126%2Fscience.1175371" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=19608861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXps1Ogt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=325&publication_year=2009&pages=834-840&author=C.+Kumarauthor=F.+Gnadauthor=M.+L.+Nielsenauthor=M.+Rehmanauthor=T.+C.+Waltherauthor=J.+V.+Olsenauthor=M.+Mannauthor=C.+Choudhary&title=Lysine+acetylation+targets+protein+complexes+and+co-regulates+major+cellular+functions&doi=10.1126%2Fscience.1175371"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions</span></div><div class="casAuthors">Choudhary, Chunaram; Kumar, Chanchal; Gnad, Florian; Nielsen, Michael L.; Rehman, Michael; Walther, Tobias C.; Olsen, Jesper V.; Mann, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">325</span>
        (<span class="NLM_cas:issue">5942</span>),
    <span class="NLM_cas:pages">834-840</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Lysine acetylation is a reversible posttranslational modification of proteins and plays a key role in regulating gene expression.  Technol. limitations have so far prevented a global anal. of lysine acetylation's cellular roles.  We used high-resoln. mass spectrometry to identify 3600 lysine acetylation sites on 1750 proteins and quantified acetylation changes in response to the deacetylase inhibitors suberoylanilide hydroxamic acid and MS-275.  Lysine acetylation preferentially targets large macromol. complexes involved in diverse cellular processes, such as chromatin remodeling, cell cycle, splicing, nuclear transport, and actin nucleation.  Acetylation impaired phosphorylation-dependent interactions of 14-3-3 and regulated the yeast cyclin-dependent kinase Cdc28.  Our data demonstrate that the regulatory scope of lysine acetylation is broad and comparable with that of other major posttranslational modifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5eICW58ngkrVg90H21EOLACvtfcHk0lg7fjXx2PkT-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXps1Ogt70%253D&md5=8f643db5ba91c50f0b61763ff3095d2c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1126%2Fscience.1175371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1175371%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DC.%26aulast%3DGnad%26aufirst%3DF.%26aulast%3DNielsen%26aufirst%3DM.%2BL.%26aulast%3DRehman%26aufirst%3DM.%26aulast%3DWalther%26aufirst%3DT.%2BC.%26aulast%3DOlsen%26aufirst%3DJ.%2BV.%26aulast%3DMann%26aufirst%3DM.%26aulast%3DChoudhary%26aufirst%3DC.%26atitle%3DLysine%2520acetylation%2520targets%2520protein%2520complexes%2520and%2520co-regulates%2520major%2520cellular%2520functions%26jtitle%3DScience%26date%3D2009%26volume%3D325%26spage%3D834%26epage%3D840%26doi%3D10.1126%2Fscience.1175371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vakoc, C. R.</span></span> <span> </span><span class="NLM_article-title">The mechanisms behind the therapeutic activity of BET bromodomain inhibition</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">728</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2014.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.molcel.2014.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=24905006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslCrtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2014&pages=728-736&author=J.+Shiauthor=C.+R.+Vakoc&title=The+mechanisms+behind+the+therapeutic+activity+of+BET+bromodomain+inhibition&doi=10.1016%2Fj.molcel.2014.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition</span></div><div class="casAuthors">Shi, Junwei; Vakoc, Christopher R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">728-736</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The bromodomain and extraterminal (BET) protein Brd4 recruits transcriptional regulatory complexes to acetylated chromatin.  While Brd4 is considered to be a general transcriptional regulator, pharmacol. inhibition of BET proteins shows therapeutic activity in a variety of different pathologies, particularly in models of cancer and inflammation.  Such effects have been attributed to a specific set of downstream target genes whose expression is disproportionately sensitive to pharmacol. targeting of BET proteins.  Emerging evidence links the transcriptional consequences of BET inhibition to the assocn. of Brd4 with enhancer elements, which tend to be involved in lineage-specific gene regulation.  Furthermore, Brd4 engages in direct regulatory interactions with several DNA-binding transcription factors to influence their disease-relevant functions.  Here we review the current understanding of mol. mechanisms that underlie the promising therapeutic effects of BET bromodomain inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJpSFRzwcR1rVg90H21EOLACvtfcHk0li5aIAqNpYkxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslCrtrk%253D&md5=f49bf3524ec378576fb1a25c64a464ae</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2014.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2014.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DVakoc%26aufirst%3DC.%2BR.%26atitle%3DThe%2520mechanisms%2520behind%2520the%2520therapeutic%2520activity%2520of%2520BET%2520bromodomain%2520inhibition%26jtitle%3DMol.%2520Cell%26date%3D2014%26volume%3D54%26spage%3D728%26epage%3D736%26doi%3D10.1016%2Fj.molcel.2014.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. C.</span></span> <span> </span><span class="NLM_article-title">HDAC inhibition decreases the expression of EGFR in colorectal cancer cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">e18087</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0018087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1371%2Fjournal.pone.0018087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=21464950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksVyjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e18087&author=C.+W.+Chouauthor=M.+S.+Wuauthor=W.+C.+Huangauthor=C.+C.+Chen&title=HDAC+inhibition+decreases+the+expression+of+EGFR+in+colorectal+cancer+cells&doi=10.1371%2Fjournal.pone.0018087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibition decreases the expression of EGFR in colorectal cancer cells</span></div><div class="casAuthors">Chou, Chia-Wei; Wu, Ming-Shiang; Huang, Wei-Chien; Chen, Ching-Chow</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e18087</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR), a receptor tyrosine kinase which promotes cell proliferation and survival, is abnormally overexpressed in numerous tumors of epithelial origin, including colorectal cancer (CRC).  EGFR monoclonal antibodies have been shown to increase the median survival and are approved for the treatment of colorectal cancer.  Histone deacetylases (HDACs), frequently overexpressed in colorectal cancer and several malignancies, are another attractive targets for cancer therapy.  Several inhibitors of HDACs (HDACi) are developed and exhibit powerful antitumor abilities.  In this study, human colorectal cancer cells treated with HDACi exhibited reduced EGFR expression, thereby disturbed EGF-induced ERK and Akt phosphorylation.  HDACi also decreased the expression of SGLT1, an active glucose transporter found to be stabilized by EGFR, and suppressed the glucose uptake of cancer cells.  HDACi suppressed the transcription of EGFR and class I HDACs were proved to be involved in this event.  Chromatin immunopptn. anal. showed that HDACi caused the dissocn. of SP1, HDAC3 and CBP from EGFR promoter.  Our data suggested that HDACi could serve as a single agent to block both EGFR and HDAC, and may bring more benefits to the development of CRC therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcexosDg835LVg90H21EOLACvtfcHk0lifP5gkKNz90Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksVyjsLs%253D&md5=925c960c49e2635aa3bba8af16ccc9de</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0018087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0018087%26sid%3Dliteratum%253Aachs%26aulast%3DChou%26aufirst%3DC.%2BW.%26aulast%3DWu%26aufirst%3DM.%2BS.%26aulast%3DHuang%26aufirst%3DW.%2BC.%26aulast%3DChen%26aufirst%3DC.%2BC.%26atitle%3DHDAC%2520inhibition%2520decreases%2520the%2520expression%2520of%2520EGFR%2520in%2520colorectal%2520cancer%2520cells%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De18087%26doi%3D10.1371%2Fjournal.pone.0018087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cecchini, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuck, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. H.</span></span> <span> </span><span class="NLM_article-title">HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">2828</span>– <span class="NLM_lpage">2835</span>, <span class="refDoi"> DOI: 10.1038/onc.2013.32</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fonc.2013.32" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=23435418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivFyqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=2828-2835&author=Y.+J.+Kimauthor=C.+B.+Greerauthor=K.+R.+Cecchiniauthor=L.+N.+Harrisauthor=D.+P.+Tuckauthor=T.+H.+Kim&title=HDAC+inhibitors+induce+transcriptional+repression+of+high+copy+number+genes+in+breast+cancer+through+elongation+blockade&doi=10.1038%2Fonc.2013.32"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade</span></div><div class="casAuthors">Kim, Y. J.; Greer, C. B.; Cecchini, K. R.; Harris, L. N.; Tuck, D. P.; Kim, T. H.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2828-2835</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Treatment with histone deacetylase inhibitors (HDACI) results in potent cytotoxicity of a variety of cancer cell types, and these drugs are used clin. to treat hematol. tumors.  They are known to repress the transcription of ERBB2 and many other oncogenes, but little is known about this mechanism.  Using global run-on sequencing (GRO-seq) to measure nascent transcription, we find that HDACI cause transcriptional repression by blocking RNA polymerase II elongation.  Our data show that HDACI preferentially repress the transcription of highly expressed genes as well as high copy no. genes in HER2+ breast cancer genomes.  In contrast, genes that are activated by HDACI are moderately expressed.  We analyzed gene copy no. in combination with microarray and GRO-seq anal. of expression level, in normal and breast cancer cells to show that high copy no. genes are more likely to be repressed by HDACI than non-amplified genes.  The inhibition of transcription of amplified oncogenes, which promote survival and proliferation of cancer cells, might explain the cancer-specific lethality of HDACI, and may represent a general therapeutic strategy for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH0C0OvnRkgrVg90H21EOLACvtfcHk0ljgzoBjQ7Ugow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivFyqtL0%253D&md5=d258aa06c9c5281dd3507fc0cd178046</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fonc.2013.32&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2013.32%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%2BJ.%26aulast%3DGreer%26aufirst%3DC.%2BB.%26aulast%3DCecchini%26aufirst%3DK.%2BR.%26aulast%3DHarris%26aufirst%3DL.%2BN.%26aulast%3DTuck%26aufirst%3DD.%2BP.%26aulast%3DKim%26aufirst%3DT.%2BH.%26atitle%3DHDAC%2520inhibitors%2520induce%2520transcriptional%2520repression%2520of%2520high%2520copy%2520number%2520genes%2520in%2520breast%2520cancer%2520through%2520elongation%2520blockade%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26spage%3D2828%26epage%3D2835%26doi%3D10.1038%2Fonc.2013.32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sancisi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandolfi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrosetti, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciarrocchi, A.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors repress tumoral expression of the proinvasive factor RUNX2</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">1868</span>– <span class="NLM_lpage">1882</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-2087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F0008-5472.CAN-14-2087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25769725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnsFels7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1868-1882&author=V.+Sancisiauthor=G.+Gandolfiauthor=D.+C.+Ambrosettiauthor=A.+Ciarrocchi&title=Histone+deacetylase+inhibitors+repress+tumoral+expression+of+the+proinvasive+factor+RUNX2&doi=10.1158%2F0008-5472.CAN-14-2087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitors Repress Tumoral Expression of the Proinvasive Factor RUNX2</span></div><div class="casAuthors">Sancisi, Valentina; Gandolfi, Greta; Ambrosetti, Davide Carlo; Ciarrocchi, Alessia</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1868-1882</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">These findings offer evidence that the cytotoxic activity of HDAC inhibitors against cancer cells relies not only on reactivating silenced tumor suppressor functions, as widely thought, but also on silencing oncogenes that drive cell survival and malignant progression.  Aberrant reactivation of embryonic pathways occurs commonly in cancer.  The transcription factor RUNX2 plays a fundamental role during embryogenesis and is aberrantly reactivated during progression and metastasization of different types of human tumors.  In this study, we attempted to dissect the mol. mechanisms governing RUNX2 expression and its aberrant reactivation.  We identified a new regulatory enhancer element, located within the RUNX2 gene, which is responsible for the activation of the RUNX2 promoter and for the regulation of its expression in cancer cells.  Furthermore, we have shown that treatment with the anticancer compds. histone deacetylase inhibitor (HDACi) results in a profound inhibition of RUNX2 expression, which is detd. by the disruption of the transcription-activating complex on the identified enhancer.  These data envisage a possible targeting strategy to counteract the oncongenic function of RUNX2 in cancer cells and provide evidence that the cytotoxic activity of HDACi in cancer is not only dependent on the reactivation of silenced oncosuppressors but also on the repression of oncogenic factors that are necessary for survival and progression.  Cancer Res; 75(9); 1868-82. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3b4i_IaNlQ7Vg90H21EOLACvtfcHk0lhxTgcdYyYdIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnsFels7c%253D&md5=6d71d5f69c54b4396a419e490bff5c01</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-2087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-2087%26sid%3Dliteratum%253Aachs%26aulast%3DSancisi%26aufirst%3DV.%26aulast%3DGandolfi%26aufirst%3DG.%26aulast%3DAmbrosetti%26aufirst%3DD.%2BC.%26aulast%3DCiarrocchi%26aufirst%3DA.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520repress%2520tumoral%2520expression%2520of%2520the%2520proinvasive%2520factor%2520RUNX2%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D1868%26epage%3D1882%26doi%3D10.1158%2F0008-5472.CAN-14-2087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schones, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, K.</span></span> <span> </span><span class="NLM_article-title">Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">1019</span>– <span class="NLM_lpage">1031</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.06.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.cell.2009.06.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=19698979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVCjs7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2009&pages=1019-1031&author=Z.+Wangauthor=C.+Zangauthor=K.+Cuiauthor=D.+E.+Schonesauthor=A.+Barskiauthor=W.+Pengauthor=K.+Zhao&title=Genome-wide+mapping+of+HATs+and+HDACs+reveals+distinct+functions+in+active+and+inactive+genes&doi=10.1016%2Fj.cell.2009.06.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes</span></div><div class="casAuthors">Wang, Zhibin; Zang, Chongzhi; Cui, Kairong; Schones, Dustin E.; Barski, Artem; Peng, Weiqun; Zhao, Keji</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1019-1031</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Histone acetyltransferases (HATs) and deacetylases (HDACs) function antagonistically to control histone acetylation.  As acetylation is a histone mark for active transcription, HATs have been assocd. with active and HDACs with inactive genes.  We describe here genome-wide mapping of HATs and HDACs binding on chromatin and find that both are found at active genes with acetylated histones.  Our data provide evidence that HATs and HDACs are both targeted to transcribed regions of active genes by phosphorylated RNA Pol II.  Furthermore, the majority of HDACs in the human genome function to reset chromatin by removing acetylation at active genes.  Inactive genes that are primed by MLL-mediated histone H3K4 methylation are subject to a dynamic cycle of acetylation and deacetylation by transient HAT/HDAC binding, preventing Pol II from binding to these genes but poising them for future activation.  Silent genes without any H3K4 methylation signal show no evidence of being bound by HDACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA44omJCFXPLVg90H21EOLACvtfcHk0ljg32jFBdRqMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVCjs7zK&md5=9cd3ba7ed87fd21765dc8e250cd4939f</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.06.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.06.049%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZang%26aufirst%3DC.%26aulast%3DCui%26aufirst%3DK.%26aulast%3DSchones%26aufirst%3DD.%2BE.%26aulast%3DBarski%26aufirst%3DA.%26aulast%3DPeng%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DK.%26atitle%3DGenome-wide%2520mapping%2520of%2520HATs%2520and%2520HDACs%2520reveals%2520distinct%2520functions%2520in%2520active%2520and%2520inactive%2520genes%26jtitle%3DCell%26date%3D2009%26volume%3D138%26spage%3D1019%26epage%3D1031%26doi%3D10.1016%2Fj.cell.2009.06.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donati, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciarrocchi, A.</span></span> <span> </span><span class="NLM_article-title">BRD4 and cancer: going beyond transcriptional regulation</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1186/s12943-018-0915-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1186%2Fs12943-018-0915-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=30466442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlWgu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=164-166&author=B.+Donatiauthor=E.+Lorenziniauthor=A.+Ciarrocchi&title=BRD4+and+cancer%3A+going+beyond+transcriptional+regulation&doi=10.1186%2Fs12943-018-0915-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">BRD4 and Cancer: going beyond transcriptional regulation</span></div><div class="casAuthors">Donati, Benedetta; Lorenzini, Eugenia; Ciarrocchi, Alessia</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">164</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  BRD4, member of the Bromodomain and Extraterminal (BET) protein family, is largely acknowledged in cancer for its role in super-enhancers (SEs) organization and oncogenes expression regulation.  Inhibition of BRD4 shortcuts the communication between SEs and target promoters with a subsequent cell-specific repression of oncogenes to which cancer cells are addicted and cell death.  To date, this is the most credited mechanism of action of BET inhibitors, a class of small mols. targeting BET proteins which are currently in clin. trials in several cancer settings.  However, recent evidence indicates that BRD4 relevance in cancer goes beyond its role in transcription regulation and identifies this protein as a keeper of genome stability.  Indeed, a non-transcriptional role of BRD4 in controlling DNA damage checkpoint activation and repair as well as telomere maintenance has been proposed, throwing new lights into the multiple functions of this protein and opening new perspectives on the use of BETi in cancer.  Here we discuss the current available information on non-canonical, non-transcriptional functions of BRD4 and on their implications in cancer biol.  Integrating this information with the already known BRD4 role in gene expression regulation, we propose a "common" model to explain BRD4 genomic function.  Furthermore, in light of the transversal function of BRD4, we provide new interpretation for the cytotoxic activity of BETi and we discuss new possibilities for a wide and focused employment of these drugs in clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbYn0mnQW7ELVg90H21EOLACvtfcHk0lhyp8sy1-pQ5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlWgu78%253D&md5=2ddfde1363d430aa67e15a52fdc2335e</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1186%2Fs12943-018-0915-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-018-0915-9%26sid%3Dliteratum%253Aachs%26aulast%3DDonati%26aufirst%3DB.%26aulast%3DLorenzini%26aufirst%3DE.%26aulast%3DCiarrocchi%26aufirst%3DA.%26atitle%3DBRD4%2520and%2520cancer%253A%2520going%2520beyond%2520transcriptional%2520regulation%26jtitle%3DMol.%2520Cancer%26date%3D2018%26volume%3D17%26spage%3D164%26epage%3D166%26doi%3D10.1186%2Fs12943-018-0915-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeRoy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, S. R</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahedi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heightman, T. D</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, B. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siebenlist, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozato, K.</span></span> <span> </span><span class="NLM_article-title">BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1047</span>– <span class="NLM_lpage">1057</span>, <span class="refDoi"> DOI: 10.1038/nsmb.2912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnsmb.2912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25383670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKlsr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=1047-1057&author=T.+Kannoauthor=Y.+Kannoauthor=G.+LeRoyauthor=E.+Camposauthor=H.-W.+Sunauthor=S.+R+Brooksauthor=G.+Vahediauthor=T.+D+Heightmanauthor=B.+A+Garciaauthor=D.+Reinbergauthor=U.+Siebenlistauthor=J.+J+O%E2%80%99Sheaauthor=K.+Ozato&title=BRD4+assists+elongation+of+both+coding+and+enhancer+RNAs+by+interacting+with+acetylated+histones&doi=10.1038%2Fnsmb.2912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones</span></div><div class="casAuthors">Kanno, Tomohiko; Kanno, Yuka; LeRoy, Gary; Campos, Eric; Sun, Hong-Wei; Brooks, Stephen R.; Vahedi, Golnaz; Heightman, Tom D.; Garcia, Benjamin A.; Reinberg, Danny; Siebenlist, Ulrich; O'Shea, John J.; Ozato, Keiko</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1047-1057</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. BET inhibitors interfere with the epigenetic interactions between acetylated histones and the bromodomains of the BET family proteins, including BRD4, and they potently inhibit growth of malignant cells by targeting cancer-promoting genes.  BRD4 interacts with the pause-release factor P-TEFb and has been proposed to release RNA polymerase II (Pol II) from promoter-proximal pausing.  We show that BRD4 occupies widespread genomic regions in mouse cells and directly stimulates elongation of both protein-coding transcripts and noncoding enhancer RNAs (eRNAs), in a manner dependent on bromodomain function.  BRD4 interacts with elongating Pol II complexes and assists Pol II in progression through hyperacetylated nucleosomes by interacting with acetylated histones via bromodomains.  On active enhancers, the BET inhibitor JQ1 antagonizes BRD4-assocd. eRNA synthesis.  Thus, BRD4 is involved in multiple steps of the transcription hierarchy, primarily by facilitating transcript elongation both at enhancers and on gene bodies independently of P-TEFb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkL9lfCmfYM7Vg90H21EOLACvtfcHk0lhyp8sy1-pQ5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKlsr7I&md5=e568fe18fac3fe96de1962ffb7dab897</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2912%26sid%3Dliteratum%253Aachs%26aulast%3DKanno%26aufirst%3DT.%26aulast%3DKanno%26aufirst%3DY.%26aulast%3DLeRoy%26aufirst%3DG.%26aulast%3DCampos%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DH.-W.%26aulast%3DBrooks%26aufirst%3DS.%2BR%26aulast%3DVahedi%26aufirst%3DG.%26aulast%3DHeightman%26aufirst%3DT.%2BD%26aulast%3DGarcia%26aufirst%3DB.%2BA%26aulast%3DReinberg%26aufirst%3DD.%26aulast%3DSiebenlist%26aufirst%3DU.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ%26aulast%3DOzato%26aufirst%3DK.%26atitle%3DBRD4%2520assists%2520elongation%2520of%2520both%2520coding%2520and%2520enhancer%2520RNAs%2520by%2520interacting%2520with%2520acetylated%2520histones%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2014%26volume%3D21%26spage%3D1047%26epage%3D1057%26doi%3D10.1038%2Fnsmb.2912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, H.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J.</span></span> <span> </span><span class="NLM_article-title">Regulation of P-TEFb elongation complex activity by CDK9 acetylation</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4641</span>– <span class="NLM_lpage">4651</span>, <span class="refDoi"> DOI: 10.1128/MCB.00857-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1128%2FMCB.00857-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=17452463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsVWrs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=4641-4651&author=J.+Fuauthor=H.-G.+Yoonauthor=J.+Qinauthor=J.+Wong&title=Regulation+of+P-TEFb+elongation+complex+activity+by+CDK9+acetylation&doi=10.1128%2FMCB.00857-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of P-TEFb elongation complex activity by CDK9 acetylation</span></div><div class="casAuthors">Fu, Junjiang; Yoon, Ho-Geun; Qin, Jun; Wong, Jiemin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4641-4651</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">P-TEFb, comprised of CDK9 and a cyclin T subunit, is a global transcriptional elongation factor important for most RNA polymerase II (pol II) transcription.  P-TEFb facilitates transcription elongation in part by phosphorylating Ser2 of the heptapeptide repeat of the carboxy-terminal domain (CTD) of the largest subunit of pol II.  Previous studies have shown that P-TEFb is subjected to neg. regulation by forming an inactive complex with 7SK small RNA and HEXIM1.  In an effort to investigate the mol. mechanism by which corepressor N-CoR mediates transcription repression, we identified HEXIM1 as an N-CoR-interacting protein.  This finding led us to test whether the P-TEFb complex is regulated by acetylation.  We demonstrate that CDK9 is an acetylated protein in cells and can be acetylated by p300 in vitro.  Through both in vitro and in vivo assays, we identified lysine 44 of CDK9 as a major acetylation site.  We present evidence that CDK9 is regulated by N-CoR and its assocd. HDAC3 and that acetylation of CDK9 affects its ability to phosphorylate the CTD of pol II.  These results suggest that acetylation of CDK9 is an important posttranslational modification that is involved in regulating P-TEFb transcriptional elongation function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1MWK4pAUTKrVg90H21EOLACvtfcHk0lhyp8sy1-pQ5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsVWrs7c%253D&md5=24a3b35574a6f126baa8bcd4a1fd62a8</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1128%2FMCB.00857-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00857-06%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DYoon%26aufirst%3DH.-G.%26aulast%3DQin%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DJ.%26atitle%3DRegulation%2520of%2520P-TEFb%2520elongation%2520complex%2520activity%2520by%2520CDK9%2520acetylation%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2007%26volume%3D27%26spage%3D4641%26epage%3D4651%26doi%3D10.1128%2FMCB.00857-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buob, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jobst, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rascle, A.</span></span> <span> </span><span class="NLM_article-title">Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">3524</span>– <span class="NLM_lpage">3545</span>, <span class="refDoi"> DOI: 10.1093/nar/gkv188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1093%2Fnar%2Fgkv188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25769527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFaisbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=3524-3545&author=S.+Pinzauthor=S.+Unserauthor=D.+Buobauthor=P.+Fischerauthor=B.+Jobstauthor=A.+Rascle&title=Deacetylase+inhibitors+repress+STAT5-mediated+transcription+by+interfering+with+bromodomain+and+extra-terminal+%28BET%29+protein+function&doi=10.1093%2Fnar%2Fgkv188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function</span></div><div class="casAuthors">Pinz, Sophia; Unser, Samy; Buob, Dominik; Fischer, Philipp; Jobst, Belinda; Rascle, Anne</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3524-3545</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription STAT5 is essential for the regulation of proliferation and survival genes.  Its activity is tightly regulated through cytokine signaling and is often upregulated in cancer.  The authors showed previously that the deacetylase inhibitor trichostatin A (TSA) inhibits STAT5-mediated transcription by preventing recruitment of the transcriptional machinery at a step following STAT5 binding to DNA.  The mechanism and factors involved in this inhibition remain unknown.  The authors now show that deacetylase inhibitors do not target STAT5 acetylation, as the authors initially hypothesized.  Instead, they induce a rapid increase in global histone acetylation apparently resulting in the delocalization of the bromodomain and extra-terminal (BET) protein Brd2 and of the Brd2-assocd. factor TBP to hyperacetylated chromatin.  Treatment with the BET inhibitor (+)-JQ1 inhibited expression of STAT5 target genes, supporting a role of BET proteins in the regulation of STAT5 activity.  Accordingly, chromatin immunopptn. demonstrated that Brd2 is assocd. with the transcriptionally active STAT5 target gene Cis and is displaced upon TSA treatment.  The authors' data therefore indicate that Brd2 is required for the proper recruitment of the transcriptional machinery at STAT5 target genes and that deacetylase inhibitors suppress STAT5-mediated transcription by interfering with Brd2 function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5x3UBMqg6VbVg90H21EOLACvtfcHk0li_Byoq8Yedew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFaisbjE&md5=b97274a797559912f296ab19fd7975e9</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkv188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkv188%26sid%3Dliteratum%253Aachs%26aulast%3DPinz%26aufirst%3DS.%26aulast%3DUnser%26aufirst%3DS.%26aulast%3DBuob%26aufirst%3DD.%26aulast%3DFischer%26aufirst%3DP.%26aulast%3DJobst%26aufirst%3DB.%26aulast%3DRascle%26aufirst%3DA.%26atitle%3DDeacetylase%2520inhibitors%2520repress%2520STAT5-mediated%2520transcription%2520by%2520interfering%2520with%2520bromodomain%2520and%2520extra-terminal%2520%2528BET%2529%2520protein%2520function%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2015%26volume%3D43%26spage%3D3524%26epage%3D3545%26doi%3D10.1093%2Fnar%2Fgkv188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span> <span> </span><span class="NLM_article-title">Histone cross-talk connects protein phosphatase 1α (PP1α) and histone deacetylase (HDAC) pathways to regulate the functional transition of bromodomain-containing 4 (BRD4) for inducible gene expression</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">23154</span>– <span class="NLM_lpage">23167</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.570812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1074%2Fjbc.M114.570812" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=24939842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlGmtbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=23154-23167&author=X.+Huauthor=X.+Luauthor=R.+Liuauthor=N.+Aiauthor=Z.+Caoauthor=Y.+Liauthor=J.+Liuauthor=B.+Yuauthor=K.+Liuauthor=H.+Wangauthor=C.+Zhouauthor=Y.+Wangauthor=A.+Hanauthor=F.+Dingauthor=R.+Chen&title=Histone+cross-talk+connects+protein+phosphatase+1%CE%B1+%28PP1%CE%B1%29+and+histone+deacetylase+%28HDAC%29+pathways+to+regulate+the+functional+transition+of+bromodomain-containing+4+%28BRD4%29+for+inducible+gene+expression&doi=10.1074%2Fjbc.M114.570812"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Histone cross-talk connects protein phosphatase 1α (PP1α) and histone deacetylase (HDAC) pathways to regulate the functional transition of bromodomain-containing 4 (BRD4) for inducible gene expression</span></div><div class="casAuthors">Hu, Xiangming; Lu, Xiaodong; Liu, Runzhong; Ai, Nanping; Cao, Zhenhua; Li, Yannan; Liu, Jiangfang; Yu, Bin; Liu, Kai; Wang, Huiping; Zhou, Chao; Wang, Yu; Han, Aidong; Ding, Feng; Chen, Ruichuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">23154-23167</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Transcription elongation has been recognized as a rate-limiting step for the expression of signal-inducible genes.  Through recruitment of pos. transcription elongation factor P-TEFb, the bromodomain-contg. protein BRD4 plays crit. roles in regulating the transcription elongation of a vast array of inducible genes that are important for multiple cellular processes.  The diverse biol. roles of BRD4 have been proposed to rely on its functional transition between chromatin targeting and transcription regulation.  The signaling pathways and the mol. mechanism for regulating this transition process, however, are largely unknown.  Here, the authors report a novel role of phosphorylated Ser10 of histone H3 (H3S10ph) in governing the functional transition of BRD4.  The authors identified that the acetylated lysines 5 and 8 of nucleosomal histone H4 (H4K5ac/K8ac) is the BRD4 binding site, and the protein phosphatase PP1α and class I histone deacetylase (HDAC1/2/3) signaling pathways are essential for the stress-induced BRD4 release from chromatin.  In the unstressed state, phosphorylated H3S10 prevents the deacetylation of nucleosomal H4K5ac/K8ac by HDAC1/2/3, thereby locking up the majority of BRD4 onto chromatin.  Upon stress, PP1α-mediated dephosphorylation of H3S10ph allows the deacetylation of nucleosomal H4K5ac/K8ac by HDAC1/2/3, thereby leading to the release of chromatin-bound BRD4 for subsequent recruitment of P-TEFb to enhance the expression of inducible genes.  Therefore, this study revealed a novel mechanism that the histone cross-talk between H3S10ph and H4K5ac/K8ac connects PP1α and HDACs to govern the functional transition of BRD4.  Combined with previous studies on the regulation of P-TEFb activation, the intricate signaling network for the tight control of transcription elongation is established.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLzn-a41szPbVg90H21EOLACvtfcHk0li_Byoq8Yedew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlGmtbjI&md5=b3b79f952cd57bffe39c6d563d564669</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.570812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.570812%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DAi%26aufirst%3DN.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DA.%26aulast%3DDing%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DR.%26atitle%3DHistone%2520cross-talk%2520connects%2520protein%2520phosphatase%25201%25CE%25B1%2520%2528PP1%25CE%25B1%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520pathways%2520to%2520regulate%2520the%2520functional%2520transition%2520of%2520bromodomain-containing%25204%2520%2528BRD4%2529%2520for%2520inducible%2520gene%2520expression%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D23154%26epage%3D23167%26doi%3D10.1074%2Fjbc.M114.570812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Targeting epigenetic reader and eraser: rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2931</span>– <span class="NLM_lpage">2935</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.04.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bmcl.2016.04.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=27142751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC28XntFCmt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2931-2935&author=Z.+Zhangauthor=S.+Houauthor=H.+Chenauthor=T.+Ranauthor=F.+Jiangauthor=Y.+Bianauthor=D.+Zhangauthor=Y.+Zhiauthor=L.+Wangauthor=L.+Zhangauthor=H.+Liauthor=Y.+Zhangauthor=W.+Tangauthor=T.+Luauthor=Y.+Chen&title=Targeting+epigenetic+reader+and+eraser%3A+rational+design%2C+synthesis+and+in+vitro+evaluation+of+dimethylisoxazoles+derivatives+as+BRD4%2FHDAC+dual+inhibitors&doi=10.1016%2Fj.bmcl.2016.04.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors</span></div><div class="casAuthors">Zhang, Zhimin; Hou, Shaohua; Chen, Hongli; Ran, Ting; Jiang, Fei; Bian, Yuanyuan; Zhang, Dewei; Zhi, Yanle; Wang, Lu; Zhang, Li; Li, Hongmei; Zhang, Yanmin; Tang, Weifang; Lu, Tao; Chen, Yadong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2931-2935</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The bromodomain protein module and histone deacetylase (HDAC), which recognize and remove acetylated lysine, resp., have emerged as important epigenetic therapeutic targets in cancer treatments.  Herein the authors presented a novel design approach for cancer drug development by combination of bromodomain and HDAC inhibitory activity in one mol.  The designed compds. were synthesized which showed inhibitory activity against bromodomain 4 and HDAC1.  The representative dual bromodomain/HDAC inhibitors, compds. N1-(3-benzoyl-5-(3,5-dimethylisoxazol-4-yl)phenyl)-N7-hydroxyheptanediamide and N1-(3-benzoyl-5-(3,5-dimethylisoxazol-4-yl)phenyl)-N8-hydroxyoctanediamide showed potent antiproliferative activities against human leukemia cell line K562 and MV4-11 in cellular assays.  This work may lay the foundation for developing dual bromodomain/HDAC inhibitors as potential anticancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriS0VB1G-QoLVg90H21EOLACvtfcHk0lgPxAi16nrB1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntFCmt7o%253D&md5=a6ebdbd6402e3117a2f9d96ed071790c</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.04.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.04.034%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DHou%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DRan%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DBian%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DZhi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DTargeting%2520epigenetic%2520reader%2520and%2520eraser%253A%2520rational%2520design%252C%2520synthesis%2520and%2520in%2520vitro%2520evaluation%2520of%2520dimethylisoxazoles%2520derivatives%2520as%2520BRD4%252FHDAC%2520dual%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D2931%26epage%3D2935%26doi%3D10.1016%2Fj.bmcl.2016.04.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4051</span>– <span class="NLM_lpage">4055</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.07.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bmcl.2017.07.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=28765013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1KqsLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=4051-4055&author=M.+Shaoauthor=L.+Heauthor=L.+Zhengauthor=L.+Huangauthor=Y.+Zhouauthor=T.+Wangauthor=Y.+Chenauthor=M.+Shenauthor=F.+Wangauthor=Z.+Yangauthor=L.+Chen&title=Structure-based+design%2C+synthesis+and+in+vitro+antiproliferative+effects+studies+of+novel+dual+BRD4%2FHDAC+inhibitors&doi=10.1016%2Fj.bmcl.2017.07.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors</span></div><div class="casAuthors">Shao, Mingfeng; He, Linhong; Zheng, Li; Huang, Lingxiao; Zhou, Yuanyuan; Wang, Taijing; Chen, Yong; Shen, Mingsheng; Wang, Fang; Yang, Zhuang; Chen, Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4051-4055</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone acetylation marks play important roles in controlling gene expressions and are removed by histone deacetylases (HDACs).  These marks are read by bromodomain and extra-terminal (BET) proteins, whose targeted inhibitors are under clin. investigation.  BET and HDAC inhibitors have been demonstrated to be synergistically killing in Myc-induced murine lymphoma.  Herein, the authors combine the inhibitory activities of BET and HDAC into one mol. through structure-based design method and evaluate its function.  The majority of these synthesized compds. showed inhibitory activity against second bromodomains(BRD) of BRD4 and HDAC1.  Among them, I presented antiproliferative effects against human acute myelogenous leukemia (AML) cell lines in vitro, and I is confirmed to reduce the expression of Myc by Western blot anal.  Those results indicated that I is a potent dual BRD4/HDAC inhibitor and deserves further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkMaHqVu_LM7Vg90H21EOLACvtfcHk0lgPxAi16nrB1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1KqsLrP&md5=c525f1a2083699dd5f6f6a262f477f24</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.07.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.07.054%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DStructure-based%2520design%252C%2520synthesis%2520and%2520in%2520vitro%2520antiproliferative%2520effects%2520studies%2520of%2520novel%2520dual%2520BRD4%252FHDAC%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D4051%26epage%3D4055%26doi%3D10.1016%2Fj.bmcl.2017.07.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soden, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angell, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giblin, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smithers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furze, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rioja, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witherington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parr, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinjha, R. K.</span></span> <span> </span><span class="NLM_article-title">The structure based design of dual HDAC/BET inhibitors as novel epigenetic probes</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">342</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.1039/C3MD00285C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1039%2FC3MD00285C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjt1ylsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=342-351&author=S.+J.+Atkinsonauthor=P.+E.+Sodenauthor=D.+C.+Angellauthor=M.+Bantscheffauthor=C.-w.+Chungauthor=K.+A.+Giblinauthor=N.+Smithersauthor=R.+C.+Furzeauthor=L.+Gordonauthor=G.+Drewesauthor=I.+Riojaauthor=J.+Witheringtonauthor=N.+J.+Parrauthor=R.+K.+Prinjha&title=The+structure+based+design+of+dual+HDAC%2FBET+inhibitors+as+novel+epigenetic+probes&doi=10.1039%2FC3MD00285C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The structure based design of dual HDAC/BET inhibitors as novel epigenetic probes</span></div><div class="casAuthors">Atkinson, Stephen J.; Soden, Peter E.; Angell, Davina C.; Bantscheff, Marcus; Chung, Chun-wa; Giblin, Kathryn A.; Smithers, Nicholas; Furze, Rebecca C.; Gordon, Laurie; Drewes, Gerard; Rioja, Inmaculada; Witherington, Jason; Parr, Nigel J.; Prinjha, Rab K.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">342-351</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Herein we describe the design and synthesis of a dual active histone deacetylase (HDAC)/bromodomain and extra terminal (BET) small mol. tool inhibitor, DUAL946 (1).  Exploiting our extensive epigenetic toolbox, we achieved the functionalisation of a BET active tetrahydroquinoline (THQ) core, with a hydroxamic acid HDAC inhibitor (HDACi) motif.  Dual inhibition of BET and HDAC proteins was confirmed by in vitro biochem. and biophys. testing and through chemoproteomic competition expts. in cell lysates.  This activity was translated into potent cellular activity in both immune and cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrozg-RkS-M_rVg90H21EOLACvtfcHk0lgPxAi16nrB1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjt1ylsr8%253D&md5=53ba095249966d2ec200d20280e64512</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1039%2FC3MD00285C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC3MD00285C%26sid%3Dliteratum%253Aachs%26aulast%3DAtkinson%26aufirst%3DS.%2BJ.%26aulast%3DSoden%26aufirst%3DP.%2BE.%26aulast%3DAngell%26aufirst%3DD.%2BC.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DC.-w.%26aulast%3DGiblin%26aufirst%3DK.%2BA.%26aulast%3DSmithers%26aufirst%3DN.%26aulast%3DFurze%26aufirst%3DR.%2BC.%26aulast%3DGordon%26aufirst%3DL.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DRioja%26aufirst%3DI.%26aulast%3DWitherington%26aufirst%3DJ.%26aulast%3DParr%26aufirst%3DN.%2BJ.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26atitle%3DThe%2520structure%2520based%2520design%2520of%2520dual%2520HDAC%252FBET%2520inhibitors%2520as%2520novel%2520epigenetic%2520probes%26jtitle%3DMedChemComm%26date%3D2014%26volume%3D5%26spage%3D342%26epage%3D351%26doi%3D10.1039%2FC3MD00285C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amemiya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi-Yachide, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of novel dual BRD4/HDAC inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3677</span>– <span class="NLM_lpage">3684</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.04.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bmc.2017.04.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=28549889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotlyitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=3677-3684&author=S.+Amemiyaauthor=T.+Yamaguchiauthor=Y.+Hashimotoauthor=T.+Noguchi-Yachide&title=Synthesis+and+evaluation+of+novel+dual+BRD4%2FHDAC+inhibitors&doi=10.1016%2Fj.bmc.2017.04.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of novel dual BRD4/HDAC inhibitors</span></div><div class="casAuthors">Amemiya, Seika; Yamaguchi, Takao; Hashimoto, Yuichi; Noguchi-Yachide, Tomomi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3677-3684</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Epigenetic regulation of gene expression via histone acetylation modulates many cellular processes, including apoptosis, the cell cycle, cell growth and differentiation, and inhibitors are promising drug candidates.  We have previously developed inhibitors of BRD4, which recognizes acetylated lysine residue on histones and recruits transcription elongation factor to the transcription start site, while inhibitors of histone deacetylase (HDAC), which catalyzes the removal of acetyl groups on histones, are already in clin. use for cancer treatment.  Based on the idea that polypharmacol. agents with multiple targets would have a more robust action, we set out to develop dual BRD4/HDAC inhibitors.  Here, we describe the design and synthesis of N6-[2-(7-hydroxyamino-7-oxoheptyloxy)benzoyl]adenine (I) as a BRD4/HDAC dual inhibitor.  This compd. showed HL-60 cell growth-inhibitory and apoptosis-inducing activity, as well as all-trans retinoic acid (ATRA)-induced HL-60 cell differentiation-enhancing activity, and c-MYC prodn.-inhibitory activity.  Interestingly, it also showed growth-inhibitory activity towards BRD4 inhibitor-resistant cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw5w5uPYmY37Vg90H21EOLACvtfcHk0ljkAtRoXyVqTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotlyitL4%253D&md5=c9099dc3d40c966d150a13fab28c2b9f</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.04.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.04.043%26sid%3Dliteratum%253Aachs%26aulast%3DAmemiya%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DT.%26aulast%3DHashimoto%26aufirst%3DY.%26aulast%3DNoguchi-Yachide%26aufirst%3DT.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520novel%2520dual%2520BRD4%252FHDAC%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D3677%26epage%3D3684%26doi%3D10.1016%2Fj.bmc.2017.04.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolven, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamborough, P.</span></span> <span> </span><span class="NLM_article-title">Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">576</span>– <span class="NLM_lpage">586</span>, <span class="refDoi"> DOI: 10.1021/jm201320w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201320w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFKktrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=576-586&author=C.+W.+Chungauthor=A.+W.+Deanauthor=J.+M.+Woolvenauthor=P.+Bamborough&title=Fragment-based+discovery+of+bromodomain+inhibitors+part+1%3A+inhibitor+binding+modes+and+implications+for+lead+discovery&doi=10.1021%2Fjm201320w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Discovery of Bromodomain Inhibitors Part 1: Inhibitor Binding Modes and Implications for Lead Discovery</span></div><div class="casAuthors">Chung, Chun-wa; Dean, Anthony W.; Woolven, James M.; Bamborough, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">576-586</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bromodomain-contg. proteins are key epigenetic regulators of gene transcription and readers of the histone code.  However, the therapeutic benefits of modulating this target class are largely unexplored due to the lack of suitable chem. probes.  This article describes the generation of lead mols. for the BET bromodomains through screening a fragment set chosen using structural insights and computational approaches.  Anal. of 40 BRD2/fragment x-ray complexes highlights both shared and disparate interaction features that may be exploited for affinity and selectivity.  Six representative crystal structures are then exemplified in detail.  Two of the fragments are completely new bromodomain chemotypes, and three have never before been crystd. in a bromodomain, so our results significantly extend the limited public knowledge-base of crystallog. small mol./bromodomain interactions.  Certain fragments (including paracetamol) bind in a consistent mode to different bromodomains such as CREBBP, suggesting their potential to act as generic bromodomain templates.  An important implication is that the bromodomains are not only a phylogenetic family but also a system in which chem. and structural knowledge of one bromodomain gives insights transferable to others.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonNb7GnZnS_rVg90H21EOLACvtfcHk0ljkAtRoXyVqTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFKktrnN&md5=5b7d7239d0de57266d94beef1ea080ae</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm201320w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201320w%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DC.%2BW.%26aulast%3DDean%26aufirst%3DA.%2BW.%26aulast%3DWoolven%26aufirst%3DJ.%2BM.%26aulast%3DBamborough%26aufirst%3DP.%26atitle%3DFragment-based%2520discovery%2520of%2520bromodomain%2520inhibitors%2520part%25201%253A%2520inhibitor%2520binding%2520modes%2520and%2520implications%2520for%2520lead%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D576%26epage%3D586%26doi%3D10.1021%2Fjm201320w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wyce, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganji, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smitheman, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korenchuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbash, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craggs, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCabe, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy-Wilson, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosmini, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parr, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanak, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinjha, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auger, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, P. J.</span></span> <span> </span><span class="NLM_article-title">BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e72967</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0072967</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1371%2Fjournal.pone.0072967" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=24009722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtl2iu7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e72967&author=A.+Wyceauthor=G.+Ganjiauthor=K.+N.+Smithemanauthor=C.-w.+Chungauthor=S.+Korenchukauthor=Y.+Baiauthor=O.+Barbashauthor=B.+Leauthor=P.+D.+Craggsauthor=M.+T.+McCabeauthor=K.+M.+Kennedy-Wilsonauthor=L.+V.+Sanchezauthor=R.+L.+Gosminiauthor=N.+Parrauthor=C.+F.+McHughauthor=D.+Dhanakauthor=R.+K.+Prinjhaauthor=K.+R.+Augerauthor=P.+J.+Tummino&title=BET+inhibition+silences+expression+of+MYCN+and+BCL2+and+induces+cytotoxicity+in+neuroblastoma+tumor+models&doi=10.1371%2Fjournal.pone.0072967"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models</span></div><div class="casAuthors">Wyce, Anastasia; Ganji, Gopinath; Smitheman, Kimberly N.; Chung, Chun-Wa; Korenchuk, Susan; Bai, Yuchen; Barbash, Olena; Le, Bao Chau; Craggs, Peter D.; McCabe, Michael T.; Kennedy-Wilson, Karen M.; Sanchez, Lydia V.; Gosmini, Romain L.; Parr, Nigel; McHugh, Charles F.; Dhanak, Dashyant; Prinjha, Rab K.; Auger, Kurt R.; Tummino, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e72967</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">BET family proteins are epigenetic regulators known to control expression of genes involved in cell growth and oncogenesis.  Selective inhibitors of BET proteins exhibit potent anti-proliferative activity in a no. of hematol. cancer models, in part through suppression of the MYC oncogene and downstream Myc-driven pathways.  However, little is currently known about the activity of BET inhibitors in solid tumor models, and whether down-regulation of MYC family genes contributes to sensitivity.  Here we provide evidence for potent BET inhibitor activity in neuroblastoma, a pediatric solid tumor assocd. with a high frequency of MYCN amplifications.  We treated a panel of neuroblastoma cell lines with a novel small mol. inhibitor of BET proteins, GSK1324726A (I-BET726), and obsd. potent growth inhibition and cytotoxicity in most cell lines irresp. of MYCN copy no. or expression level.  Gene expression analyses in neuroblastoma cell lines suggest a role of BET inhibition in apoptosis, signaling, and N-Myc-driven pathways, including the direct suppression of BCL2 and MYCN.  Reversal of MYCN or BCL2 suppression reduces the potency of I-BET726-induced cytotoxicity in a cell line-specific manner; however, neither factor fully accounts for I-BET726 sensitivity.  Oral administration of I-BET726 to mouse xenograft models of human neuroblastoma results in tumor growth inhibition and down-regulation MYCN and BCL2 expression, suggesting a potential role for these genes in tumor growth.  Taken together, our data highlight the potential of BET inhibitors as novel therapeutics for neuroblastoma, and suggest that sensitivity is driven by pleiotropic effects on cell growth and apoptotic pathways in a context-specific manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoecB0_0elFVbVg90H21EOLACvtfcHk0ljkAtRoXyVqTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtl2iu7fI&md5=d39ce25a50de58f18a278a9f67935bbc</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0072967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0072967%26sid%3Dliteratum%253Aachs%26aulast%3DWyce%26aufirst%3DA.%26aulast%3DGanji%26aufirst%3DG.%26aulast%3DSmitheman%26aufirst%3DK.%2BN.%26aulast%3DChung%26aufirst%3DC.-w.%26aulast%3DKorenchuk%26aufirst%3DS.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DBarbash%26aufirst%3DO.%26aulast%3DLe%26aufirst%3DB.%26aulast%3DCraggs%26aufirst%3DP.%2BD.%26aulast%3DMcCabe%26aufirst%3DM.%2BT.%26aulast%3DKennedy-Wilson%26aufirst%3DK.%2BM.%26aulast%3DSanchez%26aufirst%3DL.%2BV.%26aulast%3DGosmini%26aufirst%3DR.%2BL.%26aulast%3DParr%26aufirst%3DN.%26aulast%3DMcHugh%26aufirst%3DC.%2BF.%26aulast%3DDhanak%26aufirst%3DD.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DAuger%26aufirst%3DK.%2BR.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26atitle%3DBET%2520inhibition%2520silences%2520expression%2520of%2520MYCN%2520and%2520BCL2%2520and%2520induces%2520cytotoxicity%2520in%2520neuroblastoma%2520tumor%2520models%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De72967%26doi%3D10.1371%2Fjournal.pone.0072967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi-Yachide, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, T.</span></span> <span> </span><span class="NLM_article-title">Discovery and structure-activity relationship studies of <i>N</i><sub><i>6</i></sub>-benzoyladenine derivatives as novel BRD4 inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">953</span>– <span class="NLM_lpage">959</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.01.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bmc.2015.01.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25678016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslertLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=953-959&author=T.+Noguchi-Yachideauthor=T.+Sakaiauthor=Y.+Hashimotoauthor=T.+Yamaguchi&title=Discovery+and+structure-activity+relationship+studies+of+N6-benzoyladenine+derivatives+as+novel+BRD4+inhibitors&doi=10.1016%2Fj.bmc.2015.01.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and structure-activity relationship studies of N6-benzoyladenine derivatives as novel BRD4 inhibitors</span></div><div class="casAuthors">Noguchi-Yachide, Tomomi; Sakai, Taki; Hashimoto, Yuichi; Yamaguchi, Takao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">953-959</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Bromodomain and extra-terminal domain (BET) proteins are epigenetic readers that bind to acetylated lysines in histones.  Among them, BRD4 is a candidate target mol. of therapeutic agents for diverse diseases, including cancer and inflammatory disease.  As a part of the continuing structural development studies of thalidomide to obtain a broad spectrum of biol. modifiers based on the 'multitemplate' approach, in this work the authors focused on BRD4-inhibitory activity, and discovered that N6-benzoyladenine derivs. exhibit this activity.  Structure-activity relationship studies led to N6-(2,4,5-trimethoxybenzoyl)adenine I, which exhibits potent BRD4 bromodomain1 inhibitory activity with an IC50 value of 0.427 μM.  N6-Benzoyladenine appears to be a new chem. scaffold for development of BRD4 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDwaLfpkAET7Vg90H21EOLACvtfcHk0ljOGqqAnk3ucw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslertLs%253D&md5=889cf81c25fd1e62def22cb2f32dc06e</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.01.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.01.022%26sid%3Dliteratum%253Aachs%26aulast%3DNoguchi-Yachide%26aufirst%3DT.%26aulast%3DSakai%26aufirst%3DT.%26aulast%3DHashimoto%26aufirst%3DY.%26aulast%3DYamaguchi%26aufirst%3DT.%26atitle%3DDiscovery%2520and%2520structure-activity%2520relationship%2520studies%2520of%2520N6-benzoyladenine%2520derivatives%2520as%2520novel%2520BRD4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D953%26epage%3D959%26doi%3D10.1016%2Fj.bmc.2015.01.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Targeting epigenetic reader and eraser: rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2931</span>– <span class="NLM_lpage">2935</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.04.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bmcl.2016.04.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=27142751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC28XntFCmt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2931-2935&author=Z.+Zhangauthor=S.+Houauthor=H.+Chenauthor=T.+Ranauthor=F.+Jiangauthor=Y.+Bianauthor=D.+Zhangauthor=Y.+Zhiauthor=L.+Wangauthor=L.+Zhangauthor=H.+Liauthor=Y.+Zhangauthor=W.+Tangauthor=T.+Luauthor=Y.+Chen&title=Targeting+epigenetic+reader+and+eraser%3A+rational+design%2C+synthesis+and+in+vitro+evaluation+of+dimethylisoxazoles+derivatives+as+BRD4%2FHDAC+dual+inhibitors&doi=10.1016%2Fj.bmcl.2016.04.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors</span></div><div class="casAuthors">Zhang, Zhimin; Hou, Shaohua; Chen, Hongli; Ran, Ting; Jiang, Fei; Bian, Yuanyuan; Zhang, Dewei; Zhi, Yanle; Wang, Lu; Zhang, Li; Li, Hongmei; Zhang, Yanmin; Tang, Weifang; Lu, Tao; Chen, Yadong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2931-2935</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The bromodomain protein module and histone deacetylase (HDAC), which recognize and remove acetylated lysine, resp., have emerged as important epigenetic therapeutic targets in cancer treatments.  Herein the authors presented a novel design approach for cancer drug development by combination of bromodomain and HDAC inhibitory activity in one mol.  The designed compds. were synthesized which showed inhibitory activity against bromodomain 4 and HDAC1.  The representative dual bromodomain/HDAC inhibitors, compds. N1-(3-benzoyl-5-(3,5-dimethylisoxazol-4-yl)phenyl)-N7-hydroxyheptanediamide and N1-(3-benzoyl-5-(3,5-dimethylisoxazol-4-yl)phenyl)-N8-hydroxyoctanediamide showed potent antiproliferative activities against human leukemia cell line K562 and MV4-11 in cellular assays.  This work may lay the foundation for developing dual bromodomain/HDAC inhibitors as potential anticancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriS0VB1G-QoLVg90H21EOLACvtfcHk0ljOGqqAnk3ucw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntFCmt7o%253D&md5=a6ebdbd6402e3117a2f9d96ed071790c</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.04.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.04.034%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DHou%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DRan%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DBian%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DZhi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DTargeting%2520epigenetic%2520reader%2520and%2520eraser%253A%2520rational%2520design%252C%2520synthesis%2520and%2520in%2520vitro%2520evaluation%2520of%2520dimethylisoxazoles%2520derivatives%2520as%2520BRD4%252FHDAC%2520dual%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D2931%26epage%3D2935%26doi%3D10.1016%2Fj.bmcl.2016.04.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of novel indole derivatives as potential HDAC/BRD4 dual inhibitors and anti-leukemia agents</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">410</span>– <span class="NLM_lpage">417</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2018.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bioorg.2018.12.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=30554080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFaqtb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2019&pages=410-417&author=G.+Chengauthor=Z.+Wangauthor=J.+Yangauthor=Y.+Baoauthor=Q.+Xuauthor=L.+Zhaoauthor=D.+Liu&title=Design%2C+synthesis+and+biological+evaluation+of+novel+indole+derivatives+as+potential+HDAC%2FBRD4+dual+inhibitors+and+anti-leukemia+agents&doi=10.1016%2Fj.bioorg.2018.12.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of novel indole derivatives as potential HDAC/BRD4 dual inhibitors and anti-leukemia agents</span></div><div class="casAuthors">Cheng, Gaoliang; Wang, Zhi; Yang, Jinyu; Bao, Yu; Xu, Qihao; Zhao, Linxiang; Liu, Dan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">410-417</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">HDAC inhibitors and BRD4 inhibitors were considered to be potent anti-cancer agents.  Recent studies have demonstrated that HDAC and BRD4 participate in the regulation of some signal paths like PI3K-AKT.  In this work, a series of indole derivs. that combine the inhibitory activities of BRD4 and HDAC into one mol. were designed and synthesized through the structure-based design method.  Most compds. showed potent HDAC inhibitory activity and moderate BRD4 inhibitory activity.  In vitro anti-proliferation activities of the synthesized compds. were also evaluated.  Among them, 19f was the most potent inhibitor against HDAC3 with IC50 value of 5 nM and BRD4 inhibition rate of 88% at 10 μM.  It was confirmed that 19f could up-regulate the expression of Ac-H3 and reduce the expression of c-Myc by western blot anal.  These results indicated that 19f was a potent dual HDAC/BRD4 inhibitor and deserved further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkPM3yaQ5gE7Vg90H21EOLACvtfcHk0ljOGqqAnk3ucw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFaqtb%252FI&md5=e2c81b5d67fd9f49e6805c6b544438b4</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2018.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2018.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DBao%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520indole%2520derivatives%2520as%2520potential%2520HDAC%252FBRD4%2520dual%2520inhibitors%2520and%2520anti-leukemia%2520agents%26jtitle%3DBioorg.%2520Chem.%26date%3D2019%26volume%3D84%26spage%3D410%26epage%3D417%26doi%3D10.1016%2Fj.bioorg.2018.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Potent dual BET/HDAC inhibitors for efficient treatment of pancreatic cancer</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3028</span>– <span class="NLM_lpage">3032</span>, <span class="refDoi"> DOI: 10.1002/anie.201915896</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1002%2Fanie.201915896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFegtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=3028-3032&author=S.+Heauthor=G.+Dongauthor=Y.+Liauthor=S.+Wuauthor=W.+Wangauthor=C.+Sheng&title=Potent+dual+BET%2FHDAC+inhibitors+for+efficient+treatment+of+pancreatic+cancer&doi=10.1002%2Fanie.201915896"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer</span></div><div class="casAuthors">He, Shipeng; Dong, Guoqiang; Li, Yu; Wu, Shanchao; Wang, Wei; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3028-3032</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">As one of the most aggressive and lethal human malignancies with extremely poor prognosis, there is an urgent demand of more effective therapy for the treatment of pancreatic cancer.  Reported here is a new, effective therapeutic strategy and the design of small-mol. inhibitors that simultaneously target bromodomain and extra-terminal (BET) and histone deacetylase (HDAC), potentially serving as promising therapeutic agents for pancreatic cancer.  A highly potent dual inhibitor (13 a) is identified to possess excellent and balanced activities against BRD4 BD1 (IC50=11 nM) and HDAC1 (IC50=21 nM).  Notably, this compd. shows higher in vitro and in vivo antitumor potency than the BET inhibitor (+)-JQ1 and the HDAC inhibitor vorinostat, either alone or and in combination, highlighting the advantages of BET/HDAC dual inhibitors for more effective treatment of pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9BFNcLfkA4bVg90H21EOLACvtfcHk0lim4K5Gye1Vfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFegtLw%253D&md5=78db62cb533611939d9abd0e654ff5f3</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fanie.201915896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201915896%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DPotent%2520dual%2520BET%252FHDAC%2520inhibitors%2520for%2520efficient%2520treatment%2520of%2520pancreatic%2520cancer%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2020%26volume%3D59%26spage%3D3028%26epage%3D3032%26doi%3D10.1002%2Fanie.201915896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of thieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as bromodomain-containing protein 4/histone deacetylase dual inhibitors induce autophagic cell death in colorectal carcinoma cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">3678</span>– <span class="NLM_lpage">3700</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b02178</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b02178" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFajtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=3678-3700&author=Z.+Panauthor=X.+Liauthor=Y.+Wangauthor=Q.+Jiangauthor=L.+Jiangauthor=M.+Zhangauthor=N.+Zhangauthor=F.+Wuauthor=B.+Liuauthor=G.+He&title=Discovery+of+thieno%5B2%2C3-d%5Dpyrimidine-based+hydroxamic+acid+derivatives+as+bromodomain-containing+protein+4%2Fhistone+deacetylase+dual+inhibitors+induce+autophagic+cell+death+in+colorectal+carcinoma+cells&doi=10.1021%2Facs.jmedchem.9b02178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Thieno[2,3-d]pyrimidine-Based Hydroxamic Acid Derivatives as Bromodomain-Containing Protein 4/Histone Deacetylase Dual Inhibitors Induce Autophagic Cell Death in Colorectal Carcinoma Cells</span></div><div class="casAuthors">Pan, Zhaoping; Li, Xiang; Wang, Yujia; Jiang, Qinglin; Jiang, Li; Zhang, Min; Zhang, Nan; Wu, Fengbo; Liu, Bo; He, Gu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3678-3700</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bromodomain-contg. protein 4 (BRD4) and histone deacetylases (HDAC) are both attractive epigenetic targets in cancer and other chronic diseases.  Based on the integrated fragment-based drug design, synthesis, and in vitro and in vivo evaluations, a series of novel thieno[2,3-d]pyrimidine-based hydroxamic acid derivs. are discovered as selective BRD4-HDAC dual inhibitors.  Compd. 17c is the most potent inhibitor for BRD4 and HDAC with IC50 values at nanomolar levels, as well as the expression level of c-Myc, and increases the acetylation of histone H3.  Moreover, 17c presents inhibitory effects on the proliferation of colorectal carcinoma (CRC) cells via inducing autophagic cell death.  It also has a good pharmacokinetic profile in rats and oral bioavailability of 40.5%.  In the HCT-116 xenograft in vivo models, 17c displays potent inhibitory efficiency on tumor growth by inducing autophagic cell death and suppressing IL6-JAK-STAT signaling pathways.  Our results suggest that the BRD4-HDAC dual inhibition might be an attractive therapeutic strategy for CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2FHKdnuD3QLVg90H21EOLACvtfcHk0lim4K5Gye1Vfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFajtLs%253D&md5=ce6446afe48f80165d2b21aee04571f6</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b02178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b02178%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520thieno%255B2%252C3-d%255Dpyrimidine-based%2520hydroxamic%2520acid%2520derivatives%2520as%2520bromodomain-containing%2520protein%25204%252Fhistone%2520deacetylase%2520dual%2520inhibitors%2520induce%2520autophagic%2520cell%2520death%2520in%2520colorectal%2520carcinoma%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D3678%26epage%3D3700%26doi%3D10.1021%2Facs.jmedchem.9b02178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemmon, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">Cell signaling by receptor tyrosine kinases</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1134</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2010.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.cell.2010.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=20602996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2010&pages=1117-1134&author=M.+A.+Lemmonauthor=J.+Schlessinger&title=Cell+signaling+by+receptor+tyrosine+kinases&doi=10.1016%2Fj.cell.2010.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Lemmon, Mark A.; Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1117-1134</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Recent structural studies of receptor tyrosine kinases (RTKs) have revealed unexpected diversity in the mechanisms of their activation by growth factor ligands.  Strategies for inducing dimerization by ligand binding are surprisingly diverse, as are mechanisms that couple this event to activation of the intracellular tyrosine kinase domains.  As the understanding of these details becomes increasingly sophisticated, it provides an important context for therapeutically countering the effects of pathogenic RTK mutations in cancer and other diseases.  Much remains to be learned, however, about the complex signaling networks downstream from RTKs and how alterations in these networks are translated into cellular responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd5NvoN0Q9-7Vg90H21EOLACvtfcHk0ljpo2cBXSWK3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D&md5=b88b55fe7a3eebc6ff7e883425676e45</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520signaling%2520by%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D2010%26volume%3D141%26spage%3D1117%26epage%3D1134%26doi%3D10.1016%2Fj.cell.2010.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hristova, K.</span></span> <span> </span><span class="NLM_article-title">Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">6241</span>– <span class="NLM_lpage">6251</span>, <span class="refDoi"> DOI: 10.1021/bi060609y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi060609y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD28XktVSksrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2006&pages=6241-6251&author=E.+Liauthor=K.+Hristova&title=Role+of+receptor+tyrosine+kinase+transmembrane+domains+in+cell+signaling+and+human+pathologies&doi=10.1021%2Fbi060609y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Receptor Tyrosine Kinase Transmembrane Domains in Cell Signaling and Human Pathologies</span></div><div class="casAuthors">Li, Edwin; Hristova, Kalina</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6241-6251</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases (RTKs) conduct biochem. signals via lateral dimerization in the plasma membrane, and their transmembrane (TM) domains play an important role in the dimerization process.  Here we present two models of RTK-mediated signaling, and we discuss the role of the TM domains within the framework of these two models.  We summarize findings of single-amino acid mutations in RTK TM domains that induce unregulated signaling and, as a consequence, pathol. phenotypes.  We review the current knowledge of pathol. induction mechanisms due to these mutations, focusing on the structural and thermodn. basis of pathogenic dimer stabilization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyWcf9Iq0Ot7Vg90H21EOLACvtfcHk0lhTzuUPseJKwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktVSksrs%253D&md5=d42fa0811257a6494f1a74b2fc50cab4</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fbi060609y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi060609y%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DE.%26aulast%3DHristova%26aufirst%3DK.%26atitle%3DRole%2520of%2520receptor%2520tyrosine%2520kinase%2520transmembrane%2520domains%2520in%2520cell%2520signaling%2520and%2520human%2520pathologies%26jtitle%3DBiochemistry%26date%3D2006%26volume%3D45%26spage%3D6241%26epage%3D6251%26doi%3D10.1021%2Fbi060609y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. T.</span></span> <span> </span><span class="NLM_article-title">Receptor tyrosine kinases: mechanisms of activation and signaling</span>. <i>Curr. Opin. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">123</span>, <span class="refDoi"> DOI: 10.1016/j.ceb.2007.02.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.ceb.2007.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=17306972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt1Slu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2007&pages=117-123&author=S.+R.+Hubbardauthor=W.+T.+Miller&title=Receptor+tyrosine+kinases%3A+mechanisms+of+activation+and+signaling&doi=10.1016%2Fj.ceb.2007.02.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor tyrosine kinases: mechanisms of activation and signaling</span></div><div class="casAuthors">Hubbard, Stevan R.; Miller, W. Todd</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-123</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases (RTKs) are essential components of signal transduction pathways that mediate cell-to-cell communication.  These single-pass transmembrane receptors, which bind polypeptide ligands - mainly growth factors - play key roles in processes such as cellular growth, differentiation, metab. and motility.  Recent progress has been achieved towards an understanding of the precise (and varied) mechanisms by which RTKs are activated by ligand binding and by which signals are propagated from the activated receptors to downstream targets in the cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg3ej9ekC3hLVg90H21EOLACvtfcHk0lhTzuUPseJKwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt1Slu78%253D&md5=254110135c0f1a5642441c551d379bef</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2007.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2007.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26atitle%3DReceptor%2520tyrosine%2520kinases%253A%2520mechanisms%2520of%2520activation%2520and%2520signaling%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2007%26volume%3D19%26spage%3D117%26epage%3D123%26doi%3D10.1016%2Fj.ceb.2007.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemmon, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">Cell signaling by receptor tyrosine kinases</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">11134</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2010.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.cell.2010.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=20602996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2010&pages=1117-11134&author=M.+A.+Lemmonauthor=J.+Schlessinger&title=Cell+signaling+by+receptor+tyrosine+kinases&doi=10.1016%2Fj.cell.2010.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Lemmon, Mark A.; Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1117-1134</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Recent structural studies of receptor tyrosine kinases (RTKs) have revealed unexpected diversity in the mechanisms of their activation by growth factor ligands.  Strategies for inducing dimerization by ligand binding are surprisingly diverse, as are mechanisms that couple this event to activation of the intracellular tyrosine kinase domains.  As the understanding of these details becomes increasingly sophisticated, it provides an important context for therapeutically countering the effects of pathogenic RTK mutations in cancer and other diseases.  Much remains to be learned, however, about the complex signaling networks downstream from RTKs and how alterations in these networks are translated into cellular responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd5NvoN0Q9-7Vg90H21EOLACvtfcHk0lhezZhOi4g-Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D&md5=b88b55fe7a3eebc6ff7e883425676e45</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520signaling%2520by%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D2010%26volume%3D141%26spage%3D1117%26epage%3D11134%26doi%3D10.1016%2Fj.cell.2010.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, S. R.</span></span> <span> </span><span class="NLM_article-title">Juxtamembrane autoinhibition in receptor tyrosine kinases</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">464</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1038/nrm1399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnrm1399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15173825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVarsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=464-470&author=S.+R.+Hubbard&title=Juxtamembrane+autoinhibition+in+receptor+tyrosine+kinases&doi=10.1038%2Fnrm1399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Juxtamembrane autoinhibition in receptor tyrosine kinases</span></div><div class="casAuthors">Hubbard, Stevan R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">464-471</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases are essential mediators of cell growth, differentiation, migration, and metab.  Accordingly, their catalytic activity is tightly regulated by several mechanisms including autoinhibition.  Recent structural studies, together with biochem. expts., are now unraveling the mol. mechanisms by which the juxtamembrane region (between the transmembrane helix and the cytoplasmic kinase domain) neg. regulates catalytic activity in various receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPtSOSgNkh4rVg90H21EOLACvtfcHk0lhezZhOi4g-Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVarsLs%253D&md5=99f8e4d23d72e397768a7f01d41dcb56</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fnrm1399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1399%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26atitle%3DJuxtamembrane%2520autoinhibition%2520in%2520receptor%2520tyrosine%2520kinases%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2004%26volume%3D5%26spage%3D464%26epage%3D470%26doi%3D10.1038%2Fnrm1399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">Signal transduction by receptors with tyrosine kinase activity</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(90)90801-K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2F0092-8674%2890%2990801-K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=2158859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADyaK3cXktlKnu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=1990&pages=203-212&author=A.+Ullrichauthor=J.+Schlessinger&title=Signal+transduction+by+receptors+with+tyrosine+kinase+activity&doi=10.1016%2F0092-8674%2890%2990801-K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transduction by receptors with tyrosine kinase activity</span></div><div class="casAuthors">Ullrich, Axel; Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-12</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">A review, with 91 refs., of signal transduction by the title receptors during development of multicellular organisms.  Major mechanistic questions of receptor action and signal transduction are discussed, with emphasis on the EGF receptor.  The role of these receptors in neoplastic transformation is included.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrmhaKMZphVrVg90H21EOLACvtfcHk0lhezZhOi4g-Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXktlKnu74%253D&md5=d8461b736d274bebbf66d494c1b7755e</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2890%2990801-K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252890%252990801-K%26sid%3Dliteratum%253Aachs%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DSignal%2520transduction%2520by%2520receptors%2520with%2520tyrosine%2520kinase%2520activity%26jtitle%3DCell%26date%3D1990%26volume%3D61%26spage%3D203%26epage%3D212%26doi%3D10.1016%2F0092-8674%2890%2990801-K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaBonte, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazzone, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louie, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Khoueiry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladner, R. D.</span></span> <span> </span><span class="NLM_article-title">The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">3635</span>– <span class="NLM_lpage">3648</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-2430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F0008-5472.CAN-10-2430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=21464044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVGltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=3635-3648&author=M.+J.+LaBonteauthor=P.+M.+Wilsonauthor=W.+Fazzoneauthor=J.+Russellauthor=S.+G.+Louieauthor=A.+El-Khoueiryauthor=H.+J.+Lenzauthor=R.+D.+Ladner&title=The+dual+EGFR%2FHER2+inhibitor+lapatinib+synergistically+enhances+the+antitumor+activity+of+the+histone+deacetylase+inhibitor+panobinostat+in+colorectal+cancer+models&doi=10.1158%2F0008-5472.CAN-10-2430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">The Dual EGFR/HER2 Inhibitor Lapatinib Synergistically Enhances the Antitumor Activity of the Histone Deacetylase Inhibitor Panobinostat in Colorectal Cancer Models</span></div><div class="casAuthors">LaBonte, Melissa J.; Wilson, Peter M.; Fazzone, Will; Russell, Jared; Louie, Stan G.; El-Khoueiry, Anthony; Lenz, Heinz-Josef; Ladner, Robert D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3635-3648</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">As key mols. that drive progression and chemoresistance in gastrointestinal cancers, epidermal growth factor receptor (EGFR) and HER2 have become efficacious drug targets in this setting.  Lapatinib is an EGFR/HER2 kinase inhibitor suppressing signaling through the RAS/RAF/MEK (MAP/ERK kinase)/MAPK (mitogen-activated protein kinase) and PI3K (phosphoinositide 3-kinase)/AKT pathways.  Histone deacetylase inhibitors (HDACi) are a novel class of agents that induce cell cycle arrest and apoptosis following the acetylation of histone and nonhistone proteins modulating gene expression and disrupting HSP90 function inducing the degrdn. of EGFR-pathway client proteins.  This study sought to evaluate the therapeutic potential of combining lapatinib with the HDACi panobinostat in colorectal cancer (CRC) cell lines with varying EGFR/HER2 expression and KRAS/BRAF/PIK3CA mutations.  Lapatinib and panobinostat exerted concn.-dependent antiproliferative effects in vitro (panobinostat range 7.2-30 nmol/L; lapatinib range 7.6-25.8 μmol/L).  Combined lapatinib and panobinostat treatment interacted synergistically to inhibit the proliferation and colony formation in all CRC cell lines tested.  Combination treatment resulted in rapid induction of apoptosis that coincided with increased DNA double-strand breaks, caspase-8 activation, and PARP cleavage.  This was paralleled by decreased signaling through both the PI3K and MAPK pathways and increased downregulation of transcriptional targets including NF-κB1, IRAK1, and CCND1.  Panobinostat treatment induced downregulation of EGFR, HER2, and HER3 mRNA and protein through transcriptional and posttranslational mechanisms.  In the LoVo KRAS mutant CRC xenograft model, the combination showed greater antitumor activity than either agent alone, with no apparent increase in toxicity.  Our results offer preclin. rationale warranting further clin. investigation combining HDACi with EGFR and HER2-targeted therapies for CRC treatment.  Cancer Res; 71(10); 3635-48.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1SSsKxj9V_bVg90H21EOLACvtfcHk0ljB9ib_mjZvyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVGltLo%253D&md5=1c90487efab29f12e919ed5804716937</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2430%26sid%3Dliteratum%253Aachs%26aulast%3DLaBonte%26aufirst%3DM.%2BJ.%26aulast%3DWilson%26aufirst%3DP.%2BM.%26aulast%3DFazzone%26aufirst%3DW.%26aulast%3DRussell%26aufirst%3DJ.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DEl-Khoueiry%26aufirst%3DA.%26aulast%3DLenz%26aufirst%3DH.%2BJ.%26aulast%3DLadner%26aufirst%3DR.%2BD.%26atitle%3DThe%2520dual%2520EGFR%252FHER2%2520inhibitor%2520lapatinib%2520synergistically%2520enhances%2520the%2520antitumor%2520activity%2520of%2520the%2520histone%2520deacetylase%2520inhibitor%2520panobinostat%2520in%2520colorectal%2520cancer%2520models%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D3635%26epage%3D3648%26doi%3D10.1158%2F0008-5472.CAN-10-2430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rho, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J. J.</span></span> <span> </span><span class="NLM_article-title">Vorinostat enhances gefitinibinduced cell death through reactive oxygen speciesdependent cleavage of HSP90 and its clients in nonsmall cell lung cancer with the EGFR mutation</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.3892/or.2018.6814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.3892%2For.2018.6814" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=30365122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVOnu77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2019&pages=525-533&author=S.+E.+Parkauthor=D.+E.+Kimauthor=M.+J.+Kimauthor=J.+S.+Leeauthor=J.+K.+Rhoauthor=S.+Y.+Jeongauthor=E.+K.+Choiauthor=C.+S.+Kimauthor=J.+J.+Hwang&title=Vorinostat+enhances+gefitinibinduced+cell+death+through+reactive+oxygen+speciesdependent+cleavage+of+HSP90+and+its+clients+in+nonsmall+cell+lung+cancer+with+the+EGFR+mutation&doi=10.3892%2For.2018.6814"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Vorinostat enhances gefitinib-induced cell death through reactive oxygen species-dependent cleavage of HSP90 and its clients in non-small cell lung cancer with the EGFR mutation</span></div><div class="casAuthors">Park, Sang Eun; Kim, Dong Eun; Kim, Mi Joung; Lee, Jee Suk; Rho, Jin Kyung; Jeong, Seong-Yun; Choi, Eun Kyung; Kim, Choung-Soo; Hwang, Jung Jin</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">525-533</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Although different mechanisms of acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have been reported in non-small cell lung cancers (NSCLCs), the optimal treatment for patients with acquired resistance has not been clearly defined.  The purpose of this study was to investigate the antitumor effects of gefitinib in combination with vorinostat, a potent histone deacetylase inhibitor (HDACI), and their assocd. mol. mechanisms in relation to activating apoptosis in NSCLC.  The treatment using a combination of vorinostat and gefitinib was more potent in promoting cell death by activating apoptosis than gefitinib alone in parental PC9 cells that harbor an EGFR-activating mutation (EGFR exon 19 deletion) and gefitinib-resistant PC9 cells (PC9GR) with an EGFR T790M mutation.  This combination induced heat shock protein 90 (HSP90) cleavage and reduced the level of HSP90 client proteins, including EGFR, MET and AKT, in PC9 and PC9GR cells.  The addn. of 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride, a scavenger of reactive oxygen species (ROS), inhibited the degrdn. of HSP90 client proteins and HSP90 cleavage that was induced by co-treatment as well as the cleavage of caspase-3, caspase-8, and caspase-9 and cell death.  We also obsd. that cleavage of HSP90 and its clients were blocked when caspases were inhibited.  These results revealed that co-treatment with vorinostat and gefitinib induced ROS-dependent caspase activation, leading to the downregulation of HSP90 clients through HSP90 cleavage.  Collectively, our findings provide a new basis for strategies that combine vorinostat with an EGFR-TKI to reverse EGFR-TKI resistance in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrobKxHswyuvLVg90H21EOLACvtfcHk0ljB9ib_mjZvyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVOnu77L&md5=065e126a4ce27bab0056194ae77c509d</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.3892%2For.2018.6814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2018.6814%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%2BE.%26aulast%3DKim%26aufirst%3DD.%2BE.%26aulast%3DKim%26aufirst%3DM.%2BJ.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DJeong%26aufirst%3DS.%2BY.%26aulast%3DChoi%26aufirst%3DE.%2BK.%26aulast%3DKim%26aufirst%3DC.%2BS.%26aulast%3DHwang%26aufirst%3DJ.%2BJ.%26atitle%3DVorinostat%2520enhances%2520gefitinibinduced%2520cell%2520death%2520through%2520reactive%2520oxygen%2520speciesdependent%2520cleavage%2520of%2520HSP90%2520and%2520its%2520clients%2520in%2520nonsmall%2520cell%2520lung%2520cancer%2520with%2520the%2520EGFR%2520mutation%26jtitle%3DOncol.%2520Rep.%26date%3D2019%26volume%3D41%26spage%3D525%26epage%3D533%26doi%3D10.3892%2For.2018.6814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. M.</span></span> <span> </span><span class="NLM_article-title">The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e810</span>, <span class="refDoi"> DOI: 10.1038/cddis.2013.330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fcddis.2013.330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=24052078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2mtb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=e810&author=M.+C.+Chenauthor=C.+H.+Chenauthor=J.+C.+Wangauthor=A.+C.+Tsaiauthor=J.+P.+Liouauthor=S.+L.+Panauthor=C.+M.+Teng&title=The+HDAC+inhibitor%2C+MPT0E028%2C+enhances+erlotinib-induced+cell+death+in+EGFR-TKI-resistant+NSCLC+cells&doi=10.1038%2Fcddis.2013.330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells</span></div><div class="casAuthors">Chen, M.-C.; Chen, C.-H.; Wang, J.-C.; Tsai, A.-C.; Liou, J.-P.; Pan, S.-L.; Teng, C.-M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">Sept.</span>),
    <span class="NLM_cas:pages">e810</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR), which promotes cell survival and division, is found at abnormally high levels on the surface of many cancer cell types, including many cases of non-small cell lung cancer.  Erlotinib (Tarceva), an oral small-mol. tyrosine kinase inhibitor, is a so-called targeted drug that inhibits the tyrosine kinase domain of EGFR, and thus targets cancer cells with some specificity while doing less damage to normal cells.  However, erlotinib resistance can occur, reducing the efficacy of this treatment.  To develop more effective therapeutic interventions by overcoming this resistance problem, we combined the histone deacetylase inhibitor, MPT0E028, with erlotinib in an effort to increase their antitumor effects in erlotinib-resistant lung adenocarcinoma cells.  This combined treatment yielded significant growth inhibition, induced the expression of apoptotic proteins (PARP, γH2AX, and caspase-3), increased the levels of acetylated histone H3, and showed synergistic effects in vitro and in vivo.  These effects were independent of the mutation status of the genes encoding EGFR or K-Ras.  MPT0E028 synergistically blocked key regulators of the EGFR/HER2 signaling pathways, attenuating multiple compensatory pathways (e.g., AKT, extracellular signal-regulated kinase, and c-MET).  Our results indicate that this combination therapy might be a promising strategy for facilitating the effects of erlotinib monotherapy by activating various networks.  Taken together, our data provide compelling evidence that MPT0E028 has the potential to improve the treatment of heterogeneous and drug-resistant tumors that cannot be controlled with single-target agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohUhwZb0vDhbVg90H21EOLACvtfcHk0ljCTfhHx96vQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2mtb7J&md5=5fca3b66a1178f8086b61bcb42eacaa0</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2013.330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2013.330%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%2BC.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DWang%26aufirst%3DJ.%2BC.%26aulast%3DTsai%26aufirst%3DA.%2BC.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DTeng%26aufirst%3DC.%2BM.%26atitle%3DThe%2520HDAC%2520inhibitor%252C%2520MPT0E028%252C%2520enhances%2520erlotinib-induced%2520cell%2520death%2520in%2520EGFR-TKI-resistant%2520NSCLC%2520cells%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2013%26volume%3D4%26spage%3De810%26doi%3D10.1038%2Fcddis.2013.330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagliardi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Gennaro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gimigliano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pucci, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budillon, A.</span></span> <span> </span><span class="NLM_article-title">Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells</span>. <i>Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3725</span>– <span class="NLM_lpage">3742</span>, <span class="refDoi"> DOI: 10.1002/pmic.201100092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1002%2Fpmic.201100092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=21761561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFajsb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=3725-3742&author=L.+Bianchiauthor=F.+Bruzzeseauthor=A.+Leoneauthor=A.+Gagliardiauthor=M.+Pugliaauthor=E.+Di+Gennaroauthor=M.+Roccoauthor=A.+Gimiglianoauthor=B.+Pucciauthor=A.+Arminiauthor=L.+Biniauthor=A.+Budillon&title=Proteomic+analysis+identifies+differentially+expressed+proteins+after+HDAC+vorinostat+and+EGFR+inhibitor+gefitinib+treatments+in+Hep-2+cancer+cells&doi=10.1002%2Fpmic.201100092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells</span></div><div class="casAuthors">Bianchi, Laura; Bruzzese, Francesca; Leone, Alessandra; Gagliardi, Assunta; Puglia, Michele; Di Gennaro, Elena; Rocco, Monia; Gimigliano, Anna; Pucci, Biagio; Armini, Alessandro; Bini, Luca; Budillon, Alfredo</div><div class="citationInfo"><span class="NLM_cas:title">Proteomics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3725-3742</span>CODEN:
                <span class="NLM_cas:coden">PROTC7</span>;
        ISSN:<span class="NLM_cas:issn">1615-9853</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Several solid tumors are characterized by poor prognosis and few effective treatment options, other than palliative chemotherapy in the recurrent/metastatic setting.  Epidermal growth factor receptor (EGFR) has been considered an important anticancer target because it is involved in the development and progression of several solid tumors; however, only a subset of patients show a clin. meaningful response to EGFR inhibition, particularly to EGFR tyrosine kinase inhibitors such as gefitinib.  We have recently demonstrated synergistic antitumor effect of the histone deacetylase inhibitor vorinostat combined with gefitinib.  To further characterize the interaction between these two agents, cellular exts. from Hep-2 cancer cells that were untreated or treated for 24 h with either vorinostat or gefitinib alone or with a vorinostat/gefitinib combination were analyzed using 2-D DIGE.  Software anal. using DeCyder was performed, and numerous differentially expressed protein spots were visualized between the four examd. settings.  Using MALDI-TOF MS and ESI-Ion trap MS/MS, several differentially expressed proteins were identified; some of these were validated by Western blotting.  Finally, a pathway anal. of exptl. data performed using MetaCore highlighted a relevant relationship between the identified proteins and addnl. potential effectors.  In conclusion, we performed a comprehensive anal. of proteins regulated by vorinostat and gefitinib, alone and in combination, providing a useful insight into their mechanisms of action as well as their synergistic interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjWwQmorv5jbVg90H21EOLACvtfcHk0lhu_LeNTgRe9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFajsb3J&md5=edff18202a93c765e2294d2db7f8ff0a</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1002%2Fpmic.201100092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpmic.201100092%26sid%3Dliteratum%253Aachs%26aulast%3DBianchi%26aufirst%3DL.%26aulast%3DBruzzese%26aufirst%3DF.%26aulast%3DLeone%26aufirst%3DA.%26aulast%3DGagliardi%26aufirst%3DA.%26aulast%3DPuglia%26aufirst%3DM.%26aulast%3DDi%2BGennaro%26aufirst%3DE.%26aulast%3DRocco%26aufirst%3DM.%26aulast%3DGimigliano%26aufirst%3DA.%26aulast%3DPucci%26aufirst%3DB.%26aulast%3DArmini%26aufirst%3DA.%26aulast%3DBini%26aufirst%3DL.%26aulast%3DBudillon%26aufirst%3DA.%26atitle%3DProteomic%2520analysis%2520identifies%2520differentially%2520expressed%2520proteins%2520after%2520HDAC%2520vorinostat%2520and%2520EGFR%2520inhibitor%2520gefitinib%2520treatments%2520in%2520Hep-2%2520cancer%2520cells%26jtitle%3DProteomics%26date%3D2011%26volume%3D11%26spage%3D3725%26epage%3D3742%26doi%3D10.1002%2Fpmic.201100092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colburn, N. H.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">100</span>– <span class="NLM_lpage">109</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-04-0070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1541-7786.MCR-04-0070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15755876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVKku74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2005&pages=100-109&author=J.+Huauthor=N.+H.+Colburn&title=Histone+deacetylase+inhibition+down-regulates+cyclin+D1+transcription+by+inhibiting+nuclear+factor-kappaB%2Fp65+DNA+binding&doi=10.1158%2F1541-7786.MCR-04-0070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibition Down-Regulates Cyclin D1 Transcription by Inhibiting Nuclear Factor-κB/p65 DNA Binding</span></div><div class="casAuthors">Hu, Jing; Colburn, Nancy H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">100-109</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors are emerging as a promising new class of cancer therapeutic agents.  HDAC inhibitors relieve the deacetylation of histone proteins.  However, little is known about the nonhistone targets of HDAC inhibitors and their roles in gene regulation.  In this study, we addressed the mol. basis of the down-regulation of the nuclear factor-κB (NF-κB)-responsive gene cyclin D1 by the HDAC inhibitor trichostatin A in mouse JB6 cells.  Cyclin D1 plays a crit. role in cell proliferation and tumor progression.  Trichostatin A inhibits cyclin D1 expression in a NF-κB-dependent manner in JB6 cells.  Electrophoretic mobility shift assay studies showed that trichostatin A treatment prevents p65 dimer binding to NF-κB sites on DNA.  Moreover, a chromatin immunopptn. assay shows that trichostatin A treatment inhibits endogenous cyclin D1 gene transcription by preventing p65 binding to the cyclin D1 promoter.  However, acetylation of p65 is not affected by trichostatin A treatment.  Instead, trichostatin A enhances p52 acetylation and increases p52 protein level by enhancing p100 processing.  This is the first report that trichostatin A, a HDAC inhibitor, activates p100 processing and relieves the repression of p52 acetylation.  The enhanced acetylation of p52 in the nuclei may operate to cause nuclear retention of p65 by increasing the p52/p65 interaction and preventing IκBα-p65 binding.  The enhanced p52 acetylation coincides with decreased p65 DNA binding, suggesting a potential role of p52 acetylation in NF-κB regulation.  Together, the results provide the first demonstration that HDAC inhibitor trichostatin A inhibits cyclin D1 gene transcription through targeting transcription factor NF-κB/p65 DNA binding.  NF-κB is therefore identified as a transcription factor target of trichostatin A treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_10jC2vcwH7Vg90H21EOLACvtfcHk0ljHJDC7i7WPVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVKku74%253D&md5=c5c6892386af861142daa241d1d05d12</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-04-0070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-04-0070%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DColburn%26aufirst%3DN.%2BH.%26atitle%3DHistone%2520deacetylase%2520inhibition%2520down-regulates%2520cyclin%2520D1%2520transcription%2520by%2520inhibiting%2520nuclear%2520factor-kappaB%252Fp65%2520DNA%2520binding%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2005%26volume%3D3%26spage%3D100%26epage%3D109%26doi%3D10.1158%2F1541-7786.MCR-04-0070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horinaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinnoh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, T.</span></span> <span> </span><span class="NLM_article-title">A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1080</span>– <span class="NLM_lpage">1086</span>, <span class="refDoi"> DOI: 10.3892/ijo.2013.2042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.3892%2Fijo.2013.2042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=23900601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1CmsbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2013&pages=1080-1086&author=T.+Yamadaauthor=M.+Horinakaauthor=M.+Shinnohauthor=T.+Yoshiokaauthor=T.+Mikiauthor=T.+Sakai&title=A+novel+HDAC+inhibitor+OBP-801+and+a+PI3K+inhibitor+LY294002+synergistically+induce+apoptosis+via+the+suppression+of+survivin+and+XIAP+in+renal+cell+carcinoma&doi=10.3892%2Fijo.2013.2042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma</span></div><div class="casAuthors">Yamada, Takeshi; Horinaka, Mano; Shinnoh, Masahide; Yoshioka, Takashi; Miki, Tsuneharu; Sakai, Toshiyuki</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1080-1086</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Renal cell carcinoma (RCC) is resistant to traditional cancer therapies such as radiation therapy and chemotherapy.  The use of targeted therapies has improved the clin. outcomes of patients with metastatic RCC.  However, most patients acquire resistance against targeted therapies over time.  We report that the combination of the novel histone deacetylase (HDAC) inhibitor OBP-801, also known as YM753 and the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 synergistically inhibits cell growth and induces apoptosis in RCC cells.  This combination activated caspase-3, -8 and -9 and the pan-caspase inhibitor zVAD-fmk significantly reduced the apoptotic response to the treatment with OBP-801 and LY294002.  Moreover, the combined treatment induced intracellular reactive oxygen species (ROS) and the radical scavenger N-acetyl-L-cysteine (NAC) blocked the intracellular ROS and apoptosis induced by OBP-801 and LY294002.  The co-treatment with OBP-801 and LY294002 markedly decreased survivin and the X-linked inhibitor of apoptosis protein (XIAP) protein levels, but Bcl-2 family members were not altered by the OBP-801/LY294002 co-treatment.  These alterations were restored by NAC treatment.  The transient transfection of survivin and XIAP reduced the apoptotic response to the OBP-801/LY294002 co-treatment.  Addnl., OBP-801 was significantly more effective than SAHA, another HDAC inhibitor, in the combination with LY294002 against 786-O cells.  Taken together, these results strongly suggest the combination of OBP-801 and LY294002 to be a promising treatment for RCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsaAUuVoRqkrVg90H21EOLACvtfcHk0lhuGch8v5Pmmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1CmsbjK&md5=3f17423d3b17adaa7dd319da8024ec5f</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.3892%2Fijo.2013.2042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2013.2042%26sid%3Dliteratum%253Aachs%26aulast%3DYamada%26aufirst%3DT.%26aulast%3DHorinaka%26aufirst%3DM.%26aulast%3DShinnoh%26aufirst%3DM.%26aulast%3DYoshioka%26aufirst%3DT.%26aulast%3DMiki%26aufirst%3DT.%26aulast%3DSakai%26aufirst%3DT.%26atitle%3DA%2520novel%2520HDAC%2520inhibitor%2520OBP-801%2520and%2520a%2520PI3K%2520inhibitor%2520LY294002%2520synergistically%2520induce%2520apoptosis%2520via%2520the%2520suppression%2520of%2520survivin%2520and%2520XIAP%2520in%2520renal%2520cell%2520carcinoma%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2013%26volume%3D43%26spage%3D1080%26epage%3D1086%26doi%3D10.3892%2Fijo.2013.2042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Locatelli, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleris, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stirparo, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tartari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saba, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierdominici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malorni, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anichini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlo-Stella, C.</span></span> <span> </span><span class="NLM_article-title">BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi givinostat and sorafenib in hodgkin lymphoma cell line xenografts</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1861</span>– <span class="NLM_lpage">1871</span>, <span class="refDoi"> DOI: 10.1038/leu.2014.81</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fleu.2014.81" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=24561519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslGqs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=1861-1871&author=S.+L.+Locatelliauthor=L.+Clerisauthor=G.+G.+Stirparoauthor=S.+Tartariauthor=E.+Sabaauthor=M.+Pierdominiciauthor=W.+Malorniauthor=A.+Carboneauthor=A.+Anichiniauthor=C.+Carlo-Stella&title=BIM+upregulation+and+ROS-dependent+necroptosis+mediate+the+antitumor+effects+of+the+HDACi+givinostat+and+sorafenib+in+hodgkin+lymphoma+cell+line+xenografts&doi=10.1038%2Fleu.2014.81"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts</span></div><div class="casAuthors">Locatelli, S. L.; Cleris, L.; Stirparo, G. G.; Tartari, S.; Saba, E.; Pierdominici, M.; Malorni, W.; Carbone, A.; Anichini, A.; Carlo-Stella, C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1861-1871</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Relapsed/refractory Hodgkin's lymphoma (HL) is an unmet medical need requiring new therapeutic options.  Interactions between the histone deacetylase inhibitor Givinostat and the RAF/MEK/ERK inhibitor Sorafenib were examd. in HDLM-2 and L-540 HL cell lines.  Exposure to Givinostat/Sorafenib induced a synergistic inhibition of cell growth (range, 70-80%) and a marked increase in cell death (up to 96%) due to increased H3 and H4 acetylation and strong mitochondrial injury.  Gene expression profiling indicated that the synergistic effects of Givinostat/Sorafenib treatment are assocd. with the modulation of cell cycle and cell death pathways.  Exposure to Givinostat/Sorafenib resulted in sustained prodn. of reactive oxygen species (ROS) and activation of necroptotic cell death.  The necroptosis inhibitor Necrostatin-1 prevented Givinostat/Sorafenib-induced ROS prodn., mitochondrial injury, activation of BH3-only protein BIM and cell death.  Knockdown expts. identified BIM as a key signaling mol. that mediates Givinostat/Sorafenib-induced oxidative death of HL cells.  Furthermore, in vivo xenograft studies demonstrated a 50% redn. in tumor burden (P<0.0001), a 5- to 15-fold increase in BIM expression (P≤0.0001) and a fourfold increase in tumor necrosis in Givinostat/Sorafenib-treated animals compared with mice that received single agents.  These results provide a rationale for exploring Givinostat/Sorafenib combination in relapsed/refractory HL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMH9ugVrPEabVg90H21EOLACvtfcHk0ljOhEzyww4ejg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslGqs7c%253D&md5=e0a5ffa1d583fbc54fe88e439bb7bc9e</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1038%2Fleu.2014.81&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2014.81%26sid%3Dliteratum%253Aachs%26aulast%3DLocatelli%26aufirst%3DS.%2BL.%26aulast%3DCleris%26aufirst%3DL.%26aulast%3DStirparo%26aufirst%3DG.%2BG.%26aulast%3DTartari%26aufirst%3DS.%26aulast%3DSaba%26aufirst%3DE.%26aulast%3DPierdominici%26aufirst%3DM.%26aulast%3DMalorni%26aufirst%3DW.%26aulast%3DCarbone%26aufirst%3DA.%26aulast%3DAnichini%26aufirst%3DA.%26aulast%3DCarlo-Stella%26aufirst%3DC.%26atitle%3DBIM%2520upregulation%2520and%2520ROS-dependent%2520necroptosis%2520mediate%2520the%2520antitumor%2520effects%2520of%2520the%2520HDACi%2520givinostat%2520and%2520sorafenib%2520in%2520hodgkin%2520lymphoma%2520cell%2520line%2520xenografts%26jtitle%3DLeukemia%26date%3D2014%26volume%3D28%26spage%3D1861%26epage%3D1871%26doi%3D10.1038%2Fleu.2014.81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wedel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seibel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juengel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsaur, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haferkamp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaheta, R. A.</span></span> <span> </span><span class="NLM_article-title">Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">418</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2010.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.lfs.2010.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=21192952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3MXit1Gkuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2011&pages=418-424&author=S.+Wedelauthor=L.+Hudakauthor=J.+M.+Seibelauthor=E.+Juengelauthor=I.+Tsaurauthor=C.+Wiesnerauthor=A.+Haferkampauthor=R.+A.+Blaheta&title=Inhibitory+effects+of+the+HDAC+inhibitor+valproic+acid+on+prostate+cancer+growth+are+enhanced+by+simultaneous+application+of+the+mTOR+inhibitor+RAD001&doi=10.1016%2Fj.lfs.2010.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001</span></div><div class="casAuthors">Wedel, Steffen; Hudak, Lukasz; Seibel, Jens-Michael; Juengel, Eva; Tsaur, Igor; Wiesner, Christoph; Haferkamp, Axel; Blaheta, Roman A.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">9-10</span>),
    <span class="NLM_cas:pages">418-424</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">To analyze the combined impact of the histone deacetylase (HDAC) inhibitor valproic acid (VPA) and the mammalian target of rapamycin (mTOR) inhibitor RAD001 on prostate cancer cell growth.  PC-3, DU-145 and LNCaP cells were treated with RAD001, VPA or with an RAD001-VPA combination for 3 or 5 days.  Tumor cell growth, cell cycle progression and cell cycle regulating proteins were then investigated by MTT assay, flow cytometry and Western blotting, resp.  Effects of drug treatment on cell signaling pathways were detd.  Sep. application of RAD001 or VPA distinctly reduced tumor cell growth and impaired cell cycle progression.  Significant additive effects were evoked when both drugs were used in concert.  Particularly, the cell cycle regulating proteins cdk1, cdk2, cdk4 and cyclin B were reduced, whereas p21 and p27 were enhanced by the RAD001-VPA combination.  Signaling anal. revealed deactivation of EGFr, ERK1/2 and p70S6k.  Phosphorylation of Akt was diminished in DU-145 but elevated in PC-3 and LNCaP cells.  The RAD001-VPA combination exerted profound antitumor properties on a panel of prostate cancer cell lines.  Therefore, simultaneous blockage of HDAC and mTOR related pathways should be considered when designing novel therapeutic strategies for treating prostate carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-wrTgZZwog7Vg90H21EOLACvtfcHk0lj1iFQuGp8W1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXit1Gkuro%253D&md5=af7a4cb174e2b4ee1891066c348f1429</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2010.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2010.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DWedel%26aufirst%3DS.%26aulast%3DHudak%26aufirst%3DL.%26aulast%3DSeibel%26aufirst%3DJ.%2BM.%26aulast%3DJuengel%26aufirst%3DE.%26aulast%3DTsaur%26aufirst%3DI.%26aulast%3DWiesner%26aufirst%3DC.%26aulast%3DHaferkamp%26aufirst%3DA.%26aulast%3DBlaheta%26aufirst%3DR.%2BA.%26atitle%3DInhibitory%2520effects%2520of%2520the%2520HDAC%2520inhibitor%2520valproic%2520acid%2520on%2520prostate%2520cancer%2520growth%2520are%2520enhanced%2520by%2520simultaneous%2520application%2520of%2520the%2520mTOR%2520inhibitor%2520RAD001%26jtitle%3DLife%2520Sci.%26date%3D2011%26volume%3D88%26spage%3D418%26epage%3D424%26doi%3D10.1016%2Fj.lfs.2010.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahalingam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esquivel, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espitia, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberheu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swords, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carew, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giles, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawrocki, S. T.</span></span> <span> </span><span class="NLM_article-title">Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">153</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-1385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1078-0432.CCR-09-1385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=20028765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotFyk" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=141-153&author=D.+Mahalingamauthor=E.+C.+Medinaauthor=J.+A.+Esquivelauthor=C.+M.+Espitiaauthor=S.+Smithauthor=K.+Oberheuauthor=R.+Swordsauthor=K.+R.+Kellyauthor=M.+M.+Mitaauthor=A.+C.+Mitaauthor=J.+S.+Carewauthor=F.+J.+Gilesauthor=S.+T.+Nawrocki&title=Vorinostat+enhances+the+activity+of+temsirolimus+in+renal+cell+carcinoma+through+suppression+of+survivin+levels&doi=10.1158%2F1078-0432.CCR-09-1385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels</span></div><div class="casAuthors">Mahalingam, Devalingam; Medina, Ernest C.; Esquivel, Juan A., II; Espitia, Claudia M.; Smith, Sabrina; Oberheu, Kelli; Swords, Ronan; Kelly, Kevin R.; Mita, Monica M.; Mita, Alain C.; Carew, Jennifer S.; Giles, Francis J.; Nawrocki, Steffan T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">141-153</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The mammalian target of rapamycin (mTOR) inhibitor temsirolimus has exhibited promising anticancer activity for the treatment of renal cell cancers (RCC).  Survivin expression has been implicated in drug resistance and reducing its levels with the histone deacetylase (HDAC) inhibitor vorinostat may enhance the anticancer activity of temsirolimus.  Exptl. Design: The sensitivity of RCC cell lines to the combination of temsirolimus and vorinostat was detd. by measuring cell viability, clonogenic survival, and apoptosis.  The effects of this combination on survivin levels were detd. in vitro and in vivo.  Survivin expression was silenced using small interfering RNA to evaluate its role in detg. sensitivity to temsirolimus and vorinostat.  The effect of the combination on angiogenesis was also detd. in RCC xenograft models.  Results: Vorinostat synergistically improved the anticancer activity of temsirolimus in a panel of RCC cell lines in vitro and in two xenograft models in vivo.  While each single agent led to a modest decrease in survivin levels, the combination dramatically reduced its expression, which correlated with an induction of apoptosis.  Silencing survivin levels induced apoptosis and significantly improved the efficacy of temsirolimus and vorinostat.  In addn., the temsirolimus/vorinostat combination led to a strong redn. in angiogenesis.  Conclusions: Vorinostat augmented the anticancer activity of temsirolimus in both in vitro and in vivo models of RCC.  The effectiveness of the combination was due to a decrease in survivin levels and corresponding induction of apoptosis, and enhanced inhibition of angiogenesis.  Targeting survivin may be a promising therapeutic strategy to improve RCC therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-G6IvEa39vLVg90H21EOLACvtfcHk0lhSlnFZl6f5ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotFyk&md5=a76ecc1df173f60ccdc786a5a28d0ab9</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-1385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-1385%26sid%3Dliteratum%253Aachs%26aulast%3DMahalingam%26aufirst%3DD.%26aulast%3DMedina%26aufirst%3DE.%2BC.%26aulast%3DEsquivel%26aufirst%3DJ.%2BA.%26aulast%3DEspitia%26aufirst%3DC.%2BM.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DOberheu%26aufirst%3DK.%26aulast%3DSwords%26aufirst%3DR.%26aulast%3DKelly%26aufirst%3DK.%2BR.%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DMita%26aufirst%3DA.%2BC.%26aulast%3DCarew%26aufirst%3DJ.%2BS.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DNawrocki%26aufirst%3DS.%2BT.%26atitle%3DVorinostat%2520enhances%2520the%2520activity%2520of%2520temsirolimus%2520in%2520renal%2520cell%2520carcinoma%2520through%2520suppression%2520of%2520survivin%2520levels%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D141%26epage%3D153%26doi%3D10.1158%2F1078-0432.CCR-09-1385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haura, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiappori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanvetyanon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinder-Schenck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kish, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreahling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lush, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tetteh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schell, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bepler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altiok, S.</span></span> <span> </span><span class="NLM_article-title">A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1644</span>– <span class="NLM_lpage">1655</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-2235</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1078-0432.CCR-13-2235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=24429877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXks1Ojt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=1644-1655&author=J.+E.+Grayauthor=E.+Hauraauthor=A.+Chiapporiauthor=T.+Tanvetyanonauthor=C.+C.+Williamsauthor=M.+Pinder-Schenckauthor=J.+A.+Kishauthor=J.+Kreahlingauthor=R.+Lushauthor=A.+Neugerauthor=L.+Tettehauthor=A.+Akarauthor=X.+Zhaoauthor=M.+J.+Schellauthor=G.+Beplerauthor=S.+Altiok&title=A+phase+I%2C+pharmacokinetic%2C+and+pharmacodynamic+study+of+panobinostat%2C+an+HDAC+inhibitor%2C+combined+with+erlotinib+in+patients+with+advanced+aerodigestive+tract+tumors&doi=10.1158%2F1078-0432.CCR-13-2235"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors</span></div><div class="casAuthors">Gray, Jhanelle E.; Haura, Eric; Chiappori, Alberto; Tanvetyanon, Tawee; Williams, Charles C.; Pinder-Schenck, Mary; Kish, Julie A.; Kreahling, Jenny; Lush, Richard; Neuger, Anthony; Tetteh, Leticia; Akar, Angela; Zhao, Xiuhua; Schell, Michael J.; Bepler, Gerold; Altiok, Soner</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1644-1655</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Panobinostat, a histone deacetylase (HDAC) inhibitor, enhances antiproliferative activity in non-small cell lung cancer (NSCLC) cell lines when combined with erlotinib.  We evaluated this combination in patients with advanced NSCLC and head and neck cancer.  Exptl. Design: Eligible patients were enrolled in a 3+3 dose-escalation design to det. the max. tolerated dose (MTD) of twice weekly panobinostat plus daily erlotinib at four planned dose levels (DL).  Pharmacokinetics, blood, fat pad biopsies (FPB) for histone acetylation, and paired pre and posttherapy tumor biopsies for checkpoint kinase 1 (CHK1) expression were assessed.  Results: Of 42 enrolled patients, 33 were evaluable for efficacy.  Dose-limiting toxicities were prolonged-QTc and nausea at DL3.  Adverse events included fatigue and nausea (grades 1-3), and rash and anorexia (grades 1-2).  Disease control rates were 54% for NSCLC (n = 26) and 43% for head and neck cancer (n = 7).  Of 7 patients with NSCLC with EGF receptor (EGFR) mutations, 3 had partial response, 3 had stable disease, and 1 progressed.  For EGFR-mutant vs. EGFR wild-type patients, progression-free survival (PFS) was 4.7 vs. 1.9 mo (P = 0.43) and overall survival was 41 (estd.) vs. 5.2 mo (P = 0.39).  Erlotinib pharmacokinetics was not significantly affected.  Correlative studies confirmed panobinostat's pharmacodynamic effect in blood, FPB, and tumor samples.  Low CHK1 expression levels correlated with PFS (P = 0.006) and response (P = 0.02).  Conclusions: We detd. MTD at 30 mg (panobinostat) and 100 mg (erlotinib).  Further studies are needed to further explore the benefits of HDAC inhibitors in patients with EGFR-mutant NSCLC, investigate FPB as a potential surrogate source for biomarker investigations, and validate CHK1's predictive role.  Clin Cancer Res; 20(6); 1644-55. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVMjV_ljgY8rVg90H21EOLACvtfcHk0lhSlnFZl6f5ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXks1Ojt7c%253D&md5=0fedfa337b8bff4e21e23daa5d56856c</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-2235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-2235%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DHaura%26aufirst%3DE.%26aulast%3DChiappori%26aufirst%3DA.%26aulast%3DTanvetyanon%26aufirst%3DT.%26aulast%3DWilliams%26aufirst%3DC.%2BC.%26aulast%3DPinder-Schenck%26aufirst%3DM.%26aulast%3DKish%26aufirst%3DJ.%2BA.%26aulast%3DKreahling%26aufirst%3DJ.%26aulast%3DLush%26aufirst%3DR.%26aulast%3DNeuger%26aufirst%3DA.%26aulast%3DTetteh%26aufirst%3DL.%26aulast%3DAkar%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DSchell%26aufirst%3DM.%2BJ.%26aulast%3DBepler%26aufirst%3DG.%26aulast%3DAltiok%26aufirst%3DS.%26atitle%3DA%2520phase%2520I%252C%2520pharmacokinetic%252C%2520and%2520pharmacodynamic%2520study%2520of%2520panobinostat%252C%2520an%2520HDAC%2520inhibitor%252C%2520combined%2520with%2520erlotinib%2520in%2520patients%2520with%2520advanced%2520aerodigestive%2520tract%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D1644%26epage%3D1655%26doi%3D10.1158%2F1078-0432.CCR-13-2235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boothman, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattah, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skelton, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priddy, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarode, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, J. H.</span></span> <span> </span><span class="NLM_article-title">Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">541</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2015.10.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.lungcan.2015.10.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=26474959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A280%3ADC%252BC28zis1Ghtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2015&pages=534-541&author=D.+E.+Gerberauthor=D.+A.+Boothmanauthor=F.+J.+Fattahauthor=Y.+Dongauthor=H.+Zhuauthor=R.+A.+Skeltonauthor=L.+L.+Priddyauthor=P.+Voauthor=J.+E.+Dowellauthor=V.+Sarodeauthor=R.+Leffauthor=C.+Meekauthor=Y.+Xieauthor=J.+H.+Schiller&title=Phase+1+study+of+romidepsin+plus+erlotinib+in+advanced+non-small+cell+lung+cancer&doi=10.1016%2Fj.lungcan.2015.10.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer</span></div><div class="casAuthors">Gerber David E; Boothman David A; Fattah Farjana J; Dong Ying; Skelton Rachel A; Priddy Laurin L; Vo Peggy; Zhu Hong; Xie Yang; Dowell Jonathan E; Schiller Joan H; Sarode Venetia; Leff Richard; Meek Claudia</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">534-41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  Preclinical studies demonstrated anti-tumor efficacy of the combination of the histone deacetylase (HDAC) inhibitor romidepsin plus erlotinib in non-small cell lung cancer (NSCLC) models that were insensitive to erlotinib monotherapy.  We therefore studied this combination in a phase 1 clinical trial in previously treated advanced NSCLC.  METHODS:  Romidepsin (8 or 10mg/m(2)) was administered intravenously on days 1, 8, and 15 every 28 days in combination with erlotinib (150 mg orally daily), with romidepsin monotherapy lead-in during Cycle 1.  Correlative studies included peripheral blood mononuclear cell HDAC activity and histone acetylation status, and EGFR pathway activation status in skin biopsies.  RESULTS:  A total of 17 patients were enrolled.  Median number of prior lines of therapy was 3 (range 1-5).  No cases had a sensitizing EGFR mutation.  The most common related adverse events were nausea, vomiting, and fatigue (each 82%), diarrhea (65%), anorexia (53%), and rash (41%).  Dose-limiting nausea and vomiting occurred at the romidepsin 10 mg/m(2) level despite aggressive antiemetic prophylaxis and treatment.  Among 10 evaluable patients, the best response was stable disease (n=7) and progressive disease (n=3).  Median progression-free survival (PFS) was 3.3 months (range 1.4-16.5 months).  Prolonged PFS (>6 months) was noted in a KRAS mutant adenocarcinoma and a squamous cell cancer previously progressed on erlotinib monotherapy.  Romidepsin monotherapy inhibited HDAC activity, increased histone acetylation status, and inhibited EGFR phosphorylation.  CONCLUSIONS:  Romidepsin 8 mg/m(2) plus erlotinib appears well tolerated, has evidence of disease control, and exhibits effects on relevant molecular targets in an unselected advanced NSCLC population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRa-YB56BxpCMRAV4D_Ins_fW6udTcc2eba61blKa5Oy7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zis1Ghtg%253D%253D&md5=bbb7049c30b6b29abbb278eb10bab361</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2015.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2015.10.008%26sid%3Dliteratum%253Aachs%26aulast%3DGerber%26aufirst%3DD.%2BE.%26aulast%3DBoothman%26aufirst%3DD.%2BA.%26aulast%3DFattah%26aufirst%3DF.%2BJ.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DSkelton%26aufirst%3DR.%2BA.%26aulast%3DPriddy%26aufirst%3DL.%2BL.%26aulast%3DVo%26aufirst%3DP.%26aulast%3DDowell%26aufirst%3DJ.%2BE.%26aulast%3DSarode%26aufirst%3DV.%26aulast%3DLeff%26aufirst%3DR.%26aulast%3DMeek%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DSchiller%26aufirst%3DJ.%2BH.%26atitle%3DPhase%25201%2520study%2520of%2520romidepsin%2520plus%2520erlotinib%2520in%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DLung%2520Cancer%26date%3D2015%26volume%3D90%26spage%3D534%26epage%3D541%26doi%3D10.1016%2Fj.lungcan.2015.10.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of <i>N</i>-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.12.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.ejmech.2015.12.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=26741358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVOj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2016&pages=1-12&author=F.+W.+Pengauthor=J.+Xuanauthor=T.+T.+Wuauthor=J.+Y.+Xueauthor=Z.+W.+Renauthor=D.+K.+Liuauthor=X.+Q.+Wangauthor=X.+H.+Chenauthor=J.+W.+Zhangauthor=Y.+G.+Xuauthor=L.+Shi&title=Design%2C+synthesis+and+biological+evaluation+of+N-phenylquinazolin-4-amine+hybrids+as+dual+inhibitors+of+VEGFR-2+and+HDAC&doi=10.1016%2Fj.ejmech.2015.12.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC</span></div><div class="casAuthors">Peng, Fan-Wei; Xuan, Ji; Wu, Ting-Ting; Xue, Jia-Yu; Ren, Zi-Wei; Liu, Da-Ke; Wang, Xiu-Qi; Chen, Xin-Hang; Zhang, Jia-Wei; Xu, Yun-Gen; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In this work, a series of hybrids bearing N-phenylquinazolin-4-amine and hydroxamic acid moieties I (R1, R2 = H, F, Cl, Br, n = 2, 3, 4, 5) were designed and identified as dual VEGFR-2/HDAC inhibitors.  Compd. I (R1 = H, R2 = Br, n = 5) exhibited the most potent inhibitory activity against HDAC with IC50 of 2.2 nM and strong inhibitory effect against VEGFR-2 with IC50 of 74 nM.  It also showed the most potent inhibitory activity against a human breast cancer cell line MCF-7 with IC50 of 0.85 μM.  Docking simulation supported the initial pharmacophoric hypothesis and suggested a common mode of interaction at the active binding sites of VEGFR-2 and HDLP (Histone Deacetylase-Like Protein), which demonstrates that compd. I (R1 = H, R2 = Br, n = 5) is a potential agent for cancer therapy deserving further researching.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT_jbaom_UR7Vg90H21EOLACvtfcHk0lgXTZW4otDUuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVOj&md5=1a0c299ec484daa522da5969e8a35cec</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.12.033%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DF.%2BW.%26aulast%3DXuan%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DT.%2BT.%26aulast%3DXue%26aufirst%3DJ.%2BY.%26aulast%3DRen%26aufirst%3DZ.%2BW.%26aulast%3DLiu%26aufirst%3DD.%2BK.%26aulast%3DWang%26aufirst%3DX.%2BQ.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DZhang%26aufirst%3DJ.%2BW.%26aulast%3DXu%26aufirst%3DY.%2BG.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520N-phenylquinazolin-4-amine%2520hybrids%2520as%2520dual%2520inhibitors%2520of%2520VEGFR-2%2520and%2520HDAC%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D109%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.ejmech.2015.12.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5137</span>– <span class="NLM_lpage">5141</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bmcl.2015.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=26475519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1GkurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=5137-5141&author=F.+W.+Pengauthor=T.+T.+Wuauthor=Z.+W.+Renauthor=J.+Y.+Xueauthor=L.+Shi&title=Hybrids+from+4-anilinoquinazoline+and+hydroxamic+acid+as+dual+inhibitors+of+vascular+endothelial+growth+factor+receptor-2+and+histone+deacetylase&doi=10.1016%2Fj.bmcl.2015.10.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase</span></div><div class="casAuthors">Peng, Fan-Wei; Wu, Ting-Ting; Ren, Zi-Wei; Xue, Jia-Yu; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5137-5141</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of hybrids derived from 4-anilinoquinazoline and hydroxamic acid were designed, synthesized, and evaluated as dual inhibitors of vascular endothelia growth factor receptor-2 (VEGFR-2) tyrosine kinase and histone deacetylase (HDAC).  Most of these compds. exhibited potent HDAC inhibition and moderate VEGFR-2 inhibition.  Among them, compd. I exhibited the most potent inhibitory activities against VEGFR-2 (IC50 = 84 nM) and HDAC (IC50 = 2.8 nM).  It also showed the most potent antiproliferative ability against MCF-7, a human breast cancer line, with IC50 of 1.2 μM.  Docking simulation supported the initial pharmacophoric hypothesis and suggested a common mode of interaction of compd. I at the active binding sites of VEGFR-2 and HDAC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojSWQqbu8Qg7Vg90H21EOLACvtfcHk0ljxx_5rVrH4CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1GkurfI&md5=f20d34f8da22e171419b48299e253fb8</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DF.%2BW.%26aulast%3DWu%26aufirst%3DT.%2BT.%26aulast%3DRen%26aufirst%3DZ.%2BW.%26aulast%3DXue%26aufirst%3DJ.%2BY.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DHybrids%2520from%25204-anilinoquinazoline%2520and%2520hydroxamic%2520acid%2520as%2520dual%2520inhibitors%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520and%2520histone%2520deacetylase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D5137%26epage%3D5141%26doi%3D10.1016%2Fj.bmcl.2015.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span> <span> </span><span class="NLM_article-title">The design and synthesis of a new class of RTK/HDAC dual-targeted inhibitors</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">6491</span>– <span class="NLM_lpage">6503</span>, <span class="refDoi"> DOI: 10.3390/molecules18066491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.3390%2Fmolecules18066491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=23736786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvFWmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=6491-6503&author=X.+Zhangauthor=M.+Suauthor=Y.+Chenauthor=J.+Liauthor=W.+Lu&title=The+design+and+synthesis+of+a+new+class+of+RTK%2FHDAC+dual-targeted+inhibitors&doi=10.3390%2Fmolecules18066491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">The design and synthesis of a new class of RTK/HDAC dual-targeted inhibitors</span></div><div class="casAuthors">Zhang, Xuan; Su, Mingbo; Chen, Yi; Li, Jia; Lu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6491-6503</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Over the years, the development of targeted medicines has made significant achievements.  As a typical example, receptor tyrosine kinases (RTK) inhibitors have become important chemotherapy drugs for a variety of cancers.  However, the effectiveness of these agents is always hindered by poor response rates and acquired drug resistance.  In order to overcome these limitations, several dual-targeted inhibitors with quinazoline core were designed and synthesized.  Though these compds. can simultaneously inhibit histone deacetylases (HDAC) as well as RTK, the structure-activity relation (SAR) is still not clear enough.  To further explore this type of dual-targeted inhibitors, a new class of quinazoline derivs. were designed and synthesized.  Their activity evaluations include in vitro inhibitory activity of HDAC, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2).  The SAR study indicated that the introduction of polar group such as hydroxamate on the 4-position of the quinazoline core is more likely to provide a potent HDACi/HER2i hybrid rather than HDACi/EGFRi mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVCBfVcbjmH7Vg90H21EOLACvtfcHk0lhtxd1La_GAlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvFWmt7g%253D&md5=d0f0d9cf104efc4c0b2032420ed52c5c</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.3390%2Fmolecules18066491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules18066491%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DW.%26atitle%3DThe%2520design%2520and%2520synthesis%2520of%2520a%2520new%2520class%2520of%2520RTK%252FHDAC%2520dual-targeted%2520inhibitors%26jtitle%3DMolecules%26date%3D2013%26volume%3D18%26spage%3D6491%26epage%3D6503%26doi%3D10.3390%2Fmolecules18066491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Q.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of <i>N</i>-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC–EGFR dual inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4405</span>– <span class="NLM_lpage">4412</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2012.05.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bmc.2012.05.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=22698782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38XoslGgurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=4405-4412&author=M.+Zuoauthor=Y.+W.+Zhengauthor=S.+M.+Luauthor=Y.+Liauthor=S.+Q.+Zhang&title=Synthesis+and+biological+evaluation+of+N-aryl+salicylamides+with+a+hydroxamic+acid+moiety+at+5-position+as+novel+HDAC%E2%80%93EGFR+dual+inhibitors&doi=10.1016%2Fj.bmc.2012.05.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors</span></div><div class="casAuthors">Zuo, Miao; Zheng, Yue-Wen; Lu, She-Min; Li, Yan; Zhang, San-Qi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4405-4412</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of N-aryl salicylamides with a hydroxamic acid moiety at 5-position were synthesized efficiently.  Their activities against EGFR kinase and HDACs were evaluated.  All compds. displayed inhibitory activity against EGFR and HDACs.  The antiproliferative activities of synthesized compds. were evaluated by MTT method against human cancer cell lines A431, A549 and HL-60.  Compd. 1o (I) showed the most potent inhibitory activity against A431 and A549.  Compds. 1k and 1n exhibited higher potency against HL-60 than gefitinib and SAHA.  N-Aryl salicylamides with a hydroxamic acid moiety at 5-position is another new HDAC-EGFR dual inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnCB2j9XDrsbVg90H21EOLACvtfcHk0ljsJ-wccmF3Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XoslGgurY%253D&md5=f3da346bb8769252a58a4ed49f6ba7eb</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.05.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.05.034%26sid%3Dliteratum%253Aachs%26aulast%3DZuo%26aufirst%3DM.%26aulast%3DZheng%26aufirst%3DY.%2BW.%26aulast%3DLu%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.%2BQ.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520N-aryl%2520salicylamides%2520with%2520a%2520hydroxamic%2520acid%2520moiety%2520at%25205-position%2520as%2520novel%2520HDAC%25E2%2580%2593EGFR%2520dual%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D4405%26epage%3D4412%26doi%3D10.1016%2Fj.bmc.2012.05.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of novel osimertinib-based HDAC and EGFR dual inhibitors</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2407</span>– <span class="NLM_lpage">2424</span>, <span class="refDoi"> DOI: 10.3390/molecules24132407</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.3390%2Fmolecules24132407" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsleqsLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=2407-2424&author=H.+Dongauthor=H.+Yinauthor=C.+Zhaoauthor=J.+Caoauthor=W.+Xuauthor=Y.+Zhang&title=Design%2C+synthesis+and+biological+evaluation+of+novel+osimertinib-based+HDAC+and+EGFR+dual+inhibitors&doi=10.3390%2Fmolecules24132407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of novel osimertinib-based HDAC and EGFR dual inhibitors</span></div><div class="casAuthors">Dong, Hang; Yin, Hao; Zhao, Chunlong; Cao, Jiangying; Xu, Wenfang; Zhang, Yingjie</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2407</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Herein a novel series of histone deacetylases (HDACs) and epidermal growth factor receptor (EGFR) dual inhibitors were designed and synthesized based on the structure of the approved EGFR inhibitor osimertinib (AZD9291).  Among them, four compds. 5D, 5E, 9D and 9E exhibited more potent total HDAC inhibition than the approved HDAC inhibitor SAHA.  However, these compds. only showed moderate to low inhibitory potency towards EGFR with compds. 5E and 9E possessing IC50 values against EGFRWT and EGFRT790M in the micromolar range. 3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay revealed the potent antiproliferative activities of compds. 5D, 5E, 9D and 9E, among which 9E was even more potent against HeLa, MDA-MB-231, MDA-MB-468, HT-29 and KG-1 cell lines than SAHA and AZD9291.  Further selectivity profile of 9E showed that this compd. was not active against other 13 cancer-related kinases and two epigenetic targets lysine specific demethylase 1 (LSD1) and bromodomain-contg. protein 4 (BRD4).  These results support further structural modification of 9E to improve its EGFR inhibitory activity, which will lead to more potent and balanced HDAC and EGFR dual inhibitors as anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphj06EAFPZbLVg90H21EOLACvtfcHk0li7EjGScV3fTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsleqsLfI&md5=a7eab03cd3f25b6b9fed342b55c09d8c</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24132407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24132407%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520osimertinib-based%2520HDAC%2520and%2520EGFR%2520dual%2520inhibitors%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26spage%3D2407%26epage%3D2424%26doi%3D10.3390%2Fmolecules24132407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrester, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zifcak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DellaRocca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, H.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munger, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepicelli, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span> <span> </span><span class="NLM_article-title">CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">3647</span>– <span class="NLM_lpage">3656</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-3360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F0008-5472.CAN-09-3360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=20388807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlens7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=3647-3656&author=C.-J.+Laiauthor=R.+Baoauthor=X.+Taoauthor=J.+Wangauthor=R.+Atoyanauthor=H.+Quauthor=D.-G.+Wangauthor=L.+Yinauthor=M.+Samsonauthor=J.+Forresterauthor=B.+Zifcakauthor=G.-X.+Xuauthor=S.+DellaRoccaauthor=H.-X.+Zhaiauthor=X.+Caiauthor=W.+E.+Mungerauthor=M.+Keeganauthor=C.+V.+Pepicelliauthor=C.+Qian&title=CUDC-101%2C+a+multitargeted+inhibitor+of+histone+deacetylase%2C+epidermal+growth+factor+receptor%2C+and+human+epidermal+growth+factor+receptor+2%2C+exerts+potent+anticancer+activity&doi=10.1158%2F0008-5472.CAN-09-3360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity</span></div><div class="casAuthors">Lai, Cheng-Jung; Bao, Rudi; Tao, Xu; Wang, Jing; Atoyan, Ruzanna; Qu, Hui; Wang, Da-Gong; Yin, Ling; Samson, Maria; Forrester, Jeffrey; Zifcak, Brian; Xu, Guang-Xin; DellaRocca, Steven; Zhai, Hai-Xiao; Cai, Xiong; Munger, William E.; Keegan, Mitchell; Pepicelli, Carmen V.; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3647-3656</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase inhibitors have recently become important therapeutics for a variety of cancers.  However, due to the heterogeneous and dynamic nature of tumors, the effectiveness of these agents is often hindered by poor response rates and acquired drug resistance.  To overcome these limitations, we created a novel small mol., CUDC-101, which simultaneously inhibits histone deacetylase and the receptor kinases epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) in cancer cells.  Because of its integrated histone deacetylase inhibition, CUDC-101 synergistically blocked key regulators of EGFR/HER2 signaling pathways, also attenuating multiple compensatory pathways, such as AKT, HER3, and MET, which enable cancer cells to escape the effects of conventional EGFR/HER2 inhibitors.  CUDC-101 displayed potent antiproliferative and proapoptotic activities against cultured and implanted tumor cells that are sensitive or resistant to several approved single-targeted drugs.  Our results show that CUDC-101 has the potential to dramatically improve the treatment of heterogeneous and drug-resistant tumors that cannot be controlled with single-target agents.  Further, they provide a framework to create individual small mols. that simultaneously antagonize multiple biochem. distinct oncogenic targets, suggesting a general paradigm to surpass conventional, single-target cancer therapeutics.  Cancer Res; 70(9); 3647-56.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrscJsyultc3bVg90H21EOLACvtfcHk0li7EjGScV3fTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlens7o%253D&md5=bc30667b0890e3c505c9608de6fa0c68</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3360%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DC.-J.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DTao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.-G.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DG.-X.%26aulast%3DDellaRocca%26aufirst%3DS.%26aulast%3DZhai%26aufirst%3DH.-X.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DMunger%26aufirst%3DW.%2BE.%26aulast%3DKeegan%26aufirst%3DM.%26aulast%3DPepicelli%26aufirst%3DC.%2BV.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DCUDC-101%252C%2520a%2520multitargeted%2520inhibitor%2520of%2520histone%2520deacetylase%252C%2520epidermal%2520growth%2520factor%2520receptor%252C%2520and%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%252C%2520exerts%2520potent%2520anticancer%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D3647%26epage%3D3656%26doi%3D10.1158%2F0008-5472.CAN-09-3360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moertl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anastasov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, M. J.</span></span> <span> </span><span class="NLM_article-title">Comparison of radiosensitization by HDAC inhibitors CUDC-101 and SAHA in pancreatic cancer cells</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">3259</span>– <span class="NLM_lpage">3274</span>, <span class="refDoi"> DOI: 10.3390/ijms20133259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.3390%2Fijms20133259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVGht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=3259-3274&author=S.+Moertlauthor=S.+Payerauthor=R.+Kellauthor=K.+Winklerauthor=N.+Anastasovauthor=M.+J.+Atkinson&title=Comparison+of+radiosensitization+by+HDAC+inhibitors+CUDC-101+and+SAHA+in+pancreatic+cancer+cells&doi=10.3390%2Fijms20133259"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of radiosensitization by HDAC inhibitors CUDC-101 and SAHA in pancreatic cancer cells</span></div><div class="casAuthors">Moertl, Simone; Payer, Sarah; Kell, Rosemarie; Winkler, Klaudia; Anastasov, Natasa; Atkinson, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3259</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Pancreatic cancer has a poor prognosis.  New treatment options are urgently required to improve patient outcomes.  One promising new class of anticancer drugs are synthetic histone deacetylase inhibitors (HDACi) which modulate chromatin structure and gene expression by blocking histone deacetylation.  In this study, we aimed at comparing the in vitro capacities of the HDACi SAHA and CUDC-101 to increase radiosensitivity of human pancreatic tumor cell lines.  Therefore, three pancreatic cancer cell lines (Su.86.86, MIA Paca-2, T3M-4) were treated with SAHA (1.5-5 μM) or CUDC-101 (0.25-3 μM) and after 24 h irradiated.  Cell proliferation, clonogenic survival and apoptosis was detd.  Addnl., cell lysates were investigated for the expression of apoptosis-related proteins.  CUDC-101 and SAHA increased the radiation sensitivity of pancreatic tumor cell lines in a dose-dependent manner.  This was evidenced by cell proliferation and clonogenic survival.  Furthermore, enhanced radiation sensitivity after CUDC-101 or SAHA treatment was confirmed for Su.86.86 and T3M-4 cells in a 3-D microtissue approach.  Increased amts. of subG1 cells and diminished full length PARP-1 suggest increased radiation-induced apoptosis after SAHA or CUDC-101 treatment.  The comparison of both inhibitors in these assays manifested CUDC-101 as more potent radiosensitizer than SAHA.  In line, western blot quantification of the apoptosis-inhibitory proteins XIAP and survivin showed a stronger down-regulation in response to CUDC-101 treatment than after SAHA application.  These proteins may contribute to the synergy between HDAC inhibition and radiation response.  In conclusion, these preclin. results suggest that treatment with the HDAC inhibitors CUDC-101 or SAHA can enhance radiation-induced cytotoxicity in human pancreatic cells.  However, comparison of both inhibitors identified the multi target inhibitor CUDC-101 as more potent radiosensitizer than the HDAC inhibitor SAHA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRXm03i2R5-LVg90H21EOLACvtfcHk0liR1EtB1f1SBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVGht70%253D&md5=02f376958ce6f2585f1ea576e9e7f85d</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.3390%2Fijms20133259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20133259%26sid%3Dliteratum%253Aachs%26aulast%3DMoertl%26aufirst%3DS.%26aulast%3DPayer%26aufirst%3DS.%26aulast%3DKell%26aufirst%3DR.%26aulast%3DWinkler%26aufirst%3DK.%26aulast%3DAnastasov%26aufirst%3DN.%26aulast%3DAtkinson%26aufirst%3DM.%2BJ.%26atitle%3DComparison%2520of%2520radiosensitization%2520by%2520HDAC%2520inhibitors%2520CUDC-101%2520and%2520SAHA%2520in%2520pancreatic%2520cancer%2520cells%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D3259%26epage%3D3274%26doi%3D10.3390%2Fijms20133259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.1097/CAD.0000000000000847</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1097%2FCAD.0000000000000847" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=31584454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVejtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2020&pages=158-168&author=T.+Zhangauthor=D.+Maauthor=D.+Weiauthor=T.+Luauthor=K.+Yuauthor=Z.+Zhangauthor=W.+Wangauthor=Q.+Fangauthor=J.+Wang&title=CUDC-101+overcomes+arsenic+trioxide+resistance+via+caspase-dependent+promyelocytic+leukemia-retinoic+acid+receptor+alpha+degradation+in+acute+promyelocytic+leukemia&doi=10.1097%2FCAD.0000000000000847"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia</span></div><div class="casAuthors">Zhang, Tianzhuo; Ma, Dan; Wei, Danna; Lu, Tingting; Yu, Kunlin; Zhang, Zhaoyuan; Wang, Weili; Fang, Qin; Wang, Jishi</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">158-168</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">1473-5741</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Although arsenic trioxide (ATO) treatment has transformed acute promyelocytic leukemia (APL) from the most fatal to the most curable hematol. cancer, many high-risk APL patients who fail to achieve a complete mol. remission or relapse become resistant to ATO.  Herein, we report that 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) exhibits specific anticancer effects on APL and ATO-resistant APL in vitro and in vivo, while showing negligible cytotoxic effect on the noncancerous cells including normal CD34 cells and bone marrow mesenchymal stem cells from APL patients.  Further mechanistic studies show that CUDC-101 triggers caspase-dependent degrdn. of the promyelocytic leukemia-retinoic acid receptor alpha fusion protein.  As a result, APL and ATO-resistant APL cells undergo apoptosis upon CUDC-101 treatment and this apoptosis-inducing effect is even stronger than that of ATO.  Finally, using a xenograft mouse model, we demonstrated that CUDC-101 significantly represses leukemia development in vivo.  In conclusion, these results suggested that CUDC-101 can serve as a potential candidate drug for APL, particularly for ATO-resistant APL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFGAQIYt4gPrVg90H21EOLACvtfcHk0liR1EtB1f1SBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVejtA%253D%253D&md5=a7078a6b19cd1c81178d3ee4bf78cde5</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000847%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DFang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DCUDC-101%2520overcomes%2520arsenic%2520trioxide%2520resistance%2520via%2520caspase-dependent%2520promyelocytic%2520leukemia-retinoic%2520acid%2520receptor%2520alpha%2520degradation%2520in%2520acute%2520promyelocytic%2520leukemia%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2020%26volume%3D31%26spage%3D158%26epage%3D168%26doi%3D10.1097%2FCAD.0000000000000847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel pazopanib-based HDAC and VEGFR dual inhibitors targeting cancer epigenetics and angiogenesis simultaneously</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5304</span>– <span class="NLM_lpage">5322</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00384</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00384" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvVGrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5304-5322&author=J.+Zangauthor=X.+Liangauthor=Y.+Huangauthor=Y.+Jiaauthor=X.+Liauthor=W.+Xuauthor=C.+J.+Chouauthor=Y.+Zhang&title=Discovery+of+novel+pazopanib-based+HDAC+and+VEGFR+dual+inhibitors+targeting+cancer+epigenetics+and+angiogenesis+simultaneously&doi=10.1021%2Facs.jmedchem.8b00384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously</span></div><div class="casAuthors">Zang, Jie; Liang, Xuewu; Huang, Yongxue; Jia, Yuping; Li, Xiaoyang; Xu, Wenfang; Chou, C. James; Zhang, Yingjie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5304-5322</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein a novel series of pazopanib hybrids as polypharmacol. antitumor agents were developed based on the crosstalk between histone deacetylases (HDACs) and vascular endothelial growth factor (VEGF) pathway.  Among them, one ortho-aminoanilide 6d and one hydroxamic acid 13f exhibited considerable total HDACs and VEGFR-2 inhibitory activities.  The HDAC inhibitory activities endowed 6d and 13f with potent antiproliferative activities, which was not obsd. in the approved VEGFR inhibitor pazopanib.  Compds. 6d and 13f possessed comparable HDAC isoform selectivity profiles to the clin. class I HDAC inhibitor MS-275 and the approved pan-HDAC inhibitor SAHA, resp. 6d and 13f also exhibited uncompromised multiple tyrosine kinases inhibitory activities relative to pazopanib.  The intracellular dual inhibition to HDAC and VEGFR of 6d and 13f was validated by Western blot anal.  In both HUVECs tube formation assay and rat thoracic aorta rings assay, 6d and 13f showed comparable antiangiogenic potencies to pazopanib.  What's more, 6d possessed desirable pharmacokinetic profiles with the oral bioavailability of 72% in SD rats and considerable in vivo antitumor efficacy in a human colorectal adenocarcinoma (HT-29) xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpmz6rwKiKSbVg90H21EOLACvtfcHk0liR1EtB1f1SBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvVGrsL8%253D&md5=437da0a6cca1ec211219aef87a6ddbc5</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00384%26sid%3Dliteratum%253Aachs%26aulast%3DZang%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DChou%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520novel%2520pazopanib-based%2520HDAC%2520and%2520VEGFR%2520dual%2520inhibitors%2520targeting%2520cancer%2520epigenetics%2520and%2520angiogenesis%2520simultaneously%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5304%26epage%3D5322%26doi%3D10.1021%2Facs.jmedchem.8b00384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel dual histone deacetylase and mammalian target of rapamycin target inhibitors as a promising strategy for cancer therapy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1577</span>– <span class="NLM_lpage">1592</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01825</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01825" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovFeguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1577-1592&author=Y.+Chenauthor=X.+Yuanauthor=W.+Zhangauthor=M.+Tangauthor=L.+Zhengauthor=F.+Wangauthor=W.+Yanauthor=S.+Yangauthor=Y.+Weiauthor=J.+Heauthor=L.+Chen&title=Discovery+of+novel+dual+histone+deacetylase+and+mammalian+target+of+rapamycin+target+inhibitors+as+a+promising+strategy+for+cancer+therapy&doi=10.1021%2Facs.jmedchem.8b01825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Dual Histone Deacetylase and Mammalian Target of Rapamycin Target Inhibitors as a Promising Strategy for Cancer Therapy</span></div><div class="casAuthors">Chen, Yong; Yuan, Xue; Zhang, Wanhua; Tang, Minghai; Zheng, Li; Wang, Fang; Yan, Wei; Yang, Shengyong; Wei, Yuquan; He, Jun; Chen, Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1577-1592</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the present study, a series of novel dual-target histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors were designed and synthesized using pyrimidine-pyrazolyl pharmacophore to append HDAC recognition cap and hydroxamic acid as a zinc-binding motif.  Among them, I was the optimal lead compd. with potent inhibition activities against mTOR and HDAC1 with half-maximal inhibitory concn. of 1.2 and 0.19 nM, resp.  Western blot confirmed that I could upregulate acetylation of H3 and α-tubulin and downregulate mTOR-related downstream mediators.  I could also stimulate cell cycle arrest in G0/G1 phase and induce tumor cell apoptosis.  I showed comparable antitumor activity with the combination medication in MM1S xenograft model with a tumor growth inhibitory rate of 72.5%, without causing significant loss of body wt. and toxicity.  All of the results indicated that I could be a promising dual target inhibitor for treating hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ3AdehNv1ObVg90H21EOLACvtfcHk0lgmyjwaY8Z-gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovFeguw%253D%253D&md5=7a2ff5020aedb0e3c302e65d993301e6</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01825%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DYan%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520novel%2520dual%2520histone%2520deacetylase%2520and%2520mammalian%2520target%2520of%2520rapamycin%2520target%2520inhibitors%2520as%2520a%2520promising%2520strategy%2520for%2520cancer%2520therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1577%26epage%3D1592%26doi%3D10.1021%2Facs.jmedchem.8b01825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kotian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boufraqech, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaskins, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gara, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quezado, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilubol, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kebebew, E.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 inhibits thyroid cancer growth and metastases</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5044</span>– <span class="NLM_lpage">5054</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-1043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1078-0432.CCR-17-1043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=28600475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVCit7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=5044-5054&author=S.+Kotianauthor=L.+Zhangauthor=M.+Boufraqechauthor=K.+Gaskinsauthor=S.+K.+Garaauthor=M.+M.+Quezadoauthor=N.+Nilubolauthor=E.+Kebebew&title=Dual+inhibition+of+HDAC+and+tyrosine+kinase+signaling+pathways+with+CUDC-907+inhibits+thyroid+cancer+growth+and+metastases&doi=10.1158%2F1078-0432.CCR-17-1043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases</span></div><div class="casAuthors">Kotian, Shweta; Zhang, Lisa; Boufraqech, Myriem; Gaskins, Kelli; Gara, Sudheer Kumar; Quezado, Martha; Nilubol, Naris; Kebebew, Electron</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5044-5054</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">There is currently no std. therapy for anaplastic thyroid cancer (ATC) and poorly differentiated thyroid cancer (PDTC), which account for two-thirds of thyroid cancer-related deaths.  Driver mutations in the PI3K/AKT and RAF/RAS/MEK/ERK pathways are common in ATC and PDTC.  Histone deacetylases (HDAC) regulate cancer initiation and progression.  Our aim was to det. the therapeutic efficacy of simultaneously targeting these pathways in thyroid cancer with a single agent and to evaluate biomarkers of treatment response.  CUDC-907 is a first-in-class compd., functioning as a dual inhibitor of HDACs and the PI3K/AKT pathway.  We investigated its antiproliferative effect in vitro and in vivo.  CUDC-907 significantly inhibited cellular proliferation in thyroid cancer cell lines, induced G2-M arrest with decreased levels of the checkpoint regulators cyclin B1, AURKA, AURKB, PLK1, and increased p21 and p27.  Treatment induced apoptosis with increased caspase-3/7 activity and decreased survivin levels and decreased cellular migration and invasion.  CUDC-907 treatment caused H3 hyperacetylation and decreased HDAC2 expression.  HDAC2 was upregulated in ATC and other thyroid cancer histol. subtypes.  CUDC-907 treatment reduced both p-AKT and p-ERK1/2 levels.  Finally, CUDC-907 treatment, in a metastatic mouse model of thyroid cancer, showed significant inhibition of growth and metastases, and tumors from treated mice had decreased HDAC2 expression, suggesting that this may be a useful biomarker of response.  Dual inhibition of HDAC and the tyrosine kinase signaling pathways with CUDC-907 is a promising treatment strategy for advanced, metastatic thyroid cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLaRHbxu0mOrVg90H21EOLACvtfcHk0lgARDuzDhsaIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVCit7nM&md5=e0d5f7d5485dd9fba6fccd5a758a7dc3</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-1043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-1043%26sid%3Dliteratum%253Aachs%26aulast%3DKotian%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBoufraqech%26aufirst%3DM.%26aulast%3DGaskins%26aufirst%3DK.%26aulast%3DGara%26aufirst%3DS.%2BK.%26aulast%3DQuezado%26aufirst%3DM.%2BM.%26aulast%3DNilubol%26aufirst%3DN.%26aulast%3DKebebew%26aufirst%3DE.%26atitle%3DDual%2520inhibition%2520of%2520HDAC%2520and%2520tyrosine%2520kinase%2520signaling%2520pathways%2520with%2520CUDC-907%2520inhibits%2520thyroid%2520cancer%2520growth%2520and%2520metastases%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D5044%26epage%3D5054%26doi%3D10.1158%2F1078-0432.CCR-17-1043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madlambayan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kushner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzinic, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taub, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span> <span> </span><span class="NLM_article-title">Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">2225</span>– <span class="NLM_lpage">2240</span>, <span class="refDoi"> DOI: 10.3324/haematol.2018.201343</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.3324%2Fhaematol.2018.201343" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=30819918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFantb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2019&pages=2225-2240&author=X.+Liauthor=Y.+Suauthor=G.+Madlambayanauthor=H.+Edwardsauthor=L.+Polinauthor=J.+Kushnerauthor=S.+H.+Dzinicauthor=K.+Whiteauthor=J.+Maauthor=T.+Knightauthor=G.+Wangauthor=Y.+Wangauthor=J.+Yangauthor=J.+W.+Taubauthor=H.+Linauthor=Y.+Ge&title=Antileukemic+activity+and+mechanism+of+action+of+the+novel+PI3K+and+histone+deacetylase+dual+inhibitor+CUDC-907+in+acute+myeloid+leukemia&doi=10.3324%2Fhaematol.2018.201343"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia</span></div><div class="casAuthors">Li, Xinyu; Su, Yongwei; Madlambayan, Gerard; Edwards, Holly; Polin, Lisa; Kushner, Juiwanna; Dzinic, Sijana H.; White, Kathryn; Ma, Jun; Knight, Tristan; Wang, Guan; Wang, Yue; Yang, Jay; Taub, Jeffrey W.; Lin, Hai; Ge, Yubin</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2225-2240</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">1592-8721</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">I nduction therapy for patients with acute myeloid leukemia (AML) has remained largely unchanged for over 40 years, while overall survival rates remain unacceptably low, highlighting the need for new therapies.  The PI3K/Akt pathway is constitutively active in the majority of patients with AML.  Given that histone deacetylase inhibitors have been shown to synergize with PI3K inhibitors in preclin. AML models, we investigated the novel dual-acting PI3K and histone deacetylase inhibitor CUDC-907 in AML cells both in vitro and in vivo.  We demonstrated that CUDC-907 induces apoptosis in AML cell lines and primary AML samples and shows in vivo efficacy in an AML cell line-derived xenograft mouse model.  CUDC-907-induced apoptosis was partially dependent on Mcl-1, Bim, and c-Myc.  CUDC-907 induced DNA damage in AML cells while sparing normal hematopoietic cells.  Downregulation of CHK1, Wee1, and RRM1, and induction of DNA damage also contributed to CUDC-907-induced apoptosis of AML cells.  In addn., CUDC-907 treatment decreased leukemia progenitor cells in primary AML samples ex vivo, while also sparing normal hematopoietic progenitor cells.  These findings support the clin. development of CUDC-907 for the treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTfDoYe90TwbVg90H21EOLACvtfcHk0lip4w1n-srqhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFantb7I&md5=850a38d8ad0b426511353e6efa053985</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2018.201343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2018.201343%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DMadlambayan%26aufirst%3DG.%26aulast%3DEdwards%26aufirst%3DH.%26aulast%3DPolin%26aufirst%3DL.%26aulast%3DKushner%26aufirst%3DJ.%26aulast%3DDzinic%26aufirst%3DS.%2BH.%26aulast%3DWhite%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DKnight%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DTaub%26aufirst%3DJ.%2BW.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DGe%26aufirst%3DY.%26atitle%3DAntileukemic%2520activity%2520and%2520mechanism%2520of%2520action%2520of%2520the%2520novel%2520PI3K%2520and%2520histone%2520deacetylase%2520dual%2520inhibitor%2520CUDC-907%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DHaematologica%26date%3D2019%26volume%3D104%26spage%3D2225%26epage%3D2240%26doi%3D10.3324%2Fhaematol.2018.201343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borek, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellarocca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuck, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viner, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattaey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Dual HDAC and PI3K inhibitor CUDC-907 downregulates MYC and suppresses growth of MYC-dependent cancers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1535-7163.MCT-16-0390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=27980108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVertro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=285-299&author=K.+Sunauthor=R.+Atoyanauthor=M.+A.+Borekauthor=S.+Dellaroccaauthor=M.+E.+Samsonauthor=A.+W.+Maauthor=G.+X.+Xuauthor=T.+Pattersonauthor=D.+P.+Tuckauthor=J.+L.+Vinerauthor=A.+Fattaeyauthor=J.+Wang&title=Dual+HDAC+and+PI3K+inhibitor+CUDC-907+downregulates+MYC+and+suppresses+growth+of+MYC-dependent+cancers&doi=10.1158%2F1535-7163.MCT-16-0390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers</span></div><div class="casAuthors">Sun, Kaiming; Atoyan, Ruzanna; Borek, Mylissa A.; Dellarocca, Steven; Samson, Maria Elena S.; Ma, Anna W.; Xu, Guang-Xin; Patterson, Troy; Tuck, David P.; Viner, Jaye L.; Fattaey, Ali; Wang, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">285-299</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Upregulation of MYC is a common driver event in human cancers, and some tumors depend on MYC to maintain transcriptional programs that promote cell growth and proliferation.  Preclin. studies have suggested that individually targeting upstream regulators of MYC, such as histone deacetylases (HDAC) and phosphoinositide 3-kinases (PI3K), can reduce MYC protein levels and suppress the growth of MYC-driven cancers.  Synergy between HDAC and PI3K inhibition in inducing cancer cell death has also been reported, but the involvement of MYC regulation is unclear.  In this study, we demonstrated that HDAC and PI3K inhibition synergistically downregulates MYC protein levels and induces apoptosis in "double-hit" (DH) diffuse large B-cell lymphoma (DLBCL) cells.  Furthermore, CUDC-907, a small-mol. dual-acting inhibitor of both class I and II HDACs and class I PI3Ks, effectively suppresses the growth and survival of MYC-altered or MYC-dependent cancer cells, such as DH DLBCL and BRD-NUT fusion-pos. NUT midline carcinoma (NMC) cells, and MYC protein downregulation is an early event induced by CUDC-907 treatment.  Consistently, the antitumor activity of CUDC-907 against multiple MYC-driven cancer types was also demonstrated in animal models, including DLBCL and NMC xenograft models, Myc transgenic tumor syngeneic models, and MYC-amplified solid tumor patient-derived xenograft (PDX) models.  Our findings suggest that dual function HDAC and PI3K inhibitor CUDC-907 is an effective agent targeting MYC and thus may be developed as potential therapy for MYC-dependent cancers.  Mol Cancer Ther; 16(2); 285-99. 2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo82AzF-jV397Vg90H21EOLACvtfcHk0lgRwE36N3Y4SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVertro%253D&md5=d4ffd5f39546fa076448dbfb36406183</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0390%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DK.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DBorek%26aufirst%3DM.%2BA.%26aulast%3DDellarocca%26aufirst%3DS.%26aulast%3DSamson%26aufirst%3DM.%2BE.%26aulast%3DMa%26aufirst%3DA.%2BW.%26aulast%3DXu%26aufirst%3DG.%2BX.%26aulast%3DPatterson%26aufirst%3DT.%26aulast%3DTuck%26aufirst%3DD.%2BP.%26aulast%3DViner%26aufirst%3DJ.%2BL.%26aulast%3DFattaey%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DDual%2520HDAC%2520and%2520PI3K%2520inhibitor%2520CUDC-907%2520downregulates%2520MYC%2520and%2520suppresses%2520growth%2520of%2520MYC-dependent%2520cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D285%26epage%3D299%26doi%3D10.1158%2F1535-7163.MCT-16-0390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madlambayan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kushner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzinic, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taub, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span> <span> </span><span class="NLM_article-title">Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">2225</span>– <span class="NLM_lpage">2240</span>, <span class="refDoi"> DOI: 10.3324/haematol.2018.201343</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.3324%2Fhaematol.2018.201343" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=30819918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFantb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2019&pages=2225-2240&author=X.+Liauthor=Y.+Suauthor=G.+Madlambayanauthor=H.+Edwardsauthor=L.+Polinauthor=J.+Kushnerauthor=S.+H.+Dzinicauthor=K.+Whiteauthor=J.+Maauthor=T.+Knightauthor=G.+Wangauthor=Y.+Wangauthor=J.+Yangauthor=J.+W.+Taubauthor=H.+Linauthor=Y.+Ge&title=Antileukemic+activity+and+mechanism+of+action+of+the+novel+PI3K+and+histone+deacetylase+dual+inhibitor+CUDC-907+in+acute+myeloid+leukemia&doi=10.3324%2Fhaematol.2018.201343"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia</span></div><div class="casAuthors">Li, Xinyu; Su, Yongwei; Madlambayan, Gerard; Edwards, Holly; Polin, Lisa; Kushner, Juiwanna; Dzinic, Sijana H.; White, Kathryn; Ma, Jun; Knight, Tristan; Wang, Guan; Wang, Yue; Yang, Jay; Taub, Jeffrey W.; Lin, Hai; Ge, Yubin</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2225-2240</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">1592-8721</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">I nduction therapy for patients with acute myeloid leukemia (AML) has remained largely unchanged for over 40 years, while overall survival rates remain unacceptably low, highlighting the need for new therapies.  The PI3K/Akt pathway is constitutively active in the majority of patients with AML.  Given that histone deacetylase inhibitors have been shown to synergize with PI3K inhibitors in preclin. AML models, we investigated the novel dual-acting PI3K and histone deacetylase inhibitor CUDC-907 in AML cells both in vitro and in vivo.  We demonstrated that CUDC-907 induces apoptosis in AML cell lines and primary AML samples and shows in vivo efficacy in an AML cell line-derived xenograft mouse model.  CUDC-907-induced apoptosis was partially dependent on Mcl-1, Bim, and c-Myc.  CUDC-907 induced DNA damage in AML cells while sparing normal hematopoietic cells.  Downregulation of CHK1, Wee1, and RRM1, and induction of DNA damage also contributed to CUDC-907-induced apoptosis of AML cells.  In addn., CUDC-907 treatment decreased leukemia progenitor cells in primary AML samples ex vivo, while also sparing normal hematopoietic progenitor cells.  These findings support the clin. development of CUDC-907 for the treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTfDoYe90TwbVg90H21EOLACvtfcHk0lhZHZSagHhy7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFantb7I&md5=850a38d8ad0b426511353e6efa053985</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2018.201343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2018.201343%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DMadlambayan%26aufirst%3DG.%26aulast%3DEdwards%26aufirst%3DH.%26aulast%3DPolin%26aufirst%3DL.%26aulast%3DKushner%26aufirst%3DJ.%26aulast%3DDzinic%26aufirst%3DS.%2BH.%26aulast%3DWhite%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DKnight%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DTaub%26aufirst%3DJ.%2BW.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DGe%26aufirst%3DY.%26atitle%3DAntileukemic%2520activity%2520and%2520mechanism%2520of%2520action%2520of%2520the%2520novel%2520PI3K%2520and%2520histone%2520deacetylase%2520dual%2520inhibitor%2520CUDC-907%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DHaematologica%26date%3D2019%26volume%3D104%26spage%3D2225%26epage%3D2240%26doi%3D10.3324%2Fhaematol.2018.201343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okabe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotoh, A.</span></span> <span> </span><span class="NLM_article-title">Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in philadelphia chromosome-positive leukemia cells</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">401</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1007/s00280-019-04022-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1007%2Fs00280-019-04022-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=31901955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtlSruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2020&pages=401-412&author=S.+Okabeauthor=Y.+Tanakaauthor=M.+Moriyamaauthor=A.+Gotoh&title=Effect+of+dual+inhibition+of+histone+deacetylase+and+phosphatidylinositol-3+kinase+in+philadelphia+chromosome-positive+leukemia+cells&doi=10.1007%2Fs00280-019-04022-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells</span></div><div class="casAuthors">Okabe, Seiichi; Tanaka, Yuko; Moriyama, Mitsuru; Gotoh, Akihiko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">401-412</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: ABL tyrosine kinase inhibitors (TKIs) have demonstrated potency in the treatment of chronic myeloid leukemia (CML) patients.  However, resistance to ABL TKIs can develop in CML patients due to BCR-ABL point mutations.  Furthermore, CUDC-907 is an oral inhibitor of class I phosphoinositide 3-kinase (PI3K) as well as class I and II histone deacetylase (HDAC) enzymes.  Methods: In this study, we evaluated the effect of combination therapy of CUDC-907 and ABL TKIs, using BCR-ABL-pos. cell lines and primary samples.  Results: CUDC-907 treatment for 72 h resulted in cell growth inhibition.  Over the same period, an increase in histone acetylation and both caspase three and poly (ADP-ribose) polymerase (PARP) enzyme activity was obsd.  When ABL TKI treatment and CUDC-907 treatment were combined, significantly greater cytotoxicity was obsd.  Moreover, combined oral therapy with ponatinib (20 mg/kg/day) and CUDC-907 (30 mg/kg/day) greatly inhibited tumor growth compared to each drug alone.  Lastly, CUDC-907 treatment also inhibited the growth of Ba/F3 ponatinib-resistant cells, K562 nilotinib-resistant cells, and T315I mutant primary samples.  Conclusion: Taken together, our results indicate that administration of CUDC-907, a dual PI3K and HDAC inhibitor, may be an effective strategy against ABL TKI-resistant cells, including cells harboring the T315I mutation.  Moreover, CUDC-907 may enhance the cytotoxic effects of ABL TKI when a combined treatment strategy is used against Philadelphia chromosome-pos. leukemia cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOsQolZ7hEHrVg90H21EOLACvtfcHk0lhZHZSagHhy7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtlSruw%253D%253D&md5=e38b7d251096863914401d39167cc8dc</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1007%2Fs00280-019-04022-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-019-04022-x%26sid%3Dliteratum%253Aachs%26aulast%3DOkabe%26aufirst%3DS.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DMoriyama%26aufirst%3DM.%26aulast%3DGotoh%26aufirst%3DA.%26atitle%3DEffect%2520of%2520dual%2520inhibition%2520of%2520histone%2520deacetylase%2520and%2520phosphatidylinositol-3%2520kinase%2520in%2520philadelphia%2520chromosome-positive%2520leukemia%2520cells%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2020%26volume%3D85%26spage%3D401%26epage%3D412%26doi%3D10.1007%2Fs00280-019-04022-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Younes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdeja, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerecitano, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neelapu, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clancy, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viner, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oki, Y.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">622</span>– <span class="NLM_lpage">631</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(15)00584-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2FS1470-2045%2815%2900584-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=27049457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsFOhs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=622-631&author=A.+Younesauthor=J.+G.+Berdejaauthor=M.+R.+Patelauthor=I.+Flinnauthor=J.+F.+Gerecitanoauthor=S.+S.+Neelapuauthor=K.+R.+Kellyauthor=A.+R.+Copelandauthor=A.+Akinsauthor=M.+S.+Clancyauthor=L.+Gongauthor=J.+Wangauthor=A.+Maauthor=J.+L.+Vinerauthor=Y.+Oki&title=Safety%2C+tolerability%2C+and+preliminary+activity+of+CUDC-907%2C+a+first-in-class%2C+oral%2C+dual+inhibitor+of+HDAC+and+PI3K%2C+in+patients+with+relapsed+or+refractory+lymphoma+or+multiple+myeloma%3A+an+open-label%2C+dose-escalation%2C+phase+1+trial&doi=10.1016%2FS1470-2045%2815%2900584-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial</span></div><div class="casAuthors">Younes, Anas; Berdeja, Jesus G.; Patel, Manish R.; Flinn, Ian; Gerecitano, John F.; Neelapu, Sattva S.; Kelly, Kevin R.; Copeland, Amanda R.; Akins, Amy; Clancy, Myles S.; Gong, Lucy; Wang, Jing; Ma, Anna; Viner, Jaye L.; Oki, Yasuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">622-631</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Treatment options for patients with relapsed or refractory lymphoma and multiple myeloma are limited.  CUDC-907 is an oral, first-in-class, small mol. that is designed to inhibit both histone deacetylase (HDAC) and PI3K enzymes, which are members of common oncogenic pathways in haematol. malignancies.  We aimed to assess overall safety and preliminary activity in this dose-escalation study of CUDC-907 monotherapy in patients with relapsed or refractory lymphoma and multiple myeloma.  This open-label, first-in-man, phase 1 trial recruited adult patients (aged ≥18 years) with lymphoma or multiple myeloma who were refractory to or had relapsed after two or more previous regimens, from four US cancer centers.  CUDC-907 was orally administered in a std. 3 + 3 dose-escalation design at four different dosing schedules, to which participants were sequentially assigned as follows: once daily, intermittently (twice or three times weekly; simultaneous enrolment), and daily for 5 days followed by a 2-day break (5/2), in 21-day cycles.  Dosing started at 30 mg for the once-daily schedule and 60 mg for other schedules, escalating in 30 mg increments.  Patients continued to receive CUDC-907 until disease progression or until other treatment discontinuation criteria were met.  The primary objective was to det. the max. tolerated dose (MTD) and recommended phase 2 dose, assessed in patients who received at least 66% of cycle 1 doses without modification and those who had a dose-limiting toxicity (DLT) in cycle 1 irresp. of dose modification.  We assessed safety in all patients who received at least one dose of study drug.  This ongoing trial is registered at ClinicalTrials.gov, no. NCT01742988.  Between Jan 23, 2013, and July 27, 2015, we enrolled 44 patients, of whom ten were sequentially assigned to CUDC-907 once-daily (MTD 60 mg), 12 to twice-weekly (MTD 150 mg), 15 to three-times-weekly (MTD 150 mg), and seven to the 5/2 dosing schedule (MTD 60 mg). 37 (84%) patients had discontinued study drug as a result of progressive disease or clin. signs of progressive disease at the data cutoff.  Four DLTs occurred in three of 40 DLT-evaluable patients (diarrhoea and hyperglycemia in one patient on 60 mg once daily, hyperglycemia in one patient on 150 mg twice weekly, and diarrhoea in one patient on 150 mg three times weekly); no DLTs were reported in patients on the 5/2 schedule.  Grade 3 or worse adverse events occurred in 19 (43%) of 44 patients, the most common of which were thrombocytopenia (in nine [20%] of 44 patients), neutropenia (three [7%]), and hyperglycemia (three [7%]). 11 (25%) of 44 patients had serious adverse events, three of which were regarded as treatment related (epistaxis and the DLTs of diarrhoea and hyperglycemia).  Adverse events led to dose redns. in six (14%) patients and treatment discontinuation in seven (16%).  Five (14%) of 37 response-evaluable patients achieved an objective response (two complete responses and three partial responses).  All five responses occurred in the subgroup of patients with diffuse large B-cell lymphoma (DLBCL; n=9), and three occurred in those with transformed follicular lymphoma DLBCL (n=5). 21 (57%) of 37 response-evaluable patients had stable disease, including those with DLBCL, Hodgkin's lymphoma, and multiple myeloma.  On the basis of these findings, we selected CUDC-907 60 mg on the 5/2 dosing schedule as the recommended phase 2 dose.  The safety and tolerability profile of CUDC-907 and the promising preliminary evidence of response support continued development of CUDC-907 at the 60 mg 5/2 dosing schedule, alone and in combination with other therapies.  A dose-expansion trial of this dose in patients with refractory and relapsed DLBCL in particular, is ongoing.  Curis, Inc, and the Leukemia and Lymphoma Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAFEt7vSuwM7Vg90H21EOLACvtfcHk0liAtUVmAsUEsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsFOhs78%253D&md5=b759c77ac239b6ae0052d30c9bea3221</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900584-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900584-7%26sid%3Dliteratum%253Aachs%26aulast%3DYounes%26aufirst%3DA.%26aulast%3DBerdeja%26aufirst%3DJ.%2BG.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DFlinn%26aufirst%3DI.%26aulast%3DGerecitano%26aufirst%3DJ.%2BF.%26aulast%3DNeelapu%26aufirst%3DS.%2BS.%26aulast%3DKelly%26aufirst%3DK.%2BR.%26aulast%3DCopeland%26aufirst%3DA.%2BR.%26aulast%3DAkins%26aufirst%3DA.%26aulast%3DClancy%26aufirst%3DM.%2BS.%26aulast%3DGong%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DA.%26aulast%3DViner%26aufirst%3DJ.%2BL.%26aulast%3DOki%26aufirst%3DY.%26atitle%3DSafety%252C%2520tolerability%252C%2520and%2520preliminary%2520activity%2520of%2520CUDC-907%252C%2520a%2520first-in-class%252C%2520oral%252C%2520dual%2520inhibitor%2520of%2520HDAC%2520and%2520PI3K%252C%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520lymphoma%2520or%2520multiple%2520myeloma%253A%2520an%2520open-label%252C%2520dose-escalation%252C%2520phase%25201%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26spage%3D622%26epage%3D631%26doi%3D10.1016%2FS1470-2045%2815%2900584-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saijo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimodaira, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishioka, C.</span></span> <span> </span><span class="NLM_article-title">Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">1994</span>– <span class="NLM_lpage">2001</span>, <span class="refDoi"> DOI: 10.1111/cas.12002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1111%2Fcas.12002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=22924958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOqt7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2012&pages=1994-2001&author=K.+Saijoauthor=T.+Katohauthor=H.+Shimodairaauthor=A.+Odaauthor=O.+Takahashiauthor=C.+Ishioka&title=Romidepsin+%28FK228%29+and+its+analogs+directly+inhibit+phosphatidylinositol+3-kinase+activity+and+potently+induce+apoptosis+as+histone+deacetylase%2Fphosphatidylinositol+3-kinase+dual+inhibitors&doi=10.1111%2Fcas.12002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors</span></div><div class="casAuthors">Saijo, Ken; Katoh, Tadashi; Shimodaira, Hideki; Oda, Akifumi; Takahashi, Ohgi; Ishioka, Chikashi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1994-2001</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Activation of phosphatidylinositol 3-kinase (PI3K) signaling is involved in carcinogenesis and cancer progression.  The PI3K inhibitors are considered candidate drugs for cancer treatment.  Here, we describe a drug screening system for novel PI3K inhibitors using Saccharomyces cerevisiae strains with deleterious mutations in the ATP-binding cassette transporter genes, because wild-type S. cerevisiae uses drug efflux pumps for reducing intracellular drug concns.  By screening the chem. library of the Screening Committee of Anticancer Drugs, we identified the histone deacetylase (HDAC) inhibitor romidepsin (FK228) and its novel analogs.  In vitroPI3K activity assays confirmed that these compds. directly inhibit PI3K activity at μM-range concns.  FK-A5 analog was the most potent inhibitor.  Western blotting revealed that these compds. inhibit phosphorylation of protein kinase B and downstream signaling components.  Mol. modeling of the PI3K-FK228 complex indicated that FK228 binds to the ATP-binding pocket of PI3K.  At μM-range concns., FK228 and FK-A5 show potent cytotoxicity, inducing apoptosis even in HDAC inhibitor-resistant cells.  Furthermore, HDAC/PI3K dual inhibition by FK228 and FK-A5 at μM-range concns. potentiates the apoptosis induction, mimicking the effect of combining specific HDAC and PI3K inhibitors.  In this study, we showed that FK228 and its analogs directly inhibit PI3K activity and induce apoptosis at μM-range concns., similar to HDAC/PI3K dual inhibition.  In future, optimizing the potency of FK228 and its analogs against PI3K may contribute to the development of novel HDAC/PI3K dual inhibitors for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeB89Rk-RyJ7Vg90H21EOLACvtfcHk0liAtUVmAsUEsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOqt7bJ&md5=7ce4ad6038c88f276921212febc52fb5</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1111%2Fcas.12002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.12002%26sid%3Dliteratum%253Aachs%26aulast%3DSaijo%26aufirst%3DK.%26aulast%3DKatoh%26aufirst%3DT.%26aulast%3DShimodaira%26aufirst%3DH.%26aulast%3DOda%26aufirst%3DA.%26aulast%3DTakahashi%26aufirst%3DO.%26aulast%3DIshioka%26aufirst%3DC.%26atitle%3DRomidepsin%2520%2528FK228%2529%2520and%2520its%2520analogs%2520directly%2520inhibit%2520phosphatidylinositol%25203-kinase%2520activity%2520and%2520potently%2520induce%2520apoptosis%2520as%2520histone%2520deacetylase%252Fphosphatidylinositol%25203-kinase%2520dual%2520inhibitors%26jtitle%3DCancer%2520Sci.%26date%3D2012%26volume%3D103%26spage%3D1994%26epage%3D2001%26doi%3D10.1111%2Fcas.12002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saijo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chikamatsu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishioka, C.</span></span> <span> </span><span class="NLM_article-title">Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/phosphatidylinositol 3-kinase dual inhibitor</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">1469</span>– <span class="NLM_lpage">1475</span>, <span class="refDoi"> DOI: 10.1111/cas.13255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1111%2Fcas.13255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=28406576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvF2rurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2017&pages=1469-1475&author=K.+Saijoauthor=H.+Imaiauthor=S.+Chikamatsuauthor=K.+Naritaauthor=T.+Katohauthor=C.+Ishioka&title=Antitumor+activity+and+pharmacologic+characterization+of+the+depsipeptide+analog+as+a+novel+histone+deacetylase%2Fphosphatidylinositol+3-kinase+dual+inhibitor&doi=10.1111%2Fcas.13255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/ phosphatidylinositol 3-kinase dual inhibitor</span></div><div class="casAuthors">Saijo, Ken; Imai, Hiroo; Chikamatsu, Sonoko; Narita, Koichi; Katoh, Tadashi; Ishioka, Chikashi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1469-1475</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC)/phosphatidylinositol 3-kinase (PI3K) dual inhibition is a promising strategy for the treatment of intractable cancers because of the advantages of overcoming potential resistance and showing synergistic effects.  Therefore, development of an HDAC/PI3K dual inhibitor is reasonably attractive.  Romidepsin (FK228, depsipeptide) is a potent HDAC inhibitor.  We previously reported that depsipeptide and its analogs have an addnl. activity as PI3K inhibitors and are defined as HDAC/PI3K dual inhibitors.  Subsequently, we identified FK-A11 as the most potent analog and reported its biochem., biol., and structural properties as an HDAC/PI3K dual inhibitor.  In this study, we reveal the in vitro and in vivo efficacy of FK-A11 in HT1080 fibrosarcoma and PC3 prostate cancer cell xenograft mouse models.  FK-A11 showed in vivo antitumor activity by both i.v. and i.p. administration in a dose-dependent manner.  In both xenograft models, FK-A11 showed superior antitumor effects compared to other depsipeptide analogs in accordance with in vitro anti-cell proliferation effects and the potency of HDAC/PI3K dual inhibition.  In addn., we showed evidence of HDAC/PI3K dual inhibition accompanying antitumor efficacy in xenograft tumor tissues by immunohistochem.  We also detailed pharmacokinetic characterization of FK-A11 in mice.  These findings will be essential for guiding further preclin. and clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp9mk0Hg7EP7Vg90H21EOLACvtfcHk0liAtUVmAsUEsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvF2rurY%253D&md5=e5733fa98c58aaf27902d040df4f0489</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1111%2Fcas.13255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.13255%26sid%3Dliteratum%253Aachs%26aulast%3DSaijo%26aufirst%3DK.%26aulast%3DImai%26aufirst%3DH.%26aulast%3DChikamatsu%26aufirst%3DS.%26aulast%3DNarita%26aufirst%3DK.%26aulast%3DKatoh%26aufirst%3DT.%26aulast%3DIshioka%26aufirst%3DC.%26atitle%3DAntitumor%2520activity%2520and%2520pharmacologic%2520characterization%2520of%2520the%2520depsipeptide%2520analog%2520as%2520a%2520novel%2520histone%2520deacetylase%252Fphosphatidylinositol%25203-kinase%2520dual%2520inhibitor%26jtitle%3DCancer%2520Sci.%26date%3D2017%26volume%3D108%26spage%3D1469%26epage%3D1475%26doi%3D10.1111%2Fcas.13255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of 4-methyl quinazoline derivatives as anticancer agents simultaneously targeting phosphoinositide 3-kinases and histone deacetylases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6992</span>– <span class="NLM_lpage">7014</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00390</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00390" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFamtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6992-7014&author=K.+Zhangauthor=F.+Laiauthor=S.+Linauthor=M.+Jiauthor=J.+Zhangauthor=Y.+Zhangauthor=J.+Jinauthor=R.+Fuauthor=D.+Wuauthor=H.+Tianauthor=N.+Xueauthor=L.+Shengauthor=X.+Zouauthor=Y.+Liauthor=X.+Chenauthor=H.+Xu&title=Design%2C+synthesis%2C+and+biological+evaluation+of+4-methyl+quinazoline+derivatives+as+anticancer+agents+simultaneously+targeting+phosphoinositide+3-kinases+and+histone+deacetylases&doi=10.1021%2Facs.jmedchem.9b00390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases</span></div><div class="casAuthors">Zhang, Kehui; Lai, Fangfang; Lin, Songwen; Ji, Ming; Zhang, Jingbo; Zhang, Yan; Jin, Jing; Fu, Rong; Wu, Deyu; Tian, Hua; Xue, Nina; Sheng, Li; Zou, Xiaowen; Li, Yan; Chen, Xiaoguang; Xu, Heng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6992-7014</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polypharmacol. is a promising paradigm in modern drug discovery.  Herein, we have discovered a series of novel PI3K and HDAC dual inhibitors in which the hydroxamic acid moiety as the zinc binding functional group was introduced to a quinazoline-based PI3K pharmacophore through an appropriate linker.  Systematic structure-activity relationship studies resulted in lead compds. 23 (shown in graphical abstr. and duplicated as I) and 36 (II) that simultaneously inhibited PI3K and HDAC with nanomolar potencies and demonstrated favorable antiproliferative activities.  Compds. 23 and 36 efficiently modulated the expression of p-AKT and Ac-H3, arrested the cell cycle, and induced apoptosis in HCT116 cancer cells.  Following pharmacokinetic studies, 23 was further evaluated in HCT116 and HGC-27 xenograft models to show significant in vivo anticancer efficacies with tumor growth inhibitions of 45.8% (po, 150 mg/kg) and 62.6% (i.p., 30 mg/kg), resp.  Overall, this work shows promise in discovering new anticancer therapeutics by the approach of simultaneously targeting PI3K and HDAC pathways with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6xLiFaGhwk7Vg90H21EOLACvtfcHk0liTeCb6NqTmeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFamtLg%253D&md5=de4c9a630208e49eac58dcad630adcd6</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00390%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DLai%26aufirst%3DF.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DJi%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DTian%26aufirst%3DH.%26aulast%3DXue%26aufirst%3DN.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DZou%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DH.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%25204-methyl%2520quinazoline%2520derivatives%2520as%2520anticancer%2520agents%2520simultaneously%2520targeting%2520phosphoinositide%25203-kinases%2520and%2520histone%2520deacetylases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D6992%26epage%3D7014%26doi%3D10.1021%2Facs.jmedchem.9b00390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ling, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Hybrids from farnesylthiosalicylic acid and hydroxamic acid as dual ras-related signaling and histone deacetylase (HDAC) inhibitors: design, synthesis and biological evaluation</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">971</span>– <span class="NLM_lpage">976</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1002%2Fcmdc.201500019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25882299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsF2hu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=971-976&author=Y.+Lingauthor=X.+Wangauthor=C.+Wangauthor=C.+Xuauthor=W.+Zhangauthor=Y.+Zhangauthor=Y.+Zhang&title=Hybrids+from+farnesylthiosalicylic+acid+and+hydroxamic+acid+as+dual+ras-related+signaling+and+histone+deacetylase+%28HDAC%29+inhibitors%3A+design%2C+synthesis+and+biological+evaluation&doi=10.1002%2Fcmdc.201500019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrids from Farnesylthiosalicylic Acid and Hydroxamic Acid as Dual Ras-Related Signaling and Histone Deacetylase (HDAC) Inhibitors: Design, Synthesis and Biological Evaluation</span></div><div class="casAuthors">Ling, Yong; Wang, Xuemin; Wang, Chenniu; Xu, Chenjun; Zhang, Wei; Zhang, Yihua; Zhang, Yanan</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">971-976</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A novel series of hybrids was designed and synthesized by combining key elements from farnesylthiosalicylic acid (FTS) and hydroxamic acid.  Several ((3,7,11-trimethyldodeca-2,6,10-trien-1-yl) thio)benzamide derivs., particularly those with branched and linear aliph. linkers between the hydroxamic zinc binding group (ZBG) and the benzamide core, not only displayed significant antitumor activities against six human cancer cells but also exhibited histone deacetylase (HDAC) inhibitory effects in vitro.  Among them, N-(4-(hydroxyamino)-4-oxobutyl)-2-(((2E,6E)-3,7,11-trimethyldodeca-2,6, 10-trien-1-yl)thio)benzamide (8 d) was the most potent, with IC50 values of 4.9-7.6 μM; these activities are eight- to sixteen-fold more potent than FTS and comparable to that of suberoylanilide hydroxamic acid (SAHA).  Deriv. 8 d induced cell cycle arrest in the G0/G1 phase, inhibited the acetylation of histone H3 and α-tubulin, and blocked Ras-related signaling pathways in a dose-dependent manner.  The improved tumor growth inhibition and cell-cycle arrest in vitro might result from the dual inhibition.  These findings suggest dual inhibitors of Ras-related signaling pathway and HDAC hold promise as therapeutic agents for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos_kmgrsga_LVg90H21EOLACvtfcHk0liTeCb6NqTmeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsF2hu74%253D&md5=c773e2cb644f6b8fbe8585365dc9ee4a</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500019%26sid%3Dliteratum%253Aachs%26aulast%3DLing%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DHybrids%2520from%2520farnesylthiosalicylic%2520acid%2520and%2520hydroxamic%2520acid%2520as%2520dual%2520ras-related%2520signaling%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520inhibitors%253A%2520design%252C%2520synthesis%2520and%2520biological%2520evaluation%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D971%26epage%3D976%26doi%3D10.1002%2Fcmdc.201500019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geng, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1605</span>– <span class="NLM_lpage">1608</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.04.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bmcl.2019.04.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=31053508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovVOit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=1605-1608&author=A.+Gengauthor=H.+Cuiauthor=L.+Zhangauthor=X.+Chenauthor=H.+Liauthor=T.+Luauthor=Y.+Zhu&title=Discovery+of+novel+phenoxybenzamide+analogues+as+Raf%2FHDAC+dual+inhibitors&doi=10.1016%2Fj.bmcl.2019.04.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors</span></div><div class="casAuthors">Geng, Aixin; Cui, Hao; Zhang, Liyuan; Chen, Xin; Li, Hongmei; Lu, Tao; Zhu, Yong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1605-1608</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors as an important epigenetic therapeutic strategy affect signaling networks and act synergistically with kinase inhibitors for the treatment of cancer.  Herein we presented a series of novel phenoxybenzamide analogs with inhibition of Raf and HDAC.  Among them, compd. 10e(I) showed potent antiproliferative activities against Hepg2 and MDA-MB-468 in cellular assays.  This work may lay the foundation for developing novel dual Raf/HDAC inhibitors as potential anticancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCeQkNSnZrhrVg90H21EOLACvtfcHk0liS6NNiu5ogSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovVOit7w%253D&md5=2297e664553d245952780736f9ace3eb</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.04.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.04.047%26sid%3Dliteratum%253Aachs%26aulast%3DGeng%26aufirst%3DA.%26aulast%3DCui%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520novel%2520phenoxybenzamide%2520analogues%2520as%2520Raf%252FHDAC%2520dual%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D1605%26epage%3D1608%26doi%3D10.1016%2Fj.bmcl.2019.04.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitiss, J. L.</span></span> <span> </span><span class="NLM_article-title">Roles of eukaryotic topoisomerases in transcription, replication and genomic stability</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">703</span>– <span class="NLM_lpage">721</span>, <span class="refDoi"> DOI: 10.1038/nrm.2016.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnrm.2016.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=27649880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFemsbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=703-721&author=Y.+Pommierauthor=Y.+Sunauthor=S.+N.+Huangauthor=J.+L.+Nitiss&title=Roles+of+eukaryotic+topoisomerases+in+transcription%2C+replication+and+genomic+stability&doi=10.1038%2Fnrm.2016.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of eukaryotic topoisomerases in transcription, replication and genomic stability</span></div><div class="casAuthors">Pommier, Yves; Sun, Yilun; Huang, Shar-yin N.; Nitiss, John L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">703-721</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Topoisomerases introduce transient DNA breaks to relax supercoiled DNA, remove catenanes and enable chromosome segregation.  Human cells encode six topoisomerases (TOP1, TOP1mt, TOP2α, TOP2β, TOP3α and TOP3β), which act on a broad range of DNA and RNA substrates at the nuclear and mitochondrial genomes.  Their catalytic intermediates, the topoisomerase cleavage complexes (TOPcc), are therapeutic targets of various anticancer drugs.  TOPcc can also form on damaged DNA during replication and transcription, and engage specific repair pathways, such as those mediated by tyrosyl-DNA phosphodiesterase 1 (TDP1) and TDP2 and by endonucleases (MRE11, XPF-ERCC1 and MUS81).  Here, we review the roles of topoisomerases in mediating chromatin dynamics, transcription, replication, DNA damage repair and genomic stability, and discuss how deregulation of topoisomerases can cause neurodegenerative diseases, immune disorders and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2RnRxdI5gv7Vg90H21EOLACvtfcHk0ljfjB3JsmfAIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFemsbvO&md5=d1e6b3015a76a21ff92502f7e4eb5016</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1038%2Fnrm.2016.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm.2016.111%26sid%3Dliteratum%253Aachs%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DS.%2BN.%26aulast%3DNitiss%26aufirst%3DJ.%2BL.%26atitle%3DRoles%2520of%2520eukaryotic%2520topoisomerases%2520in%2520transcription%252C%2520replication%2520and%2520genomic%2520stability%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2016%26volume%3D17%26spage%3D703%26epage%3D721%26doi%3D10.1038%2Fnrm.2016.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piccartgebhart, M. J.</span></span> <span> </span><span class="NLM_article-title">Anthracyclines and the tailoring of treatment for early breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>354</i></span>,  <span class="NLM_fpage">2177</span>– <span class="NLM_lpage">2179</span>, <span class="refDoi"> DOI: 10.1056/NEJMe068065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1056%2FNEJMe068065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16707755" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2006&pages=2177-2179&author=M.+J.+Piccartgebhart&title=Anthracyclines+and+the+tailoring+of+treatment+for+early+breast+cancer&doi=10.1056%2FNEJMe068065"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1056%2FNEJMe068065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe068065%26sid%3Dliteratum%253Aachs%26aulast%3DPiccartgebhart%26aufirst%3DM.%2BJ.%26atitle%3DAnthracyclines%2520and%2520the%2520tailoring%2520of%2520treatment%2520for%2520early%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D354%26spage%3D2177%26epage%3D2179%26doi%3D10.1056%2FNEJMe068065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span> <span> </span><span class="NLM_article-title">Acridine and its derivatives: a patent review (2009 - 2013)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">664</span>, <span class="refDoi"> DOI: 10.1517/13543776.2014.902052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1517%2F13543776.2014.902052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=24848259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotF2rs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=647-664&author=B.+Zhangauthor=X.+Liauthor=B.+Liauthor=C.+Gaoauthor=Y.+Jiang&title=Acridine+and+its+derivatives%3A+a+patent+review+%282009+-+2013%29&doi=10.1517%2F13543776.2014.902052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Acridine and its derivatives: a patent review (2009 - 2013)</span></div><div class="casAuthors">Zhang, Bin; Li, Xi; Li, Bin; Gao, Chunmei; Jiang, Yuyang</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">647-664</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Acridine derivs. were extensively explored as potential therapeutic agents for the treatment of a no. of diseases, such as cancer, Alzheimer's, and bacterial and protozoan infections.  Their mode of action is mainly attributed to DNA intercalation and the subsequent effects on the biol. processes linked to DNA and its related enzymes.  This review covers the relevant efforts in developing acridine derivs. with enhanced therapeutic potency and selectivity and as fluorescent materials, with particular focus on the newly patented acridine derivs. in 2009 - 2013, acridine drugs in clin. trials and preclin. studies, and other new derivs. that emerged in 2009 - 2013.  Thousands of acridines with therapeutic and biol. activities or with photochem. properties were developed.  In addn., to modify the position and the nature of the substituent on the acridine core, more attention may be paid to the development of azaacridine or other heteroatom-substituted acridine derivs. and their synthesis methods to broaden the application of acridine derivs.  In cancer chemotherapy, the mode of action of acridine derivs. needs to be further studied.  Efficient methods for identification and optimization of acridine derivs. to localize at the sites of disease need to be further developed.  Moreover, acridine drugs may be combined with such bioactive agents as DNA repair proteins inhibitors to overcome tumor resistance and improve outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOqFeloBU-pbVg90H21EOLACvtfcHk0liU4EF3CIuBbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotF2rs7w%253D&md5=b8dfcb53419445f05a339ab76b17d2a3</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.902052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.902052%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DY.%26atitle%3DAcridine%2520and%2520its%2520derivatives%253A%2520a%2520patent%2520review%2520%25282009%2520-%25202013%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D647%26epage%3D664%26doi%3D10.1517%2F13543776.2014.902052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlhagen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrier, F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">7291</span>– <span class="NLM_lpage">7300</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=14612526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVGlt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=7291-7300&author=M.+S.+Kimauthor=M.+Blakeauthor=H.+B.+Jinauthor=G.+Kohlhagenauthor=Y.+Pommierauthor=F.+Carrier&title=Inhibition+of+histone+deacetylase+increases+cytotoxicity+to+anticancer+drugs+targeting+DNA"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Histone Deacetylase Increases Cytotoxicity to Anticancer Drugs Targeting DNA</span></div><div class="casAuthors">Kim, Myoung Sook; Blake, Mellissa; Baek, Jin Hyen; Kohlhagen, Glenda; Pommier, Yves; Carrier, France</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7291-7300</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Several anticancer drugs target DNA or enzymes acting on the DNA.  Because chromatin DNA is tightly compacted, accessibility to the drug target may reduce the efficiency of these anticancer drugs.  We thus treated four human cancer cell lines and two normal epithelial cell lines with either trichostatin A (TSA) or SAHA, two histone deacetylase inhibitors, before exposing the cells to VP-16, ellipticine, camptothecin, doxorubicin, cisplatin, 5-fluorouracil, or cyclophosphamide.  Pretreatment with TSA or SAHA increased the killing efficiency of VP-16, ellipticine, doxorubicin, and cisplatin.  The magnitude of sensitization is cell type specific and is >10-fold for VP-16 in D54, a brain tumor cell line intrinsically resistant to topoisomerase II inhibitors.  Topoisomerase II levels and activity were not affected by this treatment, but p53, p21, and Gadd45 protein levels were markedly induced.  Moreover, pretreatment with TSA also increased VP-16-induced apoptosis in a p53-dependent and -independent manner.  Treating the cells in the reverse order (anticancer drug first, followed by TSA or SAHA) had no more cytotoxic effect than the drug alone.  These data suggest that loosening-up the chromatin structure by histone acetylation can increase the efficiency of several anticancer drugs targeting DNA.  This may be advantageous for treating tumors intrinsically resistant to these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq24HjggpPirLVg90H21EOLACvtfcHk0ljse_oB7yF1Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVGlt70%253D&md5=6fe3bc8b32550917fc8f80ac648e680b</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%2BS.%26aulast%3DBlake%26aufirst%3DM.%26aulast%3DJin%26aufirst%3DH.%2BB.%26aulast%3DKohlhagen%26aufirst%3DG.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DCarrier%26aufirst%3DF.%26atitle%3DInhibition%2520of%2520histone%2520deacetylase%2520increases%2520cytotoxicity%2520to%2520anticancer%2520drugs%2520targeting%2520DNA%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D7291%26epage%3D7300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Catalano, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortunati, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugliese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosco, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastrocola, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aragno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boccuzzi, G.</span></span> <span> </span><span class="NLM_article-title">Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells</span>. <i>J. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">465</span>– <span class="NLM_lpage">472</span>, <span class="refDoi"> DOI: 10.1677/joe.1.06970</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1677%2Fjoe.1.06970" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=17088416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlejsLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2006&pages=465-472&author=M.+G.+Catalanoauthor=N.+Fortunatiauthor=M.+Puglieseauthor=R.+Poliauthor=O.+Boscoauthor=R.+Mastrocolaauthor=M.+Aragnoauthor=G.+Boccuzzi&title=Valproic+acid%2C+a+histone+deacetylase+inhibitor%2C+enhances+sensitivity+to+doxorubicin+in+anaplastic+thyroid+cancer+cells&doi=10.1677%2Fjoe.1.06970"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells</span></div><div class="casAuthors">Catalano, Maria G.; Fortunati, Nicoletta; Pugliese, Mariateresa; Poli, Roberta; Bosco, Ornella; Mastrocola, Raffaella; Aragno, Manuela; Boccuzzi, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Endocrinology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">465-472</span>CODEN:
                <span class="NLM_cas:coden">JOENAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-0795</span>.
    
            (<span class="NLM_cas:orgname">Society for Endocrinology</span>)
        </div><div class="casAbstract">Multimodality treatments (i.e. surgery, chemotherapy, and radiotherapy) are recommended for anaplastic thyroid carcinoma (ATC), an extremely lethal human cancer, but to date there is little evidence that such approaches improve survival rates.  It is thus necessary to seek new therapeutic tools.  Histone deacetylase (HDAC) inhibitors are a promising class of antineoplastic agents that induce differentiation and apoptosis.  Moreover, they may enhance the cytotoxicity of drugs targeting DNA through acetylation of histones.  Using two ATC cell lines (CAL-62 and ARO), we show here that valproic acid (VPA), a clin. available HDAC inhibitor, enhances the activity of doxorubicin, whose antitumor properties involve binding to DNA and inhibiting topoisomerase II.  A meager 0·7 mM VPA, which corresponds to serum concns. in patients treated for epilepsy, is able to increase the cytotoxicity of doxorubicin about threefold in CAL-62 cells and twofold in ARO cells.  The sensitizing effect, which is through histone acetylation, involves increased apoptosis, which is also shown by the increased caspase 3 activation and the enhancement of doxorubicin-induced G2 cell cycle arrest.  These results might offer a rationale for clin. studies of a new combined therapy in an effort to improve the outcome of patients with anaplastic thyroid cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmTtQReyIxnrVg90H21EOLACvtfcHk0lhB3UyIsfHoOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlejsLrM&md5=c5f3780cd38d2ca4b53c7812f9e49836</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1677%2Fjoe.1.06970&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252Fjoe.1.06970%26sid%3Dliteratum%253Aachs%26aulast%3DCatalano%26aufirst%3DM.%2BG.%26aulast%3DFortunati%26aufirst%3DN.%26aulast%3DPugliese%26aufirst%3DM.%26aulast%3DPoli%26aufirst%3DR.%26aulast%3DBosco%26aufirst%3DO.%26aulast%3DMastrocola%26aufirst%3DR.%26aulast%3DAragno%26aufirst%3DM.%26aulast%3DBoccuzzi%26aufirst%3DG.%26atitle%3DValproic%2520acid%252C%2520a%2520histone%2520deacetylase%2520inhibitor%252C%2520enhances%2520sensitivity%2520to%2520doxorubicin%2520in%2520anaplastic%2520thyroid%2520cancer%2520cells%26jtitle%3DJ.%2520Endocrinol.%26date%3D2006%26volume%3D191%26spage%3D465%26epage%3D472%26doi%3D10.1677%2Fjoe.1.06970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padget, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, B. M.</span></span> <span> </span><span class="NLM_article-title">Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">4539</span>– <span class="NLM_lpage">4542</span>, <span class="refDoi"> DOI: 10.1074/jbc.C000824200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1074%2Fjbc.C000824200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=11136718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtlOqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=4539-4542&author=C.+A.+Johnsonauthor=K.+Padgetauthor=C.+A.+Austinauthor=B.+M.+Turner&title=Deacetylase+activity+associates+with+topoisomerase+II+and+is+necessary+for+etoposide-induced+apoptosis&doi=10.1074%2Fjbc.C000824200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis</span></div><div class="casAuthors">Johnson, Colin A.; Padget, Kay; Austin, Caroline A.; Turner, Bryan M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4539-4542</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">DNA topoisomerase II (topo II) is a ubiquitous nuclear enzyme that is involved in DNA replication, transcription, chromosome segregation, and apoptosis.  Here we show by immunopptn., pull down with glutathione S-transferase fusion proteins, and yeast two-hybrid anal. that both topo IIα and -β phys. interact with the histone deacetylase HDAC1.  The in vitro DNA decatenation activity of recombinant topo IIα and -β is inhibited by assocn. with catalytically inactive, recombinant HDAC1.  We provide evidence for the in vivo significance of the topo II-HDAC1 assocn., showing that inhibition of HDAC activity with trichostatin A suppresses apoptosis induced by the topo II poison etoposide, but not by the topoisomerase I inhibitor camptothecin.  We suggest that chromatin remodeling by an HDAC-contg. complex facilitates both topo II-catalyzed DNA rearrangement and etoposide-induced DNA damage in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG-EArV25rfLVg90H21EOLACvtfcHk0lhB3UyIsfHoOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtlOqsLg%253D&md5=8cfacaa935b0351d3cf55aad2405b138</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C000824200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C000824200%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DC.%2BA.%26aulast%3DPadget%26aufirst%3DK.%26aulast%3DAustin%26aufirst%3DC.%2BA.%26aulast%3DTurner%26aufirst%3DB.%2BM.%26atitle%3DDeacetylase%2520activity%2520associates%2520with%2520topoisomerase%2520II%2520and%2520is%2520necessary%2520for%2520etoposide-induced%2520apoptosis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D4539%26epage%3D4542%26doi%3D10.1074%2Fjbc.C000824200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marchion, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bicaku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span> <span> </span><span class="NLM_article-title">Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1002/jcb.20045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1002%2Fjcb.20045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15108350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvVaqs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2004&pages=223-237&author=D.+C.+Marchionauthor=E.+Bicakuauthor=A.+I.+Daudauthor=V.+Richonauthor=D.+M.+Sullivanauthor=P.+N.+Munster&title=Sequence-specific+potentiation+of+topoisomerase+II+inhibitors+by+the+histone+deacetylase+inhibitor+suberoylanilide+hydroxamic+acid&doi=10.1002%2Fjcb.20045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid</span></div><div class="casAuthors">Marchion, Douglas C.; Bicaku, Elona; Daud, Adil I.; Richon, Victoria; Sullivan, Daniel M.; Munster, Pamela N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">223-237</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Acetylation of histones leads to conformational changes of DNA.  We have previously shown that the histone deacetylase (HDAC) inhibitor, suberoylanilide hydroxamic acid (SAHA), induced cell cycle arrest, differentiation, and apoptosis.  In addn. to their antitumor effects as single agents, HDAC inhibitors may cause conformational changes in the chromatin, rendering the DNA more vulnerable to DNA damaging agents.  We examd. the effects of SAHA on cell death induced by topo II inhibitors in breast cancer cell lines.  Topo II inhibitors stabilize the topo II-DNA complex, resulting in DNA damage.  Treatment of cells with SAHA promoted chromatin decondensation assocd. with increased nuclear concn. and DNA binding of the topo II inhibitor and subsequent potentiation of DNA damage.  While SAHA-induced histone hyperacetylation occurred as early as 4 h, chromatin decondensation was most profound at 48 h.  SAHA-induced potentiation of topo II inhibitors was sequence-specific.  Pre-exposure of cells to SAHA for 48 h was synergistic, whereas shorter pre-exposure periods abrogated synergy and exposure of cells to SAHA after the topo II inhibitor resulted in antagonistic effects.  Synergy was not obsd. in cells with depleted topo II levels.  These effects were not limited to specific types of topo II inhibitors.  We propose that SAHA significantly potentiates the DNA damage induced by topo II inhibitors; however, synergy is dependent on the sequence of drug administration and the expression of the target.  These findings may impact the clin. development of combining HDAC inhibitors with DNA damaging agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd_EzmdHJvU7Vg90H21EOLACvtfcHk0lhB3UyIsfHoOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvVaqs7c%253D&md5=71f10a1a96c0e666a5f410c9b32a3893</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1002%2Fjcb.20045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.20045%26sid%3Dliteratum%253Aachs%26aulast%3DMarchion%26aufirst%3DD.%2BC.%26aulast%3DBicaku%26aufirst%3DE.%26aulast%3DDaud%26aufirst%3DA.%2BI.%26aulast%3DRichon%26aufirst%3DV.%26aulast%3DSullivan%26aufirst%3DD.%2BM.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26atitle%3DSequence-specific%2520potentiation%2520of%2520topoisomerase%2520II%2520inhibitors%2520by%2520the%2520histone%2520deacetylase%2520inhibitor%2520suberoylanilide%2520hydroxamic%2520acid%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2004%26volume%3D92%26spage%3D223%26epage%3D237%26doi%3D10.1002%2Fjcb.20045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Gennaro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desideri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budillon, A.</span></span> <span> </span><span class="NLM_article-title">Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3075</span>– <span class="NLM_lpage">3087</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0254</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1535-7163.MCT-09-0254" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=19887547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlyrt7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=3075-3087&author=F.+Bruzzeseauthor=M.+Roccoauthor=S.+Castelliauthor=E.+Di+Gennaroauthor=A.+Desideriauthor=A.+Budillon&title=Synergistic+antitumor+effect+between+vorinostat+and+topotecan+in+small+cell+lung+cancer+cells+is+mediated+by+generation+of+reactive+oxygen+species+and+DNA+damage-induced+apoptosis&doi=10.1158%2F1535-7163.MCT-09-0254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis</span></div><div class="casAuthors">Bruzzese, Francesca; Rocco, Monia; Castelli, Silvia; Di Gennaro, Elena; Desideri, Alessandro; Budillon, Alfredo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3075-3087</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The topoisomerase-I (topo-I) inhibitor topotecan, deriv. of camptothecin, is the only registered drug for relapsed small cell lung cancer (SCLC).  The histone deacetylase inhibitor vorinostat has shown preclin. and clin. antitumor activities in hematol. malignancies and solid tumors, including SCLC, and has recently been approved for the treatment of cutaneous T-cell lymphomas.  In this study, we analyzed the antitumor effect of vorinostat combined with topotecan or camptothecin in topo-I inhibitor-sensitive H209 and inhibitor-resistant H526 SCLC cells.  Simultaneous or sequential exposure (24 h delay) to either agent resulted in strong synergistic cytotoxic effect in both cell lines, as shown by calcg. combination index, and confirmed by growth in soft agar.  Combination treatments increased S-phase cell cycle arrest paralleled by apoptosis as measured by hypodiploid peak formation, Annexin V binding, DNA fragmentation, and mitochondria destruction.  The apoptotic process was triggered by a caspase-dependent mechanism and can be ascribed to the phosphorylation of H2AX, a reporter of DNA double-strand breaks.  These effects were paralleled by an increase of topo-I/DNA covalent complexes induced by combination treatment and suggest a potentiation by vorinostat of topotecan-induced DNA damage.  Finally, oxidative injury played a significant functional role in the obsd. enhanced lethality because coadministration of the antioxidant N-acetyl-L-cysteine blocked reactive oxygen species generation, apoptosis, and mitochondria destruction induced by the vorinostat/topotecan combination.  To our knowledge, this is the first demonstration of a synergistic antitumor effect between topotecan and vorinostat in SCLC.  Because no well-established treatment is available for recurrent SCLC patients, our results indicate that this drug combination should be explored clin. [Mol Cancer Ther 2009;8(11):3075-87].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriNbJiuKn7ILVg90H21EOLACvtfcHk0lgi7tEVfGHyQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlyrt7%252FI&md5=0fb0ac896a935ac119556374394615a7</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0254%26sid%3Dliteratum%253Aachs%26aulast%3DBruzzese%26aufirst%3DF.%26aulast%3DRocco%26aufirst%3DM.%26aulast%3DCastelli%26aufirst%3DS.%26aulast%3DDi%2BGennaro%26aufirst%3DE.%26aulast%3DDesideri%26aufirst%3DA.%26aulast%3DBudillon%26aufirst%3DA.%26atitle%3DSynergistic%2520antitumor%2520effect%2520between%2520vorinostat%2520and%2520topotecan%2520in%2520small%2520cell%2520lung%2520cancer%2520cells%2520is%2520mediated%2520by%2520generation%2520of%2520reactive%2520oxygen%2520species%2520and%2520DNA%2520damage-induced%2520apoptosis%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D3075%26epage%3D3087%26doi%3D10.1158%2F1535-7163.MCT-09-0254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetter, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamara, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gresh, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, E. A.</span></span> <span> </span><span class="NLM_article-title">Vorinostat enhances cytotoxicity of SN-38 and temozolomide in ewing sarcoma cells and activates STAT3/AKT/MAPK pathways</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e0142704</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0142704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1371%2Fjournal.pone.0142704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=26571493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVSjsLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0142704&author=V.+B.+Sampsonauthor=N.+S.+Vetterauthor=D.+F.+Kamaraauthor=A.+B.+Collierauthor=R.+C.+Greshauthor=E.+A.+Kolb&title=Vorinostat+enhances+cytotoxicity+of+SN-38+and+temozolomide+in+ewing+sarcoma+cells+and+activates+STAT3%2FAKT%2FMAPK+pathways&doi=10.1371%2Fjournal.pone.0142704"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Vorinostat enhances cytotoxicity of SN-38 and temozolomide in Ewing sarcoma cells and activates STAT3/AKT/MAPK pathways</span></div><div class="casAuthors">Sampson, Valerie B.; Vetter, Nancy S.; Kamara, Davida F.; Collier, Anderson B.; Gresh, Renee C.; Kolb, E. Anders</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e0142704/1-e0142704/19</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACi) have been evaluated in patients with Ewing sarcoma (EWS) but demonstrated limited activity.  To better understand the potential for HDACi in EWS, we evaluated the combination of the HDACi vorinostat, with DNA damaging agents SN-38 (the active metabolite of irinotecan and topoisomerase 1 inhibitor) plus the alkylating agent temozolomide (ST).  Drugs were evaluated in sequential and simultaneous combinations in two EWS cell lines.  Results demonstrate that cell viability, DNA damage and reactive oxygen species (ROS) prodn. are dependent on the sequence of drug administration.  Enhanced cytotoxicity is exhibited in vitro in EWS cell lines treated with ST administered before vorinostat, which was modestly higher than concomitant treatment and superior to vorinostat administered before ST.  Drug combinations downregulate cyclin D1 to induce G0/G1 arrest and promote apoptosis by cleavage of caspase-3 and PARP.  When ST is administered before or concomitantly with vorinostat there is activation of STAT3, MAPK and the p53 pathway.  In contrast, when vorinostat is administered before ST, there is DNA repair, increased AKT phosphorylation and reduced H2B acetylation.  Inhibition of AKT using the small mol. inhibitor MK-2206 did not restore H2B acetylation.  Combining ST with the dual ALK and IGF-1R inhibitor, AZD3463 simultaneously inhibited STAT3 and AKT to enhance the cytotoxic effects of ST and further reduce cell growth suggesting that STAT3 and AKT activation were in part mediated by ALK and IGF-1R signaling.  In summary, potent antiproliferative and proapoptotic activity were demonstrated for ST induced DNA damage before or simultaneous with HDAC inhibition and cell death was mediated through the p53 pathway.  These observations may aid in designing new protocols for treating pediatric patients with high-risk EWS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-wHLOu1A8BrVg90H21EOLACvtfcHk0lgi7tEVfGHyQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVSjsLnE&md5=43b299bbd5a1b2d3bd102545fa5a578f</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0142704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0142704%26sid%3Dliteratum%253Aachs%26aulast%3DSampson%26aufirst%3DV.%2BB.%26aulast%3DVetter%26aufirst%3DN.%2BS.%26aulast%3DKamara%26aufirst%3DD.%2BF.%26aulast%3DCollier%26aufirst%3DA.%2BB.%26aulast%3DGresh%26aufirst%3DR.%2BC.%26aulast%3DKolb%26aufirst%3DE.%2BA.%26atitle%3DVorinostat%2520enhances%2520cytotoxicity%2520of%2520SN-38%2520and%2520temozolomide%2520in%2520ewing%2520sarcoma%2520cells%2520and%2520activates%2520STAT3%252FAKT%252FMAPK%2520pathways%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0142704%26doi%3D10.1371%2Fjournal.pone.0142704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cincinelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musso, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artali, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guglielmi, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Porta, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardile, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Signorino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fucci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frusciante, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallavalle, S.</span></span> <span> </span><span class="NLM_article-title">Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">e0205018</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0205018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1371%2Fjournal.pone.0205018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=30300374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtV2lt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=e0205018&author=R.+Cincinelliauthor=L.+Mussoauthor=R.+Artaliauthor=M.+B.+Guglielmiauthor=I.+La+Portaauthor=C.+Melitoauthor=F.+Colelliauthor=F.+Cardileauthor=G.+Signorinoauthor=A.+Fucciauthor=M.+Fruscianteauthor=C.+Pisanoauthor=S.+Dallavalle&title=Hybrid+topoisomerase+I+and+HDAC+inhibitors+as+dual+action+anticancer+agents&doi=10.1371%2Fjournal.pone.0205018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents</span></div><div class="casAuthors">Cincinelli, Raffaella; Musso, Loana; Artali, Roberto; Guglielmi, Mario B.; La Porta, Ilaria; Melito, Carmela; Colelli, Fabiana; Cardile, Francesco; Signorino, Giacomo; Fucci, Alessandra; Frusciante, Martina; Pisano, Claudio; Dallavalle, Sabrina</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e0205018/1-e0205018/22</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Recent studies have shown that HDAC inhibitors act synergistically with camptothecin derivs. in combination therapies.  To exploit this synergy, new hybrid mols. targeting simultaneously topoisomerase I and HDAC were designed.  In particular, a selected multivalent agent contg. a camptothecin and a SAHA-like template showed a broad spectrum of antiproliferative activity, with IC50 values in the nanomolar range.  Preliminary in vivo results indicated a strong antitumor activity on human mesothelioma primary cell line MM473 orthotopically xenografted in CD-1 nude mice and very high tolerability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzxTP2b69aALVg90H21EOLACvtfcHk0lgi7tEVfGHyQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtV2lt7g%253D&md5=8a96bd41321339c6ac43f108dd478cef</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0205018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0205018%26sid%3Dliteratum%253Aachs%26aulast%3DCincinelli%26aufirst%3DR.%26aulast%3DMusso%26aufirst%3DL.%26aulast%3DArtali%26aufirst%3DR.%26aulast%3DGuglielmi%26aufirst%3DM.%2BB.%26aulast%3DLa%2BPorta%26aufirst%3DI.%26aulast%3DMelito%26aufirst%3DC.%26aulast%3DColelli%26aufirst%3DF.%26aulast%3DCardile%26aufirst%3DF.%26aulast%3DSignorino%26aufirst%3DG.%26aulast%3DFucci%26aufirst%3DA.%26aulast%3DFrusciante%26aufirst%3DM.%26aulast%3DPisano%26aufirst%3DC.%26aulast%3DDallavalle%26aufirst%3DS.%26atitle%3DHybrid%2520topoisomerase%2520I%2520and%2520HDAC%2520inhibitors%2520as%2520dual%2520action%2520anticancer%2520agents%26jtitle%3DPLoS%2520One%26date%3D2018%26volume%3D13%26spage%3De0205018%26doi%3D10.1371%2Fjournal.pone.0205018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cincinelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musso, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artali, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guglielmi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardile, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallavalle, S.</span></span> <span> </span><span class="NLM_article-title">Camptothecin-psammaplin a hybrids as topoisomerase I and HDAC dual-action inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">2005</span>– <span class="NLM_lpage">2014</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.11.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.ejmech.2017.11.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=29150335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvValtrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=2005-2014&author=R.+Cincinelliauthor=L.+Mussoauthor=R.+Artaliauthor=M.+Guglielmiauthor=E.+Bianchinoauthor=F.+Cardileauthor=F.+Colelliauthor=C.+Pisanoauthor=S.+Dallavalle&title=Camptothecin-psammaplin+a+hybrids+as+topoisomerase+I+and+HDAC+dual-action+inhibitors&doi=10.1016%2Fj.ejmech.2017.11.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors</span></div><div class="casAuthors">Cincinelli, Raffaella; Musso, Loana; Artali, Roberto; Guglielmi, Mario; Bianchino, Erminia; Cardile, Francesco; Colelli, Fabiana; Pisano, Claudio; Dallavalle, Sabrina</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2005-2014</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Recent studies have demonstrated enhanced anticancer effects of combination therapy consisting of camptothecin derivs. and HDAC inhibitors.  To exploit this synergy in a single active compd., we designed new dual-acting multivalent mols. simultaneously targeting topoisomerase I and HDAC.  In particular, a selected compd. contg. a camptothecin and the psammaplin A scaffold showed a broad spectrum of antiproliferative activity, with IC50 values in the nanomolar range.  Preliminary in vivo results indicated a strong antitumor activity on human mesothelioma primary cell line MM473 orthotopically xenografted in CD-1 nude mice and very high tolerability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeTdxpoD4KiLVg90H21EOLACvtfcHk0ljYIGabB72vRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvValtrbN&md5=9fd01d994120980ed2a28fdbcf90f14d</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.11.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.11.021%26sid%3Dliteratum%253Aachs%26aulast%3DCincinelli%26aufirst%3DR.%26aulast%3DMusso%26aufirst%3DL.%26aulast%3DArtali%26aufirst%3DR.%26aulast%3DGuglielmi%26aufirst%3DM.%26aulast%3DBianchino%26aufirst%3DE.%26aulast%3DCardile%26aufirst%3DF.%26aulast%3DColelli%26aufirst%3DF.%26aulast%3DPisano%26aufirst%3DC.%26aulast%3DDallavalle%26aufirst%3DS.%26atitle%3DCamptothecin-psammaplin%2520a%2520hybrids%2520as%2520topoisomerase%2520I%2520and%2520HDAC%2520dual-action%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D143%26spage%3D2005%26epage%3D2014%26doi%3D10.1016%2Fj.ejmech.2017.11.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span> <span> </span><span class="NLM_article-title">The discovery and optimization of novel dual inhibitors of topoisomerase ii and histone deacetylase</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">6981</span>– <span class="NLM_lpage">6995</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.09.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bmc.2013.09.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=24095018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOlurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=6981-6995&author=X.+Zhangauthor=B.+Baoauthor=X.+Yuauthor=L.+Tongauthor=Y.+Luoauthor=Q.+Huangauthor=M.+Suauthor=L.+Shengauthor=J.+Liauthor=H.+Zhuauthor=B.+Yangauthor=X.+Zhangauthor=Y.+Chenauthor=W.+Lu&title=The+discovery+and+optimization+of+novel+dual+inhibitors+of+topoisomerase+ii+and+histone+deacetylase&doi=10.1016%2Fj.bmc.2013.09.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase</span></div><div class="casAuthors">Zhang, Xuan; Bao, Bin; Yu, Xiuhua; Tong, Linjiang; Luo, Yu; Huang, Qingqing; Su, Mingbo; Sheng, Li; Li, Jia; Zhu, Hong; Yang, Bo; Zhang, Xiongwen; Chen, Yi; Lu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6981-6995</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel class of podophyllotoxin derivs. have been designed and synthesized based on the synergistic antitumor effects of topoisomerase II and histone deacetylase inhibitors.  Their inhibitory activities towards histone deacetylases and Topo II and their cytotoxicities in cancer cell lines were evaluated.  The arom. capping group connection, linker length and zinc-binding group were systematically varied and preliminary conclusions regarding structure-activity relationships are discussed.  Among all of the synthesized hybrid compds., compd. I showed the most potent HDAC inhibitory activity at a low nanomolar level and exhibited powerful antiproliferative activity towards HCT116 colon carcinoma cells at a low micromolar level.  Further exploration of this series led to the discovery of potent dual inhibitor II, which exhibited the strongest in vitro cytotoxic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2q6l9WK2gW7Vg90H21EOLACvtfcHk0ljYIGabB72vRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOlurnE&md5=e983212ec3320d5606018e94063f98ad</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.09.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.09.023%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DBao%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DW.%26atitle%3DThe%2520discovery%2520and%2520optimization%2520of%2520novel%2520dual%2520inhibitors%2520of%2520topoisomerase%2520ii%2520and%2520histone%2520deacetylase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D6981%26epage%3D6995%26doi%3D10.1016%2Fj.bmc.2013.09.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3958</span>– <span class="NLM_lpage">3966</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.06.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bmc.2018.06.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=29954683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1SjsLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=3958-3966&author=J.+Chenauthor=D.+Liauthor=W.+Liauthor=J.+Yinauthor=Y.+Zhangauthor=Z.+Yuanauthor=C.+Gaoauthor=F.+Liuauthor=Y.+Jiang&title=Design%2C+synthesis+and+anticancer+evaluation+of+acridine+hydroxamic+acid+derivatives+as+dual+Topo+and+HDAC+inhibitors&doi=10.1016%2Fj.bmc.2018.06.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors</span></div><div class="casAuthors">Chen, Jiwei; Li, Dan; Li, Wenlu; Yin, Jingxian; Zhang, Yueying; Yuan, Zigao; Gao, Chunmei; Liu, Feng; Jiang, Yuyang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3958-3966</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Multitarget inhibitors design has generated great interest in cancer treatment.  Based on the synergistic effects of topoisomerase and histone deacetylase inhibitors, we designed and synthesized a new series of acridine hydroxamic acid derivs. as potential novel dual Topo and HDAC inhibitors.  MTT assays indicated that all the hybrid compds. displayed good antiproliferative activities with IC50 values in low micromolar range, among which compd. 8c displayed potent activity against U937 (IC50=0.90μM).  In addn., compd. 8c also displayed the best HDAC inhibitory activity, which was several times more potent than HDAC inhibitor SAHA.  Subsequent studies indicated that all the compds. displayed Topo II inhibition activity at 50μM.  Moreover, compd. 8c could interact with DNA and induce U937 apoptosis.  This study provides a suite of compds. for further exploration of dual Topo and HDAC inhibitors, and compd. 8c can be a new dual Topo and HDAC inhibitory anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCVb9uGhgIqrVg90H21EOLACvtfcHk0ljYIGabB72vRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1SjsLrM&md5=bb2ad2ab72c4a871c1ecabda608d31b9</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.06.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.06.016%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DJiang%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%2520and%2520anticancer%2520evaluation%2520of%2520acridine%2520hydroxamic%2520acid%2520derivatives%2520as%2520dual%2520Topo%2520and%2520HDAC%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D3958%26epage%3D3966%26doi%3D10.1016%2Fj.bmc.2018.06.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guerrant, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canzoneri, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyelere, A. K.</span></span> <span> </span><span class="NLM_article-title">Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1465</span>– <span class="NLM_lpage">1477</span>, <span class="refDoi"> DOI: 10.1021/jm200799p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200799p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVyhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1465-1477&author=W.+Guerrantauthor=V.+Patilauthor=J.+C.+Canzoneriauthor=A.+K.+Oyelere&title=Dual+targeting+of+histone+deacetylase+and+topoisomerase+II+with+novel+bifunctional+inhibitors&doi=10.1021%2Fjm200799p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Targeting of Histone Deacetylase and Topoisomerase II with Novel Bifunctional Inhibitors</span></div><div class="casAuthors">Guerrant, William; Patil, Vishal; Canzoneri, Joshua C.; Oyelere, Adegboyega K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1465-1477</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Strategies to ameliorate the flaws of current chemotherapeutic agents, while maintaining potent anticancer activity, are of particular interest.  Agents which can modulate multiple targets may have superior utility and fewer side effects than current single-target drugs.  To explore the prospect in cancer therapy of a bivalent agent that combines two complementary chemo-active groups within a single mol. architecture, we have synthesized dual-acting histone deacetylase and topoisomerase II inhibitors.  These dual-acting agents are derived from suberoylanilide hydroxamic acid (SAHA) and anthracycline daunorubicin, prototypical histone deacetylase (HDAC) and topoisomerase II (Topo II) inhibitors, resp.  For example, 4-aminobenzyl alc. reacted with suberic anhydride to give 4-HOCH2C6H4NHCO(CH2)6CO2H, which was oxidized to the corresponding benzaldehyde.  This benzaldehyde reacted with H2NOCPh3 to give the terminal O-tritylated amide, which, after addn. to daunorubicin HCl and removal of the trityl group, produced conjugate I.  We report herein that these agents present the signatures of inhibition of HDAC and Topo II in both cell-free and whole-cell assays.  Moreover, these agents potently inhibit the proliferation of representative cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_Yf6AQQjHxLVg90H21EOLACvtfcHk0li-rjuu2RKAEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVyhuw%253D%253D&md5=f0d6a8b98bb524de8e9fbbf1680610a1</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1021%2Fjm200799p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200799p%26sid%3Dliteratum%253Aachs%26aulast%3DGuerrant%26aufirst%3DW.%26aulast%3DPatil%26aufirst%3DV.%26aulast%3DCanzoneri%26aufirst%3DJ.%2BC.%26aulast%3DOyelere%26aufirst%3DA.%2BK.%26atitle%3DDual%2520targeting%2520of%2520histone%2520deacetylase%2520and%2520topoisomerase%2520II%2520with%2520novel%2520bifunctional%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1465%26epage%3D1477%26doi%3D10.1021%2Fjm200799p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di Antonio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLuckie, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span> <span> </span><span class="NLM_article-title">Reprogramming the mechanism of action of chlorambucil by coupling to a G-quadruplex ligand</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">5860</span>– <span class="NLM_lpage">5863</span>, <span class="refDoi"> DOI: 10.1021/ja5014344</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja5014344" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Crsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=5860-5863&author=M.+Di+Antonioauthor=K.+I.+McLuckieauthor=S.+Balasubramanian&title=Reprogramming+the+mechanism+of+action+of+chlorambucil+by+coupling+to+a+G-quadruplex+ligand&doi=10.1021%2Fja5014344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Reprogramming the Mechanism of Action of Chlorambucil by Coupling to a G-Quadruplex Ligand</span></div><div class="casAuthors">Di Antonio, Marco; McLuckie, Keith I. E.; Balasubramanian, Shankar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5860-5863</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The nitrogen mustard Chlorambucil (Chl) generates covalent adducts with double-helical DNA and inhibits cell proliferation.  Among these adducts, interstrand cross-links (ICLs) are the most toxic, as they stall replication by generating DNA double strand breaks (DSBs).  Conversely, intrastrand cross-links generated by Chl are efficiently repaired by a dedicated Nucleotide Excision Repair (NER) enzyme.  We synthesized a novel crosslinking agent that combines Chl with the G-quadruplex (G4) ligand PDS (PDS-Chl).  We demonstrated that PDS-Chl alkylates G4 structures at low μM concns., without reactivity toward double- or single-stranded DNA.  Since intramol. G4s arise from a single DNA strand, we reasoned that preferential alkylation of such structures might prevent the generation of ICLs, while favoring intrastrand cross-links.  We obsd. that PDS-Chl selectively impairs growth in cells genetically deficient in NER, but did not show any sensitivity to the repair gene BRCA2, involved in double-stranded break repair.  Our findings suggest that G4 targeting of this clin. important alkylating agent alters the overall mechanism of action.  These insights may inspire new opportunities for intervention in diseases specifically characterized by genetic impairment of NER, such as skin and testicular cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMn1uWWQMEzLVg90H21EOLACvtfcHk0li-rjuu2RKAEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Crsbc%253D&md5=ee185f36b219d8a8645745f02faf663c</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1021%2Fja5014344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja5014344%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BAntonio%26aufirst%3DM.%26aulast%3DMcLuckie%26aufirst%3DK.%2BI.%26aulast%3DBalasubramanian%26aufirst%3DS.%26atitle%3DReprogramming%2520the%2520mechanism%2520of%2520action%2520of%2520chlorambucil%2520by%2520coupling%2520to%2520a%2520G-quadruplex%2520ligand%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26spage%3D5860%26epage%3D5863%26doi%3D10.1021%2Fja5014344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poklar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilch, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redding, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunham, S. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslauer, K. J.</span></span> <span> </span><span class="NLM_article-title">Influence of cisplatin intrastrand crosslinking on the conformation, thermal stability, and energetics of a 20-mer DNA duplex</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">7606</span>– <span class="NLM_lpage">7611</span>, <span class="refDoi"> DOI: 10.1073/pnas.93.15.7606</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1073%2Fpnas.93.15.7606" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=8755522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADyaK28XksFSrs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=7606-7611&author=N.+Poklarauthor=D.+S.+Pilchauthor=S.+J.+Lippardauthor=E.+A.+Reddingauthor=S.+U.+Dunhamauthor=K.+J.+Breslauer&title=Influence+of+cisplatin+intrastrand+crosslinking+on+the+conformation%2C+thermal+stability%2C+and+energetics+of+a+20-mer+DNA+duplex&doi=10.1073%2Fpnas.93.15.7606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of cisplatin intrastrand crosslinking on the conformation, thermal stability, and energetics of a 20-mer DNA duplex</span></div><div class="casAuthors">Poklar, Natasa; Pilch, Daniel S.; Lippard, Stephen J.; Redding, Elizabeth A.; Dunham, Shari U.; Breslauer, Kenneth J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7606-7611</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Cis-Diamminedichloroplatinum(II) (cisplatin) is a widely used anticancer drug that binds to and crosslinks DNA.  The major DNA adduct of the drug results from coordination of two adjacent guanine bases to platinum to form the intrastrand crosslink cis-[Pt(NH3)2{d(GpG)-N7(1),-N7(2)}] (cis-Pt-GG).  In the present study, spectroscopic and calorimetric techniques were employed to characterize the influence of this crosslink on the conformation, thermal stability, and energetics of a site-specifically platinated 20-mer DNA duplex.  CD spectroscopic and thermal denaturation data revealed that the crosslink alters the structure of the host duplex, consistent with a shift from a B-like to an A-like conformation; lowers its thermal stability by ≈9°; and reduces its thermodn. stability by 6.3 kcal/mol at 25°, most of which is enthalpic in origin; but it does not alter the two-state melting behavior exhibited by the parent, unmodified duplex, despite the significant crosslink-induced changes noted above.  The energetic consequences of the cis-Pt-GG crosslink are discussed in relation to the structural perturbations it induces in DNA and to how these crosslink-induced perturbations might modulate protein binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNFO8c7rTrybVg90H21EOLACvtfcHk0lgeNWUMuDw1SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XksFSrs7k%253D&md5=56794c4c6ab9c20aa3dc37c47969c46d</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1073%2Fpnas.93.15.7606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.93.15.7606%26sid%3Dliteratum%253Aachs%26aulast%3DPoklar%26aufirst%3DN.%26aulast%3DPilch%26aufirst%3DD.%2BS.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26aulast%3DRedding%26aufirst%3DE.%2BA.%26aulast%3DDunham%26aufirst%3DS.%2BU.%26aulast%3DBreslauer%26aufirst%3DK.%2BJ.%26atitle%3DInfluence%2520of%2520cisplatin%2520intrastrand%2520crosslinking%2520on%2520the%2520conformation%252C%2520thermal%2520stability%252C%2520and%2520energetics%2520of%2520a%252020-mer%2520DNA%2520duplex%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1996%26volume%3D93%26spage%3D7606%26epage%3D7611%26doi%3D10.1073%2Fpnas.93.15.7606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bouwman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonkers, J.</span></span> <span> </span><span class="NLM_article-title">The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">598</span>, <span class="refDoi"> DOI: 10.1038/nrc3342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnrc3342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=22918414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1GhsLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=587-598&author=P.+Bouwmanauthor=J.+Jonkers&title=The+effects+of+deregulated+DNA+damage+signalling+on+cancer+chemotherapy+response+and+resistance&doi=10.1038%2Fnrc3342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance</span></div><div class="casAuthors">Bouwman, Peter; Jonkers, Jos</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">587-598</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumors with specific DNA repair defects can be completely dependent on back-up DNA repair pathways for their survival.  This dependence can be exploited therapeutically to induce synthetic lethality in tumor cells.  For instance, homologous recombination (HR)-deficient tumors can be effectively targeted by DNA double-strand break-inducing agents.  However, not all HR-defective tumors respond equally well to this type of therapy.  Tumor cells may acquire resistance by invoking biochem. mechanisms that reduce drug action or by acquiring addnl. alterations in DNA damage response pathways.  A thorough understanding of these processes is important for predicting treatment response and for the development of novel treatment strategies that prevent the emergence of therapy-resistant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNSTPQO2sEE7Vg90H21EOLACvtfcHk0li_sRftHiw72g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1GhsLnN&md5=176b61bc1ce31c537067eae10417bf90</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1038%2Fnrc3342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3342%26sid%3Dliteratum%253Aachs%26aulast%3DBouwman%26aufirst%3DP.%26aulast%3DJonkers%26aufirst%3DJ.%26atitle%3DThe%2520effects%2520of%2520deregulated%2520DNA%2520damage%2520signalling%2520on%2520cancer%2520chemotherapy%2520response%2520and%2520resistance%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D587%26epage%3D598%26doi%3D10.1038%2Fnrc3342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lord, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span> <span> </span><span class="NLM_article-title">The DNA damage response and cancer therapy</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>481</i></span>,  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1038/nature10760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnature10760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=22258607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38Xps1GmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=481&publication_year=2012&pages=287-294&author=C.+J.+Lordauthor=A.+Ashworth&title=The+DNA+damage+response+and+cancer+therapy&doi=10.1038%2Fnature10760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">The DNA damage response and cancer therapy</span></div><div class="casAuthors">Lord, Christopher J.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">481</span>
        (<span class="NLM_cas:issue">7381</span>),
    <span class="NLM_cas:pages">287-294</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Genomic instability is one of the most pervasive characteristics of tumor cells and is probably the combined effect of DNA damage, tumor-specific DNA repair defects, and a failure to stop or stall the cell cycle before the damaged DNA is passed on to daughter cells.  Although these processes drive genomic instability and ultimately the disease process, they also provide therapeutic opportunities.  A better understanding of the cellular response to DNA damage will not only inform our knowledge of cancer development but also help to refine the classification as well as the treatment of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUS1sAbqFhmrVg90H21EOLACvtfcHk0lisYIHhNe12zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xps1GmsQ%253D%253D&md5=75d12cdb52e8c9a39bced1611bf90298</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1038%2Fnature10760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10760%26sid%3Dliteratum%253Aachs%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DThe%2520DNA%2520damage%2520response%2520and%2520cancer%2520therapy%26jtitle%3DNature%26date%3D2012%26volume%3D481%26spage%3D287%26epage%3D294%26doi%3D10.1038%2Fnature10760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thurn, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raha, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qureshi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase regulation of ATM-mediated DNA damage signaling</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2078</span>– <span class="NLM_lpage">2087</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-1242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1535-7163.MCT-12-1242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=23939379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOhurvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=2078-2087&author=K.+T.+Thurnauthor=S.+Thomasauthor=P.+Rahaauthor=I.+Qureshiauthor=P.+N.+Munster&title=Histone+deacetylase+regulation+of+ATM-mediated+DNA+damage+signaling&doi=10.1158%2F1535-7163.MCT-12-1242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Regulation of ATM-Mediated DNA Damage Signaling</span></div><div class="casAuthors">Thurn, K. Ted; Thomas, Scott; Raha, Paromita; Qureshi, Ian; Munster, Pamela N.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2078-2087</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Ataxia-telangiectasia mutated (ATM) is a major regulator of the DNA damage response.  ATM promotes the activation of BRCA1, CHK2, and p53 leading to the induction of response genes such as CDKN1A (p21), GADD45A, and RRM2B that promote cell-cycle arrest and DNA repair.  The upregulation of these response genes may contribute to resistance of cancer cells to genotoxic therapies.  Here, we show that histone deacetylases (HDAC) play a major role in mitigating the response of the ATM pathway to DNA damage.  HDAC inhibition decreased ATM activation and expression, and attenuated the activation of p53 in vitro and in vivo.  Select depletion of HDAC1 and HDAC2 was sufficient to modulate ATM activation, reduce GADD45A and RRM2B induction, and increase sensitivity to DNA strand breaks.  The regulation of ATM by HDAC enzymes therefore suggests a vital role for HDAC1 and HDAC2 in the DNA damage response, and the potential use of the ATM pathway as a pharmacodynamic marker for combination therapies involving HDAC inhibitors.  Mol Cancer Ther; 12(10); 2078-87. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDH0rQ3pBvI7Vg90H21EOLACvtfcHk0li5Zo0IMY03Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOhurvN&md5=b1aff4a207ba7e193487f470036963e5</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-1242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-1242%26sid%3Dliteratum%253Aachs%26aulast%3DThurn%26aufirst%3DK.%2BT.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DRaha%26aufirst%3DP.%26aulast%3DQureshi%26aufirst%3DI.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26atitle%3DHistone%2520deacetylase%2520regulation%2520of%2520ATM-mediated%2520DNA%2520damage%2520signaling%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D2078%26epage%3D2087%26doi%3D10.1158%2F1535-7163.MCT-12-1242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">14639</span>– <span class="NLM_lpage">14644</span>, <span class="refDoi"> DOI: 10.1073/pnas.1008522107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1073%2Fpnas.1008522107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=20679231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOgsb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=14639-14644&author=J.+H.+Leeauthor=M.+L.+Choyauthor=L.+Ngoauthor=S.+S.+Fosterauthor=P.+A.+Marks&title=Histone+deacetylase+inhibitor+induces+DNA+damage%2C+which+normal+but+not+transformed+cells+can+repair&doi=10.1073%2Fpnas.1008522107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair</span></div><div class="casAuthors">Lee, J.-H.; Choy, M. L.; Ngo, L.; Foster, S. S.; Marks, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">14639-14644, S14639/1-S14639/2</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACi) developed as anti-cancer agents have a high degree of selectivity for killing cancer cells.  HDACi induce acetylation of histones and nonhistone proteins, which affect gene expression, cell cycle progression, cell migration, and cell death.  The mechanism of the tumor selective action of HDACi is unclear.  Here, we show that the HDACi, vorinostat (Suberoylanilide hydroxamic acid, SAHA), induces DNA double-strand breaks (DSBs) in normal (HFS) and cancer (LNCaP, A549) cells.  Normal cells in contrast to cancer cells repair the DSBs despite continued culture with vorinostat.  In transformed cells, phosphorylated H2AX (γH2AX), a marker of DNA DSBs, levels increased with continued culture with vorinostat, whereas in normal cells, this marker decreased with time.  Vorinostat induced the accumulation of acetylated histones within 30 min, which could alter chromatin structure-exposing DNA to damage.  After a 24-h culture of cells with vorinostat, and reculture without the HDACi, γH2AX was undetectable by 2 h in normal cells, while persisting in transformed cells for the duration of culture.  Further, we found that vorinostat suppressed DNA DSB repair proteins, e.g., RAD50, MRE11, in cancer but not normal cells.  Thus, the HDACi, vorinostat, induces DNA damage which normal but not cancer cells can repair.  This DNA damage is assocd. with cancer cell death.  These findings can explain, in part, the selectivity of vorinostat in causing cancer cell death at concns. that cause little or no normal cell death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSDKsBgz4ItbVg90H21EOLACvtfcHk0ljH77y-UPJsrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOgsb%252FN&md5=72a2d11a2b4303022e85c25c1b946564</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1008522107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1008522107%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DChoy%26aufirst%3DM.%2BL.%26aulast%3DNgo%26aufirst%3DL.%26aulast%3DFoster%26aufirst%3DS.%2BS.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DHistone%2520deacetylase%2520inhibitor%2520induces%2520DNA%2520damage%252C%2520which%2520normal%2520but%2520not%2520transformed%2520cells%2520can%2520repair%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D14639%26epage%3D14644%26doi%3D10.1073%2Fpnas.1008522107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harms, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">3145</span>– <span class="NLM_lpage">3152</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-4397</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F0008-5472.CAN-06-4397" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=17409421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksVGlu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=3145-3152&author=K.+L.+Harmsauthor=X.+Chen&title=Histone+deacetylase+2+modulates+p53+transcriptional+activities+through+regulation+of+p53-DNA+binding+activity&doi=10.1158%2F0008-5472.CAN-06-4397"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase 2 Modulates p53 Transcriptional Activities through Regulation of p53-DNA Binding Activity</span></div><div class="casAuthors">Harms, Kelly Lynn; Chen, Xinbin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3145-3152</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors are emerging as promising cancer therapeutics.  HDAC inhibitors have been found to induce cellular activities that are strikingly similar to p53-mediated responses to genotoxic stress.  For example, HDAC inhibitors induce cell cycle arrest, apoptosis, and cellular senescence.  Because at least 11 HDACs are affected by the current HDAC inhibitors, the HDAC crit. for tumor cell survival and proliferation remains unknown.  Thus, we sought to characterize the distinct roles of HDACs in the p53 pathway.  Through the use of stable MCF7 cell lines which inducibly express short hairpin RNA targeting HDAC2, we found that HDAC2 plays important roles in the p53 pathway.  Specifically, we found that knockdown of HDAC2 inhibited cellular proliferation in a dose-dependent manner which was also partly p53-dependent.  Furthermore, knockdown of HDAC2 induced cellular senescence.  Importantly, we found that knockdown of HDAC2 enhanced p53-dependent trans-repression and trans-activation of a subset of target genes.  We found that the enhancement was due to increased p53-DNA binding activity but not alterations in p53 stability or posttranslational modification(s).  Thus, for the first time, our data suggest that HDAC inhibitors function through the p53 pathway, at least in part, by activating p53-DNA binding activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_sg_TKY0bALVg90H21EOLACvtfcHk0lgfR8yhxJW94g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksVGlu7w%253D&md5=8c500357d49a7b014c658003d6baeeec</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4397%26sid%3Dliteratum%253Aachs%26aulast%3DHarms%26aufirst%3DK.%2BL.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DHistone%2520deacetylase%25202%2520modulates%2520p53%2520transcriptional%2520activities%2520through%2520regulation%2520of%2520p53-DNA%2520binding%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D3145%26epage%3D3152%26doi%3D10.1158%2F0008-5472.CAN-06-4397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Groselj, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiltie, A. E.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">748</span>– <span class="NLM_lpage">754</span>, <span class="refDoi"> DOI: 10.1038/bjc.2013.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fbjc.2013.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=23361058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslWmu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2013&pages=748-754&author=B.+Groseljauthor=N.+L.+Sharmaauthor=F.+C.+Hamdyauthor=M.+Kerrauthor=A.+E.+Kiltie&title=Histone+deacetylase+inhibitors+as+radiosensitisers%3A+effects+on+DNA+damage+signalling+and+repair&doi=10.1038%2Fbjc.2013.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair</span></div><div class="casAuthors">Groselj, B.; Sharma, N. L.; Hamdy, F. C.; Kerr, M.; Kiltie, A. E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">748-754</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Many cancers display increased expression of histone deacetylases (HDACs) and therefore transcriptionally inactive chromatin, resulting in the downregulation of genes including tumor suppressor and DNA repair genes.  Histone deacetylase inhibitors (HDACi) are a heterogeneous group of epigenetic therapeutics, showing promising anticancer effects in both pre-clin. and clin. settings, in particular the effect of radiosensitization when administered in combination with radiotherapy.  Radiotherapy remains one of the most common forms of cancer treatment, leading to cell death through the induction of DNA double-strand breaks (DSBs).  Cells have developed mechanisms to repair such DSB through two major pathways: non-homologous end-joining and homologous recombination.  Here, we explore the current evidence for the use of HDACi in combination with irradn., focusing on the effects of HDACi on DNA damage signalling and repair in vitro.  In addn., we summarise the clin. evidence for using HDACi with radiotherapy, a growing area of interest with great potential clin. utility.  British Journal of Cancer (2013) 108, 748-754; doi:10.1038/bjc.2013.21 www.bjcancer.com; published online 29 Jan. 2013.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZmWuDRAfI2LVg90H21EOLACvtfcHk0ljZmL5IXPpySw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslWmu78%253D&md5=c958f3329b3e3859a24527f81b6c7a20</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2013.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2013.21%26sid%3Dliteratum%253Aachs%26aulast%3DGroselj%26aufirst%3DB.%26aulast%3DSharma%26aufirst%3DN.%2BL.%26aulast%3DHamdy%26aufirst%3DF.%2BC.%26aulast%3DKerr%26aufirst%3DM.%26aulast%3DKiltie%26aufirst%3DA.%2BE.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520as%2520radiosensitisers%253A%2520effects%2520on%2520DNA%2520damage%2520signalling%2520and%2520repair%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2013%26volume%3D108%26spage%3D748%26epage%3D754%26doi%3D10.1038%2Fbjc.2013.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maggio, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosato, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahmani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paik, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czarnik, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S.</span></span> <span> </span><span class="NLM_article-title">The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">2590</span>– <span class="NLM_lpage">2600</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-03-2631</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F0008-5472.CAN-03-2631" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15059916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1yju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=2590-2600&author=S.+C.+Maggioauthor=R.+R.+Rosatoauthor=L.+B.+Kramerauthor=Y.+Daiauthor=M.+Rahmaniauthor=D.+S.+Paikauthor=A.+C.+Czarnikauthor=S.+G.+Payneauthor=S.+Spiegelauthor=S.+Grant&title=The+histone+deacetylase+inhibitor+MS-275+interacts+synergistically+with+fludarabine+to+induce+apoptosis+in+human+leukemia+cells&doi=10.1158%2F0008-5472.CAN-03-2631"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells</span></div><div class="casAuthors">Maggio, Sonia C.; Rosato, Roberto R.; Kramer, Lora B.; Dai, Yun; Rahmani, Mohamed; Paik, David S.; Czarnik, Ann C.; Payne, Shawn G.; Spiegel, Sarah; Grant, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2590-2600</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Interactions between the novel benzamide histone deacetylase (HDAC) inhibitor MS-275 and fludarabine were examd. in lymphoid and myeloid human leukemia cells in relation to mitochondrial injury, signal transduction events, and apoptosis.  Prior exposure of Jurkat lymphoblastic leukemia cells to a marginally toxic concn. of MS-275 (e.g., 500 nM) for 24 h sharply increased mitochondrial injury, caspase activation, and apoptosis in response to a minimally toxic concn. of fludarabine (500 nM), resulting in highly synergistic antileukemic interactions and loss of clonogenic survival.  Simultaneous exposure to MS-275 and fludarabine also led to synergistic effects, but these were not as pronounced as obsd. with sequential treatment.  Similar interactions were noted in the case of (a) other human leukemia cell lines (e.g., U937, CCRF-CEM); (b) other HDAC inhibitors (e.g., sodium butyrate); and (c) other nucleoside analogs (e.g., 1-β-D-arabinofuranosylcytosine, gemcitabine).  Potentiation of fludarabine lethality by MS-275 was assocd. with acetylation of histones H3 and H4, down-regulation of the antiapoptotic proteins XIAP and Mcl-1, enhanced cytosolic release of proapoptotic mitochondrial proteins (e.g., cytochrome c, Smac/DIABLO, and apoptosis-inducing factor), and caspase activation.  It was also accompanied by the caspase-dependent down-regulation of p27KIP1, cyclins A, E, and D1, and cleavage and diminished phosphorylation of retinoblastoma protein.  However, increased lethality of the combination was not assocd. with enhanced fludarabine triphosphate formation or DNA incorporation and occurred despite a slight redn. in the S-phase fraction.  Prior exposure to MS-275 attenuated fludarabine-mediated activation of MEK1/2, extracellular signal-regulated kinase, and Akt, and enhanced c-Jun NH2-terminal kinase phosphorylation; furthermore, inducible expression of constitutively active MEK1/2 or Akt significantly diminished MS-275/fludarabine-induced lethality.  Combined exposure of cells to MS-275 and fludarabine was assocd. with a significant increase in generation of reactive oxygen species; moreover, both the increase in reactive oxygen species and apoptosis were largely attenuated by coadministration of the free radical scavenger L-N-acetylcysteine.  Finally, prior administration of MS-275 markedly potentiated fludarabine-mediated generation of the proapoptotic lipid second messenger ceramide.  Taken together, these findings indicate that the HDAC inhibitor MS-275 induces multiple perturbations in signal transduction, survival, and cell cycle regulatory pathways that lower the threshold for fludarabine-mediated mitochondrial injury and apoptosis in human leukemia cells.  They also provide insights into possible mechanisms by which novel, clin. relevant HDAC inhibitors might be used to enhance the antileukemic activity of established nucleoside analogs such as fludarabine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaZO0fC_tDWLVg90H21EOLACvtfcHk0ljZmL5IXPpySw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1yju74%253D&md5=986686ecee2cf9aca2b1aa6ed3105883</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-03-2631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-03-2631%26sid%3Dliteratum%253Aachs%26aulast%3DMaggio%26aufirst%3DS.%2BC.%26aulast%3DRosato%26aufirst%3DR.%2BR.%26aulast%3DKramer%26aufirst%3DL.%2BB.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DRahmani%26aufirst%3DM.%26aulast%3DPaik%26aufirst%3DD.%2BS.%26aulast%3DCzarnik%26aufirst%3DA.%2BC.%26aulast%3DPayne%26aufirst%3DS.%2BG.%26aulast%3DSpiegel%26aufirst%3DS.%26aulast%3DGrant%26aufirst%3DS.%26atitle%3DThe%2520histone%2520deacetylase%2520inhibitor%2520MS-275%2520interacts%2520synergistically%2520with%2520fludarabine%2520to%2520induce%2520apoptosis%2520in%2520human%2520leukemia%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D2590%26epage%3D2600%26doi%3D10.1158%2F0008-5472.CAN-03-2631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hajji, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallenborg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlachos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyman, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermanson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, B.</span></span> <span> </span><span class="NLM_article-title">Combinatorial action of the HDAC inhibitor trichostatin a and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">3134</span>– <span class="NLM_lpage">3144</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1210976</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fsj.onc.1210976" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=18071312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvFSis7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=3134-3144&author=N.+Hajjiauthor=K.+Wallenborgauthor=P.+Vlachosauthor=U.+Nymanauthor=O.+Hermansonauthor=B.+Joseph&title=Combinatorial+action+of+the+HDAC+inhibitor+trichostatin+a+and+etoposide+induces+caspase-mediated+AIF-dependent+apoptotic+cell+death+in+non-small+cell+lung+carcinoma+cells&doi=10.1038%2Fsj.onc.1210976"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Combinatorial action of the HDAC inhibitor trichostatin A and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells</span></div><div class="casAuthors">Hajji, N.; Wallenborg, K.; Vlachos, P.; Nyman, U.; Hermanson, O.; Joseph, B.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3134-3144</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Commonly used regimens in cancer therapy rely on the induction of apoptotic cell death, and drug resistance can be attributed, at least in part, to a disabled apoptotic program.  Non-small cell lung carcinomas (NSCLC), exhibit an intrinsic resistance to chemotherapy.  Here, we show that co-treatment with etoposide (VP16) and the pan-histone deacetylase (HDAC) inhibitor trichostatin A (TSA), but not valproic acid (VPA), induced apoptotic cell death in drug-resistant NSCLC cells.  Co-treatment, but not single treatment, with VP16 and TSA induced apoptosis in a caspase-dependent manner accompanied by a crucial decrease in Bcl-xL expression allowing Bax activation and subsequent initiation of the apoptosis inducing factor (AIF)-dependent death pathway.  Importantly, AIF proved to be required for the effects of TSA/VP16 as RNA knockdown of AIF resulted in a complete abolishment of TSA/VP16-induced apoptotic cell death in drug-resistant NSCLC cells.  Our results thus provide evidence for the requirement of both caspase-dependent and caspase-independent apoptotic pathways in TSA/VP16-mediated death of drug-resistant NSCLC cells, and extend previous suggestions that HDAC inhibitors in combination with conventional chemotherapeutic drugs could be valuable in the treatment of NSCLC cancer and other malignancies in which Bcl-xL is overexpressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxjdh2HAy64LVg90H21EOLACvtfcHk0liTS8yp3Q_79w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvFSis7Y%253D&md5=1f21019a0c1b0cf7045831947c6e2144</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210976%26sid%3Dliteratum%253Aachs%26aulast%3DHajji%26aufirst%3DN.%26aulast%3DWallenborg%26aufirst%3DK.%26aulast%3DVlachos%26aufirst%3DP.%26aulast%3DNyman%26aufirst%3DU.%26aulast%3DHermanson%26aufirst%3DO.%26aulast%3DJoseph%26aufirst%3DB.%26atitle%3DCombinatorial%2520action%2520of%2520the%2520HDAC%2520inhibitor%2520trichostatin%2520a%2520and%2520etoposide%2520induces%2520caspase-mediated%2520AIF-dependent%2520apoptotic%2520cell%2520death%2520in%2520non-small%2520cell%2520lung%2520carcinoma%2520cells%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D3134%26epage%3D3144%26doi%3D10.1038%2Fsj.onc.1210976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maiso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colado, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ocio, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garayoa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandiella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San-Miguel, J. F.</span></span> <span> </span><span class="NLM_article-title">The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2265</span>– <span class="NLM_lpage">2274</span>, <span class="refDoi"> DOI: 10.1038/leu.2009.182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fleu.2009.182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=19812608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFKns7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=2265-2274&author=P.+Maisoauthor=E.+Coladoauthor=E.+M.+Ocioauthor=M.+Garayoaauthor=J.+Martinauthor=P.+Atadjaauthor=A.+Pandiellaauthor=J.+F.+San-Miguel&title=The+synergy+of+panobinostat+plus+doxorubicin+in+acute+myeloid+leukemia+suggests+a+role+for+HDAC+inhibitors+in+the+control+of+DNA+repair&doi=10.1038%2Fleu.2009.182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair</span></div><div class="casAuthors">Maiso, P.; Colado, E.; Ocio, E. M.; Garayoa, M.; Martin, J.; Atadja, P.; Pandiella, A.; San-Miguel, J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2265-2274</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) is a clonal disorder characterized by the accumulation of myeloid blasts in the bone marrow.  Here, we report the effects of the novel histone deacetylase inhibitor panobinostat (LBH589) in combination with doxorubicin on AML cells.  Panobinostat exhibited potent anti-AML activity in all AML cell lines tested and in primary AML cells from patients (IC50 < 20 n).  In addn., panobinostat potentiated the action of several std.-of-care anti-AML compds., particularly, doxorubicin.  The mol. effects induced by panobinostat and doxorubicin treatment were investigated by analyzing gene expression, cell cycle, apoptosis and signaling pathways.  Analyses of gene expression profiles identified 588 genes whose expression was exclusively affected by the combination of panobinostat and doxorubicin.  The combination induced AML cell death by an increase in the mitochondrial outer membrane permeability and release of cytochrome c from the mitochondria, resulting in caspase-dependent apoptosis and accompanied by the upregulation of Bax, Bak and, particularly, Bad.  The drug combination provoked a strong activation of a DNA damage response, indicating that this combination may trigger cell death by a mechanism that induced DNA double-strand breaks.  These data indicate that the combination of panobinostat and doxorubicin may be an effective therapy for the treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnuiXE70XeS7Vg90H21EOLACvtfcHk0liTS8yp3Q_79w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFKns7bJ&md5=2b964f893dad7fab75a40898848fca5d</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fleu.2009.182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2009.182%26sid%3Dliteratum%253Aachs%26aulast%3DMaiso%26aufirst%3DP.%26aulast%3DColado%26aufirst%3DE.%26aulast%3DOcio%26aufirst%3DE.%2BM.%26aulast%3DGarayoa%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DJ.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DPandiella%26aufirst%3DA.%26aulast%3DSan-Miguel%26aufirst%3DJ.%2BF.%26atitle%3DThe%2520synergy%2520of%2520panobinostat%2520plus%2520doxorubicin%2520in%2520acute%2520myeloid%2520leukemia%2520suggests%2520a%2520role%2520for%2520HDAC%2520inhibitors%2520in%2520the%2520control%2520of%2520DNA%2520repair%26jtitle%3DLeukemia%26date%3D2009%26volume%3D23%26spage%3D2265%26epage%3D2274%26doi%3D10.1038%2Fleu.2009.182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahat, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Q.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornmann, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConkey, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lev, D. C.</span></span> <span> </span><span class="NLM_article-title">Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3472</span>– <span class="NLM_lpage">3483</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-2714</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1078-0432.CCR-08-2714" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=19417021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVKlsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=3472-3483&author=G.+Lopezauthor=J.+Liuauthor=W.+Renauthor=W.+Weiauthor=S.+Wangauthor=G.+Lahatauthor=Q.-S.+Zhuauthor=W.+G.+Bornmannauthor=D.+J.+McConkeyauthor=R.+E.+Pollockauthor=D.+C.+Lev&title=Combining+PCI-24781%2C+a+novel+histone+deacetylase+inhibitor%2C+with+chemotherapy+for+the+treatment+of+soft+tissue+sarcoma&doi=10.1158%2F1078-0432.CCR-08-2714"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma</span></div><div class="casAuthors">Lopez, Gonzalo; Liu, Juehui; Ren, Wenhong; Wei, Wei; Wang, Suizhao; Lahat, Guy; Zhu, Quan-Sheng; Bornmann, William G.; McConkey, David J.; Pollock, Raphael E.; Lev, Dina C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3472-3483</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Histone deactylase inhibitors (HDACi) are a promising new class of anticancer therapeutics; however, little is known about HDACi activity in soft tissue sarcoma (STS), a heterogeneous cohort of mesenchymal origin malignancies.  Consequently, we investigated the novel HDACi PCI-24781, alone/in combination with conventional chemotherapy, to det. its potential anti-STS-related effects and the underlying mechanisms involved.  Exptl. Design: Immunoblotting was used to evaluate the effects of PCI-24781 on histone and nonhistone protein acetylation and expression of potential downstream targets.  Cell culture-based assays were utilized to assess the effects of PCI-24781 on STS cell growth, cell cycle progression, apoptosis, and chemosensitivity.  Quant. reverse transcription-PCR, chromatin immunopptn., and reporter assays helped elucidate mol. mechanisms resulting in PCI-24781-induced Rad51 repression.  The effect of PCI-24781, alone or with chemotherapy, on tumor and metastatic growth was tested in vivo using human STS xenograft models.  RESULTS: PCI-24781 exhibited significant anti-STS proliferative activity in vitro, inducing S phase depletion, G2/M cell cycle arrest, and increasing apoptosis.  Superior effects were seen when combined with chemotherapy.  A PCI-24781-induced redn. in Rad51, a major mediator of DNA double-strand break homologous recombination repair, was shown and may be a mechanism underlying PCI-24781 chemosensitization.  We showed that PCI-24781 transcriptionally represses Rad51 through an E2F binding-site on the Rad51 proximal promoter.  Although single-agent PCI-24781 had modest effects on STS growth and metastasis, marked inhibition was obsd. when combined with chemotherapy.  CONCLUSIONS: In light of these findings, this novel mol.-based combination may be applicable to multiple STS histol. subtypes, and potentially merits rigorous evaluation in human STS clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcaGPHupY0DrVg90H21EOLACvtfcHk0liTS8yp3Q_79w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVKlsrw%253D&md5=a5ff3455ca1a51af9e0a926d9357d0d9</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-2714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-2714%26sid%3Dliteratum%253Aachs%26aulast%3DLopez%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DW.%26aulast%3DWei%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DLahat%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DQ.-S.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DMcConkey%26aufirst%3DD.%2BJ.%26aulast%3DPollock%26aufirst%3DR.%2BE.%26aulast%3DLev%26aufirst%3DD.%2BC.%26atitle%3DCombining%2520PCI-24781%252C%2520a%2520novel%2520histone%2520deacetylase%2520inhibitor%252C%2520with%2520chemotherapy%2520for%2520the%2520treatment%2520of%2520soft%2520tissue%2520sarcoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D3472%26epage%3D3483%26doi%3D10.1158%2F1078-0432.CCR-08-2714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chao, O. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, O. B.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1755</span>– <span class="NLM_lpage">1766</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-14-0173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1541-7786.MCR-14-0173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25127709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFSitLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=1755-1766&author=O.+S.+Chaoauthor=O.+B.+Goodman&title=Synergistic+loss+of+prostate+cancer+cell+viability+by+coinhibition+of+HDAC+and+PARP&doi=10.1158%2F1541-7786.MCR-14-0173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic Loss of Prostate Cancer Cell Viability by Coinhibition of HDAC and PARP</span></div><div class="casAuthors">Chao, Olivia S.; Goodman, Oscar B., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1755-1766</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tumors with BRCA germline mutations are defective in repairing DNA double-strand breaks (DSB) through homologous recombination (HR) pathways, making them sensitive to PARP inhibitors (PARPi).  However, BRCA germline mutations are rare in prostate cancer limiting the ability to therapeutically target these pathways.  This study investigates whether histone deacetylase (HDAC) inhibitors (HDACi), reported to modulate DSB repair pathways in sporadic cancers, can downregulate DSB repair pathways and sensitize prostate cancer cells to PARPi.  Prostate cancer cells cotreated with the HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA) and the PARPi, olaparib, demonstrated a synergistic decrease in cell viability compared with single-agent treatment (combination index < 0.9), whereas normal prostatic cells did not.  Similarly, clonogenicity was significantly decreased after cotreatment.  Flow cytometric cell-cycle anal. and Annexin-V staining revealed significant apoptosis upon treatment with SAHA+olaparib.  This coincided with increased DNA damage obsd. by immunofluorescence microscopy anal. of γH2AX foci, a marker of DSBs.  In addn., immunoblot anal. showed a significant and persistent increase in nuclear γH2AX levels.  Both SAHA and olaparib downregulated the expression of HR-related proteins, BRCA1 and RAD51, whereas SAHA + olaparib had an additive effect on RAD51.  Silencing RAD51 sensitized prostate cancer cells to SAHA and olaparib alone.  Collectively, cotreatment with HDACi and PARPi downregulated HR-related protein expression and concomitantly increased DNA damage, resulting in prostate cancer cell death.  Implications: These findings provide a strong rationale for supporting the use of combined HDAC and PARP inhibition in treating advanced prostate cancer.  Mol Cancer Res; 12(12); 1755-66. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-DP9P_hxA-rVg90H21EOLACvtfcHk0lh6cqvHYITmug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFSitLbN&md5=4e52ef337be04179b2cf8fc8c5348ee8</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-14-0173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-14-0173%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DO.%2BS.%26aulast%3DGoodman%26aufirst%3DO.%2BB.%26atitle%3DSynergistic%2520loss%2520of%2520prostate%2520cancer%2520cell%2520viability%2520by%2520coinhibition%2520of%2520HDAC%2520and%2520PARP%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2014%26volume%3D12%26spage%3D1755%26epage%3D1766%26doi%3D10.1158%2F1541-7786.MCR-14-0173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Min, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, D.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, M. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, Y.-J.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1186/s13058-015-0534-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1186%2Fs13058-015-0534-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25888415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A280%3ADC%252BC2MjltlWguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=33-43&author=A.+Minauthor=S.-A.+Imauthor=D.+K.+Kimauthor=S.-H.+Songauthor=H.-J.+Kimauthor=K.-H.+Leeauthor=T.-Y.+Kimauthor=S.-W.+Hanauthor=D.-Y.+Ohauthor=T.-Y.+Kimauthor=M.+J+O%E2%80%99Connorauthor=Y.-J.+Bang&title=Histone+deacetylase+inhibitor%2C+suberoylanilide+hydroxamic+acid+%28SAHA%29%2C+enhances+anti-tumor+effects+of+the+poly+%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+olaparib+in+triple-negative+breast+cancer+cells&doi=10.1186%2Fs13058-015-0534-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells</span></div><div class="casAuthors">Min Ahrum; Im Seock-Ah; Song Sang-Hyun; Kim Hee-Jun; Lee Kyung-Hun; Kim Tae-Yong; Han Sae-Won; Oh Do-Youn; Kim Tae-You; Bang Yung-Jue; Min Ahrum; Im Seock-Ah; Lee Kyung-Hun; Kim Tae-Yong; Han Sae-Won; Oh Do-Youn; Kim Tae-You; Bang Yung-Jue; Im Seock-Ah; Lee Kyung-Hun; Kim Tae-Yong; Han Sae-Won; Oh Do-Youn; Kim Tae-You; Bang Yung-Jue; Kim Debora Keunyoung; Kim Hee-Jun; O'Connor Mark J</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer research : BCR</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has been found to have therapeutic potential for treating cancers associated with impaired DNA repair capabilities, particularly those with deficiencies in the homologous recombination repair (HRR) pathway.  Histone deacetylases (HDACs) are important for enabling functional HRR of DNA by regulating the expression of HRR-related genes and promoting the accurate assembly of HRR-directed sub-nuclear foci.  Thus, HDAC inhibitors have recently emerged as a therapeutic agent for treating cancer by inhibiting DNA repair.  Based on this, HDAC inhibition could be predicted to enhance the anti-tumor effect of PARP inhibitors in cancer cells by blocking the HRR pathway.  METHODS:  We determined whether suberoylanilide hydroxamic acid (SAHA), a HDAC inhibitor, could enhance the anti-tumor effects of olaparib on breast cancer cell lines using a cytotoxic assay, cell cycle analysis, and Western blotting.  We evaluated how exposure to SAHA affects the expression of HRR-associated genes.  The accumulation of DNA double strand breaks (DSBs) induced by combination treatment was assessed.  Induction of autophagy was monitored by imaging green fluorescent protein-tagged microtubule-associated protein 1A/1B-light chain 3 (LC3) expression following co-treatment with olaparib and SAHA.  These in vitro data were validated in vivo using a human breast cancer xenograft model.  RESULTS:  Triple-negative breast cancer cell (TNBC) lines showed heterogeneous responses to the PARP and HDAC inhibitors.  Co-administration of olaparib and SAHA synergistically inhibited the growth of TNBC cells that expressed functional Phosphatase and tensin homolog (PTEN).  This effect was associated with down-regulation of the proliferative signaling pathway, increased apoptotic and autophagic cell death, and accumulation of DNA damage.  The combined anti-tumor effect of olaparib and SAHA was also observed in a xenograft model.  These data suggest that PTEN expression in TNBC cells can sensitize the cell response to simultaneous inhibition of PARP and HDAC both in vitro and in vivo.  CONCLUSION:  Our findings suggest that expression of functional PTEN may serve as a biomarker for selecting TNBC patients that would favorably respond to a combination of olaparib with SAHA.  This provides a strong rationale for treating TNBC patients with PTEN expression with a combination therapy consisting of olaparib and SAHA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTcCnK6c-02m0bxh97K6Vt6fW6udTcc2ebMNqlxwsqRzrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjltlWguw%253D%253D&md5=4d900b24ef95ff4fca352dc27cdc2865</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1186%2Fs13058-015-0534-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-015-0534-y%26sid%3Dliteratum%253Aachs%26aulast%3DMin%26aufirst%3DA.%26aulast%3DIm%26aufirst%3DS.-A.%26aulast%3DKim%26aufirst%3DD.%2BK.%26aulast%3DSong%26aufirst%3DS.-H.%26aulast%3DKim%26aufirst%3DH.-J.%26aulast%3DLee%26aufirst%3DK.-H.%26aulast%3DKim%26aufirst%3DT.-Y.%26aulast%3DHan%26aufirst%3DS.-W.%26aulast%3DOh%26aufirst%3DD.-Y.%26aulast%3DKim%26aufirst%3DT.-Y.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ%26aulast%3DBang%26aufirst%3DY.-J.%26atitle%3DHistone%2520deacetylase%2520inhibitor%252C%2520suberoylanilide%2520hydroxamic%2520acid%2520%2528SAHA%2529%252C%2520enhances%2520anti-tumor%2520effects%2520of%2520the%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%2520olaparib%2520in%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2015%26volume%3D17%26spage%3D33%26epage%3D43%26doi%3D10.1186%2Fs13058-015-0534-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shabason, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tofilon, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camphausen, K.</span></span> <span> </span><span class="NLM_article-title">Grand rounds at the national institutes of health: HDAC inhibitors as radiation modifiers, from bench to clinic</span>. <i>J. Cell Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2735</span>– <span class="NLM_lpage">2744</span>, <span class="refDoi"> DOI: 10.1111/j.1582-4934.2011.01296.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1111%2Fj.1582-4934.2011.01296.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=21362133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FivFamsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=2735-2744&author=J.+E.+Shabasonauthor=P.+J.+Tofilonauthor=K.+Camphausen&title=Grand+rounds+at+the+national+institutes+of+health%3A+HDAC+inhibitors+as+radiation+modifiers%2C+from+bench+to+clinic&doi=10.1111%2Fj.1582-4934.2011.01296.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic</span></div><div class="casAuthors">Shabason Jacob E; Tofilon Philip J; Camphausen Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of cellular and molecular medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2735-44</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumour.  Patients afflicted with this disease unfortunately have a very poor prognosis, and fewer than 5% of patients survive for 5 years from the time of diagnosis.  Therefore, improved therapies to treat this disease are sorely needed.  One such class of drugs that have generated great enthusiasm for the treatment of numerous malignancies, including GBM, is histone deacetylase (HDAC) inhibitors.  Pre-clinical data have demonstrated the efficacy of various HDAC inhibitors as anticancer agents, with the greatest effects shown when HDAC inhibitors are used in combination with other therapies.  As a result of encouraging pre-clinical data, numerous HDAC inhibitors are under investigation in clinical trials, either as monotherapies or in conjunction with other treatments such as chemotherapy, biologic therapy or radiation therapy.  In fact, two actively studied HDAC inhibitors, vorinostat and depsipeptide, were recently approved for the treatment of refractory cutaneous T cell lymphoma.  In this review, we first present a patient with GBM, and then discuss the pathogenesis, epidemiology and current treatment options of GBM.  Finally, we examine the translation of pre-clinical studies that have demonstrated HDAC inhibitors as potent radiosensitizers in in vitro and in vivo models, to a phase II clinical trial combining the HDAC inhibitor, valproic acid, along with temozolomide and radiation therapy for the treatment of GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTjaDavY9o611WTCLT8lX9SfW6udTcc2ebMNqlxwsqRzrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FivFamsQ%253D%253D&md5=900afc5aca3a58eec21afb25e3c78e92</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1111%2Fj.1582-4934.2011.01296.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1582-4934.2011.01296.x%26sid%3Dliteratum%253Aachs%26aulast%3DShabason%26aufirst%3DJ.%2BE.%26aulast%3DTofilon%26aufirst%3DP.%2BJ.%26aulast%3DCamphausen%26aufirst%3DK.%26atitle%3DGrand%2520rounds%2520at%2520the%2520national%2520institutes%2520of%2520health%253A%2520HDAC%2520inhibitors%2520as%2520radiation%2520modifiers%252C%2520from%2520bench%2520to%2520clinic%26jtitle%3DJ.%2520Cell%2520Mol.%2520Med.%26date%3D2011%26volume%3D15%26spage%3D2735%26epage%3D2744%26doi%3D10.1111%2Fj.1582-4934.2011.01296.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radany, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. Y.</span></span> <span> </span><span class="NLM_article-title">HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells</span>. <i>Cancer Biother.Radiopharm.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">689</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.1089/cbr.2009.0629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1089%2Fcbr.2009.0629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=20025549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisV2msA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2009&pages=689-699&author=X.+Chenauthor=P.+Wongauthor=E.+Radanyauthor=J.+Y.+Wong&title=HDAC+inhibitor%2C+valproic+acid%2C+induces+p53-dependent+radiosensitization+of+colon+cancer+cells&doi=10.1089%2Fcbr.2009.0629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC Inhibitor, Valproic Acid, Induces p53-Dependent Radiosensitization of Colon Cancer Cells</span></div><div class="casAuthors">Chen, Xufeng; Wong, Patty; Radany, Eric; Wong, Jeffrey Y. C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biotherapy and Radiopharmaceuticals</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">689-699</span>CODEN:
                <span class="NLM_cas:coden">CBRAFJ</span>;
        ISSN:<span class="NLM_cas:issn">1084-9785</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Agents that inhibit histone deacetylases (HDAC inhibitors) have been shown to enhance radiation response.  The aim of this study was to evaluate the effects of low, minimally cytotoxic concns. of the HDAC inhibitor, valproic acid (VPA), on radiation response of colorectal cancer cells.  Cell lines LS174T and an isogenic pair of HCT116, which differed only for the presence of wild-type p53, were exposed to ionizing radiation (IR) alone, VPA alone, or the combination.  Clonogenic survival, γ-H2AX induction, apoptosis, changes in mitochondrial membrane potential, and mitochondrial levels of p53 and Bcl-2 family proteins were assessed.  In vivo studies monitored tumor growth suppression after therapy in mice bearing HCT116/p53+/+ and HCT116/p53-/- tumor xenografts.  VPA led to radiosensitization, which was dependent on p53 status.  A decrease in clonogenic survival, an increase in apoptosis, and an increase in levels of γ-H2AX were obsd. after VPA+IR, compared to IR alone, in wild-type p53 cells (LS174T and HCT116/p53+/+), as opposed to p53 null cells (HCT116/p53-/-).  Exposure to VPA resulted in enhancement of IR-induced mitochondrial localizations of Bax and Bcl-xL, mitochondrial membrane potential, and cytochrome c release only in wild-type p53 cell lines.  VPA also enhanced tumor growth suppression after IR only in wild-type p53 xenografts.  These data suggest that VPA may have an important role in enhancing radiotherapy response in colorectal cancer, particularly in tumors with the wild-type p53 genotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZAQL3MuzBYLVg90H21EOLACvtfcHk0lg6yDfvDQa6Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisV2msA%253D%253D&md5=fd501482186b5221594a428b4668692b</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1089%2Fcbr.2009.0629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fcbr.2009.0629%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DP.%26aulast%3DRadany%26aufirst%3DE.%26aulast%3DWong%26aufirst%3DJ.%2BY.%26atitle%3DHDAC%2520inhibitor%252C%2520valproic%2520acid%252C%2520induces%2520p53-dependent%2520radiosensitization%2520of%2520colon%2520cancer%2520cells%26jtitle%3DCancer%2520Biother.Radiopharm.%26date%3D2009%26volume%3D24%26spage%3D689%26epage%3D699%26doi%3D10.1089%2Fcbr.2009.0629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuneo, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallahan, D. E.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase (HDAC) inhibitor LBH589 increases duration of γ-H2AX Foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">11298</span>– <span class="NLM_lpage">11304</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-0049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F0008-5472.CAN-06-0049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=17145876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1KnsLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=11298-11304&author=L.+Gengauthor=K.+C.+Cuneoauthor=A.+Fuauthor=T.+Tuauthor=P.+W.+Atadjaauthor=D.+E.+Hallahan&title=Histone+deacetylase+%28HDAC%29+inhibitor+LBH589+increases+duration+of+%CE%B3-H2AX+Foci+and+confines+HDAC4+to+the+cytoplasm+in+irradiated+non-small+cell+lung+cancer&doi=10.1158%2F0008-5472.CAN-06-0049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase (HDAC) Inhibitor LBH589 Increases Duration of γ-H2AX Foci and Confines HDAC4 to the Cytoplasm in Irradiated Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Geng, Ling; Cuneo, Kyle C.; Fu, Allie; Tu, Tianxiang; Atadja, Peter W.; Hallahan, Dennis E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">11298-11304</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Histone deacetylases (HDAC) have been identified as therapeutic targets due to their regulatory function in DNA structure and organization.  LBH589 is a novel inhibitor of class I and II HDACs.  We studied the effect of LBH589 and ionizing radiation (IR) on DNA repair in two human non-small cell lung cancer (NSCLC) cell lines (H23 and H460). γ-H2AX foci present at DNA double-strand breaks (DSBs) were detected in the nuclei following 3 Gy irradn. for up to 6 h.  LBH589 administered before irradn. increased the duration of γ-H2AX foci beyond 24 h.  Furthermore, radiation alone induced translocation of HDAC4 to the nucleus.  In contrast, treatment with LBH589 followed by irradn. resulted in HDAC4 confinement to the cytoplasm, indicating that HDAC inhibition affects the nuclear localization of HDAC4.  The findings that LBH589 confines HDAC4 to the cytoplasm and increases the duration of γ-H2AX foci in irradiated cell lines suggest that HDAC4 participates in DNA damage signaling following IR.  Annexin-propidium iodide flow cytometry assays, cell morphol. studies, and cleaved caspase-3 Western blot anal. revealed a synergistic effect of LBH589 with IR in inducing apoptosis.  Clonogenic survival showed a greater than additive effect when LBH589 was administered before irradn. compared with irradn. alone.  In vivo tumor vol. studies showed a growth delay of 20 days with combined treatment compared with 4 and 2 days for radiation or LBH589 alone.  This study identifies HDAC4 as a biomarker of LBH589 activity and recognizes the ability of LBH589 to sensitize human NSCLC to radiation-induced DNA DSBs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouEeNKS1UEXLVg90H21EOLACvtfcHk0lhUVbMpYVrwWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1KnsLzO&md5=b98e5802498e26f3201f6ed68c88804d</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-0049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-0049%26sid%3Dliteratum%253Aachs%26aulast%3DGeng%26aufirst%3DL.%26aulast%3DCuneo%26aufirst%3DK.%2BC.%26aulast%3DFu%26aufirst%3DA.%26aulast%3DTu%26aufirst%3DT.%26aulast%3DAtadja%26aufirst%3DP.%2BW.%26aulast%3DHallahan%26aufirst%3DD.%2BE.%26atitle%3DHistone%2520deacetylase%2520%2528HDAC%2529%2520inhibitor%2520LBH589%2520increases%2520duration%2520of%2520%25CE%25B3-H2AX%2520Foci%2520and%2520confines%2520HDAC4%2520to%2520the%2520cytoplasm%2520in%2520irradiated%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D11298%26epage%3D11304%26doi%3D10.1158%2F0008-5472.CAN-06-0049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anupama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurland, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobbs, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismail, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyn, R. E.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">4912</span>– <span class="NLM_lpage">4922</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1078-0432.CCR-04-2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16000590" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=4912-4922&author=M.+Anupamaauthor=J.+F.+Kurlandauthor=T.+Nishikawaauthor=T.+Tanakaauthor=M.+L.+Hobbsauthor=S.+L.+Tuckerauthor=S.+Ismailauthor=C.+Stevensauthor=R.+E.+Meyn&title=Histone+deacetylase+inhibitors+radiosensitize+human+melanoma+cells+by+suppressing+DNA+repair+activity&doi=10.1158%2F1078-0432.CCR-04-2088"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-2088%26sid%3Dliteratum%253Aachs%26aulast%3DAnupama%26aufirst%3DM.%26aulast%3DKurland%26aufirst%3DJ.%2BF.%26aulast%3DNishikawa%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DHobbs%26aufirst%3DM.%2BL.%26aulast%3DTucker%26aufirst%3DS.%2BL.%26aulast%3DIsmail%26aufirst%3DS.%26aulast%3DStevens%26aufirst%3DC.%26aulast%3DMeyn%26aufirst%3DR.%2BE.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520radiosensitize%2520human%2520melanoma%2520cells%2520by%2520suppressing%2520DNA%2520repair%2520activity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D4912%26epage%3D4922%26doi%3D10.1158%2F1078-0432.CCR-04-2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marmion, C. J.</span></span> <span> </span><span class="NLM_article-title">A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">6735</span>– <span class="NLM_lpage">6737</span>, <span class="refDoi"> DOI: 10.1039/b916715c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1039%2Fb916715c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=19885462" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2009&pages=6735-6737&author=D.+Griffithauthor=M.+P.+Morganauthor=C.+J.+Marmion&title=A+novel+anti-cancer+bifunctional+platinum+drug+candidate+with+dual+DNA+binding+and+histone+deacetylase+inhibitory+activity&doi=10.1039%2Fb916715c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1039%2Fb916715c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb916715c%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DD.%26aulast%3DMorgan%26aufirst%3DM.%2BP.%26aulast%3DMarmion%26aufirst%3DC.%2BJ.%26atitle%3DA%2520novel%2520anti-cancer%2520bifunctional%2520platinum%2520drug%2520candidate%2520with%2520dual%2520DNA%2520binding%2520and%2520histone%2520deacetylase%2520inhibitory%2520activity%26jtitle%3DChem.%2520Commun.%26date%3D2009%26volume%3D44%26spage%3D6735%26epage%3D6737%26doi%3D10.1039%2Fb916715c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Q.</span></span> <span> </span><span class="NLM_article-title">Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">344</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1039/C7MD00476A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1039%2FC7MD00476A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=30108928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVCjs7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=344-352&author=R.+Xieauthor=P.+Tangauthor=Q.+Yuan&title=Rational+design+and+characterization+of+a+DNA%2FHDAC+dual-targeting+inhibitor+containing+nitrogen+mustard+and+2-aminobenzamide+moieties&doi=10.1039%2FC7MD00476A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties</span></div><div class="casAuthors">Xie, Rui; Tang, Pingwah; Yuan, Qipeng</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">344-352</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) play a key role not only in gene expression but also in DNA repair.  Herein, we report the rational design and characterization of a compd. named chlordinaline contg. nitrogen mustard and 2-aminobenzamide moieties as a DNA/HDAC dual-targeting inhibitor.  Chlordinaline exhibited moderate total HDAC inhibitory activity.  The HDAC isoform selectivity assay indicated that chlordinaline mostly inhibits HDAC3.  Chlordinaline exhibited both DNA and HDAC inhibitory activities and showed potent antiproliferative activity against all the six test cancer cell lines with IC50 values of as low as 3.1-14.2μM, which is significantly more potent than ref. drugs chlorambucil and tacedinaline.  Chlordinaline could induce the apoptosis and G2/M phase cell cycle arrest of A375 cancer cells.  This study demonstrates that combining nitrogen mustard and 2-aminobenzamide moieties into one mol. is an effective method to obtain DNA/HDAC dual-targeting inhibitors as potent antitumor agents.  Chlordinaline as the first example of such DNA/HDAC dual-targeting inhibitors could be a promising candidate for cancer therapy and could also be a lead compd. for further optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNSMpT4AGIdrVg90H21EOLACvtfcHk0lhCkUYGw18j4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVCjs7rO&md5=c1c9111452f0ecaec88ebc56bb1d4c80</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1039%2FC7MD00476A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00476A%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DR.%26aulast%3DTang%26aufirst%3DP.%26aulast%3DYuan%26aufirst%3DQ.%26atitle%3DRational%2520design%2520and%2520characterization%2520of%2520a%2520DNA%252FHDAC%2520dual-targeting%2520inhibitor%2520containing%2520nitrogen%2520mustard%2520and%25202-aminobenzamide%2520moieties%26jtitle%3DMedChemComm%26date%3D2018%26volume%3D9%26spage%3D344%26epage%3D352%26doi%3D10.1039%2FC7MD00476A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Q.</span></span> <span> </span><span class="NLM_article-title">Rational design, synthesis and preliminary antitumor activity evaluation of a chlorambucil derivative with potent DNA/HDAC dual-targeting inhibitory activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4415</span>– <span class="NLM_lpage">4420</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bmcl.2017.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=28818449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlCnsLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=4415-4420&author=R.+Xieauthor=Y.+Liauthor=P.+Tangauthor=Q.+Yuan&title=Rational+design%2C+synthesis+and+preliminary+antitumor+activity+evaluation+of+a+chlorambucil+derivative+with+potent+DNA%2FHDAC+dual-targeting+inhibitory+activity&doi=10.1016%2Fj.bmcl.2017.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design, synthesis and preliminary antitumor activity evaluation of a chlorambucil derivative with potent DNA/HDAC dual-targeting inhibitory activity</span></div><div class="casAuthors">Xie, Rui; Li, Yan; Tang, Pingwah; Yuan, Qipeng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4415-4420</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) play a pivotal role not only in gene expression but also in DNA repair.  Herein, we report the successful design, synthesis and evaluation of a chlorambucil deriv. named vorambucil with a hydroxamic acid tail as a DNA/HDAC dual-targeting inhibitor.  Vorambucil obtained both potent DNA and HDACs inhibitory activities.  Mol. docking results supported the initial pharmacophoric hypothesis and rationalized the potent inhibitory activity of vorambucil against HDAC1, HDAC2 and HDAC6.  Vorambucil showed potent antiproliferative activity against all the test four cancer cell lines with IC50 values of as low as 3.2-6.2 μM and exhibited 5.0-18.3-fold enhanced antiproliferative activity than chlorambucil.  Vorambucil also significantly inhibits colony formation of A375 cancer cells.  Further investigation showed that vorambucil remarkably induced apoptosis and arrested the cell cycle of A375 cells at G2/M phase.  Vorambucil could be a promising candidate and a useful tool to elucidate the role of those DNA/HDAC dual-targeting inhibitors for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofN9CuOj7Rs7Vg90H21EOLACvtfcHk0liaM5sq78em5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlCnsLfF&md5=07ec0652478936d105d7a7b7cad74d0d</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DP.%26aulast%3DYuan%26aufirst%3DQ.%26atitle%3DRational%2520design%252C%2520synthesis%2520and%2520preliminary%2520antitumor%2520activity%2520evaluation%2520of%2520a%2520chlorambucil%2520derivative%2520with%2520potent%2520DNA%252FHDAC%2520dual-targeting%2520inhibitory%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D4415%26epage%3D4420%26doi%3D10.1016%2Fj.bmcl.2017.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallasch, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemann, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span> <span> </span><span class="NLM_article-title">A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">449</span>, <span class="refDoi"> DOI: 10.15252/emmm.201404580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.15252%2Femmm.201404580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25759362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVKjsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=438-449&author=C.+Liuauthor=H.+Dingauthor=X.+Liauthor=C.+P.+Pallaschauthor=L.+Hongauthor=D.+Guoauthor=Y.+Chenauthor=D.+Wangauthor=W.+Wangauthor=Y.+Wangauthor=M.+T.+Hemannauthor=H.+Jiang&title=A+DNA%2FHDAC+dual-targeting+drug+CY190602+with+significantly+enhanced+anticancer+potency&doi=10.15252%2Femmm.201404580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency</span></div><div class="casAuthors">Liu, Chuan; Ding, Hongyu; Li, Xiaoxi; Pallasch, Christian P.; Hong, Liya; Guo, Dianwu; Chen, Yi; Wang, Difei; Wang, Wei; Wang, Yajie; Hemann, Michael T.; Jiang, Hai</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">438-449</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Genotoxic drugs constitute a major treatment modality for human cancers; however, cancer cells' intrinsic DNA repair capability often increases the threshold of lethality and renders these drugs ineffective.  The emerging roles of HDACs in DNA repair provide new opportunities for improving traditional genotoxic drugs.  Here, we report the development and characterization of CY190602, a novel bendamustine-derived drug with significantly enhanced anticancer potency.  We show that CY190602's enhanced potency can be attributed to its newly gained ability to inhibit HDACs.  Using this novel DNA/HDAC dual-targeting drug as a tool, we further explored HDAC's role in DNA repair.  We found that HDAC activities are essential for the expression of several genes involved in DNA synthesis and repair, including TYMS, Tip60, CBP, EP300, and MSL1.  Importantly, CY190602, the first-in-class example of such DNA/HDAC dual-targeting drugs, exhibited significantly enhanced anticancer activity in vitro and in vivo.  These findings provide rationales for incorporating HDAC inhibitory moieties into genotoxic drugs, so as to overcome the repair capacity of cancer cells.  Systematic development of similar DNA/HDAC dual-targeting drugs may represent a novel opportunity for improving cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5b1gqThxGiLVg90H21EOLACvtfcHk0lgkr1TWQi8L-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVKjsLg%253D&md5=9e0c4cf0099a474e9ddbb1f87ec8a73d</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.15252%2Femmm.201404580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Femmm.201404580%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DPallasch%26aufirst%3DC.%2BP.%26aulast%3DHong%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHemann%26aufirst%3DM.%2BT.%26aulast%3DJiang%26aufirst%3DH.%26atitle%3DA%2520DNA%252FHDAC%2520dual-targeting%2520drug%2520CY190602%2520with%2520significantly%2520enhanced%2520anticancer%2520potency%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2015%26volume%3D7%26spage%3D438%26epage%3D449%26doi%3D10.15252%2Femmm.201404580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span> <span> </span><span class="NLM_article-title">Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4100</span>– <span class="NLM_lpage">4109</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.05.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bmc.2017.05.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=28601509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpslGntbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=4100-4109&author=Z.+Yuanauthor=S.+Chenauthor=Q.+Sunauthor=N.+Wangauthor=D.+Liauthor=S.+Miaoauthor=C.+Gaoauthor=Y.+Chenauthor=C.+Tanauthor=Y.+Jiang&title=Olaparib+hydroxamic+acid+derivatives+as+dual+PARP+and+HDAC+inhibitors+for+cancer+therapy&doi=10.1016%2Fj.bmc.2017.05.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy</span></div><div class="casAuthors">Yuan, Zigao; Chen, Shaopeng; Sun, Qinsheng; Wang, Ning; Li, Dan; Miao, Shuangshuang; Gao, Chunmei; Chen, Yuzong; Tan, Chunyan; Jiang, Yuyang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4100-4109</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Olaparib was the first PARP inhibitor approved by the FDA for patients with BRCA-mutated ovarian cancer.  Recent studies have demonstrated enhanced anticancer effects of combination therapy consisting of olaparib and HDAC inhibitors.  Herein, based on rational drug design strategy, hydroxamic acid derivs. of olaparib were constructed as dual PARP and HDAC inhibitors.  These hybrid compds. showed potent inhibitory activities against PARP1/2 and HDAC1/6 with IC50 values in the nanomolar range.  Furthermore, compd. P1 exhibited broad-spectrum antiproliferative activities in selected human cancer cell lines.  Specially, P1 showed more potent activity than olaparib and SAHA in cancer cells MDA-MB-231, HCC1937 and Raji, and 4.1-fold less cytotoxicity compared with SAHA to normal cells MCF-10A.  Further mechanism study indicated that P1 could induce the cleavage of PARP and the hyperacetylation of histones, increase the expression of DNA damage biomarker γ-H2AX, decrease the level of BRCA1 and RAD51, and regulate tumor cell growth and apoptosis through modulating both mitochondrial- and death receptor-mediated pathways.  Therefore, our study suggested that compds. targeting PARP and HDAC concurrently might be a practical approach for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4Q6j2BUCmTrVg90H21EOLACvtfcHk0lgkr1TWQi8L-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpslGntbY%253D&md5=ac79d6e4d730eeefc1eda749823c80d5</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.05.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.05.058%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DMiao%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DY.%26atitle%3DOlaparib%2520hydroxamic%2520acid%2520derivatives%2520as%2520dual%2520PARP%2520and%2520HDAC%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D4100%26epage%3D4109%26doi%3D10.1016%2Fj.bmc.2017.05.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J.</span></span> <span> </span><span class="NLM_article-title">JAK kinases in health and disease: an update</span>. <i>Open Rheumatol. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">244</span>, <span class="refDoi"> DOI: 10.2174/1874312901206010232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.2174%2F1874312901206010232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=23028408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1equrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=232-244&author=A.+Laurenceauthor=M.+Pesuauthor=O.+Silvennoinenauthor=J.+O%E2%80%99Shea&title=JAK+kinases+in+health+and+disease%3A+an+update&doi=10.2174%2F1874312901206010232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">JAK kinases in health and disease: an update</span></div><div class="casAuthors">Laurence, Arian; Pesu, Marko; Silvennoinen, Olli; O'Shea, John</div><div class="citationInfo"><span class="NLM_cas:title">Open Rheumatology Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">232-244</span>CODEN:
                <span class="NLM_cas:coden">ORJPAP</span>;
        ISSN:<span class="NLM_cas:issn">1874-3129</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Janus kinases (JAKs) are crit. signaling elements for a large subset of cytokines.  As a consequence they play pivotal roles in the pathophysiol. of many diseases including neoplastic and autoimmune diseases.  Small mol. JAK inhibitors as therapeutic agents have become a reality and the palette of such inhibitors will likely expand.  This review will summarize our current knowledge on these key enzymes and their assocd. pharmaceutical inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjovQnlyAQvrVg90H21EOLACvtfcHk0lgJvEEKFc06ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1equrjO&md5=ed5d20df39001bb27ca8556cae82c289</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.2174%2F1874312901206010232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1874312901206010232%26sid%3Dliteratum%253Aachs%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%26atitle%3DJAK%2520kinases%2520in%2520health%2520and%2520disease%253A%2520an%2520update%26jtitle%3DOpen%2520Rheumatol.%2520J.%26date%3D2012%26volume%3D6%26spage%3D232%26epage%3D244%26doi%3D10.2174%2F1874312901206010232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plenge, R.</span></span> <span> </span><span class="NLM_article-title">JAK and STAT signaling molecules in immunoregulation and immune-mediated disease</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">550</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2012.03.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.immuni.2012.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=22520847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFWqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=542-550&author=J.+O%E2%80%99Sheaauthor=R.+Plenge&title=JAK+and+STAT+signaling+molecules+in+immunoregulation+and+immune-mediated+disease&doi=10.1016%2Fj.immuni.2012.03.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease</span></div><div class="casAuthors">O'Shea, John J.; Plenge, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">542-550</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The discovery of the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway, a landmark in cell biol., provided a simple mechanism for gene regulation that dramatically advanced our understanding of the action of hormones, interferons, colony-stimulating factors, and interleukins.  As we learn more about the complexities of immune responses, new insights into the functions of this pathway continue to be revealed, aided by technol. that permits genome-wide views.  As we celebrate the 20th anniversary of the discovery of this paradigm in cell signaling, it is particularly edifying to see how this knowledge has rapidly been translated to human immune disease.  Not only have genome-wide assocn. studies demonstrated that this pathway is highly relevant to human autoimmunity, but targeting JAKs is now a reality in immune-mediated disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc6dj5Zf9fdLVg90H21EOLACvtfcHk0lgJvEEKFc06ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFWqt7g%253D&md5=de187a0555549f9f00f5a41052c05352</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2012.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2012.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%26aulast%3DPlenge%26aufirst%3DR.%26atitle%3DJAK%2520and%2520STAT%2520signaling%2520molecules%2520in%2520immunoregulation%2520and%2520immune-mediated%2520disease%26jtitle%3DImmunity%26date%3D2012%26volume%3D36%26spage%3D542%26epage%3D550%26doi%3D10.1016%2Fj.immuni.2012.03.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shuai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">Regulation of JAK–STAT signalling in the immune system</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">900</span>– <span class="NLM_lpage">911</span>, <span class="refDoi"> DOI: 10.1038/nri1226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnri1226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=14668806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=900-911&author=K.+Shuaiauthor=B.+Liu&title=Regulation+of+JAK%E2%80%93STAT+signalling+in+the+immune+system&doi=10.1038%2Fnri1226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of JAK-STAT signalling in the immune system</span></div><div class="casAuthors">Shuai, Ke; Liu, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">900-911</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The cytokine-activated Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway has an important role in the control of immune responses.  Dysregulation of JAK-STAT signalling is assocd. with various immune disorders.  The signalling strength kinetics and specificity of the JAK-STAT pathway are modulated at many levels by distinct regulatory proteins.  Here, we review recent studies on the regulation of the JAK-STAT pathway that will enhance our ability to design rational therapeutic strategies for immune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDG-MzyqAi4bVg90H21EOLACvtfcHk0lgJvEEKFc06ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D&md5=cb04239e0d430052a975e930c656e31d</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1038%2Fnri1226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1226%26sid%3Dliteratum%253Aachs%26aulast%3DShuai%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DRegulation%2520of%2520JAK%25E2%2580%2593STAT%2520signalling%2520in%2520the%2520immune%2520system%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2003%26volume%3D3%26spage%3D900%26epage%3D911%26doi%3D10.1038%2Fnri1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klampfer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaby, L.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augenlicht, L.</span></span> <span> </span><span class="NLM_article-title">Requirement of histone deacetylase activity for signaling by STAT1</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">30358</span>– <span class="NLM_lpage">30368</span>, <span class="refDoi"> DOI: 10.1074/jbc.M401359200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1074%2Fjbc.M401359200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15123634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsFKiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=30358-30368&author=L.+Klampferauthor=J.+Huangauthor=L.-A.+Swabyauthor=L.+Augenlicht&title=Requirement+of+histone+deacetylase+activity+for+signaling+by+STAT1&doi=10.1074%2Fjbc.M401359200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement of Histone Deacetylase Activity for Signaling by STAT1</span></div><div class="casAuthors">Klampfer, Lidija; Huang, Jie; Swaby, Laurie-Anne; Augenlicht, Leonard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">30358-30368</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">STAT1 is a transcription factor that plays a crucial role in signaling by interferons (IFNs).  In this study the authors demonstrated that inhibitors of histone deacetylase (HDAC) activity, butyrate, trichostatin A, and suberoylanilide hydroxamic acid, prevented IFNγ-induced JAK1 activation, STAT1 phosphorylation, its nuclear translocation, and STAT1-dependent gene activation.  Furthermore, the authors showed that silencing of HDAC1, HDAC2, and HDAC3 through RNA interference markedly decreased IFNγ-driven gene activation and that overexpression of HDAC1, HDAC2, and HDAC3 enhanced STAT1-dependent transcriptional activity.  The authors' data therefore established the essential role of deacetylase activity in STAT1 signaling.  Induction of IRF-1 by IFNγ requires functional STAT1 signaling and was abrogated by butyrate, trichostatin A, suberoylanilide hydroxamic acid, and STAT1 small interfering RNA.  In contrast, silencing of STAT1 did not interfere with IFNγ-induced expression of STAT2 and caspase-7, and HDAC inhibitors did not preclude IFNγ-induced expression of STAT1, STAT2, and caspase-7, suggesting that HDAC inhibitors impede the expression of IFNγ target genes whose expression depends on STAT1 but do not interfere with STAT1-independent signaling by IFNγ.  Finally, the authors showed that inhibitors of deacetylase activity sensitized colon cancer cells to IFNγ-induced apoptosis through cooperative neg. regulation of Bcl-x expression, demonstrating that interruption of the balance between STAT1-dependent and STAT1-independent signaling significantly alters the biol. activity of IFNγ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4TaaFs2-6QrVg90H21EOLACvtfcHk0liX__gAZugp2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsFKiurg%253D&md5=4cab3911cd57a8b472d4b8e55f403335</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M401359200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M401359200%26sid%3Dliteratum%253Aachs%26aulast%3DKlampfer%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DSwaby%26aufirst%3DL.-A.%26aulast%3DAugenlicht%26aufirst%3DL.%26atitle%3DRequirement%2520of%2520histone%2520deacetylase%2520activity%2520for%2520signaling%2520by%2520STAT1%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D30358%26epage%3D30368%26doi%3D10.1074%2Fjbc.M401359200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.-m.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, L.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.-b.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, P.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, F.-j.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms</span>. <i>Exp. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">270</span>, <span class="refDoi"> DOI: 10.1016/j.exphem.2012.10.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.exphem.2012.10.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=23111066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVKnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=261-270&author=S.-m.+Gaoauthor=C.-q.+Chenauthor=L.-y.+Wangauthor=L.-l.+Hongauthor=J.-b.+Wuauthor=P.-h.+Dongauthor=F.-j.+Yu&title=Histone+deacetylases+inhibitor+sodium+butyrate+inhibits+JAK2%2FSTAT+signaling+through+upregulation+of+SOCS1+and+SOCS3+mediated+by+HDAC8+inhibition+in+myeloproliferative+neoplasms&doi=10.1016%2Fj.exphem.2012.10.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms</span></div><div class="casAuthors">Gao, Shen-meng; Chen, Chi-qi; Wang, Lu-yao; Hong, Li-li; Wu, Jian-bo; Dong, Pei-hong; Yu, Fu-jun</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Hematology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">261-270.e4</span>CODEN:
                <span class="NLM_cas:coden">EXHMA6</span>;
        ISSN:<span class="NLM_cas:issn">0301-472X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Constitutive activation of Janus kinase 2/signal transducers and activators of transcription (JAK2/STAT) signaling has an important role in the oncogenesis of myeloproliferative neoplasms (MPNs) and leukemia.  Histone deacetylases (HDACs) inhibitors have been reported to possess anticancer activity through different mechanisms.  However, whether HDACs inhibitors suppress JAK2/STAT signaling in MPNs is still unknown.  In this study, we show that the HDAC inhibitor sodium butyrate (SB) inhibited JAK2/STAT signaling and increased the expression of suppressors of cytokine signaling 1 (SOCS1) and SOCS3, both of which are the potent feedback inhibitors of JAK2/STAT signaling.  SB upregulated the expression of SOCS1 and SOCS3 by triggering the promoter-assocd. histone acetylation of SOCS1 and SOCS3 in K562 and HEL cell lines.  Importantly, we found that upon knockdown of each class I HDACs, only knockdown of HDAC8 resulted in the increased expression of SOCS1 and SOCS3.  Moreover, overexpression of SOCS1 and SOCS3 significantly inhibited cell growth and suppressed JAK2/STAT signaling in K562 and HEL cells.  Furthermore, SB increased the transcript levels of SOCS1 and SOCS3 and inhibited the clonogenic activity of hematopoietic progenitors from patients with MPNs.  Taken together, these data establish a new anticancer mechanism that SB inhibits JAK2/STAT signaling through HDAC8-mediated upregulation of SOCS1 and SOCS3.  Thus, HDACs inhibitors may have therapeutic potential for the treatment of MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUyHeZIFKSQrVg90H21EOLACvtfcHk0liX__gAZugp2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVKnsg%253D%253D&md5=b57bcdeb8347c2b49060cacf3014a66f</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.exphem.2012.10.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exphem.2012.10.012%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DS.-m.%26aulast%3DChen%26aufirst%3DC.-q.%26aulast%3DWang%26aufirst%3DL.-y.%26aulast%3DHong%26aufirst%3DL.-l.%26aulast%3DWu%26aufirst%3DJ.-b.%26aulast%3DDong%26aufirst%3DP.-h.%26aulast%3DYu%26aufirst%3DF.-j.%26atitle%3DHistone%2520deacetylases%2520inhibitor%2520sodium%2520butyrate%2520inhibits%2520JAK2%252FSTAT%2520signaling%2520through%2520upregulation%2520of%2520SOCS1%2520and%2520SOCS3%2520mediated%2520by%2520HDAC8%2520inhibition%2520in%2520myeloproliferative%2520neoplasms%26jtitle%3DExp.%2520Hematol.%26date%3D2013%26volume%3D41%26spage%3D261%26epage%3D270%26doi%3D10.1016%2Fj.exphem.2012.10.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintás-Cardama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrov, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1124</span>– <span class="NLM_lpage">1127</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2012.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.leukres.2012.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=22475363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvF2hsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=1124-1127&author=A.+Quint%C3%A1s-Cardamaauthor=H.+Kantarjianauthor=Z.+Estrovauthor=G.+Borthakurauthor=J.+Cortesauthor=S.+Verstovsek&title=Therapy+with+the+histone+deacetylase+inhibitor+pracinostat+for+patients+with+myelofibrosis&doi=10.1016%2Fj.leukres.2012.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Kantarjian, Hagop; Estrov, Zeev; Borthakur, Gautam; Cortes, Jorge; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1124-1127</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Approx. half of the patients with myelofibrosis (MF) carry mutant JAK2V617F proteins.  JAK2V617F has been recently shown to translocate to the nucleus and modify specific histones, thus regulating transcription.  We report on a phase II study testing the activity and tolerability of the histone deacetylase inhibitor pracinostat given at 60 mg every other day for three weeks per mo in 22 patients with intermediate or high risk MF.  Eight (36%) patients experienced clin. benefit, with 6 (27%) experiencing redns. in splenomegaly (median 3 cm, range 1-4 cm).  According to International Working Group criteria, 2 (9%) patients had clin. improvement (anemia response in both cases).  The most frequent side effect assocd. to pracinostat therapy was fatigue, which occurred in 20 (91%) patients (grade 2 in 3 patients).  Grade 3-4 neutropenia, anemia, and thrombocytopenia occurred in 13%, 0%, and 21%, resp.  Twenty-one patients permanently discontinued pracinostat, mainly due to lack of efficacy.  In conclusion, pracinostat at the dose tested is reasonably tolerated and has modest activity in patients with MF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWKtgUKtLxerVg90H21EOLACvtfcHk0liX__gAZugp2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvF2hsr4%253D&md5=f91f89904ae5bc95102b7b533f2d598f</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2012.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2012.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DQuint%25C3%25A1s-Cardama%26aufirst%3DA.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DTherapy%2520with%2520the%2520histone%2520deacetylase%2520inhibitor%2520pracinostat%2520for%2520patients%2520with%2520myelofibrosis%26jtitle%3DLeuk.%2520Res.%26date%3D2012%26volume%3D36%26spage%3D1124%26epage%3D1127%26doi%3D10.1016%2Fj.leukres.2012.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel janus kinase (JAK) and histone deacetylase (HDAC) dual inhibitors for the treatment of hematological malignancies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3898</span>– <span class="NLM_lpage">3923</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01597</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvVSls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3898-3923&author=X.+Liangauthor=J.+Zangauthor=X.+Liauthor=S.+Tangauthor=M.+Huangauthor=M.+Gengauthor=C.+J.+Chouauthor=C.+Liauthor=Y.+Caoauthor=W.+Xuauthor=H.+Liuauthor=Y.+Zhang&title=Discovery+of+novel+janus+kinase+%28JAK%29+and+histone+deacetylase+%28HDAC%29+dual+inhibitors+for+the+treatment+of+hematological+malignancies&doi=10.1021%2Facs.jmedchem.8b01597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies</span></div><div class="casAuthors">Liang, Xuewu; Zang, Jie; Li, Xiaoyang; Tang, Shuai; Huang, Min; Geng, Meiyu; Chou, C. James; Li, Chunpu; Cao, Yichun; Xu, Wenfang; Liu, Hong; Zhang, Yingjie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3898-3923</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Concurrent inhibition of Janus kinase (JAK) and histone deacetylase (HDAC) could potentially improve the efficacy of the HDAC inhibitors in the treatment of cancers and resolve the problem of HDAC inhibitor resistance in some tumors.  Here, a novel series of pyrimidin-2-amino-pyrazol hydroxamate derivs. as JAK and HDAC dual inhibitors was designed, synthesized, and evaluated, among which I possessed potent and balanced activities against both JAK2 and HDAC6 with half-maximal inhibitory concn. at the nanomolar level. I exhibited improved antiproliferative and proapoptotic activities over SAHA and ruxolitinib in several hematol. cell lines.  Remarkably, I exhibited more potent antiproliferation effect than the combination of SAHA and ruxolitinib in HEL cells bearing JAK2V617F mutation.  Pharmacokinetic studies in mice showed that I possessed good bioavailability after i.p. administration.  Finally, I showed antitumor efficacy with no significant toxicity in a HEL xenograft model.  Collectively, the results confirm the therapeutic potential of JAK and HDAC dual inhibitors in hematol. malignancies and provide valuable leads for further structural optimization and antitumor mechanism study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOXlwxqcv7m7Vg90H21EOLACvtfcHk0lia7tdZkW4llA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvVSls7o%253D&md5=356363f40f24ac2ef32194e23a29328e</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01597%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DZang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DChou%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520novel%2520janus%2520kinase%2520%2528JAK%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520dual%2520inhibitors%2520for%2520the%2520treatment%2520of%2520hematological%2520malignancies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3898%26epage%3D3923%26doi%3D10.1021%2Facs.jmedchem.8b01597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Thi, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohlson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of ligand efficient dual inhibitors of janus kinase (JAK) and histone deacetylase (HDAC) based on ruxolitinib and vorinostat</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8336</span>– <span class="NLM_lpage">8357</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00678</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00678" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8336-8357&author=L.+Yaoauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+Singhauthor=M.+D.+Duong-Thiauthor=J.+X.+T.+Leeauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Y.+Yenauthor=S.+Ohlsonauthor=B.+W.+Dymock&title=Design+and+synthesis+of+ligand+efficient+dual+inhibitors+of+janus+kinase+%28JAK%29+and+histone+deacetylase+%28HDAC%29+based+on+ruxolitinib+and+vorinostat&doi=10.1021%2Facs.jmedchem.7b00678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat</span></div><div class="casAuthors">Yao, Lianbin; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Singh, Prachi; Duong-Thi, Minh-Dao; Lee, Jeannie X. T.; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Ohlson, Sten; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8336-8357</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Concomitant inhibition of multiple oncogenic pathways is a desirable goal in cancer therapy.  To achieve such an outcome with a single mol. would simplify treatment regimes.  Herein the core features of ruxolitinib, a marketed JAK1/2 inhibitor, have been merged with the HDAC inhibitor vorinostat, leading to new mols. that are bispecific targeted JAK/HDAC inhibitors.  A preferred pyrazole substituted pyrrolopyrimidine, I (R = H), inhibits JAK1 and HDACs 1, 2, 3, 6, and 10 with IC50 values of less than 20 nM, is <100 nM potent against JAK2 and HDAC11, and is selective for the JAK family against a panel of 97 kinases.  Broad cellular antiproliferative potency of I (R = H) is supported by demonstration of JAK-STAT and HDAC pathway blockade in hematol. cell lines.  Me analog I (R = Me) has an even more selective profile.  This study provides new leads for assessment of JAK and HDAC pathway dual inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocWx3JXIW8YbVg90H21EOLACvtfcHk0ljrxvGKCG-P0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ&md5=5ac471ee0cc413b08b926803790de7f9</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00678%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DL.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DDuong-Thi%26aufirst%3DM.%2BD.%26aulast%3DLee%26aufirst%3DJ.%2BX.%2BT.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%2BY.%26aulast%3DOhlson%26aufirst%3DS.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520ligand%2520efficient%2520dual%2520inhibitors%2520of%2520janus%2520kinase%2520%2528JAK%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520based%2520on%2520ruxolitinib%2520and%2520vorinostat%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8336%26epage%3D8357%26doi%3D10.1021%2Facs.jmedchem.7b00678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of janus kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors as a novel strategy for combinational treatment of leukemia and invasive fungal infections</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6056</span>– <span class="NLM_lpage">6074</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00393</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00393" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Snu7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6056-6074&author=Y.+Huangauthor=G.+Dongauthor=H.+Liauthor=N.+Liuauthor=W.+Zhangauthor=C.+Sheng&title=Discovery+of+janus+kinase+2+%28JAK2%29+and+histone+deacetylase+%28HDAC%29+dual+inhibitors+as+a+novel+strategy+for+combinational+treatment+of+leukemia+and+invasive+fungal+infections&doi=10.1021%2Facs.jmedchem.8b00393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections</span></div><div class="casAuthors">Huang, Yahui; Dong, Guoqiang; Li, Huanqiu; Liu, Na; Zhang, Wannian; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6056-6074</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Clin., leukemia patients often suffer from the limited efficacy of chemotherapy and high risks of infection by invasive fungal pathogens.  Herein, a novel therapeutic strategy was developed in which a small mol. can simultaneously treat leukemia and invasive fungal infections (IFIs).  Novel Janus kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors were identified to possess potent anti-proliferative activity toward hematol. cell lines and excellent synergistic effects with fluconazole to treat resistant Candida albicans infections.  In particular, compd. I, a highly active and selective JAK2/HDAC6 dual inhibitor, showed excellent in vivo antitumor efficacy in several acute myeloid leukemia (AML) models and synergized with fluconazole for the treatment of resistant C. albicans infections.  This study highlights the therapeutic potential of JAK2/HDAC dual inhibitors in treating AML and IFIs and provides an efficient strategy for multitargeting drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3_ii7EQG1qLVg90H21EOLACvtfcHk0liI0fSozOA6ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Snu7rN&md5=ba7cf74761120f0526ab520196e3dded</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00393%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520janus%2520kinase%25202%2520%2528JAK2%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520dual%2520inhibitors%2520as%2520a%2520novel%2520strategy%2520for%2520combinational%2520treatment%2520of%2520leukemia%2520and%2520invasive%2520fungal%2520infections%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6056%26epage%3D6074%26doi%3D10.1021%2Facs.jmedchem.8b00393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of janus kinase 2 (JAK2) and histone deacetlyase (HDAC) bispecific inhibitors based on pacritinib and evidence of dual pathway inhibition in hematological cell lines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8233</span>– <span class="NLM_lpage">8262</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00157</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00157" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8233-8262&author=E.+G.+Yangauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Yenauthor=B.+W.+Dymock&title=Design+and+synthesis+of+janus+kinase+2+%28JAK2%29+and+histone+deacetlyase+%28HDAC%29+bispecific+inhibitors+based+on+pacritinib+and+evidence+of+dual+pathway+inhibition+in+hematological+cell+lines&doi=10.1021%2Facs.jmedchem.6b00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</span></div><div class="casAuthors">Yang, Eugene Guorong; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8233-8262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Blockage of more than one oncoprotein or pathway is now a std. approach in modern cancer therapy.  Multiple inhibition is typically achieved with two or more drugs.  Herein the authors describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single mols. with both JAK and HDAC targeted inhibition.  A preferred ether hydroxamate, compd. 51 (11-(4-(N-hydroxyheptanamide)oxy)-[4,1,9]dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12-(27),16,21,23-decaene) inhibits JAK2 and HDAC6 with low nanomolar potency, is <100 nM potent against HDACs 2 and 10, sub-micromolar potent against HDACs 1, 8 and 11, and >50-fold selective for JAK2 in a panel of 97 kinases.  Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematol. cell lines, inhibition of colony formation in HEL cells, and anal. of apoptosis.  This study provides new tool compds. for further exploration of dual JAK-HDAC pathway inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeUHzB39AGWrVg90H21EOLACvtfcHk0lhd9j6m9zO11Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL&md5=aa9ae07a1ac1aa21d70ee0f24621fe82</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00157%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DE.%2BG.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520janus%2520kinase%25202%2520%2528JAK2%2529%2520and%2520histone%2520deacetlyase%2520%2528HDAC%2529%2520bispecific%2520inhibitors%2520based%2520on%2520pacritinib%2520and%2520evidence%2520of%2520dual%2520pathway%2520inhibition%2520in%2520hematological%2520cell%2520lines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8233%26epage%3D8262%26doi%3D10.1021%2Facs.jmedchem.6b00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu-Farseeva, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">619</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.09.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.ejmech.2018.09.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=30243158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOltL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2018&pages=593-619&author=Y.+Y.+Chu-Farseevaauthor=N.+Mustafaauthor=A.+Poulsenauthor=E.+C.+Tanauthor=J.+J.+Y.+Yenauthor=W.+J.+Chngauthor=B.+W.+Dymock&title=Design+and+synthesis+of+potent+dual+inhibitors+of+JAK2+and+HDAC+based+on+fusing+the+pharmacophores+of+XL019+and+vorinostat&doi=10.1016%2Fj.ejmech.2018.09.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat</span></div><div class="casAuthors">Chu-Farseeva, Yu-yi; Mustafa, Nurulhuda; Poulsen, Anders; Tan, Eng Chong; Yen, Jeffrey J. Y.; Chng, Wee Joo; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">593-619</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Specifically blocking more than one oncogenic pathway simultaneously in a cancer cell with a combination of different drugs is the mainstay of the majority of cancer treatments.  Being able to do this via two targeted pathways without inducing side effects through a general mechanism, such as chemotherapy, could bring benefit to patients.  In this work we describe a new dual inhibitor of the JAK-STAT and HDAC pathways through designing and developing two types of mol. based on the JAK2 selective inhibitor XL019 and the pan-HDAC inhibitor, vorinostat.  Both series of compds. had examples with low nanomolar JAK2 and HDAC1/6 inhibition.  In some cases good HDAC1 selectivity was achieved while retaining HDAC6 activity.  The obsd. potency is explained through mol. docking studies of all three enzymes.  One example, 69c had 16-25 fold selectivity against the three other JAK-family proteins JAK1, JAK3 and TYK2.  A no. of compds. had sub-micromolar potencies against a panel of 4 solid tumor cell lines and 4 hematol. cell lines with the most potent compd., 45h, having a cellular IC50 of 70 nM against the multiple myeloma cell line KMS-12-BM.  Evidence of both JAK and HDAC pathway inhibition is presented in Hela cells showing that both pathways are modulated.  Evidence of apoptosis with two compds. in 4 sold tumor cell lines is also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppP3twGjwSkLVg90H21EOLACvtfcHk0lj_JLLz22Hpow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOltL%252FK&md5=a6a1456126270e44dfa2f28916f7b7c0</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.09.024%26sid%3Dliteratum%253Aachs%26aulast%3DChu-Farseeva%26aufirst%3DY.%2BY.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%2BY.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520potent%2520dual%2520inhibitors%2520of%2520JAK2%2520and%2520HDAC%2520based%2520on%2520fusing%2520the%2520pharmacophores%2520of%2520XL019%2520and%2520vorinostat%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D158%26spage%3D593%26epage%3D619%26doi%3D10.1016%2Fj.ejmech.2018.09.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Lockhart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forster, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishnan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greninger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellisen, L. W.</span></span> <span> </span><span class="NLM_article-title">Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0417</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F2159-8290.CD-12-0417" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=23274910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVOktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=324-337&author=L.+Heauthor=K.+Torres-Lockhartauthor=N.+Forsterauthor=S.+Ramakrishnanauthor=P.+Greningerauthor=M.+J.+Garnettauthor=U.+McDermottauthor=S.+M.+Rothenbergauthor=C.+H.+Benesauthor=L.+W.+Ellisen&title=Mcl-1+and+FBW7+control+a+dominant+survival+pathway+underlying+HDAC+and+Bcl-2+inhibitor+synergy+in+squamous+cell+carcinoma&doi=10.1158%2F2159-8290.CD-12-0417"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Mcl-1 and FBW7 Control a Dominant Survival Pathway Underlying HDAC and Bcl-2 Inhibitor Synergy in Squamous Cell Carcinoma</span></div><div class="casAuthors">He, Lei; Torres-Lockhart, Kristine; Forster, Nicole; Ramakrishnan, Saranya; Greninger, Patricia; Garnett, Mathew J.; McDermott, Ultan; Rothenberg, Stephen M.; Benes, Cyril H.; Ellisen, Leif W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">324-337</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Effective targeted therapeutics for squamous cell carcinoma (SCC) are lacking. Here, we uncover Mcl-1 as a dominant and tissue-specific survival factor in SCC1 providing a roadmap for a new therapeutic approach.  Treatment with the histone deacetylase (HDAC) inhibitor vorinostat regulates Bcl-2 family member expression to disable the Mcl-1 axis and thereby induce apoptosis in SCC cells.  Although Mcl-1 dominance renders SCC cells resistant to the BH3-mimetic ABT-7B7, vorinostat primes them for sensitivity to ABT-737 by shuttling Bim from Mcl-1 to Bcl-2/Bcl-xl, resulting in dramatic synergy for this combination and sustained tumor regression in vivo.  Moreover, somatic FBW7 mutation in SCC is assocd. with stabilized Mcl-1 and high Bim levels, resulting in a poor response to std. chemotherapy but a robust response to HDAC inhibitors and enhanced synergy with the combination vorinostat/ABT-737.  Collectively, our findings provide a biochem. rationale and predictive markers for the application of this therapeutic combination in SCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL6CPNc90gQbVg90H21EOLACvtfcHk0lix7TcT5rRjCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVOktLo%253D&md5=365514e02807e6feb57d255b910d7295</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0417%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DL.%26aulast%3DTorres-Lockhart%26aufirst%3DK.%26aulast%3DForster%26aufirst%3DN.%26aulast%3DRamakrishnan%26aufirst%3DS.%26aulast%3DGreninger%26aufirst%3DP.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DRothenberg%26aufirst%3DS.%2BM.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DEllisen%26aufirst%3DL.%2BW.%26atitle%3DMcl-1%2520and%2520FBW7%2520control%2520a%2520dominant%2520survival%2520pathway%2520underlying%2520HDAC%2520and%2520Bcl-2%2520inhibitor%2520synergy%2520in%2520squamous%2520cell%2520carcinoma%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D324%26epage%3D337%26doi%3D10.1158%2F2159-8290.CD-12-0417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minucci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelicci, P. G.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1038/nrc1779</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnrc1779" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16397526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1GgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=38-51&author=S.+Minucciauthor=P.+G.+Pelicci&title=Histone+deacetylase+inhibitors+and+the+promise+of+epigenetic+%28and+more%29+treatments+for+cancer&doi=10.1038%2Fnrc1779"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer</span></div><div class="casAuthors">Minucci, Saverio; Pelicci, Pier Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-51</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are considered to be among the most promising targets in drug development for cancer therapy, and first-generation histone deacetylase inhibitors (HDACi) are currently being tested in phase I/II clin. trials.  A wide-ranging knowledge of the role of HDACs in tumorigenesis, and of the action of HDACi, has been achieved.  However, several basic aspects are not yet fully understood.  Investigating these aspects in the context of what we now understand about HDACi action both in vitro and in vivo will further improve the design of optimized clin. protocols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxXiACZV1sK7Vg90H21EOLACvtfcHk0lix7TcT5rRjCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1GgsA%253D%253D&md5=384e1f8d676d61531e46843c060a9380</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1038%2Fnrc1779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1779%26sid%3Dliteratum%253Aachs%26aulast%3DMinucci%26aufirst%3DS.%26aulast%3DPelicci%26aufirst%3DP.%2BG.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520and%2520the%2520promise%2520of%2520epigenetic%2520%2528and%2520more%2529%2520treatments%2520for%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D38%26epage%3D51%26doi%3D10.1038%2Fnrc1779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forster, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ory, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellisen, L. W.</span></span> <span> </span><span class="NLM_article-title">Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">4373</span>– <span class="NLM_lpage">4379</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-0046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F0008-5472.CAN-11-0046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=21527555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlersLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=4373-4379&author=M.+R.+Ramseyauthor=L.+Heauthor=N.+Forsterauthor=B.+Oryauthor=L.+W.+Ellisen&title=Physical+association+of+HDAC1+and+HDAC2+with+p63+mediates+transcriptional+repression+and+tumor+maintenance+in+squamous+cell+carcinoma&doi=10.1158%2F0008-5472.CAN-11-0046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Physical Association of HDAC1 and HDAC2 with p63 Mediates Transcriptional Repression and Tumor Maintenance in Squamous Cell Carcinoma</span></div><div class="casAuthors">Ramsey, Matthew R.; He, Lei; Forster, Nicole; Ory, Benjamin; Ellisen, Leif W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4373-4379</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Squamous cell carcinoma (SCC) is a treatment-refractory subtype of human cancer arising from stratified epithelium of the skin, lung, esophagus, oropharynx, and other tissues.  A unifying feature of SCC is high-level expression of the p53-related protein p63 (TP63) in 80% of cases.  The major protein isoform of p63 expressed in SCC is ΔNp63α, an N-terminally truncated form which functions as a key SCC cell survival factor by mechanisms that are unclear.  In this study, the authors show that ΔNp63α assocs. with histone deacetylase 1 (HDAC1) and HDAC2 to form an active transcriptional repressor complex that can be targeted to therapeutic advantage.  Repression of proapoptotic Bcl-2 family member genes including p53 upregulated modulator of apoptosis (PUMA) by p63/HDAC is required for survival of SCC cells.  Cisplatin chemotherapy, a mainstay of SCC treatment, promotes dissocn. of p63 and HDAC from the PUMA promoter, leading to increased histone acetylation, PUMA activation, and apoptosis.  These effects are recapitulated upon targeting the p63/HDAC complex selectively with class I/II HDAC inhibitors using both in vitro and in vivo models.  Sensitivity to HDAC inhibition is directly correlated with p63 expression and is abrogated in tumor cells that overexpress endogenous Bcl-2.  Together, the authors' results elucidate a mechanism of p63-mediated transcriptional repression and they identify the ΔNp63α/HDAC complex as an essential tumor maintenance factor in SCC.  In addn., the authors' findings offer a rationale to apply HDAC inhibitors for SCC treatment.  Cancer Res; 71(13); 4373-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPdcU7ineSrrVg90H21EOLACvtfcHk0lix7TcT5rRjCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlersLk%253D&md5=4df165280fcfc0b929a81119c0a9ffee</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-0046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-0046%26sid%3Dliteratum%253Aachs%26aulast%3DRamsey%26aufirst%3DM.%2BR.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DForster%26aufirst%3DN.%26aulast%3DOry%26aufirst%3DB.%26aulast%3DEllisen%26aufirst%3DL.%2BW.%26atitle%3DPhysical%2520association%2520of%2520HDAC1%2520and%2520HDAC2%2520with%2520p63%2520mediates%2520transcriptional%2520repression%2520and%2520tumor%2520maintenance%2520in%2520squamous%2520cell%2520carcinoma%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D4373%26epage%3D4379%26doi%3D10.1158%2F0008-5472.CAN-11-0046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S.</span></span> <span> </span><span class="NLM_article-title">Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">6149</span>– <span class="NLM_lpage">6169</span>, <span class="refDoi"> DOI: 10.1128/MCB.01481-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1128%2FMCB.01481-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=19805519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsV2ltLbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2009&pages=6149-6169&author=S.+Chenauthor=Y.+Daiauthor=X.+Y.+Peiauthor=S.+Grant&title=Bim+upregulation+by+histone+deacetylase+inhibitors+mediates+interactions+with+the+Bcl-2+antagonist+ABT-737%3A+evidence+for+distinct+roles+for+Bcl-2%2C+Bcl-xL%2C+and+Mcl-1&doi=10.1128%2FMCB.01481-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1</span></div><div class="casAuthors">Chen, Shuang; Dai, Yun; Pei, Xin-Yan; Grant, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6149-6169</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The Bcl-2 antagonist ABT-737 kills transformed cells in assocn. with displacement of Bim from Bcl-2.  The histone deactetylase (HDAC) inhibitor suberoyl bis-hydroxamic acid (SBHA) was employed to det. whether and by what mechanism ABT-737 might interact with agents that upregulate Bim.  Expression profiling of BH3-only proteins indicated that SBHA increased Bim, Puma, and Noxa expression, while SBHA concns. that upregulated Bim significantly potentiated ABT-737 lethality.  Concordance between SBHA-mediated Bim upregulation and interactions with ABT-737 was obsd. in various human leukemia and myeloma cells.  SBHA-induced Bim was largely sequestered by Bcl-2 and Bcl-xL, rather than Mcl-1; ABT-737 attenuated these interactions, thereby triggering Bak/Bax activation and mitochondrial outer membrane permeabilization.  Knockdown of Bim (but not Puma or Noxa) by shRNA or ectopic overexpression of Bcl-2, Bcl-xL, or Mcl-1 diminished Bax/Bak activation and apoptosis.  Notably, ectopic expression of these antiapoptotic proteins disabled death signaling by sequestering different proapoptotic proteins, i.e., Bim by Bcl-2, both Bim and Bak by Bcl-xL, and Bak by Mcl-1.  Together, these findings indicate that HDAC inhibitor-inducible Bim is primarily neutralized by Bcl-2 and Bcl-xL, thus providing a mechanistic framework by which Bcl-2 antagonists potentiate the lethality of agents, such as HDAC inhibitors, which upregulate Bim.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNgeQxZ8-Yn7Vg90H21EOLACvtfcHk0lh2UfQFfDiIdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsV2ltLbK&md5=1c1113e7dbae1252d7fe92f8d59f8f67</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1128%2FMCB.01481-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.01481-08%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DPei%26aufirst%3DX.%2BY.%26aulast%3DGrant%26aufirst%3DS.%26atitle%3DBim%2520upregulation%2520by%2520histone%2520deacetylase%2520inhibitors%2520mediates%2520interactions%2520with%2520the%2520Bcl-2%2520antagonist%2520ABT-737%253A%2520evidence%2520for%2520distinct%2520roles%2520for%2520Bcl-2%252C%2520Bcl-xL%252C%2520and%2520Mcl-1%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2009%26volume%3D29%26spage%3D6149%26epage%3D6169%26doi%3D10.1128%2FMCB.01481-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefebure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shortt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellul, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidacs, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulkner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergsagel, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk MYC multiple myeloma</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e798</span>, <span class="refDoi"> DOI: 10.1038/cddis.2013.306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fcddis.2013.306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=24030150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVWrurjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=e798&author=G.+M.+Matthewsauthor=M.+Lefebureauthor=M.+A.+Doyleauthor=J.+Shorttauthor=J.+Ellulauthor=M.+Chesiauthor=K.+M.+Banksauthor=E.+Vidacsauthor=D.+Faulknerauthor=P.+Atadjaauthor=P.+L.+Bergsagelauthor=R.+W.+Johnstone&title=Preclinical+screening+of+histone+deacetylase+inhibitors+combined+with+ABT-737%2C+rhTRAIL%2FMD5-1+or+5-azacytidine+using+syngeneic+Vk+MYC+multiple+myeloma&doi=10.1038%2Fcddis.2013.306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma</span></div><div class="casAuthors">Matthews, G. M.; Lefebure, M.; Doyle, M. A.; Shortt, J.; Ellul, J.; Chesi, M.; Banks, K.-M.; Vidacs, E.; Faulkner, D.; Atadja, P.; Bergsagel, P. L.; Johnstone, R. W.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">Sept.</span>),
    <span class="NLM_cas:pages">e798</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Multiple myeloma (MM) is an incurable malignancy with an unmet need for innovative treatment options.  Histone deacetylase inhibitors (HDACi) are a new class of anticancer agent that have demonstrated activity in hematol. malignancies.  Here, we investigated the efficacy and safety of HDACi (vorinostat, panobinostat, romidepsin) and novel combination therapies using in vitro human MM cell lines and in vivo preclin. screening utilizing syngeneic transplanted Vk*MYC MM.  HDACi were combined with ABT-737, which targets the intrinsic apoptosis pathway, recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL/MD5-1), that activates the extrinsic apoptosis pathway or the DNA Me transferase inhibitor 5-azacytidine.  We demonstrate that in vitro cell line-based studies provide some insight into drug activity and combination therapies that synergistically kill MM cells; however, they do not always predict in vivo preclin. efficacy or toxicity.  Importantly, utilizing transplanted Vk*MYC MM, we report that panobinostat and 5-azacytidine synergize to prolong the survival of tumor-bearing mice.  In contrast, combined HDACi/rhTRAIL-based strategies, while efficacious, demonstrated on-target dose-limiting toxicities that precluded prolonged treatment.  Taken together, our studies provide evidence that the transplanted Vk*MYC model of MM is a useful screening tool for anti-MM drugs and should aid in the prioritization of novel drug testing in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqbECTRtEK1LVg90H21EOLACvtfcHk0lh2UfQFfDiIdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVWrurjL&md5=5ad6d6c19cdb86d35339e00dbfd26d24</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2013.306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2013.306%26sid%3Dliteratum%253Aachs%26aulast%3DMatthews%26aufirst%3DG.%2BM.%26aulast%3DLefebure%26aufirst%3DM.%26aulast%3DDoyle%26aufirst%3DM.%2BA.%26aulast%3DShortt%26aufirst%3DJ.%26aulast%3DEllul%26aufirst%3DJ.%26aulast%3DChesi%26aufirst%3DM.%26aulast%3DBanks%26aufirst%3DK.%2BM.%26aulast%3DVidacs%26aufirst%3DE.%26aulast%3DFaulkner%26aufirst%3DD.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DBergsagel%26aufirst%3DP.%2BL.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DPreclinical%2520screening%2520of%2520histone%2520deacetylase%2520inhibitors%2520combined%2520with%2520ABT-737%252C%2520rhTRAIL%252FMD5-1%2520or%25205-azacytidine%2520using%2520syngeneic%2520Vk%2520MYC%2520multiple%2520myeloma%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2013%26volume%3D4%26spage%3De798%26doi%3D10.1038%2Fcddis.2013.306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kmieciak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, R. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S.</span></span> <span> </span><span class="NLM_article-title">A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">2687</span>– <span class="NLM_lpage">2697</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-03-564534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1182%2Fblood-2014-03-564534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25208888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVygsrjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=2687-2697&author=S.+Chenauthor=Y.+Zhangauthor=L.+Zhouauthor=Y.+Lengauthor=H.+Linauthor=M.+Kmieciakauthor=X.+Y.+Peiauthor=R.+Jonesauthor=R.+Z.+Orlowskiauthor=Y.+Daiauthor=S.+Grant&title=A+Bim-targeting+strategy+overcomes+adaptive+bortezomib+resistance+in+myeloma+through+a+novel+link+between+autophagy+and+apoptosis&doi=10.1182%2Fblood-2014-03-564534"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis</span></div><div class="casAuthors">Chen, Shuang; Zhang, Yu; Zhou, Liang; Leng, Yun; Lin, Hui; Kmieciak, Maciej; Pei, Xin-Yan; Jones, Richard; Orlowski, Robert Z.; Dai, Yun; Grant, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2687-2697</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Bim contributes to resistance to various std. and novel agents.  Here we demonstrate that Bim plays a functional role in bortezomib resistance in multiple myeloma (MM) cells and that targeting Bim by combining histone deacetylase inhibitors (HDACIs) with BH3 mimetics (eg, ABT-737) overcomes bortezomib resistance.  BH3-only protein profiling revealed high Bim levels (Bimhi) in most MM cell lines and primary CD138+ MM samples.  Whereas short hairpin RNA Bim knockdown conferred bortezomib resistance in Bimhi cells, adaptive bortezomib-resistant cells displayed marked Bim downregulation.  HDACI upregulated Bim and, when combined with ABT-737, which released Bim from Bcl-2/Bcl-xL, potently killed bortezomib-resistant cells.  These events were correlated with Bim-assocd. autophagy attenuation, whereas Bim knockdown sharply increased autophagy in Bimhi cells.  In Bimlow cells, autophagy disruption by chloroquine (CQ) was required for HDACI/ABT-737 to induce Bim expression and lethality.  CQ also further enhanced HDACI/ABT-737 lethality in bortezomib-resistant cells.  Finally, HDACI failed to diminish autophagy or potentiate ABT-737-induced apoptosis in bim-/- mouse embryonic fibroblasts.  Thus, Bim deficiency represents a novel mechanism of adaptive bortezomib resistance in MM cells, and Bim-targeting strategies combining HDACIs (which upregulate Bim) and BH3 mimetics (which unleash Bim from antiapoptotic proteins) overcomes such resistance, in part by disabling cytoprotective autophagy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXinaaz9aztLVg90H21EOLACvtfcHk0lh2UfQFfDiIdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVygsrjI&md5=2cee354b8cd9d7a94cbaebde7cb3e96c</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-03-564534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-03-564534%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DLeng%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DKmieciak%26aufirst%3DM.%26aulast%3DPei%26aufirst%3DX.%2BY.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DOrlowski%26aufirst%3DR.%2BZ.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DGrant%26aufirst%3DS.%26atitle%3DA%2520Bim-targeting%2520strategy%2520overcomes%2520adaptive%2520bortezomib%2520resistance%2520in%2520myeloma%2520through%2520a%2520novel%2520link%2520between%2520autophagy%2520and%2520apoptosis%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D2687%26epage%3D2697%26doi%3D10.1182%2Fblood-2014-03-564534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, C.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.12.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bmcl.2018.12.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=30594434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1Whu7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=349-352&author=R.+Zhouauthor=S.+Fangauthor=M.+Zhangauthor=Q.+Zhangauthor=J.+Huauthor=M.+Wangauthor=C.+Wangauthor=J.+Zhuauthor=A.+Shenauthor=X.+Chenauthor=C.+Zheng&title=Design%2C+synthesis%2C+and+bioactivity+evaluation+of+novel+Bcl-2%2FHDAC+dual-target+inhibitors+for+the+treatment+of+multiple+myeloma&doi=10.1016%2Fj.bmcl.2018.12.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma</span></div><div class="casAuthors">Zhou, Ruolan; Fang, Shaoyu; Zhang, Minmin; Zhang, Qingsen; Hu, Jian; Wang, Mingping; Wang, Chongqing; Zhu, Ju; Shen, Aijun; Chen, Xin; Zheng, Canhui</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">349-352</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Multiple myeloma (MM) is the second most common hematol. malignancy.  Almost all patients with MM eventually relapse, and most recommended treatment protocols for the patients with relapsed refractory MM comprise a combination of drugs with different mechanisms of action.  Therefore novel drugs are in urgent need in clinic.  Bcl-2 inhibitors and HDAC inhibitors were proved their anti-MM effect in clinic or under clin. trials, and they were further discovered to have synergistic interactions.  A series of Bcl-2/HDAC dual-target inhibitors were designed and synthesized.  Among them, compds. 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((6-(hydroxyamino)-6-oxohexyl)amino)-3-nitrophenyl)sulfonyl)benzamide, 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((6-(hydroxyamino)-6-oxohexyl)amino)-3-nitrophenyl)sulfonyl)benzamideoheptyl-amino-3-nitrophenyl-sulfonylbenzamide, 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((8-(hydroxyamino)-8-oxooctyl)amino)-3-nitrophenyl)sulfonyl)benzamide showed good inhibitory activities against HDAC6 and high binding affinities to Bcl-2 protein simultaneously.  They also displayed good growth inhibitory activities against human MM cell line RPMI-<8226≥, which proved their potential value for the treatment of multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqAqtNXkzMhbVg90H21EOLACvtfcHk0lgaslMoCwDokQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1Whu7bO&md5=b320094c8d301d20a7b45bfb6bf899c2</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.12.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.12.052%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DFang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DC.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520bioactivity%2520evaluation%2520of%2520novel%2520Bcl-2%252FHDAC%2520dual-target%2520inhibitors%2520for%2520the%2520treatment%2520of%2520multiple%2520myeloma%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D349%26epage%3D352%26doi%3D10.1016%2Fj.bmcl.2018.12.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rotella, D. P.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase 5 inhibitors: current status and potential applications</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">674</span>– <span class="NLM_lpage">682</span>, <span class="refDoi"> DOI: 10.1038/nrd893</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnrd893" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=12209148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD38Xmslamt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=674-682&author=D.+P.+Rotella&title=Phosphodiesterase+5+inhibitors%3A+current+status+and+potential+applications&doi=10.1038%2Fnrd893"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase 5 inhibitors: current status and potential applications</span></div><div class="casAuthors">Rotella, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">674-682</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Phosphodiesterase enzymes convert cGMP and cAMP to the corresponding nucleotide monophosphates.  Phosphodiesterase 5 (PDE5) inhibition is now a widely accepted and efficacious therapeutic option for the treatment of erectile dysfunction in men, as a result of extensive clin. experience with sildenafil and other new PDE5 inhibitors.  Research in the field continues at a substantial level to identify new, selective PDE5 inhibitors and to investigate their usefulness and activity in other areas.  This review summarizes recent clin. trials with PDE5 inhibitors, advances in medicinal chem., and other activities and potential applications of this class of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1GubdxSnzj7Vg90H21EOLACvtfcHk0lgaslMoCwDokQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xmslamt78%253D&md5=fbbe68fc3f825c5d9ce215317d28f502</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1038%2Fnrd893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd893%26sid%3Dliteratum%253Aachs%26aulast%3DRotella%26aufirst%3DD.%2BP.%26atitle%3DPhosphodiesterase%25205%2520inhibitors%253A%2520current%2520status%2520and%2520potential%2520applications%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D674%26epage%3D682%26doi%3D10.1038%2Fnrd893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durrant, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salloum, F. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukreja, R. C.</span></span> <span> </span><span class="NLM_article-title">PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2014.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.pharmthera.2014.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25444755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVOkt73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2015&pages=12-21&author=A.+Dasauthor=D.+Durrantauthor=F.+N.+Salloumauthor=L.+Xiauthor=R.+C.+Kukreja&title=PDE5+inhibitors+as+therapeutics+for+heart+disease%2C+diabetes+and+cancer&doi=10.1016%2Fj.pharmthera.2014.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer</span></div><div class="casAuthors">Das, Anindita; Durrant, David; Salloum, Fadi N.; Xi, Lei; Kukreja, Rakesh C.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12-21</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The phosphodiesterase 5 (PDE5) inhibitors, including sildenafil (Viagra), vardenafil (Levitra), and tadalafil (Cialis) have been developed for treatment of erectile dysfunction.  Moreover, sildenafil and tadalafil are used for the management of pulmonary arterial hypertension in patients.  Since our first report showing the cardioprotective effect of sildenafil in 2002, there has been tremendous growth of preclin. and clin. studies on the use of PDE5 inhibitors for cardiovascular diseases and cancer.  Numerous animal studies have demonstrated that PDE5 inhibitors have powerful protective effect against myocardial ischemia/reperfusion (I/R) injury, doxorubicin cardiotoxicity, ischemic and diabetic cardiomyopathy, cardiac hypertrophy, Duchenne muscular dystrophy and the improvement of stem cell efficacy for myocardial repair.  Mechanistically, PDE5 inhibitors protect the heart against I/R injury through increased expression of nitric oxide synthases, activation of protein kinase G (PKG), PKG-dependent hydrogen sulfide generation, and phosphorylation of glycogen synthase kinase-3β - a master switch immediately proximal to mitochondrial permeability transition pore and the end effector of cardioprotection.  In addn., PDE5 inhibitors enhance the sensitivity of certain types of cancer to std. chemotherapeutic drugs, including doxorubicin.  Many clin. trials with PDE5 inhibitors have focused on the potential cardiovascular and anti-cancer benefits.  Despite mixed results of these clin. trials, there is a continuing strong interest by basic scientists and clin. investigators in exploring their new clin. uses.  It is our hope that future new mechanistic investigations and carefully designed clin. trials would help in reaping addnl. benefits of PDE5 inhibitors for cardiovascular disease and cancer in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomEKvIWnZGJLVg90H21EOLACvtfcHk0lgaslMoCwDokQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVOkt73E&md5=a6176e9ddbfe8358aaf75b328229d8db</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2014.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2014.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DA.%26aulast%3DDurrant%26aufirst%3DD.%26aulast%3DSalloum%26aufirst%3DF.%2BN.%26aulast%3DXi%26aufirst%3DL.%26aulast%3DKukreja%26aufirst%3DR.%2BC.%26atitle%3DPDE5%2520inhibitors%2520as%2520therapeutics%2520for%2520heart%2520disease%252C%2520diabetes%2520and%2520cancer%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D147%26spage%3D12%26epage%3D21%26doi%3D10.1016%2Fj.pharmthera.2014.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitari, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazerounian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Stewart, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chepenik, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldman, S. A.</span></span> <span> </span><span class="NLM_article-title">Guanylyl cyclases and signaling by cyclic GMP</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">375</span>– <span class="NLM_lpage">414</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10977868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntFCmsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2000&pages=375-414&author=K.+A.+Lucasauthor=G.+M.+Pitariauthor=S.+Kazerounianauthor=I.+Ruiz-Stewartauthor=J.+Parkauthor=S.+Schulzauthor=K.+P.+Chepenikauthor=S.+A.+Waldman&title=Guanylyl+cyclases+and+signaling+by+cyclic+GMP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Guanylyl cyclases and signaling by cyclic GMP</span></div><div class="casAuthors">Lucas, Kimberly A.; Pitari, Giovanni M.; Kazerounian, Shiva; Ruiz-Stewart, Inez; Park, Jason; Schulz, Stephanie; Chepenik, Kenneth P.; Waldman, Scott A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">375-413</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review with 393 refs.  Guanylyl cyclases are a family of enzymes that catalyze the conversion of GTP to cGMP.  The family comprises both membrane-bound and sol. isoforms that are expressed in nearly all cell types.  They are regulated by diverse extracellular agonists that include peptide hormones, bacterial toxins, and free radicals, as well as intracellular mols., such as Ca2+ and adenine nucleotides.  Stimulation of guanylyl cyclases and the resultant accumulation of cGMP regulates complex signaling cascades through immediate downstream effectors, including cGMP-dependent protein kinases, cGMP-regulated phosphodiesterases, and cyclic nucleotide-gated ion channels.  Guanylyl cyclases and cGMP-mediated signaling cascades play a central role in the regulation of diverse (patho)physiol. processes, including vascular smooth muscle motility, intestinal fluid and electrolyte homeostasis, and retinal phototransduction.  Topics addressed in this review include the structure and chromosomal localization of the genes for guanylyl cyclases, structure and function of the members of the guanylyl cyclase family, mol. mechanisms regulating enzymic activity, and mol. sequences coupling ligand binding to catalytic activity.  A brief overview is presented of the downstream events controlled by guanylyl cyclases, including the effectors that are regulated by cGMP and the role that guanylyl cyclases play in cell physiol. and pathophysiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHStLFSGOzzbVg90H21EOLACvtfcHk0ljKV7RTWproCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntFCmsbg%253D&md5=0694e83a91440f3fff3c0a2312682b15</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DK.%2BA.%26aulast%3DPitari%26aufirst%3DG.%2BM.%26aulast%3DKazerounian%26aufirst%3DS.%26aulast%3DRuiz-Stewart%26aufirst%3DI.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DSchulz%26aufirst%3DS.%26aulast%3DChepenik%26aufirst%3DK.%2BP.%26aulast%3DWaldman%26aufirst%3DS.%2BA.%26atitle%3DGuanylyl%2520cyclases%2520and%2520signaling%2520by%2520cyclic%2520GMP%26jtitle%3DPharmacol.%2520Rev.%26date%3D2000%26volume%3D52%26spage%3D375%26epage%3D414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ugarte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil-Bea, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Barroso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cedazo-Minguez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Osta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyarzabal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuadrado-Tejedor, M.</span></span> <span> </span><span class="NLM_article-title">Decreased levels of guanosine 3′, 5′-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer’s disease</span>. <i>Neuropathol. Appl. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">471</span>– <span class="NLM_lpage">482</span>, <span class="refDoi"> DOI: 10.1111/nan.12203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1111%2Fnan.12203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25488891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlCgs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2015&pages=471-482&author=A.+Ugarteauthor=F.+Gil-Beaauthor=C.+Garcia-Barrosoauthor=A.+Cedazo-Minguezauthor=M.+J.+Ramirezauthor=R.+Francoauthor=A.+Garcia-Ostaauthor=J.+Oyarzabalauthor=M.+Cuadrado-Tejedor&title=Decreased+levels+of+guanosine+3%E2%80%B2%2C+5%E2%80%B2-monophosphate+%28cGMP%29+in+cerebrospinal+fluid+%28CSF%29+are+associated+with+cognitive+decline+and+amyloid+pathology+in+Alzheimer%E2%80%99s+disease&doi=10.1111%2Fnan.12203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease</span></div><div class="casAuthors">Ugarte, Ana; Gil-Bea, Francisco; Garcia-Barroso, Carolina; Cedazo-Minguez, Angel; Ramirez, M. Javier; Franco, Rafael; Garcia-Osta, Ana; Oyarzabal, Julen; Cuadrado-Tejedor, Mar</div><div class="citationInfo"><span class="NLM_cas:title">Neuropathology and Applied Neurobiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">471-482</span>CODEN:
                <span class="NLM_cas:coden">NANEDL</span>;
        ISSN:<span class="NLM_cas:issn">0305-1846</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : Levels of the cyclic nucleotides guanosine 3', 5'-monophosphate (cGMP) or adenosine 3', 5'-monophosphate (cAMP) that play important roles in memory processes are not characterized in Alzheimer's disease (AD).  The aim of this study was to analyze the levels of these nucleotides in cerebrospinal fluid (CSF) samples from patients diagnosed with clin. and prodromal stages of AD and study the expression level of the enzymes that hydrolyzed them [phosphodiesterases (PDEs)] in the brain of AD patients vs. controls.  Methods : For cGMP and cAMP CSF anal., the cohort (n = 79) included cognitively normal participants (subjective cognitive impairment), individuals with stable mild cognitive impairment or AD converters (sMCI and cMCI), and mild AD patients.  A high throughput liq. chromatog.-tandem mass spectrometry method was used.  Interactions between CSF cGMP or cAMP with mini-mental state examn. (MMSE) score, CSF Aβ(1-42) and CSF p-tau were analyzed.  For PDE4, 5, 9 and 10 expression anal., brains of AD patients vs. controls (n = 7 and n = 8) were used.  Results : cGMP, and not cAMP levels, were significantly lower in the CSF of patients diagnosed with mild AD when compared with nondemented controls.  CSF levels of cGMP showed a significant assocn. with MMSE-diagnosed clin. dementia and with CSF biomarker Aβ42 in AD patients.  Significant increase in PDE5 expression was detected in temporal cortex of AD patients compared with that of age-matched healthy control subjects.  No changes in the expression of others PDEs were detected.  Conclusions : These results support the potential involvement of cGMP in the pathol. and clin. development of AD.  The cGMP redn. in early stages of AD might participate in the aggravation of amyloid pathol. and cognitive decline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDfphh1a73krVg90H21EOLACvtfcHk0lj-sn3BbQL3kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlCgs7s%253D&md5=4aabb42e396d12b9a74e64bd42abb064</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1111%2Fnan.12203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fnan.12203%26sid%3Dliteratum%253Aachs%26aulast%3DUgarte%26aufirst%3DA.%26aulast%3DGil-Bea%26aufirst%3DF.%26aulast%3DGarcia-Barroso%26aufirst%3DC.%26aulast%3DCedazo-Minguez%26aufirst%3DA.%26aulast%3DRamirez%26aufirst%3DM.%2BJ.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DGarcia-Osta%26aufirst%3DA.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26atitle%3DDecreased%2520levels%2520of%2520guanosine%25203%25E2%2580%25B2%252C%25205%25E2%2580%25B2-monophosphate%2520%2528cGMP%2529%2520in%2520cerebrospinal%2520fluid%2520%2528CSF%2529%2520are%2520associated%2520with%2520cognitive%2520decline%2520and%2520amyloid%2520pathology%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeuropathol.%2520Appl.%2520Neurobiol.%26date%3D2015%26volume%3D41%26spage%3D471%26epage%3D482%26doi%3D10.1111%2Fnan.12203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">García-Barroso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricobaraza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascual-Lucas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unceta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rico, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goicolea, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sallés, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanciego, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyarzabal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuadrado-Tejedor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Osta, A.</span></span> <span> </span><span class="NLM_article-title">Tadalafil crosses the blood–brain barrier and reverses cognitive dysfunction in a mouse model of AD</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">123</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2012.06.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.neuropharm.2012.06.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=22776546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtV2nu77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2013&pages=114-123&author=C.+Garc%C3%ADa-Barrosoauthor=A.+Ricobarazaauthor=M.+Pascual-Lucasauthor=N.+Uncetaauthor=A.+J.+Ricoauthor=M.+A.+Goicoleaauthor=J.+Sall%C3%A9sauthor=J.+L.+Lanciegoauthor=J.+Oyarzabalauthor=R.+Francoauthor=M.+Cuadrado-Tejedorauthor=A.+Garcia-Osta&title=Tadalafil+crosses+the+blood%E2%80%93brain+barrier+and+reverses+cognitive+dysfunction+in+a+mouse+model+of+AD&doi=10.1016%2Fj.neuropharm.2012.06.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD</span></div><div class="casAuthors">Garcia-Barroso, Carolina; Ricobaraza, Ana; Pascual-Lucas, Maria; Unceta, Nora; Rico, Alberto J.; Goicolea, Maria Aranzazu; Salles, Joan; Lanciego, Jose Luis; Oyarzabal, Julen; Franco, Rafael; Cuadrado-Tejedor, Mar; Garcia-Osta, Ana</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">114-123</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Previous studies have demonstrated that cognitive function can be restored in mouse models of Alzheimer's disease (AD) following administration of sildenafil, a specific PDE5 inhibitor (Puzzo et al., 2009; Cuadrado-Tejedor et al.).  Another very potent PDE5 inhibitor with a longer half-life and safe in chronic treatments, tadalafil, may represent a better alternative candidate for AD therapy.  However, tadalafil was proven unable to achieve similar benefits than those of sildenafil in AD animal models (Puzzo et al., 2009).  The lack of efficacy was attributed to inability to cross the blood-brain barrier (BBB).  In this paper we first measured the blood and brain levels of tadalafil to prove that the compd. crosses BBB and that chronic treatment leads to accumulation in the brain of the J20 transgenic mouse model of AD.  We demonstrated the presence of PDE5 mRNA in the brain of the mice and also in the human brain.  After a 10 wk treatment with either of these PDE5 inhibitors, the performance of the J20 mice in the Morris water maze test improved when compared with the transgenic mice that received vehicle.  Biochem. anal. revealed that neither sildenafil nor tadalafil altered the amyloid burden, although both compds. reduced Tau phosphorylation in the mouse hippocampus.  This study provides evidence of the potential benefits of a chronic tadalafil treatment in AD therapy.This article is part of a Special Issue entitled 'Cognitive Enhancers'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfkrxYqIGt7LVg90H21EOLACvtfcHk0lhetdl4bCbN2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtV2nu77O&md5=aafb7dacec3ffd9d8ef4abc38c08e0f6</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2012.06.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2012.06.052%26sid%3Dliteratum%253Aachs%26aulast%3DGarc%25C3%25ADa-Barroso%26aufirst%3DC.%26aulast%3DRicobaraza%26aufirst%3DA.%26aulast%3DPascual-Lucas%26aufirst%3DM.%26aulast%3DUnceta%26aufirst%3DN.%26aulast%3DRico%26aufirst%3DA.%2BJ.%26aulast%3DGoicolea%26aufirst%3DM.%2BA.%26aulast%3DSall%25C3%25A9s%26aufirst%3DJ.%26aulast%3DLanciego%26aufirst%3DJ.%2BL.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3DGarcia-Osta%26aufirst%3DA.%26atitle%3DTadalafil%2520crosses%2520the%2520blood%25E2%2580%2593brain%2520barrier%2520and%2520reverses%2520cognitive%2520dysfunction%2520in%2520a%2520mouse%2520model%2520of%2520AD%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D64%26spage%3D114%26epage%3D123%26doi%3D10.1016%2Fj.neuropharm.2012.06.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Puzzo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitolo, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trinchese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arancio, O.</span></span> <span> </span><span class="NLM_article-title">Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">6887</span>– <span class="NLM_lpage">6897</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.5291-04.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1523%2FJNEUROSCI.5291-04.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16033898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmslClt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=6887-6897&author=D.+Puzzoauthor=O.+Vitoloauthor=F.+Trincheseauthor=J.+P.+Jacobauthor=A.+Palmeriauthor=O.+Arancio&title=Amyloid-beta+peptide+inhibits+activation+of+the+nitric+oxide%2FcGMP%2FcAMP-responsive+element-binding+protein+pathway+during+hippocampal+synaptic+plasticity&doi=10.1523%2FJNEUROSCI.5291-04.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloid-β peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity</span></div><div class="casAuthors">Puzzo, Daniela; Vitolo, Ottavio; Trinchese, Fabrizio; Jacob, Joel P.; Palmeri, Agostino; Arancio, Ottavio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">6887-6897</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Amyloid-β (Aβ), a peptide thought to play a crucial role in Alzheimer's disease (AD), has many targets that, in turn, activate different 2nd-messenger cascades.  Interestingly, Aβ was found to markedly impair hippocampal long-term potentiation (LTP).  To identify a new pathway that might be responsible for such impairment, the authors analyzed the role of the NO/sol. guanylyl cyclase (sGC)/cGMP/cGMP-dependent protein kinase (cGK)/cAMP-responsive element-binding protein (CREB) cascade because of its involvement in LTP.  The use of the NO donor 2-(N,N-dethylamino)-diazenolate-2-oxide diethylammonium salt (DEA/NO), the sGC stimulator 3-(4-amino-5-cyclopropylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine, or the cGMP-analogs 8-bromo-cGMP and 8-(4-chlorophenylthio)-cGMP reversed the Aβ-induced impairment of CA1-LTP through cGK activation.  Furthermore, these compds. reestablished the enhancement of CREB phosphorylation occurring during LTP in slices exposed to Aβ.  We also found that Aβ blocks the increase in cGMP immunoreactivity occurring immediately after LTP and that DEA/NO counteracts the effect of Aβ.  These results strongly suggest that, when modulating hippocampal synaptic plasticity, Aβ downregulates the NO/cGMP/cGK/CREB pathway; thus, enhancement of the NO/cGMP signaling may provide a novel approach to the treatment of AD and other neurodegenerative diseases with elevated prodn. of Aβ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT_M3WUlYelLVg90H21EOLACvtfcHk0lh5NQ7Kk_w2Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmslClt78%253D&md5=448717d56147ceb9665d8c1ce8136c98</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.5291-04.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.5291-04.2005%26sid%3Dliteratum%253Aachs%26aulast%3DPuzzo%26aufirst%3DD.%26aulast%3DVitolo%26aufirst%3DO.%26aulast%3DTrinchese%26aufirst%3DF.%26aulast%3DJacob%26aufirst%3DJ.%2BP.%26aulast%3DPalmeri%26aufirst%3DA.%26aulast%3DArancio%26aufirst%3DO.%26atitle%3DAmyloid-beta%2520peptide%2520inhibits%2520activation%2520of%2520the%2520nitric%2520oxide%252FcGMP%252FcAMP-responsive%2520element-binding%2520protein%2520pathway%2520during%2520hippocampal%2520synaptic%2520plasticity%26jtitle%3DJ.%2520Neurosci.%26date%3D2005%26volume%3D25%26spage%3D6887%26epage%3D6897%26doi%3D10.1523%2FJNEUROSCI.5291-04.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Osta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuadrado-Tejedor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Barroso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyarzabal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, R.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterases as therapeutic targets for Alzheimer’s disease</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">832</span>– <span class="NLM_lpage">844</span>, <span class="refDoi"> DOI: 10.1021/cn3000907</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn3000907" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVejs7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=832-844&author=A.+Garcia-Ostaauthor=M.+Cuadrado-Tejedorauthor=C.+Garcia-Barrosoauthor=J.+Oyarzabalauthor=R.+Franco&title=Phosphodiesterases+as+therapeutic+targets+for+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fcn3000907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterases as Therapeutic Targets for Alzheimer's Disease</span></div><div class="casAuthors">Garcia-Osta, Ana; Cuadrado-Tejedor, Mar; Garcia-Barroso, Carolina; Oyarzabal, Julen; Franco, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">832-844</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is the most common form of dementia among the elderly.  In AD patients, memory loss is accompanied by the formation of beta-amyloid plaques and the appearance of tau in a pathol. form.  Given the lack of effective treatments for AD, the development of new management strategies for these patients is crit.  The continued failure to find effective therapies using mols. aimed at addressing the anti-beta amyloid pathol. has led researchers to focus on other non-amyloid-based approaches to restore memory function.  Promising non-amyloid related candidate targets include phosphosdiesterases (PDEs), and indeed, Rolipram, a specific PDE4 inhibitor, was the first compd. found to effectively restore cognitive deficits in animal models of AD.  More recently, PDE5 inhibitors have also been shown to effectively restore memory function.  Accordingly, inhibitors of other members of the PDE family may also improve memory performance in AD and non-AD animal models.  Hence, in this review, we will summarize the data supporting the use of PDE inhibitors as cognitive enhancers and we will discuss the possible mechanisms of action underlying these effects.  We shall also adopt a medicinal chem. perspective that leads us to propose the most promising PDE candidates on the basis of inhibitor selectivity, brain distribution, and mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppeOP4NskdvrVg90H21EOLACvtfcHk0lhX4yUN2voM6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVejs7nK&md5=53c6dfed22bb240b17132672b13fdcf1</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1021%2Fcn3000907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn3000907%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Osta%26aufirst%3DA.%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3DGarcia-Barroso%26aufirst%3DC.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DFranco%26aufirst%3DR.%26atitle%3DPhosphodiesterases%2520as%2520therapeutic%2520targets%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D832%26epage%3D844%26doi%3D10.1021%2Fcn3000907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benito, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbanke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awasthi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capece, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhardt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro-Sala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarajan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutz, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnsen, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luhrmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, A.</span></span> <span> </span><span class="NLM_article-title">HDAC inhibitor-dependent transcriptome and memory reinstatement in cognitive decline models</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">3572</span>– <span class="NLM_lpage">3584</span>, <span class="refDoi"> DOI: 10.1172/JCI79942</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1172%2FJCI79942" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=26280576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A280%3ADC%252BC287js12iuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=3572-3584&author=E.+Benitoauthor=H.+Urbankeauthor=B.+Ramachandranauthor=J.+Barthauthor=R.+Halderauthor=A.+Awasthiauthor=G.+Jainauthor=V.+Capeceauthor=S.+Burkhardtauthor=M.+Navarro-Salaauthor=S.+Nagarajanauthor=A.+L.+Schutzauthor=S.+A.+Johnsenauthor=S.+Bonnauthor=R.+Luhrmannauthor=C.+Deanauthor=A.+Fischer&title=HDAC+inhibitor-dependent+transcriptome+and+memory+reinstatement+in+cognitive+decline+models&doi=10.1172%2FJCI79942"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitor-dependent transcriptome and memory reinstatement in cognitive decline models</span></div><div class="casAuthors">Benito Eva; Urbanke Hendrik; Ramachandran Binu; Barth Jonas; Halder Rashi; Awasthi Ankit; Jain Gaurav; Capece Vincenzo; Burkhardt Susanne; Navarro-Sala Magdalena; Nagarajan Sankari; Schutz Anna-Lena; Johnsen Steven A; Bonn Stefan; Luhrmann Reinhardt; Dean Camin; Fischer Andre</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3572-84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Aging and increased amyloid burden are major risk factors for cognitive diseases such as Alzheimer's disease (AD).  Effective therapies for these diseases are lacking.  Here, we evaluated mouse models of age-associated memory impairment and amyloid deposition to study transcriptome and cell type-specific epigenome plasticity in the brain and peripheral organs.  We determined that aging and amyloid pathology are associated with inflammation and impaired synaptic function in the hippocampal CA1 region as the result of epigenetic-dependent alterations in gene expression.  In both amyloid and aging models, inflammation was associated with increased gene expression linked to a subset of transcription factors, while plasticity gene deregulation was differentially mediated.  Amyloid pathology impaired histone acetylation and decreased expression of plasticity genes, while aging altered H4K12 acetylation-linked differential splicing at the intron-exon junction in neurons, but not nonneuronal cells.  Furthermore, oral administration of the clinically approved histone deacetylase inhibitor vorinostat not only restored spatial memory, but also exerted antiinflammatory action and reinstated epigenetic balance and transcriptional homeostasis at the level of gene expression and exon usage.  This study provides a systems-level investigation of transcriptome plasticity in the hippocampal CA1 region in aging and AD models and suggests that histone deacetylase inhibitors should be further explored as a cost-effective therapeutic strategy against age-associated cognitive decline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTaDMtpB5WPpwyMywPm6HgQfW6udTcc2eaV0HBrQuxY7Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287js12iuw%253D%253D&md5=e30caf3ba1aaddf0a149c514d23640b8</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1172%2FJCI79942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI79942%26sid%3Dliteratum%253Aachs%26aulast%3DBenito%26aufirst%3DE.%26aulast%3DUrbanke%26aufirst%3DH.%26aulast%3DRamachandran%26aufirst%3DB.%26aulast%3DBarth%26aufirst%3DJ.%26aulast%3DHalder%26aufirst%3DR.%26aulast%3DAwasthi%26aufirst%3DA.%26aulast%3DJain%26aufirst%3DG.%26aulast%3DCapece%26aufirst%3DV.%26aulast%3DBurkhardt%26aufirst%3DS.%26aulast%3DNavarro-Sala%26aufirst%3DM.%26aulast%3DNagarajan%26aufirst%3DS.%26aulast%3DSchutz%26aufirst%3DA.%2BL.%26aulast%3DJohnsen%26aufirst%3DS.%2BA.%26aulast%3DBonn%26aufirst%3DS.%26aulast%3DLuhrmann%26aufirst%3DR.%26aulast%3DDean%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DA.%26atitle%3DHDAC%2520inhibitor-dependent%2520transcriptome%2520and%2520memory%2520reinstatement%2520in%2520cognitive%2520decline%2520models%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2015%26volume%3D125%26spage%3D3572%26epage%3D3584%26doi%3D10.1172%2FJCI79942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolan, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G. V. W.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 6 interacts with the microtubule-associated protein tau</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">2119</span>– <span class="NLM_lpage">2130</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2008.05564.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1111%2Fj.1471-4159.2008.05564.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=18636984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtV2rt7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2008&pages=2119-2130&author=H.+Dingauthor=P.+J.+Dolanauthor=G.+V.+W.+Johnson&title=Histone+deacetylase+6+interacts+with+the+microtubule-associated+protein+tau&doi=10.1111%2Fj.1471-4159.2008.05564.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 interacts with the microtubule-associated protein tau</span></div><div class="casAuthors">Ding, Huiping; Dolan, Philip J.; Johnson, Gail V. W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2119-2130</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6), a unique cytoplasmic deacetylase, likely plays a role in neurodegeneration by coordinating cell responses to abnormal protein aggregation.  Here, we provide in vitro and in vivo evidence that HDAC6 interacts with tau, a microtubule-assocd. protein that forms neurofibrillary tangles in Alzheimer's disease.  This interaction is mediated by the microtubule-binding domain on tau and the Ser/Glu tetradecapeptide domain on HDAC6.  Treatment with tubacin, a selective inhibitor of tubulin deacetylation activity of HDAC6, did not disrupt HDAC6-tau interaction.  Nonetheless tubacin treatment attenuated site-specific tau phosphorylation, as did shRNA-mediated knockdown of HDAC6.  Proteasome inhibition potentiated HDAC6-tau interactions and facilitated the concn. and co-localization of HDAC6 and tau in a perinuclear aggresome-like compartment, independent of HDAC6 tubulin deacetylase activity.  Furthermore, we obsd. that in Alzheimer's disease brains the protein level of HDAC6 was significantly increased.  These findings establish HDAC6 as a tau-interacting protein and as a potential modulator of tau phosphorylation and accumulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9OtxbhpBU9LVg90H21EOLACvtfcHk0lgLBOMf-eYQJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtV2rt7fM&md5=cf63da19f8f887459227b620d9a0898b</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2008.05564.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2008.05564.x%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%26aulast%3DDolan%26aufirst%3DP.%2BJ.%26aulast%3DJohnson%26aufirst%3DG.%2BV.%2BW.%26atitle%3DHistone%2520deacetylase%25206%2520interacts%2520with%2520the%2520microtubule-associated%2520protein%2520tau%26jtitle%3DJ.%2520Neurochem.%26date%3D2008%26volume%3D106%26spage%3D2119%26epage%3D2130%26doi%3D10.1111%2Fj.1471-4159.2008.05564.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guan, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggarty, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacometti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannenberg, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieland, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePinho, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaenisch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, L. H.</span></span> <span> </span><span class="NLM_article-title">HDAC2 negatively regulates memory formation and synaptic plasticity</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>459</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1038/nature07925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnature07925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=19424149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsF2ltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=459&publication_year=2009&pages=55-60&author=J.+S.+Guanauthor=S.+J.+Haggartyauthor=E.+Giacomettiauthor=J.+H.+Dannenbergauthor=N.+Josephauthor=J.+Gaoauthor=T.+J.+Nielandauthor=Y.+Zhouauthor=X.+Wangauthor=R.+Mazitschekauthor=J.+E.+Bradnerauthor=R.+A.+DePinhoauthor=R.+Jaenischauthor=L.+H.+Tsai&title=HDAC2+negatively+regulates+memory+formation+and+synaptic+plasticity&doi=10.1038%2Fnature07925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC2 negatively regulates memory formation and synaptic plasticity</span></div><div class="casAuthors">Guan, Ji-Song; Haggarty, Stephen J.; Giacometti, Emanuela; Dannenberg, Jan-Hermen; Joseph, Nadine; Gao, Jun; Nieland, Thomas J. F.; Zhou, Ying; Wang, Xinyu; Mazitschek, Ralph; Bradner, James E.; DePinho, Ronald A.; Jaenisch, Rudolf; Tsai, Li-Huei</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">459</span>
        (<span class="NLM_cas:issue">7243</span>),
    <span class="NLM_cas:pages">55-60</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chromatin modifications, esp. histone-tail acetylation, have been implicated in memory formation.  Increased histone-tail acetylation induced by histone deacetylases inhibitors (HDACis) facilitates learning and memory in wild-type mice as well as in mouse models of neurodegeneration.  Harnessing the therapeutic potential of HDACis requires knowledge of the specific HDAC family member(s) linked to cognitive enhancement.  Here, the authors show that neuron-specific overexpression of HDAC2, but not that of HDAC1, decreased dendritic spine d., synapse no., synaptic plasticity and memory formation.  Conversely, gene Hdac2 deficiency resulted in increased synapse no. and memory facilitation, similar to chronic treatment with HDACis in mice.  Notably, reduced synapse no. and learning impairment of HDAC2-overexpressing mice were ameliorated by chronic treatment with HDACis.  Correspondingly, treatment with HDACis failed to further facilitate memory formation in gene Hdac2-deficient mice.  Furthermore, anal. of promoter occupancy revealed an assocn. of HDAC2 with the promoters of genes implicated in synaptic plasticity and memory formation.  Taken together, these results suggest that HDAC2 functions in modulating synaptic plasticity and long-lasting changes of neural circuits, which in turn neg. regulates learning and memory.  These observations encourage the development and testing of HDAC2-selective inhibitors for human diseases assocd. with memory impairment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0MzAlmmDwLLVg90H21EOLACvtfcHk0lgLBOMf-eYQJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsF2ltro%253D&md5=bbd00accb8b6992f9c109114e8818388</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1038%2Fnature07925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07925%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DJ.%2BS.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DGiacometti%26aufirst%3DE.%26aulast%3DDannenberg%26aufirst%3DJ.%2BH.%26aulast%3DJoseph%26aufirst%3DN.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DNieland%26aufirst%3DT.%2BJ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DDePinho%26aufirst%3DR.%2BA.%26aulast%3DJaenisch%26aufirst%3DR.%26aulast%3DTsai%26aufirst%3DL.%2BH.%26atitle%3DHDAC2%2520negatively%2520regulates%2520memory%2520formation%2520and%2520synaptic%2520plasticity%26jtitle%3DNature%26date%3D2009%26volume%3D459%26spage%3D55%26epage%3D60%26doi%3D10.1038%2Fnature07925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hubbert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guardiola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nixon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, T. P.</span></span> <span> </span><span class="NLM_article-title">HDAC6 is a microtubule-associated deacetylase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>417</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">458</span>, <span class="refDoi"> DOI: 10.1038/417455a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2F417455a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=12024216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvVersr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=455-458&author=C.+Hubbertauthor=A.+Guardiolaauthor=R.+Shaoauthor=Y.+Kawaguchiauthor=A.+Itoauthor=A.+Nixonauthor=M.+Yoshidaauthor=X.+F.+Wangauthor=T.+P.+Yao&title=HDAC6+is+a+microtubule-associated+deacetylase&doi=10.1038%2F417455a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 is a microtubule-associated deacetylase</span></div><div class="casAuthors">Hubbert, Charlotte; Guardiola, Amaris; Shao, Rong; Kawaguchi, Yoshiharu; Ito, Akihiro; Nixon, Andrew; Yoshida, Minoru; Wang, Xiao-Fan; Yao, Tso-Pang</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6887</span>),
    <span class="NLM_cas:pages">455-458</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Reversible acetylation of α-tubulin has been implicated in regulating microtubule stability and function.  The distribution of acetylated α-tubulin is tightly controlled and stereotypic.  Acetylated α-tubulin is most abundant in stable microtubules but is absent from dynamic cellular structures such as neuronal growth cones and the leading edges of fibroblasts.  However, the enzymes responsible for regulating tubulin acetylation and deacetylation are not known.  Here we report that a member of the histone deacetylase family, HDAC6, functions as a tubulin deacetylase.  HDAC6 is localized exclusively in the cytoplasm, where it assocs. with microtubules and localizes with the microtubule motor complex contg. p150glued.  In vivo, the overexpression of HDAC6 leads to a global deacetylation of α-tubulin, whereas a decrease in HDAC6 increases α-tubulin acetylation.  In vitro, purified HDAC6 potently deacetylates α-tubulin in assembled microtubules.  Furthermore, overexpression of HDAC6 promotes chemotactic cell movement, supporting the idea that HDAC6-mediated deacetylation regulates microtubule-dependent cell motility.  Our results show that HDAC6 is the tubulin deacetylase, and provide evidence that reversible acetylation regulates important biol. processes beyond histone metab. and gene transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp76Er3MrWtO7Vg90H21EOLACvtfcHk0lgjBTMNxlLC8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvVersr4%253D&md5=f18cbb0af388925c606e822358ba3da6</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1038%2F417455a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F417455a%26sid%3Dliteratum%253Aachs%26aulast%3DHubbert%26aufirst%3DC.%26aulast%3DGuardiola%26aufirst%3DA.%26aulast%3DShao%26aufirst%3DR.%26aulast%3DKawaguchi%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DA.%26aulast%3DNixon%26aufirst%3DA.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%2BF.%26aulast%3DYao%26aufirst%3DT.%2BP.%26atitle%3DHDAC6%2520is%2520a%2520microtubule-associated%2520deacetylase%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D455%26epage%3D458%26doi%3D10.1038%2F417455a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cook, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gendron, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlomagno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunmore, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeTure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrucelli, L.</span></span> <span> </span><span class="NLM_article-title">Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2936</span>– <span class="NLM_lpage">2945</span>, <span class="refDoi"> DOI: 10.1093/hmg/dds125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1093%2Fhmg%2Fdds125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=22492994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1ylurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=2936-2945&author=C.+Cookauthor=T.+F.+Gendronauthor=K.+Scheffelauthor=Y.+Carlomagnoauthor=J.+Dunmoreauthor=M.+DeTureauthor=L.+Petrucelli&title=Loss+of+HDAC6%2C+a+novel+CHIP+substrate%2C+alleviates+abnormal+tau+accumulation&doi=10.1093%2Fhmg%2Fdds125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation</span></div><div class="casAuthors">Cook, Casey; Gendron, Tania F.; Scheffel, Kristyn; Carlomagno, Yari; Dunmore, Judy; DeTure, Michael; Petrucelli, Leonard</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2936-2945</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The abnormal accumulation of the microtubule-binding protein tau is assocd. with a no. of neurodegenerative conditions, and correlates with cognitive decline in Alzheimer's disease.  The ubiquitin ligase carboxy terminus of Hsp70-interacting protein (CHIP) and the mol. chaperone Hsp90 are implicated in protein triage decisions involving tau, and have consequently been targeted for therapeutic approaches aimed at decreasing tau burden.  Here, we present evidence that CHIP binds, ubiquitinates and regulates expression of histone deacetylase 6 (HDAC6).  As the deacetylase for Hsp90, HDAC6 modulates Hsp90 function and dets. the favorability of refolding vs. degrdn. of Hsp90 client proteins.  Moreover, we demonstrate that HDAC6 levels pos. correlate with tau burden, while a decrease in HDAC6 activity or expression promotes tau clearance.  Consistent with previous research on Hsp90 clients in cancer, we provide evidence that a loss of HDAC6 activity augments the efficacy of an Hsp90 inhibitor and drives client degrdn., in this case tau.  Therefore, our current findings not only identify HDAC6 as a crit. factor for the regulation of tau levels, but also indicate that a multi-faceted treatment approach could more effectively arrest tau accumulation in disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGxNKFm3ntlrVg90H21EOLACvtfcHk0lgjBTMNxlLC8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1ylurs%253D&md5=dc9f4f7cf50e42bdbbcc46c494877ccd</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fdds125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fdds125%26sid%3Dliteratum%253Aachs%26aulast%3DCook%26aufirst%3DC.%26aulast%3DGendron%26aufirst%3DT.%2BF.%26aulast%3DScheffel%26aufirst%3DK.%26aulast%3DCarlomagno%26aufirst%3DY.%26aulast%3DDunmore%26aufirst%3DJ.%26aulast%3DDeTure%26aufirst%3DM.%26aulast%3DPetrucelli%26aufirst%3DL.%26atitle%3DLoss%2520of%2520HDAC6%252C%2520a%2520novel%2520CHIP%2520substrate%252C%2520alleviates%2520abnormal%2520tau%2520accumulation%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2012%26volume%3D21%26spage%3D2936%26epage%3D2945%26doi%3D10.1093%2Fhmg%2Fdds125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cuadrado-Tejedor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Barroso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Arias, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabal, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Gonzalez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mederos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugarte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segura, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perea, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyarzabal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Osta, A.</span></span> <span> </span><span class="NLM_article-title">A first-in-class small-molecule that acts as a dual inhibitor of HDAC and PDE5 and that rescues hippocampal synaptic impairment in Alzheimer’s disease mice</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">524</span>– <span class="NLM_lpage">539</span>, <span class="refDoi"> DOI: 10.1038/npp.2016.163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnpp.2016.163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=27550730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFOntLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=524-539&author=M.+Cuadrado-Tejedorauthor=C.+Garcia-Barrosoauthor=J.+A.+Sanchez-Ariasauthor=O.+Rabalauthor=M.+Perez-Gonzalezauthor=S.+Mederosauthor=A.+Ugarteauthor=R.+Francoauthor=V.+Seguraauthor=G.+Pereaauthor=J.+Oyarzabalauthor=A.+Garcia-Osta&title=A+first-in-class+small-molecule+that+acts+as+a+dual+inhibitor+of+HDAC+and+PDE5+and+that+rescues+hippocampal+synaptic+impairment+in+Alzheimer%E2%80%99s+disease+mice&doi=10.1038%2Fnpp.2016.163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice</span></div><div class="casAuthors">Cuadrado-Tejedor, Mar; Garcia-Barroso, Carolina; Sanchez-Arias, Juan A.; Rabal, Obdulia; Perez-Gonzalez, Marta; Mederos, Sara; Ugarte, Ana; Franco, Rafael; Segura, Victor; Perea, Gertrudis; Oyarzabal, Julen; Garcia-Osta, Ana</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">524-539</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The targeting of two independent but synergistic enzymic activities, histone deacetylases (HDACs, class I and HDAC6) and phosphodiesterase 5 (PDE5), has recently been validated as a potentially novel therapeutic approach for Alzheimer's disease (AD).  Here we report the discovery of a new first-in-class small-mol. (CM-414) that acts as a dual inhibitor of PDE5 and HDACs.  We have used this compd. as a chem. probe to validate this systems therapeutics strategy, where an increase in the activation of cAMP/cGMP-responsive element-binding protein (CREB) induced by PDE5 inhibition, combined with moderate HDAC class I inhibition, leads to efficient histone acetylation.  This mol. rescued the impaired long-term potentiation evident in hippocampal slices from APP/PS1 mice.  Chronic treatment of Tg2576 mice with CM-414 diminished brain Aβ and tau phosphorylation (pTau) levels, increased the inactive form of GSK3β, reverted the decrease in dendritic spine d. on hippocampal neurons, and reversed their cognitive deficits, at least in part by inducing the expression of genes related to synaptic transmission.  Thus, CM-414 may serve as the starting point to discover balanced dual inhibitors with an optimal efficacy and safety profile for clin. testing on AD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrel_KiPL5177Vg90H21EOLACvtfcHk0lgb6OAxVsEjNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFOntLfP&md5=26482df7c58696a362ca1e73bab12264</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2016.163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2016.163%26sid%3Dliteratum%253Aachs%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3DGarcia-Barroso%26aufirst%3DC.%26aulast%3DSanchez-Arias%26aufirst%3DJ.%2BA.%26aulast%3DRabal%26aufirst%3DO.%26aulast%3DPerez-Gonzalez%26aufirst%3DM.%26aulast%3DMederos%26aufirst%3DS.%26aulast%3DUgarte%26aufirst%3DA.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DSegura%26aufirst%3DV.%26aulast%3DPerea%26aufirst%3DG.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DGarcia-Osta%26aufirst%3DA.%26atitle%3DA%2520first-in-class%2520small-molecule%2520that%2520acts%2520as%2520a%2520dual%2520inhibitor%2520of%2520HDAC%2520and%2520PDE5%2520and%2520that%2520rescues%2520hippocampal%2520synaptic%2520impairment%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520mice%26jtitle%3DNeuropsychopharmacology%26date%3D2017%26volume%3D42%26spage%3D524%26epage%3D539%26doi%3D10.1038%2Fnpp.2016.163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabal, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Arias, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuadrado-Tejedor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Miguel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Gonzalez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Barroso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugarte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estella-Hermoso de Mendoza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espelosin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ursua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haizhong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Osta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyarzabal, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of in vivo chemical probes for treating Alzheimer’s disease: dual phosphodiesterase 5 (PDE5) and class I histone deacetylase selective inhibitors</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1765</span>– <span class="NLM_lpage">1782</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.8b00648</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.8b00648" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVKjtLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1765-1782&author=O.+Rabalauthor=J.+A.+Sanchez-Ariasauthor=M.+Cuadrado-Tejedorauthor=I.+de+Miguelauthor=M.+Perez-Gonzalezauthor=C.+Garcia-Barrosoauthor=A.+Ugarteauthor=A.+Estella-Hermoso+de+Mendozaauthor=E.+Saezauthor=M.+Espelosinauthor=S.+Ursuaauthor=T.+Haizhongauthor=W.+Weiauthor=X.+Mushengauthor=A.+Garcia-Ostaauthor=J.+Oyarzabal&title=Discovery+of+in+vivo+chemical+probes+for+treating+Alzheimer%E2%80%99s+disease%3A+dual+phosphodiesterase+5+%28PDE5%29+and+class+I+histone+deacetylase+selective+inhibitors&doi=10.1021%2Facschemneuro.8b00648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of in Vivo Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective Inhibitors</span></div><div class="casAuthors">Rabal, Obdulia; Sanchez-Arias, Juan A.; Cuadrado-Tejedor, Mar; de Miguel, Irene; Perez-Gonzalez, Marta; Garcia-Barroso, Carolina; Ugarte, Ana; Estella-Hermoso de Mendoza, Ander; Saez, Elena; Espelosin, Maria; Ursua, Susana; Haizhong, Tan; Wei, Wu; Musheng, Xu; Garcia-Osta, Ana; Oyarzabal, Julen</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1765-1782</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In order to det. the contributions of histone deacetylase (HDAC) isoforms to the beneficial effects of dual phosphodiesterase 5 (PDE5) and pan-HDAC inhibitors on in vivo models of Alzheimer's disease (AD), we have designed, synthesized, and tested novel chem. probes with the desired target compd. profile of PDE5 and class I HDAC selective inhibitors.  Compared to previous hydroxamate-based series, these mols. exhibit longer residence times on HDACs.  In this scenario, shorter or longer preincubation times may have a significant impact on the IC50 values of these compds. and therefore on their corresponding selectivity profiles on the different HDAC isoforms.  On the other hand, different chem. series have been explored and, as expected, some pairwise comparisons show a clear impact of the scaffold on biol. responses.  The lead identification process led to compd. I, which shows an adequate ADME-Tox profile and in vivo target engagement (histone acetylation and cAMP/cGMP response element-binding (CREB) phosphorylation) in the central nervous system (CNS), suggesting that this compd. represents an optimized chem. probe; thus, I has been assayed in a mouse model of AD (Tg2576).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpMx-DcLUAMrVg90H21EOLACvtfcHk0liiRwA5gX1kIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVKjtLvF&md5=d3d13a9121111b166ea69c09106eb3c5</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.8b00648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.8b00648%26sid%3Dliteratum%253Aachs%26aulast%3DRabal%26aufirst%3DO.%26aulast%3DSanchez-Arias%26aufirst%3DJ.%2BA.%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3Dde%2BMiguel%26aufirst%3DI.%26aulast%3DPerez-Gonzalez%26aufirst%3DM.%26aulast%3DGarcia-Barroso%26aufirst%3DC.%26aulast%3DUgarte%26aufirst%3DA.%26aulast%3DEstella-Hermoso%2Bde%2BMendoza%26aufirst%3DA.%26aulast%3DSaez%26aufirst%3DE.%26aulast%3DEspelosin%26aufirst%3DM.%26aulast%3DUrsua%26aufirst%3DS.%26aulast%3DHaizhong%26aufirst%3DT.%26aulast%3DWei%26aufirst%3DW.%26aulast%3DMusheng%26aufirst%3DX.%26aulast%3DGarcia-Osta%26aufirst%3DA.%26aulast%3DOyarzabal%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520in%2520vivo%2520chemical%2520probes%2520for%2520treating%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520dual%2520phosphodiesterase%25205%2520%2528PDE5%2529%2520and%2520class%2520I%2520histone%2520deacetylase%2520selective%2520inhibitors%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2019%26volume%3D10%26spage%3D1765%26epage%3D1782%26doi%3D10.1021%2Facschemneuro.8b00648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabal, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Arias, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuadrado-Tejedor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Miguel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Gonzalez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Barroso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugarte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estella-Hermoso de Mendoza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espelosin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ursua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haizhong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Osta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyarzabal, J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer’s disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">506</span>– <span class="NLM_lpage">524</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.ejmech.2018.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=29549837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslaiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2018&pages=506-524&author=O.+Rabalauthor=J.+A.+Sanchez-Ariasauthor=M.+Cuadrado-Tejedorauthor=I.+de+Miguelauthor=M.+Perez-Gonzalezauthor=C.+Garcia-Barrosoauthor=A.+Ugarteauthor=A.+Estella-Hermoso+de+Mendozaauthor=E.+Saezauthor=M.+Espelosinauthor=S.+Ursuaauthor=T.+Haizhongauthor=W.+Weiauthor=X.+Mushengauthor=A.+Garcia-Ostaauthor=J.+Oyarzabal&title=Design%2C+synthesis%2C+biological+evaluation+and+in+vivo+testing+of+dual+phosphodiesterase+5+%28PDE5%29+and+histone+deacetylase+6+%28HDAC6%29-selective+inhibitors+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.ejmech.2018.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Rabal, Obdulia; Sanchez-Arias, Juan A.; Cuadrado-Tejedor, Mar; de Miguel, Irene; Perez-Gonzalez, Marta; Garcia-Barroso, Carolina; Ugarte, Ana; Estella-Hermoso de Mendoza, Ander; Saez, Elena; Espelosin, Maria; Ursua, Susana; Tan, Haizhong; Wu, Wei; Xu, Musheng; Garcia-Osta, Ana; Oyarzabal, Julen</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">506-524</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The authors have identified chem. probes that act as dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors (>1 log unit difference vs. class I HDACs) to decipher the contribution of HDAC isoforms to the pos. impact of dual-acting PDE5 and HDAC inhibitors on mouse models of Alzheimer's disease (AD) and fine-tune this systems therapeutics approach.  Structure- and knowledge-based approaches led to the design of first-in-class mols. with the desired target compd. profile: dual PDE5 and HDAC6-selective inhibitors.  Compd. 44b (5-[[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl]methyl]thiophene-2-carbohydroxamic acid), which fulfilled the biochem., functional and ADME-Tox profiling requirements and exhibited adequate pharmacokinetic properties, was selected as pharmacol. tool compd. and tested in a mouse model of AD (Tg2576) in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFqq9VoRla3bVg90H21EOLACvtfcHk0lhnf6ZAZOoxsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslaiur4%253D&md5=1ced6634343dd8c0913ea3e6be07ff91</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DRabal%26aufirst%3DO.%26aulast%3DSanchez-Arias%26aufirst%3DJ.%2BA.%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3Dde%2BMiguel%26aufirst%3DI.%26aulast%3DPerez-Gonzalez%26aufirst%3DM.%26aulast%3DGarcia-Barroso%26aufirst%3DC.%26aulast%3DUgarte%26aufirst%3DA.%26aulast%3DEstella-Hermoso%2Bde%2BMendoza%26aufirst%3DA.%26aulast%3DSaez%26aufirst%3DE.%26aulast%3DEspelosin%26aufirst%3DM.%26aulast%3DUrsua%26aufirst%3DS.%26aulast%3DHaizhong%26aufirst%3DT.%26aulast%3DWei%26aufirst%3DW.%26aulast%3DMusheng%26aufirst%3DX.%26aulast%3DGarcia-Osta%26aufirst%3DA.%26aulast%3DOyarzabal%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%252C%2520biological%2520evaluation%2520and%2520in%2520vivo%2520testing%2520of%2520dual%2520phosphodiesterase%25205%2520%2528PDE5%2529%2520and%2520histone%2520deacetylase%25206%2520%2528HDAC6%2529-selective%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D150%26spage%3D506%26epage%3D524%26doi%3D10.1016%2Fj.ejmech.2018.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, V. C.</span></span> <span> </span><span class="NLM_article-title">Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. receptor interactions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">908</span>, <span class="refDoi"> DOI: 10.1021/jm020449y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020449y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtl2ku78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=883-908&author=V.+C.+Jordan&title=Antiestrogens+and+selective+estrogen+receptor+modulators+as+multifunctional+medicines.+1.+receptor+interactions&doi=10.1021%2Fjm020449y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 1. Receptor Interactions</span></div><div class="casAuthors">Jordan, V. Craig</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">883-908</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Antiestrogens and selective Estrogen receptor modulators as multifunctional medicines are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYmuDHzDbu5LVg90H21EOLACvtfcHk0lhLUfVWBU58WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtl2ku78%253D&md5=b86cc4c3c4a4698a51eac9ab69ae9122</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Fjm020449y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020449y%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DAntiestrogens%2520and%2520selective%2520estrogen%2520receptor%2520modulators%2520as%2520multifunctional%2520medicines.%25201.%2520receptor%2520interactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D883%26epage%3D908%26doi%3D10.1021%2Fjm020449y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ulm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponnusamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, R.</span></span> <span> </span><span class="NLM_article-title">Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers</span>. <i>Endocr. Connect.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">R10</span>– <span class="NLM_lpage">R26</span>, <span class="refDoi"> DOI: 10.1530/EC-18-0425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1530%2FEC-18-0425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=30640710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1CgtLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=R10-R26&author=M.+Ulmauthor=A.+V.+Rameshauthor=K.+M.+McNamaraauthor=S.+Ponnusamyauthor=H.+Sasanoauthor=R.+Narayanan&title=Therapeutic+advances+in+hormone-dependent+cancers%3A+focus+on+prostate%2C+breast+and+ovarian+cancers&doi=10.1530%2FEC-18-0425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers</span></div><div class="casAuthors">Ulm, Michael; Ramesh, Arvind V.; McNamara, Keely M.; Ponnusamy, Suriyan; Sasano, Hironobu; Narayanan, Ramesh</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Connections</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">R10-R26</span>CODEN:
                <span class="NLM_cas:coden">ECNOCX</span>;
        ISSN:<span class="NLM_cas:issn">2049-3614</span>.
    
            (<span class="NLM_cas:orgname">Bioscientifica Ltd.</span>)
        </div><div class="casAbstract">A review.  Hormonal cancers affect over 400,000 men and women and contribute collectively to over 100,000 deaths in the United States alone.  Thanks to advances in the understanding of these cancers at the mol. level and to the discovery of several disease-modifying therapeutics, the last decade has seen a plateauing or even a decreasing trend in the no. of deaths from these cancers.  These advanced therapeutics not only effectively slow the growth of hormonal cancers, but also provide an insight on how these cancers become refractory and evolve as an altogether distinct subset.  This review summarizes the current therapeutic trends in hormonal cancers, with focus on prostate, breast and ovarian cancers.  The review discusses the clin. drugs being used now, promising mols. that are going through various stages of development and makes some predictions on how the therapeutic landscape will shift in the next decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ79Ne7WjUi7Vg90H21EOLACvtfcHk0lhDrg1fvt3C6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1CgtLrJ&md5=fc90ea2d4be544b19d078dc4c66bc9da</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1530%2FEC-18-0425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252FEC-18-0425%26sid%3Dliteratum%253Aachs%26aulast%3DUlm%26aufirst%3DM.%26aulast%3DRamesh%26aufirst%3DA.%2BV.%26aulast%3DMcNamara%26aufirst%3DK.%2BM.%26aulast%3DPonnusamy%26aufirst%3DS.%26aulast%3DSasano%26aufirst%3DH.%26aulast%3DNarayanan%26aufirst%3DR.%26atitle%3DTherapeutic%2520advances%2520in%2520hormone-dependent%2520cancers%253A%2520focus%2520on%2520prostate%252C%2520breast%2520and%2520ovarian%2520cancers%26jtitle%3DEndocr.%2520Connect.%26date%3D2019%26volume%3D8%26spage%3DR10%26epage%3DR26%26doi%3D10.1530%2FEC-18-0425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, N. E.</span></span> <span> </span><span class="NLM_article-title">Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7025</span>– <span class="NLM_lpage">7029</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=11585728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsVehsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=7025-7029&author=X.+Yangauthor=D.+L.+Phillipsauthor=A.+T.+Fergusonauthor=W.+G.+Nelsonauthor=J.+G.+Hermanauthor=N.+E.+Davidson&title=Synergistic+activation+of+functional+estrogen+receptor+%28ER%29-alpha+by+DNA+methyltransferase+and+histone+deacetylase+inhibition+in+human+ER-alpha-negative+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells</span></div><div class="casAuthors">Yang, Xiaowei; Phillips, Dawn L.; Ferguson, Anne T.; Nelson, William G.; Herman, James G.; Davidson, Nancy E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7025-7029</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Formation of transcriptional repression complexes such as DNA methyltransferase (DNMT) 1/histone deacetylase (HDAC) or methyl-CpG binding protein/HDAC is emerging as an important mechanism in silencing a variety of methylated tissue-specific and imprinted genes.  Our previous studies showed that treatment of estrogen receptor (ER)-α-neg. human breast cancer cells with the DNMT inhibitor 5-aza-2'-deoxycytidine (5-aza-dC) led to ER mRNA and protein re-expression.  Also, the HDAC inhibitor trichostatin A (TSA) could induce ER transcript about 5-fold.  Here we show that 5-aza-dC alone induced ER transcript about 30-40-fold, and the addn. of TSA elevated ER mRNA expression about 10-fold more in the human ER-neg. breast cancer cell lines MDA-MB-231 and MDA-MB-435.  Overall, the combination of 5-aza-dC and TSA induced a 300-400-fold increase in ER transcript.  Restoration of estrogen responsiveness was demonstrated by the ability of the induced ER protein to elicit estrogen response element-regulated reporter activity from an exogenous plasmid as well as induce expression of the ER target gene, progesterone receptor.  The synergistic activation of ER occurs concomitantly with markedly reduced sol. DNMT1 expression and activity, partial demethylation of the ER CpG island, and increased acetylation of histones H3 and H4.  These data suggest that the activities of both DNMT1 and HDAC are key regulators of methylation-mediated ER gene silencing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9cug6ITynn7Vg90H21EOLACvtfcHk0ljOc0tv_nvXoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsVehsrs%253D&md5=baf883039fc6660f20412b27f250df70</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%26aulast%3DPhillips%26aufirst%3DD.%2BL.%26aulast%3DFerguson%26aufirst%3DA.%2BT.%26aulast%3DNelson%26aufirst%3DW.%2BG.%26aulast%3DHerman%26aufirst%3DJ.%2BG.%26aulast%3DDavidson%26aufirst%3DN.%2BE.%26atitle%3DSynergistic%2520activation%2520of%2520functional%2520estrogen%2520receptor%2520%2528ER%2529-alpha%2520by%2520DNA%2520methyltransferase%2520and%2520histone%2520deacetylase%2520inhibition%2520in%2520human%2520ER-alpha-negative%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D7025%26epage%3D7029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sabnis, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goloubeva, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chumsri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodie, A. M. H.</span></span> <span> </span><span class="NLM_article-title">Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1893</span>– <span class="NLM_lpage">1903</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-2458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F0008-5472.CAN-10-2458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=21245100" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFCnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=1893-1903&author=G.+J.+Sabnisauthor=O.+Goloubevaauthor=S.+Chumsriauthor=N.+Nguyenauthor=S.+Sukumarauthor=A.+M.+H.+Brodie&title=Functional+activation+of+the+estrogen+receptor-%CE%B1+and+aromatase+by+the+HDAC+inhibitor+entinostat+sensitizes+ER-negative+tumors+to+letrozole&doi=10.1158%2F0008-5472.CAN-10-2458"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Functional Activation of the Estrogen Receptor-α and Aromatase by the HDAC Inhibitor Entinostat Sensitizes ER-Negative Tumors to Letrozole</span></div><div class="casAuthors">Sabnis, Gauri J.; Goloubeva, Olga; Chumsri, Saranya; Nguyen, Nguyen; Sukumar, Saraswati; Brodie, Angela M. H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1893-1903</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Approx. 25% of breast cancers do not express the estrogen receptor-α (ERα) and consequently do not respond to endocrine therapy.  In these tumors, ERα repression is often due to epigenetic modifications such as methylation and histone deacetylation.  For this reason, we investigated the ability of the histone deacetylase inhibitor entinostat (ENT) to trigger reexpression of ERα and aromatase in breast cancer cells, with the notion that this treatment would restore sensitivity to the aromatase inhibitor (AI) letrozole.  ENT treatment of tumor cells increased expression of ERα and aromatase, along with the enzymic activity of aromatase, in a dose-dependent manner both in vitro and in vivo.  Notably, ERα and aromatase upregulation resulted in sensitization of breast cancer cells to estrogen and letrozole.  Tumor growth rate was significantly lower in tumor xenografts following treatment with ENT alone and in combination with letrozole than in control tumors (P > 0.001).  ENT plus letrozole also prevented lung colonization and growth of tumor cells, with a significant redn. (P > 0.03) in both visible and microscopic foci.  Our results show that ENT treatment can be used to restore the letrozole responsiveness of ER-neg. tumors.  More generally, they provide a strong rationale for immediate clin. evaluation of combinations of histone deacetylase and aromatase inhibitors to treat ER-neg. and endocrine-resistant breast cancers.  Cancer Res; 71(5); 1893-903.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzbAv1kqIFk7Vg90H21EOLACvtfcHk0ljOc0tv_nvXoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFCnsLc%253D&md5=0c08c05719072e51936174af019b6e62</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2458%26sid%3Dliteratum%253Aachs%26aulast%3DSabnis%26aufirst%3DG.%2BJ.%26aulast%3DGoloubeva%26aufirst%3DO.%26aulast%3DChumsri%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DN.%26aulast%3DSukumar%26aufirst%3DS.%26aulast%3DBrodie%26aufirst%3DA.%2BM.%2BH.%26atitle%3DFunctional%2520activation%2520of%2520the%2520estrogen%2520receptor-%25CE%25B1%2520and%2520aromatase%2520by%2520the%2520HDAC%2520inhibitor%2520entinostat%2520sensitizes%2520ER-negative%2520tumors%2520to%2520letrozole%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D1893%26epage%3D1903%26doi%3D10.1158%2F0008-5472.CAN-10-2458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Restall, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paiman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byron, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dear, A. E.</span></span> <span> </span><span class="NLM_article-title">A novel histone deacetylase inhibitor augments tamoxifen-mediated attenuation of breast carcinoma growth</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">483</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.1002/ijc.24350</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1002%2Fijc.24350" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=19330834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1amurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2009&pages=483-487&author=C.+Restallauthor=J.+Dohertyauthor=H.+B.+Liuauthor=R.+Genoveseauthor=L.+Paimanauthor=K.+A.+Byronauthor=R.+L.+Andersonauthor=A.+E.+Dear&title=A+novel+histone+deacetylase+inhibitor+augments+tamoxifen-mediated+attenuation+of+breast+carcinoma+growth&doi=10.1002%2Fijc.24350"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">A novel histone deacetylase inhibitor augments tamoxifen-mediated attenuation of breast carcinoma growth</span></div><div class="casAuthors">Restall, Christina; Doherty, Judy; Liu, Hong Bin; Genovese, Rosemary; Paiman, Lisa; Byron, Keith A.; Anderson, Robin L.; Dear, Anthony E.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">483-487</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Earlier we generated novel derivs. of the hydroxamate-based histone deacetylase inhibitor (HDACi), Oxamflatin (Ox), which demonstrate considerable HDACi activity.  Here the effects of one such deriv., Metacept-1 (MCT-1), alone or in combination with tamoxifen on mammary tumor growth have been assessed in a syngeneic orthotopic model.  MCT-1 alone resulted in a trend towards inhibition of growth of 4T1.2 mammary tumors.  Since the combination of MCT-1 and tamoxifen up-regulates estrogen receptor expression in 4T1.2 cells in vitro, we tested this combination and found a significant redn. in primary tumor growth over tamoxifen treatment alone.  Taken together, these observations suggest that the novel HDACi MCT-1 may warrant further exploration in the treatment of estrogen receptor pos. breast carcinoma, particularly when used in combination with conventional agents such as tamoxifen.  © 2009 UICC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDB-RoQfaAubVg90H21EOLACvtfcHk0ljOc0tv_nvXoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1amurs%253D&md5=297b7ae54ac249a461485790bf3ca309</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1002%2Fijc.24350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.24350%26sid%3Dliteratum%253Aachs%26aulast%3DRestall%26aufirst%3DC.%26aulast%3DDoherty%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DH.%2BB.%26aulast%3DGenovese%26aufirst%3DR.%26aulast%3DPaiman%26aufirst%3DL.%26aulast%3DByron%26aufirst%3DK.%2BA.%26aulast%3DAnderson%26aufirst%3DR.%2BL.%26aulast%3DDear%26aufirst%3DA.%2BE.%26atitle%3DA%2520novel%2520histone%2520deacetylase%2520inhibitor%2520augments%2520tamoxifen-mediated%2520attenuation%2520of%2520breast%2520carcinoma%2520growth%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2009%26volume%3D125%26spage%3D483%26epage%3D487%26doi%3D10.1002%2Fijc.24350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sabnis, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goloubeva, O. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazi, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodie, A. H.</span></span> <span> </span><span class="NLM_article-title">HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2804</span>– <span class="NLM_lpage">2816</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1535-7163.MCT-13-0345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=24092810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVyqsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=2804-2816&author=G.+J.+Sabnisauthor=O.+G.+Goloubevaauthor=A.+A.+Kaziauthor=P.+Shahauthor=A.+H.+Brodie&title=HDAC+inhibitor+entinostat+restores+responsiveness+of+letrozole-resistant+MCF-7Ca+xenografts+to+aromatase+inhibitors+through+modulation+of+Her-2&doi=10.1158%2F1535-7163.MCT-13-0345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC Inhibitor Entinostat Restores Responsiveness of Letrozole-Resistant MCF-7Ca Xenografts to Aromatase Inhibitors through Modulation of Her-2</span></div><div class="casAuthors">Sabnis, Gauri J.; Goloubeva, Olga G.; Kazi, Armina A.; Shah, Preeti; Brodie, Angela H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2804-2816</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We previously showed that in innately resistant tumors, silencing of the estrogen receptor (ER) could be reversed by treatment with a histone deacetylase (HDAC) inhibitor, entinostat.  Tumors were then responsive to aromatase inhibitor (AI) letrozole.  Here, we investigated whether ER in the acquired letrozole-resistant tumors could be restored with entinostat.  Ovariectomized athymic mice were inoculated with MCF-7Ca cells, supplemented with androstenedione (Δ4A), the aromatizable substrate.  When the tumors reached about 300 mm3, the mice were treated with letrozole.  After initial response to letrozole, the tumors eventually became resistant (doubled their initial vol.).  The mice then were grouped to receive letrozole, exemestane (250 μg/d), entinostat (50 μg/d), or the combination of entinostat with letrozole or exemestane for 26 wk.  The growth rates of tumors of mice treated with the combination of entinostat with letrozole or exemestane were significantly slower than with the single agent (P < 0.05).  Anal. of the letrozole-resistant tumors showed entinostat increased ERα expression and aromatase activity but downregulated Her-2, p-Her-2, p-MAPK, and p-Akt.  However, the mechanism of action of entinostat in reversing acquired resistance did not involve epigenetic silencing but rather included posttranslational as well as transcriptional modulation of Her-2.  Entinostat treatment reduced the assocn. of the Her-2 protein with HSP-90, possibly by reducing the stability of Her-2 protein.  In addn., entinostat also reduced Her-2 mRNA levels and its stability.  Our results suggest that the HDAC inhibitor may reverse letrozole resistance in cells and tumors by modulating Her-2 expression and activity.  Mol Cancer Ther; 12(12); 2804-16. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9K4N7QFrXJrVg90H21EOLACvtfcHk0lju5lNr1EuL4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVyqsrvI&md5=84d2fcd2a1fb0606e350b8bdea39665f</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0345%26sid%3Dliteratum%253Aachs%26aulast%3DSabnis%26aufirst%3DG.%2BJ.%26aulast%3DGoloubeva%26aufirst%3DO.%2BG.%26aulast%3DKazi%26aufirst%3DA.%2BA.%26aulast%3DShah%26aufirst%3DP.%26aulast%3DBrodie%26aufirst%3DA.%2BH.%26atitle%3DHDAC%2520inhibitor%2520entinostat%2520restores%2520responsiveness%2520of%2520letrozole-resistant%2520MCF-7Ca%2520xenografts%2520to%2520aromatase%2520inhibitors%2520through%2520modulation%2520of%2520Her-2%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D2804%26epage%3D2816%26doi%3D10.1158%2F1535-7163.MCT-13-0345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurn, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raha, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacevic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melisko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismail-Khan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moasser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minton, S. E.</span></span> <span> </span><span class="NLM_article-title">A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">1828</span>– <span class="NLM_lpage">1835</span>, <span class="refDoi"> DOI: 10.1038/bjc.2011.156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fbjc.2011.156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=21559012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntV2hsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2011&pages=1828-1835&author=P.+N.+Munsterauthor=K.+T.+Thurnauthor=S.+Thomasauthor=P.+Rahaauthor=M.+Lacevicauthor=A.+Millerauthor=M.+Meliskoauthor=R.+Ismail-Khanauthor=H.+Rugoauthor=M.+Moasserauthor=S.+E.+Minton&title=A+phase+II+study+of+the+histone+deacetylase+inhibitor+vorinostat+combined+with+tamoxifen+for+the+treatment+of+patients+with+hormone+therapy-resistant+breast+cancer&doi=10.1038%2Fbjc.2011.156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer</span></div><div class="casAuthors">Munster, P. N.; Thurn, K. T.; Thomas, S.; Raha, P.; Lacevic, M.; Miller, A.; Melisko, M.; Ismail-Khan, R.; Rugo, H.; Moasser, M.; Minton, S. E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1828-1835</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are crucial components of the estrogen receptor (ER) transcriptional complex.  Preclinically, HDAC inhibitors can reverse tamoxifen/aromatase inhibitor resistance in hormone receptor-pos. breast cancer.  This concept was examd. in a phase II combination trial with correlative end points.  Patients with ER-pos. metastatic breast cancer progressing on endocrine therapy were treated with 400 mg of vorinostat daily for 3 of 4 wk and 20 mg tamoxifen daily, continuously.  Histone acetylation and HDAC2 expression in peripheral blood mononuclear cells were also evaluated.  In all, 43 patients (median age 56 years (31-71)) were treated, 25 (58%) received prior adjuvant tamoxifen, 29 (67%) failed one prior chemotherapy regimen, 42 (98%) progressed after one, and 23 (54%) after two aromatase inhibitors.  The objective response rate by Response Evaluation Criteria in Solid Tumors criteria was 19% and the clin. benefit rate (response or stable disease >24 wk) was 40%.  The median response duration was 10.3 mo (confidence interval: 8.1-12.4).  Histone hyperacetylation and higher baseline HDAC2 levels correlated with response.  The combination of vorinostat and tamoxifen is well tolerated and exhibits encouraging activity in reversing hormone resistance.  Correlative studies suggest that HDAC2 expression is a predictive marker and histone hyperacetylation is a useful pharmacodynamic marker for the efficacy of this combination.  British Journal of Cancer (2011) 104, 1828-1835; doi:10.1038/bjc.2011.156 www.bjcancer.com Published online 10 May 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDPB1YAqSmBLVg90H21EOLACvtfcHk0lju5lNr1EuL4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntV2hsbg%253D&md5=15e2afd6a1b658f378e4f41ed2b15ef9</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2011.156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2011.156%26sid%3Dliteratum%253Aachs%26aulast%3DMunster%26aufirst%3DP.%2BN.%26aulast%3DThurn%26aufirst%3DK.%2BT.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DRaha%26aufirst%3DP.%26aulast%3DLacevic%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DA.%26aulast%3DMelisko%26aufirst%3DM.%26aulast%3DIsmail-Khan%26aufirst%3DR.%26aulast%3DRugo%26aufirst%3DH.%26aulast%3DMoasser%26aufirst%3DM.%26aulast%3DMinton%26aufirst%3DS.%2BE.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520the%2520histone%2520deacetylase%2520inhibitor%2520vorinostat%2520combined%2520with%2520tamoxifen%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520hormone%2520therapy-resistant%2520breast%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2011%26volume%3D104%26spage%3D1828%26epage%3D1835%26doi%3D10.1038%2Fbjc.2011.156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avraham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avraham, H. K.</span></span> <span> </span><span class="NLM_article-title">Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">358</span>, <span class="refDoi"> DOI: 10.1002/ijc.11403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1002%2Fijc.11403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=14506733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Gns78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2003&pages=353-358&author=H.+Kawaiauthor=H.+Liauthor=S.+Avrahamauthor=S.+Jiangauthor=H.+K.+Avraham&title=Overexpression+of+histone+deacetylase+HDAC1+modulates+breast+cancer+progression+by+negative+regulation+of+estrogen+receptor+alpha&doi=10.1002%2Fijc.11403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor α</span></div><div class="casAuthors">Kawai, Hideki; Li, Huchun; Avraham, Shalom; Jiang, Shuxian; Avraham, Hava Karsenty</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">353-358</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The interaction between 17β-estradiol and estrogen receptor alpha (ER-α) plays an important role in breast carcinogenesis and breast cancer treatment.  ER-α is a crit. growth regulatory gene in breast cancer and its expression level is tightly linked to the prognosis and treatment outcomes of breast cancer patients.  Loss of ER-α expression in breast epithelial cells is crit. for breast cancer progression.  The underlying mol. mechanisms for this loss, however, are poorly defined.  Histone deacetylases (HDACs) are implicated in the alteration of chromatin assembly and tumorigenesis.  We show that histone deacetylase I (HDAC1) interacts with ER-α in vitro and in vivo and suppresses ER-α transcription activity.  The interaction of HDAC1 with ER-α was mediated by the AF-2 and DBD domains of ER-α.  We obsd. an endogenous interaction of HDAC1 with ER-α in breast cancer cells, which was decreased in the presence of estrogen.  Interestingly, overexpression of HDAC1 in stable transfected MCF-7 clones induced loss of ER-α and significantly increased cell proliferation and colony formation, as compared to the control MCF-7 cells, whereas treatment of stable MCF-7 clones with the HDAC specific inhibitor trichostatin A (TSA) induced re-expression of ER-α mRNA and protein.  Our findings strongly suggest that HDAC1 affects breast cancer progression by promoting cellular proliferation in assocn. with a redn. in both ER-α protein expression and transcriptional activity.  Thus, HDAC1 may be a potential target for therapeutic intervention in the treatment of a subset of ER-neg. breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeLCIVDhHWhrVg90H21EOLACvtfcHk0lju5lNr1EuL4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Gns78%253D&md5=c5ae5e91d0e3c1bd55c5b2baebef844c</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1002%2Fijc.11403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.11403%26sid%3Dliteratum%253Aachs%26aulast%3DKawai%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DAvraham%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DAvraham%26aufirst%3DH.%2BK.%26atitle%3DOverexpression%2520of%2520histone%2520deacetylase%2520HDAC1%2520modulates%2520breast%2520cancer%2520progression%2520by%2520negative%2520regulation%2520of%2520estrogen%2520receptor%2520alpha%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2003%26volume%3D107%26spage%3D353%26epage%3D358%26doi%3D10.1002%2Fijc.11403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hodgesgallagher, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kushner, P. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">297</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1007/s10549-006-9459-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1007%2Fs10549-006-9459-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=17186358" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2007&pages=297-309&author=L.+Hodgesgallagherauthor=C.+D.+Valentineauthor=S.+E.+Baderauthor=P.+J.+Kushner&title=Inhibition+of+histone+deacetylase+enhances+the+anti-proliferative+action+of+antiestrogens+on+breast+cancer+cells+and+blocks+tamoxifen-induced+proliferation+of+uterine+cells&doi=10.1007%2Fs10549-006-9459-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1007%2Fs10549-006-9459-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-006-9459-6%26sid%3Dliteratum%253Aachs%26aulast%3DHodgesgallagher%26aufirst%3DL.%26aulast%3DValentine%26aufirst%3DC.%2BD.%26aulast%3DBader%26aufirst%3DS.%2BE.%26aulast%3DKushner%26aufirst%3DP.%2BJ.%26atitle%3DInhibition%2520of%2520histone%2520deacetylase%2520enhances%2520the%2520anti-proliferative%2520action%2520of%2520antiestrogens%2520on%2520breast%2520cancer%2520cells%2520and%2520blocks%2520tamoxifen-induced%2520proliferation%2520of%2520uterine%2520cells%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2007%26volume%3D105%26spage%3D297%26epage%3D309%26doi%3D10.1007%2Fs10549-006-9459-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Margueron, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escande, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaguer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavaillès, V.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens</span>. <i>J. Mol. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">583</span>– <span class="NLM_lpage">594</span>, <span class="refDoi"> DOI: 10.1677/jme.0.0320583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1677%2Fjme.0.0320583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15072561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjslKjtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2004&pages=583-594&author=R.+Margueronauthor=V.+Duongauthor=S.+Bonnetauthor=A.+Escandeauthor=F.+Vignonauthor=P.+Balaguerauthor=V.+Cavaill%C3%A8s&title=Histone+deacetylase+inhibition+and+estrogen+receptor+alpha+levels+modulate+the+transcriptional+activity+of+partial+antiestrogens&doi=10.1677%2Fjme.0.0320583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibition and estrogen receptor α levels modulate the transcriptional activity of partial antiestrogens</span></div><div class="casAuthors">Margueron, R.; Duong, V.; Bonnet, S.; Escande, A.; Vignon, F.; Balaguer, P.; Cavailles, V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Endocrinology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">583-594</span>CODEN:
                <span class="NLM_cas:coden">JMLEEI</span>;
        ISSN:<span class="NLM_cas:issn">0952-5041</span>.
    
            (<span class="NLM_cas:orgname">Society for Endocrinology</span>)
        </div><div class="casAbstract">In this study, the authors have analyzed the effects of histone deacetylase (HDAC) inhibition on estrogen receptor (ER) expression and on its transcriptional activity in response to antiestrogens.  In several breast cancer cell lines, trichostatin A (TSA), a potent HDAC inhibitor, strongly decreases ERα expression in a dose-dependent manner.  This repression is obsd. independently of the presence of ligand and also occurs in ovarian and endometrial cell lines.  In addn., the authors show that in MCF7 cells bearing a stably transfected reporter plasmid (MELN cells), partial antiestrogens such as 4-OH-tamoxifen (OHTam), raloxifen or LY117018, switch to an agonist activity upon HDAC inhibition.  This effect is blocked by the pure antiestrogen ICI182780 and exhibits a half-maximal concn. of OHTam equiv. to its affinity for ERα.  The TSA-dependent decrease of ERα expression is required to induce the agonist switch of OHTam properties as it is lost in cells constitutively expressing exogenous receptors (MELN-ERα or ERβ).  By contrast, the transrepression activity of OHTam is abolished by TSA independently of the decrease of ERα expression.  Interestingly, in MELN-ERα, ICI182780 remains inhibitory suggesting the involvement of HDAC-independent mechanisms.  Finally, in the absence of TSA, transcriptional activity in response to OHTam is significantly raised in MELN cells expressing low levels of ERα after transfection of antisense oligonucleotides.  In conclusion, inhibition of HDAC enzymic activity and modulation of ERα levels tightly control the relative agonist activity of partial antiestrogens on a stably integrated reporter transgene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQTrvnGSsEvbVg90H21EOLACvtfcHk0lglh9a-aH9TLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjslKjtLw%253D&md5=4ba639a4180a390ed67ba7bf4acaeec8</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1677%2Fjme.0.0320583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252Fjme.0.0320583%26sid%3Dliteratum%253Aachs%26aulast%3DMargueron%26aufirst%3DR.%26aulast%3DDuong%26aufirst%3DV.%26aulast%3DBonnet%26aufirst%3DS.%26aulast%3DEscande%26aufirst%3DA.%26aulast%3DVignon%26aufirst%3DF.%26aulast%3DBalaguer%26aufirst%3DP.%26aulast%3DCavaill%25C3%25A8s%26aufirst%3DV.%26atitle%3DHistone%2520deacetylase%2520inhibition%2520and%2520estrogen%2520receptor%2520alpha%2520levels%2520modulate%2520the%2520transcriptional%2520activity%2520of%2520partial%2520antiestrogens%26jtitle%3DJ.%2520Mol.%2520Endocrinol.%26date%3D2004%26volume%3D32%26spage%3D583%26epage%3D594%26doi%3D10.1677%2Fjme.0.0320583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H. B.</span></span> <span> </span><span class="NLM_article-title">Novel bioactive hybrid compounds dual targeting estrogen receptor and histone deacetylase for treatment of breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4550</span>– <span class="NLM_lpage">4572</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00099</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00099" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovVShsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4550-4572&author=C.+Tangauthor=C.+Liauthor=S.+Zhangauthor=Z.+Huauthor=J.+Wuauthor=C.+Dongauthor=J.+Huangauthor=H.+B.+Zhou&title=Novel+bioactive+hybrid+compounds+dual+targeting+estrogen+receptor+and+histone+deacetylase+for+treatment+of+breast+cancer&doi=10.1021%2Facs.jmedchem.5b00099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer</span></div><div class="casAuthors">Tang, Chu; Li, Changhao; Zhang, Silong; Hu, Zhiye; Wu, Jun; Dong, Chune; Huang, Jian; Zhou, Hai-Bing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4550-4572</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A strategy to develop chemotherapeutic agents by combining several active groups into a single mol. as a conjugate that can modulate multiple cellular pathways may produce compds. having higher efficacy compared to that of single-target drugs.  In this article, we describe the synthesis and evaluation of an array of dual-acting ER and histone deacetylase inhibitors.  These novel hybrid compds. combine an indirect antagonism structure motif of ER (OBHS, oxabicycloheptene sulfonate) with the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA).  These OBHS-HDACi conjugates I (R = OH, NHOH; Ar = Ph, 1-naphthyl, 2-naphthyl, 4-MeC6H5, 3-MeC6H5, 2-MeC6H5, 2-MeOC6H5, etc.) exhibited good ER binding affinity and excellent ERα antagonistic activity, and they also exhibited potent inhibitory activities against HDACs.  Compared with the approved drug tamoxifen, these conjugates exhibited higher antitumor potency in ERα-pos. breast cancer cells (MCF-7).  Moreover, these conjugates not only showed selective anticancer activity that was more potent against MCF-7 cells than DU 145 (prostate cancer), but they had no toxicity toward normal cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokzR9bn5jLU7Vg90H21EOLACvtfcHk0lglh9a-aH9TLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovVShsbk%253D&md5=223b9c3c43e1f8f012efcd1771547ee1</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00099%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DH.%2BB.%26atitle%3DNovel%2520bioactive%2520hybrid%2520compounds%2520dual%2520targeting%2520estrogen%2520receptor%2520and%2520histone%2520deacetylase%2520for%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4550%26epage%3D4572%26doi%3D10.1021%2Facs.jmedchem.5b00099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beckett, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huxley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, M.</span></span> <span> </span><span class="NLM_article-title">Recent advances in matrix metalloproteinase inhibitor research</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/1359-6446(96)89115-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2F1359-6446%2896%2989115-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADyaK28XhtFyrsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1996&pages=16-26&author=R.+P.+Beckettauthor=A.+H.+Davidsonauthor=A.+H.+Drummondauthor=P.+Huxleyauthor=M.+Whittaker&title=Recent+advances+in+matrix+metalloproteinase+inhibitor+research&doi=10.1016%2F1359-6446%2896%2989115-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in matrix metalloproteinase inhibitor research</span></div><div class="casAuthors">Beckett, R. Paul; Davidson, Alan H.; Drummond, Alan H.; Huxley, Philip; Whittaker, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-26</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 88 refs. The matrix metalloproteinases (MMPs) are a family of zinc-dependent enzymes that degrade all of the major components of the extracellular matrix.  Over-expression and activation of MMPs have been linked with a range of diseases for which good therapeutic approaches are currently sought, such as arthritis, cancer and multiple sclerosis.  Inhibition of MMPs has therefore become the focus of considerable interest, and potential therapeutic applications continue to grow.  Orally active, broad-spectrum inhibitors have been identified, and some of these are undergoing clin. evaluation.  Structural information on MMP-inhibitor complexes is now available, enabling the structure-based design of selective MMP inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorKdCxN8GmNrVg90H21EOLACvtfcHk0lih2qGNYjy8fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhtFyrsrY%253D&md5=a92e257fc7f31a93ce7f6c60758f2d3e</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2F1359-6446%2896%2989115-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F1359-6446%252896%252989115-X%26sid%3Dliteratum%253Aachs%26aulast%3DBeckett%26aufirst%3DR.%2BP.%26aulast%3DDavidson%26aufirst%3DA.%2BH.%26aulast%3DDrummond%26aufirst%3DA.%2BH.%26aulast%3DHuxley%26aufirst%3DP.%26aulast%3DWhittaker%26aufirst%3DM.%26atitle%3DRecent%2520advances%2520in%2520matrix%2520metalloproteinase%2520inhibitor%2520research%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D1996%26volume%3D1%26spage%3D16%26epage%3D26%26doi%3D10.1016%2F1359-6446%2896%2989115-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Overall, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleifeld, O.</span></span> <span> </span><span class="NLM_article-title">Tumour microenvironment — opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">227</span>– <span class="NLM_lpage">239</span>, <span class="refDoi"> DOI: 10.1038/nrc1821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnrc1821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16498445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhslelt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=227-239&author=C.+M.+Overallauthor=O.+Kleifeld&title=Tumour+microenvironment+%E2%80%94+opinion%3A+validating+matrix+metalloproteinases+as+drug+targets+and+anti-targets+for+cancer+therapy&doi=10.1038%2Fnrc1821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Tumour microenvironment - Opinion: Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy</span></div><div class="casAuthors">Overall, Christopher M.; Kleifeld, Oded</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">227-239</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The matrix metalloproteinases (MMPs) mediate homeostasis of the extracellular environment.  They have multiple signaling activities that are commonly altered during tumorigenesis and that might serve as intervention points for anticancer drugs.  However, there are many criteria to consider in validating MMPs as drug targets and for the development of MMP inhibitors.  The inhibition of some MMPs could have pro-tumorigenic effects (making them anti-targets), counterbalancing the benefits of target inhibition.  These effects might partially account for the failure of MMP inhibitors in clin. trials.  What are the major challenges in MMP target validation and MMP-inhibitor-drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc3iBQEggRc7Vg90H21EOLACvtfcHk0lhXnVqiruP1Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhslelt70%253D&md5=3edfeca153a62c759443d0893a6212e2</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1038%2Fnrc1821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1821%26sid%3Dliteratum%253Aachs%26aulast%3DOverall%26aufirst%3DC.%2BM.%26aulast%3DKleifeld%26aufirst%3DO.%26atitle%3DTumour%2520microenvironment%2520%25E2%2580%2594%2520opinion%253A%2520validating%2520matrix%2520metalloproteinases%2520as%2520drug%2520targets%2520and%2520anti-targets%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D227%26epage%3D239%26doi%3D10.1038%2Fnrc1821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Egeblad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werb, Z.</span></span> <span> </span><span class="NLM_article-title">New functions for the matrix metalloproteinases in cancer progression</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1038/nrc745</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnrc745" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=11990853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1KktL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=161-174&author=M.+Egebladauthor=Z.+Werb&title=New+functions+for+the+matrix+metalloproteinases+in+cancer+progression&doi=10.1038%2Fnrc745"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">New functions for the matrix metalloproteinases in cancer progression</span></div><div class="casAuthors">Egeblad, Mikala; Werb, Zena</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">161-174</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Matrix metalloproteinases (MMPs) have long been assocd. with cancer-cell invasion and metastasis.  This provided the rationale for clin. trials of MMP inhibitors, unfortunately with disappointing results.  We now know, however, that the MMPs have functions other than promotion of invasion, have substrates other than components of the extracellular matrix, and that they function before invasion in the development of cancer.  With this knowledge in hand, can we rethink the use of MMP inhibitors in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtDQGs5M_BzLVg90H21EOLACvtfcHk0lhG1atl4A3q_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1KktL8%253D&md5=56dd558362155cb25c9adbea4d478aa8</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1038%2Fnrc745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc745%26sid%3Dliteratum%253Aachs%26aulast%3DEgeblad%26aufirst%3DM.%26aulast%3DWerb%26aufirst%3DZ.%26atitle%3DNew%2520functions%2520for%2520the%2520matrix%2520metalloproteinases%2520in%2520cancer%2520progression%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D161%26epage%3D174%26doi%3D10.1038%2Fnrc745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Page-McCaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewald, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werb, Z.</span></span> <span> </span><span class="NLM_article-title">Matrix metalloproteinases and the regulation of tissue remodelling</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1038/nrm2125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnrm2125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=17318226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=221-233&author=A.+Page-McCawauthor=A.+J.+Ewaldauthor=Z.+Werb&title=Matrix+metalloproteinases+and+the+regulation+of+tissue+remodelling&doi=10.1038%2Fnrm2125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Matrix metalloproteinases and the regulation of tissue remodelling</span></div><div class="casAuthors">Page-McCaw, Andrea; Ewald, Andrew J.; Werb, Zena</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">221-233</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Matrix metalloproteinases (MMPs) were discovered because of their role in amphibian metamorphosis, yet they have attracted more attention because of their roles in disease.  Despite intensive scrutiny in vitro, in cell culture and in animal models, the normal physiol. roles of these extracellular proteases have been elusive.  Recent studies in mice and flies point to essential roles of MMPs as mediators of change and phys. adaptation in tissues, whether developmentally regulated, environmentally induced or disease assocd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruFGsYuEMGL7Vg90H21EOLACvtfcHk0ljGqwxyKczBDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrs74%253D&md5=8c3655e653939cd016e2949c6b017e93</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1038%2Fnrm2125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2125%26sid%3Dliteratum%253Aachs%26aulast%3DPage-McCaw%26aufirst%3DA.%26aulast%3DEwald%26aufirst%3DA.%2BJ.%26aulast%3DWerb%26aufirst%3DZ.%26atitle%3DMatrix%2520metalloproteinases%2520and%2520the%2520regulation%2520of%2520tissue%2520remodelling%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2007%26volume%3D8%26spage%3D221%26epage%3D233%26doi%3D10.1038%2Fnrm2125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, T.</span></span> <span> </span><span class="NLM_article-title">Arylsulfonamides and selectivity of matrix metalloproteinase-2: an overview</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">109</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.02.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.ejmech.2017.02.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=28219048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtVelu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=72-109&author=N.+Adhikariauthor=A.+Mukherjeeauthor=A.+Sahaauthor=T.+Jha&title=Arylsulfonamides+and+selectivity+of+matrix+metalloproteinase-2%3A+an+overview&doi=10.1016%2Fj.ejmech.2017.02.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Arylsulfonamides and selectivity of matrix metalloproteinase-2: An overview</span></div><div class="casAuthors">Adhikari, Nilanjan; Mukherjee, Avinaba; Saha, Achintya; Jha, Tarun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">72-109</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Uncontrolled regulation of specific metalloenzymes plays important roles in several diseases like tumor metastasis and inflammation.  Therefore, selective metalloenzyme inhibition may be a potential target for drug design and development.  Matrix metalloproteinase inhibitors (MMPIs) opened up a new horizon as the possible treatment of arthritis, cancer, and emphysema.  However, due to adverse effects and poor pharmacokinetics, first generation MMPIs failed in clin. trials.  Therefore, development of potential and selective MMPIs is still in demand.  Moreover, the flexibility of the enzyme S1' pocket is variable in length and shape making the designing approach more challenging.  In this article, arylsulfonamides have been highlighted as potential and selective MMP-2 inhibitors through structure-activity relationships study.  It may be postulated that sulfonamide moiety may provide better direction to the assocd. aryl group to accommodate the deep hydrophobic S1' pocket.  Tetrahedral geometry of the sulfonyl function may be favorable than planar carboxyl function regarding the interaction between the aryl group and S1' pocket.  Hydroxamates may impart higher inhibition than corresponding carboxylates due to addnl. hydrogen bonding.  Moreover, MMP-2 selectivity is not only dependent on zinc binders but also on the aryl functions directed towards S1 and S2' pockets.  Therefore, this review may help in designing potential and selective MMP-2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphb5pVEplLcbVg90H21EOLACvtfcHk0ljzMX8GXuOLvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtVelu7g%253D&md5=550e8018477cfa802407443195c41d89</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.02.014%26sid%3Dliteratum%253Aachs%26aulast%3DAdhikari%26aufirst%3DN.%26aulast%3DMukherjee%26aufirst%3DA.%26aulast%3DSaha%26aufirst%3DA.%26aulast%3DJha%26aufirst%3DT.%26atitle%3DArylsulfonamides%2520and%2520selectivity%2520of%2520matrix%2520metalloproteinase-2%253A%2520an%2520overview%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D129%26spage%3D72%26epage%3D109%26doi%3D10.1016%2Fj.ejmech.2017.02.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amin, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, T.</span></span> <span> </span><span class="NLM_article-title">Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies?</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2017.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.phrs.2017.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=28501516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVGrs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2017&pages=8-19&author=S.+A.+Aminauthor=N.+Adhikariauthor=T.+Jha&title=Is+dual+inhibition+of+metalloenzymes+HDAC-8+and+MMP-2+a+potential+pharmacological+target+to+combat+hematological+malignancies%3F&doi=10.1016%2Fj.phrs.2017.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies?</span></div><div class="casAuthors">Amin, Sk. Abdul; Adhikari, Nilanjan; Jha, Tarun</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8-19</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">For the last three decades, metalloenzymes such as histone deacetylases (HDACs) and matrix metalloproteinases (MMPs) have been identified in promoting solid as well as hematol. carcinogenesis.  Histone deacetylase 8 (HDAC-8), a class I HDAC enzyme, may serve as 'epigenetic player' that affects in the regulation of transcription factors and alters the structure of chromosome assocd. with tumorigenesis.  It is established that the influence of MMP-2 in invasion, metastasis and angiogenetic events of hematol. malignancies may be suppressed by HDAC inhibitors through reversion-inducing-cysteine-rich protein with kazal motifs (RECK) protein.  Therefore, the isoform-specific HDAC-8 and MMP-2 inhibitors may provide synergistic medicinal benefit in leukemia.  However, a paucity of articles is available on dual acting HDAC-8/MMP-2 inhibitors.  In this circumstance, a lot of works are still necessary to identify novel dual HDAC-8/MMP-2 inhibitors and this review will surely provide an initial idea regarding the utility of designing such type of dual inhibitors.  Here, the importance of MMP-2 and HDAC-8 inhibition in hematol. malignancies are focussed for the first time as per our knowledge along with the structure-activity relationships (SARs) of a handful of mols., some of which were synthesized inhouse, have been highlighted that will inspire more interactions between the medicinal chem. and biol. community to harness their expertise in design and discovery of the better acting dual inhibitors in future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUOVqI4P-EsLVg90H21EOLACvtfcHk0lg7TaJ9oGluKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVGrs7w%253D&md5=a3284a3b2836efb3e6d721d4a0d8e713</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2017.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2017.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DAmin%26aufirst%3DS.%2BA.%26aulast%3DAdhikari%26aufirst%3DN.%26aulast%3DJha%26aufirst%3DT.%26atitle%3DIs%2520dual%2520inhibition%2520of%2520metalloenzymes%2520HDAC-8%2520and%2520MMP-2%2520a%2520potential%2520pharmacological%2520target%2520to%2520combat%2520hematological%2520malignancies%253F%26jtitle%3DPharmacol.%2520Res.%26date%3D2017%26volume%3D122%26spage%3D8%26epage%3D19%26doi%3D10.1016%2Fj.phrs.2017.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chakrabarti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehme, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">HDAC8: a multifaceted target for therapeutic interventions</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">492</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2015.04.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.tips.2015.04.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=26013035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlGqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=481-492&author=A.+Chakrabartiauthor=I.+Oehmeauthor=O.+Wittauthor=G.+Oliveiraauthor=W.+Sipplauthor=C.+Romierauthor=R.+J.+Pierceauthor=M.+Jung&title=HDAC8%3A+a+multifaceted+target+for+therapeutic+interventions&doi=10.1016%2Fj.tips.2015.04.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC8: a multifaceted target for therapeutic interventions</span></div><div class="casAuthors">Chakrabarti, Alokta; Oehme, Ina; Witt, Olaf; Oliveira, Guilherme; Sippl, Wolfgang; Romier, Christophe; Pierce, Raymond J.; Jung, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">481-492</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Histone deacetylase 8 (HDAC8) is a class I histone deacetylase implicated as a therapeutic target in various diseases, including cancer, X-linked intellectual disability, and parasitic infections.  It is a structurally well-characterized enzyme that also deacetylates nonhistone proteins.  In cancer, HDAC8 is a major 'epigenetic player' that is linked to deregulated expression or interaction with transcription factors crit. to tumorigenesis.  In the parasite Schistosoma mansoni and in viral infections, HDAC8 is a novel target to subdue infection.  The current challenge remains in the development of potent selective inhibitors that would specifically target HDAC8 with fewer adverse effects compared with pan-HDAC inhibitors.  Here, we review HDAC8 as a drug target and discuss inhibitors with respect to their structural features and therapeutic interventions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPwG01nKtWHLVg90H21EOLACvtfcHk0lg7TaJ9oGluKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlGqsL4%253D&md5=c99b5c390930dc17398d15f20127758b</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DChakrabarti%26aufirst%3DA.%26aulast%3DOehme%26aufirst%3DI.%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DOliveira%26aufirst%3DG.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DRomier%26aufirst%3DC.%26aulast%3DPierce%26aufirst%3DR.%2BJ.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DHDAC8%253A%2520a%2520multifaceted%2520target%2520for%2520therapeutic%2520interventions%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D481%26epage%3D492%26doi%3D10.1016%2Fj.tips.2015.04.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chakrabarti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melesina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolbinger, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehme, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1609</span>– <span class="NLM_lpage">1634</span>, <span class="refDoi"> DOI: 10.4155/fmc-2016-0117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.4155%2Ffmc-2016-0117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=27572818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKhsrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=1609-1634&author=A.+Chakrabartiauthor=J.+Melesinaauthor=F.+R.+Kolbingerauthor=I.+Oehmeauthor=J.+Sengerauthor=O.+Wittauthor=W.+Sipplauthor=M.+Jung&title=Targeting+histone+deacetylase+8+as+a+therapeutic+approach+to+cancer+and+neurodegenerative+diseases&doi=10.4155%2Ffmc-2016-0117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases</span></div><div class="casAuthors">Chakrabarti, Alokta; Melesina, Jelena; Kolbinger, Fiona R.; Oehme, Ina; Senger, Johanna; Witt, Olaf; Sippl, Wolfgang; Jung, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1609-1634</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Histone deacetylase 8 (HDAC8), a unique class I zinc-dependent HDAC, is an emerging target in cancer and other diseases.  Its substrate repertoire extends beyond histones to many nonhistone proteins.  Besides being a deacetylase, HDAC8 also mediates signaling via scaffolding functions.  Aberrant expression or deregulated interactions with transcription factors are crit. in HDAC8-dependent cancers.  Many potent HDAC8-selective inhibitors with cellular activity and anticancer effects have been reported.  We present HDAC8 as a druggable target and discuss inhibitors of different chem. scaffolds with cellular effects.  Furthermore, we review HDAC8 activators that revert activity of mutant enzymes.  Isotype-selective HDAC8 targeting in patients with HDAC8-relevant cancers is challenging, however, is promising to avoid adverse side effects as obsd. with pan-HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAgIFjNGH66LVg90H21EOLACvtfcHk0lg7TaJ9oGluKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKhsrzF&md5=942984331e8f3c589b9257c17d2a9ec2</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2016-0117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2016-0117%26sid%3Dliteratum%253Aachs%26aulast%3DChakrabarti%26aufirst%3DA.%26aulast%3DMelesina%26aufirst%3DJ.%26aulast%3DKolbinger%26aufirst%3DF.%2BR.%26aulast%3DOehme%26aufirst%3DI.%26aulast%3DSenger%26aufirst%3DJ.%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DTargeting%2520histone%2520deacetylase%25208%2520as%2520a%2520therapeutic%2520approach%2520to%2520cancer%2520and%2520neurodegenerative%2520diseases%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2016%26volume%3D8%26spage%3D1609%26epage%3D1634%26doi%3D10.4155%2Ffmc-2016-0117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellenga, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraaije, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamps, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bont, E. S.</span></span> <span> </span><span class="NLM_article-title">The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia</span>. <i>Crit. Rev. Oncol. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2003.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.critrevonc.2003.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15157658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A280%3ADC%252BD2c3lvFCjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2004&pages=87-100&author=G.+Kleinauthor=E.+Vellengaauthor=M.+W.+Fraaijeauthor=W.+A.+Kampsauthor=E.+S.+de+Bont&title=The+possible+role+of+matrix+metalloproteinase+%28MMP%29-2+and+MMP-9+in+cancer%2C+e.g.+acute+leukemia&doi=10.1016%2Fj.critrevonc.2003.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia</span></div><div class="casAuthors">Klein G; Vellenga E; Fraaije M W; Kamps W A; de Bont E S J M</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-100</span>
        ISSN:<span class="NLM_cas:issn">1040-8428</span>.
    </div><div class="casAbstract">In the past decades, a lot of effort has been put in identifying the role of matrix metalloproteinases (MMPs) in cancer.  The main role of MMPs in angiogenesis, tumor growth and metastasis is degradation of extracellular matrix (ECM) and release and/or activation of growth factors through their degradative activity.  The degradative activity finally results in cancer progression.  MMP-inhibitors (MMPIs) have already been designed and tested, based on the degradative role of MMPs in cancer progression.  First clinical trials with MMPIs have been performed with disappointing results, showing that in order to use MMP-inhibition the mechanisms underlying MMP-expression in cancer have to be further elucidated.  This paper reviews the mechanisms of MMPs on molecular and cellular level and discusses the role for MMPs and MMP-inhibition in cancer with special focus on acute leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHKDAY2m_YX-vW160gIxP_fW6udTcc2eZeboxk7EIZ3bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3lvFCjuw%253D%253D&md5=19112f90fed85d9bd147c1475b1c3c58</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2003.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2003.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DKlein%26aufirst%3DG.%26aulast%3DVellenga%26aufirst%3DE.%26aulast%3DFraaije%26aufirst%3DM.%2BW.%26aulast%3DKamps%26aufirst%3DW.%2BA.%26aulast%3Dde%2BBont%26aufirst%3DE.%2BS.%26atitle%3DThe%2520possible%2520role%2520of%2520matrix%2520metalloproteinase%2520%2528MMP%2529-2%2520and%2520MMP-9%2520in%2520cancer%252C%2520e.g.%2520acute%2520leukemia%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2004%26volume%3D50%26spage%3D87%26epage%3D100%26doi%3D10.1016%2Fj.critrevonc.2003.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, S. H.</span></span> <span> </span><span class="NLM_article-title">HDAC inhibitors and RECK modulate endoplasmic reticulum stress in tumor cells</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">258</span>, <span class="refDoi"> DOI: 10.3390/ijms18020258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.3390%2Fijms18020258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsFCmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=258&author=Y.+Chenauthor=Y.+H.+Tsaiauthor=S.+H.+Tseng&title=HDAC+inhibitors+and+RECK+modulate+endoplasmic+reticulum+stress+in+tumor+cells&doi=10.3390%2Fijms18020258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitors and RECK modulate endoplasmic reticulum stress in tumor cells</span></div><div class="casAuthors">Chen, Yun; Tsai, Ya-Hui; Tseng, Sheng-Hong</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">258/1-258/9</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">In the tumor microenvironment hypoxia and nutrient deprived states can induce endoplasmic reticulum (ER) stress.  If ER stress is not relieved, the tumor cells may become apoptotic.  Therefore, targeting ER homeostasis is a potential strategy for cancer treatment.  Various chemotherapeutic agents including histone deacetylase (HDAC) inhibitors can induce ER stress to cause cell death in cancers.  Some HDAC inhibitors can prevent HDAC from binding to the specificity protein 1-binding site of the promoter of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) and up-regulate RECK expression.  Up-regulation of RECK expression by HDAC inhibitors has been obsd. in various cancer types.  RECK is a tumor and metastasis suppressor gene and is crit. for regulating tumor cell invasiveness and metastasis.  RECK also modulates ER stress via binding to and sequestering glucose-regulated protein 78 protein, so that the transmembrane sensors, such as protein kinase RNA-like ER kinase are released to activate eukaryotic translational initiation factor 2α phosphorylation and enhance ER stress.  Therefore, HDAC inhibitors may directly induce ER stress or indirectly induce this stress by up-regulating RECK in cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX53c53XHhHLVg90H21EOLACvtfcHk0lgfDtyd5fYhqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsFCmtbs%253D&md5=b6487b31b9fe8b9363a3443dc88c4523</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.3390%2Fijms18020258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18020258%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTsai%26aufirst%3DY.%2BH.%26aulast%3DTseng%26aufirst%3DS.%2BH.%26atitle%3DHDAC%2520inhibitors%2520and%2520RECK%2520modulate%2520endoplasmic%2520reticulum%2520stress%2520in%2520tumor%2520cells%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D258%26doi%3D10.3390%2Fijms18020258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, W.-C.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">3069</span>– <span class="NLM_lpage">3072</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=12810630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD3sXks1eitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=3069-3072&author=L.-T.+Liuauthor=H.-C.+Changauthor=L.-C.+Chiangauthor=W.-C.+Hung&title=Histone+deacetylase+inhibitor+up-regulates+RECK+to+inhibit+MMP-2+activation+and+cancer+cell+invasion"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitor Up-Regulates RECK to Inhibit MMP-2 Activation and Cancer Cell Invasion</span></div><div class="casAuthors">Liu, Li-Teh; Chang, Hui-Chiu; Chiang, Lien-Chai; Hung, Wen-Chun</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3069-3072</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors are known to exert antimetastatic and antiangiogenic activity in vitro and in vivo.  RECK is a membrane-anchored glycoprotein that neg. regulates matrix metalloproteinases (MMPs) and inhibits tumor metastasis and angiogenesis.  In this study, we test the possibility that HDAC inhibitor may increase RECK expression to inhibit MMP activation and cancer cell invasion.  Our results showed that trichostatin A (TSA) up-regulated RECK via transcriptional activation in CL-1 human lung cancer cells.  Flow cytometric anal. demonstrated that RECK protein on cell surface was increased after treatment of TSA.  Moreover, up-regulation of RECK expression by TSA attenuated MMP-2 activity.  To explore whether HDAC inhibitor-induced inhibition of MMP-2 activation is indeed mediated via RECK, we used small interference RNA (siRNA) to block RECK expression and found that inhibition of RECK by siRNA abolished the inhibitory effect of TSA on MMP-2 activation.  In addn., TSA suppressed the invasive ability of CL-1 cells.  Taken together, this study reveals a novel mechanism by which HDAC inhibitors suppress tumor invasion and provides a new strategy for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBPNbfE-AnIrVg90H21EOLACvtfcHk0lgfDtyd5fYhqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXks1eitLk%253D&md5=92b3c13b7eaa1f61d53f5345e2f1f7da</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.-T.%26aulast%3DChang%26aufirst%3DH.-C.%26aulast%3DChiang%26aufirst%3DL.-C.%26aulast%3DHung%26aufirst%3DW.-C.%26atitle%3DHistone%2520deacetylase%2520inhibitor%2520up-regulates%2520RECK%2520to%2520inhibit%2520MMP-2%2520activation%2520and%2520cancer%2520cell%2520invasion%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D3069%26epage%3D3072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takemoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuramae, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, J.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriuchi, T.</span></span> <span> </span><span class="NLM_article-title">Low expression of reversion-inducing cysteine-rich protein with kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">376</span>– <span class="NLM_lpage">383</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2007.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.lungcan.2007.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=17714826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A280%3ADC%252BD2sjmtVanug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2007&pages=376-383&author=N.+Takemotoauthor=M.+Tadaauthor=Y.+Hidaauthor=T.+Asanoauthor=S.+Chengauthor=T.+Kuramaeauthor=J.-I.+Hamadaauthor=M.+Miyamotoauthor=S.+Kondoauthor=T.+Moriuchi&title=Low+expression+of+reversion-inducing+cysteine-rich+protein+with+kazal+motifs+%28RECK%29+indicates+a+shorter+survival+after+resection+in+patients+with+adenocarcinoma+of+the+lung&doi=10.1016%2Fj.lungcan.2007.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Low expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung</span></div><div class="casAuthors">Takemoto Norihiro; Tada Mitsuhiro; Hida Yasuhiro; Asano Toshimichi; Cheng Shaoqiang; Kuramae Tarou; Hamada Jun-Ichi; Miyamoto Masaki; Kondo Satoshi; Moriuchi Tetsuya</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">376-83</span>
        ISSN:<span class="NLM_cas:issn">0169-5002</span>.
    </div><div class="casAbstract">It has been reported that an endogenous matrix metalloproteinase (MMP) inhibitor, reversion-inducing cysteine-rich protein with Kazal motifs (RECK), is able to inhibit tumour angiogenesis, invasion, and metastasis through inhibition of MMP-2, MMP-9, and membrane type-1 (MT1)-MMP (MMP-14) secretion and activity.  In this study, using quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR), we have analysed RECK expression levels in resected non-small-cell lung cancer (NSCLC) tissue and compared these data with the clinicopathological features of these patients to investigate the role of RECK in NSCLC.  We have also analysed the expression of MMP-2, MMP-9, and MMP-14 and compared the data with those for RECK expression.  Tissue samples of primary lung cancers were obtained from a total of 83 patients [46 with adenocarcinomas (ADC) and 37 with squamous cell carcinomas (SCC)] who underwent curative resection.  The samples were taken from 83 tumours and 20 matched normal lung tissue samples as controls.  Expressions of RECK in ADC and SCC were significantly lower than in the control.  In ADC tissue, the expression of RECK was higher in stage IA than in stage IB-IIIA.  There was no such a correlation in SCC.  In ADC, univariate analysis for relapse-free survival using Cox regression analysis identified low RECK expression (p=0.036), low MMP-14 expression (p=0.038), and tumour T2 (p=0.034) as significant negative prognostic predictors.  However, in SCC, none of the clinicopathological factors assessed, including RECK expression, had prognostic value.  In conclusion, our study suggests that suppression of RECK expression is involved in the progression of ADC of the lung and that RECK expression in resected ADC of the lung is a favorable predictor of patients' prognosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT1wVUn54DMxEcLvDNbOD4DfW6udTcc2eZWHi9O7XEQqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjmtVanug%253D%253D&md5=f2943e51bd570acc3037d692f05c3a4b</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2007.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2007.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DTakemoto%26aufirst%3DN.%26aulast%3DTada%26aufirst%3DM.%26aulast%3DHida%26aufirst%3DY.%26aulast%3DAsano%26aufirst%3DT.%26aulast%3DCheng%26aufirst%3DS.%26aulast%3DKuramae%26aufirst%3DT.%26aulast%3DHamada%26aufirst%3DJ.-I.%26aulast%3DMiyamoto%26aufirst%3DM.%26aulast%3DKondo%26aufirst%3DS.%26aulast%3DMoriuchi%26aufirst%3DT.%26atitle%3DLow%2520expression%2520of%2520reversion-inducing%2520cysteine-rich%2520protein%2520with%2520kazal%2520motifs%2520%2528RECK%2529%2520indicates%2520a%2520shorter%2520survival%2520after%2520resection%2520in%2520patients%2520with%2520adenocarcinoma%2520of%2520the%2520lung%26jtitle%3DLung%2520Cancer%26date%3D2007%26volume%3D58%26spage%3D376%26epage%3D383%26doi%3D10.1016%2Fj.lungcan.2007.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span> <span> </span><span class="NLM_article-title">Expression of RECK and MMP-2 in salivary adenoid cystic carcinoma: correlation with tumor progression and patient prognosis</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1549</span>– <span class="NLM_lpage">1555</span>, <span class="refDoi"> DOI: 10.3892/ol.2014.1906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.3892%2Fol.2014.1906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=24765174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1egtbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=1549-1555&author=X.+Zhouauthor=S.+Huangauthor=L.+Jiangauthor=S.+Zhangauthor=W.+Liauthor=Z.+Chenauthor=D.+Zhang&title=Expression+of+RECK+and+MMP-2+in+salivary+adenoid+cystic+carcinoma%3A+correlation+with+tumor+progression+and+patient+prognosis&doi=10.3892%2Fol.2014.1906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of RECK and MMP-2 in salivary adenoid cystic carcinoma: correlation with tumor progression and patient prognosis</span></div><div class="casAuthors">Zhou, Xiaoqing; Huang, Shengyun; Jiang, Licheng; Zhang, Shizhou; Li, Wengang; Chen, Zhanwei; Zhang, Dongsheng</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1549-1555</span>CODEN:
                <span class="NLM_cas:coden">OLNEB5</span>;
        ISSN:<span class="NLM_cas:issn">1792-1074</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Reversion-inducing cysteine-rich protein with Kazal motifs (RECK), a glycosylphosphatidylinositol-anchored glycoprotein, inhibits the enzymic activities of certain matrix metalloproteinases (MMPs).  RECK has been studied in numerous human tumors, but the expression of RECK in salivary adenoid cystic carcinoma (SACC), and its correlation with patient prognosis, has never been investigated thus far.  In the present study, the expression of RECK and MMP-2 was evaluated in two ACC cell lines and in 83 patients with SACC.  The results of quant. polymerase chain reaction and western blot anal. revealed that the ACC-2 and ACC-M cell lines expressed RECK and MMP-2 mRNA and protein.  The immunohistochem. staining in the patients demonstrated that pos. expression of RECK and MMP-2 was obsd. in 21/83 (25.3%) and 69/83 (83.1%) cases, resp., and that RECK expression was significantly assocd. with the tumor-node-metastasis stage, histol. grade and perineural invasion of patients with SACC (P<0.05).  Furthermore, there was a significant assocn. between the pos. expression of RECK and that of MMP-2 (P<0.0001).  Univariate and multivariate analyses confirmed that a lack of RECK expression was an independent and significant factor for the prediction of a poor prognosis.  In conclusion, RECK is a promising prognostic marker and potential therapeutic agent in SACC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEsWU5CQRRI7Vg90H21EOLACvtfcHk0lhJ9qGHlrmPpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1egtbjJ&md5=a5e7ff027c7fcbc4a52ccfa9c1ee5f61</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.3892%2Fol.2014.1906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2014.1906%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DD.%26atitle%3DExpression%2520of%2520RECK%2520and%2520MMP-2%2520in%2520salivary%2520adenoid%2520cystic%2520carcinoma%253A%2520correlation%2520with%2520tumor%2520progression%2520and%2520patient%2520prognosis%26jtitle%3DOncol.%2520Lett.%26date%3D2014%26volume%3D7%26spage%3D1549%26epage%3D1555%26doi%3D10.3892%2Fol.2014.1906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, D.</span></span> <span> </span><span class="NLM_article-title">Low expression of RECK indicates a shorter survival for patients with invasive breast cancer</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">1084</span>– <span class="NLM_lpage">1089</span>, <span class="refDoi"> DOI: 10.1111/j.1349-7006.2012.02265.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1111%2Fj.1349-7006.2012.02265.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=22404079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38XnslKhsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2012&pages=1084-1089&author=Y.+Zhangauthor=S.+Chengauthor=G.+Zhangauthor=W.+Maauthor=Y.+Liuauthor=R.+Zhaoauthor=Q.+Zhangauthor=D.+Pang&title=Low+expression+of+RECK+indicates+a+shorter+survival+for+patients+with+invasive+breast+cancer&doi=10.1111%2Fj.1349-7006.2012.02265.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Low expression of RECK indicates a shorter survival for patients with invasive breast cancer</span></div><div class="casAuthors">Zhang, Yue; Cheng, Shaoqiang; Zhang, Guoqiang; Ma, Wenjie; Liu, Yang; Zhao, Rui; Zhang, Qingyuan; Pang, Da</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1084-1089</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Expression cloning was used to initially isolate the reversion-inducing cysteine-rich protein with Kazal motifs (RECK) gene as a suppressor of transformation.  The gene was found to encode a membrane-anchored regulator of MMPs.  Exptl. studies showed that RECK can suppress tumor invasion, metastasis, and angiogenesis.  However, the clin. impact of RECK remains unclear.  To assess the clin. significance of RECK expression in invasive breast cancer, a total of 119 patients with invasive breast cancer were retrospectively examd.  Expression of RECK in tumor tissues was assessed by immunohistochem. staining.  A significant correlation between RECK expression and 5-yr survival rate was documented.  The 5-yr survival rate for patients with strong RECK expression was significantly higher than that for patients with weakly expressing tumors.  Univariate and multivariate analyses confirmed that reduced RECK expression was an independent and significant factor in predicting a poor prognosis.  In conclusion, RECK expression is a significant prognostic factor correlated with long-term survival for patients with invasive breast cancer.  RECK expression is therefore a potentially useful prognostic marker for breast cancer. (Cancer Sci 2012; 103: 1084-1089).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodDVql2M-ImrVg90H21EOLACvtfcHk0lhJ9qGHlrmPpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnslKhsLw%253D&md5=6900ce8bd6a7dbb003ceb4d0471cb918</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2012.02265.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2012.02265.x%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DPang%26aufirst%3DD.%26atitle%3DLow%2520expression%2520of%2520RECK%2520indicates%2520a%2520shorter%2520survival%2520for%2520patients%2520with%2520invasive%2520breast%2520cancer%26jtitle%3DCancer%2520Sci.%26date%3D2012%26volume%3D103%26spage%3D1084%26epage%3D1089%26doi%3D10.1111%2Fj.1349-7006.2012.02265.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. M.</span></span> <span> </span><span class="NLM_article-title">Spermidine inhibits MMP-2 via modulation of histone acetyltransferase and histone deacetylase in HDFs</span>. <i>Int. J. Biol. Macromol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1003</span>– <span class="NLM_lpage">1007</span>, <span class="refDoi"> DOI: 10.1016/j.ijbiomac.2012.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.ijbiomac.2012.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=22925630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFCltL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=1003-1007&author=I.+H.+Parkauthor=M.+M.+Kim&title=Spermidine+inhibits+MMP-2+via+modulation+of+histone+acetyltransferase+and+histone+deacetylase+in+HDFs&doi=10.1016%2Fj.ijbiomac.2012.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Spermidine inhibits MMP-2 via modulation of histone acetyltransferase and histone deacetylase in HDFs</span></div><div class="casAuthors">Park, In-Hwan; Kim, Moon-Moo</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biological Macromolecules</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1003-1007</span>CODEN:
                <span class="NLM_cas:coden">IJBMDR</span>;
        ISSN:<span class="NLM_cas:issn">0141-8130</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In recent years, aging has been reported to be regulated by HAT.  In this study, the inhibitory effects of spermidine on the matrix metalloproteinase-2 (MMP-2) activity and expression were investigated in human dermal fibroblasts (HDFs).  It was obsd. that spermidine inhibits MMP-2 activity and expression.  In addn., the expression levels of histone acetyltransferase (HAT), phospho-extracellular-signal related kinase (p-ERK), phospho-c-jun N-terminal kinase (p-JNK), and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) are decreased in the presence of spermidine.  In contrast, the expression levels of histone deacetylase 1 (HDAC1), sirtuin 1 (SIRT1), phospho-p38 (p-p38) are increased by spermidine.  In conclusion, our results suggest that spermidine could have a therapeutic potential in inhibition of metastasis through the inhibitory effects on activity and expression of MMP-2 via regulation of HAT and HDAC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC-HeX-aJ4WbVg90H21EOLACvtfcHk0lhD_a7NSNoc4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFCltL3F&md5=8211e2e91a30222797064c99eb1d18f9</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1016%2Fj.ijbiomac.2012.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijbiomac.2012.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DI.%2BH.%26aulast%3DKim%26aufirst%3DM.%2BM.%26atitle%3DSpermidine%2520inhibits%2520MMP-2%2520via%2520modulation%2520of%2520histone%2520acetyltransferase%2520and%2520histone%2520deacetylase%2520in%2520HDFs%26jtitle%3DInt.%2520J.%2520Biol.%2520Macromol.%26date%3D2012%26volume%3D51%26spage%3D1003%26epage%3D1007%26doi%3D10.1016%2Fj.ijbiomac.2012.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, W. C.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">3069</span>– <span class="NLM_lpage">3072</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=12810630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD3sXks1eitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=3069-3072&author=L.+T.+Liuauthor=H.+C.+Changauthor=L.+C.+Chiangauthor=W.+C.+Hung&title=Histone+deacetylase+inhibitor+up-regulates+RECK+to+inhibit+MMP-2+activation+and+cancer+cell+invasion"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitor Up-Regulates RECK to Inhibit MMP-2 Activation and Cancer Cell Invasion</span></div><div class="casAuthors">Liu, Li-Teh; Chang, Hui-Chiu; Chiang, Lien-Chai; Hung, Wen-Chun</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3069-3072</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors are known to exert antimetastatic and antiangiogenic activity in vitro and in vivo.  RECK is a membrane-anchored glycoprotein that neg. regulates matrix metalloproteinases (MMPs) and inhibits tumor metastasis and angiogenesis.  In this study, we test the possibility that HDAC inhibitor may increase RECK expression to inhibit MMP activation and cancer cell invasion.  Our results showed that trichostatin A (TSA) up-regulated RECK via transcriptional activation in CL-1 human lung cancer cells.  Flow cytometric anal. demonstrated that RECK protein on cell surface was increased after treatment of TSA.  Moreover, up-regulation of RECK expression by TSA attenuated MMP-2 activity.  To explore whether HDAC inhibitor-induced inhibition of MMP-2 activation is indeed mediated via RECK, we used small interference RNA (siRNA) to block RECK expression and found that inhibition of RECK by siRNA abolished the inhibitory effect of TSA on MMP-2 activation.  In addn., TSA suppressed the invasive ability of CL-1 cells.  Taken together, this study reveals a novel mechanism by which HDAC inhibitors suppress tumor invasion and provides a new strategy for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBPNbfE-AnIrVg90H21EOLACvtfcHk0lh3j_C8xiEMRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXks1eitLk%253D&md5=92b3c13b7eaa1f61d53f5345e2f1f7da</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%2BT.%26aulast%3DChang%26aufirst%3DH.%2BC.%26aulast%3DChiang%26aufirst%3DL.%2BC.%26aulast%3DHung%26aufirst%3DW.%2BC.%26atitle%3DHistone%2520deacetylase%2520inhibitor%2520up-regulates%2520RECK%2520to%2520inhibit%2520MMP-2%2520activation%2520and%2520cancer%2520cell%2520invasion%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D3069%26epage%3D3072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span> <span> </span><span class="NLM_article-title">Expression of RECK and MMP-2 in salivary adenoid cystic carcinoma: correlation with tumor progression and patient prognosis</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1549</span>– <span class="NLM_lpage">1555</span>, <span class="refDoi"> DOI: 10.3892/ol.2014.1906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.3892%2Fol.2014.1906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=24765174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1egtbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=1549-1555&author=X.+Zhouauthor=S.+Huangauthor=L.+Jiangauthor=S.+Zhangauthor=W.+Liauthor=Z.+Chenauthor=D.+Zhang&title=Expression+of+RECK+and+MMP-2+in+salivary+adenoid+cystic+carcinoma%3A+correlation+with+tumor+progression+and+patient+prognosis&doi=10.3892%2Fol.2014.1906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of RECK and MMP-2 in salivary adenoid cystic carcinoma: correlation with tumor progression and patient prognosis</span></div><div class="casAuthors">Zhou, Xiaoqing; Huang, Shengyun; Jiang, Licheng; Zhang, Shizhou; Li, Wengang; Chen, Zhanwei; Zhang, Dongsheng</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1549-1555</span>CODEN:
                <span class="NLM_cas:coden">OLNEB5</span>;
        ISSN:<span class="NLM_cas:issn">1792-1074</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Reversion-inducing cysteine-rich protein with Kazal motifs (RECK), a glycosylphosphatidylinositol-anchored glycoprotein, inhibits the enzymic activities of certain matrix metalloproteinases (MMPs).  RECK has been studied in numerous human tumors, but the expression of RECK in salivary adenoid cystic carcinoma (SACC), and its correlation with patient prognosis, has never been investigated thus far.  In the present study, the expression of RECK and MMP-2 was evaluated in two ACC cell lines and in 83 patients with SACC.  The results of quant. polymerase chain reaction and western blot anal. revealed that the ACC-2 and ACC-M cell lines expressed RECK and MMP-2 mRNA and protein.  The immunohistochem. staining in the patients demonstrated that pos. expression of RECK and MMP-2 was obsd. in 21/83 (25.3%) and 69/83 (83.1%) cases, resp., and that RECK expression was significantly assocd. with the tumor-node-metastasis stage, histol. grade and perineural invasion of patients with SACC (P<0.05).  Furthermore, there was a significant assocn. between the pos. expression of RECK and that of MMP-2 (P<0.0001).  Univariate and multivariate analyses confirmed that a lack of RECK expression was an independent and significant factor for the prediction of a poor prognosis.  In conclusion, RECK is a promising prognostic marker and potential therapeutic agent in SACC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEsWU5CQRRI7Vg90H21EOLACvtfcHk0liwIONwQNdE7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1egtbjJ&md5=a5e7ff027c7fcbc4a52ccfa9c1ee5f61</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.3892%2Fol.2014.1906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2014.1906%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DD.%26atitle%3DExpression%2520of%2520RECK%2520and%2520MMP-2%2520in%2520salivary%2520adenoid%2520cystic%2520carcinoma%253A%2520correlation%2520with%2520tumor%2520progression%2520and%2520patient%2520prognosis%26jtitle%3DOncol.%2520Lett.%26date%3D2014%26volume%3D7%26spage%3D1549%26epage%3D1555%26doi%3D10.3892%2Fol.2014.1906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karthik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varunkumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravikumar, V.</span></span> <span> </span><span class="NLM_article-title">Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">334</span>, <span class="refDoi"> DOI: 10.1016/j.biopha.2014.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.biopha.2014.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=24485799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Kiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2014&pages=327-334&author=S.+Karthikauthor=R.+Sankarauthor=K.+Varunkumarauthor=V.+Ravikumar&title=Romidepsin+induces+cell+cycle+arrest%2C+apoptosis%2C+histone+hyperacetylation+and+reduces+matrix+metalloproteinases+2+and+9+expression+in+bortezomib+sensitized+non-small+cell+lung+cancer+cells&doi=10.1016%2Fj.biopha.2014.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells</span></div><div class="casAuthors">Karthik, Selvaraju; Sankar, Renu; Varunkumar, Krishnamoorthy; Ravikumar, Vilwanathan</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">327-334</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors have been proven to be effective therapeutic agents to kill cancer cells through inhibiting HDAC activity or altering the structure of chromatin.  We recently reported that chemotherapy by the HDAC inhibitor, romidepsin activates the anti- apoptotic transcription factor NF-κB in A549 non-small cell lung cancer (NSCLC) cells and fails to induce significant levels of apoptosis.  We also demonstrated that NF-κB inhibition with proteasome inhibitor bortezomib enhanced HDAC inhibitor induced mitochondrial injury and sensitize A549 NSCLC cells to apoptosis through the generation of reactive oxygen species.  In this study, we investigate whether combined treatment with romidepsin and bortezomib would induce apoptosis in A549 NSCLC cells by activating cell cycle arrest, enhanced generation of p21 and p53, down-regulation of matrix metalloproteinases (MMPs) 2,9 also altering the acetylation status of histone proteins.  Our data show that combination of romidepsin and bortezomib caused cell cycle arrest at Sub G0-G1 transition, up-regulation of cell cycle protein p21 and tumor suppressor protein p53.  In addn., romidepsin down-regulated the expression of MMP-2,9 and hyperacetylation of histone H3 and H4 in bortezomib sensitized A549 NSCLC cells.  From this study we concluded that romidepsin and bortezomib cooperatively inhibit A549 NSCLC cell proliferation by altering the histone acetylation status, expression of cell cycle regulators and MMPs.  Romidepsin along with bortezomib might be an effective treatment approach for A549 NSCLC cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowFboPEMP8h7Vg90H21EOLACvtfcHk0lilnt66bnJL1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Kiuro%253D&md5=e061f1e42888b1a731ee5bf95e3ba803</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2014.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2014.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DKarthik%26aufirst%3DS.%26aulast%3DSankar%26aufirst%3DR.%26aulast%3DVarunkumar%26aufirst%3DK.%26aulast%3DRavikumar%26aufirst%3DV.%26atitle%3DRomidepsin%2520induces%2520cell%2520cycle%2520arrest%252C%2520apoptosis%252C%2520histone%2520hyperacetylation%2520and%2520reduces%2520matrix%2520metalloproteinases%25202%2520and%25209%2520expression%2520in%2520bortezomib%2520sensitized%2520non-small%2520cell%2520lung%2520cancer%2520cells%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2014%26volume%3D68%26spage%3D327%26epage%3D334%26doi%3D10.1016%2Fj.biopha.2014.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Hierarchical virtual screening of the dual MMP-2/HDAC-6 inhibitors from natural products based on pharmacophore models and molecular docking</span>. <i>J. Biomol. Struct. Dyn.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">649</span>– <span class="NLM_lpage">670</span>, <span class="refDoi"> DOI: 10.1080/07391102.2018.1434833</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1080%2F07391102.2018.1434833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=29380672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXislSjt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=649-670&author=Y.+Wangauthor=L.+Yangauthor=J.+Houauthor=Q.+Zouauthor=Q.+Gaoauthor=W.+Yaoauthor=Q.+Yaoauthor=J.+Zhang&title=Hierarchical+virtual+screening+of+the+dual+MMP-2%2FHDAC-6+inhibitors+from+natural+products+based+on+pharmacophore+models+and+molecular+docking&doi=10.1080%2F07391102.2018.1434833"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Hierarchical virtual screening of the dual MMP-2/HDAC-6 inhibitors from natural products based on pharmacophore models and molecular docking</span></div><div class="casAuthors">Wang, Yijun; Yang, Limei; Hou, Jiaying; Zou, Qing; Gao, Qi; Yao, Wenhui; Yao, Qizheng; Zhang, Ji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Structure and Dynamics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">649-670</span>CODEN:
                <span class="NLM_cas:coden">JBSDD6</span>;
        ISSN:<span class="NLM_cas:issn">0739-1102</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The dual-target inhibitors tend to improve the response rate in treating tumors, comparing with the single-target inhibitors.  Matrix metalloproteinase-2 (MMP-2) and histone deacetylase-6 (HDAC-6) are attractive targets for cancer therapy.  In this study, the hierarchical virtual screening of dual MMP-2/HDAC-6 inhibitors from natural products is investigated.  The pharmacophore model of MMP-2 inhibitors is built based on ligands, but the pharmacophore model of HDAC-6 inhibitors is built based on the exptl. crystal structures of multiple receptor-ligand complexes.  The reliability of these two pharmacophore models is validated subsequently.  The hierarchical virtual screening, combining these two different pharmacophore models of MMP-2 and HDAC-6 inhibitors with mol. docking, is carried out to identify the dual MMP-2/HDAC-6 inhibitors from a database of natural products.  The four potential dual MMP-2/HDAC-6 inhibitors of natural products, STOCK1 N-46177, STOCK1 N-52245, STOCK1 N-55477, and STOCK1 N-69706, are found.  The studies of binding modes show that the screened four natural products can simultaneously well bind with the MMP-2 and HDAC-6 active sites by different kinds of interactions, to inhibit the MMP-2 and HDAC-6 activities.  In addn., the ADMET properties of screened four natural products are assessed.  These found dual MMP-2/HDAC-6 inhibitors of natural products could serve as the lead compds. for designing the new dual MMP-2/HDAC-6 inhibitors having higher biol. activities by carrying out structural modifications and optimizations in the future studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj-OBmoj28F7Vg90H21EOLACvtfcHk0ljrohTSuG-zpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXislSjt7c%253D&md5=7fe92585a5c37b548ff3e569c851214f</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1080%2F07391102.2018.1434833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07391102.2018.1434833%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DQ.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DYao%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DHierarchical%2520virtual%2520screening%2520of%2520the%2520dual%2520MMP-2%252FHDAC-6%2520inhibitors%2520from%2520natural%2520products%2520based%2520on%2520pharmacophore%2520models%2520and%2520molecular%2520docking%26jtitle%3DJ.%2520Biomol.%2520Struct.%2520Dyn.%26date%3D2019%26volume%3D37%26spage%3D649%26epage%3D670%26doi%3D10.1080%2F07391102.2018.1434833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, A. J.</span></span> <span> </span><span class="NLM_article-title">The regulation of multiple p53 stress responses is mediated through MDM2</span>. <i>Genes Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1177/1947601912454734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1177%2F1947601912454734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=23150753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsVSlsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=199-208&author=W.+Huauthor=Z.+Fengauthor=A.+J.+Levine&title=The+regulation+of+multiple+p53+stress+responses+is+mediated+through+MDM2&doi=10.1177%2F1947601912454734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">The regulation of multiple p53 stress responses is mediated through MDM2</span></div><div class="casAuthors">Hu, Wenwei; Feng, Zhaohui; Levine, Arnold J.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">199-208, 10</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  The MDM2 oncogene is a key neg. regulator of the p53 tumor suppressor protein.  MDM2 and p53 form an autoregulatory feedback loop to tightly control the proper cellular responses to various stress signals in order to prevent mutations and tumor formation.  The levels and function of the MDM2 protein, an E3 ubiquitin ligase, are regulated by a wide variety of extracellular and intracellular stress signals through distinct signaling pathways and mechanisms.  These signals regulate the E3 ubiquitin ligase activity of MDM2, the ability of MDM2 to interact with p53 and a no. of other proteins, and the cellular localization of MDM2, which in turn impact significantly upon p53 function.  This review provides an overview of the regulation of MDM2 activities by the signals and factors that regulate the MDM2 protein, including genotoxic stress signals, oncogenic activation, cell cycle transition, ribosomal stress, chronic stress, neurohormones, and microRNAs.  Disruption of the proper regulation of the MDM2-p53 neg. feedback loop impacts significantly upon the frequency of tumorigenesis in a host.  A better understanding of the complex regulation of MDM2 and its impact upon p53 function in cells under different conditions will help to develop novel and more effective strategies for cancer therapy and prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS47PnIALZFrVg90H21EOLACvtfcHk0lioD_ze0CQbiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsVSlsL4%253D&md5=118063f81d7ae8eb68189bf3a4ddce30</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1177%2F1947601912454734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601912454734%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DW.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DLevine%26aufirst%3DA.%2BJ.%26atitle%3DThe%2520regulation%2520of%2520multiple%2520p53%2520stress%2520responses%2520is%2520mediated%2520through%2520MDM2%26jtitle%3DGenes%2520Cancer%26date%3D2012%26volume%3D3%26spage%3D199%26epage%3D208%26doi%3D10.1177%2F1947601912454734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Small molecules simultaneously inhibiting p53-murine double minute 2 (MDM2) interaction and histone deacetylases (HDACs): discovery of novel multitargeting antitumor agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7245</span>– <span class="NLM_lpage">7260</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00664</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00664" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlykur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7245-7260&author=S.+Heauthor=G.+Dongauthor=S.+Wuauthor=K.+Fangauthor=Z.+Miaoauthor=W.+Wangauthor=C.+Sheng&title=Small+molecules+simultaneously+inhibiting+p53-murine+double+minute+2+%28MDM2%29+interaction+and+histone+deacetylases+%28HDACs%29%3A+discovery+of+novel+multitargeting+antitumor+agents&doi=10.1021%2Facs.jmedchem.8b00664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents</span></div><div class="casAuthors">He, Shipeng; Dong, Guoqiang; Wu, Shanchao; Fang, Kun; Miao, Zhenyuan; Wang, Wei; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7245-7260</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">P53-Murine double minute 2 (MDM2) interaction and histone deacetylases (HDACs) are important targets in antitumor drug development.  Inspired by the synergistic effects between MDM2 and HDACs, the first MDM2/HDACs dual inhibitors were identified, which showed excellent activities against both targets.  In particular, compd. 14d was proven to be a potent and orally active MDM2/HDAC dual inhibitor, whose antitumor mechanisms were validated in cancer cells.  Compd. 14d showed excellent in vivo antitumor potency in the A549 xenograft model, providing a promising lead compd. for the development of novel antitumor agents.  Also, this proof-of-concept study offers a novel and efficient strategy for multitargeting antitumor drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx94Uvm3pP8bVg90H21EOLACvtfcHk0lioD_ze0CQbiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlykur3L&md5=68871e41ecb786e135b01742e59eec85</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00664%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DFang%26aufirst%3DK.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DSmall%2520molecules%2520simultaneously%2520inhibiting%2520p53-murine%2520double%2520minute%25202%2520%2528MDM2%2529%2520interaction%2520and%2520histone%2520deacetylases%2520%2528HDACs%2529%253A%2520discovery%2520of%2520novel%2520multitargeting%2520antitumor%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7245%26epage%3D7260%26doi%3D10.1021%2Facs.jmedchem.8b00664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haaland, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forthun, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huseby, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gausdal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knappskog, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Micklem, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorens, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruserud, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gjertsen, B. T.</span></span> <span> </span><span class="NLM_article-title">Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">910</span>– <span class="NLM_lpage">917</span>, <span class="refDoi"> DOI: 10.1038/leu.2011.315</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fleu.2011.315" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=22064349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvFemsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=910-917&author=E.+McCormackauthor=I.+Haalandauthor=G.+Venasauthor=R.+B.+Forthunauthor=S.+Husebyauthor=G.+Gausdalauthor=S.+Knappskogauthor=D.+R.+Micklemauthor=J.+B.+Lorensauthor=O.+Bruserudauthor=B.+T.+Gjertsen&title=Synergistic+induction+of+p53+mediated+apoptosis+by+valproic+acid+and+nutlin-3+in+acute+myeloid+leukemia&doi=10.1038%2Fleu.2011.315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia</span></div><div class="casAuthors">McCormack, E.; Haaland, I.; Venas, G.; Forthun, R. B.; Huseby, S.; Gausdal, G.; Knappskog, S.; Micklem, D. R.; Lorens, J. B.; Bruserud, O.; Gjertsen, B. T.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">910-917</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although TP53 mutations are rare in acute myeloid leukemia (AML), wild type p53 function is habitually annulled through overexpression of MDM2 or through various mechanisms including epigenetic silencing by histone deacetylases (HDACs).  We hypothesized that co-inhibition of MDM2 and HDACs, with nutlin-3 and valproic acid (VPA) would additively inhibit growth in leukemic cells expressing wild type TP53 and induce p53-mediated apoptosis.  In vitro studies with the combination demonstrated synergistic induction of apoptosis in AML cell lines and patient cells.  Nutlin-3 and VPA co-treatment resulted in massive induction of p53, acetylated p53 and p53 target genes in comparison with either agent alone, followed by p53 dependent cell death with autophagic features.  In primary AML cells, inhibition of proliferation by the combination therapy correlated with the CD34 expression level of AML blasts.  To evaluate the combination in vivo, we developed an orthotopic, NOD/SCID IL2rγnull xenograft model of MOLM-13 (AML FAB M5a; wild type TP53) expressing firefly luciferase.  Survival anal. and bioluminescent imaging demonstrated the superior in vivo efficacy of the dual inhibition of MDM2 and HDAC in comparison with controls.  Our results suggest the concomitant targeting of MDM2-p53 and HDAC inhibition, may be an effective therapeutic strategy for the treatment of AML.  Leukemia (2012) 26, 910-917; doi:10.1038/leu.2011.315; published online 8 Nov. 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqDcdeQ4hD6rVg90H21EOLACvtfcHk0lh4aOc-q3Tytw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvFemsbg%253D&md5=0e9f5076fc4458681edaa04d6231a28f</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1038%2Fleu.2011.315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2011.315%26sid%3Dliteratum%253Aachs%26aulast%3DMcCormack%26aufirst%3DE.%26aulast%3DHaaland%26aufirst%3DI.%26aulast%3DVenas%26aufirst%3DG.%26aulast%3DForthun%26aufirst%3DR.%2BB.%26aulast%3DHuseby%26aufirst%3DS.%26aulast%3DGausdal%26aufirst%3DG.%26aulast%3DKnappskog%26aufirst%3DS.%26aulast%3DMicklem%26aufirst%3DD.%2BR.%26aulast%3DLorens%26aufirst%3DJ.%2BB.%26aulast%3DBruserud%26aufirst%3DO.%26aulast%3DGjertsen%26aufirst%3DB.%2BT.%26atitle%3DSynergistic%2520induction%2520of%2520p53%2520mediated%2520apoptosis%2520by%2520valproic%2520acid%2520and%2520nutlin-3%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26spage%3D910%26epage%3D917%26doi%3D10.1038%2Fleu.2011.315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of peptide boronate derivatives as histone deacetylase (HDAC) and proteasome dual inhibitors for overcoming bortezomib resistance of multiple myeloma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b02161</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b02161" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=Y.+Zhouauthor=X.+Liuauthor=J.+Xueauthor=L.+Liuauthor=T.+Liangauthor=W.+Liauthor=X.+Yangauthor=X.+Houauthor=H.+Fang&title=Discovery+of+peptide+boronate+derivatives+as+histone+deacetylase+%28HDAC%29+and+proteasome+dual+inhibitors+for+overcoming+bortezomib+resistance+of+multiple+myeloma&doi=10.1021%2Facs.jmedchem.9b02161"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b02161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b02161%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DXue%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520peptide%2520boronate%2520derivatives%2520as%2520histone%2520deacetylase%2520%2528HDAC%2529%2520and%2520proteasome%2520dual%2520inhibitors%2520for%2520overcoming%2520bortezomib%2520resistance%2520of%2520multiple%2520myeloma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26doi%3D10.1021%2Facs.jmedchem.9b02161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romanelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stazi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fioravanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwergel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Bello, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomella, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battistelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strippoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripodi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">del Bufalo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rota, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trisciuoglio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valente, S.</span></span> <span> </span><span class="NLM_article-title">Design of first-in-class dual EZH2/HDAC inhibitor: biochemical activity and biological evaluation in cancer cells</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00014</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=A.+Romanelliauthor=G.+Staziauthor=R.+Fioravantiauthor=C.+Zwergelauthor=E.+Di+Belloauthor=S.+Pomellaauthor=C.+Perroneauthor=C.+Battistelliauthor=R.+Strippoliauthor=M.+Tripodiauthor=D.+del+Bufaloauthor=R.+Rotaauthor=D.+Trisciuoglioauthor=A.+Maiauthor=S.+Valente&title=Design+of+first-in-class+dual+EZH2%2FHDAC+inhibitor%3A+biochemical+activity+and+biological+evaluation+in+cancer+cells&doi=10.1021%2Facsmedchemlett.0c00014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00014%26sid%3Dliteratum%253Aachs%26aulast%3DRomanelli%26aufirst%3DA.%26aulast%3DStazi%26aufirst%3DG.%26aulast%3DFioravanti%26aufirst%3DR.%26aulast%3DZwergel%26aufirst%3DC.%26aulast%3DDi%2BBello%26aufirst%3DE.%26aulast%3DPomella%26aufirst%3DS.%26aulast%3DPerrone%26aufirst%3DC.%26aulast%3DBattistelli%26aufirst%3DC.%26aulast%3DStrippoli%26aufirst%3DR.%26aulast%3DTripodi%26aufirst%3DM.%26aulast%3Ddel%2BBufalo%26aufirst%3DD.%26aulast%3DRota%26aufirst%3DR.%26aulast%3DTrisciuoglio%26aufirst%3DD.%26aulast%3DMai%26aufirst%3DA.%26aulast%3DValente%26aufirst%3DS.%26atitle%3DDesign%2520of%2520first-in-class%2520dual%2520EZH2%252FHDAC%2520inhibitor%253A%2520biochemical%2520activity%2520and%2520biological%2520evaluation%2520in%2520cancer%2520cells%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26doi%3D10.1021%2Facsmedchemlett.0c00014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.ejmech.2015.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25805446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVWis7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2015&pages=127-135&author=X.+Zhangauthor=Y.+Kongauthor=J.+Zhangauthor=M.+Suauthor=Y.+Zhouauthor=Y.+Zangauthor=J.+Liauthor=Y.+Chenauthor=Y.+Fangauthor=X.+Zhangauthor=W.+Lu&title=Design%2C+synthesis+and+biological+evaluation+of+colchicine+derivatives+as+novel+tubulin+and+histone+deacetylase+dual+inhibitors&doi=10.1016%2Fj.ejmech.2015.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors</span></div><div class="casAuthors">Zhang, Xuan; Kong, Yannan; Zhang, Jie; Su, Mingbo; Zhou, Yubo; Zang, Yi; Li, Jia; Chen, Yi; Fang, Yanfen; Zhang, Xiongwen; Lu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">127-135</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A new class of colchicine derivs. were designed and synthesized as tubulin-HDAC dual inhibitors.  Biol. evaluations of these hybrids included the inhibitory activity of HDAC, tubulin polymn. anal., in vitro cell cycle anal. in HCT-116 cells and cytotoxicity against different cancer cell lines.  Hybrid I behaved as potent HDAC-tubulin dual inhibitor and showed comparable cytotoxicity with colchicine.  Compd. II exhibited powerful tubulin inhibitory activity, moderate anti-HDAC activity and the most potent cytotoxicity (IC50 = 2-105 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6P07-g6WBfbVg90H21EOLACvtfcHk0lh4aOc-q3Tytw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVWis7o%253D&md5=e532028d8f03179da99f533eefa62568</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DKong%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DW.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520colchicine%2520derivatives%2520as%2520novel%2520tubulin%2520and%2520histone%2520deacetylase%2520dual%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D95%26spage%3D127%26epage%3D135%26doi%3D10.1016%2Fj.ejmech.2015.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Dual NAMPT/HDAC inhibitors as a new strategy for multitargeting antitumor drug discovery</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00414</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00414" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOqsrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=34-38&author=W.+Chenauthor=G.+Dongauthor=Y.+Wuauthor=W.+Zhangauthor=C.+Miaoauthor=C.+Sheng&title=Dual+NAMPT%2FHDAC+inhibitors+as+a+new+strategy+for+multitargeting+antitumor+drug+discovery&doi=10.1021%2Facsmedchemlett.7b00414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery</span></div><div class="casAuthors">Chen, Wei; Dong, Guoqiang; Wu, Ying; Zhang, Wannian; Miao, Chaoyu; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-38</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel dual nicotinamide phosphoribosyltransferase (NAMPT) and histone deacetylase (HDAC) inhibitors were designed by a pharmacophore fusion approach.  The thiazolocarboxamide inhibitors were highly active for both targets.  In particular, compd. 7f (NAMPT IC50 = 15 nM, HDAC1 IC50 = 2 nM) showed potent in vivo antitumor efficacy in the HCT116 xenograft model.  The study offers a new strategy for multi-target antitumor drug discovery by simultaneously acting on cancer metab. and epigenetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeCOjvPbhLxbVg90H21EOLACvtfcHk0ljS8c-QBO_qMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOqsrjJ&md5=72fc5750e9b6d3b1a0331f1f3a8a3f5c</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00414%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DW.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DMiao%26aufirst%3DC.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DDual%2520NAMPT%252FHDAC%2520inhibitors%2520as%2520a%2520new%2520strategy%2520for%2520multitargeting%2520antitumor%2520drug%2520discovery%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D34%26epage%3D38%26doi%3D10.1021%2Facsmedchemlett.7b00414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 1-(2-Aminophenyl)-3-arylurea derivatives as potential EphA2 and HDAC dual inhibitors</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">1136</span>– <span class="NLM_lpage">1141</span>, <span class="refDoi"> DOI: 10.1248/cpb.c16-00154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1248%2Fcpb.c16-00154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=27477652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFyru7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=1136-1141&author=Y.+Zhuauthor=T.+Ranauthor=X.+Chenauthor=J.+Niuauthor=S.+Zhaoauthor=T.+Luauthor=W.+Tang&title=Synthesis+and+biological+evaluation+of+1-%282-Aminophenyl%29-3-arylurea+derivatives+as+potential+EphA2+and+HDAC+dual+inhibitors&doi=10.1248%2Fcpb.c16-00154"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of 1-(2-aminophenyl)-3-arylurea derivatives as potential EphA2 and HDAC dual inhibitors</span></div><div class="casAuthors">Zhu, Yong; Ran, Ting; Chen, Xin; Niu, Jiaqi; Zhao, Shuang; Lu, Tao; Tang, Weifang</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1136-1141</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">A series of 1-(2-aminophenyl)-3-arylurea novel derivs. were synthesized and evaluated against Ephrin type-A receptor 2 (EphA2) and histone deacetylases (HDACs) kinase.  Most of the compds. exhibited inhibitory activity against EphA2 and HDAC.  The antiproliferative activities were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (thiazolyl blue, tetrazolium blue) against the human cancer cell lines HCT116, K562 and MCF7.  Compds. (I) (R1 = 3-pyridyl, 4-methoxyphenyl) showed the most potent inhibitory activity against EphA2 and HDAC.  However, compd. I (R1 = 4-methoxyphenyl) exhibited higher potency against HCT116 (IC50 = 5.29 μm) and MCF7 (IC50 = 7.42 μm).  1-(2-Aminophenyl)-3-arylurea analogs may serve as new EphA2-HDAC dual inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWik4Z7qFvSLVg90H21EOLACvtfcHk0ljS8c-QBO_qMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFyru7vM&md5=4bd5f4b4d7cf57e1b713c0a778520e68</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1248%2Fcpb.c16-00154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.c16-00154%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DRan%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DNiu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DTang%26aufirst%3DW.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25201-%25282-Aminophenyl%2529-3-arylurea%2520derivatives%2520as%2520potential%2520EphA2%2520and%2520HDAC%2520dual%2520inhibitors%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2016%26volume%3D64%26spage%3D1136%26epage%3D1141%26doi%3D10.1248%2Fcpb.c16-00154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel indoleamine 2,3-dioxygenase 1 (IDO1) and histone deacetylase (HDAC) dual inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">312</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00487</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00487" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtVWrurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=312-317&author=K.+Fangauthor=G.+Dongauthor=Y.+Liauthor=S.+Heauthor=Y.+Wuauthor=S.+Wuauthor=W.+Wangauthor=C.+Sheng&title=Discovery+of+novel+indoleamine+2%2C3-dioxygenase+1+%28IDO1%29+and+histone+deacetylase+%28HDAC%29+dual+inhibitors&doi=10.1021%2Facsmedchemlett.7b00487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors</span></div><div class="casAuthors">Fang, Kun; Dong, Guoqiang; Li, Yu; He, Shipeng; Wu, Ying; Wu, Shanchao; Wang, Wei; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">312-317</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In order to take advantage of both immunotherapeutic and epigenetic antitumor agents, the first generation of dual indoleamine 2,3-dioxygenase 1 (IDO1) and histone deacetylase (HDAC) inhibitors were designed.  The highly active dual inhibitor 10 showed excellent and balanced activity against both IDO1 (IC50 = 69.0 nM) and HDAC1 (IC50 = 66.5 nM), whose dual targeting mechanisms were validated in cancer cells.  Compd. 10 had good pharmacokinetic profiles as an orally active antitumor agent and significantly reduced the L-kynurenine level in plasma.  In particular, it showed excellent in vivo antitumor efficacy in the murine LLC tumor model with low toxicity.  This proof-of-concept study provided a novel strategy for cancer treatment.  Compd. 10 represents a promising lead compd. for the development of novel antitumor agents and can also be used as a valuable probe to clarify the relationships and mechanisms between cancer immunotherapy and epigenetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEDqXRR2J0zrVg90H21EOLACvtfcHk0lgksJ96LBaxig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtVWrurc%253D&md5=c808b75f03d703dc7e66798759457f4a</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00487%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520novel%2520indoleamine%25202%252C3-dioxygenase%25201%2520%2528IDO1%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520dual%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D312%26epage%3D317%26doi%3D10.1021%2Facsmedchemlett.7b00487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nebbioso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voltz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germain, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrosino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bontempo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiavone, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bresciani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Lera, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gronemeyer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altucci, L.</span></span> <span> </span><span class="NLM_article-title">Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1038/nm1161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnm1161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15619633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A280%3ADC%252BD2M%252FgvFeitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=77-84&author=A.+Nebbiosoauthor=N.+Clarkeauthor=E.+Voltzauthor=E.+Germainauthor=C.+Ambrosinoauthor=P.+Bontempoauthor=R.+Alvarezauthor=E.+M.+Schiavoneauthor=F.+Ferraraauthor=F.+Brescianiauthor=A.+Weiszauthor=A.+R.+de+Leraauthor=H.+Gronemeyerauthor=L.+Altucci&title=Tumor-selective+action+of+HDAC+inhibitors+involves+TRAIL+induction+in+acute+myeloid+leukemia+cells&doi=10.1038%2Fnm1161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells</span></div><div class="casAuthors">Nebbioso Angela; Clarke Nicole; Voltz Emilie; Germain Emmanuelle; Ambrosino Concetta; Bontempo Paola; Alvarez Rosana; Schiavone Ettore M; Ferrara Felicetto; Bresciani Francesco; Weisz Alessandro; de Lera Angel R; Gronemeyer Hinrich; Altucci Lucia</div><div class="citationInfo"><span class="NLM_cas:title">Nature medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-84</span>
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    </div><div class="casAbstract">Chromatin is a dynamic macromolecular structure epigenetically modified to regulate specific gene expression.  Altered chromatin function can lead to aberrant expression of growth regulators and may, ultimately, cause cancer.  That many human diseases have epigenetic etiology has stimulated the development of 'epigenetic' therapies.  Inhibitors of histone deacetylases (HDACIs) induce proliferation arrest, maturation and apoptosis of cancer cells, but not normal cells, in vitro and in vivo, and are currently being tested in clinical trials.  We investigated the mechanism(s) underlying this tumor selectivity.  We report that HDACIs induce, in addition to p21, expression of TRAIL (Apo2L, TNFSF10) by directly activating the TNFSF10 promoter, thereby triggering tumor-selective death signaling in acute myeloid leukemia (AML) cells and the blasts of individuals with AML.  RNA interference revealed that the induction of p21, TRAIL and differentiation are separable activities of HDACIs.  HDACIs induced proliferation arrest, TRAIL-mediated apoptosis and suppression of AML blast clonogenicity irrespective of French-American-British (FAB) classification status, karyotype and immunophenotype.  No apoptosis was seen in normal CD34(+) progenitor cells.  Our results identify TRAIL as a mediator of the anticancer action of HDACIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQQMQxhEeVK8Hqj_yg7twvpfW6udTcc2eZRDaY914-AOLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M%252FgvFeitg%253D%253D&md5=675e025a119adb957d2ae708419e7216</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1038%2Fnm1161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1161%26sid%3Dliteratum%253Aachs%26aulast%3DNebbioso%26aufirst%3DA.%26aulast%3DClarke%26aufirst%3DN.%26aulast%3DVoltz%26aufirst%3DE.%26aulast%3DGermain%26aufirst%3DE.%26aulast%3DAmbrosino%26aufirst%3DC.%26aulast%3DBontempo%26aufirst%3DP.%26aulast%3DAlvarez%26aufirst%3DR.%26aulast%3DSchiavone%26aufirst%3DE.%2BM.%26aulast%3DFerrara%26aufirst%3DF.%26aulast%3DBresciani%26aufirst%3DF.%26aulast%3DWeisz%26aufirst%3DA.%26aulast%3Dde%2BLera%26aufirst%3DA.%2BR.%26aulast%3DGronemeyer%26aufirst%3DH.%26aulast%3DAltucci%26aufirst%3DL.%26atitle%3DTumor-selective%2520action%2520of%2520HDAC%2520inhibitors%2520involves%2520TRAIL%2520induction%2520in%2520acute%2520myeloid%2520leukemia%2520cells%26jtitle%3DNat.%2520Med.%26date%3D2005%26volume%3D11%26spage%3D77%26epage%3D84%26doi%3D10.1038%2Fnm1161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macfarlane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheat, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, G. M.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">S193</span>– <span class="NLM_lpage">S206</span>, <span class="refDoi"> DOI: 10.1038/sj.cdd.4401535</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fsj.cdd.4401535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15608694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVyqtrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=S193-S206&author=S.+Inoueauthor=M.+Macfarlaneauthor=N.+Harperauthor=L.+M.+Wheatauthor=M.+J.+Dyerauthor=G.+M.+Cohen&title=Histone+deacetylase+inhibitors+potentiate+TNF-related+apoptosis-inducing+ligand+%28TRAIL%29-induced+apoptosis+in+lymphoid+malignancies&doi=10.1038%2Fsj.cdd.4401535"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies</span></div><div class="casAuthors">Inoue, S.; MacFarlane, M.; Harper, N.; Wheat, L. M. C.; Dyer, M. J. S.; Cohen, G. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">Suppl. 2</span>),
    <span class="NLM_cas:pages">S193-S206</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">New therapies are required for chronic lymphocytic leukemia (CLL), an incurable disease characterized by failure of mature lymphocytes to undergo apoptosis.  Activation of cell surface death receptors, such as via TRAIL receptor ligation, may provide a novel therapeutic target for various malignancies.  However, CLL and other lymphoid malignancies are resistant to TRAIL.  The authors report that low concns. of histone deacetylase (HDAC) inhibitors, such as depsipeptide, which alone failed to induce apoptosis, markedly sensitize CLL cells and other primary lymphoid malignancies to TRAIL-induced apoptosis.  These combinations caused little or no toxicity to normal lymphocytes.  HDAC inhibitors sensitized resistant cells to TRAIL-induced apoptosis by facilitating formation of an active death-inducing signaling complex (DISC), leading to the rapid activation of caspase-8.  The facilitated DISC formation also occurred in the absence of TRAIL-R2 upregulation.  Thus, the combination of HDAC inhibitors and TRAIL may be valuable in the treatment of various hemopoietic malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZUbiS50swSLVg90H21EOLACvtfcHk0liI90Hhga94Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVyqtrnP&md5=70ea27149269ee1a8353686753aea0ac</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1038%2Fsj.cdd.4401535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.cdd.4401535%26sid%3Dliteratum%253Aachs%26aulast%3DInoue%26aufirst%3DS.%26aulast%3DMacfarlane%26aufirst%3DM.%26aulast%3DHarper%26aufirst%3DN.%26aulast%3DWheat%26aufirst%3DL.%2BM.%26aulast%3DDyer%26aufirst%3DM.%2BJ.%26aulast%3DCohen%26aufirst%3DG.%2BM.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520potentiate%2520TNF-related%2520apoptosis-inducing%2520ligand%2520%2528TRAIL%2529-induced%2520apoptosis%2520in%2520lymphoid%2520malignancies%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2004%26volume%3D11%26spage%3DS193%26epage%3DS206%26doi%3D10.1038%2Fsj.cdd.4401535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skok, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zidar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikelj, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilas, J.</span></span> <span> </span><span class="NLM_article-title">Dual inhibitors of human DNA topoisomerase II and other cancer-related targets</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">884</span>– <span class="NLM_lpage">904</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00726</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00726" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFalu7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=884-904&author=Z.+Skokauthor=N.+Zidarauthor=D.+Kikeljauthor=J.+Ilas&title=Dual+inhibitors+of+human+DNA+topoisomerase+II+and+other+cancer-related+targets&doi=10.1021%2Facs.jmedchem.9b00726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets</span></div><div class="casAuthors">Skok, Ziga; Zidar, Nace; Kikelj, Danijel; Ilas, Janez</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">884-904</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Human DNA topoisomerase II is an important target in anticancer therapy.  Despite the clin. success of drugs that target topoisomerase II, the development of resistant cancer cells can limit their clin. efficacy.  To maximize the therapeutic potential of anticancer drugs, combination therapies and multi-target drugs have been suggested in many studies, where the use of multi-target drugs is advantageous from the pharmacokinetics point of view.  There are various different options for the prepn. of dual-target or multiple-target inhibitors, as topoisomerase II is both structurally (e.g., topoisomerase I, Hsp90, kinases) and functionally (e.g., histone deacetylases, proteasome) connected to many validated anticancer targets.  In this article, we discuss the scientific background behind targeting topoisomerase II together with a no. of other targets important in cancer therapy, we review the present status and discuss further options in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_2Nk9XaQ1KbVg90H21EOLACvtfcHk0ljOxk3qJNA0dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFalu7nP&md5=2115c6cfef1ab63422f39f07dd9eb708</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00726%26sid%3Dliteratum%253Aachs%26aulast%3DSkok%26aufirst%3DZ.%26aulast%3DZidar%26aufirst%3DN.%26aulast%3DKikelj%26aufirst%3DD.%26aulast%3DIlas%26aufirst%3DJ.%26atitle%3DDual%2520inhibitors%2520of%2520human%2520DNA%2520topoisomerase%2520II%2520and%2520other%2520cancer-related%2520targets%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D884%26epage%3D904%26doi%3D10.1021%2Facs.jmedchem.9b00726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 21 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Xiaopeng Peng, Jingxuan Chen, Ling Li, Zhiqiang Sun, Jin Liu, Yichang Ren, Junli Huang, <span class="NLM_string-name hlFld-ContribAuthor">Jianjun Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8447-8473. <a href="https://doi.org/10.1021/acs.jmedchem.1c00413" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00413</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00413%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEfficient%252BSynthesis%252Band%252BBioevaluation%252Bof%252BNovel%252BDual%252BTubulin%25252FHistone%252BDeacetylase%252B3%252BInhibitors%252Bas%252BPotential%252BAnticancer%252BAgents%26aulast%3DPeng%26aufirst%3DXiaopeng%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D08032021%26date%3D07062021%26volume%3D64%26issue%3D12%26spage%3D8447%26epage%3D8473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Pan Tang, Jifa Zhang, Jie Liu, Cheng-Ming Chiang, <span class="NLM_string-name hlFld-ContribAuthor">Liang Ouyang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (5)
                                     , 2419-2435. <a href="https://doi.org/10.1021/acs.jmedchem.0c01487" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01487</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01487%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BBromodomain%252Band%252BExtraterminal%252BProteins%252Bfor%252BDrug%252BDiscovery%25253A%252BFrom%252BCurrent%252BProgress%252Bto%252BTechnological%252BDevelopment%26aulast%3DTang%26aufirst%3DPan%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D26082020%26date%3D22022021%26volume%3D64%26issue%3D5%26spage%3D2419%26epage%3D2435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xuewu Liang, Shuai Tang, Xuyi Liu, Yingluo Liu, Qifu Xu, Xiaomin Wang, Abdusaid Saidahmatov, Chunpu Li, Jiang Wang, Yu Zhou, Yingjie Zhang, Meiyu Geng, Min Huang, <span class="NLM_string-name hlFld-ContribAuthor">Hong Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021</strong>, Article ASAP.</span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02111%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BPyrrolo%25255B2%25252C3-d%25255Dpyrimidine-based%252BDerivatives%252Bas%252BPotent%252BJAK%25252FHDAC%252BDual%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BRefractory%252BSolid%252BTumors%26aulast%3DLiang%26aufirst%3DXuewu%26date%3D2021%26date%3D2020%26date%3D07122020%26volume%3D0%26issue%3D0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lei Chen, Shiyi Jin, Jian Gao, Tongtong Liu, Yuebo Shao, Jie Feng, Kangyi Wang, Tao Lu, <span class="NLM_string-name hlFld-ContribAuthor">Ding Du</span>. </span><span class="cited-content_cbyCitation_article-title">N-Heterocyclic Carbene/Magnesium Cocatalyzed Radical Relay Assembly of Aliphatic Keto Nitriles. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2021,</strong> <em>23 </em>
                                    (2)
                                     , 394-399. <a href="https://doi.org/10.1021/acs.orglett.0c03883" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c03883</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c03883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c03883%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DN-Heterocyclic%252BCarbene%25252FMagnesium%252BCocatalyzed%252BRadical%252BRelay%252BAssembly%252Bof%252BAliphatic%252BKeto%252BNitriles%26aulast%3DChen%26aufirst%3DLei%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D24112020%26date%3D29122020%26volume%3D23%26issue%3D2%26spage%3D394%26epage%3D399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jacynthe L. Toulouse, Genbin Shi, Claudèle Lemay-St-Denis, Maximilian C. C. J. C. Ebert, Daniel Deon, Marc Gagnon, Edward Ruediger, Kévin Saint-Jacques, Delphine Forge, Jean Jacques Vanden Eynde, Anne Marinier, Xinhua Ji, <span class="NLM_string-name hlFld-ContribAuthor">Joelle N. Pelletier</span>. </span><span class="cited-content_cbyCitation_article-title">Dual-Target Inhibitors of the Folate Pathway Inhibit Intrinsically Trimethoprim-Resistant DfrB Dihydrofolate Reductases. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (11)
                                     , 2261-2267. <a href="https://doi.org/10.1021/acsmedchemlett.0c00393" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00393</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00393%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDual-Target%252BInhibitors%252Bof%252Bthe%252BFolate%252BPathway%252BInhibit%252BIntrinsically%252BTrimethoprim-Resistant%252BDfrB%252BDihydrofolate%252BReductases%26aulast%3DToulouse%26aufirst%3DJacynthe%2BL.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D15072020%26date%3D28092020%26date%3D05102020%26date%3D28092020%26volume%3D11%26issue%3D11%26spage%3D2261%26epage%3D2267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying-Chao  Duan</span>, <span class="hlFld-ContribAuthor ">Shao-Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiao-Jing  Shi</span>, <span class="hlFld-ContribAuthor ">Lin-Feng  Jin</span>, <span class="hlFld-ContribAuthor ">Tong  Yu</span>, <span class="hlFld-ContribAuthor ">Yu  Song</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Guan</span>. </span><span class="cited-content_cbyCitation_article-title">Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>222 </em>, 113588. <a href="https://doi.org/10.1016/j.ejmech.2021.113588" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113588</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113588%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DResearch%252Bprogress%252Bof%252Bdual%252Binhibitors%252Btargeting%252Bcrosstalk%252Bbetween%252Bhistone%252Bepigenetic%252Bmodulators%252Bfor%252Bcancer%252Btherapy%26aulast%3DDuan%26aufirst%3DYing-Chao%26date%3D2021%26volume%3D222%26spage%3D113588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying-Chao  Duan</span>, <span class="hlFld-ContribAuthor ">Lin-Feng  Jin</span>, <span class="hlFld-ContribAuthor ">Hong-Mei  Ren</span>, <span class="hlFld-ContribAuthor ">Shao-Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Yue-Jiao  Liu</span>, <span class="hlFld-ContribAuthor ">Yong-Tao  Xu</span>, <span class="hlFld-ContribAuthor ">Zi-Hao  He</span>, <span class="hlFld-ContribAuthor ">Yu  Song</span>, <span class="hlFld-ContribAuthor ">Hang  Yuan</span>, <span class="hlFld-ContribAuthor ">Shu-Hui  Chen</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Guan</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>220 </em>, 113453. <a href="https://doi.org/10.1016/j.ejmech.2021.113453" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113453</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113453%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bdual%252Binhibitors%252Btargeting%252Blysine%252Bspecific%252Bdemethylase%252B1%252B%252528LSD1%252529%252Band%252Bhistone%252Bdeacetylases%252B%252528HDAC%252529%252Bfor%252Btreatment%252Bof%252Bgastric%252Bcancer%26aulast%3DDuan%26aufirst%3DYing-Chao%26date%3D2021%26volume%3D220%26spage%3D113453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ma  Su</span>, <span class="hlFld-ContribAuthor ">Xingyu  Gong</span>, <span class="hlFld-ContribAuthor ">Feng  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>16 </em>
                                    (7)
                                     , 745-761. <a href="https://doi.org/10.1080/17460441.2021.1877656" title="DOI URL">https://doi.org/10.1080/17460441.2021.1877656</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2021.1877656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2021.1877656%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DAn%252Bupdate%252Bon%252Bthe%252Bemerging%252Bapproaches%252Bfor%252Bhistone%252Bdeacetylase%252B%252528HDAC%252529%252Binhibitor%252Bdrug%252Bdiscovery%252Band%252Bfuture%252Bperspectives%26aulast%3DSu%26aufirst%3DMa%26date%3D2021%26date%3D2021%26volume%3D16%26issue%3D7%26spage%3D745%26epage%3D761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eclair Venturini  Filho</span>, <span class="hlFld-ContribAuthor ">Erick M.C.  Pinheiro</span>, <span class="hlFld-ContribAuthor ">Sergio  Pinheiro</span>, <span class="hlFld-ContribAuthor ">Sandro J.  Greco</span>. </span><span class="cited-content_cbyCitation_article-title">Aminopyrimidines: Recent synthetic procedures and anticancer activities. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2021,</strong> <em>92 </em>, 132256. <a href="https://doi.org/10.1016/j.tet.2021.132256" title="DOI URL">https://doi.org/10.1016/j.tet.2021.132256</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2021.132256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2021.132256%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DAminopyrimidines%25253A%252BRecent%252Bsynthetic%252Bprocedures%252Band%252Banticancer%252Bactivities%26aulast%3DFilho%26aufirst%3DEclair%2BVenturini%26date%3D2021%26volume%3D92%26spage%3D132256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yasemin  Öner</span>, <span class="hlFld-ContribAuthor ">Malena  Serrano</span>, <span class="hlFld-ContribAuthor ">Pilar  Sarto</span>, <span class="hlFld-ContribAuthor ">Laura Pilar  Iguácel</span>, <span class="hlFld-ContribAuthor ">María  Piquer-Sabanza</span>, <span class="hlFld-ContribAuthor ">Olaia  Estrada</span>, <span class="hlFld-ContribAuthor ">Teresa  Juan</span>, <span class="hlFld-ContribAuthor ">Jorge Hugo  Calvo</span>. </span><span class="cited-content_cbyCitation_article-title">Genome-Wide Association Studies of Somatic Cell Count in the Assaf Breed. </span><span class="cited-content_cbyCitation_journal-name">Animals</span><span> <strong>2021,</strong> <em>11 </em>
                                    (6)
                                     , 1531. <a href="https://doi.org/10.3390/ani11061531" title="DOI URL">https://doi.org/10.3390/ani11061531</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ani11061531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fani11061531%26sid%3Dliteratum%253Aachs%26jtitle%3DAnimals%26atitle%3DGenome-Wide%252BAssociation%252BStudies%252Bof%252BSomatic%252BCell%252BCount%252Bin%252Bthe%252BAssaf%252BBreed%26aulast%3D%25C3%2596ner%26aufirst%3DYasemin%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D6%26spage%3D1531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaolan  Xing</span>, <span class="hlFld-ContribAuthor ">Peng  Guan</span>, <span class="hlFld-ContribAuthor ">Shubin  Song</span>, <span class="hlFld-ContribAuthor ">Guirong  You</span>, <span class="hlFld-ContribAuthor ">Chengcai  Xia</span>, <span class="hlFld-ContribAuthor ">Tingting  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress in agents targeting polo-like kinases: Promising therapeutic strategies. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>217 </em>, 113314. <a href="https://doi.org/10.1016/j.ejmech.2021.113314" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113314</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113314%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bprogress%252Bin%252Bagents%252Btargeting%252Bpolo-like%252Bkinases%25253A%252BPromising%252Btherapeutic%252Bstrategies%26aulast%3DZhang%26aufirst%3DZheng%26date%3D2021%26volume%3D217%26spage%3D113314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marta  Szumilak</span>, <span class="hlFld-ContribAuthor ">Anna  Wiktorowska-Owczarek</span>, <span class="hlFld-ContribAuthor ">Andrzej  Stanczak</span>. </span><span class="cited-content_cbyCitation_article-title">Hybrid Drugs—A Strategy for Overcoming Anticancer Drug Resistance?. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (9)
                                     , 2601. <a href="https://doi.org/10.3390/molecules26092601" title="DOI URL">https://doi.org/10.3390/molecules26092601</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26092601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26092601%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DHybrid%252BDrugs%2525E2%252580%252594A%252BStrategy%252Bfor%252BOvercoming%252BAnticancer%252BDrug%252BResistance%25253F%26aulast%3DSzumilak%26aufirst%3DMarta%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D9%26spage%3D2601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shulun  Chen</span>, <span class="hlFld-ContribAuthor ">Jing  Tan</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">The ups, downs and new trends of IDO1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>110 </em>, 104815. <a href="https://doi.org/10.1016/j.bioorg.2021.104815" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104815</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104815%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DThe%252Bups%25252C%252Bdowns%252Band%252Bnew%252Btrends%252Bof%252BIDO1%252Binhibitors%26aulast%3DChen%26aufirst%3DShulun%26date%3D2021%26volume%3D110%26spage%3D104815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Angeliki  Andrikopoulou</span>, <span class="hlFld-ContribAuthor ">Michalis  Liontos</span>, <span class="hlFld-ContribAuthor ">Konstantinos  Koutsoukos</span>, <span class="hlFld-ContribAuthor ">Meletios-Athanasios  Dimopoulos</span>, <span class="hlFld-ContribAuthor ">Flora  Zagouri</span>. </span><span class="cited-content_cbyCitation_article-title">Clinical perspectives of BET inhibition in ovarian cancer. </span><span class="cited-content_cbyCitation_journal-name">Cellular Oncology</span><span> <strong>2021,</strong> <em>44 </em>
                                    (2)
                                     , 237-249. <a href="https://doi.org/10.1007/s13402-020-00578-6" title="DOI URL">https://doi.org/10.1007/s13402-020-00578-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s13402-020-00578-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs13402-020-00578-6%26sid%3Dliteratum%253Aachs%26jtitle%3DCellular%2520Oncology%26atitle%3DClinical%252Bperspectives%252Bof%252BBET%252Binhibition%252Bin%252Bovarian%252Bcancer%26aulast%3DAndrikopoulou%26aufirst%3DAngeliki%26date%3D2021%26date%3D2021%26volume%3D44%26issue%3D2%26spage%3D237%26epage%3D249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qinghua  Ren</span>, <span class="hlFld-ContribAuthor ">Wenqian  Gao</span>. </span><span class="cited-content_cbyCitation_article-title">Current status in the discovery of dual BET/HDAC inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>38 </em>, 127829. <a href="https://doi.org/10.1016/j.bmcl.2021.127829" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127829</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127829%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DCurrent%252Bstatus%252Bin%252Bthe%252Bdiscovery%252Bof%252Bdual%252BBET%25252FHDAC%252Binhibitors%26aulast%3DRen%26aufirst%3DQinghua%26date%3D2021%26volume%3D38%26spage%3D127829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Jenke</span>, <span class="hlFld-ContribAuthor ">Nina  Reßing</span>, <span class="hlFld-ContribAuthor ">Finn K.  Hansen</span>, <span class="hlFld-ContribAuthor ">Achim  Aigner</span>, <span class="hlFld-ContribAuthor ">Thomas  Büch</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (4)
                                     , 634. <a href="https://doi.org/10.3390/cancers13040634" title="DOI URL">https://doi.org/10.3390/cancers13040634</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13040634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13040634%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DAnticancer%252BTherapy%252Bwith%252BHDAC%252BInhibitors%25253A%252BMechanism-Based%252BCombination%252BStrategies%252Band%252BFuture%252BPerspectives%26aulast%3DJenke%26aufirst%3DRobert%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D4%26spage%3D634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qinsheng  Sun</span>, <span class="hlFld-ContribAuthor ">Qiuzi  Dai</span>, <span class="hlFld-ContribAuthor ">Cunlong  Zhang</span>, <span class="hlFld-ContribAuthor ">Yan  Chen</span>, <span class="hlFld-ContribAuthor ">Lei  Zhao</span>, <span class="hlFld-ContribAuthor ">Zigao  Yuan</span>, <span class="hlFld-ContribAuthor ">Yuyang  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and antitumor evaluations of nucleoside base hydroxamic acid derivatives as DNMT and HDAC dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chinese Chemical Letters</span><span> <strong>2021,</strong> <em>59 </em><a href="https://doi.org/10.1016/j.cclet.2021.02.004" title="DOI URL">https://doi.org/10.1016/j.cclet.2021.02.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cclet.2021.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cclet.2021.02.004%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Chemical%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bantitumor%252Bevaluations%252Bof%252Bnucleoside%252Bbase%252Bhydroxamic%252Bacid%252Bderivatives%252Bas%252BDNMT%252Band%252BHDAC%252Bdual%252Binhibitors%26aulast%3DSun%26aufirst%3DQinsheng%26date%3D2021%26volume%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qinghua  Ren</span>, <span class="hlFld-ContribAuthor ">Wenqian  Gao</span>. </span><span class="cited-content_cbyCitation_article-title">Current status in the discovery of dual BET/HDAC inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>31 </em>, 127671. <a href="https://doi.org/10.1016/j.bmcl.2020.127671" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127671</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127671%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DCurrent%252Bstatus%252Bin%252Bthe%252Bdiscovery%252Bof%252Bdual%252BBET%25252FHDAC%252Binhibitors%26aulast%3DRen%26aufirst%3DQinghua%26date%3D2021%26volume%3D31%26spage%3D127671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amr K.A.  Bass</span>, <span class="hlFld-ContribAuthor ">Mona S.  El-Zoghbi</span>, <span class="hlFld-ContribAuthor ">El-Shimaa M.  Nageeb</span>, <span class="hlFld-ContribAuthor ">Mamdouh F.A.  Mohamed</span>, <span class="hlFld-ContribAuthor ">Mohamed  Badr</span>, <span class="hlFld-ContribAuthor ">Gamal El-Din A.  Abuo-Rahma</span>. </span><span class="cited-content_cbyCitation_article-title">Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112904. <a href="https://doi.org/10.1016/j.ejmech.2020.112904" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112904</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112904%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DComprehensive%252Breview%252Bfor%252Banticancer%252Bhybridized%252Bmultitargeting%252BHDAC%252Binhibitors%26aulast%3DBass%26aufirst%3DAmr%2BK.A.%26date%3D2021%26volume%3D209%26spage%3D112904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaona  Chen</span>, <span class="hlFld-ContribAuthor ">Yanhong  He</span>, <span class="hlFld-ContribAuthor ">Wenjun  Fu</span>, <span class="hlFld-ContribAuthor ">Amirhossein  Sahebkar</span>, <span class="hlFld-ContribAuthor ">Yuhui  Tan</span>, <span class="hlFld-ContribAuthor ">Suowen  Xu</span>, <span class="hlFld-ContribAuthor ">Hong  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Histone Deacetylases (HDACs) and Atherosclerosis: A Mechanistic and Pharmacological Review. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2020,</strong> <em>8 </em><a href="https://doi.org/10.3389/fcell.2020.581015" title="DOI URL">https://doi.org/10.3389/fcell.2020.581015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2020.581015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2020.581015%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DHistone%252BDeacetylases%252B%252528HDACs%252529%252Band%252BAtherosclerosis%25253A%252BA%252BMechanistic%252Band%252BPharmacological%252BReview%26aulast%3DChen%26aufirst%3DXiaona%26date%3D2020%26date%3D2020%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yufeng  Xiao</span>, <span class="hlFld-ContribAuthor ">Xuan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in small molecular modulators targeting histone deacetylase 6. </span><span class="cited-content_cbyCitation_journal-name">Future Drug Discovery</span><span> <strong>2020,</strong> <em>2 </em>
                                    (4)
                                     , FDD53. <a href="https://doi.org/10.4155/fdd-2020-0023" title="DOI URL">https://doi.org/10.4155/fdd-2020-0023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fdd-2020-0023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffdd-2020-0023%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Drug%2520Discovery%26atitle%3DRecent%252Badvances%252Bin%252Bsmall%252Bmolecular%252Bmodulators%252Btargeting%252Bhistone%252Bdeacetylase%252B6%26aulast%3DXiao%26aufirst%3DYufeng%26date%3D2020%26volume%3D2%26issue%3D4%26spage%3DFDD53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0028.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Scaffold for transcription factors binding. BRD4 can read acetylated histones and bind to other acetylated proteins like transcription factor (TF) or cofactors, hence functioning as a scaffold unit. HDACs can damage BRD4 functions by effectively removing acetylated residues from histones or other proteins.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0012.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Model of histone–chaperone interaction. BRD4 has histone–chaperone activity: it can assist RNA Pol II to pass through acetylated nucleosomes. A change in the BRD4 presence on nucleosomes and on chromatin-associated protein complexes is caused by impaired BRD4 functions by HDACs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0021.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Overlay of I-BET726 bonds to BRD4<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> and the structure of I-BET295.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0022.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Three series of dual BRD4/HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0023.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures of representative compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0024.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Representatives of three series of dual BRD4/HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0025.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Representatives of thieno[2,3-<i>d</i>]pyrimidine based hydroxamic acid derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0026.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Binding modes of <b>7c</b> to BRD4 (A, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZW1">4ZW1</a>) and HDAC2 (B, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LXZ">4LXZ</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0027.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Quinazoline derivatives as HDAC/RTK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0002.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. HDAC/EGFR pathway inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0003.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Pazopanid derivatives as HDAC/VEGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0004.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Pyrimidine-pyrazolyl-based compounds as HDAC/mTOR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0005.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. 4-Methylquinazoline derivatives as HDAC/PI3K inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0006.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. HDAC/RTK pathway inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0007.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Camptothecin derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0008.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Podophyllotoxin derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0009.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Acridine derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0010.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. <i>N</i>-Benzyl doxorubicin derivatives as dual-acting Topo-HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0011.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Design strategies of DNA/HDAC dual-targeting drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0013.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Design strategy of PARP/HDAC dual inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0014.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Representative JAK/HDAC dual inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0015.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Bcl-2/HDAC dual inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0016.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Representatives of PDE-5/HDAC dual inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0017.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Design of OBHS-HDAC inhibitor conjugates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0018.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Molecular structures of dual HDAC-6/MMP-2 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0019.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Structures of dual MDM2/HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/medium/jm0c00491_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0020.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Binding modes of compound <b>31d</b> enantiomers with MDM2 and HDAC1.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> (A) Compound <b>31d-2</b> with MDM2. (B) Compound <b>31d-2</b> with HDAC1. (C) Binding mode of compound <b>31d-1</b> with MDM2. (D) Proposed binding mode of <b>31d-1</b> with HDAC1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00491/20200903/images/large/jm0c00491_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00491&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i48">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14782" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14782" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 209 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mokhtari, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homayouni, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baluch, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgatskaya, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeger, H.</span></span> <span> </span><span class="NLM_article-title">Combination therapy in combating cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">38022</span>– <span class="NLM_lpage">38043</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.16723</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.18632%2Foncotarget.16723" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=28410237" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=38022-38043&author=R.+B.+Mokhtariauthor=T.+S.+Homayouniauthor=N.+Baluchauthor=E.+Morgatskayaauthor=S.+Kumarauthor=B.+Dasauthor=H.+Yeger&title=Combination+therapy+in+combating+cancer&doi=10.18632%2Foncotarget.16723"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.16723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.16723%26sid%3Dliteratum%253Aachs%26aulast%3DMokhtari%26aufirst%3DR.%2BB.%26aulast%3DHomayouni%26aufirst%3DT.%2BS.%26aulast%3DBaluch%26aufirst%3DN.%26aulast%3DMorgatskaya%26aufirst%3DE.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DDas%26aufirst%3DB.%26aulast%3DYeger%26aufirst%3DH.%26atitle%3DCombination%2520therapy%2520in%2520combating%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D38022%26epage%3D38043%26doi%3D10.18632%2Foncotarget.16723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blagosklonny, M. V.</span></span> <span> </span><span class="NLM_article-title">Overcoming limitations of natural anticancer drugs by combining with artificial agents</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2004.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.tips.2004.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15681024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2MXoslagsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=77-81&author=M.+V.+Blagosklonny&title=Overcoming+limitations+of+natural+anticancer+drugs+by+combining+with+artificial+agents&doi=10.1016%2Fj.tips.2004.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming limitations of natural anticancer drugs by combining with artificial agents</span></div><div class="casAuthors">Blagosklonny, Mikhail V.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">77-81</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  During a billion years of evolution, living creatures have perfected cytotoxic agents to kill other organisms without killing themselves, thus providing us with antibiotics to kill bacteria without killing eukaryotic (e.g. human) cells.  Some natural agents inhibit specifically most vital cellular structures and functions in cancer cells.  However, nature was not creating antibiotics for cancer, and natural agents kill cancer cells precisely because they share targets with normal cells.  To discriminate between particular cancer cells and normal cells, one can design or select artificial agents that are not necessarily lethal but are aimed either at cancer-specific targets or at dispensable and even unavailable (in cancer cells) targets.  Using rational drug combinations, such selective agents can assist natural agents to eradicate cancer cells selectively.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHEqPHb7M1qbVg90H21EOLACvtfcHk0liJjnxnYwv2UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXoslagsg%253D%253D&md5=6160179fcd3935adebbab83716b470c5</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2004.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2004.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DBlagosklonny%26aufirst%3DM.%2BV.%26atitle%3DOvercoming%2520limitations%2520of%2520natural%2520anticancer%2520drugs%2520by%2520combining%2520with%2520artificial%2520agents%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2005%26volume%3D26%26spage%3D77%26epage%3D81%26doi%3D10.1016%2Fj.tips.2004.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinarivala, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span> <span> </span><span class="NLM_article-title">Multi-targeting anticancer agents: rational approaches, synthetic routes and structure activity relationship</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">842</span>– <span class="NLM_lpage">874</span>, <span class="refDoi"> DOI: 10.2174/1871520619666190118120708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.2174%2F1871520619666190118120708" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=30657048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFCisbnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=842-874&author=H.+Singhauthor=N.+Kinarivalaauthor=S.+Sharma&title=Multi-targeting+anticancer+agents%3A+rational+approaches%2C+synthetic+routes+and+structure+activity+relationship&doi=10.2174%2F1871520619666190118120708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-Targeting Anticancer Agents: Rational Approaches, Synthetic Routes and Structure Activity Relationship</span></div><div class="casAuthors">Singh, Harbinder; Kinarivala, Nihar; Sharma, Sahil</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">842-874</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  We live in a world with complex diseases such as cancer which cannot be cured with one-compd. one-target based therapeutic paradigm.  This could be due to the involvement of multiple pathogenic mechanisms.  One-compd.-various-targets stratagem has become a prevailing research topic in anti-cancer drug discovery.  The simultaneous interruption of two or more targets has improved the therapeutic efficacy as compared to the specific targeted based therapy.  In this review, six types of dual targeting agents along with some interesting strategies used for their design and synthesis are discussed.  Their pharmacol. with various types of the mol. interactions within their specific targets has also been described.  This assemblage will reveal the recent trends and insights in front of the scientific community working in dual inhibitors and help them in designing the next generation of multi-targeted anti-cancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojOVp3ZXdphrVg90H21EOLACvtfcHk0liJjnxnYwv2UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFCisbnO&md5=c8cdf59ab0e86c63b7d1f4fd4bde682d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2174%2F1871520619666190118120708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520619666190118120708%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DH.%26aulast%3DKinarivala%26aufirst%3DN.%26aulast%3DSharma%26aufirst%3DS.%26atitle%3DMulti-targeting%2520anticancer%2520agents%253A%2520rational%2520approaches%252C%2520synthetic%2520routes%2520and%2520structure%2520activity%2520relationship%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2019%26volume%3D19%26spage%3D842%26epage%3D874%26doi%3D10.2174%2F1871520619666190118120708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hesham, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasheen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abouzid, K. A. M.</span></span> <span> </span><span class="NLM_article-title">Chimeric HDAC inhibitors: comprehensive review on the HDAC-based strategies developed to combat cancer</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">2058</span>– <span class="NLM_lpage">2109</span>, <span class="refDoi"> DOI: 10.1002/med.21505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1002%2Fmed.21505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=29733427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A280%3ADC%252BC1MfgsV2htQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=2058-2109&author=H.+M.+Heshamauthor=D.+S.+Lasheenauthor=K.+A.+M.+Abouzid&title=Chimeric+HDAC+inhibitors%3A+comprehensive+review+on+the+HDAC-based+strategies+developed+to+combat+cancer&doi=10.1002%2Fmed.21505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer</span></div><div class="casAuthors">Hesham Heba M; Lasheen Deena S; Abouzid Khaled A M</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2058-2109</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Recently, molecular hybridization paradigm became an interesting and smart way to defeat the multifaceted cancer disease by a single molecular entity that acts via several mechanisms just like a magic bullet.  Also, HDAC is an important epigenetic target in drug discovery, and the HDAC inhibitors showed successful pattern as cytotoxic agents.  Because of their flexible structure activity relationship, it was easy to link them to other anticancer scaffolds.  So, many dual action HDAC inhibitors have been developed and most of these hybrids have higher potency than the constituting parents in fighting of the cancer cells.  This review describes potential applications of chimeric HDAC inhibitors, which simultaneously modulate not only HDAC but also multiple targets, in treatment of relapsing and drug-resistant cancers.  We have nearly collected most of the reported dual action HDAC inhibitors yet to provide a comprehensive guide for the drug discovery process for developing more efficient anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7h5aD28C1RtbHMBt0mMIXfW6udTcc2eYkDoD4gcjSRrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MfgsV2htQ%253D%253D&md5=c935014e94bf04c21eafbcb2f8ef8218</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fmed.21505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21505%26sid%3Dliteratum%253Aachs%26aulast%3DHesham%26aufirst%3DH.%2BM.%26aulast%3DLasheen%26aufirst%3DD.%2BS.%26aulast%3DAbouzid%26aufirst%3DK.%2BA.%2BM.%26atitle%3DChimeric%2520HDAC%2520inhibitors%253A%2520comprehensive%2520review%2520on%2520the%2520HDAC-based%2520strategies%2520developed%2520to%2520combat%2520cancer%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26spage%3D2058%26epage%3D2109%26doi%3D10.1002%2Fmed.21505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Harbi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazumder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsi, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almasan, A.</span></span> <span> </span><span class="NLM_article-title">MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">e1593</span>, <span class="refDoi"> DOI: 10.1038/cddis.2014.525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fcddis.2014.525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25590803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=e1593&author=G.+S.+Choudharyauthor=S.+Al-Harbiauthor=S.+Mazumderauthor=B.+T.+Hillauthor=M.+R.+Smithauthor=J.+Bodoauthor=E.+D.+Hsiauthor=A.+Almasan&title=MCL-1+and+BCL-xL-dependent+resistance+to+the+BCL-2+inhibitor+ABT-199+can+be+overcome+by+preventing+PI3K%2FAKT%2FmTOR+activation+in+lymphoid+malignancies&doi=10.1038%2Fcddis.2014.525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies</span></div><div class="casAuthors">Choudhary, G. S.; Al-harbi, S.; Mazumder, S.; Hill, B. T.; Smith, M. R.; Bodo, J.; Hsi, E. D.; Almasan, A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e1593</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Overexpression of anti-apoptotic BCL-2 family members is a hallmark of many lymphoid malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) that can be targeted with small mol. inhibitors.  ABT-199 is a rationally designed BCL-2 homol. (BH)-3 mimetic that specifically binds to BCL-2, but not to MCL-1 and BCL-xL.  Although the thrombocytopenia that occurs with navitoclax treatment has not been a problem with ABT-199, clin. trials in CLL could benefit by lowering the ABT-199 concn. through targeting other survival pathways.  In this study, we investigated the mechanisms of resistance that develops to ABT-199 therapy by generating ABT-199-resistant (ABT199-R) cell lines via chronic exposure of NHL cell lines to ABT-199.  Acquired resistance resulted in substantial AKT activation and upregulation of MCL-1 and BCL-xL levels that sequestered BIM.  ABT199-R cells exhibited increased MCL-1 stability and failed to activate BAX in response to ABT-199.  The ABT-199 acquired and inherent resistant cells were sensitized to treatment with ABT-199 by inhibitors of the PI3K, AKT, and mTOR pathways, NVP-BEZ235 and GS-1101.  NVP-BEZ235, a dual inhibitor of p-AKT and mTOR, reduced MCL-1 levels causing BIM release from MCL-1 and BCL-xL, thus leading to cell death by BAX activation.  The PI3Kδ inhibitor GS-1101 (idelalisib) downregulated MCL-1 and sensitized ABT199-R cells through AKT-mediated BAX activation.  A genetic approach, through siRNA-mediated down-regulation of AKT, MCL-1, and BCL-xL, significantly decreased cell survival, demonstrating the importance of these cell survival factors for ABT-199 resistance.  Our findings suggest a novel mechanism that modulates the expression and activity of pro-survival proteins to confer treatment resistance that could be exploited by a rational combination therapeutic regimen that could be effective for treating lymphoid malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ3IPkt2N8BbVg90H21EOLACvtfcHk0li147EPMhKihg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOitbY%253D&md5=bf94dc99ed80e1c7b5880b5dee25c522</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2014.525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2014.525%26sid%3Dliteratum%253Aachs%26aulast%3DChoudhary%26aufirst%3DG.%2BS.%26aulast%3DAl-Harbi%26aufirst%3DS.%26aulast%3DMazumder%26aufirst%3DS.%26aulast%3DHill%26aufirst%3DB.%2BT.%26aulast%3DSmith%26aufirst%3DM.%2BR.%26aulast%3DBodo%26aufirst%3DJ.%26aulast%3DHsi%26aufirst%3DE.%2BD.%26aulast%3DAlmasan%26aufirst%3DA.%26atitle%3DMCL-1%2520and%2520BCL-xL-dependent%2520resistance%2520to%2520the%2520BCL-2%2520inhibitor%2520ABT-199%2520can%2520be%2520overcome%2520by%2520preventing%2520PI3K%252FAKT%252FmTOR%2520activation%2520in%2520lymphoid%2520malignancies%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2015%26volume%3D6%26spage%3De1593%26doi%3D10.1038%2Fcddis.2014.525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bailly, C.</span></span> <span> </span><span class="NLM_article-title">Contemporary challenges in the design of topoisomerase II inhibitors for cancer chemotherapy</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">3611</span>– <span class="NLM_lpage">3640</span>, <span class="refDoi"> DOI: 10.1021/cr200325f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr200325f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsVChtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2012&pages=3611-3640&author=C.+Bailly&title=Contemporary+challenges+in+the+design+of+topoisomerase+II+inhibitors+for+cancer+chemotherapy&doi=10.1021%2Fcr200325f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Contemporary Challenges in the Design of Topoisomerase II Inhibitors for Cancer Chemotherapy</span></div><div class="casAuthors">Bailly, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3611-3640</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review reports the use of topoisomerase II modulators as anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozIpYLsh9eCLVg90H21EOLACvtfcHk0lgrmrVs9M3M4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsVChtbY%253D&md5=f5ba565e42cd9ff9a38e47ad7c1e77c0</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fcr200325f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr200325f%26sid%3Dliteratum%253Aachs%26aulast%3DBailly%26aufirst%3DC.%26atitle%3DContemporary%2520challenges%2520in%2520the%2520design%2520of%2520topoisomerase%2520II%2520inhibitors%2520for%2520cancer%2520chemotherapy%26jtitle%3DChem.%2520Rev.%26date%3D2012%26volume%3D112%26spage%3D3611%26epage%3D3640%26doi%3D10.1021%2Fcr200325f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jenuwein, T.</span></span> <span> </span><span class="NLM_article-title">Translating the histone code</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>293</i></span>,  <span class="NLM_fpage">1074</span>– <span class="NLM_lpage">1080</span>, <span class="refDoi"> DOI: 10.1126/science.1063127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1126%2Fscience.1063127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=11498575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmtVWltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2001&pages=1074-1080&author=T.+Jenuwein&title=Translating+the+histone+code&doi=10.1126%2Fscience.1063127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Translating the histone code</span></div><div class="casAuthors">Jenuwein, Thomas; Allis, C. David</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">293</span>
        (<span class="NLM_cas:issue">5532</span>),
    <span class="NLM_cas:pages">1074-1080</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The review.  Chromatin, the physiol. template of all eukaryotic genetic information, is subject to a diverse array of posttranslational modifications that largely impinge on histone amino termini, thereby regulating access to the underlying DNA.  Distinct histone amino-terminal modifications can generate synergistic or antagonistic interaction affinities for chromatin-assocd. proteins, which in turn dictate dynamic transitions between transcriptionally active or transcriptionally silent chromatin states.  The combinatorial nature of histone amino-terminal modifications thus reveals a "histone code" that considerably extends the information potential of the genetic code.  We propose that this epigenetic marking system represents a fundamental regulatory mechanism that has an impact on most, if not all; chromatin-templated processes, with far-reaching consequences for cell fate decisions and both normal and pathol. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUFyHNepKcUbVg90H21EOLACvtfcHk0lgfqQWxIX9jIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmtVWltro%253D&md5=021dcd98a5e5bf2ed7eedef1897b2269</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1126%2Fscience.1063127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1063127%26sid%3Dliteratum%253Aachs%26aulast%3DJenuwein%26aufirst%3DT.%26atitle%3DTranslating%2520the%2520histone%2520code%26jtitle%3DScience%26date%3D2001%26volume%3D293%26spage%3D1074%26epage%3D1080%26doi%3D10.1126%2Fscience.1063127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glozak, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sengupta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span> <span> </span><span class="NLM_article-title">Acetylation and deacetylation of non-histone proteins</span>. <i>Gene</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1016/j.gene.2005.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.gene.2005.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16289629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Klu7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2005&pages=15-23&author=M.+A.+Glozakauthor=N.+Senguptaauthor=X.+Zhangauthor=E.+Seto&title=Acetylation+and+deacetylation+of+non-histone+proteins&doi=10.1016%2Fj.gene.2005.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Acetylation and deacetylation of non-histone proteins</span></div><div class="casAuthors">Glozak, Michele A.; Sengupta, Nilanjan; Zhang, Xiaohong; Seto, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Gene</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15-23</span>CODEN:
                <span class="NLM_cas:coden">GENED6</span>;
        ISSN:<span class="NLM_cas:issn">0378-1119</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Since the first report of p53 as a non-histone target of a histone acetyltransferase (HAT), there has been a rapid proliferation in the description of new non-histone targets of HATs.  Of these, transcription factors comprise the largest class of new targets.  The substrates for HATs extend to cytoskeletal proteins, mol. chaperones and nuclear import factors.  Deacetylation of these non-histone proteins by histone deacetylases (HDACs) opens yet another exciting new field of discovery in the role of the dynamic acetylation and deacetylation on cellular function.  This review will focus on these non-histone targets of HATs and HDACs and the consequences of their modification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrghezJOUSImbVg90H21EOLACvtfcHk0lg5hKIJwgUqNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Klu7%252FN&md5=c6befd12e4556a9154628d9fe9ebe53a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.gene.2005.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gene.2005.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DGlozak%26aufirst%3DM.%2BA.%26aulast%3DSengupta%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSeto%26aufirst%3DE.%26atitle%3DAcetylation%2520and%2520deacetylation%2520of%2520non-histone%2520proteins%26jtitle%3DGene%26date%3D2005%26volume%3D363%26spage%3D15%26epage%3D23%26doi%3D10.1016%2Fj.gene.2005.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minucci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelicci, P. G.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1038/nrc1779</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnrc1779" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16397526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1GgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=38-51&author=S.+Minucciauthor=P.+G.+Pelicci&title=Histone+deacetylase+inhibitors+and+the+promise+of+epigenetic+%28and+more%29+treatments+for+cancer&doi=10.1038%2Fnrc1779"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer</span></div><div class="casAuthors">Minucci, Saverio; Pelicci, Pier Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-51</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are considered to be among the most promising targets in drug development for cancer therapy, and first-generation histone deacetylase inhibitors (HDACi) are currently being tested in phase I/II clin. trials.  A wide-ranging knowledge of the role of HDACs in tumorigenesis, and of the action of HDACi, has been achieved.  However, several basic aspects are not yet fully understood.  Investigating these aspects in the context of what we now understand about HDACi action both in vitro and in vivo will further improve the design of optimized clin. protocols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxXiACZV1sK7Vg90H21EOLACvtfcHk0ljqu_AFNIlq4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1GgsA%253D%253D&md5=384e1f8d676d61531e46843c060a9380</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrc1779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1779%26sid%3Dliteratum%253Aachs%26aulast%3DMinucci%26aufirst%3DS.%26aulast%3DPelicci%26aufirst%3DP.%2BG.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520and%2520the%2520promise%2520of%2520epigenetic%2520%2528and%2520more%2529%2520treatments%2520for%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D38%26epage%3D51%26doi%3D10.1038%2Fnrc1779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotili, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerbara, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valente, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeoni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragno, R.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylation in epigenetics: an attractive target for anticancer therapy</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1002/med.20024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1002%2Fmed.20024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15717297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslGit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=261-309&author=A.+Maiauthor=S.+Massaauthor=D.+Rotiliauthor=I.+Cerbaraauthor=S.+Valenteauthor=R.+Pezziauthor=S.+Simeoniauthor=R.+Ragno&title=Histone+deacetylation+in+epigenetics%3A+an+attractive+target+for+anticancer+therapy&doi=10.1002%2Fmed.20024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylation in epigenetics: An attractive target for anticancer therapy</span></div><div class="casAuthors">Mai, Antonello; Massa, Silvio; Rotili, Dante; Cerbara, Ilaria; Valente, Sergio; Pezzi, Riccardo; Simeoni, Silvia; Ragno, Rino</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">261-309</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The reversible histone acetylation and deacetylation are epigenetic phenomena that play crit. roles in the modulation of chromatin topol. and the regulation of gene expression.  Aberrant transcription due to altered expression or mutation of genes that encode histone acetyltransferase (HAT) or histone deacetylase (HDAC) enzymes or their binding partners, has been clearly linked to carcinogenesis.  The histone deacetylase inhibitors are a new promising class of anticancer agents (some of which in clin. trials), that inhibit the proliferation of tumor cells in culture and in vivo by inducing cell-cycle arrest, terminal differentiation, and/or apoptosis.  This report reviews the chem. and the biol. of HDACs and HDAC inhibitors, laying particular emphasis on agents actually in clin. trials for cancer therapy and on new potential anticancer lead compds. more selective and less toxic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDbzbbO5ZKrLVg90H21EOLACvtfcHk0ljqu_AFNIlq4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslGit7w%253D&md5=60112258470a6d520cbc0af24046e994</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fmed.20024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20024%26sid%3Dliteratum%253Aachs%26aulast%3DMai%26aufirst%3DA.%26aulast%3DMassa%26aufirst%3DS.%26aulast%3DRotili%26aufirst%3DD.%26aulast%3DCerbara%26aufirst%3DI.%26aulast%3DValente%26aufirst%3DS.%26aulast%3DPezzi%26aufirst%3DR.%26aulast%3DSimeoni%26aufirst%3DS.%26aulast%3DRagno%26aufirst%3DR.%26atitle%3DHistone%2520deacetylation%2520in%2520epigenetics%253A%2520an%2520attractive%2520target%2520for%2520anticancer%2520therapy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2005%26volume%3D25%26spage%3D261%26epage%3D309%26doi%3D10.1002%2Fmed.20024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dokmanovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: overview and perspectives</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">981</span>– <span class="NLM_lpage">989</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-07-0324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1541-7786.MCR-07-0324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=17951399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFygsLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2007&pages=981-989&author=M.+Dokmanovicauthor=C.+Clarkeauthor=P.+A.+Marks&title=Histone+deacetylase+inhibitors%3A+overview+and+perspectives&doi=10.1158%2F1541-7786.MCR-07-0324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitors: Overview and Perspectives</span></div><div class="casAuthors">Dokmanovic, Milos; Clarke, Cathy; Marks, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">981-989</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase inhibitors (HDACi) comprise structurally diverse compds. that are a group of targeted anticancer agents.  The first of these new HDACi, vorinostat (suberoylanilide hydroxamic acid), has received Food and Drug Administration approval for treating patients with cutaneous T-cell lymphoma.  This review focuses on the activities of the 11 zinc-contg. HDACs, their histone and nonhistone protein substrates, and the different pathways by which HDACi induce transformed cell death.  A hypothesis is presented to explain the relative resistance of normal cells to HDACi-induced cell death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_V1LFFdlQYbVg90H21EOLACvtfcHk0li07Eq7jfcsSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFygsLvN&md5=8696ff3e0f8e910fd6fc6a7e38579b95</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-07-0324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-07-0324%26sid%3Dliteratum%253Aachs%26aulast%3DDokmanovic%26aufirst%3DM.%26aulast%3DClarke%26aufirst%3DC.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520overview%2520and%2520perspectives%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2007%26volume%3D5%26spage%3D981%26epage%3D989%26doi%3D10.1158%2F1541-7786.MCR-07-0324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haberland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E. N.</span></span> <span> </span><span class="NLM_article-title">The many roles of histone deacetylases in development and physiology: implications for disease and therapy</span>. <i>Nat. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1038/nrg2485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnrg2485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=19065135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFWis7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=32-42&author=M.+Haberlandauthor=R.+L.+Montgomeryauthor=E.+N.+Olson&title=The+many+roles+of+histone+deacetylases+in+development+and+physiology%3A+implications+for+disease+and+therapy&doi=10.1038%2Fnrg2485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The many roles of histone deacetylases in development and physiology: implications for disease and therapy</span></div><div class="casAuthors">Haberland, Michael; Montgomery, Rusty L.; Olson, Eric N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-42</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The expression of many histone deacetylase (HDAC) isoforms in eukaryotic cells raises questions regarding their specificity and the programs of gene expression that they control.  HDAC knockout mice are a powerful tool for addressing these questions and have revealed that individual HDACs have specific functions in development and disease.  Histone deacetylases (HDACs) are part of a vast family of enzymes that have crucial roles in numerous biol. processes, largely through their repressive influence on transcription.  The expression of many HDAC isoforms in eukaryotic cells raises questions about their possible specificity or redundancy, and whether they control global or specific programs of gene expression.  Recent analyses of HDAC knockout mice have revealed highly specific functions of individual HDACs in development and disease.  Mutant mice lacking individual HDACs are a powerful tool for defining the functions of HDACs in vivo and the mol. targets of HDAC inhibitors in disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMWcIo3mrsM7Vg90H21EOLACvtfcHk0li07Eq7jfcsSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFWis7bI&md5=0678d8655e86994cd4f0174c1e9d0eb1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrg2485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg2485%26sid%3Dliteratum%253Aachs%26aulast%3DHaberland%26aufirst%3DM.%26aulast%3DMontgomery%26aufirst%3DR.%2BL.%26aulast%3DOlson%26aufirst%3DE.%2BN.%26atitle%3DThe%2520many%2520roles%2520of%2520histone%2520deacetylases%2520in%2520development%2520and%2520physiology%253A%2520implications%2520for%2520disease%2520and%2520therapy%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2009%26volume%3D10%26spage%3D32%26epage%3D42%26doi%3D10.1038%2Fnrg2485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, T. C.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases and mechanisms of regulation of gene expression</span>. <i>Crit. Rev. Oncog.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1615/CritRevOncog.2015012997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1615%2FCritRevOncog.2015012997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25746103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A280%3ADC%252BC2MnhslCgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=35-47&author=H.+P.+Chenauthor=Y.+T.+Zhaoauthor=T.+C.+Zhao&title=Histone+deacetylases+and+mechanisms+of+regulation+of+gene+expression&doi=10.1615%2FCritRevOncog.2015012997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases and mechanisms of regulation of gene expression</span></div><div class="casAuthors">Chen Hong Ping; Zhao Yu Tina; Zhao Ting C</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncogenesis</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">35-47</span>
        ISSN:<span class="NLM_cas:issn">0893-9675</span>.
    </div><div class="casAbstract">In recent years it has become widely recognized that histone modification plays a pivotal role in controlling gene expression and is involved in a wide spectrum of disease regulation.  Histone acetylation is a major modification that affects gene transcription and is controlled by histone acetyltransferases (HATs) and histone deacetylases (HDACs).  HATs acetylate lysines of histone proteins, resulting in the relaxation of chromatin structure, and they also facilitate gene activation.  Conversely, HDACs remove acetyl groups from hyperacetylated histones and suppress general gene transcription.  In addition to histones, numerous nonhistone proteins can be acetylated and deacetylated, and they also are involved in the regulation of a wide range of diseases.  To date there are 18 HDACs in mammals classified into 4 classes based on homology to yeast HDACs.  Accumulating evidence has revealed that HDACs play crucial roles in a variety of biological processes including inflammation, cell proliferation, apoptosis, and carcinogenesis.  In this review we summarize the current state of knowledge of HDACs in carcinogenesis and describe the involvement of HDACs in cancer-associated molecular processes.  It is hoped than an understanding of the role of HDACs in cancer will lead to the design of more potent and specific drugs targeting selective HDAC proteins for the treatment of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSe2viLetAEXjMsgLhIoICsfW6udTcc2ea3Xl1PNihWXLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnhslCgsg%253D%253D&md5=1ff0202b04c8b2280ae60d82ac81e8f8</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1615%2FCritRevOncog.2015012997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1615%252FCritRevOncog.2015012997%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%2BP.%26aulast%3DZhao%26aufirst%3DY.%2BT.%26aulast%3DZhao%26aufirst%3DT.%2BC.%26atitle%3DHistone%2520deacetylases%2520and%2520mechanisms%2520of%2520regulation%2520of%2520gene%2520expression%26jtitle%3DCrit.%2520Rev.%2520Oncog.%26date%3D2015%26volume%3D20%26spage%3D35%26epage%3D47%26doi%3D10.1615%2FCritRevOncog.2015012997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregoretti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodson, H. V.</span></span> <span> </span><span class="NLM_article-title">Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>338</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2004.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.jmb.2004.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15050820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisFyksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2004&pages=17-31&author=I.+Gregorettiauthor=Y.-M.+Leeauthor=H.+V.+Goodson&title=Molecular+evolution+of+the+histone+deacetylase+family%3A+functional+implications+of+phylogenetic+analysis&doi=10.1016%2Fj.jmb.2004.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Evolution of the Histone Deacetylase Family: Functional Implications of Phylogenetic Analysis</span></div><div class="casAuthors">Gregoretti, Ivan V.; Lee, Yun-Mi; Goodson, Holly V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-31</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) modify core histones and participate in large regulatory complexes that both suppress and enhance transcription.  Recent studies indicate that some HDACs can act on non-histone proteins as well.  Interest in these enzymes is growing because HDAC inhibitors appear to be promising therapeutic agents against cancer and a variety of other diseases.  Thus far, 11 members of the HDAC family have been identified in humans, but few have been characterized in detail.  To better define the biol. function of these proteins, make maximal use of studies performed in other systems, and assist in drug development efforts, we have performed a phylogenetic anal. of all HDAC-related proteins in all fully sequenced free-living organisms.  Previous analyses have divided non-sirtuin HDACs into two groups, classes 1 and 2.  We find that HDACs can be divided into three equally distinct groups: class 1, class 2, and a third class consisting of proteins related to the recently identified human HDAC11 gene.  We term this novel group "class 4" to distinguish it from the unrelated "class 3" sirtuin deacetylases.  Anal. of gene duplication events indicates that the common ancestor of metazoan organisms contained two class 1, two class 2, and a single class 4 HDAC.  Examn. of HDAC characteristics in light of these evolutionary relationships leads to functional predictions, among them that self-assocn. is common among HDAC proteins.  All three HDAC classes (including class 4) exist in eubacteria.  Phylogenetic anal. of bacterial HDAC relatives suggests that all three HDAC classes precede the evolution of histone proteins and raises the possibility that the primary activity of some "histone deacetylase" enzymes is directed against non-histone substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVqdtToKvZgLVg90H21EOLACvtfcHk0li07Eq7jfcsSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisFyksro%253D&md5=1748e3b88d8f3b774db50eb19799f63c</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2004.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2004.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DGregoretti%26aufirst%3DI.%26aulast%3DLee%26aufirst%3DY.-M.%26aulast%3DGoodson%26aufirst%3DH.%2BV.%26atitle%3DMolecular%2520evolution%2520of%2520the%2520histone%2520deacetylase%2520family%253A%2520functional%2520implications%2520of%2520phylogenetic%2520analysis%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2004%26volume%3D338%26spage%3D17%26epage%3D31%26doi%3D10.1016%2Fj.jmb.2004.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blander, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guarente, L.</span></span> <span> </span><span class="NLM_article-title">The sir2 family of protein decetylases</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">417</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.73.011303.073651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1146%2Fannurev.biochem.73.011303.073651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15189148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslags7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2004&pages=417-435&author=G.+Blanderauthor=L.+Guarente&title=The+sir2+family+of+protein+decetylases&doi=10.1146%2Fannurev.biochem.73.011303.073651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The Sir2 family of protein deacetylases</span></div><div class="casAuthors">Blander, Gil; Guarente, Leonard</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">417-435</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The yeast SIR protein complex has been implicated in transcription silencing and suppression of recombination.  The Sir complex represses transcription at telomeres, mating-type loci, and ribosomal DNA.  Unlike SIR3 and SIR4, the SIR2 gene is highly conserved in organisms ranging from archaea to humans.  Interestingly, Sir2 is active as an NAD+-dependent deacetylase, which is broadly conserved from bacteria to higher eukaryotes.  In this review, we discuss the role of NAD+, the unusual products of the deacetylation reaction, the Sir2 structure, and the Sir2 chem. inhibitors and activators that were recently identified.  We summarize the current knowledge of the Sir2 homologs from different organisms, and finally we discuss the role of Sir2 in caloric restriction and aging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGOpp_Sk7r0rVg90H21EOLACvtfcHk0lj0UWA_l6txEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslags7c%253D&md5=0ee832d37d4865477d458ea5ce579c6a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.73.011303.073651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.73.011303.073651%26sid%3Dliteratum%253Aachs%26aulast%3DBlander%26aufirst%3DG.%26aulast%3DGuarente%26aufirst%3DL.%26atitle%3DThe%2520sir2%2520family%2520of%2520protein%2520decetylases%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2004%26volume%3D73%26spage%3D417%26epage%3D435%26doi%3D10.1146%2Fannurev.biochem.73.011303.073651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Ruijter, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gennip, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kuilenburg, A. B.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases (HDACs): characterization of the classical HDAC family</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">737</span>– <span class="NLM_lpage">749</span>, <span class="refDoi"> DOI: 10.1042/bj20021321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1042%2Fbj20021321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=12429021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvFKiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2003&pages=737-749&author=A.+J.+de%0ARuijterauthor=A.+H.+van+Gennipauthor=H.+N.+Caronauthor=S.+Kempauthor=A.+B.+van+Kuilenburg&title=Histone+deacetylases+%28HDACs%29%3A+characterization+of+the+classical+HDAC+family&doi=10.1042%2Fbj20021321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases (HDACs): characterization of the classical HDAC family</span></div><div class="casAuthors">de Ruijter, Annemieke J. M.; van Gennip, Albert H.; Caron, Huib N.; Kemp, Stephan; van Kuilenburg, Andre B. P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">737-749</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review, with refs.  Transcriptional regulation in eukaryotes occurs within a chromatin setting, and is strongly influenced by the post-translational modification of histones, the building blocks of chromatin, such as methylation, phosphorylation and acetylation.  Acetylation is probably the best understood of these modifications: hyperacetylation leads to an increase in the expression of particular genes, and hypoacetylation has the opposite effect.  Many studies have identified several large, multisubunit enzyme complexes that are responsible for the targeted deacetylation of histones.  The aim of this review is to give a comprehensive overview of the structure, function and tissue distribution of members of the classical histone deacetylase (HDAC) family, in order to gain insight into the regulation of gene expression through HDAC activity.  SAGE (serial anal. of gene expression) data show that HDACs are generally expressed in almost all tissues investigated.  Surprisingly, no major differences were obsd. between the expression pattern in normal and malignant tissues.  However, significant variation in HDAC expression was obsd. within tissue types.  HDAC inhibitors have been shown to induce specific changes in gene expression and to influence a variety of other processes, including growth arrest, differentiation, cytotoxicity and induction of apoptosis.  This challenging field has generated many fascinating results which will ultimately lead to a better understanding of the mechanism of gene transcription as a whole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN1-6ct5EQtrVg90H21EOLACvtfcHk0lj0UWA_l6txEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvFKiu7o%253D&md5=8a521cd3ddcf046b4b806ebf9f1476b4</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1042%2Fbj20021321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj20021321%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BRuijter%26aufirst%3DA.%2BJ.%26aulast%3Dvan%2BGennip%26aufirst%3DA.%2BH.%26aulast%3DCaron%26aufirst%3DH.%2BN.%26aulast%3DKemp%26aufirst%3DS.%26aulast%3Dvan%2BKuilenburg%26aufirst%3DA.%2BB.%26atitle%3DHistone%2520deacetylases%2520%2528HDACs%2529%253A%2520characterization%2520of%2520the%2520classical%2520HDAC%2520family%26jtitle%3DBiochem.%2520J.%26date%3D2003%26volume%3D370%26spage%3D737%26epage%3D749%26doi%3D10.1042%2Fbj20021321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holbert, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marmorstein, R.</span></span> <span> </span><span class="NLM_article-title">Structure and activity of enzymes that remove histone modifications</span>. <i>Curr. Opin. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">680</span>, <span class="refDoi"> DOI: 10.1016/j.sbi.2005.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.sbi.2005.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16263263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1GnsrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=673-680&author=M.+A.+Holbertauthor=R.+Marmorstein&title=Structure+and+activity+of+enzymes+that+remove+histone+modifications&doi=10.1016%2Fj.sbi.2005.10.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and activity of enzymes that remove histone modifications</span></div><div class="casAuthors">Holbert, Marc A.; Marmorstein, Ronen</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">673-680</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The post-translational modification of histones plays an important role in chromatin regulation, a process that insures the fidelity of gene expression and other DNA transactions.  Equally important as the enzymes that generate these modifications are the enzymes that remove them.  Recent studies have identified some of the enzymes that remove histone modifications and have characterized their activities.  In addn., structural and biochem. studies of these enzymes have focused on histone lysine deacetylase HDAC8, and sirtuin, and on arginine and lysine demethylases PAD and BHC110/LSD1, resp.  These new findings may be used as a context to present new information that contributes to an understanding of chromatin regulation, and to pose remaining questions pertaining to the activities of these enzymes and the roles they play in chromatin regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5ESHacfk8eLVg90H21EOLACvtfcHk0lj0UWA_l6txEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1GnsrzN&md5=ab2aa48fa7d7f49f7a56e1c55a0cc413</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2005.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2005.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DHolbert%26aufirst%3DM.%2BA.%26aulast%3DMarmorstein%26aufirst%3DR.%26atitle%3DStructure%2520and%2520activity%2520of%2520enzymes%2520that%2520remove%2520histone%2520modifications%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2005%26volume%3D15%26spage%3D673%26epage%3D680%26doi%3D10.1016%2Fj.sbi.2005.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zupkovitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tischler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadzak, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grausenburger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweifer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiocca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiser, C.</span></span> <span> </span><span class="NLM_article-title">Negative and positive regulation of gene expression by mouse histone deacetylase 1</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">7913</span>– <span class="NLM_lpage">7928</span>, <span class="refDoi"> DOI: 10.1128/MCB.01220-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1128%2FMCB.01220-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16940178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFemur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2006&pages=7913-7928&author=G.+Zupkovitzauthor=J.+Tischlerauthor=M.+Poschauthor=I.+Sadzakauthor=K.+Ramsauerauthor=G.+Eggerauthor=R.+Grausenburgerauthor=N.+Schweiferauthor=S.+Chioccaauthor=T.+Deckerauthor=C.+Seiser&title=Negative+and+positive+regulation+of+gene+expression+by+mouse+histone+deacetylase+1&doi=10.1128%2FMCB.01220-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Negative and positive regulation of gene expression by mouse histone deacetylase 1</span></div><div class="casAuthors">Zupkovitz, Gordin; Tischler, Julia; Posch, Markus; Sadzak, Iwona; Ramsauer, Katrin; Egger, Gerda; Grausenburger, Reinhard; Schweifer, Norbert; Chiocca, Susanna; Decker, Thomas; Seiser, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7913-7928</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) catalyze the removal of acetyl groups from core histones.  Because of their capacity to induce local condensation of chromatin, HDACs are generally considered repressors of transcription.  In this report, we analyzed the role of the class I histone deacetylase HDAC1 as a transcriptional regulator by comparing the expression profiles of wild-type and HDAC1-deficient embryonic stem cells.  A specific subset of mouse genes (7%) was deregulated in the absence of HDAC1.  We identified several putative tumor suppressors (JunB, Prss11, and Plagl1) and imprinted genes (Igf2, H19, and p57) as novel HDAC1 targets.  The majority of HDAC1 target genes showed reduced expression accompanied by recruitment of HDAC1 and local redn. in histone acetylation at regulatory regions.  At some target genes, the related deacetylase HDAC2 partially masks the loss of HDAC1.  A second group of genes was found to be downregulated in HDAC1-deficient cells, predominantly by addnl. recruitment of HDAC2 in the absence of HDAC1.  Finally, a small set of genes (Gja1, Irf1, and Gbp2) was found to require HDAC activity and recruitment of HDAC1 for their transcriptional activation.  Our study reveals a regulatory cross talk between HDAC1 and HDAC2 and a novel function for HDAC1 as a transcriptional coactivator.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoizxopSxe3nLVg90H21EOLACvtfcHk0lggw1u60P0WhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFemur%252FJ&md5=4ec90ff6da2f26688f1c932dd8a27d93</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1128%2FMCB.01220-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.01220-06%26sid%3Dliteratum%253Aachs%26aulast%3DZupkovitz%26aufirst%3DG.%26aulast%3DTischler%26aufirst%3DJ.%26aulast%3DPosch%26aufirst%3DM.%26aulast%3DSadzak%26aufirst%3DI.%26aulast%3DRamsauer%26aufirst%3DK.%26aulast%3DEgger%26aufirst%3DG.%26aulast%3DGrausenburger%26aufirst%3DR.%26aulast%3DSchweifer%26aufirst%3DN.%26aulast%3DChiocca%26aufirst%3DS.%26aulast%3DDecker%26aufirst%3DT.%26aulast%3DSeiser%26aufirst%3DC.%26atitle%3DNegative%2520and%2520positive%2520regulation%2520of%2520gene%2520expression%2520by%2520mouse%2520histone%2520deacetylase%25201%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2006%26volume%3D26%26spage%3D7913%26epage%3D7928%26doi%3D10.1128%2FMCB.01220-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lagger, G.</span></span> <span> </span><span class="NLM_article-title">Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2672</span>– <span class="NLM_lpage">2681</span>, <span class="refDoi"> DOI: 10.1093/emboj/21.11.2672</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1093%2Femboj%2F21.11.2672" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=12032080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvV2is70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=2672-2681&author=G.+Lagger&title=Essential+function+of+histone+deacetylase+1+in+proliferation+control+and+CDK+inhibitor+repression&doi=10.1093%2Femboj%2F21.11.2672"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression</span></div><div class="casAuthors">Lagger, Gerda; O'Carroll, Donal; Rembold, Martina; Khier, Harald; Tischler, Julia; Weitzer, Georg; Schuettengruber, Bernd; Hauser, Christoph; Brunmeir, Reinhard; Jenuwein, Thomas; Seiser, Christian</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2672-2681</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) modulate chromatin structure and transcription, but little is known about their function in mammalian development.  HDAC1 was implicated previously in the repression of genes required for cell proliferation and differentiation.  Here we show that targeted disruption of both HDAC1 alleles results in embryonic lethality before E10.5 due to severe proliferation defects and retardation in development.  HDAC1-deficient embryonic stem cells show reduced proliferation rates, which correlate with decreased cyclin-assocd. kinase activities and elevated levels of the cyclin-dependent kinase inhibitors p21WAF1/CIP1 and p27KIP1.  Similarly, expression of p21 and p27 is up-regulated in HDAC1-null embryos.  In addn., loss of HDAC1 leads to significantly reduced overall deacetylase activity, hyperacetylation of a subset of histones H3 and H4 and concomitant changes in other histone modifications.  The expression of HDAC2 and HDAC3 is induced in HDAC1-deficient cells, but cannot compensate for loss of the enzyme, suggesting a unique function for HDAC1.  Our study provides the first evidence that a histone deacetylase is essential for unrestricted cell proliferation by repressing the expression of selective cell cycle inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK1zFkPbWlqbVg90H21EOLACvtfcHk0lggw1u60P0WhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvV2is70%253D&md5=371e6d091fde2eb4c5efd030bd34e7f6</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F21.11.2672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F21.11.2672%26sid%3Dliteratum%253Aachs%26aulast%3DLagger%26aufirst%3DG.%26atitle%3DEssential%2520function%2520of%2520histone%2520deacetylase%25201%2520in%2520proliferation%2520control%2520and%2520CDK%2520inhibitor%2520repression%26jtitle%3DEMBO%2520J.%26date%3D2002%26volume%3D21%26spage%3D2672%26epage%3D2681%26doi%3D10.1093%2Femboj%2F21.11.2672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potthoff, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fielitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E. N.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1790</span>– <span class="NLM_lpage">1802</span>, <span class="refDoi"> DOI: 10.1101/gad.1563807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1101%2Fgad.1563807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=17639084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2sXoslSisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=1790-1802&author=R.+L.+Montgomeryauthor=C.+A.+Davisauthor=M.+J.+Potthoffauthor=M.+Haberlandauthor=J.+Fielitzauthor=X.+Qiauthor=J.+A.+Hillauthor=J.+A.+Richardsonauthor=E.+N.+Olson&title=Histone+deacetylases+1+and+2+redundantly+regulate+cardiac+morphogenesis%2C+growth%2C+and+contractility&doi=10.1101%2Fgad.1563807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility</span></div><div class="casAuthors">Montgomery, Rusty L.; Davis, Christopher A.; Potthoff, Matthew J.; Haberland, Michael; Fielitz, Jens; Qi, Xiaoxia; Hill, Joseph A.; Richardson, James A.; Olson, Eric N.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1790-1802</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) tighten chromatin structure and repress gene expression through the removal of acetyl groups from histone tails.  The class I HDACs, HDAC1 and HDAC2, are expressed ubiquitously, but their potential roles in tissue-specific gene expression and organogenesis have not been defined.  To explore the functions of HDAC1 and HDAC2 in vivo, the authors generated mice with conditional null alleles of both genes.  Whereas global deletion of HDAC1 results in death by embryonic day 9.5, mice lacking HDAC2 survive until the perinatal period, when they succumb to a spectrum of cardiac defects, including obliteration of the lumen of the right ventricle, excessive hyperplasia and apoptosis of cardiomyocytes, and bradycardia.  Cardiac-specific deletion of either HDAC1 or HDAC2 does not evoke a phenotype, whereas cardiac-specific deletion of both genes results in neonatal lethality, accompanied by cardiac arrhythmias, dilated cardiomyopathy, and up-regulation of genes encoding skeletal muscle-specific contractile proteins and calcium channels.  These results reveal cell-autonomous and non-cell-autonomous functions for HDAC1 and HDAC2 in the control of myocardial growth, morphogenesis, and contractility, which reflect partially redundant roles of these enzymes in tissue-specific transcriptional repression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9hvzvEx0USbVg90H21EOLACvtfcHk0lggw1u60P0WhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXoslSisb0%253D&md5=d650513a79a442a07af5a631a8d4c1a3</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1101%2Fgad.1563807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1563807%26sid%3Dliteratum%253Aachs%26aulast%3DMontgomery%26aufirst%3DR.%2BL.%26aulast%3DDavis%26aufirst%3DC.%2BA.%26aulast%3DPotthoff%26aufirst%3DM.%2BJ.%26aulast%3DHaberland%26aufirst%3DM.%26aulast%3DFielitz%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DX.%26aulast%3DHill%26aufirst%3DJ.%2BA.%26aulast%3DRichardson%26aufirst%3DJ.%2BA.%26aulast%3DOlson%26aufirst%3DE.%2BN.%26atitle%3DHistone%2520deacetylases%25201%2520and%25202%2520redundantly%2520regulate%2520cardiac%2520morphogenesis%252C%2520growth%252C%2520and%2520contractility%26jtitle%3DGenes%2520Dev.%26date%3D2007%26volume%3D21%26spage%3D1790%26epage%3D1802%26doi%3D10.1101%2Fgad.1563807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinsey, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antos, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E. N.</span></span> <span> </span><span class="NLM_article-title">Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">479</span>– <span class="NLM_lpage">488</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(02)00861-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2FS0092-8674%2802%2900861-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=12202037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD38Xmslyjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2002&pages=479-488&author=C.+L.+Zhangauthor=T.+A.+McKinseyauthor=S.+Changauthor=C.+L.+Antosauthor=J.+A.+Hillauthor=E.+N.+Olson&title=Class+II+histone+deacetylases+act+as+signal-responsive+repressors+of+cardiac+hypertrophy&doi=10.1016%2FS0092-8674%2802%2900861-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy</span></div><div class="casAuthors">Zhang, Chun Li; McKinsey, Timothy A.; Chang, Shurong; Antos, Christopher L.; Hill, Joseph A.; Olson, Eric N.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">479-488</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The heart responds to stress signals by hypertrophic growth, which is accompanied by activation of the MEF2 transcription factor and reprogramming of cardiac gene expression.  We show here that class II histone deacetylases (HDACs), which repress MEF2 activity, are substrates for a stress-responsive kinase specific for conserved serines that regulate MEF2-HDAC interactions.  Signal-resistant HDAC mutants lacking these phosphorylation sites are refractory to hypertrophic signaling and inhibit cardiomyocyte hypertrophy.  Conversely, mutant mice lacking the class II HDAC, HDAC9, are sensitized to hypertrophic signals and exhibit stress-dependent cardiomegaly.  Thus, class II HDACs act as signal-responsive suppressors of the transcriptional program governing cardiac hypertrophy and heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov5BKDzDFqOrVg90H21EOLACvtfcHk0lismN-yk18xrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xmslyjt7w%253D&md5=9eb74a943a5e10834d5fc343879737e2</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2802%2900861-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252802%252900861-9%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%2BL.%26aulast%3DMcKinsey%26aufirst%3DT.%2BA.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DAntos%26aufirst%3DC.%2BL.%26aulast%3DHill%26aufirst%3DJ.%2BA.%26aulast%3DOlson%26aufirst%3DE.%2BN.%26atitle%3DClass%2520II%2520histone%2520deacetylases%2520act%2520as%2520signal-responsive%2520repressors%2520of%2520cardiac%2520hypertrophy%26jtitle%3DCell%26date%3D2002%26volume%3D110%26spage%3D479%26epage%3D488%26doi%3D10.1016%2FS0092-8674%2802%2900861-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolger, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, T.-P.</span></span> <span> </span><span class="NLM_article-title">Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">9544</span>– <span class="NLM_lpage">9553</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.1826-05.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1523%2FJNEUROSCI.1826-05.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16221865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFGmu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=9544-9553&author=T.+A.+Bolgerauthor=T.-P.+Yao&title=Intracellular+trafficking+of+histone+deacetylase+4+regulates+neuronal+cell+death&doi=10.1523%2FJNEUROSCI.1826-05.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death</span></div><div class="casAuthors">Bolger, Timothy A.; Yao, Tso-Pang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">9544-9553</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Histone deacetylase 4 (HDAC4) undergoes signal-dependent shuttling between the cytoplasm and nucleus, which is regulated in part by Ca2+/calmodulin-dependent kinase (CaMK)-mediated phosphorylation.  Here, the authors report that HDAC4 intracellular trafficking is important in regulating neuronal cell death.  HDAC4 is normally localized to the cytoplasm in brain tissue and cultured cerebellar granule neurons (CGNs).  However, in response to low-K+ or excitotoxic glutamate conditions that induce neuronal cell death, HDAC4 rapidly translocates into the nucleus of cultured CGNs.  Treatment with neuronal survival factor BDNF suppressed HDAC4 nuclear translocation, whereas a pro-apoptotic CaMK inhibitor stimulated HDAC4 nuclear accumulation.  Moreover, ectopic expression of nuclear-localized HDAC4 promoted neuronal apoptosis and repressed the transcriptional activities of myocyte enhancer factor 2 and cAMP response element-binding protein, survival factors in neurons.  In contrast, inactivation of HDAC4 by small interfering RNA or HDAC inhibitors suppressed neuronal cell death.  Finally, an increase of nuclear HDAC4 in granule neurons was also obsd. in weaver mice, which harbored a mutation that promoted CGN apoptosis.  The data identified HDAC4 and its intracellular trafficking as key effectors of multiple pathways that regulate neuronal cell death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv9TwUmr7aY7Vg90H21EOLACvtfcHk0lgenKkBTH68NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFGmu7jI&md5=c258df67be207d4af476d4f8ed6f4d40</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.1826-05.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.1826-05.2005%26sid%3Dliteratum%253Aachs%26aulast%3DBolger%26aufirst%3DT.%2BA.%26aulast%3DYao%26aufirst%3DT.-P.%26atitle%3DIntracellular%2520trafficking%2520of%2520histone%2520deacetylase%25204%2520regulates%2520neuronal%2520cell%2520death%26jtitle%3DJ.%2520Neurosci.%26date%3D2005%26volume%3D25%26spage%3D9544%26epage%3D9553%26doi%3D10.1523%2FJNEUROSCI.1826-05.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Outeiro, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontopoulos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kufareva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strathearn, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amore, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volk, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxwell, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochet, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abagyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feany, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazantsev, A. G.</span></span> <span> </span><span class="NLM_article-title">Sirtuin 2 inhibitors rescue α-synuclein-mediated toxicity in models of Parkinson’s disease</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>317</i></span>,  <span class="NLM_fpage">516</span>– <span class="NLM_lpage">519</span>, <span class="refDoi"> DOI: 10.1126/science.1143780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1126%2Fscience.1143780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=17588900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotFylurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=317&publication_year=2007&pages=516-519&author=T.+F.+Outeiroauthor=E.+Kontopoulosauthor=S.+M.+Altmannauthor=I.+Kufarevaauthor=K.+E.+Strathearnauthor=A.+M.+Amoreauthor=C.+B.+Volkauthor=M.+M.+Maxwellauthor=J.-C.+Rochetauthor=P.+J.+McLeanauthor=A.+B.+Youngauthor=R.+Abagyanauthor=M.+B.+Feanyauthor=B.+T.+Hymanauthor=A.+G.+Kazantsev&title=Sirtuin+2+inhibitors+rescue+%CE%B1-synuclein-mediated+toxicity+in+models+of+Parkinson%E2%80%99s+disease&doi=10.1126%2Fscience.1143780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Sirtuin 2 Inhibitors Rescue α-Synuclein-Mediated Toxicity in Models of Parkinson's Disease</span></div><div class="casAuthors">Outeiro, Tiago Fleming; Kontopoulos, Eirene; Altmann, Stephen M.; Kufareva, Irina; Strathearn, Katherine E.; Amore, Allison M.; Volk, Catherine B.; Maxwell, Michele M.; Rochet, Jean-Christophe; McLean, Pamela J.; Young, Anne B.; Abagyan, Ruben; Feany, Mel B.; Hyman, Bradley T.; Kazantsev, Aleksey G.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">317</span>
        (<span class="NLM_cas:issue">5837</span>),
    <span class="NLM_cas:pages">516-519</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The sirtuins are members of the histone deacetylase family of proteins that participate in a variety of cellular functions and play a role in aging.  We identified a potent inhibitor of sirtuin 2 (SIRT2) and found that inhibition of SIRT2 rescued α-synuclein toxicity and modified inclusion morphol. in a cellular model of Parkinson's disease.  Genetic inhibition of SIRT2 via small interfering RNA similarly rescued α-synuclein toxicity.  Furthermore, the inhibitors protected against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson's disease.  The results suggest a link between neurodegeneration and aging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm5psHCGzkkLVg90H21EOLACvtfcHk0lg2p1KvkggmEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotFylurs%253D&md5=4b8914c34ad0f45fb51b94701609bfa6</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1126%2Fscience.1143780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1143780%26sid%3Dliteratum%253Aachs%26aulast%3DOuteiro%26aufirst%3DT.%2BF.%26aulast%3DKontopoulos%26aufirst%3DE.%26aulast%3DAltmann%26aufirst%3DS.%2BM.%26aulast%3DKufareva%26aufirst%3DI.%26aulast%3DStrathearn%26aufirst%3DK.%2BE.%26aulast%3DAmore%26aufirst%3DA.%2BM.%26aulast%3DVolk%26aufirst%3DC.%2BB.%26aulast%3DMaxwell%26aufirst%3DM.%2BM.%26aulast%3DRochet%26aufirst%3DJ.-C.%26aulast%3DMcLean%26aufirst%3DP.%2BJ.%26aulast%3DYoung%26aufirst%3DA.%2BB.%26aulast%3DAbagyan%26aufirst%3DR.%26aulast%3DFeany%26aufirst%3DM.%2BB.%26aulast%3DHyman%26aufirst%3DB.%2BT.%26aulast%3DKazantsev%26aufirst%3DA.%2BG.%26atitle%3DSirtuin%25202%2520inhibitors%2520rescue%2520%25CE%25B1-synuclein-mediated%2520toxicity%2520in%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DScience%26date%3D2007%26volume%3D317%26spage%3D516%26epage%3D519%26doi%3D10.1126%2Fscience.1143780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ota, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokunaga, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hikasa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iijima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akishita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneki, M.</span></span> <span> </span><span class="NLM_article-title">Sirt1 inhibitor, sirtinol, induces senescence-like growth arrest with attenuated Ras–MAPK signaling in human cancer cells</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">176</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1209049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fsj.onc.1209049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16170353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtV2isA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=176-185&author=H.+Otaauthor=E.+Tokunagaauthor=K.+Changauthor=M.+Hikasaauthor=K.+Iijimaauthor=M.+Etoauthor=K.+Kozakiauthor=M.+Akishitaauthor=Y.+Ouchiauthor=M.+Kaneki&title=Sirt1+inhibitor%2C+sirtinol%2C+induces+senescence-like+growth+arrest+with+attenuated+Ras%E2%80%93MAPK+signaling+in+human+cancer+cells&doi=10.1038%2Fsj.onc.1209049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells</span></div><div class="casAuthors">Ota, H.; Tokunaga, E.; Chang, K.; Hikasa, M.; Iijima, K.; Eto, M.; Kozaki, K.; Akishita, M.; Ouchi, Y.; Kaneki, M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">176-185</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The induction of senescence-like growth arrest has emerged as a putative contributor to the anticancer effects of chemotherapeutic agents.  Clin. trials are underway to evaluate the efficacy of inhibitors for class I and II histone deacetylases to treat malignancies.  However, a potential antiproliferative effect of inhibitor for Sirt1, which is an NAD+-dependent deacetylase and belongs to class III histone deacetylases, has not yet been explored.  Here, we show that Sirt1 inhibitor, Sirtinol, induced senescence-like growth arrest characterized by induction of senescence-assocd. β-galactosidase activity and increased expression of plasminogen activator inhibitor 1 in human breast cancer MCF-7 cells and lung cancer H1299 cells.  Sirtinol-induced senescence-like growth arrest was accompanied by impaired activation of mitogen-activated protein kinase (MAPK) pathways, namely, extracellular-regulated protein kinase, c-jun N-terminal kinase and p38 MAPK, in response to epidermal growth factor (EGF) and insulin-like growth factor-I (IGF-I).  Active Ras was reduced in Sirtinol-treated senescent cells compared with untreated cells.  However, tyrosine phosphorylation of the receptors for EGF and IGF-I and Akt/PKB activation were unaltered by Sirtinol treatment.  These results suggest that inhibitors for Sirt1 may have anticancer potential, and that impaired activation of Ras-MAPK pathway might take part in a senescence-like growth arrest program induced by Sirtinol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA2FwjUcUUy7Vg90H21EOLACvtfcHk0lg2p1KvkggmEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtV2isA%253D%253D&md5=f2ea6ec5fffad873813d6b7979deb8e3</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1209049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1209049%26sid%3Dliteratum%253Aachs%26aulast%3DOta%26aufirst%3DH.%26aulast%3DTokunaga%26aufirst%3DE.%26aulast%3DChang%26aufirst%3DK.%26aulast%3DHikasa%26aufirst%3DM.%26aulast%3DIijima%26aufirst%3DK.%26aulast%3DEto%26aufirst%3DM.%26aulast%3DKozaki%26aufirst%3DK.%26aulast%3DAkishita%26aufirst%3DM.%26aulast%3DOuchi%26aufirst%3DY.%26aulast%3DKaneki%26aufirst%3DM.%26atitle%3DSirt1%2520inhibitor%252C%2520sirtinol%252C%2520induces%2520senescence-like%2520growth%2520arrest%2520with%2520attenuated%2520Ras%25E2%2580%2593MAPK%2520signaling%2520in%2520human%2520cancer%2520cells%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26spage%3D176%26epage%3D185%26doi%3D10.1038%2Fsj.onc.1209049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span> <span> </span><span class="NLM_article-title">The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1038/nrm2346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnrm2346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=18292778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitlGnurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=206-218&author=X.-J.+Yangauthor=E.+Seto&title=The+Rpd3%2FHda1+family+of+lysine+deacetylases%3A+from+bacteria+and+yeast+to+mice+and+men&doi=10.1038%2Fnrm2346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men</span></div><div class="casAuthors">Yang, Xiang-Jiao; Seto, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">206-218</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein lysine deacetylases have a pivotal role in numerous biol. processes and can be divided into the Rpd3/Hda1 and sirtuin families, each having members in diverse organisms including prokaryotes.  In vertebrates, the Rpd3/Hda1 family contains 11 members, traditionally referred to as histone deacetylases (HDAC) 1-11, which are further grouped into classes I, II and IV.  Whereas most class I HDACs are subunits of multiprotein nuclear complexes that are crucial for transcriptional repression and epigenetic landscaping, class II members regulate cytoplasmic processes or function as signal transducers that shuttle between the cytoplasm and the nucleus.  Little is known about class IV HDAC11, although its evolutionary conservation implies a fundamental role in various organisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRiVyZexxGn7Vg90H21EOLACvtfcHk0ljaAn0Kcpgrjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitlGnurk%253D&md5=f11f89567feadf9cd38b3852dc44c382</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrm2346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2346%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.-J.%26aulast%3DSeto%26aufirst%3DE.%26atitle%3DThe%2520Rpd3%252FHda1%2520family%2520of%2520lysine%2520deacetylases%253A%2520from%2520bacteria%2520and%2520yeast%2520to%2520mice%2520and%2520men%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2008%26volume%3D9%26spage%3D206%26epage%3D218%26doi%3D10.1038%2Fnrm2346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M.</span></span> <span> </span><span class="NLM_article-title">Epigenome-based personalized medicine in human cancer</span>. <i>Epigenomics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">133</span>, <span class="refDoi"> DOI: 10.2217/epi.15.84</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.2217%2Fepi.15.84" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=26344672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC28Xos1aqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=119-133&author=W.+Yanauthor=J.+G.+Hermanauthor=M.+Guo&title=Epigenome-based+personalized+medicine+in+human+cancer&doi=10.2217%2Fepi.15.84"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenome-based personalized medicine in human cancer</span></div><div class="casAuthors">Yan, Wenji; Herman, James G.; Guo, Mingzhou</div><div class="citationInfo"><span class="NLM_cas:title">Epigenomics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">119-133</span>CODEN:
                <span class="NLM_cas:coden">EPIGC7</span>;
        ISSN:<span class="NLM_cas:issn">1750-192X</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Cancer genome sequencing has created an opportunity for precision medicine.  Thus far, genetic alterations can only be used to guide treatment for small subsets of certain cancer types with these key alterations.  Similar to mutations, epigenetic events are equally suitable for personalized medicine.  DNA methylation alterations have been used to identify tumor-specific drug responsive markers.  Methylation of MGMT sensitizes gliomas to alkylating agents is an example of epigenetic personalized medicine.  Recent studies have revealed that 5-azacytidine and decitabine show activity in myelodysplasia, lung and other cancers.  There are currently at least 20 kinds of histone deacetylase inhibitors in clin. testing.  Inhibitors targeting other epigenetic regulators are being clin. tested, such as EZH2 inhibitor EPZ-6438.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_za-KvY9spLVg90H21EOLACvtfcHk0ljaAn0Kcpgrjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xos1aqtA%253D%253D&md5=f872718075e1a9b7f7788965fe143c53</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2217%2Fepi.15.84&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fepi.15.84%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DW.%26aulast%3DHerman%26aufirst%3DJ.%2BG.%26aulast%3DGuo%26aufirst%3DM.%26atitle%3DEpigenome-based%2520personalized%2520medicine%2520in%2520human%2520cancer%26jtitle%3DEpigenomics%26date%3D2016%26volume%3D8%26spage%3D119%26epage%3D133%26doi%3D10.2217%2Fepi.15.84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halkidou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaughan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, C. N.</span></span> <span> </span><span class="NLM_article-title">Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer</span>. <i>Prostate</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1002/pros.20022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1002%2Fpros.20022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15042618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktl2lsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2004&pages=177-189&author=K.+Halkidouauthor=L.+Gaughanauthor=S.+Cookauthor=H.+Y.+Leungauthor=D.+E.+Nealauthor=C.+N.+Robson&title=Upregulation+and+nuclear+recruitment+of+HDAC1+in+hormone+refractory+prostate+cancer&doi=10.1002%2Fpros.20022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer</span></div><div class="casAuthors">Halkidou, Kalipso; Gaughan, Luke; Cook, Susan; Leung, Hing Y.; Neal, David E.; Robson, Craig N.</div><div class="citationInfo"><span class="NLM_cas:title">Prostate (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">177-189</span>CODEN:
                <span class="NLM_cas:coden">PRSTDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-4137</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Histone deacetylase 1(HDAC1) is a co-repressor involved in differentiation and proliferation control.  It is upregulated in malignant compared to benign tissue, and targets a no. of transcription factors including p53.  By immunohistochem., HDAC1 protein expression was investigated in human prostate specimens and the CWR22 mouse xenograft model.  Flow cytometry and deconvolution immunofluorescence were also performed.  HDAC1 was upregulated in pre-malignant and malignant lesions, with the highest increase in expression in hormone refractory (HR) cancer.  Using the CWR22 xenograft model the authors showed androgen dependent regulation of HDAC1.  HDAC1 overexpression led to a significant increase in proliferation and a shift towards the undifferentiated cytokeratin (CK) profile in a PC3M deriv. clone constitutively expressing HDAC1.  This study underlines the importance of HDAC1 in cell proliferation and the development of prostate cancer (CaP) and proposes a mechanism for HDAC1 nuclear recruitment.  HDAC1 may constitute a crucial therapeutic target particularly in the most lethal phase of androgen independence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos2Ok-5duE2bVg90H21EOLACvtfcHk0ljaAn0Kcpgrjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktl2lsLo%253D&md5=f5a4d076fdd9b3334cd756c1133c58f4</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fpros.20022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpros.20022%26sid%3Dliteratum%253Aachs%26aulast%3DHalkidou%26aufirst%3DK.%26aulast%3DGaughan%26aufirst%3DL.%26aulast%3DCook%26aufirst%3DS.%26aulast%3DLeung%26aufirst%3DH.%2BY.%26aulast%3DNeal%26aufirst%3DD.%2BE.%26aulast%3DRobson%26aufirst%3DC.%2BN.%26atitle%3DUpregulation%2520and%2520nuclear%2520recruitment%2520of%2520HDAC1%2520in%2520hormone%2520refractory%2520prostate%2520cancer%26jtitle%3DProstate%26date%3D2004%26volume%3D59%26spage%3D177%26epage%3D189%26doi%3D10.1002%2Fpros.20022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joo, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. Y.</span></span> <span> </span><span class="NLM_article-title">Expression profile of histone deacetylase 1 in gastric cancer tissues</span>. <i>Jpn. J. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">1300</span>– <span class="NLM_lpage">1304</span>, <span class="refDoi"> DOI: 10.1111/j.1349-7006.2001.tb02153.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1111%2Fj.1349-7006.2001.tb02153.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=11749695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtV2jt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2001&pages=1300-1304&author=J.+H.+Choiauthor=H.+J.+Kwonauthor=B.+I.+Yoonauthor=J.+H.+Kimauthor=S.+U.+Hanauthor=H.+J.+Jooauthor=D.+Y.+Kim&title=Expression+profile+of+histone+deacetylase+1+in+gastric+cancer+tissues&doi=10.1111%2Fj.1349-7006.2001.tb02153.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Expression profile of histone deacetylase 1 in gastric cancer tissues</span></div><div class="casAuthors">Choi, Jae-Hoon; Kwon, Ho Jeong; Yoon, Byung-Il; Kim, Jin-Hyun; Han, Sang Uk; Joo, Hee Jae; Kim, Dae-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Japanese Journal of Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1300-1304</span>CODEN:
                <span class="NLM_cas:coden">JJCREP</span>;
        ISSN:<span class="NLM_cas:issn">0910-5050</span>.
    
            (<span class="NLM_cas:orgname">Japanese Cancer Association</span>)
        </div><div class="casAbstract">Although histone deacetylases (HDACs) appear to play a crucial role in carcinogenesis, the expression status of HDACs in primary human cancer tissues has not yet been reported.  In this study, we investigated the expression level of HDAC1 in 25 paired primary human gastric cancer (GC) tissues and corresponding normal tissues through semi-quant. RT-PCR and immunoblot anal.  The HDAC1 expression pattern was also topol. examd. through immunohistochem.  Overexpression of HDAC1 mRNA was detected in 68% of GC tissues (17 of 25), and the relative d. of HDAC1 mRNA in GC tissue was increased 1.8-fold vs. the normal counterpart (P<0.01).  Elevated expression of HDAC1 protein was also detected in 61% of GC samples (11 of 18), which also showed an increased mRNA level of HDAC.  Immunohistochem., overexpression of HDAC1 was predominantly localized in the nuclei of most neoplastic cells, including embolic tumor cells, whereas normal glandular epithelial cells revealed only weak HDAC1 expression that was focal in distribution.  Thus, the present study clearly demonstrates that HDAC1 is overexpressed in GC and probably plays a significant role in gastric carcinogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8nWdwWipzTLVg90H21EOLACvtfcHk0ljzfe2T6loTcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtV2jt7c%253D&md5=acc60d0eaa2076c8aa7c5f6fef8c3c6d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2001.tb02153.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2001.tb02153.x%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DJ.%2BH.%26aulast%3DKwon%26aufirst%3DH.%2BJ.%26aulast%3DYoon%26aufirst%3DB.%2BI.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DHan%26aufirst%3DS.%2BU.%26aulast%3DJoo%26aufirst%3DH.%2BJ.%26aulast%3DKim%26aufirst%3DD.%2BY.%26atitle%3DExpression%2520profile%2520of%2520histone%2520deacetylase%25201%2520in%2520gastric%2520cancer%2520tissues%26jtitle%3DJpn.%2520J.%2520Cancer%2520Res.%26date%3D2001%26volume%3D92%26spage%3D1300%26epage%3D1304%26doi%3D10.1111%2Fj.1349-7006.2001.tb02153.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamaguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwase, H.</span></span> <span> </span><span class="NLM_article-title">Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1007/s10549-005-6001-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1007%2Fs10549-005-6001-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16172792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVyltbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2005&pages=11-16&author=Z.+Zhangauthor=H.+Yamashitaauthor=T.+Toyamaauthor=H.+Sugiuraauthor=Y.+Andoauthor=K.+Mitaauthor=M.+Hamaguchiauthor=Y.+Haraauthor=S.+Kobayashiauthor=H.+Iwase&title=Quantitation+of+HDAC1+mRNA+expression+in+invasive+carcinoma+of+the+breast&doi=10.1007%2Fs10549-005-6001-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast</span></div><div class="casAuthors">Zhang, Zhenhuan; Yamashita, Hiroko; Toyama, Tatsuya; Sugiura, Hiroshi; Ando, Yoshiaki; Mita, Keiko; Hamaguchi, Maho; Hara, Yasuo; Kobayashi, Shunzo; Iwase, Hirotaka</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-16</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Estrogen is well-established as a mitogenic factor implicated in the tumorigenesis and progression of breast cancer via its binding to the estrogen receptor α (ERα).  Recent data indicate that chromatin inactivation mediated by histone deacetylation (HDAC) and DNA methylation is a crit. component of ERα silencing in human breast cancer cells.  The aim of this study was to det. the expression of the HDAC1 gene in malignant human breast tissue and to correlate our observations with available clin. information.  In the present study, the level of expression of HDAC1 mRNA was assessed by LightCycler-based quant. real-time reverse transcriptase (RT)-PCR anal. in 162 cases of invasive carcinoma of the breast.  Assocns. between HDAC1 mRNA expression and different clinicopathol. factors were sought.  It was found that HDAC1 mRNA was expressed at significantly higher levels in tumors from patients over 50 years of age and in those tumors without axillary lymph node involvement, that are less than 2 cm, that are of a non-high histol. grade, that are HER2 neg. and that are ERα/PgR pos.  Patients with tumors displaying high levels of HDAC1 mRNA expression tended to have a better prognosis in terms of both disease-free and overall survival.  However, univariate and multivariate anal. did not show HDAC1 mRNA expression level to be an independent prognostic factor for either disease-free or overall survival.  These results imply that HDAC1 mRNA expression could have potential as an endocrine response marker and may have prognostic implications for breast cancer progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXQ0D466PdgrVg90H21EOLACvtfcHk0ljzfe2T6loTcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVyltbjK&md5=2481b26970c84afab7b464d6769014da</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2Fs10549-005-6001-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-005-6001-1%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DYamashita%26aufirst%3DH.%26aulast%3DToyama%26aufirst%3DT.%26aulast%3DSugiura%26aufirst%3DH.%26aulast%3DAndo%26aufirst%3DY.%26aulast%3DMita%26aufirst%3DK.%26aulast%3DHamaguchi%26aufirst%3DM.%26aulast%3DHara%26aufirst%3DY.%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DIwase%26aufirst%3DH.%26atitle%3DQuantitation%2520of%2520HDAC1%2520mRNA%2520expression%2520in%2520invasive%2520carcinoma%2520of%2520the%2520breast%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2005%26volume%3D94%26spage%3D11%26epage%3D16%26doi%3D10.1007%2Fs10549-005-6001-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mengwasser, J. r.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlag, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, K.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Göttlicher, M.</span></span> <span> </span><span class="NLM_article-title">Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">463</span>, <span class="refDoi"> DOI: 10.1016/S1535-6108(04)00114-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2FS1535-6108%2804%2900114-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15144953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksFCmt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=455-463&author=P.+Zhuauthor=E.+Martinauthor=J.+r.+Mengwasserauthor=P.+Schlagauthor=K.-P.+Janssenauthor=M.+G%C3%B6ttlicher&title=Induction+of+HDAC2+expression+upon+loss+of+APC+in+colorectal+tumorigenesis&doi=10.1016%2FS1535-6108%2804%2900114-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis</span></div><div class="casAuthors">Zhu, Ping; Martin, Elke; Mengwasser, Joerg; Schlag, Peter; Janssen, Klaus-Peter; Goettlicher, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">455-463</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inappropriate transcriptional repression involving histone deacetylases (HDACs) is a prominent cause for the development of leukemia.  We now identify faulty expression of a specific mediator of transcriptional repression in a solid tumor.  Loss of the adenomatosis polyposis coli (APC) tumor suppressor induces HDAC2 expression depending on the Wnt pathway and c-Myc.  Increased HDAC2 expression is found in the majority of human colon cancer explants, as well as in intestinal mucosa and polyps of APC-deficient mice.  HDAC2 is required for, and sufficient on its own to prevent, apoptosis of colonic cancer cells.  Interference with HDAC2 by valproic acid largely diminishes adenoma formation in APCmin mice.  These findings point toward HDAC2 as a particularly relevant potential target in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP4i9iItBfArVg90H21EOLACvtfcHk0ljzfe2T6loTcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksFCmt7c%253D&md5=bfd948db793310e303ad8d71d8cbf8b0</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS1535-6108%2804%2900114-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-6108%252804%252900114-X%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DE.%26aulast%3DMengwasser%26aufirst%3DJ.%2Br.%26aulast%3DSchlag%26aufirst%3DP.%26aulast%3DJanssen%26aufirst%3DK.-P.%26aulast%3DG%25C3%25B6ttlicher%26aufirst%3DM.%26atitle%3DInduction%2520of%2520HDAC2%2520expression%2520upon%2520loss%2520of%2520APC%2520in%2520colorectal%2520tumorigenesis%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D5%26spage%3D455%26epage%3D463%26doi%3D10.1016%2FS1535-6108%2804%2900114-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noh, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eun, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, S. W.</span></span> <span> </span><span class="NLM_article-title">Increased expression of histone deacetylase 2 is found in human gastric cancer</span>. <i>APMIS</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">264</span>– <span class="NLM_lpage">268</span>, <span class="refDoi"> DOI: 10.1111/j.1600-0463.2005.apm_04.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1111%2Fj.1600-0463.2005.apm_04.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15865607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltlOjtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2005&pages=264-268&author=J.+Songauthor=J.+H.+Nohauthor=J.+H.+Leeauthor=J.+W.+Eunauthor=Y.+M.+Ahnauthor=S.+Y.+Kimauthor=S.+H.+Leeauthor=W.+S.+Parkauthor=N.+J.+Yooauthor=J.+Y.+Leeauthor=S.+W.+Nam&title=Increased+expression+of+histone+deacetylase+2+is+found+in+human+gastric+cancer&doi=10.1111%2Fj.1600-0463.2005.apm_04.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Increased expression of histone deacetylase 2 is found in human gastric cancer</span></div><div class="casAuthors">Song, Jaehwi; Noh, Ji Heon; Lee, Jong Heun; Eun, Jung Woo; Ahn, Young Min; Kim, Su Young; Lee, Sug Hyung; Park, Won Sang; Yoo, Nam Jin; Lee, Jung Young; Nam, Suk Woo</div><div class="citationInfo"><span class="NLM_cas:title">APMIS</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">264-268</span>CODEN:
                <span class="NLM_cas:coden">APMSEL</span>;
        ISSN:<span class="NLM_cas:issn">0903-4641</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Accumulated evidence has established that aberrant regulation of histone deacetylases (HDACs) is one of the major causes of the development of human malignancies.  Among different isoenzymes of HDAC and sirtuins grouped as the HDAC super family, little is known as to how historic deacetylase 2 (HDAC2) causes carcinogenesis in solid tumors.  Here, in order to investigate the possible role of HDAC2 in gastric carcinogenesis, we analyzed the expression of HDAC2 in 71 gastric adenocarcinomas by immunohistochem.  Moderate to strong expression of HDAC2 was found in 44 (62%) out of a total of 71 tumors.  The majority of pos. tumors, which were detected in the nucleus but not in normal gastric epithelium, did not express HDAC2 or showed only weak pos. staining.  Interestingly, we also noted that HDAC2 expression appeared to be assocd. with tumor aggressiveness as HDAC2 expression was obsd. to be statistically significant in advanced gastric cancer (P=0.0023, Chi-square test) and in pos. lymph node metastasis (P=0.0713, Chi-square test).  Taken together, these results suggest that HDAC2 may play an important role in the aggressiveness of gastric cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyCR3h4ZoipLVg90H21EOLACvtfcHk0lhp3RhHLREurg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltlOjtb0%253D&md5=996e6dc8a3e52e1c12509e8c1f143663</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0463.2005.apm_04.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0463.2005.apm_04.x%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DNoh%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DEun%26aufirst%3DJ.%2BW.%26aulast%3DAhn%26aufirst%3DY.%2BM.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DPark%26aufirst%3DW.%2BS.%26aulast%3DYoo%26aufirst%3DN.%2BJ.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DNam%26aufirst%3DS.%2BW.%26atitle%3DIncreased%2520expression%2520of%2520histone%2520deacetylase%25202%2520is%2520found%2520in%2520human%2520gastric%2520cancer%26jtitle%3DAPMIS%26date%3D2005%26volume%3D113%26spage%3D264%26epage%3D268%26doi%3D10.1111%2Fj.1600-0463.2005.apm_04.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byun, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popova, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">L’Italien, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sowa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arango, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velcich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augenlicht, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariadason, J. M.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">13548</span>– <span class="NLM_lpage">13558</span>, <span class="refDoi"> DOI: 10.1074/jbc.M510023200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1074%2Fjbc.M510023200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16533812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD28Xkt1ymt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=13548-13558&author=A.+J.+Wilsonauthor=D.+S.+Byunauthor=N.+Popovaauthor=L.+B.+Murrayauthor=K.+L%E2%80%99Italienauthor=Y.+Sowaauthor=D.+Arangoauthor=A.+Velcichauthor=L.+H.+Augenlichtauthor=J.+M.+Mariadason&title=Histone+deacetylase+3+%28HDAC3%29+and+other+class+I+HDACs+regulate+colon+cell+maturation+and+p21+expression+and+are+deregulated+in+human+colon+cancer&doi=10.1074%2Fjbc.M510023200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer</span></div><div class="casAuthors">Wilson, Andrew J.; Byun, Do-Sun; Popova, Natalia; Murray, Lucas B.; L'Italien, Kaitlin; Sowa, Yoshihiro; Arango, Diego; Velcich, Anna; Augenlicht, Leonard H.; Mariadason, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">13548-13558</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Inhibitors of histone deacetylases (HDACs) induce growth arrest, differentiation, and apoptosis of colon cancer cell lines in vitro and have demonstrated anti-cancer efficacy in clin. trials.  Whereas a role for HDAC1 and -2 in mediating components of the HDAC inhibitor response has been reported, the role of HDAC3 is unknown.  Here we demonstrate increased protein expression of HDAC3 in human colon tumors and in duodenal adenomas from Apc1638N/+ mice.  HDAC3 was also maximally expressed in proliferating crypt cells in normal intestine.  Silencing of HDAC3 expression in colon cancer cell lines resulted in growth inhibition, a decrease in cell survival, and increased apoptosis.  Similar effects were obsd. for HDAC2 and, to a lesser extent, for HDAC1.  HDAC3 silencing also selectively induced expression of alk. phosphatase, a marker of colon cell maturation.  Concurrent with its effect on cell growth, overexpression of HDAC3 and other Class I HDACs inhibited basal and butyrate-induced p21 transcription in a Sp1/Sp3-dependent manner, whereas silencing of HDAC3 stimulated p21 promoter activity and expression.  However, the magnitude of the effects elicited by silencing of individual Class I HDACs was significantly less than that induced by HDAC inhibitors.  These findings identify HDAC3 as a gene deregulated in human colon cancer and as a novel regulator of colon cell maturation and p21 expression.  These findings also demonstrate that multiple Class I HDACs are involved in repressing p21 and suggest that the growth-inhibitory and apoptotic effects induced by HDAC inhibitors are probably mediated through the inhibition of multiple HDACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3RTpbaBl4gLVg90H21EOLACvtfcHk0lhp3RhHLREurg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xkt1ymt7Y%253D&md5=10da7c0a6ec5fa4fc494716323dece9d</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M510023200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M510023200%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DA.%2BJ.%26aulast%3DByun%26aufirst%3DD.%2BS.%26aulast%3DPopova%26aufirst%3DN.%26aulast%3DMurray%26aufirst%3DL.%2BB.%26aulast%3DL%25E2%2580%2599Italien%26aufirst%3DK.%26aulast%3DSowa%26aufirst%3DY.%26aulast%3DArango%26aufirst%3DD.%26aulast%3DVelcich%26aufirst%3DA.%26aulast%3DAugenlicht%26aufirst%3DL.%2BH.%26aulast%3DMariadason%26aufirst%3DJ.%2BM.%26atitle%3DHistone%2520deacetylase%25203%2520%2528HDAC3%2529%2520and%2520other%2520class%2520I%2520HDACs%2520regulate%2520colon%2520cell%2520maturation%2520and%2520p21%2520expression%2520and%2520are%2520deregulated%2520in%2520human%2520colon%2520cancer%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D13548%26epage%3D13558%26doi%3D10.1074%2Fjbc.M510023200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolden, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peart, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Anticancer activities of histone deacetylase inhibitors</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">769</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1038/nrd2133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnrd2133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16955068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=769-784&author=J.+E.+Boldenauthor=M.+J.+Peartauthor=R.+W.+Johnstone&title=Anticancer+activities+of+histone+deacetylase+inhibitors&doi=10.1038%2Fnrd2133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer activities of histone deacetylase inhibitors</span></div><div class="casAuthors">Bolden, Jessica E.; Peart, Melissa J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">769-784</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are enzymes involved in the remodelling of chromatin, and have a key role in the epigenetic regulation of gene expression.  In addn., the activity of non-histone proteins can be regulated through HDAC-mediated hypo-acetylation.  In recent years, inhibition of HDACs has emerged as a potential strategy to reverse aberrant epigenetic changes assocd. with cancer, and several classes of HDAC inhibitors have been found to have potent and specific anticancer activities in preclin. studies.  However, such studies have also indicated that the effects of HDAC inhibitors could be considerably broader and more complicated than originally understood.  Here we summarize recent advances in the understanding of the mol. events that underlie the anticancer effects of HDAC inhibitors, and discuss how such information could be used in optimizing the development and application of these agents in the clinic, either as monotherapies or in combination with other anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhfqS1awkOHbVg90H21EOLACvtfcHk0lhp3RhHLREurg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltrY%253D&md5=91e55ee942fda3e4e2055ddf299fc866</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnrd2133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2133%26sid%3Dliteratum%253Aachs%26aulast%3DBolden%26aufirst%3DJ.%2BE.%26aulast%3DPeart%26aufirst%3DM.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DAnticancer%2520activities%2520of%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D769%26epage%3D784%26doi%3D10.1038%2Fnrd2133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aishima, S.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuneyoshi, M.</span></span> <span> </span><span class="NLM_article-title">Expression profile of class I histone deacetylases in human cancer tissues</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">769</span>– <span class="NLM_lpage">774</span>, <span class="refDoi"> DOI: 10.3892/or.18.4.769</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.3892%2For.18.4.769" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=17786334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFygu7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2007&pages=769-774&author=M.+Nakagawaauthor=Y.+Odaauthor=T.+Eguchiauthor=S.-I.+Aishimaauthor=T.+Yaoauthor=F.+Hosoiauthor=Y.+Basakiauthor=M.+Onoauthor=M.+Kuwanoauthor=M.+Tanakaauthor=M.+Tsuneyoshi&title=Expression+profile+of+class+I+histone+deacetylases+in+human+cancer+tissues&doi=10.3892%2For.18.4.769"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Expression profile of class I histone deacetylases in human cancer tissues</span></div><div class="casAuthors">Nakagawa, Masamune; Oda, Yoshinao; Eguchi, Takashi; Aishima, Shin-Ichi; Yao, Takashi; Hosoi, Fumihito; Basaki, Yuji; Ono, Mayumi; Kuwano, Michihiko; Tanaka, Masao; Tsuneyoshi, Masazumi</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">769-774</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Oncology Reports</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) activity is one of the widely used and well-established mechanisms for regulation of various genes in cancer.  To identify which subtype of class I HDACs are overexpressed in cancers, we analyzed the expression of class I HDAC isotypes composed of HDAC1, 2, 3 and 8 in several cell lines and human cancer tissues, including cancer of the stomach, esophagus, colon, prostate, breast, ovary, lung, pancreas and thyroid.  The results showed that >75% of human cancer tissues and their corresponding non-cancerous epithelium showed high expression of these class I HDACs.  However, the immunoreactivity of HDAC8 in both prostatic cancer tissue and non-cancerous prostate glands was lower than that in other cancer tissues.  Furthermore, 5-40% of cancer tissues overexpressed class I HDACs, when compared with normal epithelium.  The results suggest the potential usefulness of HDAC inhibitors for the treatment of a wide variety of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj0FRA62UIeLVg90H21EOLACvtfcHk0liQjwRwkO-0Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFygu7vK&md5=d060cf1947074edc9ca3323e2490165e</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3892%2For.18.4.769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.18.4.769%26sid%3Dliteratum%253Aachs%26aulast%3DNakagawa%26aufirst%3DM.%26aulast%3DOda%26aufirst%3DY.%26aulast%3DEguchi%26aufirst%3DT.%26aulast%3DAishima%26aufirst%3DS.-I.%26aulast%3DYao%26aufirst%3DT.%26aulast%3DHosoi%26aufirst%3DF.%26aulast%3DBasaki%26aufirst%3DY.%26aulast%3DOno%26aufirst%3DM.%26aulast%3DKuwano%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DTsuneyoshi%26aufirst%3DM.%26atitle%3DExpression%2520profile%2520of%2520class%2520I%2520histone%2520deacetylases%2520in%2520human%2520cancer%2520tissues%26jtitle%3DOncol.%2520Rep.%26date%3D2007%26volume%3D18%26spage%3D769%26epage%3D774%26doi%3D10.3892%2For.18.4.769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oehme, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deubzer, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegener, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linke, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hero, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopp-Schneider, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westermann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Deimling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 8 in neuroblastoma tumorigenesis</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-0684</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1078-0432.CCR-08-0684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=19118036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Cjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=91-99&author=I.+Oehmeauthor=H.+E.+Deubzerauthor=D.+Wegenerauthor=D.+Pickertauthor=J.-P.+Linkeauthor=B.+Heroauthor=A.+Kopp-Schneiderauthor=F.+Westermannauthor=S.+M.+Ulrichauthor=A.+von+Deimlingauthor=M.+Fischerauthor=O.+Witt&title=Histone+deacetylase+8+in+neuroblastoma+tumorigenesis&doi=10.1158%2F1078-0432.CCR-08-0684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase 8 in Neuroblastoma Tumorigenesis</span></div><div class="casAuthors">Oehme, Ina; Deubzer, Hedwig E.; Wegener, Dennis; Pickert, Diana; Linke, Jan-Peter; Hero, Barbara; Kopp-Schneider, Annette; Westermann, Frank; Ulrich, Scott M.; von Deimling, Andreas; Fischer, Matthias; Witt, Olaf</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">91-99</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The effects of pan-histone deacetylase (HDAC) inhibitors on cancer cells have shown that HDACs are involved in fundamental tumor biol. processes such as cell cycle control, differentiation, and apoptosis.  However, because of the unselective nature of these compds., little is known about the contribution of individual HDAC family members to tumorigenesis and progression.  The purpose of this study was to evaluate the role of individual HDACs in neuroblastoma tumorigenesis.  Exptl. Design: We have investigated the mRNA expression of all HDAC1-11 family members in a large cohort of primary neuroblastoma samples covering the full spectrum of the disease.  HDACs assocd. with disease stage and survival were subsequently functionally evaluated in cell culture models.  RESULTS: Only HDAC8 expression was significantly correlated with advanced disease and metastasis and down-regulated in stage 4S neuroblastoma assocd. with spontaneous regression.  High HDAC8 expression was assocd. with poor prognostic markers and poor overall and event-free survival.  The knockdown of HDAC8 resulted in the inhibition of proliferation, reduced clonogenic growth, cell cycle arrest, and differentiation in cultured neuroblastoma cells.  The treatment of neuroblastoma cell lines as well as short-term-culture neuroblastoma cells with an HDAC8-selective small-mol. inhibitor inhibited cell proliferation and clone formation, induced differentiation, and thus reproduced the HDAC8 knockdown phenotype.  Global histone 4 acetylation was not affected by HDAC8 knockdown or by selective inhibitor treatment.  CONCLUSIONS: Our data point toward an important role of HDAC8 in neuroblastoma pathogenesis and identify this HDAC family member as a specific drug target for the differentiation therapy of neuroblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsN9HmNgpdA7Vg90H21EOLACvtfcHk0lhcH35s4xxyhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Cjuw%253D%253D&md5=8c8e0b989c0036b233332a74a355dece</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0684%26sid%3Dliteratum%253Aachs%26aulast%3DOehme%26aufirst%3DI.%26aulast%3DDeubzer%26aufirst%3DH.%2BE.%26aulast%3DWegener%26aufirst%3DD.%26aulast%3DPickert%26aufirst%3DD.%26aulast%3DLinke%26aufirst%3DJ.-P.%26aulast%3DHero%26aufirst%3DB.%26aulast%3DKopp-Schneider%26aufirst%3DA.%26aulast%3DWestermann%26aufirst%3DF.%26aulast%3DUlrich%26aufirst%3DS.%2BM.%26aulast%3Dvon%2BDeimling%26aufirst%3DA.%26aulast%3DFischer%26aufirst%3DM.%26aulast%3DWitt%26aufirst%3DO.%26atitle%3DHistone%2520deacetylase%25208%2520in%2520neuroblastoma%2520tumorigenesis%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D91%26epage%3D99%26doi%3D10.1158%2F1078-0432.CCR-08-0684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Girija, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steven, G.</span></span> <span> </span><span class="NLM_article-title">Retraction: synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4959</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-1914</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1078-0432.CCR-16-1914" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=27697993" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=4959&author=D.+Girijaauthor=Y.+Nitinauthor=D.+Yunauthor=D.+Paulauthor=G.+Steven&title=Retraction%3A+synergistic+interactions+between+vorinostat+and+sorafenib+in+chronic+myelogenous+leukemia+cells+involve+Mcl-1+and+p21CIP1+down-regulation&doi=10.1158%2F1078-0432.CCR-16-1914"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-1914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-1914%26sid%3Dliteratum%253Aachs%26aulast%3DGirija%26aufirst%3DD.%26aulast%3DNitin%26aufirst%3DY.%26aulast%3DYun%26aufirst%3DD.%26aulast%3DPaul%26aufirst%3DD.%26aulast%3DSteven%26aufirst%3DG.%26atitle%3DRetraction%253A%2520synergistic%2520interactions%2520between%2520vorinostat%2520and%2520sorafenib%2520in%2520chronic%2520myelogenous%2520leukemia%2520cells%2520involve%2520Mcl-1%2520and%2520p21CIP1%2520down-regulation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D4959%26doi%3D10.1158%2F1078-0432.CCR-16-1914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernatchez, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span> <span> </span><span class="NLM_article-title">Kinase and histone deacetylase hybrid inhibitors for cancer therapy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3171</span>– <span class="NLM_lpage">3183</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00189</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00189" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFKntbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3171-3183&author=Y.+Luanauthor=J.+Liauthor=J.+A.+Bernatchezauthor=R.+Li&title=Kinase+and+histone+deacetylase+hybrid+inhibitors+for+cancer+therapy&doi=10.1021%2Facs.jmedchem.8b00189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy</span></div><div class="casAuthors">Luan, Yepeng; Li, Jerry; Bernatchez, Jean A.; Li, Rongshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3171-3183</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs), encompassing at least 18 members, are promising targets for anticancer drug discovery and development.  To date, five histone deacetylase inhibitors (HDACis) have been approved for cancer treatment, and numerous others are undergoing clin. trials.  It has been well validated that an agent that can simultaneously and effectively inhibit two or more targets may offer greater therapeutic benefits over single-acting agents in preventing resistance to treatment and in potentiating synergistic effects.  A prime example of a bifunctional agent is the hybrid HDAC inhibitor.  In this perspective, the authors review the majority of reported kinase/HDAC hybrid inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvS3FgFwT7r7Vg90H21EOLACvtfcHk0limlvAfnlWpGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFKntbnF&md5=a75c9578b68044a0f702bbf901c3cdcf</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00189%26sid%3Dliteratum%253Aachs%26aulast%3DLuan%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DBernatchez%26aufirst%3DJ.%2BA.%26aulast%3DLi%26aufirst%3DR.%26atitle%3DKinase%2520and%2520histone%2520deacetylase%2520hybrid%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3171%26epage%3D3183%26doi%3D10.1021%2Facs.jmedchem.8b00189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walther, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, C.</span></span> <span> </span><span class="NLM_article-title">Lysine acetylation targets protein complexes and co-regulates major cellular functions</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>325</i></span>,  <span class="NLM_fpage">834</span>– <span class="NLM_lpage">840</span>, <span class="refDoi"> DOI: 10.1126/science.1175371</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1126%2Fscience.1175371" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=19608861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXps1Ogt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=325&publication_year=2009&pages=834-840&author=C.+Kumarauthor=F.+Gnadauthor=M.+L.+Nielsenauthor=M.+Rehmanauthor=T.+C.+Waltherauthor=J.+V.+Olsenauthor=M.+Mannauthor=C.+Choudhary&title=Lysine+acetylation+targets+protein+complexes+and+co-regulates+major+cellular+functions&doi=10.1126%2Fscience.1175371"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions</span></div><div class="casAuthors">Choudhary, Chunaram; Kumar, Chanchal; Gnad, Florian; Nielsen, Michael L.; Rehman, Michael; Walther, Tobias C.; Olsen, Jesper V.; Mann, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">325</span>
        (<span class="NLM_cas:issue">5942</span>),
    <span class="NLM_cas:pages">834-840</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Lysine acetylation is a reversible posttranslational modification of proteins and plays a key role in regulating gene expression.  Technol. limitations have so far prevented a global anal. of lysine acetylation's cellular roles.  We used high-resoln. mass spectrometry to identify 3600 lysine acetylation sites on 1750 proteins and quantified acetylation changes in response to the deacetylase inhibitors suberoylanilide hydroxamic acid and MS-275.  Lysine acetylation preferentially targets large macromol. complexes involved in diverse cellular processes, such as chromatin remodeling, cell cycle, splicing, nuclear transport, and actin nucleation.  Acetylation impaired phosphorylation-dependent interactions of 14-3-3 and regulated the yeast cyclin-dependent kinase Cdc28.  Our data demonstrate that the regulatory scope of lysine acetylation is broad and comparable with that of other major posttranslational modifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5eICW58ngkrVg90H21EOLACvtfcHk0lhlq1jpkjYF7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXps1Ogt70%253D&md5=8f643db5ba91c50f0b61763ff3095d2c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1126%2Fscience.1175371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1175371%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DC.%26aulast%3DGnad%26aufirst%3DF.%26aulast%3DNielsen%26aufirst%3DM.%2BL.%26aulast%3DRehman%26aufirst%3DM.%26aulast%3DWalther%26aufirst%3DT.%2BC.%26aulast%3DOlsen%26aufirst%3DJ.%2BV.%26aulast%3DMann%26aufirst%3DM.%26aulast%3DChoudhary%26aufirst%3DC.%26atitle%3DLysine%2520acetylation%2520targets%2520protein%2520complexes%2520and%2520co-regulates%2520major%2520cellular%2520functions%26jtitle%3DScience%26date%3D2009%26volume%3D325%26spage%3D834%26epage%3D840%26doi%3D10.1126%2Fscience.1175371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vakoc, C. R.</span></span> <span> </span><span class="NLM_article-title">The mechanisms behind the therapeutic activity of BET bromodomain inhibition</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">728</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2014.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.molcel.2014.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=24905006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslCrtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2014&pages=728-736&author=J.+Shiauthor=C.+R.+Vakoc&title=The+mechanisms+behind+the+therapeutic+activity+of+BET+bromodomain+inhibition&doi=10.1016%2Fj.molcel.2014.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition</span></div><div class="casAuthors">Shi, Junwei; Vakoc, Christopher R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">728-736</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The bromodomain and extraterminal (BET) protein Brd4 recruits transcriptional regulatory complexes to acetylated chromatin.  While Brd4 is considered to be a general transcriptional regulator, pharmacol. inhibition of BET proteins shows therapeutic activity in a variety of different pathologies, particularly in models of cancer and inflammation.  Such effects have been attributed to a specific set of downstream target genes whose expression is disproportionately sensitive to pharmacol. targeting of BET proteins.  Emerging evidence links the transcriptional consequences of BET inhibition to the assocn. of Brd4 with enhancer elements, which tend to be involved in lineage-specific gene regulation.  Furthermore, Brd4 engages in direct regulatory interactions with several DNA-binding transcription factors to influence their disease-relevant functions.  Here we review the current understanding of mol. mechanisms that underlie the promising therapeutic effects of BET bromodomain inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJpSFRzwcR1rVg90H21EOLACvtfcHk0liMYTZ-X2cjmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslCrtrk%253D&md5=f49bf3524ec378576fb1a25c64a464ae</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2014.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2014.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DVakoc%26aufirst%3DC.%2BR.%26atitle%3DThe%2520mechanisms%2520behind%2520the%2520therapeutic%2520activity%2520of%2520BET%2520bromodomain%2520inhibition%26jtitle%3DMol.%2520Cell%26date%3D2014%26volume%3D54%26spage%3D728%26epage%3D736%26doi%3D10.1016%2Fj.molcel.2014.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. C.</span></span> <span> </span><span class="NLM_article-title">HDAC inhibition decreases the expression of EGFR in colorectal cancer cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">e18087</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0018087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1371%2Fjournal.pone.0018087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=21464950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksVyjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e18087&author=C.+W.+Chouauthor=M.+S.+Wuauthor=W.+C.+Huangauthor=C.+C.+Chen&title=HDAC+inhibition+decreases+the+expression+of+EGFR+in+colorectal+cancer+cells&doi=10.1371%2Fjournal.pone.0018087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibition decreases the expression of EGFR in colorectal cancer cells</span></div><div class="casAuthors">Chou, Chia-Wei; Wu, Ming-Shiang; Huang, Wei-Chien; Chen, Ching-Chow</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e18087</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR), a receptor tyrosine kinase which promotes cell proliferation and survival, is abnormally overexpressed in numerous tumors of epithelial origin, including colorectal cancer (CRC).  EGFR monoclonal antibodies have been shown to increase the median survival and are approved for the treatment of colorectal cancer.  Histone deacetylases (HDACs), frequently overexpressed in colorectal cancer and several malignancies, are another attractive targets for cancer therapy.  Several inhibitors of HDACs (HDACi) are developed and exhibit powerful antitumor abilities.  In this study, human colorectal cancer cells treated with HDACi exhibited reduced EGFR expression, thereby disturbed EGF-induced ERK and Akt phosphorylation.  HDACi also decreased the expression of SGLT1, an active glucose transporter found to be stabilized by EGFR, and suppressed the glucose uptake of cancer cells.  HDACi suppressed the transcription of EGFR and class I HDACs were proved to be involved in this event.  Chromatin immunopptn. anal. showed that HDACi caused the dissocn. of SP1, HDAC3 and CBP from EGFR promoter.  Our data suggested that HDACi could serve as a single agent to block both EGFR and HDAC, and may bring more benefits to the development of CRC therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcexosDg835LVg90H21EOLACvtfcHk0ljNuXNL4D3WCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksVyjsLs%253D&md5=925c960c49e2635aa3bba8af16ccc9de</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0018087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0018087%26sid%3Dliteratum%253Aachs%26aulast%3DChou%26aufirst%3DC.%2BW.%26aulast%3DWu%26aufirst%3DM.%2BS.%26aulast%3DHuang%26aufirst%3DW.%2BC.%26aulast%3DChen%26aufirst%3DC.%2BC.%26atitle%3DHDAC%2520inhibition%2520decreases%2520the%2520expression%2520of%2520EGFR%2520in%2520colorectal%2520cancer%2520cells%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De18087%26doi%3D10.1371%2Fjournal.pone.0018087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cecchini, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuck, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. H.</span></span> <span> </span><span class="NLM_article-title">HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">2828</span>– <span class="NLM_lpage">2835</span>, <span class="refDoi"> DOI: 10.1038/onc.2013.32</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fonc.2013.32" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=23435418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivFyqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=2828-2835&author=Y.+J.+Kimauthor=C.+B.+Greerauthor=K.+R.+Cecchiniauthor=L.+N.+Harrisauthor=D.+P.+Tuckauthor=T.+H.+Kim&title=HDAC+inhibitors+induce+transcriptional+repression+of+high+copy+number+genes+in+breast+cancer+through+elongation+blockade&doi=10.1038%2Fonc.2013.32"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade</span></div><div class="casAuthors">Kim, Y. J.; Greer, C. B.; Cecchini, K. R.; Harris, L. N.; Tuck, D. P.; Kim, T. H.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2828-2835</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Treatment with histone deacetylase inhibitors (HDACI) results in potent cytotoxicity of a variety of cancer cell types, and these drugs are used clin. to treat hematol. tumors.  They are known to repress the transcription of ERBB2 and many other oncogenes, but little is known about this mechanism.  Using global run-on sequencing (GRO-seq) to measure nascent transcription, we find that HDACI cause transcriptional repression by blocking RNA polymerase II elongation.  Our data show that HDACI preferentially repress the transcription of highly expressed genes as well as high copy no. genes in HER2+ breast cancer genomes.  In contrast, genes that are activated by HDACI are moderately expressed.  We analyzed gene copy no. in combination with microarray and GRO-seq anal. of expression level, in normal and breast cancer cells to show that high copy no. genes are more likely to be repressed by HDACI than non-amplified genes.  The inhibition of transcription of amplified oncogenes, which promote survival and proliferation of cancer cells, might explain the cancer-specific lethality of HDACI, and may represent a general therapeutic strategy for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH0C0OvnRkgrVg90H21EOLACvtfcHk0lg0q93XZ0lK3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivFyqtL0%253D&md5=d258aa06c9c5281dd3507fc0cd178046</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fonc.2013.32&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2013.32%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%2BJ.%26aulast%3DGreer%26aufirst%3DC.%2BB.%26aulast%3DCecchini%26aufirst%3DK.%2BR.%26aulast%3DHarris%26aufirst%3DL.%2BN.%26aulast%3DTuck%26aufirst%3DD.%2BP.%26aulast%3DKim%26aufirst%3DT.%2BH.%26atitle%3DHDAC%2520inhibitors%2520induce%2520transcriptional%2520repression%2520of%2520high%2520copy%2520number%2520genes%2520in%2520breast%2520cancer%2520through%2520elongation%2520blockade%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26spage%3D2828%26epage%3D2835%26doi%3D10.1038%2Fonc.2013.32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sancisi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandolfi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrosetti, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciarrocchi, A.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors repress tumoral expression of the proinvasive factor RUNX2</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">1868</span>– <span class="NLM_lpage">1882</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-2087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F0008-5472.CAN-14-2087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25769725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnsFels7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1868-1882&author=V.+Sancisiauthor=G.+Gandolfiauthor=D.+C.+Ambrosettiauthor=A.+Ciarrocchi&title=Histone+deacetylase+inhibitors+repress+tumoral+expression+of+the+proinvasive+factor+RUNX2&doi=10.1158%2F0008-5472.CAN-14-2087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitors Repress Tumoral Expression of the Proinvasive Factor RUNX2</span></div><div class="casAuthors">Sancisi, Valentina; Gandolfi, Greta; Ambrosetti, Davide Carlo; Ciarrocchi, Alessia</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1868-1882</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">These findings offer evidence that the cytotoxic activity of HDAC inhibitors against cancer cells relies not only on reactivating silenced tumor suppressor functions, as widely thought, but also on silencing oncogenes that drive cell survival and malignant progression.  Aberrant reactivation of embryonic pathways occurs commonly in cancer.  The transcription factor RUNX2 plays a fundamental role during embryogenesis and is aberrantly reactivated during progression and metastasization of different types of human tumors.  In this study, we attempted to dissect the mol. mechanisms governing RUNX2 expression and its aberrant reactivation.  We identified a new regulatory enhancer element, located within the RUNX2 gene, which is responsible for the activation of the RUNX2 promoter and for the regulation of its expression in cancer cells.  Furthermore, we have shown that treatment with the anticancer compds. histone deacetylase inhibitor (HDACi) results in a profound inhibition of RUNX2 expression, which is detd. by the disruption of the transcription-activating complex on the identified enhancer.  These data envisage a possible targeting strategy to counteract the oncongenic function of RUNX2 in cancer cells and provide evidence that the cytotoxic activity of HDACi in cancer is not only dependent on the reactivation of silenced oncosuppressors but also on the repression of oncogenic factors that are necessary for survival and progression.  Cancer Res; 75(9); 1868-82. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3b4i_IaNlQ7Vg90H21EOLACvtfcHk0lg0q93XZ0lK3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnsFels7c%253D&md5=6d71d5f69c54b4396a419e490bff5c01</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-2087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-2087%26sid%3Dliteratum%253Aachs%26aulast%3DSancisi%26aufirst%3DV.%26aulast%3DGandolfi%26aufirst%3DG.%26aulast%3DAmbrosetti%26aufirst%3DD.%2BC.%26aulast%3DCiarrocchi%26aufirst%3DA.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520repress%2520tumoral%2520expression%2520of%2520the%2520proinvasive%2520factor%2520RUNX2%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D1868%26epage%3D1882%26doi%3D10.1158%2F0008-5472.CAN-14-2087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schones, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, K.</span></span> <span> </span><span class="NLM_article-title">Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">1019</span>– <span class="NLM_lpage">1031</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.06.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.cell.2009.06.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=19698979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVCjs7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2009&pages=1019-1031&author=Z.+Wangauthor=C.+Zangauthor=K.+Cuiauthor=D.+E.+Schonesauthor=A.+Barskiauthor=W.+Pengauthor=K.+Zhao&title=Genome-wide+mapping+of+HATs+and+HDACs+reveals+distinct+functions+in+active+and+inactive+genes&doi=10.1016%2Fj.cell.2009.06.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes</span></div><div class="casAuthors">Wang, Zhibin; Zang, Chongzhi; Cui, Kairong; Schones, Dustin E.; Barski, Artem; Peng, Weiqun; Zhao, Keji</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1019-1031</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Histone acetyltransferases (HATs) and deacetylases (HDACs) function antagonistically to control histone acetylation.  As acetylation is a histone mark for active transcription, HATs have been assocd. with active and HDACs with inactive genes.  We describe here genome-wide mapping of HATs and HDACs binding on chromatin and find that both are found at active genes with acetylated histones.  Our data provide evidence that HATs and HDACs are both targeted to transcribed regions of active genes by phosphorylated RNA Pol II.  Furthermore, the majority of HDACs in the human genome function to reset chromatin by removing acetylation at active genes.  Inactive genes that are primed by MLL-mediated histone H3K4 methylation are subject to a dynamic cycle of acetylation and deacetylation by transient HAT/HDAC binding, preventing Pol II from binding to these genes but poising them for future activation.  Silent genes without any H3K4 methylation signal show no evidence of being bound by HDACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA44omJCFXPLVg90H21EOLACvtfcHk0lg0q93XZ0lK3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVCjs7zK&md5=9cd3ba7ed87fd21765dc8e250cd4939f</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.06.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.06.049%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZang%26aufirst%3DC.%26aulast%3DCui%26aufirst%3DK.%26aulast%3DSchones%26aufirst%3DD.%2BE.%26aulast%3DBarski%26aufirst%3DA.%26aulast%3DPeng%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DK.%26atitle%3DGenome-wide%2520mapping%2520of%2520HATs%2520and%2520HDACs%2520reveals%2520distinct%2520functions%2520in%2520active%2520and%2520inactive%2520genes%26jtitle%3DCell%26date%3D2009%26volume%3D138%26spage%3D1019%26epage%3D1031%26doi%3D10.1016%2Fj.cell.2009.06.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donati, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciarrocchi, A.</span></span> <span> </span><span class="NLM_article-title">BRD4 and cancer: going beyond transcriptional regulation</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1186/s12943-018-0915-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1186%2Fs12943-018-0915-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=30466442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlWgu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=164-166&author=B.+Donatiauthor=E.+Lorenziniauthor=A.+Ciarrocchi&title=BRD4+and+cancer%3A+going+beyond+transcriptional+regulation&doi=10.1186%2Fs12943-018-0915-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">BRD4 and Cancer: going beyond transcriptional regulation</span></div><div class="casAuthors">Donati, Benedetta; Lorenzini, Eugenia; Ciarrocchi, Alessia</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">164</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  BRD4, member of the Bromodomain and Extraterminal (BET) protein family, is largely acknowledged in cancer for its role in super-enhancers (SEs) organization and oncogenes expression regulation.  Inhibition of BRD4 shortcuts the communication between SEs and target promoters with a subsequent cell-specific repression of oncogenes to which cancer cells are addicted and cell death.  To date, this is the most credited mechanism of action of BET inhibitors, a class of small mols. targeting BET proteins which are currently in clin. trials in several cancer settings.  However, recent evidence indicates that BRD4 relevance in cancer goes beyond its role in transcription regulation and identifies this protein as a keeper of genome stability.  Indeed, a non-transcriptional role of BRD4 in controlling DNA damage checkpoint activation and repair as well as telomere maintenance has been proposed, throwing new lights into the multiple functions of this protein and opening new perspectives on the use of BETi in cancer.  Here we discuss the current available information on non-canonical, non-transcriptional functions of BRD4 and on their implications in cancer biol.  Integrating this information with the already known BRD4 role in gene expression regulation, we propose a "common" model to explain BRD4 genomic function.  Furthermore, in light of the transversal function of BRD4, we provide new interpretation for the cytotoxic activity of BETi and we discuss new possibilities for a wide and focused employment of these drugs in clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbYn0mnQW7ELVg90H21EOLACvtfcHk0lifwvOtBAMB9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlWgu78%253D&md5=2ddfde1363d430aa67e15a52fdc2335e</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1186%2Fs12943-018-0915-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-018-0915-9%26sid%3Dliteratum%253Aachs%26aulast%3DDonati%26aufirst%3DB.%26aulast%3DLorenzini%26aufirst%3DE.%26aulast%3DCiarrocchi%26aufirst%3DA.%26atitle%3DBRD4%2520and%2520cancer%253A%2520going%2520beyond%2520transcriptional%2520regulation%26jtitle%3DMol.%2520Cancer%26date%3D2018%26volume%3D17%26spage%3D164%26epage%3D166%26doi%3D10.1186%2Fs12943-018-0915-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeRoy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, S. R</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahedi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heightman, T. D</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, B. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siebenlist, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozato, K.</span></span> <span> </span><span class="NLM_article-title">BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1047</span>– <span class="NLM_lpage">1057</span>, <span class="refDoi"> DOI: 10.1038/nsmb.2912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnsmb.2912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25383670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKlsr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=1047-1057&author=T.+Kannoauthor=Y.+Kannoauthor=G.+LeRoyauthor=E.+Camposauthor=H.-W.+Sunauthor=S.+R+Brooksauthor=G.+Vahediauthor=T.+D+Heightmanauthor=B.+A+Garciaauthor=D.+Reinbergauthor=U.+Siebenlistauthor=J.+J+O%E2%80%99Sheaauthor=K.+Ozato&title=BRD4+assists+elongation+of+both+coding+and+enhancer+RNAs+by+interacting+with+acetylated+histones&doi=10.1038%2Fnsmb.2912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones</span></div><div class="casAuthors">Kanno, Tomohiko; Kanno, Yuka; LeRoy, Gary; Campos, Eric; Sun, Hong-Wei; Brooks, Stephen R.; Vahedi, Golnaz; Heightman, Tom D.; Garcia, Benjamin A.; Reinberg, Danny; Siebenlist, Ulrich; O'Shea, John J.; Ozato, Keiko</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1047-1057</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. BET inhibitors interfere with the epigenetic interactions between acetylated histones and the bromodomains of the BET family proteins, including BRD4, and they potently inhibit growth of malignant cells by targeting cancer-promoting genes.  BRD4 interacts with the pause-release factor P-TEFb and has been proposed to release RNA polymerase II (Pol II) from promoter-proximal pausing.  We show that BRD4 occupies widespread genomic regions in mouse cells and directly stimulates elongation of both protein-coding transcripts and noncoding enhancer RNAs (eRNAs), in a manner dependent on bromodomain function.  BRD4 interacts with elongating Pol II complexes and assists Pol II in progression through hyperacetylated nucleosomes by interacting with acetylated histones via bromodomains.  On active enhancers, the BET inhibitor JQ1 antagonizes BRD4-assocd. eRNA synthesis.  Thus, BRD4 is involved in multiple steps of the transcription hierarchy, primarily by facilitating transcript elongation both at enhancers and on gene bodies independently of P-TEFb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkL9lfCmfYM7Vg90H21EOLACvtfcHk0lgTPiEm3AfF8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKlsr7I&md5=e568fe18fac3fe96de1962ffb7dab897</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2912%26sid%3Dliteratum%253Aachs%26aulast%3DKanno%26aufirst%3DT.%26aulast%3DKanno%26aufirst%3DY.%26aulast%3DLeRoy%26aufirst%3DG.%26aulast%3DCampos%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DH.-W.%26aulast%3DBrooks%26aufirst%3DS.%2BR%26aulast%3DVahedi%26aufirst%3DG.%26aulast%3DHeightman%26aufirst%3DT.%2BD%26aulast%3DGarcia%26aufirst%3DB.%2BA%26aulast%3DReinberg%26aufirst%3DD.%26aulast%3DSiebenlist%26aufirst%3DU.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ%26aulast%3DOzato%26aufirst%3DK.%26atitle%3DBRD4%2520assists%2520elongation%2520of%2520both%2520coding%2520and%2520enhancer%2520RNAs%2520by%2520interacting%2520with%2520acetylated%2520histones%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2014%26volume%3D21%26spage%3D1047%26epage%3D1057%26doi%3D10.1038%2Fnsmb.2912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, H.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J.</span></span> <span> </span><span class="NLM_article-title">Regulation of P-TEFb elongation complex activity by CDK9 acetylation</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4641</span>– <span class="NLM_lpage">4651</span>, <span class="refDoi"> DOI: 10.1128/MCB.00857-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1128%2FMCB.00857-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=17452463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsVWrs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=4641-4651&author=J.+Fuauthor=H.-G.+Yoonauthor=J.+Qinauthor=J.+Wong&title=Regulation+of+P-TEFb+elongation+complex+activity+by+CDK9+acetylation&doi=10.1128%2FMCB.00857-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of P-TEFb elongation complex activity by CDK9 acetylation</span></div><div class="casAuthors">Fu, Junjiang; Yoon, Ho-Geun; Qin, Jun; Wong, Jiemin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4641-4651</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">P-TEFb, comprised of CDK9 and a cyclin T subunit, is a global transcriptional elongation factor important for most RNA polymerase II (pol II) transcription.  P-TEFb facilitates transcription elongation in part by phosphorylating Ser2 of the heptapeptide repeat of the carboxy-terminal domain (CTD) of the largest subunit of pol II.  Previous studies have shown that P-TEFb is subjected to neg. regulation by forming an inactive complex with 7SK small RNA and HEXIM1.  In an effort to investigate the mol. mechanism by which corepressor N-CoR mediates transcription repression, we identified HEXIM1 as an N-CoR-interacting protein.  This finding led us to test whether the P-TEFb complex is regulated by acetylation.  We demonstrate that CDK9 is an acetylated protein in cells and can be acetylated by p300 in vitro.  Through both in vitro and in vivo assays, we identified lysine 44 of CDK9 as a major acetylation site.  We present evidence that CDK9 is regulated by N-CoR and its assocd. HDAC3 and that acetylation of CDK9 affects its ability to phosphorylate the CTD of pol II.  These results suggest that acetylation of CDK9 is an important posttranslational modification that is involved in regulating P-TEFb transcriptional elongation function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1MWK4pAUTKrVg90H21EOLACvtfcHk0lg3DXYW_7uxXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsVWrs7c%253D&md5=24a3b35574a6f126baa8bcd4a1fd62a8</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1128%2FMCB.00857-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00857-06%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DYoon%26aufirst%3DH.-G.%26aulast%3DQin%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DJ.%26atitle%3DRegulation%2520of%2520P-TEFb%2520elongation%2520complex%2520activity%2520by%2520CDK9%2520acetylation%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2007%26volume%3D27%26spage%3D4641%26epage%3D4651%26doi%3D10.1128%2FMCB.00857-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buob, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jobst, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rascle, A.</span></span> <span> </span><span class="NLM_article-title">Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">3524</span>– <span class="NLM_lpage">3545</span>, <span class="refDoi"> DOI: 10.1093/nar/gkv188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1093%2Fnar%2Fgkv188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25769527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFaisbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=3524-3545&author=S.+Pinzauthor=S.+Unserauthor=D.+Buobauthor=P.+Fischerauthor=B.+Jobstauthor=A.+Rascle&title=Deacetylase+inhibitors+repress+STAT5-mediated+transcription+by+interfering+with+bromodomain+and+extra-terminal+%28BET%29+protein+function&doi=10.1093%2Fnar%2Fgkv188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function</span></div><div class="casAuthors">Pinz, Sophia; Unser, Samy; Buob, Dominik; Fischer, Philipp; Jobst, Belinda; Rascle, Anne</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3524-3545</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription STAT5 is essential for the regulation of proliferation and survival genes.  Its activity is tightly regulated through cytokine signaling and is often upregulated in cancer.  The authors showed previously that the deacetylase inhibitor trichostatin A (TSA) inhibits STAT5-mediated transcription by preventing recruitment of the transcriptional machinery at a step following STAT5 binding to DNA.  The mechanism and factors involved in this inhibition remain unknown.  The authors now show that deacetylase inhibitors do not target STAT5 acetylation, as the authors initially hypothesized.  Instead, they induce a rapid increase in global histone acetylation apparently resulting in the delocalization of the bromodomain and extra-terminal (BET) protein Brd2 and of the Brd2-assocd. factor TBP to hyperacetylated chromatin.  Treatment with the BET inhibitor (+)-JQ1 inhibited expression of STAT5 target genes, supporting a role of BET proteins in the regulation of STAT5 activity.  Accordingly, chromatin immunopptn. demonstrated that Brd2 is assocd. with the transcriptionally active STAT5 target gene Cis and is displaced upon TSA treatment.  The authors' data therefore indicate that Brd2 is required for the proper recruitment of the transcriptional machinery at STAT5 target genes and that deacetylase inhibitors suppress STAT5-mediated transcription by interfering with Brd2 function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5x3UBMqg6VbVg90H21EOLACvtfcHk0lg6Cw-rJgOkJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFaisbjE&md5=b97274a797559912f296ab19fd7975e9</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkv188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkv188%26sid%3Dliteratum%253Aachs%26aulast%3DPinz%26aufirst%3DS.%26aulast%3DUnser%26aufirst%3DS.%26aulast%3DBuob%26aufirst%3DD.%26aulast%3DFischer%26aufirst%3DP.%26aulast%3DJobst%26aufirst%3DB.%26aulast%3DRascle%26aufirst%3DA.%26atitle%3DDeacetylase%2520inhibitors%2520repress%2520STAT5-mediated%2520transcription%2520by%2520interfering%2520with%2520bromodomain%2520and%2520extra-terminal%2520%2528BET%2529%2520protein%2520function%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2015%26volume%3D43%26spage%3D3524%26epage%3D3545%26doi%3D10.1093%2Fnar%2Fgkv188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span> <span> </span><span class="NLM_article-title">Histone cross-talk connects protein phosphatase 1α (PP1α) and histone deacetylase (HDAC) pathways to regulate the functional transition of bromodomain-containing 4 (BRD4) for inducible gene expression</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">23154</span>– <span class="NLM_lpage">23167</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.570812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1074%2Fjbc.M114.570812" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=24939842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlGmtbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=23154-23167&author=X.+Huauthor=X.+Luauthor=R.+Liuauthor=N.+Aiauthor=Z.+Caoauthor=Y.+Liauthor=J.+Liuauthor=B.+Yuauthor=K.+Liuauthor=H.+Wangauthor=C.+Zhouauthor=Y.+Wangauthor=A.+Hanauthor=F.+Dingauthor=R.+Chen&title=Histone+cross-talk+connects+protein+phosphatase+1%CE%B1+%28PP1%CE%B1%29+and+histone+deacetylase+%28HDAC%29+pathways+to+regulate+the+functional+transition+of+bromodomain-containing+4+%28BRD4%29+for+inducible+gene+expression&doi=10.1074%2Fjbc.M114.570812"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Histone cross-talk connects protein phosphatase 1α (PP1α) and histone deacetylase (HDAC) pathways to regulate the functional transition of bromodomain-containing 4 (BRD4) for inducible gene expression</span></div><div class="casAuthors">Hu, Xiangming; Lu, Xiaodong; Liu, Runzhong; Ai, Nanping; Cao, Zhenhua; Li, Yannan; Liu, Jiangfang; Yu, Bin; Liu, Kai; Wang, Huiping; Zhou, Chao; Wang, Yu; Han, Aidong; Ding, Feng; Chen, Ruichuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">23154-23167</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Transcription elongation has been recognized as a rate-limiting step for the expression of signal-inducible genes.  Through recruitment of pos. transcription elongation factor P-TEFb, the bromodomain-contg. protein BRD4 plays crit. roles in regulating the transcription elongation of a vast array of inducible genes that are important for multiple cellular processes.  The diverse biol. roles of BRD4 have been proposed to rely on its functional transition between chromatin targeting and transcription regulation.  The signaling pathways and the mol. mechanism for regulating this transition process, however, are largely unknown.  Here, the authors report a novel role of phosphorylated Ser10 of histone H3 (H3S10ph) in governing the functional transition of BRD4.  The authors identified that the acetylated lysines 5 and 8 of nucleosomal histone H4 (H4K5ac/K8ac) is the BRD4 binding site, and the protein phosphatase PP1α and class I histone deacetylase (HDAC1/2/3) signaling pathways are essential for the stress-induced BRD4 release from chromatin.  In the unstressed state, phosphorylated H3S10 prevents the deacetylation of nucleosomal H4K5ac/K8ac by HDAC1/2/3, thereby locking up the majority of BRD4 onto chromatin.  Upon stress, PP1α-mediated dephosphorylation of H3S10ph allows the deacetylation of nucleosomal H4K5ac/K8ac by HDAC1/2/3, thereby leading to the release of chromatin-bound BRD4 for subsequent recruitment of P-TEFb to enhance the expression of inducible genes.  Therefore, this study revealed a novel mechanism that the histone cross-talk between H3S10ph and H4K5ac/K8ac connects PP1α and HDACs to govern the functional transition of BRD4.  Combined with previous studies on the regulation of P-TEFb activation, the intricate signaling network for the tight control of transcription elongation is established.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLzn-a41szPbVg90H21EOLACvtfcHk0lj_rVSDETnwQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlGmtbjI&md5=b3b79f952cd57bffe39c6d563d564669</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.570812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.570812%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DAi%26aufirst%3DN.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DA.%26aulast%3DDing%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DR.%26atitle%3DHistone%2520cross-talk%2520connects%2520protein%2520phosphatase%25201%25CE%25B1%2520%2528PP1%25CE%25B1%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520pathways%2520to%2520regulate%2520the%2520functional%2520transition%2520of%2520bromodomain-containing%25204%2520%2528BRD4%2529%2520for%2520inducible%2520gene%2520expression%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D23154%26epage%3D23167%26doi%3D10.1074%2Fjbc.M114.570812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Targeting epigenetic reader and eraser: rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2931</span>– <span class="NLM_lpage">2935</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.04.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bmcl.2016.04.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=27142751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC28XntFCmt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2931-2935&author=Z.+Zhangauthor=S.+Houauthor=H.+Chenauthor=T.+Ranauthor=F.+Jiangauthor=Y.+Bianauthor=D.+Zhangauthor=Y.+Zhiauthor=L.+Wangauthor=L.+Zhangauthor=H.+Liauthor=Y.+Zhangauthor=W.+Tangauthor=T.+Luauthor=Y.+Chen&title=Targeting+epigenetic+reader+and+eraser%3A+rational+design%2C+synthesis+and+in+vitro+evaluation+of+dimethylisoxazoles+derivatives+as+BRD4%2FHDAC+dual+inhibitors&doi=10.1016%2Fj.bmcl.2016.04.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors</span></div><div class="casAuthors">Zhang, Zhimin; Hou, Shaohua; Chen, Hongli; Ran, Ting; Jiang, Fei; Bian, Yuanyuan; Zhang, Dewei; Zhi, Yanle; Wang, Lu; Zhang, Li; Li, Hongmei; Zhang, Yanmin; Tang, Weifang; Lu, Tao; Chen, Yadong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2931-2935</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The bromodomain protein module and histone deacetylase (HDAC), which recognize and remove acetylated lysine, resp., have emerged as important epigenetic therapeutic targets in cancer treatments.  Herein the authors presented a novel design approach for cancer drug development by combination of bromodomain and HDAC inhibitory activity in one mol.  The designed compds. were synthesized which showed inhibitory activity against bromodomain 4 and HDAC1.  The representative dual bromodomain/HDAC inhibitors, compds. N1-(3-benzoyl-5-(3,5-dimethylisoxazol-4-yl)phenyl)-N7-hydroxyheptanediamide and N1-(3-benzoyl-5-(3,5-dimethylisoxazol-4-yl)phenyl)-N8-hydroxyoctanediamide showed potent antiproliferative activities against human leukemia cell line K562 and MV4-11 in cellular assays.  This work may lay the foundation for developing dual bromodomain/HDAC inhibitors as potential anticancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriS0VB1G-QoLVg90H21EOLACvtfcHk0ljhOp9q1Zrmjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntFCmt7o%253D&md5=a6ebdbd6402e3117a2f9d96ed071790c</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.04.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.04.034%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DHou%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DRan%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DBian%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DZhi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DTargeting%2520epigenetic%2520reader%2520and%2520eraser%253A%2520rational%2520design%252C%2520synthesis%2520and%2520in%2520vitro%2520evaluation%2520of%2520dimethylisoxazoles%2520derivatives%2520as%2520BRD4%252FHDAC%2520dual%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D2931%26epage%3D2935%26doi%3D10.1016%2Fj.bmcl.2016.04.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4051</span>– <span class="NLM_lpage">4055</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.07.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bmcl.2017.07.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=28765013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1KqsLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=4051-4055&author=M.+Shaoauthor=L.+Heauthor=L.+Zhengauthor=L.+Huangauthor=Y.+Zhouauthor=T.+Wangauthor=Y.+Chenauthor=M.+Shenauthor=F.+Wangauthor=Z.+Yangauthor=L.+Chen&title=Structure-based+design%2C+synthesis+and+in+vitro+antiproliferative+effects+studies+of+novel+dual+BRD4%2FHDAC+inhibitors&doi=10.1016%2Fj.bmcl.2017.07.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors</span></div><div class="casAuthors">Shao, Mingfeng; He, Linhong; Zheng, Li; Huang, Lingxiao; Zhou, Yuanyuan; Wang, Taijing; Chen, Yong; Shen, Mingsheng; Wang, Fang; Yang, Zhuang; Chen, Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4051-4055</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone acetylation marks play important roles in controlling gene expressions and are removed by histone deacetylases (HDACs).  These marks are read by bromodomain and extra-terminal (BET) proteins, whose targeted inhibitors are under clin. investigation.  BET and HDAC inhibitors have been demonstrated to be synergistically killing in Myc-induced murine lymphoma.  Herein, the authors combine the inhibitory activities of BET and HDAC into one mol. through structure-based design method and evaluate its function.  The majority of these synthesized compds. showed inhibitory activity against second bromodomains(BRD) of BRD4 and HDAC1.  Among them, I presented antiproliferative effects against human acute myelogenous leukemia (AML) cell lines in vitro, and I is confirmed to reduce the expression of Myc by Western blot anal.  Those results indicated that I is a potent dual BRD4/HDAC inhibitor and deserves further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkMaHqVu_LM7Vg90H21EOLACvtfcHk0liCfipf3axjKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1KqsLrP&md5=c525f1a2083699dd5f6f6a262f477f24</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.07.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.07.054%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DStructure-based%2520design%252C%2520synthesis%2520and%2520in%2520vitro%2520antiproliferative%2520effects%2520studies%2520of%2520novel%2520dual%2520BRD4%252FHDAC%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D4051%26epage%3D4055%26doi%3D10.1016%2Fj.bmcl.2017.07.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soden, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angell, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giblin, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smithers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furze, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rioja, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witherington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parr, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinjha, R. K.</span></span> <span> </span><span class="NLM_article-title">The structure based design of dual HDAC/BET inhibitors as novel epigenetic probes</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">342</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.1039/C3MD00285C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1039%2FC3MD00285C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjt1ylsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=342-351&author=S.+J.+Atkinsonauthor=P.+E.+Sodenauthor=D.+C.+Angellauthor=M.+Bantscheffauthor=C.-w.+Chungauthor=K.+A.+Giblinauthor=N.+Smithersauthor=R.+C.+Furzeauthor=L.+Gordonauthor=G.+Drewesauthor=I.+Riojaauthor=J.+Witheringtonauthor=N.+J.+Parrauthor=R.+K.+Prinjha&title=The+structure+based+design+of+dual+HDAC%2FBET+inhibitors+as+novel+epigenetic+probes&doi=10.1039%2FC3MD00285C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The structure based design of dual HDAC/BET inhibitors as novel epigenetic probes</span></div><div class="casAuthors">Atkinson, Stephen J.; Soden, Peter E.; Angell, Davina C.; Bantscheff, Marcus; Chung, Chun-wa; Giblin, Kathryn A.; Smithers, Nicholas; Furze, Rebecca C.; Gordon, Laurie; Drewes, Gerard; Rioja, Inmaculada; Witherington, Jason; Parr, Nigel J.; Prinjha, Rab K.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">342-351</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Herein we describe the design and synthesis of a dual active histone deacetylase (HDAC)/bromodomain and extra terminal (BET) small mol. tool inhibitor, DUAL946 (1).  Exploiting our extensive epigenetic toolbox, we achieved the functionalisation of a BET active tetrahydroquinoline (THQ) core, with a hydroxamic acid HDAC inhibitor (HDACi) motif.  Dual inhibition of BET and HDAC proteins was confirmed by in vitro biochem. and biophys. testing and through chemoproteomic competition expts. in cell lysates.  This activity was translated into potent cellular activity in both immune and cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrozg-RkS-M_rVg90H21EOLACvtfcHk0lgIjOSlZIvykQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjt1ylsr8%253D&md5=53ba095249966d2ec200d20280e64512</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1039%2FC3MD00285C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC3MD00285C%26sid%3Dliteratum%253Aachs%26aulast%3DAtkinson%26aufirst%3DS.%2BJ.%26aulast%3DSoden%26aufirst%3DP.%2BE.%26aulast%3DAngell%26aufirst%3DD.%2BC.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DC.-w.%26aulast%3DGiblin%26aufirst%3DK.%2BA.%26aulast%3DSmithers%26aufirst%3DN.%26aulast%3DFurze%26aufirst%3DR.%2BC.%26aulast%3DGordon%26aufirst%3DL.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DRioja%26aufirst%3DI.%26aulast%3DWitherington%26aufirst%3DJ.%26aulast%3DParr%26aufirst%3DN.%2BJ.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26atitle%3DThe%2520structure%2520based%2520design%2520of%2520dual%2520HDAC%252FBET%2520inhibitors%2520as%2520novel%2520epigenetic%2520probes%26jtitle%3DMedChemComm%26date%3D2014%26volume%3D5%26spage%3D342%26epage%3D351%26doi%3D10.1039%2FC3MD00285C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amemiya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi-Yachide, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of novel dual BRD4/HDAC inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3677</span>– <span class="NLM_lpage">3684</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.04.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bmc.2017.04.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=28549889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotlyitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=3677-3684&author=S.+Amemiyaauthor=T.+Yamaguchiauthor=Y.+Hashimotoauthor=T.+Noguchi-Yachide&title=Synthesis+and+evaluation+of+novel+dual+BRD4%2FHDAC+inhibitors&doi=10.1016%2Fj.bmc.2017.04.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of novel dual BRD4/HDAC inhibitors</span></div><div class="casAuthors">Amemiya, Seika; Yamaguchi, Takao; Hashimoto, Yuichi; Noguchi-Yachide, Tomomi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3677-3684</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Epigenetic regulation of gene expression via histone acetylation modulates many cellular processes, including apoptosis, the cell cycle, cell growth and differentiation, and inhibitors are promising drug candidates.  We have previously developed inhibitors of BRD4, which recognizes acetylated lysine residue on histones and recruits transcription elongation factor to the transcription start site, while inhibitors of histone deacetylase (HDAC), which catalyzes the removal of acetyl groups on histones, are already in clin. use for cancer treatment.  Based on the idea that polypharmacol. agents with multiple targets would have a more robust action, we set out to develop dual BRD4/HDAC inhibitors.  Here, we describe the design and synthesis of N6-[2-(7-hydroxyamino-7-oxoheptyloxy)benzoyl]adenine (I) as a BRD4/HDAC dual inhibitor.  This compd. showed HL-60 cell growth-inhibitory and apoptosis-inducing activity, as well as all-trans retinoic acid (ATRA)-induced HL-60 cell differentiation-enhancing activity, and c-MYC prodn.-inhibitory activity.  Interestingly, it also showed growth-inhibitory activity towards BRD4 inhibitor-resistant cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw5w5uPYmY37Vg90H21EOLACvtfcHk0lhF39vDET6tBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotlyitL4%253D&md5=c9099dc3d40c966d150a13fab28c2b9f</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.04.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.04.043%26sid%3Dliteratum%253Aachs%26aulast%3DAmemiya%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DT.%26aulast%3DHashimoto%26aufirst%3DY.%26aulast%3DNoguchi-Yachide%26aufirst%3DT.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520novel%2520dual%2520BRD4%252FHDAC%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D3677%26epage%3D3684%26doi%3D10.1016%2Fj.bmc.2017.04.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolven, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamborough, P.</span></span> <span> </span><span class="NLM_article-title">Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">576</span>– <span class="NLM_lpage">586</span>, <span class="refDoi"> DOI: 10.1021/jm201320w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201320w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFKktrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=576-586&author=C.+W.+Chungauthor=A.+W.+Deanauthor=J.+M.+Woolvenauthor=P.+Bamborough&title=Fragment-based+discovery+of+bromodomain+inhibitors+part+1%3A+inhibitor+binding+modes+and+implications+for+lead+discovery&doi=10.1021%2Fjm201320w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Discovery of Bromodomain Inhibitors Part 1: Inhibitor Binding Modes and Implications for Lead Discovery</span></div><div class="casAuthors">Chung, Chun-wa; Dean, Anthony W.; Woolven, James M.; Bamborough, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">576-586</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bromodomain-contg. proteins are key epigenetic regulators of gene transcription and readers of the histone code.  However, the therapeutic benefits of modulating this target class are largely unexplored due to the lack of suitable chem. probes.  This article describes the generation of lead mols. for the BET bromodomains through screening a fragment set chosen using structural insights and computational approaches.  Anal. of 40 BRD2/fragment x-ray complexes highlights both shared and disparate interaction features that may be exploited for affinity and selectivity.  Six representative crystal structures are then exemplified in detail.  Two of the fragments are completely new bromodomain chemotypes, and three have never before been crystd. in a bromodomain, so our results significantly extend the limited public knowledge-base of crystallog. small mol./bromodomain interactions.  Certain fragments (including paracetamol) bind in a consistent mode to different bromodomains such as CREBBP, suggesting their potential to act as generic bromodomain templates.  An important implication is that the bromodomains are not only a phylogenetic family but also a system in which chem. and structural knowledge of one bromodomain gives insights transferable to others.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonNb7GnZnS_rVg90H21EOLACvtfcHk0lhF39vDET6tBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFKktrnN&md5=5b7d7239d0de57266d94beef1ea080ae</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm201320w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201320w%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DC.%2BW.%26aulast%3DDean%26aufirst%3DA.%2BW.%26aulast%3DWoolven%26aufirst%3DJ.%2BM.%26aulast%3DBamborough%26aufirst%3DP.%26atitle%3DFragment-based%2520discovery%2520of%2520bromodomain%2520inhibitors%2520part%25201%253A%2520inhibitor%2520binding%2520modes%2520and%2520implications%2520for%2520lead%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D576%26epage%3D586%26doi%3D10.1021%2Fjm201320w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wyce, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganji, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smitheman, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korenchuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbash, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craggs, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCabe, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy-Wilson, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosmini, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parr, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanak, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinjha, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auger, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, P. J.</span></span> <span> </span><span class="NLM_article-title">BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e72967</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0072967</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1371%2Fjournal.pone.0072967" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=24009722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtl2iu7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e72967&author=A.+Wyceauthor=G.+Ganjiauthor=K.+N.+Smithemanauthor=C.-w.+Chungauthor=S.+Korenchukauthor=Y.+Baiauthor=O.+Barbashauthor=B.+Leauthor=P.+D.+Craggsauthor=M.+T.+McCabeauthor=K.+M.+Kennedy-Wilsonauthor=L.+V.+Sanchezauthor=R.+L.+Gosminiauthor=N.+Parrauthor=C.+F.+McHughauthor=D.+Dhanakauthor=R.+K.+Prinjhaauthor=K.+R.+Augerauthor=P.+J.+Tummino&title=BET+inhibition+silences+expression+of+MYCN+and+BCL2+and+induces+cytotoxicity+in+neuroblastoma+tumor+models&doi=10.1371%2Fjournal.pone.0072967"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models</span></div><div class="casAuthors">Wyce, Anastasia; Ganji, Gopinath; Smitheman, Kimberly N.; Chung, Chun-Wa; Korenchuk, Susan; Bai, Yuchen; Barbash, Olena; Le, Bao Chau; Craggs, Peter D.; McCabe, Michael T.; Kennedy-Wilson, Karen M.; Sanchez, Lydia V.; Gosmini, Romain L.; Parr, Nigel; McHugh, Charles F.; Dhanak, Dashyant; Prinjha, Rab K.; Auger, Kurt R.; Tummino, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e72967</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">BET family proteins are epigenetic regulators known to control expression of genes involved in cell growth and oncogenesis.  Selective inhibitors of BET proteins exhibit potent anti-proliferative activity in a no. of hematol. cancer models, in part through suppression of the MYC oncogene and downstream Myc-driven pathways.  However, little is currently known about the activity of BET inhibitors in solid tumor models, and whether down-regulation of MYC family genes contributes to sensitivity.  Here we provide evidence for potent BET inhibitor activity in neuroblastoma, a pediatric solid tumor assocd. with a high frequency of MYCN amplifications.  We treated a panel of neuroblastoma cell lines with a novel small mol. inhibitor of BET proteins, GSK1324726A (I-BET726), and obsd. potent growth inhibition and cytotoxicity in most cell lines irresp. of MYCN copy no. or expression level.  Gene expression analyses in neuroblastoma cell lines suggest a role of BET inhibition in apoptosis, signaling, and N-Myc-driven pathways, including the direct suppression of BCL2 and MYCN.  Reversal of MYCN or BCL2 suppression reduces the potency of I-BET726-induced cytotoxicity in a cell line-specific manner; however, neither factor fully accounts for I-BET726 sensitivity.  Oral administration of I-BET726 to mouse xenograft models of human neuroblastoma results in tumor growth inhibition and down-regulation MYCN and BCL2 expression, suggesting a potential role for these genes in tumor growth.  Taken together, our data highlight the potential of BET inhibitors as novel therapeutics for neuroblastoma, and suggest that sensitivity is driven by pleiotropic effects on cell growth and apoptotic pathways in a context-specific manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoecB0_0elFVbVg90H21EOLACvtfcHk0lhF39vDET6tBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtl2iu7fI&md5=d39ce25a50de58f18a278a9f67935bbc</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0072967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0072967%26sid%3Dliteratum%253Aachs%26aulast%3DWyce%26aufirst%3DA.%26aulast%3DGanji%26aufirst%3DG.%26aulast%3DSmitheman%26aufirst%3DK.%2BN.%26aulast%3DChung%26aufirst%3DC.-w.%26aulast%3DKorenchuk%26aufirst%3DS.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DBarbash%26aufirst%3DO.%26aulast%3DLe%26aufirst%3DB.%26aulast%3DCraggs%26aufirst%3DP.%2BD.%26aulast%3DMcCabe%26aufirst%3DM.%2BT.%26aulast%3DKennedy-Wilson%26aufirst%3DK.%2BM.%26aulast%3DSanchez%26aufirst%3DL.%2BV.%26aulast%3DGosmini%26aufirst%3DR.%2BL.%26aulast%3DParr%26aufirst%3DN.%26aulast%3DMcHugh%26aufirst%3DC.%2BF.%26aulast%3DDhanak%26aufirst%3DD.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DAuger%26aufirst%3DK.%2BR.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26atitle%3DBET%2520inhibition%2520silences%2520expression%2520of%2520MYCN%2520and%2520BCL2%2520and%2520induces%2520cytotoxicity%2520in%2520neuroblastoma%2520tumor%2520models%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De72967%26doi%3D10.1371%2Fjournal.pone.0072967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi-Yachide, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, T.</span></span> <span> </span><span class="NLM_article-title">Discovery and structure-activity relationship studies of <i>N</i><sub><i>6</i></sub>-benzoyladenine derivatives as novel BRD4 inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">953</span>– <span class="NLM_lpage">959</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.01.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bmc.2015.01.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25678016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslertLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=953-959&author=T.+Noguchi-Yachideauthor=T.+Sakaiauthor=Y.+Hashimotoauthor=T.+Yamaguchi&title=Discovery+and+structure-activity+relationship+studies+of+N6-benzoyladenine+derivatives+as+novel+BRD4+inhibitors&doi=10.1016%2Fj.bmc.2015.01.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and structure-activity relationship studies of N6-benzoyladenine derivatives as novel BRD4 inhibitors</span></div><div class="casAuthors">Noguchi-Yachide, Tomomi; Sakai, Taki; Hashimoto, Yuichi; Yamaguchi, Takao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">953-959</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Bromodomain and extra-terminal domain (BET) proteins are epigenetic readers that bind to acetylated lysines in histones.  Among them, BRD4 is a candidate target mol. of therapeutic agents for diverse diseases, including cancer and inflammatory disease.  As a part of the continuing structural development studies of thalidomide to obtain a broad spectrum of biol. modifiers based on the 'multitemplate' approach, in this work the authors focused on BRD4-inhibitory activity, and discovered that N6-benzoyladenine derivs. exhibit this activity.  Structure-activity relationship studies led to N6-(2,4,5-trimethoxybenzoyl)adenine I, which exhibits potent BRD4 bromodomain1 inhibitory activity with an IC50 value of 0.427 μM.  N6-Benzoyladenine appears to be a new chem. scaffold for development of BRD4 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDwaLfpkAET7Vg90H21EOLACvtfcHk0lhn8L80K11kcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslertLs%253D&md5=889cf81c25fd1e62def22cb2f32dc06e</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.01.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.01.022%26sid%3Dliteratum%253Aachs%26aulast%3DNoguchi-Yachide%26aufirst%3DT.%26aulast%3DSakai%26aufirst%3DT.%26aulast%3DHashimoto%26aufirst%3DY.%26aulast%3DYamaguchi%26aufirst%3DT.%26atitle%3DDiscovery%2520and%2520structure-activity%2520relationship%2520studies%2520of%2520N6-benzoyladenine%2520derivatives%2520as%2520novel%2520BRD4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D953%26epage%3D959%26doi%3D10.1016%2Fj.bmc.2015.01.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Targeting epigenetic reader and eraser: rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2931</span>– <span class="NLM_lpage">2935</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.04.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bmcl.2016.04.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=27142751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC28XntFCmt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2931-2935&author=Z.+Zhangauthor=S.+Houauthor=H.+Chenauthor=T.+Ranauthor=F.+Jiangauthor=Y.+Bianauthor=D.+Zhangauthor=Y.+Zhiauthor=L.+Wangauthor=L.+Zhangauthor=H.+Liauthor=Y.+Zhangauthor=W.+Tangauthor=T.+Luauthor=Y.+Chen&title=Targeting+epigenetic+reader+and+eraser%3A+rational+design%2C+synthesis+and+in+vitro+evaluation+of+dimethylisoxazoles+derivatives+as+BRD4%2FHDAC+dual+inhibitors&doi=10.1016%2Fj.bmcl.2016.04.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors</span></div><div class="casAuthors">Zhang, Zhimin; Hou, Shaohua; Chen, Hongli; Ran, Ting; Jiang, Fei; Bian, Yuanyuan; Zhang, Dewei; Zhi, Yanle; Wang, Lu; Zhang, Li; Li, Hongmei; Zhang, Yanmin; Tang, Weifang; Lu, Tao; Chen, Yadong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2931-2935</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The bromodomain protein module and histone deacetylase (HDAC), which recognize and remove acetylated lysine, resp., have emerged as important epigenetic therapeutic targets in cancer treatments.  Herein the authors presented a novel design approach for cancer drug development by combination of bromodomain and HDAC inhibitory activity in one mol.  The designed compds. were synthesized which showed inhibitory activity against bromodomain 4 and HDAC1.  The representative dual bromodomain/HDAC inhibitors, compds. N1-(3-benzoyl-5-(3,5-dimethylisoxazol-4-yl)phenyl)-N7-hydroxyheptanediamide and N1-(3-benzoyl-5-(3,5-dimethylisoxazol-4-yl)phenyl)-N8-hydroxyoctanediamide showed potent antiproliferative activities against human leukemia cell line K562 and MV4-11 in cellular assays.  This work may lay the foundation for developing dual bromodomain/HDAC inhibitors as potential anticancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriS0VB1G-QoLVg90H21EOLACvtfcHk0lhn8L80K11kcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntFCmt7o%253D&md5=a6ebdbd6402e3117a2f9d96ed071790c</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.04.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.04.034%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DHou%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DRan%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DBian%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DZhi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DTargeting%2520epigenetic%2520reader%2520and%2520eraser%253A%2520rational%2520design%252C%2520synthesis%2520and%2520in%2520vitro%2520evaluation%2520of%2520dimethylisoxazoles%2520derivatives%2520as%2520BRD4%252FHDAC%2520dual%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D2931%26epage%3D2935%26doi%3D10.1016%2Fj.bmcl.2016.04.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of novel indole derivatives as potential HDAC/BRD4 dual inhibitors and anti-leukemia agents</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">410</span>– <span class="NLM_lpage">417</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2018.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bioorg.2018.12.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=30554080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFaqtb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2019&pages=410-417&author=G.+Chengauthor=Z.+Wangauthor=J.+Yangauthor=Y.+Baoauthor=Q.+Xuauthor=L.+Zhaoauthor=D.+Liu&title=Design%2C+synthesis+and+biological+evaluation+of+novel+indole+derivatives+as+potential+HDAC%2FBRD4+dual+inhibitors+and+anti-leukemia+agents&doi=10.1016%2Fj.bioorg.2018.12.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of novel indole derivatives as potential HDAC/BRD4 dual inhibitors and anti-leukemia agents</span></div><div class="casAuthors">Cheng, Gaoliang; Wang, Zhi; Yang, Jinyu; Bao, Yu; Xu, Qihao; Zhao, Linxiang; Liu, Dan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">410-417</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">HDAC inhibitors and BRD4 inhibitors were considered to be potent anti-cancer agents.  Recent studies have demonstrated that HDAC and BRD4 participate in the regulation of some signal paths like PI3K-AKT.  In this work, a series of indole derivs. that combine the inhibitory activities of BRD4 and HDAC into one mol. were designed and synthesized through the structure-based design method.  Most compds. showed potent HDAC inhibitory activity and moderate BRD4 inhibitory activity.  In vitro anti-proliferation activities of the synthesized compds. were also evaluated.  Among them, 19f was the most potent inhibitor against HDAC3 with IC50 value of 5 nM and BRD4 inhibition rate of 88% at 10 μM.  It was confirmed that 19f could up-regulate the expression of Ac-H3 and reduce the expression of c-Myc by western blot anal.  These results indicated that 19f was a potent dual HDAC/BRD4 inhibitor and deserved further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkPM3yaQ5gE7Vg90H21EOLACvtfcHk0lhn8L80K11kcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFaqtb%252FI&md5=e2c81b5d67fd9f49e6805c6b544438b4</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2018.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2018.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DBao%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520indole%2520derivatives%2520as%2520potential%2520HDAC%252FBRD4%2520dual%2520inhibitors%2520and%2520anti-leukemia%2520agents%26jtitle%3DBioorg.%2520Chem.%26date%3D2019%26volume%3D84%26spage%3D410%26epage%3D417%26doi%3D10.1016%2Fj.bioorg.2018.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Potent dual BET/HDAC inhibitors for efficient treatment of pancreatic cancer</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3028</span>– <span class="NLM_lpage">3032</span>, <span class="refDoi"> DOI: 10.1002/anie.201915896</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1002%2Fanie.201915896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFegtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=3028-3032&author=S.+Heauthor=G.+Dongauthor=Y.+Liauthor=S.+Wuauthor=W.+Wangauthor=C.+Sheng&title=Potent+dual+BET%2FHDAC+inhibitors+for+efficient+treatment+of+pancreatic+cancer&doi=10.1002%2Fanie.201915896"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer</span></div><div class="casAuthors">He, Shipeng; Dong, Guoqiang; Li, Yu; Wu, Shanchao; Wang, Wei; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3028-3032</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">As one of the most aggressive and lethal human malignancies with extremely poor prognosis, there is an urgent demand of more effective therapy for the treatment of pancreatic cancer.  Reported here is a new, effective therapeutic strategy and the design of small-mol. inhibitors that simultaneously target bromodomain and extra-terminal (BET) and histone deacetylase (HDAC), potentially serving as promising therapeutic agents for pancreatic cancer.  A highly potent dual inhibitor (13 a) is identified to possess excellent and balanced activities against BRD4 BD1 (IC50=11 nM) and HDAC1 (IC50=21 nM).  Notably, this compd. shows higher in vitro and in vivo antitumor potency than the BET inhibitor (+)-JQ1 and the HDAC inhibitor vorinostat, either alone or and in combination, highlighting the advantages of BET/HDAC dual inhibitors for more effective treatment of pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9BFNcLfkA4bVg90H21EOLACvtfcHk0lhzT5lTwICJjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFegtLw%253D&md5=78db62cb533611939d9abd0e654ff5f3</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fanie.201915896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201915896%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DPotent%2520dual%2520BET%252FHDAC%2520inhibitors%2520for%2520efficient%2520treatment%2520of%2520pancreatic%2520cancer%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2020%26volume%3D59%26spage%3D3028%26epage%3D3032%26doi%3D10.1002%2Fanie.201915896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of thieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as bromodomain-containing protein 4/histone deacetylase dual inhibitors induce autophagic cell death in colorectal carcinoma cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">3678</span>– <span class="NLM_lpage">3700</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b02178</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b02178" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFajtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=3678-3700&author=Z.+Panauthor=X.+Liauthor=Y.+Wangauthor=Q.+Jiangauthor=L.+Jiangauthor=M.+Zhangauthor=N.+Zhangauthor=F.+Wuauthor=B.+Liuauthor=G.+He&title=Discovery+of+thieno%5B2%2C3-d%5Dpyrimidine-based+hydroxamic+acid+derivatives+as+bromodomain-containing+protein+4%2Fhistone+deacetylase+dual+inhibitors+induce+autophagic+cell+death+in+colorectal+carcinoma+cells&doi=10.1021%2Facs.jmedchem.9b02178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Thieno[2,3-d]pyrimidine-Based Hydroxamic Acid Derivatives as Bromodomain-Containing Protein 4/Histone Deacetylase Dual Inhibitors Induce Autophagic Cell Death in Colorectal Carcinoma Cells</span></div><div class="casAuthors">Pan, Zhaoping; Li, Xiang; Wang, Yujia; Jiang, Qinglin; Jiang, Li; Zhang, Min; Zhang, Nan; Wu, Fengbo; Liu, Bo; He, Gu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3678-3700</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bromodomain-contg. protein 4 (BRD4) and histone deacetylases (HDAC) are both attractive epigenetic targets in cancer and other chronic diseases.  Based on the integrated fragment-based drug design, synthesis, and in vitro and in vivo evaluations, a series of novel thieno[2,3-d]pyrimidine-based hydroxamic acid derivs. are discovered as selective BRD4-HDAC dual inhibitors.  Compd. 17c is the most potent inhibitor for BRD4 and HDAC with IC50 values at nanomolar levels, as well as the expression level of c-Myc, and increases the acetylation of histone H3.  Moreover, 17c presents inhibitory effects on the proliferation of colorectal carcinoma (CRC) cells via inducing autophagic cell death.  It also has a good pharmacokinetic profile in rats and oral bioavailability of 40.5%.  In the HCT-116 xenograft in vivo models, 17c displays potent inhibitory efficiency on tumor growth by inducing autophagic cell death and suppressing IL6-JAK-STAT signaling pathways.  Our results suggest that the BRD4-HDAC dual inhibition might be an attractive therapeutic strategy for CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2FHKdnuD3QLVg90H21EOLACvtfcHk0lhzT5lTwICJjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFajtLs%253D&md5=ce6446afe48f80165d2b21aee04571f6</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b02178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b02178%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520thieno%255B2%252C3-d%255Dpyrimidine-based%2520hydroxamic%2520acid%2520derivatives%2520as%2520bromodomain-containing%2520protein%25204%252Fhistone%2520deacetylase%2520dual%2520inhibitors%2520induce%2520autophagic%2520cell%2520death%2520in%2520colorectal%2520carcinoma%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D3678%26epage%3D3700%26doi%3D10.1021%2Facs.jmedchem.9b02178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemmon, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">Cell signaling by receptor tyrosine kinases</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1134</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2010.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.cell.2010.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=20602996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2010&pages=1117-1134&author=M.+A.+Lemmonauthor=J.+Schlessinger&title=Cell+signaling+by+receptor+tyrosine+kinases&doi=10.1016%2Fj.cell.2010.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Lemmon, Mark A.; Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1117-1134</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Recent structural studies of receptor tyrosine kinases (RTKs) have revealed unexpected diversity in the mechanisms of their activation by growth factor ligands.  Strategies for inducing dimerization by ligand binding are surprisingly diverse, as are mechanisms that couple this event to activation of the intracellular tyrosine kinase domains.  As the understanding of these details becomes increasingly sophisticated, it provides an important context for therapeutically countering the effects of pathogenic RTK mutations in cancer and other diseases.  Much remains to be learned, however, about the complex signaling networks downstream from RTKs and how alterations in these networks are translated into cellular responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd5NvoN0Q9-7Vg90H21EOLACvtfcHk0lgIZ2RJ-8Wjvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D&md5=b88b55fe7a3eebc6ff7e883425676e45</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520signaling%2520by%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D2010%26volume%3D141%26spage%3D1117%26epage%3D1134%26doi%3D10.1016%2Fj.cell.2010.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hristova, K.</span></span> <span> </span><span class="NLM_article-title">Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">6241</span>– <span class="NLM_lpage">6251</span>, <span class="refDoi"> DOI: 10.1021/bi060609y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi060609y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD28XktVSksrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2006&pages=6241-6251&author=E.+Liauthor=K.+Hristova&title=Role+of+receptor+tyrosine+kinase+transmembrane+domains+in+cell+signaling+and+human+pathologies&doi=10.1021%2Fbi060609y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Receptor Tyrosine Kinase Transmembrane Domains in Cell Signaling and Human Pathologies</span></div><div class="casAuthors">Li, Edwin; Hristova, Kalina</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6241-6251</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases (RTKs) conduct biochem. signals via lateral dimerization in the plasma membrane, and their transmembrane (TM) domains play an important role in the dimerization process.  Here we present two models of RTK-mediated signaling, and we discuss the role of the TM domains within the framework of these two models.  We summarize findings of single-amino acid mutations in RTK TM domains that induce unregulated signaling and, as a consequence, pathol. phenotypes.  We review the current knowledge of pathol. induction mechanisms due to these mutations, focusing on the structural and thermodn. basis of pathogenic dimer stabilization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyWcf9Iq0Ot7Vg90H21EOLACvtfcHk0ljKjgqIGLClpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktVSksrs%253D&md5=d42fa0811257a6494f1a74b2fc50cab4</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fbi060609y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi060609y%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DE.%26aulast%3DHristova%26aufirst%3DK.%26atitle%3DRole%2520of%2520receptor%2520tyrosine%2520kinase%2520transmembrane%2520domains%2520in%2520cell%2520signaling%2520and%2520human%2520pathologies%26jtitle%3DBiochemistry%26date%3D2006%26volume%3D45%26spage%3D6241%26epage%3D6251%26doi%3D10.1021%2Fbi060609y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. T.</span></span> <span> </span><span class="NLM_article-title">Receptor tyrosine kinases: mechanisms of activation and signaling</span>. <i>Curr. Opin. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">123</span>, <span class="refDoi"> DOI: 10.1016/j.ceb.2007.02.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.ceb.2007.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=17306972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt1Slu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2007&pages=117-123&author=S.+R.+Hubbardauthor=W.+T.+Miller&title=Receptor+tyrosine+kinases%3A+mechanisms+of+activation+and+signaling&doi=10.1016%2Fj.ceb.2007.02.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor tyrosine kinases: mechanisms of activation and signaling</span></div><div class="casAuthors">Hubbard, Stevan R.; Miller, W. Todd</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-123</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases (RTKs) are essential components of signal transduction pathways that mediate cell-to-cell communication.  These single-pass transmembrane receptors, which bind polypeptide ligands - mainly growth factors - play key roles in processes such as cellular growth, differentiation, metab. and motility.  Recent progress has been achieved towards an understanding of the precise (and varied) mechanisms by which RTKs are activated by ligand binding and by which signals are propagated from the activated receptors to downstream targets in the cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg3ej9ekC3hLVg90H21EOLACvtfcHk0liR551oaHZnFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt1Slu78%253D&md5=254110135c0f1a5642441c551d379bef</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2007.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2007.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26atitle%3DReceptor%2520tyrosine%2520kinases%253A%2520mechanisms%2520of%2520activation%2520and%2520signaling%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2007%26volume%3D19%26spage%3D117%26epage%3D123%26doi%3D10.1016%2Fj.ceb.2007.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemmon, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">Cell signaling by receptor tyrosine kinases</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">11134</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2010.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.cell.2010.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=20602996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2010&pages=1117-11134&author=M.+A.+Lemmonauthor=J.+Schlessinger&title=Cell+signaling+by+receptor+tyrosine+kinases&doi=10.1016%2Fj.cell.2010.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Lemmon, Mark A.; Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1117-1134</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Recent structural studies of receptor tyrosine kinases (RTKs) have revealed unexpected diversity in the mechanisms of their activation by growth factor ligands.  Strategies for inducing dimerization by ligand binding are surprisingly diverse, as are mechanisms that couple this event to activation of the intracellular tyrosine kinase domains.  As the understanding of these details becomes increasingly sophisticated, it provides an important context for therapeutically countering the effects of pathogenic RTK mutations in cancer and other diseases.  Much remains to be learned, however, about the complex signaling networks downstream from RTKs and how alterations in these networks are translated into cellular responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd5NvoN0Q9-7Vg90H21EOLACvtfcHk0lhX9LTJgk8bUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D&md5=b88b55fe7a3eebc6ff7e883425676e45</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520signaling%2520by%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D2010%26volume%3D141%26spage%3D1117%26epage%3D11134%26doi%3D10.1016%2Fj.cell.2010.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, S. R.</span></span> <span> </span><span class="NLM_article-title">Juxtamembrane autoinhibition in receptor tyrosine kinases</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">464</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1038/nrm1399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnrm1399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15173825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVarsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=464-470&author=S.+R.+Hubbard&title=Juxtamembrane+autoinhibition+in+receptor+tyrosine+kinases&doi=10.1038%2Fnrm1399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Juxtamembrane autoinhibition in receptor tyrosine kinases</span></div><div class="casAuthors">Hubbard, Stevan R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">464-471</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases are essential mediators of cell growth, differentiation, migration, and metab.  Accordingly, their catalytic activity is tightly regulated by several mechanisms including autoinhibition.  Recent structural studies, together with biochem. expts., are now unraveling the mol. mechanisms by which the juxtamembrane region (between the transmembrane helix and the cytoplasmic kinase domain) neg. regulates catalytic activity in various receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPtSOSgNkh4rVg90H21EOLACvtfcHk0libP9wrV4IDgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVarsLs%253D&md5=99f8e4d23d72e397768a7f01d41dcb56</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fnrm1399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1399%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26atitle%3DJuxtamembrane%2520autoinhibition%2520in%2520receptor%2520tyrosine%2520kinases%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2004%26volume%3D5%26spage%3D464%26epage%3D470%26doi%3D10.1038%2Fnrm1399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">Signal transduction by receptors with tyrosine kinase activity</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(90)90801-K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2F0092-8674%2890%2990801-K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=2158859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADyaK3cXktlKnu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=1990&pages=203-212&author=A.+Ullrichauthor=J.+Schlessinger&title=Signal+transduction+by+receptors+with+tyrosine+kinase+activity&doi=10.1016%2F0092-8674%2890%2990801-K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transduction by receptors with tyrosine kinase activity</span></div><div class="casAuthors">Ullrich, Axel; Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-12</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">A review, with 91 refs., of signal transduction by the title receptors during development of multicellular organisms.  Major mechanistic questions of receptor action and signal transduction are discussed, with emphasis on the EGF receptor.  The role of these receptors in neoplastic transformation is included.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrmhaKMZphVrVg90H21EOLACvtfcHk0libP9wrV4IDgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXktlKnu74%253D&md5=d8461b736d274bebbf66d494c1b7755e</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2890%2990801-K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252890%252990801-K%26sid%3Dliteratum%253Aachs%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DSignal%2520transduction%2520by%2520receptors%2520with%2520tyrosine%2520kinase%2520activity%26jtitle%3DCell%26date%3D1990%26volume%3D61%26spage%3D203%26epage%3D212%26doi%3D10.1016%2F0092-8674%2890%2990801-K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaBonte, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazzone, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louie, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Khoueiry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladner, R. D.</span></span> <span> </span><span class="NLM_article-title">The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">3635</span>– <span class="NLM_lpage">3648</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-2430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F0008-5472.CAN-10-2430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=21464044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVGltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=3635-3648&author=M.+J.+LaBonteauthor=P.+M.+Wilsonauthor=W.+Fazzoneauthor=J.+Russellauthor=S.+G.+Louieauthor=A.+El-Khoueiryauthor=H.+J.+Lenzauthor=R.+D.+Ladner&title=The+dual+EGFR%2FHER2+inhibitor+lapatinib+synergistically+enhances+the+antitumor+activity+of+the+histone+deacetylase+inhibitor+panobinostat+in+colorectal+cancer+models&doi=10.1158%2F0008-5472.CAN-10-2430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">The Dual EGFR/HER2 Inhibitor Lapatinib Synergistically Enhances the Antitumor Activity of the Histone Deacetylase Inhibitor Panobinostat in Colorectal Cancer Models</span></div><div class="casAuthors">LaBonte, Melissa J.; Wilson, Peter M.; Fazzone, Will; Russell, Jared; Louie, Stan G.; El-Khoueiry, Anthony; Lenz, Heinz-Josef; Ladner, Robert D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3635-3648</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">As key mols. that drive progression and chemoresistance in gastrointestinal cancers, epidermal growth factor receptor (EGFR) and HER2 have become efficacious drug targets in this setting.  Lapatinib is an EGFR/HER2 kinase inhibitor suppressing signaling through the RAS/RAF/MEK (MAP/ERK kinase)/MAPK (mitogen-activated protein kinase) and PI3K (phosphoinositide 3-kinase)/AKT pathways.  Histone deacetylase inhibitors (HDACi) are a novel class of agents that induce cell cycle arrest and apoptosis following the acetylation of histone and nonhistone proteins modulating gene expression and disrupting HSP90 function inducing the degrdn. of EGFR-pathway client proteins.  This study sought to evaluate the therapeutic potential of combining lapatinib with the HDACi panobinostat in colorectal cancer (CRC) cell lines with varying EGFR/HER2 expression and KRAS/BRAF/PIK3CA mutations.  Lapatinib and panobinostat exerted concn.-dependent antiproliferative effects in vitro (panobinostat range 7.2-30 nmol/L; lapatinib range 7.6-25.8 μmol/L).  Combined lapatinib and panobinostat treatment interacted synergistically to inhibit the proliferation and colony formation in all CRC cell lines tested.  Combination treatment resulted in rapid induction of apoptosis that coincided with increased DNA double-strand breaks, caspase-8 activation, and PARP cleavage.  This was paralleled by decreased signaling through both the PI3K and MAPK pathways and increased downregulation of transcriptional targets including NF-κB1, IRAK1, and CCND1.  Panobinostat treatment induced downregulation of EGFR, HER2, and HER3 mRNA and protein through transcriptional and posttranslational mechanisms.  In the LoVo KRAS mutant CRC xenograft model, the combination showed greater antitumor activity than either agent alone, with no apparent increase in toxicity.  Our results offer preclin. rationale warranting further clin. investigation combining HDACi with EGFR and HER2-targeted therapies for CRC treatment.  Cancer Res; 71(10); 3635-48.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1SSsKxj9V_bVg90H21EOLACvtfcHk0libP9wrV4IDgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVGltLo%253D&md5=1c90487efab29f12e919ed5804716937</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2430%26sid%3Dliteratum%253Aachs%26aulast%3DLaBonte%26aufirst%3DM.%2BJ.%26aulast%3DWilson%26aufirst%3DP.%2BM.%26aulast%3DFazzone%26aufirst%3DW.%26aulast%3DRussell%26aufirst%3DJ.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DEl-Khoueiry%26aufirst%3DA.%26aulast%3DLenz%26aufirst%3DH.%2BJ.%26aulast%3DLadner%26aufirst%3DR.%2BD.%26atitle%3DThe%2520dual%2520EGFR%252FHER2%2520inhibitor%2520lapatinib%2520synergistically%2520enhances%2520the%2520antitumor%2520activity%2520of%2520the%2520histone%2520deacetylase%2520inhibitor%2520panobinostat%2520in%2520colorectal%2520cancer%2520models%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D3635%26epage%3D3648%26doi%3D10.1158%2F0008-5472.CAN-10-2430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rho, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J. J.</span></span> <span> </span><span class="NLM_article-title">Vorinostat enhances gefitinibinduced cell death through reactive oxygen speciesdependent cleavage of HSP90 and its clients in nonsmall cell lung cancer with the EGFR mutation</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.3892/or.2018.6814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.3892%2For.2018.6814" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=30365122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVOnu77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2019&pages=525-533&author=S.+E.+Parkauthor=D.+E.+Kimauthor=M.+J.+Kimauthor=J.+S.+Leeauthor=J.+K.+Rhoauthor=S.+Y.+Jeongauthor=E.+K.+Choiauthor=C.+S.+Kimauthor=J.+J.+Hwang&title=Vorinostat+enhances+gefitinibinduced+cell+death+through+reactive+oxygen+speciesdependent+cleavage+of+HSP90+and+its+clients+in+nonsmall+cell+lung+cancer+with+the+EGFR+mutation&doi=10.3892%2For.2018.6814"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Vorinostat enhances gefitinib-induced cell death through reactive oxygen species-dependent cleavage of HSP90 and its clients in non-small cell lung cancer with the EGFR mutation</span></div><div class="casAuthors">Park, Sang Eun; Kim, Dong Eun; Kim, Mi Joung; Lee, Jee Suk; Rho, Jin Kyung; Jeong, Seong-Yun; Choi, Eun Kyung; Kim, Choung-Soo; Hwang, Jung Jin</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">525-533</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Although different mechanisms of acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have been reported in non-small cell lung cancers (NSCLCs), the optimal treatment for patients with acquired resistance has not been clearly defined.  The purpose of this study was to investigate the antitumor effects of gefitinib in combination with vorinostat, a potent histone deacetylase inhibitor (HDACI), and their assocd. mol. mechanisms in relation to activating apoptosis in NSCLC.  The treatment using a combination of vorinostat and gefitinib was more potent in promoting cell death by activating apoptosis than gefitinib alone in parental PC9 cells that harbor an EGFR-activating mutation (EGFR exon 19 deletion) and gefitinib-resistant PC9 cells (PC9GR) with an EGFR T790M mutation.  This combination induced heat shock protein 90 (HSP90) cleavage and reduced the level of HSP90 client proteins, including EGFR, MET and AKT, in PC9 and PC9GR cells.  The addn. of 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride, a scavenger of reactive oxygen species (ROS), inhibited the degrdn. of HSP90 client proteins and HSP90 cleavage that was induced by co-treatment as well as the cleavage of caspase-3, caspase-8, and caspase-9 and cell death.  We also obsd. that cleavage of HSP90 and its clients were blocked when caspases were inhibited.  These results revealed that co-treatment with vorinostat and gefitinib induced ROS-dependent caspase activation, leading to the downregulation of HSP90 clients through HSP90 cleavage.  Collectively, our findings provide a new basis for strategies that combine vorinostat with an EGFR-TKI to reverse EGFR-TKI resistance in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrobKxHswyuvLVg90H21EOLACvtfcHk0libP9wrV4IDgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVOnu77L&md5=065e126a4ce27bab0056194ae77c509d</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.3892%2For.2018.6814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2018.6814%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%2BE.%26aulast%3DKim%26aufirst%3DD.%2BE.%26aulast%3DKim%26aufirst%3DM.%2BJ.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DJeong%26aufirst%3DS.%2BY.%26aulast%3DChoi%26aufirst%3DE.%2BK.%26aulast%3DKim%26aufirst%3DC.%2BS.%26aulast%3DHwang%26aufirst%3DJ.%2BJ.%26atitle%3DVorinostat%2520enhances%2520gefitinibinduced%2520cell%2520death%2520through%2520reactive%2520oxygen%2520speciesdependent%2520cleavage%2520of%2520HSP90%2520and%2520its%2520clients%2520in%2520nonsmall%2520cell%2520lung%2520cancer%2520with%2520the%2520EGFR%2520mutation%26jtitle%3DOncol.%2520Rep.%26date%3D2019%26volume%3D41%26spage%3D525%26epage%3D533%26doi%3D10.3892%2For.2018.6814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. M.</span></span> <span> </span><span class="NLM_article-title">The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e810</span>, <span class="refDoi"> DOI: 10.1038/cddis.2013.330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fcddis.2013.330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=24052078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2mtb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=e810&author=M.+C.+Chenauthor=C.+H.+Chenauthor=J.+C.+Wangauthor=A.+C.+Tsaiauthor=J.+P.+Liouauthor=S.+L.+Panauthor=C.+M.+Teng&title=The+HDAC+inhibitor%2C+MPT0E028%2C+enhances+erlotinib-induced+cell+death+in+EGFR-TKI-resistant+NSCLC+cells&doi=10.1038%2Fcddis.2013.330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells</span></div><div class="casAuthors">Chen, M.-C.; Chen, C.-H.; Wang, J.-C.; Tsai, A.-C.; Liou, J.-P.; Pan, S.-L.; Teng, C.-M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">Sept.</span>),
    <span class="NLM_cas:pages">e810</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR), which promotes cell survival and division, is found at abnormally high levels on the surface of many cancer cell types, including many cases of non-small cell lung cancer.  Erlotinib (Tarceva), an oral small-mol. tyrosine kinase inhibitor, is a so-called targeted drug that inhibits the tyrosine kinase domain of EGFR, and thus targets cancer cells with some specificity while doing less damage to normal cells.  However, erlotinib resistance can occur, reducing the efficacy of this treatment.  To develop more effective therapeutic interventions by overcoming this resistance problem, we combined the histone deacetylase inhibitor, MPT0E028, with erlotinib in an effort to increase their antitumor effects in erlotinib-resistant lung adenocarcinoma cells.  This combined treatment yielded significant growth inhibition, induced the expression of apoptotic proteins (PARP, γH2AX, and caspase-3), increased the levels of acetylated histone H3, and showed synergistic effects in vitro and in vivo.  These effects were independent of the mutation status of the genes encoding EGFR or K-Ras.  MPT0E028 synergistically blocked key regulators of the EGFR/HER2 signaling pathways, attenuating multiple compensatory pathways (e.g., AKT, extracellular signal-regulated kinase, and c-MET).  Our results indicate that this combination therapy might be a promising strategy for facilitating the effects of erlotinib monotherapy by activating various networks.  Taken together, our data provide compelling evidence that MPT0E028 has the potential to improve the treatment of heterogeneous and drug-resistant tumors that cannot be controlled with single-target agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohUhwZb0vDhbVg90H21EOLACvtfcHk0lgItue4tJcIug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2mtb7J&md5=5fca3b66a1178f8086b61bcb42eacaa0</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2013.330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2013.330%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%2BC.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DWang%26aufirst%3DJ.%2BC.%26aulast%3DTsai%26aufirst%3DA.%2BC.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DTeng%26aufirst%3DC.%2BM.%26atitle%3DThe%2520HDAC%2520inhibitor%252C%2520MPT0E028%252C%2520enhances%2520erlotinib-induced%2520cell%2520death%2520in%2520EGFR-TKI-resistant%2520NSCLC%2520cells%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2013%26volume%3D4%26spage%3De810%26doi%3D10.1038%2Fcddis.2013.330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagliardi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Gennaro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gimigliano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pucci, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budillon, A.</span></span> <span> </span><span class="NLM_article-title">Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells</span>. <i>Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3725</span>– <span class="NLM_lpage">3742</span>, <span class="refDoi"> DOI: 10.1002/pmic.201100092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1002%2Fpmic.201100092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=21761561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFajsb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=3725-3742&author=L.+Bianchiauthor=F.+Bruzzeseauthor=A.+Leoneauthor=A.+Gagliardiauthor=M.+Pugliaauthor=E.+Di+Gennaroauthor=M.+Roccoauthor=A.+Gimiglianoauthor=B.+Pucciauthor=A.+Arminiauthor=L.+Biniauthor=A.+Budillon&title=Proteomic+analysis+identifies+differentially+expressed+proteins+after+HDAC+vorinostat+and+EGFR+inhibitor+gefitinib+treatments+in+Hep-2+cancer+cells&doi=10.1002%2Fpmic.201100092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells</span></div><div class="casAuthors">Bianchi, Laura; Bruzzese, Francesca; Leone, Alessandra; Gagliardi, Assunta; Puglia, Michele; Di Gennaro, Elena; Rocco, Monia; Gimigliano, Anna; Pucci, Biagio; Armini, Alessandro; Bini, Luca; Budillon, Alfredo</div><div class="citationInfo"><span class="NLM_cas:title">Proteomics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3725-3742</span>CODEN:
                <span class="NLM_cas:coden">PROTC7</span>;
        ISSN:<span class="NLM_cas:issn">1615-9853</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Several solid tumors are characterized by poor prognosis and few effective treatment options, other than palliative chemotherapy in the recurrent/metastatic setting.  Epidermal growth factor receptor (EGFR) has been considered an important anticancer target because it is involved in the development and progression of several solid tumors; however, only a subset of patients show a clin. meaningful response to EGFR inhibition, particularly to EGFR tyrosine kinase inhibitors such as gefitinib.  We have recently demonstrated synergistic antitumor effect of the histone deacetylase inhibitor vorinostat combined with gefitinib.  To further characterize the interaction between these two agents, cellular exts. from Hep-2 cancer cells that were untreated or treated for 24 h with either vorinostat or gefitinib alone or with a vorinostat/gefitinib combination were analyzed using 2-D DIGE.  Software anal. using DeCyder was performed, and numerous differentially expressed protein spots were visualized between the four examd. settings.  Using MALDI-TOF MS and ESI-Ion trap MS/MS, several differentially expressed proteins were identified; some of these were validated by Western blotting.  Finally, a pathway anal. of exptl. data performed using MetaCore highlighted a relevant relationship between the identified proteins and addnl. potential effectors.  In conclusion, we performed a comprehensive anal. of proteins regulated by vorinostat and gefitinib, alone and in combination, providing a useful insight into their mechanisms of action as well as their synergistic interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjWwQmorv5jbVg90H21EOLACvtfcHk0lgItue4tJcIug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFajsb3J&md5=edff18202a93c765e2294d2db7f8ff0a</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1002%2Fpmic.201100092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpmic.201100092%26sid%3Dliteratum%253Aachs%26aulast%3DBianchi%26aufirst%3DL.%26aulast%3DBruzzese%26aufirst%3DF.%26aulast%3DLeone%26aufirst%3DA.%26aulast%3DGagliardi%26aufirst%3DA.%26aulast%3DPuglia%26aufirst%3DM.%26aulast%3DDi%2BGennaro%26aufirst%3DE.%26aulast%3DRocco%26aufirst%3DM.%26aulast%3DGimigliano%26aufirst%3DA.%26aulast%3DPucci%26aufirst%3DB.%26aulast%3DArmini%26aufirst%3DA.%26aulast%3DBini%26aufirst%3DL.%26aulast%3DBudillon%26aufirst%3DA.%26atitle%3DProteomic%2520analysis%2520identifies%2520differentially%2520expressed%2520proteins%2520after%2520HDAC%2520vorinostat%2520and%2520EGFR%2520inhibitor%2520gefitinib%2520treatments%2520in%2520Hep-2%2520cancer%2520cells%26jtitle%3DProteomics%26date%3D2011%26volume%3D11%26spage%3D3725%26epage%3D3742%26doi%3D10.1002%2Fpmic.201100092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colburn, N. H.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">100</span>– <span class="NLM_lpage">109</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-04-0070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1541-7786.MCR-04-0070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15755876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVKku74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2005&pages=100-109&author=J.+Huauthor=N.+H.+Colburn&title=Histone+deacetylase+inhibition+down-regulates+cyclin+D1+transcription+by+inhibiting+nuclear+factor-kappaB%2Fp65+DNA+binding&doi=10.1158%2F1541-7786.MCR-04-0070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibition Down-Regulates Cyclin D1 Transcription by Inhibiting Nuclear Factor-κB/p65 DNA Binding</span></div><div class="casAuthors">Hu, Jing; Colburn, Nancy H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">100-109</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors are emerging as a promising new class of cancer therapeutic agents.  HDAC inhibitors relieve the deacetylation of histone proteins.  However, little is known about the nonhistone targets of HDAC inhibitors and their roles in gene regulation.  In this study, we addressed the mol. basis of the down-regulation of the nuclear factor-κB (NF-κB)-responsive gene cyclin D1 by the HDAC inhibitor trichostatin A in mouse JB6 cells.  Cyclin D1 plays a crit. role in cell proliferation and tumor progression.  Trichostatin A inhibits cyclin D1 expression in a NF-κB-dependent manner in JB6 cells.  Electrophoretic mobility shift assay studies showed that trichostatin A treatment prevents p65 dimer binding to NF-κB sites on DNA.  Moreover, a chromatin immunopptn. assay shows that trichostatin A treatment inhibits endogenous cyclin D1 gene transcription by preventing p65 binding to the cyclin D1 promoter.  However, acetylation of p65 is not affected by trichostatin A treatment.  Instead, trichostatin A enhances p52 acetylation and increases p52 protein level by enhancing p100 processing.  This is the first report that trichostatin A, a HDAC inhibitor, activates p100 processing and relieves the repression of p52 acetylation.  The enhanced acetylation of p52 in the nuclei may operate to cause nuclear retention of p65 by increasing the p52/p65 interaction and preventing IκBα-p65 binding.  The enhanced p52 acetylation coincides with decreased p65 DNA binding, suggesting a potential role of p52 acetylation in NF-κB regulation.  Together, the results provide the first demonstration that HDAC inhibitor trichostatin A inhibits cyclin D1 gene transcription through targeting transcription factor NF-κB/p65 DNA binding.  NF-κB is therefore identified as a transcription factor target of trichostatin A treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_10jC2vcwH7Vg90H21EOLACvtfcHk0lgItue4tJcIug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVKku74%253D&md5=c5c6892386af861142daa241d1d05d12</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-04-0070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-04-0070%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DColburn%26aufirst%3DN.%2BH.%26atitle%3DHistone%2520deacetylase%2520inhibition%2520down-regulates%2520cyclin%2520D1%2520transcription%2520by%2520inhibiting%2520nuclear%2520factor-kappaB%252Fp65%2520DNA%2520binding%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2005%26volume%3D3%26spage%3D100%26epage%3D109%26doi%3D10.1158%2F1541-7786.MCR-04-0070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horinaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinnoh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, T.</span></span> <span> </span><span class="NLM_article-title">A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1080</span>– <span class="NLM_lpage">1086</span>, <span class="refDoi"> DOI: 10.3892/ijo.2013.2042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.3892%2Fijo.2013.2042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=23900601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1CmsbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2013&pages=1080-1086&author=T.+Yamadaauthor=M.+Horinakaauthor=M.+Shinnohauthor=T.+Yoshiokaauthor=T.+Mikiauthor=T.+Sakai&title=A+novel+HDAC+inhibitor+OBP-801+and+a+PI3K+inhibitor+LY294002+synergistically+induce+apoptosis+via+the+suppression+of+survivin+and+XIAP+in+renal+cell+carcinoma&doi=10.3892%2Fijo.2013.2042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma</span></div><div class="casAuthors">Yamada, Takeshi; Horinaka, Mano; Shinnoh, Masahide; Yoshioka, Takashi; Miki, Tsuneharu; Sakai, Toshiyuki</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1080-1086</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Renal cell carcinoma (RCC) is resistant to traditional cancer therapies such as radiation therapy and chemotherapy.  The use of targeted therapies has improved the clin. outcomes of patients with metastatic RCC.  However, most patients acquire resistance against targeted therapies over time.  We report that the combination of the novel histone deacetylase (HDAC) inhibitor OBP-801, also known as YM753 and the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 synergistically inhibits cell growth and induces apoptosis in RCC cells.  This combination activated caspase-3, -8 and -9 and the pan-caspase inhibitor zVAD-fmk significantly reduced the apoptotic response to the treatment with OBP-801 and LY294002.  Moreover, the combined treatment induced intracellular reactive oxygen species (ROS) and the radical scavenger N-acetyl-L-cysteine (NAC) blocked the intracellular ROS and apoptosis induced by OBP-801 and LY294002.  The co-treatment with OBP-801 and LY294002 markedly decreased survivin and the X-linked inhibitor of apoptosis protein (XIAP) protein levels, but Bcl-2 family members were not altered by the OBP-801/LY294002 co-treatment.  These alterations were restored by NAC treatment.  The transient transfection of survivin and XIAP reduced the apoptotic response to the OBP-801/LY294002 co-treatment.  Addnl., OBP-801 was significantly more effective than SAHA, another HDAC inhibitor, in the combination with LY294002 against 786-O cells.  Taken together, these results strongly suggest the combination of OBP-801 and LY294002 to be a promising treatment for RCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsaAUuVoRqkrVg90H21EOLACvtfcHk0liyYbu1Lg3tdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1CmsbjK&md5=3f17423d3b17adaa7dd319da8024ec5f</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.3892%2Fijo.2013.2042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2013.2042%26sid%3Dliteratum%253Aachs%26aulast%3DYamada%26aufirst%3DT.%26aulast%3DHorinaka%26aufirst%3DM.%26aulast%3DShinnoh%26aufirst%3DM.%26aulast%3DYoshioka%26aufirst%3DT.%26aulast%3DMiki%26aufirst%3DT.%26aulast%3DSakai%26aufirst%3DT.%26atitle%3DA%2520novel%2520HDAC%2520inhibitor%2520OBP-801%2520and%2520a%2520PI3K%2520inhibitor%2520LY294002%2520synergistically%2520induce%2520apoptosis%2520via%2520the%2520suppression%2520of%2520survivin%2520and%2520XIAP%2520in%2520renal%2520cell%2520carcinoma%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2013%26volume%3D43%26spage%3D1080%26epage%3D1086%26doi%3D10.3892%2Fijo.2013.2042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Locatelli, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleris, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stirparo, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tartari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saba, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierdominici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malorni, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anichini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlo-Stella, C.</span></span> <span> </span><span class="NLM_article-title">BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi givinostat and sorafenib in hodgkin lymphoma cell line xenografts</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1861</span>– <span class="NLM_lpage">1871</span>, <span class="refDoi"> DOI: 10.1038/leu.2014.81</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fleu.2014.81" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=24561519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslGqs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=1861-1871&author=S.+L.+Locatelliauthor=L.+Clerisauthor=G.+G.+Stirparoauthor=S.+Tartariauthor=E.+Sabaauthor=M.+Pierdominiciauthor=W.+Malorniauthor=A.+Carboneauthor=A.+Anichiniauthor=C.+Carlo-Stella&title=BIM+upregulation+and+ROS-dependent+necroptosis+mediate+the+antitumor+effects+of+the+HDACi+givinostat+and+sorafenib+in+hodgkin+lymphoma+cell+line+xenografts&doi=10.1038%2Fleu.2014.81"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts</span></div><div class="casAuthors">Locatelli, S. L.; Cleris, L.; Stirparo, G. G.; Tartari, S.; Saba, E.; Pierdominici, M.; Malorni, W.; Carbone, A.; Anichini, A.; Carlo-Stella, C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1861-1871</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Relapsed/refractory Hodgkin's lymphoma (HL) is an unmet medical need requiring new therapeutic options.  Interactions between the histone deacetylase inhibitor Givinostat and the RAF/MEK/ERK inhibitor Sorafenib were examd. in HDLM-2 and L-540 HL cell lines.  Exposure to Givinostat/Sorafenib induced a synergistic inhibition of cell growth (range, 70-80%) and a marked increase in cell death (up to 96%) due to increased H3 and H4 acetylation and strong mitochondrial injury.  Gene expression profiling indicated that the synergistic effects of Givinostat/Sorafenib treatment are assocd. with the modulation of cell cycle and cell death pathways.  Exposure to Givinostat/Sorafenib resulted in sustained prodn. of reactive oxygen species (ROS) and activation of necroptotic cell death.  The necroptosis inhibitor Necrostatin-1 prevented Givinostat/Sorafenib-induced ROS prodn., mitochondrial injury, activation of BH3-only protein BIM and cell death.  Knockdown expts. identified BIM as a key signaling mol. that mediates Givinostat/Sorafenib-induced oxidative death of HL cells.  Furthermore, in vivo xenograft studies demonstrated a 50% redn. in tumor burden (P<0.0001), a 5- to 15-fold increase in BIM expression (P≤0.0001) and a fourfold increase in tumor necrosis in Givinostat/Sorafenib-treated animals compared with mice that received single agents.  These results provide a rationale for exploring Givinostat/Sorafenib combination in relapsed/refractory HL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMH9ugVrPEabVg90H21EOLACvtfcHk0liyYbu1Lg3tdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslGqs7c%253D&md5=e0a5ffa1d583fbc54fe88e439bb7bc9e</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1038%2Fleu.2014.81&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2014.81%26sid%3Dliteratum%253Aachs%26aulast%3DLocatelli%26aufirst%3DS.%2BL.%26aulast%3DCleris%26aufirst%3DL.%26aulast%3DStirparo%26aufirst%3DG.%2BG.%26aulast%3DTartari%26aufirst%3DS.%26aulast%3DSaba%26aufirst%3DE.%26aulast%3DPierdominici%26aufirst%3DM.%26aulast%3DMalorni%26aufirst%3DW.%26aulast%3DCarbone%26aufirst%3DA.%26aulast%3DAnichini%26aufirst%3DA.%26aulast%3DCarlo-Stella%26aufirst%3DC.%26atitle%3DBIM%2520upregulation%2520and%2520ROS-dependent%2520necroptosis%2520mediate%2520the%2520antitumor%2520effects%2520of%2520the%2520HDACi%2520givinostat%2520and%2520sorafenib%2520in%2520hodgkin%2520lymphoma%2520cell%2520line%2520xenografts%26jtitle%3DLeukemia%26date%3D2014%26volume%3D28%26spage%3D1861%26epage%3D1871%26doi%3D10.1038%2Fleu.2014.81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wedel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seibel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juengel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsaur, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haferkamp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaheta, R. A.</span></span> <span> </span><span class="NLM_article-title">Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">418</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2010.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.lfs.2010.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=21192952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3MXit1Gkuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2011&pages=418-424&author=S.+Wedelauthor=L.+Hudakauthor=J.+M.+Seibelauthor=E.+Juengelauthor=I.+Tsaurauthor=C.+Wiesnerauthor=A.+Haferkampauthor=R.+A.+Blaheta&title=Inhibitory+effects+of+the+HDAC+inhibitor+valproic+acid+on+prostate+cancer+growth+are+enhanced+by+simultaneous+application+of+the+mTOR+inhibitor+RAD001&doi=10.1016%2Fj.lfs.2010.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001</span></div><div class="casAuthors">Wedel, Steffen; Hudak, Lukasz; Seibel, Jens-Michael; Juengel, Eva; Tsaur, Igor; Wiesner, Christoph; Haferkamp, Axel; Blaheta, Roman A.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">9-10</span>),
    <span class="NLM_cas:pages">418-424</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">To analyze the combined impact of the histone deacetylase (HDAC) inhibitor valproic acid (VPA) and the mammalian target of rapamycin (mTOR) inhibitor RAD001 on prostate cancer cell growth.  PC-3, DU-145 and LNCaP cells were treated with RAD001, VPA or with an RAD001-VPA combination for 3 or 5 days.  Tumor cell growth, cell cycle progression and cell cycle regulating proteins were then investigated by MTT assay, flow cytometry and Western blotting, resp.  Effects of drug treatment on cell signaling pathways were detd.  Sep. application of RAD001 or VPA distinctly reduced tumor cell growth and impaired cell cycle progression.  Significant additive effects were evoked when both drugs were used in concert.  Particularly, the cell cycle regulating proteins cdk1, cdk2, cdk4 and cyclin B were reduced, whereas p21 and p27 were enhanced by the RAD001-VPA combination.  Signaling anal. revealed deactivation of EGFr, ERK1/2 and p70S6k.  Phosphorylation of Akt was diminished in DU-145 but elevated in PC-3 and LNCaP cells.  The RAD001-VPA combination exerted profound antitumor properties on a panel of prostate cancer cell lines.  Therefore, simultaneous blockage of HDAC and mTOR related pathways should be considered when designing novel therapeutic strategies for treating prostate carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-wrTgZZwog7Vg90H21EOLACvtfcHk0liyYbu1Lg3tdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXit1Gkuro%253D&md5=af7a4cb174e2b4ee1891066c348f1429</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2010.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2010.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DWedel%26aufirst%3DS.%26aulast%3DHudak%26aufirst%3DL.%26aulast%3DSeibel%26aufirst%3DJ.%2BM.%26aulast%3DJuengel%26aufirst%3DE.%26aulast%3DTsaur%26aufirst%3DI.%26aulast%3DWiesner%26aufirst%3DC.%26aulast%3DHaferkamp%26aufirst%3DA.%26aulast%3DBlaheta%26aufirst%3DR.%2BA.%26atitle%3DInhibitory%2520effects%2520of%2520the%2520HDAC%2520inhibitor%2520valproic%2520acid%2520on%2520prostate%2520cancer%2520growth%2520are%2520enhanced%2520by%2520simultaneous%2520application%2520of%2520the%2520mTOR%2520inhibitor%2520RAD001%26jtitle%3DLife%2520Sci.%26date%3D2011%26volume%3D88%26spage%3D418%26epage%3D424%26doi%3D10.1016%2Fj.lfs.2010.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahalingam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esquivel, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espitia, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberheu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swords, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carew, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giles, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawrocki, S. T.</span></span> <span> </span><span class="NLM_article-title">Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">153</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-1385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1078-0432.CCR-09-1385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=20028765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotFyk" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=141-153&author=D.+Mahalingamauthor=E.+C.+Medinaauthor=J.+A.+Esquivelauthor=C.+M.+Espitiaauthor=S.+Smithauthor=K.+Oberheuauthor=R.+Swordsauthor=K.+R.+Kellyauthor=M.+M.+Mitaauthor=A.+C.+Mitaauthor=J.+S.+Carewauthor=F.+J.+Gilesauthor=S.+T.+Nawrocki&title=Vorinostat+enhances+the+activity+of+temsirolimus+in+renal+cell+carcinoma+through+suppression+of+survivin+levels&doi=10.1158%2F1078-0432.CCR-09-1385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels</span></div><div class="casAuthors">Mahalingam, Devalingam; Medina, Ernest C.; Esquivel, Juan A., II; Espitia, Claudia M.; Smith, Sabrina; Oberheu, Kelli; Swords, Ronan; Kelly, Kevin R.; Mita, Monica M.; Mita, Alain C.; Carew, Jennifer S.; Giles, Francis J.; Nawrocki, Steffan T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">141-153</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The mammalian target of rapamycin (mTOR) inhibitor temsirolimus has exhibited promising anticancer activity for the treatment of renal cell cancers (RCC).  Survivin expression has been implicated in drug resistance and reducing its levels with the histone deacetylase (HDAC) inhibitor vorinostat may enhance the anticancer activity of temsirolimus.  Exptl. Design: The sensitivity of RCC cell lines to the combination of temsirolimus and vorinostat was detd. by measuring cell viability, clonogenic survival, and apoptosis.  The effects of this combination on survivin levels were detd. in vitro and in vivo.  Survivin expression was silenced using small interfering RNA to evaluate its role in detg. sensitivity to temsirolimus and vorinostat.  The effect of the combination on angiogenesis was also detd. in RCC xenograft models.  Results: Vorinostat synergistically improved the anticancer activity of temsirolimus in a panel of RCC cell lines in vitro and in two xenograft models in vivo.  While each single agent led to a modest decrease in survivin levels, the combination dramatically reduced its expression, which correlated with an induction of apoptosis.  Silencing survivin levels induced apoptosis and significantly improved the efficacy of temsirolimus and vorinostat.  In addn., the temsirolimus/vorinostat combination led to a strong redn. in angiogenesis.  Conclusions: Vorinostat augmented the anticancer activity of temsirolimus in both in vitro and in vivo models of RCC.  The effectiveness of the combination was due to a decrease in survivin levels and corresponding induction of apoptosis, and enhanced inhibition of angiogenesis.  Targeting survivin may be a promising therapeutic strategy to improve RCC therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-G6IvEa39vLVg90H21EOLACvtfcHk0ljURhr9udOUyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotFyk&md5=a76ecc1df173f60ccdc786a5a28d0ab9</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-1385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-1385%26sid%3Dliteratum%253Aachs%26aulast%3DMahalingam%26aufirst%3DD.%26aulast%3DMedina%26aufirst%3DE.%2BC.%26aulast%3DEsquivel%26aufirst%3DJ.%2BA.%26aulast%3DEspitia%26aufirst%3DC.%2BM.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DOberheu%26aufirst%3DK.%26aulast%3DSwords%26aufirst%3DR.%26aulast%3DKelly%26aufirst%3DK.%2BR.%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DMita%26aufirst%3DA.%2BC.%26aulast%3DCarew%26aufirst%3DJ.%2BS.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DNawrocki%26aufirst%3DS.%2BT.%26atitle%3DVorinostat%2520enhances%2520the%2520activity%2520of%2520temsirolimus%2520in%2520renal%2520cell%2520carcinoma%2520through%2520suppression%2520of%2520survivin%2520levels%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D141%26epage%3D153%26doi%3D10.1158%2F1078-0432.CCR-09-1385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haura, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiappori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanvetyanon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinder-Schenck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kish, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreahling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lush, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tetteh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schell, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bepler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altiok, S.</span></span> <span> </span><span class="NLM_article-title">A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1644</span>– <span class="NLM_lpage">1655</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-2235</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1078-0432.CCR-13-2235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=24429877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXks1Ojt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=1644-1655&author=J.+E.+Grayauthor=E.+Hauraauthor=A.+Chiapporiauthor=T.+Tanvetyanonauthor=C.+C.+Williamsauthor=M.+Pinder-Schenckauthor=J.+A.+Kishauthor=J.+Kreahlingauthor=R.+Lushauthor=A.+Neugerauthor=L.+Tettehauthor=A.+Akarauthor=X.+Zhaoauthor=M.+J.+Schellauthor=G.+Beplerauthor=S.+Altiok&title=A+phase+I%2C+pharmacokinetic%2C+and+pharmacodynamic+study+of+panobinostat%2C+an+HDAC+inhibitor%2C+combined+with+erlotinib+in+patients+with+advanced+aerodigestive+tract+tumors&doi=10.1158%2F1078-0432.CCR-13-2235"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors</span></div><div class="casAuthors">Gray, Jhanelle E.; Haura, Eric; Chiappori, Alberto; Tanvetyanon, Tawee; Williams, Charles C.; Pinder-Schenck, Mary; Kish, Julie A.; Kreahling, Jenny; Lush, Richard; Neuger, Anthony; Tetteh, Leticia; Akar, Angela; Zhao, Xiuhua; Schell, Michael J.; Bepler, Gerold; Altiok, Soner</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1644-1655</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Panobinostat, a histone deacetylase (HDAC) inhibitor, enhances antiproliferative activity in non-small cell lung cancer (NSCLC) cell lines when combined with erlotinib.  We evaluated this combination in patients with advanced NSCLC and head and neck cancer.  Exptl. Design: Eligible patients were enrolled in a 3+3 dose-escalation design to det. the max. tolerated dose (MTD) of twice weekly panobinostat plus daily erlotinib at four planned dose levels (DL).  Pharmacokinetics, blood, fat pad biopsies (FPB) for histone acetylation, and paired pre and posttherapy tumor biopsies for checkpoint kinase 1 (CHK1) expression were assessed.  Results: Of 42 enrolled patients, 33 were evaluable for efficacy.  Dose-limiting toxicities were prolonged-QTc and nausea at DL3.  Adverse events included fatigue and nausea (grades 1-3), and rash and anorexia (grades 1-2).  Disease control rates were 54% for NSCLC (n = 26) and 43% for head and neck cancer (n = 7).  Of 7 patients with NSCLC with EGF receptor (EGFR) mutations, 3 had partial response, 3 had stable disease, and 1 progressed.  For EGFR-mutant vs. EGFR wild-type patients, progression-free survival (PFS) was 4.7 vs. 1.9 mo (P = 0.43) and overall survival was 41 (estd.) vs. 5.2 mo (P = 0.39).  Erlotinib pharmacokinetics was not significantly affected.  Correlative studies confirmed panobinostat's pharmacodynamic effect in blood, FPB, and tumor samples.  Low CHK1 expression levels correlated with PFS (P = 0.006) and response (P = 0.02).  Conclusions: We detd. MTD at 30 mg (panobinostat) and 100 mg (erlotinib).  Further studies are needed to further explore the benefits of HDAC inhibitors in patients with EGFR-mutant NSCLC, investigate FPB as a potential surrogate source for biomarker investigations, and validate CHK1's predictive role.  Clin Cancer Res; 20(6); 1644-55. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVMjV_ljgY8rVg90H21EOLACvtfcHk0ljURhr9udOUyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXks1Ojt7c%253D&md5=0fedfa337b8bff4e21e23daa5d56856c</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-2235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-2235%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DHaura%26aufirst%3DE.%26aulast%3DChiappori%26aufirst%3DA.%26aulast%3DTanvetyanon%26aufirst%3DT.%26aulast%3DWilliams%26aufirst%3DC.%2BC.%26aulast%3DPinder-Schenck%26aufirst%3DM.%26aulast%3DKish%26aufirst%3DJ.%2BA.%26aulast%3DKreahling%26aufirst%3DJ.%26aulast%3DLush%26aufirst%3DR.%26aulast%3DNeuger%26aufirst%3DA.%26aulast%3DTetteh%26aufirst%3DL.%26aulast%3DAkar%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DSchell%26aufirst%3DM.%2BJ.%26aulast%3DBepler%26aufirst%3DG.%26aulast%3DAltiok%26aufirst%3DS.%26atitle%3DA%2520phase%2520I%252C%2520pharmacokinetic%252C%2520and%2520pharmacodynamic%2520study%2520of%2520panobinostat%252C%2520an%2520HDAC%2520inhibitor%252C%2520combined%2520with%2520erlotinib%2520in%2520patients%2520with%2520advanced%2520aerodigestive%2520tract%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D1644%26epage%3D1655%26doi%3D10.1158%2F1078-0432.CCR-13-2235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boothman, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattah, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skelton, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priddy, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarode, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, J. H.</span></span> <span> </span><span class="NLM_article-title">Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">541</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2015.10.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.lungcan.2015.10.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=26474959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A280%3ADC%252BC28zis1Ghtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2015&pages=534-541&author=D.+E.+Gerberauthor=D.+A.+Boothmanauthor=F.+J.+Fattahauthor=Y.+Dongauthor=H.+Zhuauthor=R.+A.+Skeltonauthor=L.+L.+Priddyauthor=P.+Voauthor=J.+E.+Dowellauthor=V.+Sarodeauthor=R.+Leffauthor=C.+Meekauthor=Y.+Xieauthor=J.+H.+Schiller&title=Phase+1+study+of+romidepsin+plus+erlotinib+in+advanced+non-small+cell+lung+cancer&doi=10.1016%2Fj.lungcan.2015.10.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer</span></div><div class="casAuthors">Gerber David E; Boothman David A; Fattah Farjana J; Dong Ying; Skelton Rachel A; Priddy Laurin L; Vo Peggy; Zhu Hong; Xie Yang; Dowell Jonathan E; Schiller Joan H; Sarode Venetia; Leff Richard; Meek Claudia</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">534-41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  Preclinical studies demonstrated anti-tumor efficacy of the combination of the histone deacetylase (HDAC) inhibitor romidepsin plus erlotinib in non-small cell lung cancer (NSCLC) models that were insensitive to erlotinib monotherapy.  We therefore studied this combination in a phase 1 clinical trial in previously treated advanced NSCLC.  METHODS:  Romidepsin (8 or 10mg/m(2)) was administered intravenously on days 1, 8, and 15 every 28 days in combination with erlotinib (150 mg orally daily), with romidepsin monotherapy lead-in during Cycle 1.  Correlative studies included peripheral blood mononuclear cell HDAC activity and histone acetylation status, and EGFR pathway activation status in skin biopsies.  RESULTS:  A total of 17 patients were enrolled.  Median number of prior lines of therapy was 3 (range 1-5).  No cases had a sensitizing EGFR mutation.  The most common related adverse events were nausea, vomiting, and fatigue (each 82%), diarrhea (65%), anorexia (53%), and rash (41%).  Dose-limiting nausea and vomiting occurred at the romidepsin 10 mg/m(2) level despite aggressive antiemetic prophylaxis and treatment.  Among 10 evaluable patients, the best response was stable disease (n=7) and progressive disease (n=3).  Median progression-free survival (PFS) was 3.3 months (range 1.4-16.5 months).  Prolonged PFS (>6 months) was noted in a KRAS mutant adenocarcinoma and a squamous cell cancer previously progressed on erlotinib monotherapy.  Romidepsin monotherapy inhibited HDAC activity, increased histone acetylation status, and inhibited EGFR phosphorylation.  CONCLUSIONS:  Romidepsin 8 mg/m(2) plus erlotinib appears well tolerated, has evidence of disease control, and exhibits effects on relevant molecular targets in an unselected advanced NSCLC population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRa-YB56BxpCMRAV4D_Ins_fW6udTcc2ebsfRxsQ6N9pbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zis1Ghtg%253D%253D&md5=bbb7049c30b6b29abbb278eb10bab361</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2015.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2015.10.008%26sid%3Dliteratum%253Aachs%26aulast%3DGerber%26aufirst%3DD.%2BE.%26aulast%3DBoothman%26aufirst%3DD.%2BA.%26aulast%3DFattah%26aufirst%3DF.%2BJ.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DSkelton%26aufirst%3DR.%2BA.%26aulast%3DPriddy%26aufirst%3DL.%2BL.%26aulast%3DVo%26aufirst%3DP.%26aulast%3DDowell%26aufirst%3DJ.%2BE.%26aulast%3DSarode%26aufirst%3DV.%26aulast%3DLeff%26aufirst%3DR.%26aulast%3DMeek%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DSchiller%26aufirst%3DJ.%2BH.%26atitle%3DPhase%25201%2520study%2520of%2520romidepsin%2520plus%2520erlotinib%2520in%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DLung%2520Cancer%26date%3D2015%26volume%3D90%26spage%3D534%26epage%3D541%26doi%3D10.1016%2Fj.lungcan.2015.10.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of <i>N</i>-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.12.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.ejmech.2015.12.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=26741358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVOj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2016&pages=1-12&author=F.+W.+Pengauthor=J.+Xuanauthor=T.+T.+Wuauthor=J.+Y.+Xueauthor=Z.+W.+Renauthor=D.+K.+Liuauthor=X.+Q.+Wangauthor=X.+H.+Chenauthor=J.+W.+Zhangauthor=Y.+G.+Xuauthor=L.+Shi&title=Design%2C+synthesis+and+biological+evaluation+of+N-phenylquinazolin-4-amine+hybrids+as+dual+inhibitors+of+VEGFR-2+and+HDAC&doi=10.1016%2Fj.ejmech.2015.12.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC</span></div><div class="casAuthors">Peng, Fan-Wei; Xuan, Ji; Wu, Ting-Ting; Xue, Jia-Yu; Ren, Zi-Wei; Liu, Da-Ke; Wang, Xiu-Qi; Chen, Xin-Hang; Zhang, Jia-Wei; Xu, Yun-Gen; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In this work, a series of hybrids bearing N-phenylquinazolin-4-amine and hydroxamic acid moieties I (R1, R2 = H, F, Cl, Br, n = 2, 3, 4, 5) were designed and identified as dual VEGFR-2/HDAC inhibitors.  Compd. I (R1 = H, R2 = Br, n = 5) exhibited the most potent inhibitory activity against HDAC with IC50 of 2.2 nM and strong inhibitory effect against VEGFR-2 with IC50 of 74 nM.  It also showed the most potent inhibitory activity against a human breast cancer cell line MCF-7 with IC50 of 0.85 μM.  Docking simulation supported the initial pharmacophoric hypothesis and suggested a common mode of interaction at the active binding sites of VEGFR-2 and HDLP (Histone Deacetylase-Like Protein), which demonstrates that compd. I (R1 = H, R2 = Br, n = 5) is a potential agent for cancer therapy deserving further researching.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT_jbaom_UR7Vg90H21EOLACvtfcHk0ljPUUrDoip4DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVOj&md5=1a0c299ec484daa522da5969e8a35cec</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.12.033%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DF.%2BW.%26aulast%3DXuan%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DT.%2BT.%26aulast%3DXue%26aufirst%3DJ.%2BY.%26aulast%3DRen%26aufirst%3DZ.%2BW.%26aulast%3DLiu%26aufirst%3DD.%2BK.%26aulast%3DWang%26aufirst%3DX.%2BQ.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DZhang%26aufirst%3DJ.%2BW.%26aulast%3DXu%26aufirst%3DY.%2BG.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520N-phenylquinazolin-4-amine%2520hybrids%2520as%2520dual%2520inhibitors%2520of%2520VEGFR-2%2520and%2520HDAC%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D109%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.ejmech.2015.12.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5137</span>– <span class="NLM_lpage">5141</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bmcl.2015.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=26475519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1GkurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=5137-5141&author=F.+W.+Pengauthor=T.+T.+Wuauthor=Z.+W.+Renauthor=J.+Y.+Xueauthor=L.+Shi&title=Hybrids+from+4-anilinoquinazoline+and+hydroxamic+acid+as+dual+inhibitors+of+vascular+endothelial+growth+factor+receptor-2+and+histone+deacetylase&doi=10.1016%2Fj.bmcl.2015.10.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase</span></div><div class="casAuthors">Peng, Fan-Wei; Wu, Ting-Ting; Ren, Zi-Wei; Xue, Jia-Yu; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5137-5141</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of hybrids derived from 4-anilinoquinazoline and hydroxamic acid were designed, synthesized, and evaluated as dual inhibitors of vascular endothelia growth factor receptor-2 (VEGFR-2) tyrosine kinase and histone deacetylase (HDAC).  Most of these compds. exhibited potent HDAC inhibition and moderate VEGFR-2 inhibition.  Among them, compd. I exhibited the most potent inhibitory activities against VEGFR-2 (IC50 = 84 nM) and HDAC (IC50 = 2.8 nM).  It also showed the most potent antiproliferative ability against MCF-7, a human breast cancer line, with IC50 of 1.2 μM.  Docking simulation supported the initial pharmacophoric hypothesis and suggested a common mode of interaction of compd. I at the active binding sites of VEGFR-2 and HDAC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojSWQqbu8Qg7Vg90H21EOLACvtfcHk0lgKbJXAdpHjVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1GkurfI&md5=f20d34f8da22e171419b48299e253fb8</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DF.%2BW.%26aulast%3DWu%26aufirst%3DT.%2BT.%26aulast%3DRen%26aufirst%3DZ.%2BW.%26aulast%3DXue%26aufirst%3DJ.%2BY.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DHybrids%2520from%25204-anilinoquinazoline%2520and%2520hydroxamic%2520acid%2520as%2520dual%2520inhibitors%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520and%2520histone%2520deacetylase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D5137%26epage%3D5141%26doi%3D10.1016%2Fj.bmcl.2015.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span> <span> </span><span class="NLM_article-title">The design and synthesis of a new class of RTK/HDAC dual-targeted inhibitors</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">6491</span>– <span class="NLM_lpage">6503</span>, <span class="refDoi"> DOI: 10.3390/molecules18066491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.3390%2Fmolecules18066491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=23736786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvFWmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=6491-6503&author=X.+Zhangauthor=M.+Suauthor=Y.+Chenauthor=J.+Liauthor=W.+Lu&title=The+design+and+synthesis+of+a+new+class+of+RTK%2FHDAC+dual-targeted+inhibitors&doi=10.3390%2Fmolecules18066491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">The design and synthesis of a new class of RTK/HDAC dual-targeted inhibitors</span></div><div class="casAuthors">Zhang, Xuan; Su, Mingbo; Chen, Yi; Li, Jia; Lu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6491-6503</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Over the years, the development of targeted medicines has made significant achievements.  As a typical example, receptor tyrosine kinases (RTK) inhibitors have become important chemotherapy drugs for a variety of cancers.  However, the effectiveness of these agents is always hindered by poor response rates and acquired drug resistance.  In order to overcome these limitations, several dual-targeted inhibitors with quinazoline core were designed and synthesized.  Though these compds. can simultaneously inhibit histone deacetylases (HDAC) as well as RTK, the structure-activity relation (SAR) is still not clear enough.  To further explore this type of dual-targeted inhibitors, a new class of quinazoline derivs. were designed and synthesized.  Their activity evaluations include in vitro inhibitory activity of HDAC, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2).  The SAR study indicated that the introduction of polar group such as hydroxamate on the 4-position of the quinazoline core is more likely to provide a potent HDACi/HER2i hybrid rather than HDACi/EGFRi mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVCBfVcbjmH7Vg90H21EOLACvtfcHk0liO4i0kqZwDWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvFWmt7g%253D&md5=d0f0d9cf104efc4c0b2032420ed52c5c</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.3390%2Fmolecules18066491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules18066491%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DW.%26atitle%3DThe%2520design%2520and%2520synthesis%2520of%2520a%2520new%2520class%2520of%2520RTK%252FHDAC%2520dual-targeted%2520inhibitors%26jtitle%3DMolecules%26date%3D2013%26volume%3D18%26spage%3D6491%26epage%3D6503%26doi%3D10.3390%2Fmolecules18066491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Q.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of <i>N</i>-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC–EGFR dual inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4405</span>– <span class="NLM_lpage">4412</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2012.05.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bmc.2012.05.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=22698782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38XoslGgurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=4405-4412&author=M.+Zuoauthor=Y.+W.+Zhengauthor=S.+M.+Luauthor=Y.+Liauthor=S.+Q.+Zhang&title=Synthesis+and+biological+evaluation+of+N-aryl+salicylamides+with+a+hydroxamic+acid+moiety+at+5-position+as+novel+HDAC%E2%80%93EGFR+dual+inhibitors&doi=10.1016%2Fj.bmc.2012.05.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors</span></div><div class="casAuthors">Zuo, Miao; Zheng, Yue-Wen; Lu, She-Min; Li, Yan; Zhang, San-Qi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4405-4412</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of N-aryl salicylamides with a hydroxamic acid moiety at 5-position were synthesized efficiently.  Their activities against EGFR kinase and HDACs were evaluated.  All compds. displayed inhibitory activity against EGFR and HDACs.  The antiproliferative activities of synthesized compds. were evaluated by MTT method against human cancer cell lines A431, A549 and HL-60.  Compd. 1o (I) showed the most potent inhibitory activity against A431 and A549.  Compds. 1k and 1n exhibited higher potency against HL-60 than gefitinib and SAHA.  N-Aryl salicylamides with a hydroxamic acid moiety at 5-position is another new HDAC-EGFR dual inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnCB2j9XDrsbVg90H21EOLACvtfcHk0lhgmxnYjLRm4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XoslGgurY%253D&md5=f3da346bb8769252a58a4ed49f6ba7eb</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.05.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.05.034%26sid%3Dliteratum%253Aachs%26aulast%3DZuo%26aufirst%3DM.%26aulast%3DZheng%26aufirst%3DY.%2BW.%26aulast%3DLu%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.%2BQ.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520N-aryl%2520salicylamides%2520with%2520a%2520hydroxamic%2520acid%2520moiety%2520at%25205-position%2520as%2520novel%2520HDAC%25E2%2580%2593EGFR%2520dual%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D4405%26epage%3D4412%26doi%3D10.1016%2Fj.bmc.2012.05.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of novel osimertinib-based HDAC and EGFR dual inhibitors</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2407</span>– <span class="NLM_lpage">2424</span>, <span class="refDoi"> DOI: 10.3390/molecules24132407</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.3390%2Fmolecules24132407" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsleqsLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=2407-2424&author=H.+Dongauthor=H.+Yinauthor=C.+Zhaoauthor=J.+Caoauthor=W.+Xuauthor=Y.+Zhang&title=Design%2C+synthesis+and+biological+evaluation+of+novel+osimertinib-based+HDAC+and+EGFR+dual+inhibitors&doi=10.3390%2Fmolecules24132407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of novel osimertinib-based HDAC and EGFR dual inhibitors</span></div><div class="casAuthors">Dong, Hang; Yin, Hao; Zhao, Chunlong; Cao, Jiangying; Xu, Wenfang; Zhang, Yingjie</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2407</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Herein a novel series of histone deacetylases (HDACs) and epidermal growth factor receptor (EGFR) dual inhibitors were designed and synthesized based on the structure of the approved EGFR inhibitor osimertinib (AZD9291).  Among them, four compds. 5D, 5E, 9D and 9E exhibited more potent total HDAC inhibition than the approved HDAC inhibitor SAHA.  However, these compds. only showed moderate to low inhibitory potency towards EGFR with compds. 5E and 9E possessing IC50 values against EGFRWT and EGFRT790M in the micromolar range. 3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay revealed the potent antiproliferative activities of compds. 5D, 5E, 9D and 9E, among which 9E was even more potent against HeLa, MDA-MB-231, MDA-MB-468, HT-29 and KG-1 cell lines than SAHA and AZD9291.  Further selectivity profile of 9E showed that this compd. was not active against other 13 cancer-related kinases and two epigenetic targets lysine specific demethylase 1 (LSD1) and bromodomain-contg. protein 4 (BRD4).  These results support further structural modification of 9E to improve its EGFR inhibitory activity, which will lead to more potent and balanced HDAC and EGFR dual inhibitors as anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphj06EAFPZbLVg90H21EOLACvtfcHk0lhgmxnYjLRm4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsleqsLfI&md5=a7eab03cd3f25b6b9fed342b55c09d8c</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24132407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24132407%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520osimertinib-based%2520HDAC%2520and%2520EGFR%2520dual%2520inhibitors%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26spage%3D2407%26epage%3D2424%26doi%3D10.3390%2Fmolecules24132407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrester, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zifcak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DellaRocca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, H.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munger, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepicelli, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span> <span> </span><span class="NLM_article-title">CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">3647</span>– <span class="NLM_lpage">3656</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-3360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F0008-5472.CAN-09-3360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=20388807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlens7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=3647-3656&author=C.-J.+Laiauthor=R.+Baoauthor=X.+Taoauthor=J.+Wangauthor=R.+Atoyanauthor=H.+Quauthor=D.-G.+Wangauthor=L.+Yinauthor=M.+Samsonauthor=J.+Forresterauthor=B.+Zifcakauthor=G.-X.+Xuauthor=S.+DellaRoccaauthor=H.-X.+Zhaiauthor=X.+Caiauthor=W.+E.+Mungerauthor=M.+Keeganauthor=C.+V.+Pepicelliauthor=C.+Qian&title=CUDC-101%2C+a+multitargeted+inhibitor+of+histone+deacetylase%2C+epidermal+growth+factor+receptor%2C+and+human+epidermal+growth+factor+receptor+2%2C+exerts+potent+anticancer+activity&doi=10.1158%2F0008-5472.CAN-09-3360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity</span></div><div class="casAuthors">Lai, Cheng-Jung; Bao, Rudi; Tao, Xu; Wang, Jing; Atoyan, Ruzanna; Qu, Hui; Wang, Da-Gong; Yin, Ling; Samson, Maria; Forrester, Jeffrey; Zifcak, Brian; Xu, Guang-Xin; DellaRocca, Steven; Zhai, Hai-Xiao; Cai, Xiong; Munger, William E.; Keegan, Mitchell; Pepicelli, Carmen V.; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3647-3656</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase inhibitors have recently become important therapeutics for a variety of cancers.  However, due to the heterogeneous and dynamic nature of tumors, the effectiveness of these agents is often hindered by poor response rates and acquired drug resistance.  To overcome these limitations, we created a novel small mol., CUDC-101, which simultaneously inhibits histone deacetylase and the receptor kinases epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) in cancer cells.  Because of its integrated histone deacetylase inhibition, CUDC-101 synergistically blocked key regulators of EGFR/HER2 signaling pathways, also attenuating multiple compensatory pathways, such as AKT, HER3, and MET, which enable cancer cells to escape the effects of conventional EGFR/HER2 inhibitors.  CUDC-101 displayed potent antiproliferative and proapoptotic activities against cultured and implanted tumor cells that are sensitive or resistant to several approved single-targeted drugs.  Our results show that CUDC-101 has the potential to dramatically improve the treatment of heterogeneous and drug-resistant tumors that cannot be controlled with single-target agents.  Further, they provide a framework to create individual small mols. that simultaneously antagonize multiple biochem. distinct oncogenic targets, suggesting a general paradigm to surpass conventional, single-target cancer therapeutics.  Cancer Res; 70(9); 3647-56.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrscJsyultc3bVg90H21EOLACvtfcHk0lhgmxnYjLRm4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlens7o%253D&md5=bc30667b0890e3c505c9608de6fa0c68</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3360%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DC.-J.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DTao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.-G.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DG.-X.%26aulast%3DDellaRocca%26aufirst%3DS.%26aulast%3DZhai%26aufirst%3DH.-X.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DMunger%26aufirst%3DW.%2BE.%26aulast%3DKeegan%26aufirst%3DM.%26aulast%3DPepicelli%26aufirst%3DC.%2BV.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DCUDC-101%252C%2520a%2520multitargeted%2520inhibitor%2520of%2520histone%2520deacetylase%252C%2520epidermal%2520growth%2520factor%2520receptor%252C%2520and%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%252C%2520exerts%2520potent%2520anticancer%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D3647%26epage%3D3656%26doi%3D10.1158%2F0008-5472.CAN-09-3360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moertl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anastasov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, M. J.</span></span> <span> </span><span class="NLM_article-title">Comparison of radiosensitization by HDAC inhibitors CUDC-101 and SAHA in pancreatic cancer cells</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">3259</span>– <span class="NLM_lpage">3274</span>, <span class="refDoi"> DOI: 10.3390/ijms20133259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.3390%2Fijms20133259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVGht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=3259-3274&author=S.+Moertlauthor=S.+Payerauthor=R.+Kellauthor=K.+Winklerauthor=N.+Anastasovauthor=M.+J.+Atkinson&title=Comparison+of+radiosensitization+by+HDAC+inhibitors+CUDC-101+and+SAHA+in+pancreatic+cancer+cells&doi=10.3390%2Fijms20133259"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of radiosensitization by HDAC inhibitors CUDC-101 and SAHA in pancreatic cancer cells</span></div><div class="casAuthors">Moertl, Simone; Payer, Sarah; Kell, Rosemarie; Winkler, Klaudia; Anastasov, Natasa; Atkinson, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3259</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Pancreatic cancer has a poor prognosis.  New treatment options are urgently required to improve patient outcomes.  One promising new class of anticancer drugs are synthetic histone deacetylase inhibitors (HDACi) which modulate chromatin structure and gene expression by blocking histone deacetylation.  In this study, we aimed at comparing the in vitro capacities of the HDACi SAHA and CUDC-101 to increase radiosensitivity of human pancreatic tumor cell lines.  Therefore, three pancreatic cancer cell lines (Su.86.86, MIA Paca-2, T3M-4) were treated with SAHA (1.5-5 μM) or CUDC-101 (0.25-3 μM) and after 24 h irradiated.  Cell proliferation, clonogenic survival and apoptosis was detd.  Addnl., cell lysates were investigated for the expression of apoptosis-related proteins.  CUDC-101 and SAHA increased the radiation sensitivity of pancreatic tumor cell lines in a dose-dependent manner.  This was evidenced by cell proliferation and clonogenic survival.  Furthermore, enhanced radiation sensitivity after CUDC-101 or SAHA treatment was confirmed for Su.86.86 and T3M-4 cells in a 3-D microtissue approach.  Increased amts. of subG1 cells and diminished full length PARP-1 suggest increased radiation-induced apoptosis after SAHA or CUDC-101 treatment.  The comparison of both inhibitors in these assays manifested CUDC-101 as more potent radiosensitizer than SAHA.  In line, western blot quantification of the apoptosis-inhibitory proteins XIAP and survivin showed a stronger down-regulation in response to CUDC-101 treatment than after SAHA application.  These proteins may contribute to the synergy between HDAC inhibition and radiation response.  In conclusion, these preclin. results suggest that treatment with the HDAC inhibitors CUDC-101 or SAHA can enhance radiation-induced cytotoxicity in human pancreatic cells.  However, comparison of both inhibitors identified the multi target inhibitor CUDC-101 as more potent radiosensitizer than the HDAC inhibitor SAHA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRXm03i2R5-LVg90H21EOLACvtfcHk0lhilMSg_kp88Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVGht70%253D&md5=02f376958ce6f2585f1ea576e9e7f85d</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.3390%2Fijms20133259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20133259%26sid%3Dliteratum%253Aachs%26aulast%3DMoertl%26aufirst%3DS.%26aulast%3DPayer%26aufirst%3DS.%26aulast%3DKell%26aufirst%3DR.%26aulast%3DWinkler%26aufirst%3DK.%26aulast%3DAnastasov%26aufirst%3DN.%26aulast%3DAtkinson%26aufirst%3DM.%2BJ.%26atitle%3DComparison%2520of%2520radiosensitization%2520by%2520HDAC%2520inhibitors%2520CUDC-101%2520and%2520SAHA%2520in%2520pancreatic%2520cancer%2520cells%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D3259%26epage%3D3274%26doi%3D10.3390%2Fijms20133259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.1097/CAD.0000000000000847</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1097%2FCAD.0000000000000847" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=31584454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVejtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2020&pages=158-168&author=T.+Zhangauthor=D.+Maauthor=D.+Weiauthor=T.+Luauthor=K.+Yuauthor=Z.+Zhangauthor=W.+Wangauthor=Q.+Fangauthor=J.+Wang&title=CUDC-101+overcomes+arsenic+trioxide+resistance+via+caspase-dependent+promyelocytic+leukemia-retinoic+acid+receptor+alpha+degradation+in+acute+promyelocytic+leukemia&doi=10.1097%2FCAD.0000000000000847"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia</span></div><div class="casAuthors">Zhang, Tianzhuo; Ma, Dan; Wei, Danna; Lu, Tingting; Yu, Kunlin; Zhang, Zhaoyuan; Wang, Weili; Fang, Qin; Wang, Jishi</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">158-168</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">1473-5741</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Although arsenic trioxide (ATO) treatment has transformed acute promyelocytic leukemia (APL) from the most fatal to the most curable hematol. cancer, many high-risk APL patients who fail to achieve a complete mol. remission or relapse become resistant to ATO.  Herein, we report that 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) exhibits specific anticancer effects on APL and ATO-resistant APL in vitro and in vivo, while showing negligible cytotoxic effect on the noncancerous cells including normal CD34 cells and bone marrow mesenchymal stem cells from APL patients.  Further mechanistic studies show that CUDC-101 triggers caspase-dependent degrdn. of the promyelocytic leukemia-retinoic acid receptor alpha fusion protein.  As a result, APL and ATO-resistant APL cells undergo apoptosis upon CUDC-101 treatment and this apoptosis-inducing effect is even stronger than that of ATO.  Finally, using a xenograft mouse model, we demonstrated that CUDC-101 significantly represses leukemia development in vivo.  In conclusion, these results suggested that CUDC-101 can serve as a potential candidate drug for APL, particularly for ATO-resistant APL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFGAQIYt4gPrVg90H21EOLACvtfcHk0lhilMSg_kp88Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVejtA%253D%253D&md5=a7078a6b19cd1c81178d3ee4bf78cde5</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000847%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DFang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DCUDC-101%2520overcomes%2520arsenic%2520trioxide%2520resistance%2520via%2520caspase-dependent%2520promyelocytic%2520leukemia-retinoic%2520acid%2520receptor%2520alpha%2520degradation%2520in%2520acute%2520promyelocytic%2520leukemia%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2020%26volume%3D31%26spage%3D158%26epage%3D168%26doi%3D10.1097%2FCAD.0000000000000847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel pazopanib-based HDAC and VEGFR dual inhibitors targeting cancer epigenetics and angiogenesis simultaneously</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5304</span>– <span class="NLM_lpage">5322</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00384</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00384" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvVGrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5304-5322&author=J.+Zangauthor=X.+Liangauthor=Y.+Huangauthor=Y.+Jiaauthor=X.+Liauthor=W.+Xuauthor=C.+J.+Chouauthor=Y.+Zhang&title=Discovery+of+novel+pazopanib-based+HDAC+and+VEGFR+dual+inhibitors+targeting+cancer+epigenetics+and+angiogenesis+simultaneously&doi=10.1021%2Facs.jmedchem.8b00384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously</span></div><div class="casAuthors">Zang, Jie; Liang, Xuewu; Huang, Yongxue; Jia, Yuping; Li, Xiaoyang; Xu, Wenfang; Chou, C. James; Zhang, Yingjie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5304-5322</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein a novel series of pazopanib hybrids as polypharmacol. antitumor agents were developed based on the crosstalk between histone deacetylases (HDACs) and vascular endothelial growth factor (VEGF) pathway.  Among them, one ortho-aminoanilide 6d and one hydroxamic acid 13f exhibited considerable total HDACs and VEGFR-2 inhibitory activities.  The HDAC inhibitory activities endowed 6d and 13f with potent antiproliferative activities, which was not obsd. in the approved VEGFR inhibitor pazopanib.  Compds. 6d and 13f possessed comparable HDAC isoform selectivity profiles to the clin. class I HDAC inhibitor MS-275 and the approved pan-HDAC inhibitor SAHA, resp. 6d and 13f also exhibited uncompromised multiple tyrosine kinases inhibitory activities relative to pazopanib.  The intracellular dual inhibition to HDAC and VEGFR of 6d and 13f was validated by Western blot anal.  In both HUVECs tube formation assay and rat thoracic aorta rings assay, 6d and 13f showed comparable antiangiogenic potencies to pazopanib.  What's more, 6d possessed desirable pharmacokinetic profiles with the oral bioavailability of 72% in SD rats and considerable in vivo antitumor efficacy in a human colorectal adenocarcinoma (HT-29) xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpmz6rwKiKSbVg90H21EOLACvtfcHk0lhilMSg_kp88Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvVGrsL8%253D&md5=437da0a6cca1ec211219aef87a6ddbc5</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00384%26sid%3Dliteratum%253Aachs%26aulast%3DZang%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DChou%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520novel%2520pazopanib-based%2520HDAC%2520and%2520VEGFR%2520dual%2520inhibitors%2520targeting%2520cancer%2520epigenetics%2520and%2520angiogenesis%2520simultaneously%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5304%26epage%3D5322%26doi%3D10.1021%2Facs.jmedchem.8b00384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel dual histone deacetylase and mammalian target of rapamycin target inhibitors as a promising strategy for cancer therapy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1577</span>– <span class="NLM_lpage">1592</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01825</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01825" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovFeguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1577-1592&author=Y.+Chenauthor=X.+Yuanauthor=W.+Zhangauthor=M.+Tangauthor=L.+Zhengauthor=F.+Wangauthor=W.+Yanauthor=S.+Yangauthor=Y.+Weiauthor=J.+Heauthor=L.+Chen&title=Discovery+of+novel+dual+histone+deacetylase+and+mammalian+target+of+rapamycin+target+inhibitors+as+a+promising+strategy+for+cancer+therapy&doi=10.1021%2Facs.jmedchem.8b01825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Dual Histone Deacetylase and Mammalian Target of Rapamycin Target Inhibitors as a Promising Strategy for Cancer Therapy</span></div><div class="casAuthors">Chen, Yong; Yuan, Xue; Zhang, Wanhua; Tang, Minghai; Zheng, Li; Wang, Fang; Yan, Wei; Yang, Shengyong; Wei, Yuquan; He, Jun; Chen, Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1577-1592</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the present study, a series of novel dual-target histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors were designed and synthesized using pyrimidine-pyrazolyl pharmacophore to append HDAC recognition cap and hydroxamic acid as a zinc-binding motif.  Among them, I was the optimal lead compd. with potent inhibition activities against mTOR and HDAC1 with half-maximal inhibitory concn. of 1.2 and 0.19 nM, resp.  Western blot confirmed that I could upregulate acetylation of H3 and α-tubulin and downregulate mTOR-related downstream mediators.  I could also stimulate cell cycle arrest in G0/G1 phase and induce tumor cell apoptosis.  I showed comparable antitumor activity with the combination medication in MM1S xenograft model with a tumor growth inhibitory rate of 72.5%, without causing significant loss of body wt. and toxicity.  All of the results indicated that I could be a promising dual target inhibitor for treating hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ3AdehNv1ObVg90H21EOLACvtfcHk0lgLREate_3ufA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovFeguw%253D%253D&md5=7a2ff5020aedb0e3c302e65d993301e6</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01825%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DYan%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520novel%2520dual%2520histone%2520deacetylase%2520and%2520mammalian%2520target%2520of%2520rapamycin%2520target%2520inhibitors%2520as%2520a%2520promising%2520strategy%2520for%2520cancer%2520therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1577%26epage%3D1592%26doi%3D10.1021%2Facs.jmedchem.8b01825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kotian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boufraqech, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaskins, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gara, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quezado, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilubol, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kebebew, E.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 inhibits thyroid cancer growth and metastases</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5044</span>– <span class="NLM_lpage">5054</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-1043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1078-0432.CCR-17-1043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=28600475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVCit7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=5044-5054&author=S.+Kotianauthor=L.+Zhangauthor=M.+Boufraqechauthor=K.+Gaskinsauthor=S.+K.+Garaauthor=M.+M.+Quezadoauthor=N.+Nilubolauthor=E.+Kebebew&title=Dual+inhibition+of+HDAC+and+tyrosine+kinase+signaling+pathways+with+CUDC-907+inhibits+thyroid+cancer+growth+and+metastases&doi=10.1158%2F1078-0432.CCR-17-1043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases</span></div><div class="casAuthors">Kotian, Shweta; Zhang, Lisa; Boufraqech, Myriem; Gaskins, Kelli; Gara, Sudheer Kumar; Quezado, Martha; Nilubol, Naris; Kebebew, Electron</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5044-5054</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">There is currently no std. therapy for anaplastic thyroid cancer (ATC) and poorly differentiated thyroid cancer (PDTC), which account for two-thirds of thyroid cancer-related deaths.  Driver mutations in the PI3K/AKT and RAF/RAS/MEK/ERK pathways are common in ATC and PDTC.  Histone deacetylases (HDAC) regulate cancer initiation and progression.  Our aim was to det. the therapeutic efficacy of simultaneously targeting these pathways in thyroid cancer with a single agent and to evaluate biomarkers of treatment response.  CUDC-907 is a first-in-class compd., functioning as a dual inhibitor of HDACs and the PI3K/AKT pathway.  We investigated its antiproliferative effect in vitro and in vivo.  CUDC-907 significantly inhibited cellular proliferation in thyroid cancer cell lines, induced G2-M arrest with decreased levels of the checkpoint regulators cyclin B1, AURKA, AURKB, PLK1, and increased p21 and p27.  Treatment induced apoptosis with increased caspase-3/7 activity and decreased survivin levels and decreased cellular migration and invasion.  CUDC-907 treatment caused H3 hyperacetylation and decreased HDAC2 expression.  HDAC2 was upregulated in ATC and other thyroid cancer histol. subtypes.  CUDC-907 treatment reduced both p-AKT and p-ERK1/2 levels.  Finally, CUDC-907 treatment, in a metastatic mouse model of thyroid cancer, showed significant inhibition of growth and metastases, and tumors from treated mice had decreased HDAC2 expression, suggesting that this may be a useful biomarker of response.  Dual inhibition of HDAC and the tyrosine kinase signaling pathways with CUDC-907 is a promising treatment strategy for advanced, metastatic thyroid cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLaRHbxu0mOrVg90H21EOLACvtfcHk0lgLREate_3ufA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVCit7nM&md5=e0d5f7d5485dd9fba6fccd5a758a7dc3</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-1043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-1043%26sid%3Dliteratum%253Aachs%26aulast%3DKotian%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBoufraqech%26aufirst%3DM.%26aulast%3DGaskins%26aufirst%3DK.%26aulast%3DGara%26aufirst%3DS.%2BK.%26aulast%3DQuezado%26aufirst%3DM.%2BM.%26aulast%3DNilubol%26aufirst%3DN.%26aulast%3DKebebew%26aufirst%3DE.%26atitle%3DDual%2520inhibition%2520of%2520HDAC%2520and%2520tyrosine%2520kinase%2520signaling%2520pathways%2520with%2520CUDC-907%2520inhibits%2520thyroid%2520cancer%2520growth%2520and%2520metastases%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D5044%26epage%3D5054%26doi%3D10.1158%2F1078-0432.CCR-17-1043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madlambayan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kushner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzinic, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taub, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span> <span> </span><span class="NLM_article-title">Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">2225</span>– <span class="NLM_lpage">2240</span>, <span class="refDoi"> DOI: 10.3324/haematol.2018.201343</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.3324%2Fhaematol.2018.201343" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=30819918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFantb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2019&pages=2225-2240&author=X.+Liauthor=Y.+Suauthor=G.+Madlambayanauthor=H.+Edwardsauthor=L.+Polinauthor=J.+Kushnerauthor=S.+H.+Dzinicauthor=K.+Whiteauthor=J.+Maauthor=T.+Knightauthor=G.+Wangauthor=Y.+Wangauthor=J.+Yangauthor=J.+W.+Taubauthor=H.+Linauthor=Y.+Ge&title=Antileukemic+activity+and+mechanism+of+action+of+the+novel+PI3K+and+histone+deacetylase+dual+inhibitor+CUDC-907+in+acute+myeloid+leukemia&doi=10.3324%2Fhaematol.2018.201343"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia</span></div><div class="casAuthors">Li, Xinyu; Su, Yongwei; Madlambayan, Gerard; Edwards, Holly; Polin, Lisa; Kushner, Juiwanna; Dzinic, Sijana H.; White, Kathryn; Ma, Jun; Knight, Tristan; Wang, Guan; Wang, Yue; Yang, Jay; Taub, Jeffrey W.; Lin, Hai; Ge, Yubin</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2225-2240</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">1592-8721</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">I nduction therapy for patients with acute myeloid leukemia (AML) has remained largely unchanged for over 40 years, while overall survival rates remain unacceptably low, highlighting the need for new therapies.  The PI3K/Akt pathway is constitutively active in the majority of patients with AML.  Given that histone deacetylase inhibitors have been shown to synergize with PI3K inhibitors in preclin. AML models, we investigated the novel dual-acting PI3K and histone deacetylase inhibitor CUDC-907 in AML cells both in vitro and in vivo.  We demonstrated that CUDC-907 induces apoptosis in AML cell lines and primary AML samples and shows in vivo efficacy in an AML cell line-derived xenograft mouse model.  CUDC-907-induced apoptosis was partially dependent on Mcl-1, Bim, and c-Myc.  CUDC-907 induced DNA damage in AML cells while sparing normal hematopoietic cells.  Downregulation of CHK1, Wee1, and RRM1, and induction of DNA damage also contributed to CUDC-907-induced apoptosis of AML cells.  In addn., CUDC-907 treatment decreased leukemia progenitor cells in primary AML samples ex vivo, while also sparing normal hematopoietic progenitor cells.  These findings support the clin. development of CUDC-907 for the treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTfDoYe90TwbVg90H21EOLACvtfcHk0liibHjPBLxk5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFantb7I&md5=850a38d8ad0b426511353e6efa053985</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2018.201343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2018.201343%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DMadlambayan%26aufirst%3DG.%26aulast%3DEdwards%26aufirst%3DH.%26aulast%3DPolin%26aufirst%3DL.%26aulast%3DKushner%26aufirst%3DJ.%26aulast%3DDzinic%26aufirst%3DS.%2BH.%26aulast%3DWhite%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DKnight%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DTaub%26aufirst%3DJ.%2BW.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DGe%26aufirst%3DY.%26atitle%3DAntileukemic%2520activity%2520and%2520mechanism%2520of%2520action%2520of%2520the%2520novel%2520PI3K%2520and%2520histone%2520deacetylase%2520dual%2520inhibitor%2520CUDC-907%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DHaematologica%26date%3D2019%26volume%3D104%26spage%3D2225%26epage%3D2240%26doi%3D10.3324%2Fhaematol.2018.201343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borek, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellarocca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuck, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viner, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattaey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Dual HDAC and PI3K inhibitor CUDC-907 downregulates MYC and suppresses growth of MYC-dependent cancers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1535-7163.MCT-16-0390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=27980108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVertro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=285-299&author=K.+Sunauthor=R.+Atoyanauthor=M.+A.+Borekauthor=S.+Dellaroccaauthor=M.+E.+Samsonauthor=A.+W.+Maauthor=G.+X.+Xuauthor=T.+Pattersonauthor=D.+P.+Tuckauthor=J.+L.+Vinerauthor=A.+Fattaeyauthor=J.+Wang&title=Dual+HDAC+and+PI3K+inhibitor+CUDC-907+downregulates+MYC+and+suppresses+growth+of+MYC-dependent+cancers&doi=10.1158%2F1535-7163.MCT-16-0390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers</span></div><div class="casAuthors">Sun, Kaiming; Atoyan, Ruzanna; Borek, Mylissa A.; Dellarocca, Steven; Samson, Maria Elena S.; Ma, Anna W.; Xu, Guang-Xin; Patterson, Troy; Tuck, David P.; Viner, Jaye L.; Fattaey, Ali; Wang, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">285-299</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Upregulation of MYC is a common driver event in human cancers, and some tumors depend on MYC to maintain transcriptional programs that promote cell growth and proliferation.  Preclin. studies have suggested that individually targeting upstream regulators of MYC, such as histone deacetylases (HDAC) and phosphoinositide 3-kinases (PI3K), can reduce MYC protein levels and suppress the growth of MYC-driven cancers.  Synergy between HDAC and PI3K inhibition in inducing cancer cell death has also been reported, but the involvement of MYC regulation is unclear.  In this study, we demonstrated that HDAC and PI3K inhibition synergistically downregulates MYC protein levels and induces apoptosis in "double-hit" (DH) diffuse large B-cell lymphoma (DLBCL) cells.  Furthermore, CUDC-907, a small-mol. dual-acting inhibitor of both class I and II HDACs and class I PI3Ks, effectively suppresses the growth and survival of MYC-altered or MYC-dependent cancer cells, such as DH DLBCL and BRD-NUT fusion-pos. NUT midline carcinoma (NMC) cells, and MYC protein downregulation is an early event induced by CUDC-907 treatment.  Consistently, the antitumor activity of CUDC-907 against multiple MYC-driven cancer types was also demonstrated in animal models, including DLBCL and NMC xenograft models, Myc transgenic tumor syngeneic models, and MYC-amplified solid tumor patient-derived xenograft (PDX) models.  Our findings suggest that dual function HDAC and PI3K inhibitor CUDC-907 is an effective agent targeting MYC and thus may be developed as potential therapy for MYC-dependent cancers.  Mol Cancer Ther; 16(2); 285-99. 2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo82AzF-jV397Vg90H21EOLACvtfcHk0lgt8O71kMfbfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVertro%253D&md5=d4ffd5f39546fa076448dbfb36406183</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0390%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DK.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DBorek%26aufirst%3DM.%2BA.%26aulast%3DDellarocca%26aufirst%3DS.%26aulast%3DSamson%26aufirst%3DM.%2BE.%26aulast%3DMa%26aufirst%3DA.%2BW.%26aulast%3DXu%26aufirst%3DG.%2BX.%26aulast%3DPatterson%26aufirst%3DT.%26aulast%3DTuck%26aufirst%3DD.%2BP.%26aulast%3DViner%26aufirst%3DJ.%2BL.%26aulast%3DFattaey%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DDual%2520HDAC%2520and%2520PI3K%2520inhibitor%2520CUDC-907%2520downregulates%2520MYC%2520and%2520suppresses%2520growth%2520of%2520MYC-dependent%2520cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D285%26epage%3D299%26doi%3D10.1158%2F1535-7163.MCT-16-0390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madlambayan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kushner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzinic, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taub, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span> <span> </span><span class="NLM_article-title">Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">2225</span>– <span class="NLM_lpage">2240</span>, <span class="refDoi"> DOI: 10.3324/haematol.2018.201343</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.3324%2Fhaematol.2018.201343" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=30819918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFantb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2019&pages=2225-2240&author=X.+Liauthor=Y.+Suauthor=G.+Madlambayanauthor=H.+Edwardsauthor=L.+Polinauthor=J.+Kushnerauthor=S.+H.+Dzinicauthor=K.+Whiteauthor=J.+Maauthor=T.+Knightauthor=G.+Wangauthor=Y.+Wangauthor=J.+Yangauthor=J.+W.+Taubauthor=H.+Linauthor=Y.+Ge&title=Antileukemic+activity+and+mechanism+of+action+of+the+novel+PI3K+and+histone+deacetylase+dual+inhibitor+CUDC-907+in+acute+myeloid+leukemia&doi=10.3324%2Fhaematol.2018.201343"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia</span></div><div class="casAuthors">Li, Xinyu; Su, Yongwei; Madlambayan, Gerard; Edwards, Holly; Polin, Lisa; Kushner, Juiwanna; Dzinic, Sijana H.; White, Kathryn; Ma, Jun; Knight, Tristan; Wang, Guan; Wang, Yue; Yang, Jay; Taub, Jeffrey W.; Lin, Hai; Ge, Yubin</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2225-2240</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">1592-8721</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">I nduction therapy for patients with acute myeloid leukemia (AML) has remained largely unchanged for over 40 years, while overall survival rates remain unacceptably low, highlighting the need for new therapies.  The PI3K/Akt pathway is constitutively active in the majority of patients with AML.  Given that histone deacetylase inhibitors have been shown to synergize with PI3K inhibitors in preclin. AML models, we investigated the novel dual-acting PI3K and histone deacetylase inhibitor CUDC-907 in AML cells both in vitro and in vivo.  We demonstrated that CUDC-907 induces apoptosis in AML cell lines and primary AML samples and shows in vivo efficacy in an AML cell line-derived xenograft mouse model.  CUDC-907-induced apoptosis was partially dependent on Mcl-1, Bim, and c-Myc.  CUDC-907 induced DNA damage in AML cells while sparing normal hematopoietic cells.  Downregulation of CHK1, Wee1, and RRM1, and induction of DNA damage also contributed to CUDC-907-induced apoptosis of AML cells.  In addn., CUDC-907 treatment decreased leukemia progenitor cells in primary AML samples ex vivo, while also sparing normal hematopoietic progenitor cells.  These findings support the clin. development of CUDC-907 for the treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTfDoYe90TwbVg90H21EOLACvtfcHk0lhgQeGQeN9sOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFantb7I&md5=850a38d8ad0b426511353e6efa053985</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2018.201343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2018.201343%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DMadlambayan%26aufirst%3DG.%26aulast%3DEdwards%26aufirst%3DH.%26aulast%3DPolin%26aufirst%3DL.%26aulast%3DKushner%26aufirst%3DJ.%26aulast%3DDzinic%26aufirst%3DS.%2BH.%26aulast%3DWhite%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DKnight%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DTaub%26aufirst%3DJ.%2BW.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DGe%26aufirst%3DY.%26atitle%3DAntileukemic%2520activity%2520and%2520mechanism%2520of%2520action%2520of%2520the%2520novel%2520PI3K%2520and%2520histone%2520deacetylase%2520dual%2520inhibitor%2520CUDC-907%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DHaematologica%26date%3D2019%26volume%3D104%26spage%3D2225%26epage%3D2240%26doi%3D10.3324%2Fhaematol.2018.201343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okabe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotoh, A.</span></span> <span> </span><span class="NLM_article-title">Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in philadelphia chromosome-positive leukemia cells</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">401</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1007/s00280-019-04022-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1007%2Fs00280-019-04022-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=31901955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtlSruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2020&pages=401-412&author=S.+Okabeauthor=Y.+Tanakaauthor=M.+Moriyamaauthor=A.+Gotoh&title=Effect+of+dual+inhibition+of+histone+deacetylase+and+phosphatidylinositol-3+kinase+in+philadelphia+chromosome-positive+leukemia+cells&doi=10.1007%2Fs00280-019-04022-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells</span></div><div class="casAuthors">Okabe, Seiichi; Tanaka, Yuko; Moriyama, Mitsuru; Gotoh, Akihiko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">401-412</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: ABL tyrosine kinase inhibitors (TKIs) have demonstrated potency in the treatment of chronic myeloid leukemia (CML) patients.  However, resistance to ABL TKIs can develop in CML patients due to BCR-ABL point mutations.  Furthermore, CUDC-907 is an oral inhibitor of class I phosphoinositide 3-kinase (PI3K) as well as class I and II histone deacetylase (HDAC) enzymes.  Methods: In this study, we evaluated the effect of combination therapy of CUDC-907 and ABL TKIs, using BCR-ABL-pos. cell lines and primary samples.  Results: CUDC-907 treatment for 72 h resulted in cell growth inhibition.  Over the same period, an increase in histone acetylation and both caspase three and poly (ADP-ribose) polymerase (PARP) enzyme activity was obsd.  When ABL TKI treatment and CUDC-907 treatment were combined, significantly greater cytotoxicity was obsd.  Moreover, combined oral therapy with ponatinib (20 mg/kg/day) and CUDC-907 (30 mg/kg/day) greatly inhibited tumor growth compared to each drug alone.  Lastly, CUDC-907 treatment also inhibited the growth of Ba/F3 ponatinib-resistant cells, K562 nilotinib-resistant cells, and T315I mutant primary samples.  Conclusion: Taken together, our results indicate that administration of CUDC-907, a dual PI3K and HDAC inhibitor, may be an effective strategy against ABL TKI-resistant cells, including cells harboring the T315I mutation.  Moreover, CUDC-907 may enhance the cytotoxic effects of ABL TKI when a combined treatment strategy is used against Philadelphia chromosome-pos. leukemia cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOsQolZ7hEHrVg90H21EOLACvtfcHk0ljRib_IS2eQ8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtlSruw%253D%253D&md5=e38b7d251096863914401d39167cc8dc</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1007%2Fs00280-019-04022-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-019-04022-x%26sid%3Dliteratum%253Aachs%26aulast%3DOkabe%26aufirst%3DS.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DMoriyama%26aufirst%3DM.%26aulast%3DGotoh%26aufirst%3DA.%26atitle%3DEffect%2520of%2520dual%2520inhibition%2520of%2520histone%2520deacetylase%2520and%2520phosphatidylinositol-3%2520kinase%2520in%2520philadelphia%2520chromosome-positive%2520leukemia%2520cells%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2020%26volume%3D85%26spage%3D401%26epage%3D412%26doi%3D10.1007%2Fs00280-019-04022-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Younes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdeja, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerecitano, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neelapu, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clancy, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viner, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oki, Y.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">622</span>– <span class="NLM_lpage">631</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(15)00584-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2FS1470-2045%2815%2900584-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=27049457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsFOhs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=622-631&author=A.+Younesauthor=J.+G.+Berdejaauthor=M.+R.+Patelauthor=I.+Flinnauthor=J.+F.+Gerecitanoauthor=S.+S.+Neelapuauthor=K.+R.+Kellyauthor=A.+R.+Copelandauthor=A.+Akinsauthor=M.+S.+Clancyauthor=L.+Gongauthor=J.+Wangauthor=A.+Maauthor=J.+L.+Vinerauthor=Y.+Oki&title=Safety%2C+tolerability%2C+and+preliminary+activity+of+CUDC-907%2C+a+first-in-class%2C+oral%2C+dual+inhibitor+of+HDAC+and+PI3K%2C+in+patients+with+relapsed+or+refractory+lymphoma+or+multiple+myeloma%3A+an+open-label%2C+dose-escalation%2C+phase+1+trial&doi=10.1016%2FS1470-2045%2815%2900584-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial</span></div><div class="casAuthors">Younes, Anas; Berdeja, Jesus G.; Patel, Manish R.; Flinn, Ian; Gerecitano, John F.; Neelapu, Sattva S.; Kelly, Kevin R.; Copeland, Amanda R.; Akins, Amy; Clancy, Myles S.; Gong, Lucy; Wang, Jing; Ma, Anna; Viner, Jaye L.; Oki, Yasuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">622-631</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Treatment options for patients with relapsed or refractory lymphoma and multiple myeloma are limited.  CUDC-907 is an oral, first-in-class, small mol. that is designed to inhibit both histone deacetylase (HDAC) and PI3K enzymes, which are members of common oncogenic pathways in haematol. malignancies.  We aimed to assess overall safety and preliminary activity in this dose-escalation study of CUDC-907 monotherapy in patients with relapsed or refractory lymphoma and multiple myeloma.  This open-label, first-in-man, phase 1 trial recruited adult patients (aged ≥18 years) with lymphoma or multiple myeloma who were refractory to or had relapsed after two or more previous regimens, from four US cancer centers.  CUDC-907 was orally administered in a std. 3 + 3 dose-escalation design at four different dosing schedules, to which participants were sequentially assigned as follows: once daily, intermittently (twice or three times weekly; simultaneous enrolment), and daily for 5 days followed by a 2-day break (5/2), in 21-day cycles.  Dosing started at 30 mg for the once-daily schedule and 60 mg for other schedules, escalating in 30 mg increments.  Patients continued to receive CUDC-907 until disease progression or until other treatment discontinuation criteria were met.  The primary objective was to det. the max. tolerated dose (MTD) and recommended phase 2 dose, assessed in patients who received at least 66% of cycle 1 doses without modification and those who had a dose-limiting toxicity (DLT) in cycle 1 irresp. of dose modification.  We assessed safety in all patients who received at least one dose of study drug.  This ongoing trial is registered at ClinicalTrials.gov, no. NCT01742988.  Between Jan 23, 2013, and July 27, 2015, we enrolled 44 patients, of whom ten were sequentially assigned to CUDC-907 once-daily (MTD 60 mg), 12 to twice-weekly (MTD 150 mg), 15 to three-times-weekly (MTD 150 mg), and seven to the 5/2 dosing schedule (MTD 60 mg). 37 (84%) patients had discontinued study drug as a result of progressive disease or clin. signs of progressive disease at the data cutoff.  Four DLTs occurred in three of 40 DLT-evaluable patients (diarrhoea and hyperglycemia in one patient on 60 mg once daily, hyperglycemia in one patient on 150 mg twice weekly, and diarrhoea in one patient on 150 mg three times weekly); no DLTs were reported in patients on the 5/2 schedule.  Grade 3 or worse adverse events occurred in 19 (43%) of 44 patients, the most common of which were thrombocytopenia (in nine [20%] of 44 patients), neutropenia (three [7%]), and hyperglycemia (three [7%]). 11 (25%) of 44 patients had serious adverse events, three of which were regarded as treatment related (epistaxis and the DLTs of diarrhoea and hyperglycemia).  Adverse events led to dose redns. in six (14%) patients and treatment discontinuation in seven (16%).  Five (14%) of 37 response-evaluable patients achieved an objective response (two complete responses and three partial responses).  All five responses occurred in the subgroup of patients with diffuse large B-cell lymphoma (DLBCL; n=9), and three occurred in those with transformed follicular lymphoma DLBCL (n=5). 21 (57%) of 37 response-evaluable patients had stable disease, including those with DLBCL, Hodgkin's lymphoma, and multiple myeloma.  On the basis of these findings, we selected CUDC-907 60 mg on the 5/2 dosing schedule as the recommended phase 2 dose.  The safety and tolerability profile of CUDC-907 and the promising preliminary evidence of response support continued development of CUDC-907 at the 60 mg 5/2 dosing schedule, alone and in combination with other therapies.  A dose-expansion trial of this dose in patients with refractory and relapsed DLBCL in particular, is ongoing.  Curis, Inc, and the Leukemia and Lymphoma Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAFEt7vSuwM7Vg90H21EOLACvtfcHk0lidhW9xWUAqgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsFOhs78%253D&md5=b759c77ac239b6ae0052d30c9bea3221</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900584-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900584-7%26sid%3Dliteratum%253Aachs%26aulast%3DYounes%26aufirst%3DA.%26aulast%3DBerdeja%26aufirst%3DJ.%2BG.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DFlinn%26aufirst%3DI.%26aulast%3DGerecitano%26aufirst%3DJ.%2BF.%26aulast%3DNeelapu%26aufirst%3DS.%2BS.%26aulast%3DKelly%26aufirst%3DK.%2BR.%26aulast%3DCopeland%26aufirst%3DA.%2BR.%26aulast%3DAkins%26aufirst%3DA.%26aulast%3DClancy%26aufirst%3DM.%2BS.%26aulast%3DGong%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DA.%26aulast%3DViner%26aufirst%3DJ.%2BL.%26aulast%3DOki%26aufirst%3DY.%26atitle%3DSafety%252C%2520tolerability%252C%2520and%2520preliminary%2520activity%2520of%2520CUDC-907%252C%2520a%2520first-in-class%252C%2520oral%252C%2520dual%2520inhibitor%2520of%2520HDAC%2520and%2520PI3K%252C%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520lymphoma%2520or%2520multiple%2520myeloma%253A%2520an%2520open-label%252C%2520dose-escalation%252C%2520phase%25201%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26spage%3D622%26epage%3D631%26doi%3D10.1016%2FS1470-2045%2815%2900584-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saijo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimodaira, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishioka, C.</span></span> <span> </span><span class="NLM_article-title">Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">1994</span>– <span class="NLM_lpage">2001</span>, <span class="refDoi"> DOI: 10.1111/cas.12002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1111%2Fcas.12002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=22924958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOqt7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2012&pages=1994-2001&author=K.+Saijoauthor=T.+Katohauthor=H.+Shimodairaauthor=A.+Odaauthor=O.+Takahashiauthor=C.+Ishioka&title=Romidepsin+%28FK228%29+and+its+analogs+directly+inhibit+phosphatidylinositol+3-kinase+activity+and+potently+induce+apoptosis+as+histone+deacetylase%2Fphosphatidylinositol+3-kinase+dual+inhibitors&doi=10.1111%2Fcas.12002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors</span></div><div class="casAuthors">Saijo, Ken; Katoh, Tadashi; Shimodaira, Hideki; Oda, Akifumi; Takahashi, Ohgi; Ishioka, Chikashi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1994-2001</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Activation of phosphatidylinositol 3-kinase (PI3K) signaling is involved in carcinogenesis and cancer progression.  The PI3K inhibitors are considered candidate drugs for cancer treatment.  Here, we describe a drug screening system for novel PI3K inhibitors using Saccharomyces cerevisiae strains with deleterious mutations in the ATP-binding cassette transporter genes, because wild-type S. cerevisiae uses drug efflux pumps for reducing intracellular drug concns.  By screening the chem. library of the Screening Committee of Anticancer Drugs, we identified the histone deacetylase (HDAC) inhibitor romidepsin (FK228) and its novel analogs.  In vitroPI3K activity assays confirmed that these compds. directly inhibit PI3K activity at μM-range concns.  FK-A5 analog was the most potent inhibitor.  Western blotting revealed that these compds. inhibit phosphorylation of protein kinase B and downstream signaling components.  Mol. modeling of the PI3K-FK228 complex indicated that FK228 binds to the ATP-binding pocket of PI3K.  At μM-range concns., FK228 and FK-A5 show potent cytotoxicity, inducing apoptosis even in HDAC inhibitor-resistant cells.  Furthermore, HDAC/PI3K dual inhibition by FK228 and FK-A5 at μM-range concns. potentiates the apoptosis induction, mimicking the effect of combining specific HDAC and PI3K inhibitors.  In this study, we showed that FK228 and its analogs directly inhibit PI3K activity and induce apoptosis at μM-range concns., similar to HDAC/PI3K dual inhibition.  In future, optimizing the potency of FK228 and its analogs against PI3K may contribute to the development of novel HDAC/PI3K dual inhibitors for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeB89Rk-RyJ7Vg90H21EOLACvtfcHk0lilPCXr98OCdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOqt7bJ&md5=7ce4ad6038c88f276921212febc52fb5</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1111%2Fcas.12002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.12002%26sid%3Dliteratum%253Aachs%26aulast%3DSaijo%26aufirst%3DK.%26aulast%3DKatoh%26aufirst%3DT.%26aulast%3DShimodaira%26aufirst%3DH.%26aulast%3DOda%26aufirst%3DA.%26aulast%3DTakahashi%26aufirst%3DO.%26aulast%3DIshioka%26aufirst%3DC.%26atitle%3DRomidepsin%2520%2528FK228%2529%2520and%2520its%2520analogs%2520directly%2520inhibit%2520phosphatidylinositol%25203-kinase%2520activity%2520and%2520potently%2520induce%2520apoptosis%2520as%2520histone%2520deacetylase%252Fphosphatidylinositol%25203-kinase%2520dual%2520inhibitors%26jtitle%3DCancer%2520Sci.%26date%3D2012%26volume%3D103%26spage%3D1994%26epage%3D2001%26doi%3D10.1111%2Fcas.12002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saijo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chikamatsu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishioka, C.</span></span> <span> </span><span class="NLM_article-title">Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/phosphatidylinositol 3-kinase dual inhibitor</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">1469</span>– <span class="NLM_lpage">1475</span>, <span class="refDoi"> DOI: 10.1111/cas.13255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1111%2Fcas.13255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=28406576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvF2rurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2017&pages=1469-1475&author=K.+Saijoauthor=H.+Imaiauthor=S.+Chikamatsuauthor=K.+Naritaauthor=T.+Katohauthor=C.+Ishioka&title=Antitumor+activity+and+pharmacologic+characterization+of+the+depsipeptide+analog+as+a+novel+histone+deacetylase%2Fphosphatidylinositol+3-kinase+dual+inhibitor&doi=10.1111%2Fcas.13255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/ phosphatidylinositol 3-kinase dual inhibitor</span></div><div class="casAuthors">Saijo, Ken; Imai, Hiroo; Chikamatsu, Sonoko; Narita, Koichi; Katoh, Tadashi; Ishioka, Chikashi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1469-1475</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC)/phosphatidylinositol 3-kinase (PI3K) dual inhibition is a promising strategy for the treatment of intractable cancers because of the advantages of overcoming potential resistance and showing synergistic effects.  Therefore, development of an HDAC/PI3K dual inhibitor is reasonably attractive.  Romidepsin (FK228, depsipeptide) is a potent HDAC inhibitor.  We previously reported that depsipeptide and its analogs have an addnl. activity as PI3K inhibitors and are defined as HDAC/PI3K dual inhibitors.  Subsequently, we identified FK-A11 as the most potent analog and reported its biochem., biol., and structural properties as an HDAC/PI3K dual inhibitor.  In this study, we reveal the in vitro and in vivo efficacy of FK-A11 in HT1080 fibrosarcoma and PC3 prostate cancer cell xenograft mouse models.  FK-A11 showed in vivo antitumor activity by both i.v. and i.p. administration in a dose-dependent manner.  In both xenograft models, FK-A11 showed superior antitumor effects compared to other depsipeptide analogs in accordance with in vitro anti-cell proliferation effects and the potency of HDAC/PI3K dual inhibition.  In addn., we showed evidence of HDAC/PI3K dual inhibition accompanying antitumor efficacy in xenograft tumor tissues by immunohistochem.  We also detailed pharmacokinetic characterization of FK-A11 in mice.  These findings will be essential for guiding further preclin. and clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp9mk0Hg7EP7Vg90H21EOLACvtfcHk0lhZEZVlRf-DHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvF2rurY%253D&md5=e5733fa98c58aaf27902d040df4f0489</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1111%2Fcas.13255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.13255%26sid%3Dliteratum%253Aachs%26aulast%3DSaijo%26aufirst%3DK.%26aulast%3DImai%26aufirst%3DH.%26aulast%3DChikamatsu%26aufirst%3DS.%26aulast%3DNarita%26aufirst%3DK.%26aulast%3DKatoh%26aufirst%3DT.%26aulast%3DIshioka%26aufirst%3DC.%26atitle%3DAntitumor%2520activity%2520and%2520pharmacologic%2520characterization%2520of%2520the%2520depsipeptide%2520analog%2520as%2520a%2520novel%2520histone%2520deacetylase%252Fphosphatidylinositol%25203-kinase%2520dual%2520inhibitor%26jtitle%3DCancer%2520Sci.%26date%3D2017%26volume%3D108%26spage%3D1469%26epage%3D1475%26doi%3D10.1111%2Fcas.13255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of 4-methyl quinazoline derivatives as anticancer agents simultaneously targeting phosphoinositide 3-kinases and histone deacetylases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6992</span>– <span class="NLM_lpage">7014</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00390</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00390" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFamtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6992-7014&author=K.+Zhangauthor=F.+Laiauthor=S.+Linauthor=M.+Jiauthor=J.+Zhangauthor=Y.+Zhangauthor=J.+Jinauthor=R.+Fuauthor=D.+Wuauthor=H.+Tianauthor=N.+Xueauthor=L.+Shengauthor=X.+Zouauthor=Y.+Liauthor=X.+Chenauthor=H.+Xu&title=Design%2C+synthesis%2C+and+biological+evaluation+of+4-methyl+quinazoline+derivatives+as+anticancer+agents+simultaneously+targeting+phosphoinositide+3-kinases+and+histone+deacetylases&doi=10.1021%2Facs.jmedchem.9b00390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases</span></div><div class="casAuthors">Zhang, Kehui; Lai, Fangfang; Lin, Songwen; Ji, Ming; Zhang, Jingbo; Zhang, Yan; Jin, Jing; Fu, Rong; Wu, Deyu; Tian, Hua; Xue, Nina; Sheng, Li; Zou, Xiaowen; Li, Yan; Chen, Xiaoguang; Xu, Heng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6992-7014</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polypharmacol. is a promising paradigm in modern drug discovery.  Herein, we have discovered a series of novel PI3K and HDAC dual inhibitors in which the hydroxamic acid moiety as the zinc binding functional group was introduced to a quinazoline-based PI3K pharmacophore through an appropriate linker.  Systematic structure-activity relationship studies resulted in lead compds. 23 (shown in graphical abstr. and duplicated as I) and 36 (II) that simultaneously inhibited PI3K and HDAC with nanomolar potencies and demonstrated favorable antiproliferative activities.  Compds. 23 and 36 efficiently modulated the expression of p-AKT and Ac-H3, arrested the cell cycle, and induced apoptosis in HCT116 cancer cells.  Following pharmacokinetic studies, 23 was further evaluated in HCT116 and HGC-27 xenograft models to show significant in vivo anticancer efficacies with tumor growth inhibitions of 45.8% (po, 150 mg/kg) and 62.6% (i.p., 30 mg/kg), resp.  Overall, this work shows promise in discovering new anticancer therapeutics by the approach of simultaneously targeting PI3K and HDAC pathways with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6xLiFaGhwk7Vg90H21EOLACvtfcHk0lhZEZVlRf-DHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFamtLg%253D&md5=de4c9a630208e49eac58dcad630adcd6</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00390%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DLai%26aufirst%3DF.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DJi%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DTian%26aufirst%3DH.%26aulast%3DXue%26aufirst%3DN.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DZou%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DH.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%25204-methyl%2520quinazoline%2520derivatives%2520as%2520anticancer%2520agents%2520simultaneously%2520targeting%2520phosphoinositide%25203-kinases%2520and%2520histone%2520deacetylases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D6992%26epage%3D7014%26doi%3D10.1021%2Facs.jmedchem.9b00390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ling, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Hybrids from farnesylthiosalicylic acid and hydroxamic acid as dual ras-related signaling and histone deacetylase (HDAC) inhibitors: design, synthesis and biological evaluation</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">971</span>– <span class="NLM_lpage">976</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1002%2Fcmdc.201500019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25882299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsF2hu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=971-976&author=Y.+Lingauthor=X.+Wangauthor=C.+Wangauthor=C.+Xuauthor=W.+Zhangauthor=Y.+Zhangauthor=Y.+Zhang&title=Hybrids+from+farnesylthiosalicylic+acid+and+hydroxamic+acid+as+dual+ras-related+signaling+and+histone+deacetylase+%28HDAC%29+inhibitors%3A+design%2C+synthesis+and+biological+evaluation&doi=10.1002%2Fcmdc.201500019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrids from Farnesylthiosalicylic Acid and Hydroxamic Acid as Dual Ras-Related Signaling and Histone Deacetylase (HDAC) Inhibitors: Design, Synthesis and Biological Evaluation</span></div><div class="casAuthors">Ling, Yong; Wang, Xuemin; Wang, Chenniu; Xu, Chenjun; Zhang, Wei; Zhang, Yihua; Zhang, Yanan</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">971-976</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A novel series of hybrids was designed and synthesized by combining key elements from farnesylthiosalicylic acid (FTS) and hydroxamic acid.  Several ((3,7,11-trimethyldodeca-2,6,10-trien-1-yl) thio)benzamide derivs., particularly those with branched and linear aliph. linkers between the hydroxamic zinc binding group (ZBG) and the benzamide core, not only displayed significant antitumor activities against six human cancer cells but also exhibited histone deacetylase (HDAC) inhibitory effects in vitro.  Among them, N-(4-(hydroxyamino)-4-oxobutyl)-2-(((2E,6E)-3,7,11-trimethyldodeca-2,6, 10-trien-1-yl)thio)benzamide (8 d) was the most potent, with IC50 values of 4.9-7.6 μM; these activities are eight- to sixteen-fold more potent than FTS and comparable to that of suberoylanilide hydroxamic acid (SAHA).  Deriv. 8 d induced cell cycle arrest in the G0/G1 phase, inhibited the acetylation of histone H3 and α-tubulin, and blocked Ras-related signaling pathways in a dose-dependent manner.  The improved tumor growth inhibition and cell-cycle arrest in vitro might result from the dual inhibition.  These findings suggest dual inhibitors of Ras-related signaling pathway and HDAC hold promise as therapeutic agents for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos_kmgrsga_LVg90H21EOLACvtfcHk0lhZEZVlRf-DHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsF2hu74%253D&md5=c773e2cb644f6b8fbe8585365dc9ee4a</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500019%26sid%3Dliteratum%253Aachs%26aulast%3DLing%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DHybrids%2520from%2520farnesylthiosalicylic%2520acid%2520and%2520hydroxamic%2520acid%2520as%2520dual%2520ras-related%2520signaling%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520inhibitors%253A%2520design%252C%2520synthesis%2520and%2520biological%2520evaluation%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D971%26epage%3D976%26doi%3D10.1002%2Fcmdc.201500019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geng, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1605</span>– <span class="NLM_lpage">1608</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.04.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bmcl.2019.04.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=31053508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovVOit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=1605-1608&author=A.+Gengauthor=H.+Cuiauthor=L.+Zhangauthor=X.+Chenauthor=H.+Liauthor=T.+Luauthor=Y.+Zhu&title=Discovery+of+novel+phenoxybenzamide+analogues+as+Raf%2FHDAC+dual+inhibitors&doi=10.1016%2Fj.bmcl.2019.04.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors</span></div><div class="casAuthors">Geng, Aixin; Cui, Hao; Zhang, Liyuan; Chen, Xin; Li, Hongmei; Lu, Tao; Zhu, Yong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1605-1608</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors as an important epigenetic therapeutic strategy affect signaling networks and act synergistically with kinase inhibitors for the treatment of cancer.  Herein we presented a series of novel phenoxybenzamide analogs with inhibition of Raf and HDAC.  Among them, compd. 10e(I) showed potent antiproliferative activities against Hepg2 and MDA-MB-468 in cellular assays.  This work may lay the foundation for developing novel dual Raf/HDAC inhibitors as potential anticancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCeQkNSnZrhrVg90H21EOLACvtfcHk0lg-tcs5vMOXJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovVOit7w%253D&md5=2297e664553d245952780736f9ace3eb</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.04.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.04.047%26sid%3Dliteratum%253Aachs%26aulast%3DGeng%26aufirst%3DA.%26aulast%3DCui%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520novel%2520phenoxybenzamide%2520analogues%2520as%2520Raf%252FHDAC%2520dual%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D1605%26epage%3D1608%26doi%3D10.1016%2Fj.bmcl.2019.04.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitiss, J. L.</span></span> <span> </span><span class="NLM_article-title">Roles of eukaryotic topoisomerases in transcription, replication and genomic stability</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">703</span>– <span class="NLM_lpage">721</span>, <span class="refDoi"> DOI: 10.1038/nrm.2016.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnrm.2016.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=27649880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFemsbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=703-721&author=Y.+Pommierauthor=Y.+Sunauthor=S.+N.+Huangauthor=J.+L.+Nitiss&title=Roles+of+eukaryotic+topoisomerases+in+transcription%2C+replication+and+genomic+stability&doi=10.1038%2Fnrm.2016.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of eukaryotic topoisomerases in transcription, replication and genomic stability</span></div><div class="casAuthors">Pommier, Yves; Sun, Yilun; Huang, Shar-yin N.; Nitiss, John L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">703-721</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Topoisomerases introduce transient DNA breaks to relax supercoiled DNA, remove catenanes and enable chromosome segregation.  Human cells encode six topoisomerases (TOP1, TOP1mt, TOP2α, TOP2β, TOP3α and TOP3β), which act on a broad range of DNA and RNA substrates at the nuclear and mitochondrial genomes.  Their catalytic intermediates, the topoisomerase cleavage complexes (TOPcc), are therapeutic targets of various anticancer drugs.  TOPcc can also form on damaged DNA during replication and transcription, and engage specific repair pathways, such as those mediated by tyrosyl-DNA phosphodiesterase 1 (TDP1) and TDP2 and by endonucleases (MRE11, XPF-ERCC1 and MUS81).  Here, we review the roles of topoisomerases in mediating chromatin dynamics, transcription, replication, DNA damage repair and genomic stability, and discuss how deregulation of topoisomerases can cause neurodegenerative diseases, immune disorders and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2RnRxdI5gv7Vg90H21EOLACvtfcHk0lg-tcs5vMOXJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFemsbvO&md5=d1e6b3015a76a21ff92502f7e4eb5016</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1038%2Fnrm.2016.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm.2016.111%26sid%3Dliteratum%253Aachs%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DS.%2BN.%26aulast%3DNitiss%26aufirst%3DJ.%2BL.%26atitle%3DRoles%2520of%2520eukaryotic%2520topoisomerases%2520in%2520transcription%252C%2520replication%2520and%2520genomic%2520stability%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2016%26volume%3D17%26spage%3D703%26epage%3D721%26doi%3D10.1038%2Fnrm.2016.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piccartgebhart, M. J.</span></span> <span> </span><span class="NLM_article-title">Anthracyclines and the tailoring of treatment for early breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>354</i></span>,  <span class="NLM_fpage">2177</span>– <span class="NLM_lpage">2179</span>, <span class="refDoi"> DOI: 10.1056/NEJMe068065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1056%2FNEJMe068065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16707755" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2006&pages=2177-2179&author=M.+J.+Piccartgebhart&title=Anthracyclines+and+the+tailoring+of+treatment+for+early+breast+cancer&doi=10.1056%2FNEJMe068065"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1056%2FNEJMe068065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe068065%26sid%3Dliteratum%253Aachs%26aulast%3DPiccartgebhart%26aufirst%3DM.%2BJ.%26atitle%3DAnthracyclines%2520and%2520the%2520tailoring%2520of%2520treatment%2520for%2520early%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D354%26spage%3D2177%26epage%3D2179%26doi%3D10.1056%2FNEJMe068065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span> <span> </span><span class="NLM_article-title">Acridine and its derivatives: a patent review (2009 - 2013)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">664</span>, <span class="refDoi"> DOI: 10.1517/13543776.2014.902052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1517%2F13543776.2014.902052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=24848259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotF2rs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=647-664&author=B.+Zhangauthor=X.+Liauthor=B.+Liauthor=C.+Gaoauthor=Y.+Jiang&title=Acridine+and+its+derivatives%3A+a+patent+review+%282009+-+2013%29&doi=10.1517%2F13543776.2014.902052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Acridine and its derivatives: a patent review (2009 - 2013)</span></div><div class="casAuthors">Zhang, Bin; Li, Xi; Li, Bin; Gao, Chunmei; Jiang, Yuyang</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">647-664</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Acridine derivs. were extensively explored as potential therapeutic agents for the treatment of a no. of diseases, such as cancer, Alzheimer's, and bacterial and protozoan infections.  Their mode of action is mainly attributed to DNA intercalation and the subsequent effects on the biol. processes linked to DNA and its related enzymes.  This review covers the relevant efforts in developing acridine derivs. with enhanced therapeutic potency and selectivity and as fluorescent materials, with particular focus on the newly patented acridine derivs. in 2009 - 2013, acridine drugs in clin. trials and preclin. studies, and other new derivs. that emerged in 2009 - 2013.  Thousands of acridines with therapeutic and biol. activities or with photochem. properties were developed.  In addn., to modify the position and the nature of the substituent on the acridine core, more attention may be paid to the development of azaacridine or other heteroatom-substituted acridine derivs. and their synthesis methods to broaden the application of acridine derivs.  In cancer chemotherapy, the mode of action of acridine derivs. needs to be further studied.  Efficient methods for identification and optimization of acridine derivs. to localize at the sites of disease need to be further developed.  Moreover, acridine drugs may be combined with such bioactive agents as DNA repair proteins inhibitors to overcome tumor resistance and improve outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOqFeloBU-pbVg90H21EOLACvtfcHk0lh7RKbRiypcWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotF2rs7w%253D&md5=b8dfcb53419445f05a339ab76b17d2a3</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.902052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.902052%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DY.%26atitle%3DAcridine%2520and%2520its%2520derivatives%253A%2520a%2520patent%2520review%2520%25282009%2520-%25202013%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D647%26epage%3D664%26doi%3D10.1517%2F13543776.2014.902052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlhagen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrier, F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">7291</span>– <span class="NLM_lpage">7300</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=14612526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVGlt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=7291-7300&author=M.+S.+Kimauthor=M.+Blakeauthor=H.+B.+Jinauthor=G.+Kohlhagenauthor=Y.+Pommierauthor=F.+Carrier&title=Inhibition+of+histone+deacetylase+increases+cytotoxicity+to+anticancer+drugs+targeting+DNA"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Histone Deacetylase Increases Cytotoxicity to Anticancer Drugs Targeting DNA</span></div><div class="casAuthors">Kim, Myoung Sook; Blake, Mellissa; Baek, Jin Hyen; Kohlhagen, Glenda; Pommier, Yves; Carrier, France</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7291-7300</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Several anticancer drugs target DNA or enzymes acting on the DNA.  Because chromatin DNA is tightly compacted, accessibility to the drug target may reduce the efficiency of these anticancer drugs.  We thus treated four human cancer cell lines and two normal epithelial cell lines with either trichostatin A (TSA) or SAHA, two histone deacetylase inhibitors, before exposing the cells to VP-16, ellipticine, camptothecin, doxorubicin, cisplatin, 5-fluorouracil, or cyclophosphamide.  Pretreatment with TSA or SAHA increased the killing efficiency of VP-16, ellipticine, doxorubicin, and cisplatin.  The magnitude of sensitization is cell type specific and is >10-fold for VP-16 in D54, a brain tumor cell line intrinsically resistant to topoisomerase II inhibitors.  Topoisomerase II levels and activity were not affected by this treatment, but p53, p21, and Gadd45 protein levels were markedly induced.  Moreover, pretreatment with TSA also increased VP-16-induced apoptosis in a p53-dependent and -independent manner.  Treating the cells in the reverse order (anticancer drug first, followed by TSA or SAHA) had no more cytotoxic effect than the drug alone.  These data suggest that loosening-up the chromatin structure by histone acetylation can increase the efficiency of several anticancer drugs targeting DNA.  This may be advantageous for treating tumors intrinsically resistant to these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq24HjggpPirLVg90H21EOLACvtfcHk0ljltNTq1t5UqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVGlt70%253D&md5=6fe3bc8b32550917fc8f80ac648e680b</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%2BS.%26aulast%3DBlake%26aufirst%3DM.%26aulast%3DJin%26aufirst%3DH.%2BB.%26aulast%3DKohlhagen%26aufirst%3DG.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DCarrier%26aufirst%3DF.%26atitle%3DInhibition%2520of%2520histone%2520deacetylase%2520increases%2520cytotoxicity%2520to%2520anticancer%2520drugs%2520targeting%2520DNA%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D7291%26epage%3D7300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Catalano, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortunati, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugliese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosco, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastrocola, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aragno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boccuzzi, G.</span></span> <span> </span><span class="NLM_article-title">Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells</span>. <i>J. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">465</span>– <span class="NLM_lpage">472</span>, <span class="refDoi"> DOI: 10.1677/joe.1.06970</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1677%2Fjoe.1.06970" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=17088416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlejsLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2006&pages=465-472&author=M.+G.+Catalanoauthor=N.+Fortunatiauthor=M.+Puglieseauthor=R.+Poliauthor=O.+Boscoauthor=R.+Mastrocolaauthor=M.+Aragnoauthor=G.+Boccuzzi&title=Valproic+acid%2C+a+histone+deacetylase+inhibitor%2C+enhances+sensitivity+to+doxorubicin+in+anaplastic+thyroid+cancer+cells&doi=10.1677%2Fjoe.1.06970"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells</span></div><div class="casAuthors">Catalano, Maria G.; Fortunati, Nicoletta; Pugliese, Mariateresa; Poli, Roberta; Bosco, Ornella; Mastrocola, Raffaella; Aragno, Manuela; Boccuzzi, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Endocrinology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">465-472</span>CODEN:
                <span class="NLM_cas:coden">JOENAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-0795</span>.
    
            (<span class="NLM_cas:orgname">Society for Endocrinology</span>)
        </div><div class="casAbstract">Multimodality treatments (i.e. surgery, chemotherapy, and radiotherapy) are recommended for anaplastic thyroid carcinoma (ATC), an extremely lethal human cancer, but to date there is little evidence that such approaches improve survival rates.  It is thus necessary to seek new therapeutic tools.  Histone deacetylase (HDAC) inhibitors are a promising class of antineoplastic agents that induce differentiation and apoptosis.  Moreover, they may enhance the cytotoxicity of drugs targeting DNA through acetylation of histones.  Using two ATC cell lines (CAL-62 and ARO), we show here that valproic acid (VPA), a clin. available HDAC inhibitor, enhances the activity of doxorubicin, whose antitumor properties involve binding to DNA and inhibiting topoisomerase II.  A meager 0·7 mM VPA, which corresponds to serum concns. in patients treated for epilepsy, is able to increase the cytotoxicity of doxorubicin about threefold in CAL-62 cells and twofold in ARO cells.  The sensitizing effect, which is through histone acetylation, involves increased apoptosis, which is also shown by the increased caspase 3 activation and the enhancement of doxorubicin-induced G2 cell cycle arrest.  These results might offer a rationale for clin. studies of a new combined therapy in an effort to improve the outcome of patients with anaplastic thyroid cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmTtQReyIxnrVg90H21EOLACvtfcHk0liMdrCbuIfoIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlejsLrM&md5=c5f3780cd38d2ca4b53c7812f9e49836</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1677%2Fjoe.1.06970&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252Fjoe.1.06970%26sid%3Dliteratum%253Aachs%26aulast%3DCatalano%26aufirst%3DM.%2BG.%26aulast%3DFortunati%26aufirst%3DN.%26aulast%3DPugliese%26aufirst%3DM.%26aulast%3DPoli%26aufirst%3DR.%26aulast%3DBosco%26aufirst%3DO.%26aulast%3DMastrocola%26aufirst%3DR.%26aulast%3DAragno%26aufirst%3DM.%26aulast%3DBoccuzzi%26aufirst%3DG.%26atitle%3DValproic%2520acid%252C%2520a%2520histone%2520deacetylase%2520inhibitor%252C%2520enhances%2520sensitivity%2520to%2520doxorubicin%2520in%2520anaplastic%2520thyroid%2520cancer%2520cells%26jtitle%3DJ.%2520Endocrinol.%26date%3D2006%26volume%3D191%26spage%3D465%26epage%3D472%26doi%3D10.1677%2Fjoe.1.06970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padget, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, B. M.</span></span> <span> </span><span class="NLM_article-title">Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">4539</span>– <span class="NLM_lpage">4542</span>, <span class="refDoi"> DOI: 10.1074/jbc.C000824200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1074%2Fjbc.C000824200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=11136718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtlOqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=4539-4542&author=C.+A.+Johnsonauthor=K.+Padgetauthor=C.+A.+Austinauthor=B.+M.+Turner&title=Deacetylase+activity+associates+with+topoisomerase+II+and+is+necessary+for+etoposide-induced+apoptosis&doi=10.1074%2Fjbc.C000824200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis</span></div><div class="casAuthors">Johnson, Colin A.; Padget, Kay; Austin, Caroline A.; Turner, Bryan M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4539-4542</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">DNA topoisomerase II (topo II) is a ubiquitous nuclear enzyme that is involved in DNA replication, transcription, chromosome segregation, and apoptosis.  Here we show by immunopptn., pull down with glutathione S-transferase fusion proteins, and yeast two-hybrid anal. that both topo IIα and -β phys. interact with the histone deacetylase HDAC1.  The in vitro DNA decatenation activity of recombinant topo IIα and -β is inhibited by assocn. with catalytically inactive, recombinant HDAC1.  We provide evidence for the in vivo significance of the topo II-HDAC1 assocn., showing that inhibition of HDAC activity with trichostatin A suppresses apoptosis induced by the topo II poison etoposide, but not by the topoisomerase I inhibitor camptothecin.  We suggest that chromatin remodeling by an HDAC-contg. complex facilitates both topo II-catalyzed DNA rearrangement and etoposide-induced DNA damage in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG-EArV25rfLVg90H21EOLACvtfcHk0lhmXTAYFnZBWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtlOqsLg%253D&md5=8cfacaa935b0351d3cf55aad2405b138</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C000824200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C000824200%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DC.%2BA.%26aulast%3DPadget%26aufirst%3DK.%26aulast%3DAustin%26aufirst%3DC.%2BA.%26aulast%3DTurner%26aufirst%3DB.%2BM.%26atitle%3DDeacetylase%2520activity%2520associates%2520with%2520topoisomerase%2520II%2520and%2520is%2520necessary%2520for%2520etoposide-induced%2520apoptosis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D4539%26epage%3D4542%26doi%3D10.1074%2Fjbc.C000824200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marchion, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bicaku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span> <span> </span><span class="NLM_article-title">Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1002/jcb.20045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1002%2Fjcb.20045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15108350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvVaqs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2004&pages=223-237&author=D.+C.+Marchionauthor=E.+Bicakuauthor=A.+I.+Daudauthor=V.+Richonauthor=D.+M.+Sullivanauthor=P.+N.+Munster&title=Sequence-specific+potentiation+of+topoisomerase+II+inhibitors+by+the+histone+deacetylase+inhibitor+suberoylanilide+hydroxamic+acid&doi=10.1002%2Fjcb.20045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid</span></div><div class="casAuthors">Marchion, Douglas C.; Bicaku, Elona; Daud, Adil I.; Richon, Victoria; Sullivan, Daniel M.; Munster, Pamela N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">223-237</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Acetylation of histones leads to conformational changes of DNA.  We have previously shown that the histone deacetylase (HDAC) inhibitor, suberoylanilide hydroxamic acid (SAHA), induced cell cycle arrest, differentiation, and apoptosis.  In addn. to their antitumor effects as single agents, HDAC inhibitors may cause conformational changes in the chromatin, rendering the DNA more vulnerable to DNA damaging agents.  We examd. the effects of SAHA on cell death induced by topo II inhibitors in breast cancer cell lines.  Topo II inhibitors stabilize the topo II-DNA complex, resulting in DNA damage.  Treatment of cells with SAHA promoted chromatin decondensation assocd. with increased nuclear concn. and DNA binding of the topo II inhibitor and subsequent potentiation of DNA damage.  While SAHA-induced histone hyperacetylation occurred as early as 4 h, chromatin decondensation was most profound at 48 h.  SAHA-induced potentiation of topo II inhibitors was sequence-specific.  Pre-exposure of cells to SAHA for 48 h was synergistic, whereas shorter pre-exposure periods abrogated synergy and exposure of cells to SAHA after the topo II inhibitor resulted in antagonistic effects.  Synergy was not obsd. in cells with depleted topo II levels.  These effects were not limited to specific types of topo II inhibitors.  We propose that SAHA significantly potentiates the DNA damage induced by topo II inhibitors; however, synergy is dependent on the sequence of drug administration and the expression of the target.  These findings may impact the clin. development of combining HDAC inhibitors with DNA damaging agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd_EzmdHJvU7Vg90H21EOLACvtfcHk0lhpevCRgLwYag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvVaqs7c%253D&md5=71f10a1a96c0e666a5f410c9b32a3893</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1002%2Fjcb.20045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.20045%26sid%3Dliteratum%253Aachs%26aulast%3DMarchion%26aufirst%3DD.%2BC.%26aulast%3DBicaku%26aufirst%3DE.%26aulast%3DDaud%26aufirst%3DA.%2BI.%26aulast%3DRichon%26aufirst%3DV.%26aulast%3DSullivan%26aufirst%3DD.%2BM.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26atitle%3DSequence-specific%2520potentiation%2520of%2520topoisomerase%2520II%2520inhibitors%2520by%2520the%2520histone%2520deacetylase%2520inhibitor%2520suberoylanilide%2520hydroxamic%2520acid%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2004%26volume%3D92%26spage%3D223%26epage%3D237%26doi%3D10.1002%2Fjcb.20045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Gennaro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desideri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budillon, A.</span></span> <span> </span><span class="NLM_article-title">Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3075</span>– <span class="NLM_lpage">3087</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0254</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1535-7163.MCT-09-0254" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=19887547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlyrt7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=3075-3087&author=F.+Bruzzeseauthor=M.+Roccoauthor=S.+Castelliauthor=E.+Di+Gennaroauthor=A.+Desideriauthor=A.+Budillon&title=Synergistic+antitumor+effect+between+vorinostat+and+topotecan+in+small+cell+lung+cancer+cells+is+mediated+by+generation+of+reactive+oxygen+species+and+DNA+damage-induced+apoptosis&doi=10.1158%2F1535-7163.MCT-09-0254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis</span></div><div class="casAuthors">Bruzzese, Francesca; Rocco, Monia; Castelli, Silvia; Di Gennaro, Elena; Desideri, Alessandro; Budillon, Alfredo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3075-3087</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The topoisomerase-I (topo-I) inhibitor topotecan, deriv. of camptothecin, is the only registered drug for relapsed small cell lung cancer (SCLC).  The histone deacetylase inhibitor vorinostat has shown preclin. and clin. antitumor activities in hematol. malignancies and solid tumors, including SCLC, and has recently been approved for the treatment of cutaneous T-cell lymphomas.  In this study, we analyzed the antitumor effect of vorinostat combined with topotecan or camptothecin in topo-I inhibitor-sensitive H209 and inhibitor-resistant H526 SCLC cells.  Simultaneous or sequential exposure (24 h delay) to either agent resulted in strong synergistic cytotoxic effect in both cell lines, as shown by calcg. combination index, and confirmed by growth in soft agar.  Combination treatments increased S-phase cell cycle arrest paralleled by apoptosis as measured by hypodiploid peak formation, Annexin V binding, DNA fragmentation, and mitochondria destruction.  The apoptotic process was triggered by a caspase-dependent mechanism and can be ascribed to the phosphorylation of H2AX, a reporter of DNA double-strand breaks.  These effects were paralleled by an increase of topo-I/DNA covalent complexes induced by combination treatment and suggest a potentiation by vorinostat of topotecan-induced DNA damage.  Finally, oxidative injury played a significant functional role in the obsd. enhanced lethality because coadministration of the antioxidant N-acetyl-L-cysteine blocked reactive oxygen species generation, apoptosis, and mitochondria destruction induced by the vorinostat/topotecan combination.  To our knowledge, this is the first demonstration of a synergistic antitumor effect between topotecan and vorinostat in SCLC.  Because no well-established treatment is available for recurrent SCLC patients, our results indicate that this drug combination should be explored clin. [Mol Cancer Ther 2009;8(11):3075-87].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriNbJiuKn7ILVg90H21EOLACvtfcHk0liXbKpi70-GTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlyrt7%252FI&md5=0fb0ac896a935ac119556374394615a7</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0254%26sid%3Dliteratum%253Aachs%26aulast%3DBruzzese%26aufirst%3DF.%26aulast%3DRocco%26aufirst%3DM.%26aulast%3DCastelli%26aufirst%3DS.%26aulast%3DDi%2BGennaro%26aufirst%3DE.%26aulast%3DDesideri%26aufirst%3DA.%26aulast%3DBudillon%26aufirst%3DA.%26atitle%3DSynergistic%2520antitumor%2520effect%2520between%2520vorinostat%2520and%2520topotecan%2520in%2520small%2520cell%2520lung%2520cancer%2520cells%2520is%2520mediated%2520by%2520generation%2520of%2520reactive%2520oxygen%2520species%2520and%2520DNA%2520damage-induced%2520apoptosis%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D3075%26epage%3D3087%26doi%3D10.1158%2F1535-7163.MCT-09-0254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetter, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamara, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gresh, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, E. A.</span></span> <span> </span><span class="NLM_article-title">Vorinostat enhances cytotoxicity of SN-38 and temozolomide in ewing sarcoma cells and activates STAT3/AKT/MAPK pathways</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e0142704</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0142704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1371%2Fjournal.pone.0142704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=26571493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVSjsLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0142704&author=V.+B.+Sampsonauthor=N.+S.+Vetterauthor=D.+F.+Kamaraauthor=A.+B.+Collierauthor=R.+C.+Greshauthor=E.+A.+Kolb&title=Vorinostat+enhances+cytotoxicity+of+SN-38+and+temozolomide+in+ewing+sarcoma+cells+and+activates+STAT3%2FAKT%2FMAPK+pathways&doi=10.1371%2Fjournal.pone.0142704"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Vorinostat enhances cytotoxicity of SN-38 and temozolomide in Ewing sarcoma cells and activates STAT3/AKT/MAPK pathways</span></div><div class="casAuthors">Sampson, Valerie B.; Vetter, Nancy S.; Kamara, Davida F.; Collier, Anderson B.; Gresh, Renee C.; Kolb, E. Anders</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e0142704/1-e0142704/19</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACi) have been evaluated in patients with Ewing sarcoma (EWS) but demonstrated limited activity.  To better understand the potential for HDACi in EWS, we evaluated the combination of the HDACi vorinostat, with DNA damaging agents SN-38 (the active metabolite of irinotecan and topoisomerase 1 inhibitor) plus the alkylating agent temozolomide (ST).  Drugs were evaluated in sequential and simultaneous combinations in two EWS cell lines.  Results demonstrate that cell viability, DNA damage and reactive oxygen species (ROS) prodn. are dependent on the sequence of drug administration.  Enhanced cytotoxicity is exhibited in vitro in EWS cell lines treated with ST administered before vorinostat, which was modestly higher than concomitant treatment and superior to vorinostat administered before ST.  Drug combinations downregulate cyclin D1 to induce G0/G1 arrest and promote apoptosis by cleavage of caspase-3 and PARP.  When ST is administered before or concomitantly with vorinostat there is activation of STAT3, MAPK and the p53 pathway.  In contrast, when vorinostat is administered before ST, there is DNA repair, increased AKT phosphorylation and reduced H2B acetylation.  Inhibition of AKT using the small mol. inhibitor MK-2206 did not restore H2B acetylation.  Combining ST with the dual ALK and IGF-1R inhibitor, AZD3463 simultaneously inhibited STAT3 and AKT to enhance the cytotoxic effects of ST and further reduce cell growth suggesting that STAT3 and AKT activation were in part mediated by ALK and IGF-1R signaling.  In summary, potent antiproliferative and proapoptotic activity were demonstrated for ST induced DNA damage before or simultaneous with HDAC inhibition and cell death was mediated through the p53 pathway.  These observations may aid in designing new protocols for treating pediatric patients with high-risk EWS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-wHLOu1A8BrVg90H21EOLACvtfcHk0ljtAwUq8c0k5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVSjsLnE&md5=43b299bbd5a1b2d3bd102545fa5a578f</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0142704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0142704%26sid%3Dliteratum%253Aachs%26aulast%3DSampson%26aufirst%3DV.%2BB.%26aulast%3DVetter%26aufirst%3DN.%2BS.%26aulast%3DKamara%26aufirst%3DD.%2BF.%26aulast%3DCollier%26aufirst%3DA.%2BB.%26aulast%3DGresh%26aufirst%3DR.%2BC.%26aulast%3DKolb%26aufirst%3DE.%2BA.%26atitle%3DVorinostat%2520enhances%2520cytotoxicity%2520of%2520SN-38%2520and%2520temozolomide%2520in%2520ewing%2520sarcoma%2520cells%2520and%2520activates%2520STAT3%252FAKT%252FMAPK%2520pathways%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0142704%26doi%3D10.1371%2Fjournal.pone.0142704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cincinelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musso, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artali, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guglielmi, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Porta, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardile, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Signorino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fucci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frusciante, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallavalle, S.</span></span> <span> </span><span class="NLM_article-title">Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">e0205018</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0205018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1371%2Fjournal.pone.0205018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=30300374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtV2lt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=e0205018&author=R.+Cincinelliauthor=L.+Mussoauthor=R.+Artaliauthor=M.+B.+Guglielmiauthor=I.+La+Portaauthor=C.+Melitoauthor=F.+Colelliauthor=F.+Cardileauthor=G.+Signorinoauthor=A.+Fucciauthor=M.+Fruscianteauthor=C.+Pisanoauthor=S.+Dallavalle&title=Hybrid+topoisomerase+I+and+HDAC+inhibitors+as+dual+action+anticancer+agents&doi=10.1371%2Fjournal.pone.0205018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents</span></div><div class="casAuthors">Cincinelli, Raffaella; Musso, Loana; Artali, Roberto; Guglielmi, Mario B.; La Porta, Ilaria; Melito, Carmela; Colelli, Fabiana; Cardile, Francesco; Signorino, Giacomo; Fucci, Alessandra; Frusciante, Martina; Pisano, Claudio; Dallavalle, Sabrina</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e0205018/1-e0205018/22</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Recent studies have shown that HDAC inhibitors act synergistically with camptothecin derivs. in combination therapies.  To exploit this synergy, new hybrid mols. targeting simultaneously topoisomerase I and HDAC were designed.  In particular, a selected multivalent agent contg. a camptothecin and a SAHA-like template showed a broad spectrum of antiproliferative activity, with IC50 values in the nanomolar range.  Preliminary in vivo results indicated a strong antitumor activity on human mesothelioma primary cell line MM473 orthotopically xenografted in CD-1 nude mice and very high tolerability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzxTP2b69aALVg90H21EOLACvtfcHk0lg3TIvFqyGWTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtV2lt7g%253D&md5=8a96bd41321339c6ac43f108dd478cef</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0205018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0205018%26sid%3Dliteratum%253Aachs%26aulast%3DCincinelli%26aufirst%3DR.%26aulast%3DMusso%26aufirst%3DL.%26aulast%3DArtali%26aufirst%3DR.%26aulast%3DGuglielmi%26aufirst%3DM.%2BB.%26aulast%3DLa%2BPorta%26aufirst%3DI.%26aulast%3DMelito%26aufirst%3DC.%26aulast%3DColelli%26aufirst%3DF.%26aulast%3DCardile%26aufirst%3DF.%26aulast%3DSignorino%26aufirst%3DG.%26aulast%3DFucci%26aufirst%3DA.%26aulast%3DFrusciante%26aufirst%3DM.%26aulast%3DPisano%26aufirst%3DC.%26aulast%3DDallavalle%26aufirst%3DS.%26atitle%3DHybrid%2520topoisomerase%2520I%2520and%2520HDAC%2520inhibitors%2520as%2520dual%2520action%2520anticancer%2520agents%26jtitle%3DPLoS%2520One%26date%3D2018%26volume%3D13%26spage%3De0205018%26doi%3D10.1371%2Fjournal.pone.0205018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cincinelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musso, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artali, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guglielmi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardile, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallavalle, S.</span></span> <span> </span><span class="NLM_article-title">Camptothecin-psammaplin a hybrids as topoisomerase I and HDAC dual-action inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">2005</span>– <span class="NLM_lpage">2014</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.11.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.ejmech.2017.11.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=29150335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvValtrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=2005-2014&author=R.+Cincinelliauthor=L.+Mussoauthor=R.+Artaliauthor=M.+Guglielmiauthor=E.+Bianchinoauthor=F.+Cardileauthor=F.+Colelliauthor=C.+Pisanoauthor=S.+Dallavalle&title=Camptothecin-psammaplin+a+hybrids+as+topoisomerase+I+and+HDAC+dual-action+inhibitors&doi=10.1016%2Fj.ejmech.2017.11.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors</span></div><div class="casAuthors">Cincinelli, Raffaella; Musso, Loana; Artali, Roberto; Guglielmi, Mario; Bianchino, Erminia; Cardile, Francesco; Colelli, Fabiana; Pisano, Claudio; Dallavalle, Sabrina</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2005-2014</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Recent studies have demonstrated enhanced anticancer effects of combination therapy consisting of camptothecin derivs. and HDAC inhibitors.  To exploit this synergy in a single active compd., we designed new dual-acting multivalent mols. simultaneously targeting topoisomerase I and HDAC.  In particular, a selected compd. contg. a camptothecin and the psammaplin A scaffold showed a broad spectrum of antiproliferative activity, with IC50 values in the nanomolar range.  Preliminary in vivo results indicated a strong antitumor activity on human mesothelioma primary cell line MM473 orthotopically xenografted in CD-1 nude mice and very high tolerability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeTdxpoD4KiLVg90H21EOLACvtfcHk0lgO6xMQoN5HOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvValtrbN&md5=9fd01d994120980ed2a28fdbcf90f14d</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.11.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.11.021%26sid%3Dliteratum%253Aachs%26aulast%3DCincinelli%26aufirst%3DR.%26aulast%3DMusso%26aufirst%3DL.%26aulast%3DArtali%26aufirst%3DR.%26aulast%3DGuglielmi%26aufirst%3DM.%26aulast%3DBianchino%26aufirst%3DE.%26aulast%3DCardile%26aufirst%3DF.%26aulast%3DColelli%26aufirst%3DF.%26aulast%3DPisano%26aufirst%3DC.%26aulast%3DDallavalle%26aufirst%3DS.%26atitle%3DCamptothecin-psammaplin%2520a%2520hybrids%2520as%2520topoisomerase%2520I%2520and%2520HDAC%2520dual-action%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D143%26spage%3D2005%26epage%3D2014%26doi%3D10.1016%2Fj.ejmech.2017.11.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span> <span> </span><span class="NLM_article-title">The discovery and optimization of novel dual inhibitors of topoisomerase ii and histone deacetylase</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">6981</span>– <span class="NLM_lpage">6995</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.09.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bmc.2013.09.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=24095018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOlurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=6981-6995&author=X.+Zhangauthor=B.+Baoauthor=X.+Yuauthor=L.+Tongauthor=Y.+Luoauthor=Q.+Huangauthor=M.+Suauthor=L.+Shengauthor=J.+Liauthor=H.+Zhuauthor=B.+Yangauthor=X.+Zhangauthor=Y.+Chenauthor=W.+Lu&title=The+discovery+and+optimization+of+novel+dual+inhibitors+of+topoisomerase+ii+and+histone+deacetylase&doi=10.1016%2Fj.bmc.2013.09.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase</span></div><div class="casAuthors">Zhang, Xuan; Bao, Bin; Yu, Xiuhua; Tong, Linjiang; Luo, Yu; Huang, Qingqing; Su, Mingbo; Sheng, Li; Li, Jia; Zhu, Hong; Yang, Bo; Zhang, Xiongwen; Chen, Yi; Lu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6981-6995</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel class of podophyllotoxin derivs. have been designed and synthesized based on the synergistic antitumor effects of topoisomerase II and histone deacetylase inhibitors.  Their inhibitory activities towards histone deacetylases and Topo II and their cytotoxicities in cancer cell lines were evaluated.  The arom. capping group connection, linker length and zinc-binding group were systematically varied and preliminary conclusions regarding structure-activity relationships are discussed.  Among all of the synthesized hybrid compds., compd. I showed the most potent HDAC inhibitory activity at a low nanomolar level and exhibited powerful antiproliferative activity towards HCT116 colon carcinoma cells at a low micromolar level.  Further exploration of this series led to the discovery of potent dual inhibitor II, which exhibited the strongest in vitro cytotoxic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2q6l9WK2gW7Vg90H21EOLACvtfcHk0liUWJTTMLrzBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOlurnE&md5=e983212ec3320d5606018e94063f98ad</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.09.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.09.023%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DBao%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DW.%26atitle%3DThe%2520discovery%2520and%2520optimization%2520of%2520novel%2520dual%2520inhibitors%2520of%2520topoisomerase%2520ii%2520and%2520histone%2520deacetylase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D6981%26epage%3D6995%26doi%3D10.1016%2Fj.bmc.2013.09.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3958</span>– <span class="NLM_lpage">3966</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.06.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bmc.2018.06.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=29954683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1SjsLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=3958-3966&author=J.+Chenauthor=D.+Liauthor=W.+Liauthor=J.+Yinauthor=Y.+Zhangauthor=Z.+Yuanauthor=C.+Gaoauthor=F.+Liuauthor=Y.+Jiang&title=Design%2C+synthesis+and+anticancer+evaluation+of+acridine+hydroxamic+acid+derivatives+as+dual+Topo+and+HDAC+inhibitors&doi=10.1016%2Fj.bmc.2018.06.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors</span></div><div class="casAuthors">Chen, Jiwei; Li, Dan; Li, Wenlu; Yin, Jingxian; Zhang, Yueying; Yuan, Zigao; Gao, Chunmei; Liu, Feng; Jiang, Yuyang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3958-3966</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Multitarget inhibitors design has generated great interest in cancer treatment.  Based on the synergistic effects of topoisomerase and histone deacetylase inhibitors, we designed and synthesized a new series of acridine hydroxamic acid derivs. as potential novel dual Topo and HDAC inhibitors.  MTT assays indicated that all the hybrid compds. displayed good antiproliferative activities with IC50 values in low micromolar range, among which compd. 8c displayed potent activity against U937 (IC50=0.90μM).  In addn., compd. 8c also displayed the best HDAC inhibitory activity, which was several times more potent than HDAC inhibitor SAHA.  Subsequent studies indicated that all the compds. displayed Topo II inhibition activity at 50μM.  Moreover, compd. 8c could interact with DNA and induce U937 apoptosis.  This study provides a suite of compds. for further exploration of dual Topo and HDAC inhibitors, and compd. 8c can be a new dual Topo and HDAC inhibitory anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCVb9uGhgIqrVg90H21EOLACvtfcHk0lj8IEDWPQ8LCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1SjsLrM&md5=bb2ad2ab72c4a871c1ecabda608d31b9</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.06.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.06.016%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DJiang%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%2520and%2520anticancer%2520evaluation%2520of%2520acridine%2520hydroxamic%2520acid%2520derivatives%2520as%2520dual%2520Topo%2520and%2520HDAC%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D3958%26epage%3D3966%26doi%3D10.1016%2Fj.bmc.2018.06.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guerrant, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canzoneri, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyelere, A. K.</span></span> <span> </span><span class="NLM_article-title">Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1465</span>– <span class="NLM_lpage">1477</span>, <span class="refDoi"> DOI: 10.1021/jm200799p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200799p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVyhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1465-1477&author=W.+Guerrantauthor=V.+Patilauthor=J.+C.+Canzoneriauthor=A.+K.+Oyelere&title=Dual+targeting+of+histone+deacetylase+and+topoisomerase+II+with+novel+bifunctional+inhibitors&doi=10.1021%2Fjm200799p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Targeting of Histone Deacetylase and Topoisomerase II with Novel Bifunctional Inhibitors</span></div><div class="casAuthors">Guerrant, William; Patil, Vishal; Canzoneri, Joshua C.; Oyelere, Adegboyega K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1465-1477</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Strategies to ameliorate the flaws of current chemotherapeutic agents, while maintaining potent anticancer activity, are of particular interest.  Agents which can modulate multiple targets may have superior utility and fewer side effects than current single-target drugs.  To explore the prospect in cancer therapy of a bivalent agent that combines two complementary chemo-active groups within a single mol. architecture, we have synthesized dual-acting histone deacetylase and topoisomerase II inhibitors.  These dual-acting agents are derived from suberoylanilide hydroxamic acid (SAHA) and anthracycline daunorubicin, prototypical histone deacetylase (HDAC) and topoisomerase II (Topo II) inhibitors, resp.  For example, 4-aminobenzyl alc. reacted with suberic anhydride to give 4-HOCH2C6H4NHCO(CH2)6CO2H, which was oxidized to the corresponding benzaldehyde.  This benzaldehyde reacted with H2NOCPh3 to give the terminal O-tritylated amide, which, after addn. to daunorubicin HCl and removal of the trityl group, produced conjugate I.  We report herein that these agents present the signatures of inhibition of HDAC and Topo II in both cell-free and whole-cell assays.  Moreover, these agents potently inhibit the proliferation of representative cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_Yf6AQQjHxLVg90H21EOLACvtfcHk0lhcZuCcc1CZ6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVyhuw%253D%253D&md5=f0d6a8b98bb524de8e9fbbf1680610a1</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1021%2Fjm200799p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200799p%26sid%3Dliteratum%253Aachs%26aulast%3DGuerrant%26aufirst%3DW.%26aulast%3DPatil%26aufirst%3DV.%26aulast%3DCanzoneri%26aufirst%3DJ.%2BC.%26aulast%3DOyelere%26aufirst%3DA.%2BK.%26atitle%3DDual%2520targeting%2520of%2520histone%2520deacetylase%2520and%2520topoisomerase%2520II%2520with%2520novel%2520bifunctional%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1465%26epage%3D1477%26doi%3D10.1021%2Fjm200799p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di Antonio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLuckie, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span> <span> </span><span class="NLM_article-title">Reprogramming the mechanism of action of chlorambucil by coupling to a G-quadruplex ligand</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">5860</span>– <span class="NLM_lpage">5863</span>, <span class="refDoi"> DOI: 10.1021/ja5014344</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja5014344" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Crsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=5860-5863&author=M.+Di+Antonioauthor=K.+I.+McLuckieauthor=S.+Balasubramanian&title=Reprogramming+the+mechanism+of+action+of+chlorambucil+by+coupling+to+a+G-quadruplex+ligand&doi=10.1021%2Fja5014344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Reprogramming the Mechanism of Action of Chlorambucil by Coupling to a G-Quadruplex Ligand</span></div><div class="casAuthors">Di Antonio, Marco; McLuckie, Keith I. E.; Balasubramanian, Shankar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5860-5863</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The nitrogen mustard Chlorambucil (Chl) generates covalent adducts with double-helical DNA and inhibits cell proliferation.  Among these adducts, interstrand cross-links (ICLs) are the most toxic, as they stall replication by generating DNA double strand breaks (DSBs).  Conversely, intrastrand cross-links generated by Chl are efficiently repaired by a dedicated Nucleotide Excision Repair (NER) enzyme.  We synthesized a novel crosslinking agent that combines Chl with the G-quadruplex (G4) ligand PDS (PDS-Chl).  We demonstrated that PDS-Chl alkylates G4 structures at low μM concns., without reactivity toward double- or single-stranded DNA.  Since intramol. G4s arise from a single DNA strand, we reasoned that preferential alkylation of such structures might prevent the generation of ICLs, while favoring intrastrand cross-links.  We obsd. that PDS-Chl selectively impairs growth in cells genetically deficient in NER, but did not show any sensitivity to the repair gene BRCA2, involved in double-stranded break repair.  Our findings suggest that G4 targeting of this clin. important alkylating agent alters the overall mechanism of action.  These insights may inspire new opportunities for intervention in diseases specifically characterized by genetic impairment of NER, such as skin and testicular cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMn1uWWQMEzLVg90H21EOLACvtfcHk0lhcZuCcc1CZ6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Crsbc%253D&md5=ee185f36b219d8a8645745f02faf663c</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1021%2Fja5014344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja5014344%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BAntonio%26aufirst%3DM.%26aulast%3DMcLuckie%26aufirst%3DK.%2BI.%26aulast%3DBalasubramanian%26aufirst%3DS.%26atitle%3DReprogramming%2520the%2520mechanism%2520of%2520action%2520of%2520chlorambucil%2520by%2520coupling%2520to%2520a%2520G-quadruplex%2520ligand%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26spage%3D5860%26epage%3D5863%26doi%3D10.1021%2Fja5014344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poklar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilch, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redding, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunham, S. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslauer, K. J.</span></span> <span> </span><span class="NLM_article-title">Influence of cisplatin intrastrand crosslinking on the conformation, thermal stability, and energetics of a 20-mer DNA duplex</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">7606</span>– <span class="NLM_lpage">7611</span>, <span class="refDoi"> DOI: 10.1073/pnas.93.15.7606</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1073%2Fpnas.93.15.7606" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=8755522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADyaK28XksFSrs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=7606-7611&author=N.+Poklarauthor=D.+S.+Pilchauthor=S.+J.+Lippardauthor=E.+A.+Reddingauthor=S.+U.+Dunhamauthor=K.+J.+Breslauer&title=Influence+of+cisplatin+intrastrand+crosslinking+on+the+conformation%2C+thermal+stability%2C+and+energetics+of+a+20-mer+DNA+duplex&doi=10.1073%2Fpnas.93.15.7606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of cisplatin intrastrand crosslinking on the conformation, thermal stability, and energetics of a 20-mer DNA duplex</span></div><div class="casAuthors">Poklar, Natasa; Pilch, Daniel S.; Lippard, Stephen J.; Redding, Elizabeth A.; Dunham, Shari U.; Breslauer, Kenneth J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7606-7611</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Cis-Diamminedichloroplatinum(II) (cisplatin) is a widely used anticancer drug that binds to and crosslinks DNA.  The major DNA adduct of the drug results from coordination of two adjacent guanine bases to platinum to form the intrastrand crosslink cis-[Pt(NH3)2{d(GpG)-N7(1),-N7(2)}] (cis-Pt-GG).  In the present study, spectroscopic and calorimetric techniques were employed to characterize the influence of this crosslink on the conformation, thermal stability, and energetics of a site-specifically platinated 20-mer DNA duplex.  CD spectroscopic and thermal denaturation data revealed that the crosslink alters the structure of the host duplex, consistent with a shift from a B-like to an A-like conformation; lowers its thermal stability by ≈9°; and reduces its thermodn. stability by 6.3 kcal/mol at 25°, most of which is enthalpic in origin; but it does not alter the two-state melting behavior exhibited by the parent, unmodified duplex, despite the significant crosslink-induced changes noted above.  The energetic consequences of the cis-Pt-GG crosslink are discussed in relation to the structural perturbations it induces in DNA and to how these crosslink-induced perturbations might modulate protein binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNFO8c7rTrybVg90H21EOLACvtfcHk0li1YaQW7GbRUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XksFSrs7k%253D&md5=56794c4c6ab9c20aa3dc37c47969c46d</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1073%2Fpnas.93.15.7606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.93.15.7606%26sid%3Dliteratum%253Aachs%26aulast%3DPoklar%26aufirst%3DN.%26aulast%3DPilch%26aufirst%3DD.%2BS.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26aulast%3DRedding%26aufirst%3DE.%2BA.%26aulast%3DDunham%26aufirst%3DS.%2BU.%26aulast%3DBreslauer%26aufirst%3DK.%2BJ.%26atitle%3DInfluence%2520of%2520cisplatin%2520intrastrand%2520crosslinking%2520on%2520the%2520conformation%252C%2520thermal%2520stability%252C%2520and%2520energetics%2520of%2520a%252020-mer%2520DNA%2520duplex%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1996%26volume%3D93%26spage%3D7606%26epage%3D7611%26doi%3D10.1073%2Fpnas.93.15.7606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bouwman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonkers, J.</span></span> <span> </span><span class="NLM_article-title">The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">598</span>, <span class="refDoi"> DOI: 10.1038/nrc3342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnrc3342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=22918414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1GhsLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=587-598&author=P.+Bouwmanauthor=J.+Jonkers&title=The+effects+of+deregulated+DNA+damage+signalling+on+cancer+chemotherapy+response+and+resistance&doi=10.1038%2Fnrc3342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance</span></div><div class="casAuthors">Bouwman, Peter; Jonkers, Jos</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">587-598</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumors with specific DNA repair defects can be completely dependent on back-up DNA repair pathways for their survival.  This dependence can be exploited therapeutically to induce synthetic lethality in tumor cells.  For instance, homologous recombination (HR)-deficient tumors can be effectively targeted by DNA double-strand break-inducing agents.  However, not all HR-defective tumors respond equally well to this type of therapy.  Tumor cells may acquire resistance by invoking biochem. mechanisms that reduce drug action or by acquiring addnl. alterations in DNA damage response pathways.  A thorough understanding of these processes is important for predicting treatment response and for the development of novel treatment strategies that prevent the emergence of therapy-resistant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNSTPQO2sEE7Vg90H21EOLACvtfcHk0lijkOAxWFO1-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1GhsLnN&md5=176b61bc1ce31c537067eae10417bf90</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1038%2Fnrc3342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3342%26sid%3Dliteratum%253Aachs%26aulast%3DBouwman%26aufirst%3DP.%26aulast%3DJonkers%26aufirst%3DJ.%26atitle%3DThe%2520effects%2520of%2520deregulated%2520DNA%2520damage%2520signalling%2520on%2520cancer%2520chemotherapy%2520response%2520and%2520resistance%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D587%26epage%3D598%26doi%3D10.1038%2Fnrc3342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lord, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span> <span> </span><span class="NLM_article-title">The DNA damage response and cancer therapy</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>481</i></span>,  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1038/nature10760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnature10760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=22258607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38Xps1GmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=481&publication_year=2012&pages=287-294&author=C.+J.+Lordauthor=A.+Ashworth&title=The+DNA+damage+response+and+cancer+therapy&doi=10.1038%2Fnature10760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">The DNA damage response and cancer therapy</span></div><div class="casAuthors">Lord, Christopher J.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">481</span>
        (<span class="NLM_cas:issue">7381</span>),
    <span class="NLM_cas:pages">287-294</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Genomic instability is one of the most pervasive characteristics of tumor cells and is probably the combined effect of DNA damage, tumor-specific DNA repair defects, and a failure to stop or stall the cell cycle before the damaged DNA is passed on to daughter cells.  Although these processes drive genomic instability and ultimately the disease process, they also provide therapeutic opportunities.  A better understanding of the cellular response to DNA damage will not only inform our knowledge of cancer development but also help to refine the classification as well as the treatment of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUS1sAbqFhmrVg90H21EOLACvtfcHk0liLTerXasZOXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xps1GmsQ%253D%253D&md5=75d12cdb52e8c9a39bced1611bf90298</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1038%2Fnature10760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10760%26sid%3Dliteratum%253Aachs%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DThe%2520DNA%2520damage%2520response%2520and%2520cancer%2520therapy%26jtitle%3DNature%26date%3D2012%26volume%3D481%26spage%3D287%26epage%3D294%26doi%3D10.1038%2Fnature10760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thurn, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raha, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qureshi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase regulation of ATM-mediated DNA damage signaling</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2078</span>– <span class="NLM_lpage">2087</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-1242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1535-7163.MCT-12-1242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=23939379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOhurvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=2078-2087&author=K.+T.+Thurnauthor=S.+Thomasauthor=P.+Rahaauthor=I.+Qureshiauthor=P.+N.+Munster&title=Histone+deacetylase+regulation+of+ATM-mediated+DNA+damage+signaling&doi=10.1158%2F1535-7163.MCT-12-1242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Regulation of ATM-Mediated DNA Damage Signaling</span></div><div class="casAuthors">Thurn, K. Ted; Thomas, Scott; Raha, Paromita; Qureshi, Ian; Munster, Pamela N.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2078-2087</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Ataxia-telangiectasia mutated (ATM) is a major regulator of the DNA damage response.  ATM promotes the activation of BRCA1, CHK2, and p53 leading to the induction of response genes such as CDKN1A (p21), GADD45A, and RRM2B that promote cell-cycle arrest and DNA repair.  The upregulation of these response genes may contribute to resistance of cancer cells to genotoxic therapies.  Here, we show that histone deacetylases (HDAC) play a major role in mitigating the response of the ATM pathway to DNA damage.  HDAC inhibition decreased ATM activation and expression, and attenuated the activation of p53 in vitro and in vivo.  Select depletion of HDAC1 and HDAC2 was sufficient to modulate ATM activation, reduce GADD45A and RRM2B induction, and increase sensitivity to DNA strand breaks.  The regulation of ATM by HDAC enzymes therefore suggests a vital role for HDAC1 and HDAC2 in the DNA damage response, and the potential use of the ATM pathway as a pharmacodynamic marker for combination therapies involving HDAC inhibitors.  Mol Cancer Ther; 12(10); 2078-87. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDH0rQ3pBvI7Vg90H21EOLACvtfcHk0lhYETIXimJd8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOhurvN&md5=b1aff4a207ba7e193487f470036963e5</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-1242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-1242%26sid%3Dliteratum%253Aachs%26aulast%3DThurn%26aufirst%3DK.%2BT.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DRaha%26aufirst%3DP.%26aulast%3DQureshi%26aufirst%3DI.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26atitle%3DHistone%2520deacetylase%2520regulation%2520of%2520ATM-mediated%2520DNA%2520damage%2520signaling%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D2078%26epage%3D2087%26doi%3D10.1158%2F1535-7163.MCT-12-1242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">14639</span>– <span class="NLM_lpage">14644</span>, <span class="refDoi"> DOI: 10.1073/pnas.1008522107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1073%2Fpnas.1008522107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=20679231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOgsb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=14639-14644&author=J.+H.+Leeauthor=M.+L.+Choyauthor=L.+Ngoauthor=S.+S.+Fosterauthor=P.+A.+Marks&title=Histone+deacetylase+inhibitor+induces+DNA+damage%2C+which+normal+but+not+transformed+cells+can+repair&doi=10.1073%2Fpnas.1008522107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair</span></div><div class="casAuthors">Lee, J.-H.; Choy, M. L.; Ngo, L.; Foster, S. S.; Marks, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">14639-14644, S14639/1-S14639/2</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACi) developed as anti-cancer agents have a high degree of selectivity for killing cancer cells.  HDACi induce acetylation of histones and nonhistone proteins, which affect gene expression, cell cycle progression, cell migration, and cell death.  The mechanism of the tumor selective action of HDACi is unclear.  Here, we show that the HDACi, vorinostat (Suberoylanilide hydroxamic acid, SAHA), induces DNA double-strand breaks (DSBs) in normal (HFS) and cancer (LNCaP, A549) cells.  Normal cells in contrast to cancer cells repair the DSBs despite continued culture with vorinostat.  In transformed cells, phosphorylated H2AX (γH2AX), a marker of DNA DSBs, levels increased with continued culture with vorinostat, whereas in normal cells, this marker decreased with time.  Vorinostat induced the accumulation of acetylated histones within 30 min, which could alter chromatin structure-exposing DNA to damage.  After a 24-h culture of cells with vorinostat, and reculture without the HDACi, γH2AX was undetectable by 2 h in normal cells, while persisting in transformed cells for the duration of culture.  Further, we found that vorinostat suppressed DNA DSB repair proteins, e.g., RAD50, MRE11, in cancer but not normal cells.  Thus, the HDACi, vorinostat, induces DNA damage which normal but not cancer cells can repair.  This DNA damage is assocd. with cancer cell death.  These findings can explain, in part, the selectivity of vorinostat in causing cancer cell death at concns. that cause little or no normal cell death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSDKsBgz4ItbVg90H21EOLACvtfcHk0liwir9veJZUPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOgsb%252FN&md5=72a2d11a2b4303022e85c25c1b946564</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1008522107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1008522107%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DChoy%26aufirst%3DM.%2BL.%26aulast%3DNgo%26aufirst%3DL.%26aulast%3DFoster%26aufirst%3DS.%2BS.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DHistone%2520deacetylase%2520inhibitor%2520induces%2520DNA%2520damage%252C%2520which%2520normal%2520but%2520not%2520transformed%2520cells%2520can%2520repair%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D14639%26epage%3D14644%26doi%3D10.1073%2Fpnas.1008522107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harms, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">3145</span>– <span class="NLM_lpage">3152</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-4397</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F0008-5472.CAN-06-4397" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=17409421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksVGlu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=3145-3152&author=K.+L.+Harmsauthor=X.+Chen&title=Histone+deacetylase+2+modulates+p53+transcriptional+activities+through+regulation+of+p53-DNA+binding+activity&doi=10.1158%2F0008-5472.CAN-06-4397"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase 2 Modulates p53 Transcriptional Activities through Regulation of p53-DNA Binding Activity</span></div><div class="casAuthors">Harms, Kelly Lynn; Chen, Xinbin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3145-3152</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors are emerging as promising cancer therapeutics.  HDAC inhibitors have been found to induce cellular activities that are strikingly similar to p53-mediated responses to genotoxic stress.  For example, HDAC inhibitors induce cell cycle arrest, apoptosis, and cellular senescence.  Because at least 11 HDACs are affected by the current HDAC inhibitors, the HDAC crit. for tumor cell survival and proliferation remains unknown.  Thus, we sought to characterize the distinct roles of HDACs in the p53 pathway.  Through the use of stable MCF7 cell lines which inducibly express short hairpin RNA targeting HDAC2, we found that HDAC2 plays important roles in the p53 pathway.  Specifically, we found that knockdown of HDAC2 inhibited cellular proliferation in a dose-dependent manner which was also partly p53-dependent.  Furthermore, knockdown of HDAC2 induced cellular senescence.  Importantly, we found that knockdown of HDAC2 enhanced p53-dependent trans-repression and trans-activation of a subset of target genes.  We found that the enhancement was due to increased p53-DNA binding activity but not alterations in p53 stability or posttranslational modification(s).  Thus, for the first time, our data suggest that HDAC inhibitors function through the p53 pathway, at least in part, by activating p53-DNA binding activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_sg_TKY0bALVg90H21EOLACvtfcHk0lg0D19NMrTxtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksVGlu7w%253D&md5=8c500357d49a7b014c658003d6baeeec</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4397%26sid%3Dliteratum%253Aachs%26aulast%3DHarms%26aufirst%3DK.%2BL.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DHistone%2520deacetylase%25202%2520modulates%2520p53%2520transcriptional%2520activities%2520through%2520regulation%2520of%2520p53-DNA%2520binding%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D3145%26epage%3D3152%26doi%3D10.1158%2F0008-5472.CAN-06-4397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Groselj, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiltie, A. E.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">748</span>– <span class="NLM_lpage">754</span>, <span class="refDoi"> DOI: 10.1038/bjc.2013.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fbjc.2013.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=23361058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslWmu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2013&pages=748-754&author=B.+Groseljauthor=N.+L.+Sharmaauthor=F.+C.+Hamdyauthor=M.+Kerrauthor=A.+E.+Kiltie&title=Histone+deacetylase+inhibitors+as+radiosensitisers%3A+effects+on+DNA+damage+signalling+and+repair&doi=10.1038%2Fbjc.2013.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair</span></div><div class="casAuthors">Groselj, B.; Sharma, N. L.; Hamdy, F. C.; Kerr, M.; Kiltie, A. E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">748-754</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Many cancers display increased expression of histone deacetylases (HDACs) and therefore transcriptionally inactive chromatin, resulting in the downregulation of genes including tumor suppressor and DNA repair genes.  Histone deacetylase inhibitors (HDACi) are a heterogeneous group of epigenetic therapeutics, showing promising anticancer effects in both pre-clin. and clin. settings, in particular the effect of radiosensitization when administered in combination with radiotherapy.  Radiotherapy remains one of the most common forms of cancer treatment, leading to cell death through the induction of DNA double-strand breaks (DSBs).  Cells have developed mechanisms to repair such DSB through two major pathways: non-homologous end-joining and homologous recombination.  Here, we explore the current evidence for the use of HDACi in combination with irradn., focusing on the effects of HDACi on DNA damage signalling and repair in vitro.  In addn., we summarise the clin. evidence for using HDACi with radiotherapy, a growing area of interest with great potential clin. utility.  British Journal of Cancer (2013) 108, 748-754; doi:10.1038/bjc.2013.21 www.bjcancer.com; published online 29 Jan. 2013.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZmWuDRAfI2LVg90H21EOLACvtfcHk0lg0D19NMrTxtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslWmu78%253D&md5=c958f3329b3e3859a24527f81b6c7a20</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2013.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2013.21%26sid%3Dliteratum%253Aachs%26aulast%3DGroselj%26aufirst%3DB.%26aulast%3DSharma%26aufirst%3DN.%2BL.%26aulast%3DHamdy%26aufirst%3DF.%2BC.%26aulast%3DKerr%26aufirst%3DM.%26aulast%3DKiltie%26aufirst%3DA.%2BE.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520as%2520radiosensitisers%253A%2520effects%2520on%2520DNA%2520damage%2520signalling%2520and%2520repair%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2013%26volume%3D108%26spage%3D748%26epage%3D754%26doi%3D10.1038%2Fbjc.2013.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maggio, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosato, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahmani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paik, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czarnik, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S.</span></span> <span> </span><span class="NLM_article-title">The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">2590</span>– <span class="NLM_lpage">2600</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-03-2631</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F0008-5472.CAN-03-2631" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15059916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1yju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=2590-2600&author=S.+C.+Maggioauthor=R.+R.+Rosatoauthor=L.+B.+Kramerauthor=Y.+Daiauthor=M.+Rahmaniauthor=D.+S.+Paikauthor=A.+C.+Czarnikauthor=S.+G.+Payneauthor=S.+Spiegelauthor=S.+Grant&title=The+histone+deacetylase+inhibitor+MS-275+interacts+synergistically+with+fludarabine+to+induce+apoptosis+in+human+leukemia+cells&doi=10.1158%2F0008-5472.CAN-03-2631"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells</span></div><div class="casAuthors">Maggio, Sonia C.; Rosato, Roberto R.; Kramer, Lora B.; Dai, Yun; Rahmani, Mohamed; Paik, David S.; Czarnik, Ann C.; Payne, Shawn G.; Spiegel, Sarah; Grant, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2590-2600</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Interactions between the novel benzamide histone deacetylase (HDAC) inhibitor MS-275 and fludarabine were examd. in lymphoid and myeloid human leukemia cells in relation to mitochondrial injury, signal transduction events, and apoptosis.  Prior exposure of Jurkat lymphoblastic leukemia cells to a marginally toxic concn. of MS-275 (e.g., 500 nM) for 24 h sharply increased mitochondrial injury, caspase activation, and apoptosis in response to a minimally toxic concn. of fludarabine (500 nM), resulting in highly synergistic antileukemic interactions and loss of clonogenic survival.  Simultaneous exposure to MS-275 and fludarabine also led to synergistic effects, but these were not as pronounced as obsd. with sequential treatment.  Similar interactions were noted in the case of (a) other human leukemia cell lines (e.g., U937, CCRF-CEM); (b) other HDAC inhibitors (e.g., sodium butyrate); and (c) other nucleoside analogs (e.g., 1-β-D-arabinofuranosylcytosine, gemcitabine).  Potentiation of fludarabine lethality by MS-275 was assocd. with acetylation of histones H3 and H4, down-regulation of the antiapoptotic proteins XIAP and Mcl-1, enhanced cytosolic release of proapoptotic mitochondrial proteins (e.g., cytochrome c, Smac/DIABLO, and apoptosis-inducing factor), and caspase activation.  It was also accompanied by the caspase-dependent down-regulation of p27KIP1, cyclins A, E, and D1, and cleavage and diminished phosphorylation of retinoblastoma protein.  However, increased lethality of the combination was not assocd. with enhanced fludarabine triphosphate formation or DNA incorporation and occurred despite a slight redn. in the S-phase fraction.  Prior exposure to MS-275 attenuated fludarabine-mediated activation of MEK1/2, extracellular signal-regulated kinase, and Akt, and enhanced c-Jun NH2-terminal kinase phosphorylation; furthermore, inducible expression of constitutively active MEK1/2 or Akt significantly diminished MS-275/fludarabine-induced lethality.  Combined exposure of cells to MS-275 and fludarabine was assocd. with a significant increase in generation of reactive oxygen species; moreover, both the increase in reactive oxygen species and apoptosis were largely attenuated by coadministration of the free radical scavenger L-N-acetylcysteine.  Finally, prior administration of MS-275 markedly potentiated fludarabine-mediated generation of the proapoptotic lipid second messenger ceramide.  Taken together, these findings indicate that the HDAC inhibitor MS-275 induces multiple perturbations in signal transduction, survival, and cell cycle regulatory pathways that lower the threshold for fludarabine-mediated mitochondrial injury and apoptosis in human leukemia cells.  They also provide insights into possible mechanisms by which novel, clin. relevant HDAC inhibitors might be used to enhance the antileukemic activity of established nucleoside analogs such as fludarabine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaZO0fC_tDWLVg90H21EOLACvtfcHk0lgBUUUWeQvsog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1yju74%253D&md5=986686ecee2cf9aca2b1aa6ed3105883</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-03-2631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-03-2631%26sid%3Dliteratum%253Aachs%26aulast%3DMaggio%26aufirst%3DS.%2BC.%26aulast%3DRosato%26aufirst%3DR.%2BR.%26aulast%3DKramer%26aufirst%3DL.%2BB.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DRahmani%26aufirst%3DM.%26aulast%3DPaik%26aufirst%3DD.%2BS.%26aulast%3DCzarnik%26aufirst%3DA.%2BC.%26aulast%3DPayne%26aufirst%3DS.%2BG.%26aulast%3DSpiegel%26aufirst%3DS.%26aulast%3DGrant%26aufirst%3DS.%26atitle%3DThe%2520histone%2520deacetylase%2520inhibitor%2520MS-275%2520interacts%2520synergistically%2520with%2520fludarabine%2520to%2520induce%2520apoptosis%2520in%2520human%2520leukemia%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D2590%26epage%3D2600%26doi%3D10.1158%2F0008-5472.CAN-03-2631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hajji, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallenborg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlachos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyman, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermanson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, B.</span></span> <span> </span><span class="NLM_article-title">Combinatorial action of the HDAC inhibitor trichostatin a and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">3134</span>– <span class="NLM_lpage">3144</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1210976</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fsj.onc.1210976" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=18071312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvFSis7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=3134-3144&author=N.+Hajjiauthor=K.+Wallenborgauthor=P.+Vlachosauthor=U.+Nymanauthor=O.+Hermansonauthor=B.+Joseph&title=Combinatorial+action+of+the+HDAC+inhibitor+trichostatin+a+and+etoposide+induces+caspase-mediated+AIF-dependent+apoptotic+cell+death+in+non-small+cell+lung+carcinoma+cells&doi=10.1038%2Fsj.onc.1210976"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Combinatorial action of the HDAC inhibitor trichostatin A and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells</span></div><div class="casAuthors">Hajji, N.; Wallenborg, K.; Vlachos, P.; Nyman, U.; Hermanson, O.; Joseph, B.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3134-3144</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Commonly used regimens in cancer therapy rely on the induction of apoptotic cell death, and drug resistance can be attributed, at least in part, to a disabled apoptotic program.  Non-small cell lung carcinomas (NSCLC), exhibit an intrinsic resistance to chemotherapy.  Here, we show that co-treatment with etoposide (VP16) and the pan-histone deacetylase (HDAC) inhibitor trichostatin A (TSA), but not valproic acid (VPA), induced apoptotic cell death in drug-resistant NSCLC cells.  Co-treatment, but not single treatment, with VP16 and TSA induced apoptosis in a caspase-dependent manner accompanied by a crucial decrease in Bcl-xL expression allowing Bax activation and subsequent initiation of the apoptosis inducing factor (AIF)-dependent death pathway.  Importantly, AIF proved to be required for the effects of TSA/VP16 as RNA knockdown of AIF resulted in a complete abolishment of TSA/VP16-induced apoptotic cell death in drug-resistant NSCLC cells.  Our results thus provide evidence for the requirement of both caspase-dependent and caspase-independent apoptotic pathways in TSA/VP16-mediated death of drug-resistant NSCLC cells, and extend previous suggestions that HDAC inhibitors in combination with conventional chemotherapeutic drugs could be valuable in the treatment of NSCLC cancer and other malignancies in which Bcl-xL is overexpressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxjdh2HAy64LVg90H21EOLACvtfcHk0lgBUUUWeQvsog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvFSis7Y%253D&md5=1f21019a0c1b0cf7045831947c6e2144</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210976%26sid%3Dliteratum%253Aachs%26aulast%3DHajji%26aufirst%3DN.%26aulast%3DWallenborg%26aufirst%3DK.%26aulast%3DVlachos%26aufirst%3DP.%26aulast%3DNyman%26aufirst%3DU.%26aulast%3DHermanson%26aufirst%3DO.%26aulast%3DJoseph%26aufirst%3DB.%26atitle%3DCombinatorial%2520action%2520of%2520the%2520HDAC%2520inhibitor%2520trichostatin%2520a%2520and%2520etoposide%2520induces%2520caspase-mediated%2520AIF-dependent%2520apoptotic%2520cell%2520death%2520in%2520non-small%2520cell%2520lung%2520carcinoma%2520cells%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D3134%26epage%3D3144%26doi%3D10.1038%2Fsj.onc.1210976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maiso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colado, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ocio, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garayoa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandiella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San-Miguel, J. F.</span></span> <span> </span><span class="NLM_article-title">The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2265</span>– <span class="NLM_lpage">2274</span>, <span class="refDoi"> DOI: 10.1038/leu.2009.182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fleu.2009.182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=19812608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFKns7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=2265-2274&author=P.+Maisoauthor=E.+Coladoauthor=E.+M.+Ocioauthor=M.+Garayoaauthor=J.+Martinauthor=P.+Atadjaauthor=A.+Pandiellaauthor=J.+F.+San-Miguel&title=The+synergy+of+panobinostat+plus+doxorubicin+in+acute+myeloid+leukemia+suggests+a+role+for+HDAC+inhibitors+in+the+control+of+DNA+repair&doi=10.1038%2Fleu.2009.182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair</span></div><div class="casAuthors">Maiso, P.; Colado, E.; Ocio, E. M.; Garayoa, M.; Martin, J.; Atadja, P.; Pandiella, A.; San-Miguel, J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2265-2274</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) is a clonal disorder characterized by the accumulation of myeloid blasts in the bone marrow.  Here, we report the effects of the novel histone deacetylase inhibitor panobinostat (LBH589) in combination with doxorubicin on AML cells.  Panobinostat exhibited potent anti-AML activity in all AML cell lines tested and in primary AML cells from patients (IC50 < 20 n).  In addn., panobinostat potentiated the action of several std.-of-care anti-AML compds., particularly, doxorubicin.  The mol. effects induced by panobinostat and doxorubicin treatment were investigated by analyzing gene expression, cell cycle, apoptosis and signaling pathways.  Analyses of gene expression profiles identified 588 genes whose expression was exclusively affected by the combination of panobinostat and doxorubicin.  The combination induced AML cell death by an increase in the mitochondrial outer membrane permeability and release of cytochrome c from the mitochondria, resulting in caspase-dependent apoptosis and accompanied by the upregulation of Bax, Bak and, particularly, Bad.  The drug combination provoked a strong activation of a DNA damage response, indicating that this combination may trigger cell death by a mechanism that induced DNA double-strand breaks.  These data indicate that the combination of panobinostat and doxorubicin may be an effective therapy for the treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnuiXE70XeS7Vg90H21EOLACvtfcHk0lgBUUUWeQvsog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFKns7bJ&md5=2b964f893dad7fab75a40898848fca5d</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fleu.2009.182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2009.182%26sid%3Dliteratum%253Aachs%26aulast%3DMaiso%26aufirst%3DP.%26aulast%3DColado%26aufirst%3DE.%26aulast%3DOcio%26aufirst%3DE.%2BM.%26aulast%3DGarayoa%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DJ.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DPandiella%26aufirst%3DA.%26aulast%3DSan-Miguel%26aufirst%3DJ.%2BF.%26atitle%3DThe%2520synergy%2520of%2520panobinostat%2520plus%2520doxorubicin%2520in%2520acute%2520myeloid%2520leukemia%2520suggests%2520a%2520role%2520for%2520HDAC%2520inhibitors%2520in%2520the%2520control%2520of%2520DNA%2520repair%26jtitle%3DLeukemia%26date%3D2009%26volume%3D23%26spage%3D2265%26epage%3D2274%26doi%3D10.1038%2Fleu.2009.182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahat, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Q.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornmann, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConkey, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lev, D. C.</span></span> <span> </span><span class="NLM_article-title">Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3472</span>– <span class="NLM_lpage">3483</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-2714</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1078-0432.CCR-08-2714" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=19417021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVKlsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=3472-3483&author=G.+Lopezauthor=J.+Liuauthor=W.+Renauthor=W.+Weiauthor=S.+Wangauthor=G.+Lahatauthor=Q.-S.+Zhuauthor=W.+G.+Bornmannauthor=D.+J.+McConkeyauthor=R.+E.+Pollockauthor=D.+C.+Lev&title=Combining+PCI-24781%2C+a+novel+histone+deacetylase+inhibitor%2C+with+chemotherapy+for+the+treatment+of+soft+tissue+sarcoma&doi=10.1158%2F1078-0432.CCR-08-2714"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma</span></div><div class="casAuthors">Lopez, Gonzalo; Liu, Juehui; Ren, Wenhong; Wei, Wei; Wang, Suizhao; Lahat, Guy; Zhu, Quan-Sheng; Bornmann, William G.; McConkey, David J.; Pollock, Raphael E.; Lev, Dina C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3472-3483</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Histone deactylase inhibitors (HDACi) are a promising new class of anticancer therapeutics; however, little is known about HDACi activity in soft tissue sarcoma (STS), a heterogeneous cohort of mesenchymal origin malignancies.  Consequently, we investigated the novel HDACi PCI-24781, alone/in combination with conventional chemotherapy, to det. its potential anti-STS-related effects and the underlying mechanisms involved.  Exptl. Design: Immunoblotting was used to evaluate the effects of PCI-24781 on histone and nonhistone protein acetylation and expression of potential downstream targets.  Cell culture-based assays were utilized to assess the effects of PCI-24781 on STS cell growth, cell cycle progression, apoptosis, and chemosensitivity.  Quant. reverse transcription-PCR, chromatin immunopptn., and reporter assays helped elucidate mol. mechanisms resulting in PCI-24781-induced Rad51 repression.  The effect of PCI-24781, alone or with chemotherapy, on tumor and metastatic growth was tested in vivo using human STS xenograft models.  RESULTS: PCI-24781 exhibited significant anti-STS proliferative activity in vitro, inducing S phase depletion, G2/M cell cycle arrest, and increasing apoptosis.  Superior effects were seen when combined with chemotherapy.  A PCI-24781-induced redn. in Rad51, a major mediator of DNA double-strand break homologous recombination repair, was shown and may be a mechanism underlying PCI-24781 chemosensitization.  We showed that PCI-24781 transcriptionally represses Rad51 through an E2F binding-site on the Rad51 proximal promoter.  Although single-agent PCI-24781 had modest effects on STS growth and metastasis, marked inhibition was obsd. when combined with chemotherapy.  CONCLUSIONS: In light of these findings, this novel mol.-based combination may be applicable to multiple STS histol. subtypes, and potentially merits rigorous evaluation in human STS clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcaGPHupY0DrVg90H21EOLACvtfcHk0ljJ4mt54qM4sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVKlsrw%253D&md5=a5ff3455ca1a51af9e0a926d9357d0d9</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-2714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-2714%26sid%3Dliteratum%253Aachs%26aulast%3DLopez%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DW.%26aulast%3DWei%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DLahat%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DQ.-S.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DMcConkey%26aufirst%3DD.%2BJ.%26aulast%3DPollock%26aufirst%3DR.%2BE.%26aulast%3DLev%26aufirst%3DD.%2BC.%26atitle%3DCombining%2520PCI-24781%252C%2520a%2520novel%2520histone%2520deacetylase%2520inhibitor%252C%2520with%2520chemotherapy%2520for%2520the%2520treatment%2520of%2520soft%2520tissue%2520sarcoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D3472%26epage%3D3483%26doi%3D10.1158%2F1078-0432.CCR-08-2714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chao, O. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, O. B.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1755</span>– <span class="NLM_lpage">1766</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-14-0173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1541-7786.MCR-14-0173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25127709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFSitLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=1755-1766&author=O.+S.+Chaoauthor=O.+B.+Goodman&title=Synergistic+loss+of+prostate+cancer+cell+viability+by+coinhibition+of+HDAC+and+PARP&doi=10.1158%2F1541-7786.MCR-14-0173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic Loss of Prostate Cancer Cell Viability by Coinhibition of HDAC and PARP</span></div><div class="casAuthors">Chao, Olivia S.; Goodman, Oscar B., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1755-1766</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tumors with BRCA germline mutations are defective in repairing DNA double-strand breaks (DSB) through homologous recombination (HR) pathways, making them sensitive to PARP inhibitors (PARPi).  However, BRCA germline mutations are rare in prostate cancer limiting the ability to therapeutically target these pathways.  This study investigates whether histone deacetylase (HDAC) inhibitors (HDACi), reported to modulate DSB repair pathways in sporadic cancers, can downregulate DSB repair pathways and sensitize prostate cancer cells to PARPi.  Prostate cancer cells cotreated with the HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA) and the PARPi, olaparib, demonstrated a synergistic decrease in cell viability compared with single-agent treatment (combination index < 0.9), whereas normal prostatic cells did not.  Similarly, clonogenicity was significantly decreased after cotreatment.  Flow cytometric cell-cycle anal. and Annexin-V staining revealed significant apoptosis upon treatment with SAHA+olaparib.  This coincided with increased DNA damage obsd. by immunofluorescence microscopy anal. of γH2AX foci, a marker of DSBs.  In addn., immunoblot anal. showed a significant and persistent increase in nuclear γH2AX levels.  Both SAHA and olaparib downregulated the expression of HR-related proteins, BRCA1 and RAD51, whereas SAHA + olaparib had an additive effect on RAD51.  Silencing RAD51 sensitized prostate cancer cells to SAHA and olaparib alone.  Collectively, cotreatment with HDACi and PARPi downregulated HR-related protein expression and concomitantly increased DNA damage, resulting in prostate cancer cell death.  Implications: These findings provide a strong rationale for supporting the use of combined HDAC and PARP inhibition in treating advanced prostate cancer.  Mol Cancer Res; 12(12); 1755-66. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-DP9P_hxA-rVg90H21EOLACvtfcHk0ljJ4mt54qM4sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFSitLbN&md5=4e52ef337be04179b2cf8fc8c5348ee8</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-14-0173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-14-0173%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DO.%2BS.%26aulast%3DGoodman%26aufirst%3DO.%2BB.%26atitle%3DSynergistic%2520loss%2520of%2520prostate%2520cancer%2520cell%2520viability%2520by%2520coinhibition%2520of%2520HDAC%2520and%2520PARP%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2014%26volume%3D12%26spage%3D1755%26epage%3D1766%26doi%3D10.1158%2F1541-7786.MCR-14-0173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Min, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, D.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, M. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, Y.-J.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1186/s13058-015-0534-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1186%2Fs13058-015-0534-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25888415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A280%3ADC%252BC2MjltlWguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=33-43&author=A.+Minauthor=S.-A.+Imauthor=D.+K.+Kimauthor=S.-H.+Songauthor=H.-J.+Kimauthor=K.-H.+Leeauthor=T.-Y.+Kimauthor=S.-W.+Hanauthor=D.-Y.+Ohauthor=T.-Y.+Kimauthor=M.+J+O%E2%80%99Connorauthor=Y.-J.+Bang&title=Histone+deacetylase+inhibitor%2C+suberoylanilide+hydroxamic+acid+%28SAHA%29%2C+enhances+anti-tumor+effects+of+the+poly+%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+olaparib+in+triple-negative+breast+cancer+cells&doi=10.1186%2Fs13058-015-0534-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells</span></div><div class="casAuthors">Min Ahrum; Im Seock-Ah; Song Sang-Hyun; Kim Hee-Jun; Lee Kyung-Hun; Kim Tae-Yong; Han Sae-Won; Oh Do-Youn; Kim Tae-You; Bang Yung-Jue; Min Ahrum; Im Seock-Ah; Lee Kyung-Hun; Kim Tae-Yong; Han Sae-Won; Oh Do-Youn; Kim Tae-You; Bang Yung-Jue; Im Seock-Ah; Lee Kyung-Hun; Kim Tae-Yong; Han Sae-Won; Oh Do-Youn; Kim Tae-You; Bang Yung-Jue; Kim Debora Keunyoung; Kim Hee-Jun; O'Connor Mark J</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer research : BCR</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has been found to have therapeutic potential for treating cancers associated with impaired DNA repair capabilities, particularly those with deficiencies in the homologous recombination repair (HRR) pathway.  Histone deacetylases (HDACs) are important for enabling functional HRR of DNA by regulating the expression of HRR-related genes and promoting the accurate assembly of HRR-directed sub-nuclear foci.  Thus, HDAC inhibitors have recently emerged as a therapeutic agent for treating cancer by inhibiting DNA repair.  Based on this, HDAC inhibition could be predicted to enhance the anti-tumor effect of PARP inhibitors in cancer cells by blocking the HRR pathway.  METHODS:  We determined whether suberoylanilide hydroxamic acid (SAHA), a HDAC inhibitor, could enhance the anti-tumor effects of olaparib on breast cancer cell lines using a cytotoxic assay, cell cycle analysis, and Western blotting.  We evaluated how exposure to SAHA affects the expression of HRR-associated genes.  The accumulation of DNA double strand breaks (DSBs) induced by combination treatment was assessed.  Induction of autophagy was monitored by imaging green fluorescent protein-tagged microtubule-associated protein 1A/1B-light chain 3 (LC3) expression following co-treatment with olaparib and SAHA.  These in vitro data were validated in vivo using a human breast cancer xenograft model.  RESULTS:  Triple-negative breast cancer cell (TNBC) lines showed heterogeneous responses to the PARP and HDAC inhibitors.  Co-administration of olaparib and SAHA synergistically inhibited the growth of TNBC cells that expressed functional Phosphatase and tensin homolog (PTEN).  This effect was associated with down-regulation of the proliferative signaling pathway, increased apoptotic and autophagic cell death, and accumulation of DNA damage.  The combined anti-tumor effect of olaparib and SAHA was also observed in a xenograft model.  These data suggest that PTEN expression in TNBC cells can sensitize the cell response to simultaneous inhibition of PARP and HDAC both in vitro and in vivo.  CONCLUSION:  Our findings suggest that expression of functional PTEN may serve as a biomarker for selecting TNBC patients that would favorably respond to a combination of olaparib with SAHA.  This provides a strong rationale for treating TNBC patients with PTEN expression with a combination therapy consisting of olaparib and SAHA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTcCnK6c-02m0bxh97K6Vt6fW6udTcc2ebcSSUCX2kBtrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjltlWguw%253D%253D&md5=4d900b24ef95ff4fca352dc27cdc2865</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1186%2Fs13058-015-0534-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-015-0534-y%26sid%3Dliteratum%253Aachs%26aulast%3DMin%26aufirst%3DA.%26aulast%3DIm%26aufirst%3DS.-A.%26aulast%3DKim%26aufirst%3DD.%2BK.%26aulast%3DSong%26aufirst%3DS.-H.%26aulast%3DKim%26aufirst%3DH.-J.%26aulast%3DLee%26aufirst%3DK.-H.%26aulast%3DKim%26aufirst%3DT.-Y.%26aulast%3DHan%26aufirst%3DS.-W.%26aulast%3DOh%26aufirst%3DD.-Y.%26aulast%3DKim%26aufirst%3DT.-Y.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ%26aulast%3DBang%26aufirst%3DY.-J.%26atitle%3DHistone%2520deacetylase%2520inhibitor%252C%2520suberoylanilide%2520hydroxamic%2520acid%2520%2528SAHA%2529%252C%2520enhances%2520anti-tumor%2520effects%2520of%2520the%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%2520olaparib%2520in%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2015%26volume%3D17%26spage%3D33%26epage%3D43%26doi%3D10.1186%2Fs13058-015-0534-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shabason, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tofilon, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camphausen, K.</span></span> <span> </span><span class="NLM_article-title">Grand rounds at the national institutes of health: HDAC inhibitors as radiation modifiers, from bench to clinic</span>. <i>J. Cell Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2735</span>– <span class="NLM_lpage">2744</span>, <span class="refDoi"> DOI: 10.1111/j.1582-4934.2011.01296.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1111%2Fj.1582-4934.2011.01296.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=21362133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FivFamsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=2735-2744&author=J.+E.+Shabasonauthor=P.+J.+Tofilonauthor=K.+Camphausen&title=Grand+rounds+at+the+national+institutes+of+health%3A+HDAC+inhibitors+as+radiation+modifiers%2C+from+bench+to+clinic&doi=10.1111%2Fj.1582-4934.2011.01296.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic</span></div><div class="casAuthors">Shabason Jacob E; Tofilon Philip J; Camphausen Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of cellular and molecular medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2735-44</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumour.  Patients afflicted with this disease unfortunately have a very poor prognosis, and fewer than 5% of patients survive for 5 years from the time of diagnosis.  Therefore, improved therapies to treat this disease are sorely needed.  One such class of drugs that have generated great enthusiasm for the treatment of numerous malignancies, including GBM, is histone deacetylase (HDAC) inhibitors.  Pre-clinical data have demonstrated the efficacy of various HDAC inhibitors as anticancer agents, with the greatest effects shown when HDAC inhibitors are used in combination with other therapies.  As a result of encouraging pre-clinical data, numerous HDAC inhibitors are under investigation in clinical trials, either as monotherapies or in conjunction with other treatments such as chemotherapy, biologic therapy or radiation therapy.  In fact, two actively studied HDAC inhibitors, vorinostat and depsipeptide, were recently approved for the treatment of refractory cutaneous T cell lymphoma.  In this review, we first present a patient with GBM, and then discuss the pathogenesis, epidemiology and current treatment options of GBM.  Finally, we examine the translation of pre-clinical studies that have demonstrated HDAC inhibitors as potent radiosensitizers in in vitro and in vivo models, to a phase II clinical trial combining the HDAC inhibitor, valproic acid, along with temozolomide and radiation therapy for the treatment of GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTjaDavY9o611WTCLT8lX9SfW6udTcc2eamkMM4KPWfRrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FivFamsQ%253D%253D&md5=900afc5aca3a58eec21afb25e3c78e92</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1111%2Fj.1582-4934.2011.01296.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1582-4934.2011.01296.x%26sid%3Dliteratum%253Aachs%26aulast%3DShabason%26aufirst%3DJ.%2BE.%26aulast%3DTofilon%26aufirst%3DP.%2BJ.%26aulast%3DCamphausen%26aufirst%3DK.%26atitle%3DGrand%2520rounds%2520at%2520the%2520national%2520institutes%2520of%2520health%253A%2520HDAC%2520inhibitors%2520as%2520radiation%2520modifiers%252C%2520from%2520bench%2520to%2520clinic%26jtitle%3DJ.%2520Cell%2520Mol.%2520Med.%26date%3D2011%26volume%3D15%26spage%3D2735%26epage%3D2744%26doi%3D10.1111%2Fj.1582-4934.2011.01296.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radany, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. Y.</span></span> <span> </span><span class="NLM_article-title">HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells</span>. <i>Cancer Biother.Radiopharm.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">689</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.1089/cbr.2009.0629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1089%2Fcbr.2009.0629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=20025549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisV2msA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2009&pages=689-699&author=X.+Chenauthor=P.+Wongauthor=E.+Radanyauthor=J.+Y.+Wong&title=HDAC+inhibitor%2C+valproic+acid%2C+induces+p53-dependent+radiosensitization+of+colon+cancer+cells&doi=10.1089%2Fcbr.2009.0629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC Inhibitor, Valproic Acid, Induces p53-Dependent Radiosensitization of Colon Cancer Cells</span></div><div class="casAuthors">Chen, Xufeng; Wong, Patty; Radany, Eric; Wong, Jeffrey Y. C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biotherapy and Radiopharmaceuticals</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">689-699</span>CODEN:
                <span class="NLM_cas:coden">CBRAFJ</span>;
        ISSN:<span class="NLM_cas:issn">1084-9785</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Agents that inhibit histone deacetylases (HDAC inhibitors) have been shown to enhance radiation response.  The aim of this study was to evaluate the effects of low, minimally cytotoxic concns. of the HDAC inhibitor, valproic acid (VPA), on radiation response of colorectal cancer cells.  Cell lines LS174T and an isogenic pair of HCT116, which differed only for the presence of wild-type p53, were exposed to ionizing radiation (IR) alone, VPA alone, or the combination.  Clonogenic survival, γ-H2AX induction, apoptosis, changes in mitochondrial membrane potential, and mitochondrial levels of p53 and Bcl-2 family proteins were assessed.  In vivo studies monitored tumor growth suppression after therapy in mice bearing HCT116/p53+/+ and HCT116/p53-/- tumor xenografts.  VPA led to radiosensitization, which was dependent on p53 status.  A decrease in clonogenic survival, an increase in apoptosis, and an increase in levels of γ-H2AX were obsd. after VPA+IR, compared to IR alone, in wild-type p53 cells (LS174T and HCT116/p53+/+), as opposed to p53 null cells (HCT116/p53-/-).  Exposure to VPA resulted in enhancement of IR-induced mitochondrial localizations of Bax and Bcl-xL, mitochondrial membrane potential, and cytochrome c release only in wild-type p53 cell lines.  VPA also enhanced tumor growth suppression after IR only in wild-type p53 xenografts.  These data suggest that VPA may have an important role in enhancing radiotherapy response in colorectal cancer, particularly in tumors with the wild-type p53 genotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZAQL3MuzBYLVg90H21EOLACvtfcHk0lh0zSRjKEnbBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisV2msA%253D%253D&md5=fd501482186b5221594a428b4668692b</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1089%2Fcbr.2009.0629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fcbr.2009.0629%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DP.%26aulast%3DRadany%26aufirst%3DE.%26aulast%3DWong%26aufirst%3DJ.%2BY.%26atitle%3DHDAC%2520inhibitor%252C%2520valproic%2520acid%252C%2520induces%2520p53-dependent%2520radiosensitization%2520of%2520colon%2520cancer%2520cells%26jtitle%3DCancer%2520Biother.Radiopharm.%26date%3D2009%26volume%3D24%26spage%3D689%26epage%3D699%26doi%3D10.1089%2Fcbr.2009.0629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuneo, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallahan, D. E.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase (HDAC) inhibitor LBH589 increases duration of γ-H2AX Foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">11298</span>– <span class="NLM_lpage">11304</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-0049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F0008-5472.CAN-06-0049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=17145876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1KnsLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=11298-11304&author=L.+Gengauthor=K.+C.+Cuneoauthor=A.+Fuauthor=T.+Tuauthor=P.+W.+Atadjaauthor=D.+E.+Hallahan&title=Histone+deacetylase+%28HDAC%29+inhibitor+LBH589+increases+duration+of+%CE%B3-H2AX+Foci+and+confines+HDAC4+to+the+cytoplasm+in+irradiated+non-small+cell+lung+cancer&doi=10.1158%2F0008-5472.CAN-06-0049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase (HDAC) Inhibitor LBH589 Increases Duration of γ-H2AX Foci and Confines HDAC4 to the Cytoplasm in Irradiated Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Geng, Ling; Cuneo, Kyle C.; Fu, Allie; Tu, Tianxiang; Atadja, Peter W.; Hallahan, Dennis E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">11298-11304</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Histone deacetylases (HDAC) have been identified as therapeutic targets due to their regulatory function in DNA structure and organization.  LBH589 is a novel inhibitor of class I and II HDACs.  We studied the effect of LBH589 and ionizing radiation (IR) on DNA repair in two human non-small cell lung cancer (NSCLC) cell lines (H23 and H460). γ-H2AX foci present at DNA double-strand breaks (DSBs) were detected in the nuclei following 3 Gy irradn. for up to 6 h.  LBH589 administered before irradn. increased the duration of γ-H2AX foci beyond 24 h.  Furthermore, radiation alone induced translocation of HDAC4 to the nucleus.  In contrast, treatment with LBH589 followed by irradn. resulted in HDAC4 confinement to the cytoplasm, indicating that HDAC inhibition affects the nuclear localization of HDAC4.  The findings that LBH589 confines HDAC4 to the cytoplasm and increases the duration of γ-H2AX foci in irradiated cell lines suggest that HDAC4 participates in DNA damage signaling following IR.  Annexin-propidium iodide flow cytometry assays, cell morphol. studies, and cleaved caspase-3 Western blot anal. revealed a synergistic effect of LBH589 with IR in inducing apoptosis.  Clonogenic survival showed a greater than additive effect when LBH589 was administered before irradn. compared with irradn. alone.  In vivo tumor vol. studies showed a growth delay of 20 days with combined treatment compared with 4 and 2 days for radiation or LBH589 alone.  This study identifies HDAC4 as a biomarker of LBH589 activity and recognizes the ability of LBH589 to sensitize human NSCLC to radiation-induced DNA DSBs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouEeNKS1UEXLVg90H21EOLACvtfcHk0ljunGPlS-PSow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1KnsLzO&md5=b98e5802498e26f3201f6ed68c88804d</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-0049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-0049%26sid%3Dliteratum%253Aachs%26aulast%3DGeng%26aufirst%3DL.%26aulast%3DCuneo%26aufirst%3DK.%2BC.%26aulast%3DFu%26aufirst%3DA.%26aulast%3DTu%26aufirst%3DT.%26aulast%3DAtadja%26aufirst%3DP.%2BW.%26aulast%3DHallahan%26aufirst%3DD.%2BE.%26atitle%3DHistone%2520deacetylase%2520%2528HDAC%2529%2520inhibitor%2520LBH589%2520increases%2520duration%2520of%2520%25CE%25B3-H2AX%2520Foci%2520and%2520confines%2520HDAC4%2520to%2520the%2520cytoplasm%2520in%2520irradiated%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D11298%26epage%3D11304%26doi%3D10.1158%2F0008-5472.CAN-06-0049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anupama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurland, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobbs, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismail, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyn, R. E.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">4912</span>– <span class="NLM_lpage">4922</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1078-0432.CCR-04-2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16000590" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=4912-4922&author=M.+Anupamaauthor=J.+F.+Kurlandauthor=T.+Nishikawaauthor=T.+Tanakaauthor=M.+L.+Hobbsauthor=S.+L.+Tuckerauthor=S.+Ismailauthor=C.+Stevensauthor=R.+E.+Meyn&title=Histone+deacetylase+inhibitors+radiosensitize+human+melanoma+cells+by+suppressing+DNA+repair+activity&doi=10.1158%2F1078-0432.CCR-04-2088"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-2088%26sid%3Dliteratum%253Aachs%26aulast%3DAnupama%26aufirst%3DM.%26aulast%3DKurland%26aufirst%3DJ.%2BF.%26aulast%3DNishikawa%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DHobbs%26aufirst%3DM.%2BL.%26aulast%3DTucker%26aufirst%3DS.%2BL.%26aulast%3DIsmail%26aufirst%3DS.%26aulast%3DStevens%26aufirst%3DC.%26aulast%3DMeyn%26aufirst%3DR.%2BE.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520radiosensitize%2520human%2520melanoma%2520cells%2520by%2520suppressing%2520DNA%2520repair%2520activity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D4912%26epage%3D4922%26doi%3D10.1158%2F1078-0432.CCR-04-2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marmion, C. J.</span></span> <span> </span><span class="NLM_article-title">A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">6735</span>– <span class="NLM_lpage">6737</span>, <span class="refDoi"> DOI: 10.1039/b916715c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1039%2Fb916715c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=19885462" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2009&pages=6735-6737&author=D.+Griffithauthor=M.+P.+Morganauthor=C.+J.+Marmion&title=A+novel+anti-cancer+bifunctional+platinum+drug+candidate+with+dual+DNA+binding+and+histone+deacetylase+inhibitory+activity&doi=10.1039%2Fb916715c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1039%2Fb916715c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb916715c%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DD.%26aulast%3DMorgan%26aufirst%3DM.%2BP.%26aulast%3DMarmion%26aufirst%3DC.%2BJ.%26atitle%3DA%2520novel%2520anti-cancer%2520bifunctional%2520platinum%2520drug%2520candidate%2520with%2520dual%2520DNA%2520binding%2520and%2520histone%2520deacetylase%2520inhibitory%2520activity%26jtitle%3DChem.%2520Commun.%26date%3D2009%26volume%3D44%26spage%3D6735%26epage%3D6737%26doi%3D10.1039%2Fb916715c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Q.</span></span> <span> </span><span class="NLM_article-title">Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">344</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1039/C7MD00476A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1039%2FC7MD00476A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=30108928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVCjs7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=344-352&author=R.+Xieauthor=P.+Tangauthor=Q.+Yuan&title=Rational+design+and+characterization+of+a+DNA%2FHDAC+dual-targeting+inhibitor+containing+nitrogen+mustard+and+2-aminobenzamide+moieties&doi=10.1039%2FC7MD00476A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties</span></div><div class="casAuthors">Xie, Rui; Tang, Pingwah; Yuan, Qipeng</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">344-352</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) play a key role not only in gene expression but also in DNA repair.  Herein, we report the rational design and characterization of a compd. named chlordinaline contg. nitrogen mustard and 2-aminobenzamide moieties as a DNA/HDAC dual-targeting inhibitor.  Chlordinaline exhibited moderate total HDAC inhibitory activity.  The HDAC isoform selectivity assay indicated that chlordinaline mostly inhibits HDAC3.  Chlordinaline exhibited both DNA and HDAC inhibitory activities and showed potent antiproliferative activity against all the six test cancer cell lines with IC50 values of as low as 3.1-14.2μM, which is significantly more potent than ref. drugs chlorambucil and tacedinaline.  Chlordinaline could induce the apoptosis and G2/M phase cell cycle arrest of A375 cancer cells.  This study demonstrates that combining nitrogen mustard and 2-aminobenzamide moieties into one mol. is an effective method to obtain DNA/HDAC dual-targeting inhibitors as potent antitumor agents.  Chlordinaline as the first example of such DNA/HDAC dual-targeting inhibitors could be a promising candidate for cancer therapy and could also be a lead compd. for further optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNSMpT4AGIdrVg90H21EOLACvtfcHk0liuE2RBt2PFDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVCjs7rO&md5=c1c9111452f0ecaec88ebc56bb1d4c80</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1039%2FC7MD00476A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00476A%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DR.%26aulast%3DTang%26aufirst%3DP.%26aulast%3DYuan%26aufirst%3DQ.%26atitle%3DRational%2520design%2520and%2520characterization%2520of%2520a%2520DNA%252FHDAC%2520dual-targeting%2520inhibitor%2520containing%2520nitrogen%2520mustard%2520and%25202-aminobenzamide%2520moieties%26jtitle%3DMedChemComm%26date%3D2018%26volume%3D9%26spage%3D344%26epage%3D352%26doi%3D10.1039%2FC7MD00476A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Q.</span></span> <span> </span><span class="NLM_article-title">Rational design, synthesis and preliminary antitumor activity evaluation of a chlorambucil derivative with potent DNA/HDAC dual-targeting inhibitory activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4415</span>– <span class="NLM_lpage">4420</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bmcl.2017.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=28818449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlCnsLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=4415-4420&author=R.+Xieauthor=Y.+Liauthor=P.+Tangauthor=Q.+Yuan&title=Rational+design%2C+synthesis+and+preliminary+antitumor+activity+evaluation+of+a+chlorambucil+derivative+with+potent+DNA%2FHDAC+dual-targeting+inhibitory+activity&doi=10.1016%2Fj.bmcl.2017.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design, synthesis and preliminary antitumor activity evaluation of a chlorambucil derivative with potent DNA/HDAC dual-targeting inhibitory activity</span></div><div class="casAuthors">Xie, Rui; Li, Yan; Tang, Pingwah; Yuan, Qipeng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4415-4420</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) play a pivotal role not only in gene expression but also in DNA repair.  Herein, we report the successful design, synthesis and evaluation of a chlorambucil deriv. named vorambucil with a hydroxamic acid tail as a DNA/HDAC dual-targeting inhibitor.  Vorambucil obtained both potent DNA and HDACs inhibitory activities.  Mol. docking results supported the initial pharmacophoric hypothesis and rationalized the potent inhibitory activity of vorambucil against HDAC1, HDAC2 and HDAC6.  Vorambucil showed potent antiproliferative activity against all the test four cancer cell lines with IC50 values of as low as 3.2-6.2 μM and exhibited 5.0-18.3-fold enhanced antiproliferative activity than chlorambucil.  Vorambucil also significantly inhibits colony formation of A375 cancer cells.  Further investigation showed that vorambucil remarkably induced apoptosis and arrested the cell cycle of A375 cells at G2/M phase.  Vorambucil could be a promising candidate and a useful tool to elucidate the role of those DNA/HDAC dual-targeting inhibitors for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofN9CuOj7Rs7Vg90H21EOLACvtfcHk0lh7IUY7nqXkvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlCnsLfF&md5=07ec0652478936d105d7a7b7cad74d0d</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DP.%26aulast%3DYuan%26aufirst%3DQ.%26atitle%3DRational%2520design%252C%2520synthesis%2520and%2520preliminary%2520antitumor%2520activity%2520evaluation%2520of%2520a%2520chlorambucil%2520derivative%2520with%2520potent%2520DNA%252FHDAC%2520dual-targeting%2520inhibitory%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D4415%26epage%3D4420%26doi%3D10.1016%2Fj.bmcl.2017.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallasch, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemann, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span> <span> </span><span class="NLM_article-title">A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">449</span>, <span class="refDoi"> DOI: 10.15252/emmm.201404580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.15252%2Femmm.201404580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25759362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVKjsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=438-449&author=C.+Liuauthor=H.+Dingauthor=X.+Liauthor=C.+P.+Pallaschauthor=L.+Hongauthor=D.+Guoauthor=Y.+Chenauthor=D.+Wangauthor=W.+Wangauthor=Y.+Wangauthor=M.+T.+Hemannauthor=H.+Jiang&title=A+DNA%2FHDAC+dual-targeting+drug+CY190602+with+significantly+enhanced+anticancer+potency&doi=10.15252%2Femmm.201404580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency</span></div><div class="casAuthors">Liu, Chuan; Ding, Hongyu; Li, Xiaoxi; Pallasch, Christian P.; Hong, Liya; Guo, Dianwu; Chen, Yi; Wang, Difei; Wang, Wei; Wang, Yajie; Hemann, Michael T.; Jiang, Hai</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">438-449</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Genotoxic drugs constitute a major treatment modality for human cancers; however, cancer cells' intrinsic DNA repair capability often increases the threshold of lethality and renders these drugs ineffective.  The emerging roles of HDACs in DNA repair provide new opportunities for improving traditional genotoxic drugs.  Here, we report the development and characterization of CY190602, a novel bendamustine-derived drug with significantly enhanced anticancer potency.  We show that CY190602's enhanced potency can be attributed to its newly gained ability to inhibit HDACs.  Using this novel DNA/HDAC dual-targeting drug as a tool, we further explored HDAC's role in DNA repair.  We found that HDAC activities are essential for the expression of several genes involved in DNA synthesis and repair, including TYMS, Tip60, CBP, EP300, and MSL1.  Importantly, CY190602, the first-in-class example of such DNA/HDAC dual-targeting drugs, exhibited significantly enhanced anticancer activity in vitro and in vivo.  These findings provide rationales for incorporating HDAC inhibitory moieties into genotoxic drugs, so as to overcome the repair capacity of cancer cells.  Systematic development of similar DNA/HDAC dual-targeting drugs may represent a novel opportunity for improving cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5b1gqThxGiLVg90H21EOLACvtfcHk0lh7IUY7nqXkvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVKjsLg%253D&md5=9e0c4cf0099a474e9ddbb1f87ec8a73d</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.15252%2Femmm.201404580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Femmm.201404580%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DPallasch%26aufirst%3DC.%2BP.%26aulast%3DHong%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHemann%26aufirst%3DM.%2BT.%26aulast%3DJiang%26aufirst%3DH.%26atitle%3DA%2520DNA%252FHDAC%2520dual-targeting%2520drug%2520CY190602%2520with%2520significantly%2520enhanced%2520anticancer%2520potency%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2015%26volume%3D7%26spage%3D438%26epage%3D449%26doi%3D10.15252%2Femmm.201404580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span> <span> </span><span class="NLM_article-title">Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4100</span>– <span class="NLM_lpage">4109</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.05.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bmc.2017.05.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=28601509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpslGntbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=4100-4109&author=Z.+Yuanauthor=S.+Chenauthor=Q.+Sunauthor=N.+Wangauthor=D.+Liauthor=S.+Miaoauthor=C.+Gaoauthor=Y.+Chenauthor=C.+Tanauthor=Y.+Jiang&title=Olaparib+hydroxamic+acid+derivatives+as+dual+PARP+and+HDAC+inhibitors+for+cancer+therapy&doi=10.1016%2Fj.bmc.2017.05.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy</span></div><div class="casAuthors">Yuan, Zigao; Chen, Shaopeng; Sun, Qinsheng; Wang, Ning; Li, Dan; Miao, Shuangshuang; Gao, Chunmei; Chen, Yuzong; Tan, Chunyan; Jiang, Yuyang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4100-4109</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Olaparib was the first PARP inhibitor approved by the FDA for patients with BRCA-mutated ovarian cancer.  Recent studies have demonstrated enhanced anticancer effects of combination therapy consisting of olaparib and HDAC inhibitors.  Herein, based on rational drug design strategy, hydroxamic acid derivs. of olaparib were constructed as dual PARP and HDAC inhibitors.  These hybrid compds. showed potent inhibitory activities against PARP1/2 and HDAC1/6 with IC50 values in the nanomolar range.  Furthermore, compd. P1 exhibited broad-spectrum antiproliferative activities in selected human cancer cell lines.  Specially, P1 showed more potent activity than olaparib and SAHA in cancer cells MDA-MB-231, HCC1937 and Raji, and 4.1-fold less cytotoxicity compared with SAHA to normal cells MCF-10A.  Further mechanism study indicated that P1 could induce the cleavage of PARP and the hyperacetylation of histones, increase the expression of DNA damage biomarker γ-H2AX, decrease the level of BRCA1 and RAD51, and regulate tumor cell growth and apoptosis through modulating both mitochondrial- and death receptor-mediated pathways.  Therefore, our study suggested that compds. targeting PARP and HDAC concurrently might be a practical approach for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4Q6j2BUCmTrVg90H21EOLACvtfcHk0lh7IUY7nqXkvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpslGntbY%253D&md5=ac79d6e4d730eeefc1eda749823c80d5</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.05.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.05.058%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DMiao%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DY.%26atitle%3DOlaparib%2520hydroxamic%2520acid%2520derivatives%2520as%2520dual%2520PARP%2520and%2520HDAC%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D4100%26epage%3D4109%26doi%3D10.1016%2Fj.bmc.2017.05.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J.</span></span> <span> </span><span class="NLM_article-title">JAK kinases in health and disease: an update</span>. <i>Open Rheumatol. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">244</span>, <span class="refDoi"> DOI: 10.2174/1874312901206010232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.2174%2F1874312901206010232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=23028408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1equrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=232-244&author=A.+Laurenceauthor=M.+Pesuauthor=O.+Silvennoinenauthor=J.+O%E2%80%99Shea&title=JAK+kinases+in+health+and+disease%3A+an+update&doi=10.2174%2F1874312901206010232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">JAK kinases in health and disease: an update</span></div><div class="casAuthors">Laurence, Arian; Pesu, Marko; Silvennoinen, Olli; O'Shea, John</div><div class="citationInfo"><span class="NLM_cas:title">Open Rheumatology Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">232-244</span>CODEN:
                <span class="NLM_cas:coden">ORJPAP</span>;
        ISSN:<span class="NLM_cas:issn">1874-3129</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Janus kinases (JAKs) are crit. signaling elements for a large subset of cytokines.  As a consequence they play pivotal roles in the pathophysiol. of many diseases including neoplastic and autoimmune diseases.  Small mol. JAK inhibitors as therapeutic agents have become a reality and the palette of such inhibitors will likely expand.  This review will summarize our current knowledge on these key enzymes and their assocd. pharmaceutical inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjovQnlyAQvrVg90H21EOLACvtfcHk0lixlDrT1KRdAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1equrjO&md5=ed5d20df39001bb27ca8556cae82c289</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.2174%2F1874312901206010232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1874312901206010232%26sid%3Dliteratum%253Aachs%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%26atitle%3DJAK%2520kinases%2520in%2520health%2520and%2520disease%253A%2520an%2520update%26jtitle%3DOpen%2520Rheumatol.%2520J.%26date%3D2012%26volume%3D6%26spage%3D232%26epage%3D244%26doi%3D10.2174%2F1874312901206010232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plenge, R.</span></span> <span> </span><span class="NLM_article-title">JAK and STAT signaling molecules in immunoregulation and immune-mediated disease</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">550</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2012.03.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.immuni.2012.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=22520847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFWqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=542-550&author=J.+O%E2%80%99Sheaauthor=R.+Plenge&title=JAK+and+STAT+signaling+molecules+in+immunoregulation+and+immune-mediated+disease&doi=10.1016%2Fj.immuni.2012.03.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease</span></div><div class="casAuthors">O'Shea, John J.; Plenge, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">542-550</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The discovery of the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway, a landmark in cell biol., provided a simple mechanism for gene regulation that dramatically advanced our understanding of the action of hormones, interferons, colony-stimulating factors, and interleukins.  As we learn more about the complexities of immune responses, new insights into the functions of this pathway continue to be revealed, aided by technol. that permits genome-wide views.  As we celebrate the 20th anniversary of the discovery of this paradigm in cell signaling, it is particularly edifying to see how this knowledge has rapidly been translated to human immune disease.  Not only have genome-wide assocn. studies demonstrated that this pathway is highly relevant to human autoimmunity, but targeting JAKs is now a reality in immune-mediated disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc6dj5Zf9fdLVg90H21EOLACvtfcHk0lixlDrT1KRdAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFWqt7g%253D&md5=de187a0555549f9f00f5a41052c05352</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2012.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2012.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%26aulast%3DPlenge%26aufirst%3DR.%26atitle%3DJAK%2520and%2520STAT%2520signaling%2520molecules%2520in%2520immunoregulation%2520and%2520immune-mediated%2520disease%26jtitle%3DImmunity%26date%3D2012%26volume%3D36%26spage%3D542%26epage%3D550%26doi%3D10.1016%2Fj.immuni.2012.03.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shuai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">Regulation of JAK–STAT signalling in the immune system</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">900</span>– <span class="NLM_lpage">911</span>, <span class="refDoi"> DOI: 10.1038/nri1226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnri1226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=14668806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=900-911&author=K.+Shuaiauthor=B.+Liu&title=Regulation+of+JAK%E2%80%93STAT+signalling+in+the+immune+system&doi=10.1038%2Fnri1226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of JAK-STAT signalling in the immune system</span></div><div class="casAuthors">Shuai, Ke; Liu, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">900-911</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The cytokine-activated Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway has an important role in the control of immune responses.  Dysregulation of JAK-STAT signalling is assocd. with various immune disorders.  The signalling strength kinetics and specificity of the JAK-STAT pathway are modulated at many levels by distinct regulatory proteins.  Here, we review recent studies on the regulation of the JAK-STAT pathway that will enhance our ability to design rational therapeutic strategies for immune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDG-MzyqAi4bVg90H21EOLACvtfcHk0ljgBlyntLYD4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D&md5=cb04239e0d430052a975e930c656e31d</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1038%2Fnri1226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1226%26sid%3Dliteratum%253Aachs%26aulast%3DShuai%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DRegulation%2520of%2520JAK%25E2%2580%2593STAT%2520signalling%2520in%2520the%2520immune%2520system%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2003%26volume%3D3%26spage%3D900%26epage%3D911%26doi%3D10.1038%2Fnri1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klampfer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaby, L.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augenlicht, L.</span></span> <span> </span><span class="NLM_article-title">Requirement of histone deacetylase activity for signaling by STAT1</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">30358</span>– <span class="NLM_lpage">30368</span>, <span class="refDoi"> DOI: 10.1074/jbc.M401359200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1074%2Fjbc.M401359200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15123634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsFKiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=30358-30368&author=L.+Klampferauthor=J.+Huangauthor=L.-A.+Swabyauthor=L.+Augenlicht&title=Requirement+of+histone+deacetylase+activity+for+signaling+by+STAT1&doi=10.1074%2Fjbc.M401359200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement of Histone Deacetylase Activity for Signaling by STAT1</span></div><div class="casAuthors">Klampfer, Lidija; Huang, Jie; Swaby, Laurie-Anne; Augenlicht, Leonard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">30358-30368</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">STAT1 is a transcription factor that plays a crucial role in signaling by interferons (IFNs).  In this study the authors demonstrated that inhibitors of histone deacetylase (HDAC) activity, butyrate, trichostatin A, and suberoylanilide hydroxamic acid, prevented IFNγ-induced JAK1 activation, STAT1 phosphorylation, its nuclear translocation, and STAT1-dependent gene activation.  Furthermore, the authors showed that silencing of HDAC1, HDAC2, and HDAC3 through RNA interference markedly decreased IFNγ-driven gene activation and that overexpression of HDAC1, HDAC2, and HDAC3 enhanced STAT1-dependent transcriptional activity.  The authors' data therefore established the essential role of deacetylase activity in STAT1 signaling.  Induction of IRF-1 by IFNγ requires functional STAT1 signaling and was abrogated by butyrate, trichostatin A, suberoylanilide hydroxamic acid, and STAT1 small interfering RNA.  In contrast, silencing of STAT1 did not interfere with IFNγ-induced expression of STAT2 and caspase-7, and HDAC inhibitors did not preclude IFNγ-induced expression of STAT1, STAT2, and caspase-7, suggesting that HDAC inhibitors impede the expression of IFNγ target genes whose expression depends on STAT1 but do not interfere with STAT1-independent signaling by IFNγ.  Finally, the authors showed that inhibitors of deacetylase activity sensitized colon cancer cells to IFNγ-induced apoptosis through cooperative neg. regulation of Bcl-x expression, demonstrating that interruption of the balance between STAT1-dependent and STAT1-independent signaling significantly alters the biol. activity of IFNγ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4TaaFs2-6QrVg90H21EOLACvtfcHk0lhl1PVInPw_Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsFKiurg%253D&md5=4cab3911cd57a8b472d4b8e55f403335</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M401359200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M401359200%26sid%3Dliteratum%253Aachs%26aulast%3DKlampfer%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DSwaby%26aufirst%3DL.-A.%26aulast%3DAugenlicht%26aufirst%3DL.%26atitle%3DRequirement%2520of%2520histone%2520deacetylase%2520activity%2520for%2520signaling%2520by%2520STAT1%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D30358%26epage%3D30368%26doi%3D10.1074%2Fjbc.M401359200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.-m.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, L.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.-b.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, P.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, F.-j.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms</span>. <i>Exp. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">270</span>, <span class="refDoi"> DOI: 10.1016/j.exphem.2012.10.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.exphem.2012.10.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=23111066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVKnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=261-270&author=S.-m.+Gaoauthor=C.-q.+Chenauthor=L.-y.+Wangauthor=L.-l.+Hongauthor=J.-b.+Wuauthor=P.-h.+Dongauthor=F.-j.+Yu&title=Histone+deacetylases+inhibitor+sodium+butyrate+inhibits+JAK2%2FSTAT+signaling+through+upregulation+of+SOCS1+and+SOCS3+mediated+by+HDAC8+inhibition+in+myeloproliferative+neoplasms&doi=10.1016%2Fj.exphem.2012.10.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms</span></div><div class="casAuthors">Gao, Shen-meng; Chen, Chi-qi; Wang, Lu-yao; Hong, Li-li; Wu, Jian-bo; Dong, Pei-hong; Yu, Fu-jun</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Hematology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">261-270.e4</span>CODEN:
                <span class="NLM_cas:coden">EXHMA6</span>;
        ISSN:<span class="NLM_cas:issn">0301-472X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Constitutive activation of Janus kinase 2/signal transducers and activators of transcription (JAK2/STAT) signaling has an important role in the oncogenesis of myeloproliferative neoplasms (MPNs) and leukemia.  Histone deacetylases (HDACs) inhibitors have been reported to possess anticancer activity through different mechanisms.  However, whether HDACs inhibitors suppress JAK2/STAT signaling in MPNs is still unknown.  In this study, we show that the HDAC inhibitor sodium butyrate (SB) inhibited JAK2/STAT signaling and increased the expression of suppressors of cytokine signaling 1 (SOCS1) and SOCS3, both of which are the potent feedback inhibitors of JAK2/STAT signaling.  SB upregulated the expression of SOCS1 and SOCS3 by triggering the promoter-assocd. histone acetylation of SOCS1 and SOCS3 in K562 and HEL cell lines.  Importantly, we found that upon knockdown of each class I HDACs, only knockdown of HDAC8 resulted in the increased expression of SOCS1 and SOCS3.  Moreover, overexpression of SOCS1 and SOCS3 significantly inhibited cell growth and suppressed JAK2/STAT signaling in K562 and HEL cells.  Furthermore, SB increased the transcript levels of SOCS1 and SOCS3 and inhibited the clonogenic activity of hematopoietic progenitors from patients with MPNs.  Taken together, these data establish a new anticancer mechanism that SB inhibits JAK2/STAT signaling through HDAC8-mediated upregulation of SOCS1 and SOCS3.  Thus, HDACs inhibitors may have therapeutic potential for the treatment of MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUyHeZIFKSQrVg90H21EOLACvtfcHk0lg1Ohk0mBepKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVKnsg%253D%253D&md5=b57bcdeb8347c2b49060cacf3014a66f</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.exphem.2012.10.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exphem.2012.10.012%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DS.-m.%26aulast%3DChen%26aufirst%3DC.-q.%26aulast%3DWang%26aufirst%3DL.-y.%26aulast%3DHong%26aufirst%3DL.-l.%26aulast%3DWu%26aufirst%3DJ.-b.%26aulast%3DDong%26aufirst%3DP.-h.%26aulast%3DYu%26aufirst%3DF.-j.%26atitle%3DHistone%2520deacetylases%2520inhibitor%2520sodium%2520butyrate%2520inhibits%2520JAK2%252FSTAT%2520signaling%2520through%2520upregulation%2520of%2520SOCS1%2520and%2520SOCS3%2520mediated%2520by%2520HDAC8%2520inhibition%2520in%2520myeloproliferative%2520neoplasms%26jtitle%3DExp.%2520Hematol.%26date%3D2013%26volume%3D41%26spage%3D261%26epage%3D270%26doi%3D10.1016%2Fj.exphem.2012.10.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintás-Cardama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrov, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1124</span>– <span class="NLM_lpage">1127</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2012.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.leukres.2012.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=22475363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvF2hsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=1124-1127&author=A.+Quint%C3%A1s-Cardamaauthor=H.+Kantarjianauthor=Z.+Estrovauthor=G.+Borthakurauthor=J.+Cortesauthor=S.+Verstovsek&title=Therapy+with+the+histone+deacetylase+inhibitor+pracinostat+for+patients+with+myelofibrosis&doi=10.1016%2Fj.leukres.2012.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Kantarjian, Hagop; Estrov, Zeev; Borthakur, Gautam; Cortes, Jorge; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1124-1127</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Approx. half of the patients with myelofibrosis (MF) carry mutant JAK2V617F proteins.  JAK2V617F has been recently shown to translocate to the nucleus and modify specific histones, thus regulating transcription.  We report on a phase II study testing the activity and tolerability of the histone deacetylase inhibitor pracinostat given at 60 mg every other day for three weeks per mo in 22 patients with intermediate or high risk MF.  Eight (36%) patients experienced clin. benefit, with 6 (27%) experiencing redns. in splenomegaly (median 3 cm, range 1-4 cm).  According to International Working Group criteria, 2 (9%) patients had clin. improvement (anemia response in both cases).  The most frequent side effect assocd. to pracinostat therapy was fatigue, which occurred in 20 (91%) patients (grade 2 in 3 patients).  Grade 3-4 neutropenia, anemia, and thrombocytopenia occurred in 13%, 0%, and 21%, resp.  Twenty-one patients permanently discontinued pracinostat, mainly due to lack of efficacy.  In conclusion, pracinostat at the dose tested is reasonably tolerated and has modest activity in patients with MF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWKtgUKtLxerVg90H21EOLACvtfcHk0liYYCMVnbiU_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvF2hsr4%253D&md5=f91f89904ae5bc95102b7b533f2d598f</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2012.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2012.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DQuint%25C3%25A1s-Cardama%26aufirst%3DA.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DTherapy%2520with%2520the%2520histone%2520deacetylase%2520inhibitor%2520pracinostat%2520for%2520patients%2520with%2520myelofibrosis%26jtitle%3DLeuk.%2520Res.%26date%3D2012%26volume%3D36%26spage%3D1124%26epage%3D1127%26doi%3D10.1016%2Fj.leukres.2012.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel janus kinase (JAK) and histone deacetylase (HDAC) dual inhibitors for the treatment of hematological malignancies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3898</span>– <span class="NLM_lpage">3923</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01597</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvVSls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3898-3923&author=X.+Liangauthor=J.+Zangauthor=X.+Liauthor=S.+Tangauthor=M.+Huangauthor=M.+Gengauthor=C.+J.+Chouauthor=C.+Liauthor=Y.+Caoauthor=W.+Xuauthor=H.+Liuauthor=Y.+Zhang&title=Discovery+of+novel+janus+kinase+%28JAK%29+and+histone+deacetylase+%28HDAC%29+dual+inhibitors+for+the+treatment+of+hematological+malignancies&doi=10.1021%2Facs.jmedchem.8b01597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies</span></div><div class="casAuthors">Liang, Xuewu; Zang, Jie; Li, Xiaoyang; Tang, Shuai; Huang, Min; Geng, Meiyu; Chou, C. James; Li, Chunpu; Cao, Yichun; Xu, Wenfang; Liu, Hong; Zhang, Yingjie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3898-3923</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Concurrent inhibition of Janus kinase (JAK) and histone deacetylase (HDAC) could potentially improve the efficacy of the HDAC inhibitors in the treatment of cancers and resolve the problem of HDAC inhibitor resistance in some tumors.  Here, a novel series of pyrimidin-2-amino-pyrazol hydroxamate derivs. as JAK and HDAC dual inhibitors was designed, synthesized, and evaluated, among which I possessed potent and balanced activities against both JAK2 and HDAC6 with half-maximal inhibitory concn. at the nanomolar level. I exhibited improved antiproliferative and proapoptotic activities over SAHA and ruxolitinib in several hematol. cell lines.  Remarkably, I exhibited more potent antiproliferation effect than the combination of SAHA and ruxolitinib in HEL cells bearing JAK2V617F mutation.  Pharmacokinetic studies in mice showed that I possessed good bioavailability after i.p. administration.  Finally, I showed antitumor efficacy with no significant toxicity in a HEL xenograft model.  Collectively, the results confirm the therapeutic potential of JAK and HDAC dual inhibitors in hematol. malignancies and provide valuable leads for further structural optimization and antitumor mechanism study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOXlwxqcv7m7Vg90H21EOLACvtfcHk0lhTfizs2CEWYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvVSls7o%253D&md5=356363f40f24ac2ef32194e23a29328e</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01597%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DZang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DChou%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520novel%2520janus%2520kinase%2520%2528JAK%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520dual%2520inhibitors%2520for%2520the%2520treatment%2520of%2520hematological%2520malignancies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3898%26epage%3D3923%26doi%3D10.1021%2Facs.jmedchem.8b01597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Thi, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohlson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of ligand efficient dual inhibitors of janus kinase (JAK) and histone deacetylase (HDAC) based on ruxolitinib and vorinostat</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8336</span>– <span class="NLM_lpage">8357</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00678</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00678" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8336-8357&author=L.+Yaoauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+Singhauthor=M.+D.+Duong-Thiauthor=J.+X.+T.+Leeauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Y.+Yenauthor=S.+Ohlsonauthor=B.+W.+Dymock&title=Design+and+synthesis+of+ligand+efficient+dual+inhibitors+of+janus+kinase+%28JAK%29+and+histone+deacetylase+%28HDAC%29+based+on+ruxolitinib+and+vorinostat&doi=10.1021%2Facs.jmedchem.7b00678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat</span></div><div class="casAuthors">Yao, Lianbin; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Singh, Prachi; Duong-Thi, Minh-Dao; Lee, Jeannie X. T.; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Ohlson, Sten; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8336-8357</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Concomitant inhibition of multiple oncogenic pathways is a desirable goal in cancer therapy.  To achieve such an outcome with a single mol. would simplify treatment regimes.  Herein the core features of ruxolitinib, a marketed JAK1/2 inhibitor, have been merged with the HDAC inhibitor vorinostat, leading to new mols. that are bispecific targeted JAK/HDAC inhibitors.  A preferred pyrazole substituted pyrrolopyrimidine, I (R = H), inhibits JAK1 and HDACs 1, 2, 3, 6, and 10 with IC50 values of less than 20 nM, is <100 nM potent against JAK2 and HDAC11, and is selective for the JAK family against a panel of 97 kinases.  Broad cellular antiproliferative potency of I (R = H) is supported by demonstration of JAK-STAT and HDAC pathway blockade in hematol. cell lines.  Me analog I (R = Me) has an even more selective profile.  This study provides new leads for assessment of JAK and HDAC pathway dual inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocWx3JXIW8YbVg90H21EOLACvtfcHk0lgOh-_UKL9MOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ&md5=5ac471ee0cc413b08b926803790de7f9</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00678%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DL.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DDuong-Thi%26aufirst%3DM.%2BD.%26aulast%3DLee%26aufirst%3DJ.%2BX.%2BT.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%2BY.%26aulast%3DOhlson%26aufirst%3DS.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520ligand%2520efficient%2520dual%2520inhibitors%2520of%2520janus%2520kinase%2520%2528JAK%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520based%2520on%2520ruxolitinib%2520and%2520vorinostat%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8336%26epage%3D8357%26doi%3D10.1021%2Facs.jmedchem.7b00678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of janus kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors as a novel strategy for combinational treatment of leukemia and invasive fungal infections</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6056</span>– <span class="NLM_lpage">6074</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00393</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00393" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Snu7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6056-6074&author=Y.+Huangauthor=G.+Dongauthor=H.+Liauthor=N.+Liuauthor=W.+Zhangauthor=C.+Sheng&title=Discovery+of+janus+kinase+2+%28JAK2%29+and+histone+deacetylase+%28HDAC%29+dual+inhibitors+as+a+novel+strategy+for+combinational+treatment+of+leukemia+and+invasive+fungal+infections&doi=10.1021%2Facs.jmedchem.8b00393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections</span></div><div class="casAuthors">Huang, Yahui; Dong, Guoqiang; Li, Huanqiu; Liu, Na; Zhang, Wannian; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6056-6074</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Clin., leukemia patients often suffer from the limited efficacy of chemotherapy and high risks of infection by invasive fungal pathogens.  Herein, a novel therapeutic strategy was developed in which a small mol. can simultaneously treat leukemia and invasive fungal infections (IFIs).  Novel Janus kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors were identified to possess potent anti-proliferative activity toward hematol. cell lines and excellent synergistic effects with fluconazole to treat resistant Candida albicans infections.  In particular, compd. I, a highly active and selective JAK2/HDAC6 dual inhibitor, showed excellent in vivo antitumor efficacy in several acute myeloid leukemia (AML) models and synergized with fluconazole for the treatment of resistant C. albicans infections.  This study highlights the therapeutic potential of JAK2/HDAC dual inhibitors in treating AML and IFIs and provides an efficient strategy for multitargeting drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3_ii7EQG1qLVg90H21EOLACvtfcHk0lgOh-_UKL9MOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Snu7rN&md5=ba7cf74761120f0526ab520196e3dded</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00393%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520janus%2520kinase%25202%2520%2528JAK2%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520dual%2520inhibitors%2520as%2520a%2520novel%2520strategy%2520for%2520combinational%2520treatment%2520of%2520leukemia%2520and%2520invasive%2520fungal%2520infections%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6056%26epage%3D6074%26doi%3D10.1021%2Facs.jmedchem.8b00393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of janus kinase 2 (JAK2) and histone deacetlyase (HDAC) bispecific inhibitors based on pacritinib and evidence of dual pathway inhibition in hematological cell lines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8233</span>– <span class="NLM_lpage">8262</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00157</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00157" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8233-8262&author=E.+G.+Yangauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Yenauthor=B.+W.+Dymock&title=Design+and+synthesis+of+janus+kinase+2+%28JAK2%29+and+histone+deacetlyase+%28HDAC%29+bispecific+inhibitors+based+on+pacritinib+and+evidence+of+dual+pathway+inhibition+in+hematological+cell+lines&doi=10.1021%2Facs.jmedchem.6b00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</span></div><div class="casAuthors">Yang, Eugene Guorong; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8233-8262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Blockage of more than one oncoprotein or pathway is now a std. approach in modern cancer therapy.  Multiple inhibition is typically achieved with two or more drugs.  Herein the authors describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single mols. with both JAK and HDAC targeted inhibition.  A preferred ether hydroxamate, compd. 51 (11-(4-(N-hydroxyheptanamide)oxy)-[4,1,9]dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12-(27),16,21,23-decaene) inhibits JAK2 and HDAC6 with low nanomolar potency, is <100 nM potent against HDACs 2 and 10, sub-micromolar potent against HDACs 1, 8 and 11, and >50-fold selective for JAK2 in a panel of 97 kinases.  Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematol. cell lines, inhibition of colony formation in HEL cells, and anal. of apoptosis.  This study provides new tool compds. for further exploration of dual JAK-HDAC pathway inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeUHzB39AGWrVg90H21EOLACvtfcHk0lgOh-_UKL9MOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL&md5=aa9ae07a1ac1aa21d70ee0f24621fe82</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00157%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DE.%2BG.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520janus%2520kinase%25202%2520%2528JAK2%2529%2520and%2520histone%2520deacetlyase%2520%2528HDAC%2529%2520bispecific%2520inhibitors%2520based%2520on%2520pacritinib%2520and%2520evidence%2520of%2520dual%2520pathway%2520inhibition%2520in%2520hematological%2520cell%2520lines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8233%26epage%3D8262%26doi%3D10.1021%2Facs.jmedchem.6b00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu-Farseeva, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">619</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.09.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.ejmech.2018.09.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=30243158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOltL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2018&pages=593-619&author=Y.+Y.+Chu-Farseevaauthor=N.+Mustafaauthor=A.+Poulsenauthor=E.+C.+Tanauthor=J.+J.+Y.+Yenauthor=W.+J.+Chngauthor=B.+W.+Dymock&title=Design+and+synthesis+of+potent+dual+inhibitors+of+JAK2+and+HDAC+based+on+fusing+the+pharmacophores+of+XL019+and+vorinostat&doi=10.1016%2Fj.ejmech.2018.09.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat</span></div><div class="casAuthors">Chu-Farseeva, Yu-yi; Mustafa, Nurulhuda; Poulsen, Anders; Tan, Eng Chong; Yen, Jeffrey J. Y.; Chng, Wee Joo; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">593-619</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Specifically blocking more than one oncogenic pathway simultaneously in a cancer cell with a combination of different drugs is the mainstay of the majority of cancer treatments.  Being able to do this via two targeted pathways without inducing side effects through a general mechanism, such as chemotherapy, could bring benefit to patients.  In this work we describe a new dual inhibitor of the JAK-STAT and HDAC pathways through designing and developing two types of mol. based on the JAK2 selective inhibitor XL019 and the pan-HDAC inhibitor, vorinostat.  Both series of compds. had examples with low nanomolar JAK2 and HDAC1/6 inhibition.  In some cases good HDAC1 selectivity was achieved while retaining HDAC6 activity.  The obsd. potency is explained through mol. docking studies of all three enzymes.  One example, 69c had 16-25 fold selectivity against the three other JAK-family proteins JAK1, JAK3 and TYK2.  A no. of compds. had sub-micromolar potencies against a panel of 4 solid tumor cell lines and 4 hematol. cell lines with the most potent compd., 45h, having a cellular IC50 of 70 nM against the multiple myeloma cell line KMS-12-BM.  Evidence of both JAK and HDAC pathway inhibition is presented in Hela cells showing that both pathways are modulated.  Evidence of apoptosis with two compds. in 4 sold tumor cell lines is also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppP3twGjwSkLVg90H21EOLACvtfcHk0li3SZWmWyLb-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOltL%252FK&md5=a6a1456126270e44dfa2f28916f7b7c0</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.09.024%26sid%3Dliteratum%253Aachs%26aulast%3DChu-Farseeva%26aufirst%3DY.%2BY.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%2BY.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520potent%2520dual%2520inhibitors%2520of%2520JAK2%2520and%2520HDAC%2520based%2520on%2520fusing%2520the%2520pharmacophores%2520of%2520XL019%2520and%2520vorinostat%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D158%26spage%3D593%26epage%3D619%26doi%3D10.1016%2Fj.ejmech.2018.09.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Lockhart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forster, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishnan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greninger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellisen, L. W.</span></span> <span> </span><span class="NLM_article-title">Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0417</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F2159-8290.CD-12-0417" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=23274910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVOktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=324-337&author=L.+Heauthor=K.+Torres-Lockhartauthor=N.+Forsterauthor=S.+Ramakrishnanauthor=P.+Greningerauthor=M.+J.+Garnettauthor=U.+McDermottauthor=S.+M.+Rothenbergauthor=C.+H.+Benesauthor=L.+W.+Ellisen&title=Mcl-1+and+FBW7+control+a+dominant+survival+pathway+underlying+HDAC+and+Bcl-2+inhibitor+synergy+in+squamous+cell+carcinoma&doi=10.1158%2F2159-8290.CD-12-0417"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Mcl-1 and FBW7 Control a Dominant Survival Pathway Underlying HDAC and Bcl-2 Inhibitor Synergy in Squamous Cell Carcinoma</span></div><div class="casAuthors">He, Lei; Torres-Lockhart, Kristine; Forster, Nicole; Ramakrishnan, Saranya; Greninger, Patricia; Garnett, Mathew J.; McDermott, Ultan; Rothenberg, Stephen M.; Benes, Cyril H.; Ellisen, Leif W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">324-337</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Effective targeted therapeutics for squamous cell carcinoma (SCC) are lacking. Here, we uncover Mcl-1 as a dominant and tissue-specific survival factor in SCC1 providing a roadmap for a new therapeutic approach.  Treatment with the histone deacetylase (HDAC) inhibitor vorinostat regulates Bcl-2 family member expression to disable the Mcl-1 axis and thereby induce apoptosis in SCC cells.  Although Mcl-1 dominance renders SCC cells resistant to the BH3-mimetic ABT-7B7, vorinostat primes them for sensitivity to ABT-737 by shuttling Bim from Mcl-1 to Bcl-2/Bcl-xl, resulting in dramatic synergy for this combination and sustained tumor regression in vivo.  Moreover, somatic FBW7 mutation in SCC is assocd. with stabilized Mcl-1 and high Bim levels, resulting in a poor response to std. chemotherapy but a robust response to HDAC inhibitors and enhanced synergy with the combination vorinostat/ABT-737.  Collectively, our findings provide a biochem. rationale and predictive markers for the application of this therapeutic combination in SCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL6CPNc90gQbVg90H21EOLACvtfcHk0li3SZWmWyLb-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVOktLo%253D&md5=365514e02807e6feb57d255b910d7295</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0417%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DL.%26aulast%3DTorres-Lockhart%26aufirst%3DK.%26aulast%3DForster%26aufirst%3DN.%26aulast%3DRamakrishnan%26aufirst%3DS.%26aulast%3DGreninger%26aufirst%3DP.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DRothenberg%26aufirst%3DS.%2BM.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DEllisen%26aufirst%3DL.%2BW.%26atitle%3DMcl-1%2520and%2520FBW7%2520control%2520a%2520dominant%2520survival%2520pathway%2520underlying%2520HDAC%2520and%2520Bcl-2%2520inhibitor%2520synergy%2520in%2520squamous%2520cell%2520carcinoma%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D324%26epage%3D337%26doi%3D10.1158%2F2159-8290.CD-12-0417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minucci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelicci, P. G.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1038/nrc1779</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnrc1779" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16397526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1GgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=38-51&author=S.+Minucciauthor=P.+G.+Pelicci&title=Histone+deacetylase+inhibitors+and+the+promise+of+epigenetic+%28and+more%29+treatments+for+cancer&doi=10.1038%2Fnrc1779"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer</span></div><div class="casAuthors">Minucci, Saverio; Pelicci, Pier Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-51</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are considered to be among the most promising targets in drug development for cancer therapy, and first-generation histone deacetylase inhibitors (HDACi) are currently being tested in phase I/II clin. trials.  A wide-ranging knowledge of the role of HDACs in tumorigenesis, and of the action of HDACi, has been achieved.  However, several basic aspects are not yet fully understood.  Investigating these aspects in the context of what we now understand about HDACi action both in vitro and in vivo will further improve the design of optimized clin. protocols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxXiACZV1sK7Vg90H21EOLACvtfcHk0li3SZWmWyLb-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1GgsA%253D%253D&md5=384e1f8d676d61531e46843c060a9380</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1038%2Fnrc1779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1779%26sid%3Dliteratum%253Aachs%26aulast%3DMinucci%26aufirst%3DS.%26aulast%3DPelicci%26aufirst%3DP.%2BG.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520and%2520the%2520promise%2520of%2520epigenetic%2520%2528and%2520more%2529%2520treatments%2520for%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D38%26epage%3D51%26doi%3D10.1038%2Fnrc1779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forster, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ory, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellisen, L. W.</span></span> <span> </span><span class="NLM_article-title">Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">4373</span>– <span class="NLM_lpage">4379</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-0046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F0008-5472.CAN-11-0046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=21527555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlersLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=4373-4379&author=M.+R.+Ramseyauthor=L.+Heauthor=N.+Forsterauthor=B.+Oryauthor=L.+W.+Ellisen&title=Physical+association+of+HDAC1+and+HDAC2+with+p63+mediates+transcriptional+repression+and+tumor+maintenance+in+squamous+cell+carcinoma&doi=10.1158%2F0008-5472.CAN-11-0046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Physical Association of HDAC1 and HDAC2 with p63 Mediates Transcriptional Repression and Tumor Maintenance in Squamous Cell Carcinoma</span></div><div class="casAuthors">Ramsey, Matthew R.; He, Lei; Forster, Nicole; Ory, Benjamin; Ellisen, Leif W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4373-4379</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Squamous cell carcinoma (SCC) is a treatment-refractory subtype of human cancer arising from stratified epithelium of the skin, lung, esophagus, oropharynx, and other tissues.  A unifying feature of SCC is high-level expression of the p53-related protein p63 (TP63) in 80% of cases.  The major protein isoform of p63 expressed in SCC is ΔNp63α, an N-terminally truncated form which functions as a key SCC cell survival factor by mechanisms that are unclear.  In this study, the authors show that ΔNp63α assocs. with histone deacetylase 1 (HDAC1) and HDAC2 to form an active transcriptional repressor complex that can be targeted to therapeutic advantage.  Repression of proapoptotic Bcl-2 family member genes including p53 upregulated modulator of apoptosis (PUMA) by p63/HDAC is required for survival of SCC cells.  Cisplatin chemotherapy, a mainstay of SCC treatment, promotes dissocn. of p63 and HDAC from the PUMA promoter, leading to increased histone acetylation, PUMA activation, and apoptosis.  These effects are recapitulated upon targeting the p63/HDAC complex selectively with class I/II HDAC inhibitors using both in vitro and in vivo models.  Sensitivity to HDAC inhibition is directly correlated with p63 expression and is abrogated in tumor cells that overexpress endogenous Bcl-2.  Together, the authors' results elucidate a mechanism of p63-mediated transcriptional repression and they identify the ΔNp63α/HDAC complex as an essential tumor maintenance factor in SCC.  In addn., the authors' findings offer a rationale to apply HDAC inhibitors for SCC treatment.  Cancer Res; 71(13); 4373-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPdcU7ineSrrVg90H21EOLACvtfcHk0lg4WQ6KDshZfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlersLk%253D&md5=4df165280fcfc0b929a81119c0a9ffee</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-0046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-0046%26sid%3Dliteratum%253Aachs%26aulast%3DRamsey%26aufirst%3DM.%2BR.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DForster%26aufirst%3DN.%26aulast%3DOry%26aufirst%3DB.%26aulast%3DEllisen%26aufirst%3DL.%2BW.%26atitle%3DPhysical%2520association%2520of%2520HDAC1%2520and%2520HDAC2%2520with%2520p63%2520mediates%2520transcriptional%2520repression%2520and%2520tumor%2520maintenance%2520in%2520squamous%2520cell%2520carcinoma%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D4373%26epage%3D4379%26doi%3D10.1158%2F0008-5472.CAN-11-0046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S.</span></span> <span> </span><span class="NLM_article-title">Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">6149</span>– <span class="NLM_lpage">6169</span>, <span class="refDoi"> DOI: 10.1128/MCB.01481-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1128%2FMCB.01481-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=19805519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsV2ltLbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2009&pages=6149-6169&author=S.+Chenauthor=Y.+Daiauthor=X.+Y.+Peiauthor=S.+Grant&title=Bim+upregulation+by+histone+deacetylase+inhibitors+mediates+interactions+with+the+Bcl-2+antagonist+ABT-737%3A+evidence+for+distinct+roles+for+Bcl-2%2C+Bcl-xL%2C+and+Mcl-1&doi=10.1128%2FMCB.01481-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1</span></div><div class="casAuthors">Chen, Shuang; Dai, Yun; Pei, Xin-Yan; Grant, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6149-6169</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The Bcl-2 antagonist ABT-737 kills transformed cells in assocn. with displacement of Bim from Bcl-2.  The histone deactetylase (HDAC) inhibitor suberoyl bis-hydroxamic acid (SBHA) was employed to det. whether and by what mechanism ABT-737 might interact with agents that upregulate Bim.  Expression profiling of BH3-only proteins indicated that SBHA increased Bim, Puma, and Noxa expression, while SBHA concns. that upregulated Bim significantly potentiated ABT-737 lethality.  Concordance between SBHA-mediated Bim upregulation and interactions with ABT-737 was obsd. in various human leukemia and myeloma cells.  SBHA-induced Bim was largely sequestered by Bcl-2 and Bcl-xL, rather than Mcl-1; ABT-737 attenuated these interactions, thereby triggering Bak/Bax activation and mitochondrial outer membrane permeabilization.  Knockdown of Bim (but not Puma or Noxa) by shRNA or ectopic overexpression of Bcl-2, Bcl-xL, or Mcl-1 diminished Bax/Bak activation and apoptosis.  Notably, ectopic expression of these antiapoptotic proteins disabled death signaling by sequestering different proapoptotic proteins, i.e., Bim by Bcl-2, both Bim and Bak by Bcl-xL, and Bak by Mcl-1.  Together, these findings indicate that HDAC inhibitor-inducible Bim is primarily neutralized by Bcl-2 and Bcl-xL, thus providing a mechanistic framework by which Bcl-2 antagonists potentiate the lethality of agents, such as HDAC inhibitors, which upregulate Bim.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNgeQxZ8-Yn7Vg90H21EOLACvtfcHk0lg4WQ6KDshZfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsV2ltLbK&md5=1c1113e7dbae1252d7fe92f8d59f8f67</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1128%2FMCB.01481-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.01481-08%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DPei%26aufirst%3DX.%2BY.%26aulast%3DGrant%26aufirst%3DS.%26atitle%3DBim%2520upregulation%2520by%2520histone%2520deacetylase%2520inhibitors%2520mediates%2520interactions%2520with%2520the%2520Bcl-2%2520antagonist%2520ABT-737%253A%2520evidence%2520for%2520distinct%2520roles%2520for%2520Bcl-2%252C%2520Bcl-xL%252C%2520and%2520Mcl-1%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2009%26volume%3D29%26spage%3D6149%26epage%3D6169%26doi%3D10.1128%2FMCB.01481-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefebure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shortt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellul, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidacs, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulkner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergsagel, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk MYC multiple myeloma</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e798</span>, <span class="refDoi"> DOI: 10.1038/cddis.2013.306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fcddis.2013.306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=24030150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVWrurjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=e798&author=G.+M.+Matthewsauthor=M.+Lefebureauthor=M.+A.+Doyleauthor=J.+Shorttauthor=J.+Ellulauthor=M.+Chesiauthor=K.+M.+Banksauthor=E.+Vidacsauthor=D.+Faulknerauthor=P.+Atadjaauthor=P.+L.+Bergsagelauthor=R.+W.+Johnstone&title=Preclinical+screening+of+histone+deacetylase+inhibitors+combined+with+ABT-737%2C+rhTRAIL%2FMD5-1+or+5-azacytidine+using+syngeneic+Vk+MYC+multiple+myeloma&doi=10.1038%2Fcddis.2013.306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma</span></div><div class="casAuthors">Matthews, G. M.; Lefebure, M.; Doyle, M. A.; Shortt, J.; Ellul, J.; Chesi, M.; Banks, K.-M.; Vidacs, E.; Faulkner, D.; Atadja, P.; Bergsagel, P. L.; Johnstone, R. W.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">Sept.</span>),
    <span class="NLM_cas:pages">e798</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Multiple myeloma (MM) is an incurable malignancy with an unmet need for innovative treatment options.  Histone deacetylase inhibitors (HDACi) are a new class of anticancer agent that have demonstrated activity in hematol. malignancies.  Here, we investigated the efficacy and safety of HDACi (vorinostat, panobinostat, romidepsin) and novel combination therapies using in vitro human MM cell lines and in vivo preclin. screening utilizing syngeneic transplanted Vk*MYC MM.  HDACi were combined with ABT-737, which targets the intrinsic apoptosis pathway, recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL/MD5-1), that activates the extrinsic apoptosis pathway or the DNA Me transferase inhibitor 5-azacytidine.  We demonstrate that in vitro cell line-based studies provide some insight into drug activity and combination therapies that synergistically kill MM cells; however, they do not always predict in vivo preclin. efficacy or toxicity.  Importantly, utilizing transplanted Vk*MYC MM, we report that panobinostat and 5-azacytidine synergize to prolong the survival of tumor-bearing mice.  In contrast, combined HDACi/rhTRAIL-based strategies, while efficacious, demonstrated on-target dose-limiting toxicities that precluded prolonged treatment.  Taken together, our studies provide evidence that the transplanted Vk*MYC model of MM is a useful screening tool for anti-MM drugs and should aid in the prioritization of novel drug testing in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqbECTRtEK1LVg90H21EOLACvtfcHk0lg4WQ6KDshZfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVWrurjL&md5=5ad6d6c19cdb86d35339e00dbfd26d24</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2013.306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2013.306%26sid%3Dliteratum%253Aachs%26aulast%3DMatthews%26aufirst%3DG.%2BM.%26aulast%3DLefebure%26aufirst%3DM.%26aulast%3DDoyle%26aufirst%3DM.%2BA.%26aulast%3DShortt%26aufirst%3DJ.%26aulast%3DEllul%26aufirst%3DJ.%26aulast%3DChesi%26aufirst%3DM.%26aulast%3DBanks%26aufirst%3DK.%2BM.%26aulast%3DVidacs%26aufirst%3DE.%26aulast%3DFaulkner%26aufirst%3DD.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DBergsagel%26aufirst%3DP.%2BL.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DPreclinical%2520screening%2520of%2520histone%2520deacetylase%2520inhibitors%2520combined%2520with%2520ABT-737%252C%2520rhTRAIL%252FMD5-1%2520or%25205-azacytidine%2520using%2520syngeneic%2520Vk%2520MYC%2520multiple%2520myeloma%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2013%26volume%3D4%26spage%3De798%26doi%3D10.1038%2Fcddis.2013.306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kmieciak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, R. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S.</span></span> <span> </span><span class="NLM_article-title">A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">2687</span>– <span class="NLM_lpage">2697</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-03-564534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1182%2Fblood-2014-03-564534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25208888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVygsrjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=2687-2697&author=S.+Chenauthor=Y.+Zhangauthor=L.+Zhouauthor=Y.+Lengauthor=H.+Linauthor=M.+Kmieciakauthor=X.+Y.+Peiauthor=R.+Jonesauthor=R.+Z.+Orlowskiauthor=Y.+Daiauthor=S.+Grant&title=A+Bim-targeting+strategy+overcomes+adaptive+bortezomib+resistance+in+myeloma+through+a+novel+link+between+autophagy+and+apoptosis&doi=10.1182%2Fblood-2014-03-564534"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis</span></div><div class="casAuthors">Chen, Shuang; Zhang, Yu; Zhou, Liang; Leng, Yun; Lin, Hui; Kmieciak, Maciej; Pei, Xin-Yan; Jones, Richard; Orlowski, Robert Z.; Dai, Yun; Grant, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2687-2697</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Bim contributes to resistance to various std. and novel agents.  Here we demonstrate that Bim plays a functional role in bortezomib resistance in multiple myeloma (MM) cells and that targeting Bim by combining histone deacetylase inhibitors (HDACIs) with BH3 mimetics (eg, ABT-737) overcomes bortezomib resistance.  BH3-only protein profiling revealed high Bim levels (Bimhi) in most MM cell lines and primary CD138+ MM samples.  Whereas short hairpin RNA Bim knockdown conferred bortezomib resistance in Bimhi cells, adaptive bortezomib-resistant cells displayed marked Bim downregulation.  HDACI upregulated Bim and, when combined with ABT-737, which released Bim from Bcl-2/Bcl-xL, potently killed bortezomib-resistant cells.  These events were correlated with Bim-assocd. autophagy attenuation, whereas Bim knockdown sharply increased autophagy in Bimhi cells.  In Bimlow cells, autophagy disruption by chloroquine (CQ) was required for HDACI/ABT-737 to induce Bim expression and lethality.  CQ also further enhanced HDACI/ABT-737 lethality in bortezomib-resistant cells.  Finally, HDACI failed to diminish autophagy or potentiate ABT-737-induced apoptosis in bim-/- mouse embryonic fibroblasts.  Thus, Bim deficiency represents a novel mechanism of adaptive bortezomib resistance in MM cells, and Bim-targeting strategies combining HDACIs (which upregulate Bim) and BH3 mimetics (which unleash Bim from antiapoptotic proteins) overcomes such resistance, in part by disabling cytoprotective autophagy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXinaaz9aztLVg90H21EOLACvtfcHk0lhLly4CF3NueQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVygsrjI&md5=2cee354b8cd9d7a94cbaebde7cb3e96c</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-03-564534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-03-564534%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DLeng%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DKmieciak%26aufirst%3DM.%26aulast%3DPei%26aufirst%3DX.%2BY.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DOrlowski%26aufirst%3DR.%2BZ.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DGrant%26aufirst%3DS.%26atitle%3DA%2520Bim-targeting%2520strategy%2520overcomes%2520adaptive%2520bortezomib%2520resistance%2520in%2520myeloma%2520through%2520a%2520novel%2520link%2520between%2520autophagy%2520and%2520apoptosis%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D2687%26epage%3D2697%26doi%3D10.1182%2Fblood-2014-03-564534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, C.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.12.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.bmcl.2018.12.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=30594434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1Whu7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=349-352&author=R.+Zhouauthor=S.+Fangauthor=M.+Zhangauthor=Q.+Zhangauthor=J.+Huauthor=M.+Wangauthor=C.+Wangauthor=J.+Zhuauthor=A.+Shenauthor=X.+Chenauthor=C.+Zheng&title=Design%2C+synthesis%2C+and+bioactivity+evaluation+of+novel+Bcl-2%2FHDAC+dual-target+inhibitors+for+the+treatment+of+multiple+myeloma&doi=10.1016%2Fj.bmcl.2018.12.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma</span></div><div class="casAuthors">Zhou, Ruolan; Fang, Shaoyu; Zhang, Minmin; Zhang, Qingsen; Hu, Jian; Wang, Mingping; Wang, Chongqing; Zhu, Ju; Shen, Aijun; Chen, Xin; Zheng, Canhui</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">349-352</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Multiple myeloma (MM) is the second most common hematol. malignancy.  Almost all patients with MM eventually relapse, and most recommended treatment protocols for the patients with relapsed refractory MM comprise a combination of drugs with different mechanisms of action.  Therefore novel drugs are in urgent need in clinic.  Bcl-2 inhibitors and HDAC inhibitors were proved their anti-MM effect in clinic or under clin. trials, and they were further discovered to have synergistic interactions.  A series of Bcl-2/HDAC dual-target inhibitors were designed and synthesized.  Among them, compds. 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((6-(hydroxyamino)-6-oxohexyl)amino)-3-nitrophenyl)sulfonyl)benzamide, 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((6-(hydroxyamino)-6-oxohexyl)amino)-3-nitrophenyl)sulfonyl)benzamideoheptyl-amino-3-nitrophenyl-sulfonylbenzamide, 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((8-(hydroxyamino)-8-oxooctyl)amino)-3-nitrophenyl)sulfonyl)benzamide showed good inhibitory activities against HDAC6 and high binding affinities to Bcl-2 protein simultaneously.  They also displayed good growth inhibitory activities against human MM cell line RPMI-<8226≥, which proved their potential value for the treatment of multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqAqtNXkzMhbVg90H21EOLACvtfcHk0lhLly4CF3NueQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1Whu7bO&md5=b320094c8d301d20a7b45bfb6bf899c2</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.12.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.12.052%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DFang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DC.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520bioactivity%2520evaluation%2520of%2520novel%2520Bcl-2%252FHDAC%2520dual-target%2520inhibitors%2520for%2520the%2520treatment%2520of%2520multiple%2520myeloma%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D349%26epage%3D352%26doi%3D10.1016%2Fj.bmcl.2018.12.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rotella, D. P.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase 5 inhibitors: current status and potential applications</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">674</span>– <span class="NLM_lpage">682</span>, <span class="refDoi"> DOI: 10.1038/nrd893</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnrd893" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=12209148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD38Xmslamt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=674-682&author=D.+P.+Rotella&title=Phosphodiesterase+5+inhibitors%3A+current+status+and+potential+applications&doi=10.1038%2Fnrd893"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase 5 inhibitors: current status and potential applications</span></div><div class="casAuthors">Rotella, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">674-682</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Phosphodiesterase enzymes convert cGMP and cAMP to the corresponding nucleotide monophosphates.  Phosphodiesterase 5 (PDE5) inhibition is now a widely accepted and efficacious therapeutic option for the treatment of erectile dysfunction in men, as a result of extensive clin. experience with sildenafil and other new PDE5 inhibitors.  Research in the field continues at a substantial level to identify new, selective PDE5 inhibitors and to investigate their usefulness and activity in other areas.  This review summarizes recent clin. trials with PDE5 inhibitors, advances in medicinal chem., and other activities and potential applications of this class of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1GubdxSnzj7Vg90H21EOLACvtfcHk0lhLly4CF3NueQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xmslamt78%253D&md5=fbbe68fc3f825c5d9ce215317d28f502</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1038%2Fnrd893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd893%26sid%3Dliteratum%253Aachs%26aulast%3DRotella%26aufirst%3DD.%2BP.%26atitle%3DPhosphodiesterase%25205%2520inhibitors%253A%2520current%2520status%2520and%2520potential%2520applications%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D674%26epage%3D682%26doi%3D10.1038%2Fnrd893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durrant, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salloum, F. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukreja, R. C.</span></span> <span> </span><span class="NLM_article-title">PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2014.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.pharmthera.2014.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25444755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVOkt73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2015&pages=12-21&author=A.+Dasauthor=D.+Durrantauthor=F.+N.+Salloumauthor=L.+Xiauthor=R.+C.+Kukreja&title=PDE5+inhibitors+as+therapeutics+for+heart+disease%2C+diabetes+and+cancer&doi=10.1016%2Fj.pharmthera.2014.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer</span></div><div class="casAuthors">Das, Anindita; Durrant, David; Salloum, Fadi N.; Xi, Lei; Kukreja, Rakesh C.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12-21</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The phosphodiesterase 5 (PDE5) inhibitors, including sildenafil (Viagra), vardenafil (Levitra), and tadalafil (Cialis) have been developed for treatment of erectile dysfunction.  Moreover, sildenafil and tadalafil are used for the management of pulmonary arterial hypertension in patients.  Since our first report showing the cardioprotective effect of sildenafil in 2002, there has been tremendous growth of preclin. and clin. studies on the use of PDE5 inhibitors for cardiovascular diseases and cancer.  Numerous animal studies have demonstrated that PDE5 inhibitors have powerful protective effect against myocardial ischemia/reperfusion (I/R) injury, doxorubicin cardiotoxicity, ischemic and diabetic cardiomyopathy, cardiac hypertrophy, Duchenne muscular dystrophy and the improvement of stem cell efficacy for myocardial repair.  Mechanistically, PDE5 inhibitors protect the heart against I/R injury through increased expression of nitric oxide synthases, activation of protein kinase G (PKG), PKG-dependent hydrogen sulfide generation, and phosphorylation of glycogen synthase kinase-3β - a master switch immediately proximal to mitochondrial permeability transition pore and the end effector of cardioprotection.  In addn., PDE5 inhibitors enhance the sensitivity of certain types of cancer to std. chemotherapeutic drugs, including doxorubicin.  Many clin. trials with PDE5 inhibitors have focused on the potential cardiovascular and anti-cancer benefits.  Despite mixed results of these clin. trials, there is a continuing strong interest by basic scientists and clin. investigators in exploring their new clin. uses.  It is our hope that future new mechanistic investigations and carefully designed clin. trials would help in reaping addnl. benefits of PDE5 inhibitors for cardiovascular disease and cancer in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomEKvIWnZGJLVg90H21EOLACvtfcHk0lgZbDBZU1qHDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVOkt73E&md5=a6176e9ddbfe8358aaf75b328229d8db</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2014.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2014.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DA.%26aulast%3DDurrant%26aufirst%3DD.%26aulast%3DSalloum%26aufirst%3DF.%2BN.%26aulast%3DXi%26aufirst%3DL.%26aulast%3DKukreja%26aufirst%3DR.%2BC.%26atitle%3DPDE5%2520inhibitors%2520as%2520therapeutics%2520for%2520heart%2520disease%252C%2520diabetes%2520and%2520cancer%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D147%26spage%3D12%26epage%3D21%26doi%3D10.1016%2Fj.pharmthera.2014.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitari, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazerounian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Stewart, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chepenik, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldman, S. A.</span></span> <span> </span><span class="NLM_article-title">Guanylyl cyclases and signaling by cyclic GMP</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">375</span>– <span class="NLM_lpage">414</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10977868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntFCmsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2000&pages=375-414&author=K.+A.+Lucasauthor=G.+M.+Pitariauthor=S.+Kazerounianauthor=I.+Ruiz-Stewartauthor=J.+Parkauthor=S.+Schulzauthor=K.+P.+Chepenikauthor=S.+A.+Waldman&title=Guanylyl+cyclases+and+signaling+by+cyclic+GMP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Guanylyl cyclases and signaling by cyclic GMP</span></div><div class="casAuthors">Lucas, Kimberly A.; Pitari, Giovanni M.; Kazerounian, Shiva; Ruiz-Stewart, Inez; Park, Jason; Schulz, Stephanie; Chepenik, Kenneth P.; Waldman, Scott A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">375-413</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review with 393 refs.  Guanylyl cyclases are a family of enzymes that catalyze the conversion of GTP to cGMP.  The family comprises both membrane-bound and sol. isoforms that are expressed in nearly all cell types.  They are regulated by diverse extracellular agonists that include peptide hormones, bacterial toxins, and free radicals, as well as intracellular mols., such as Ca2+ and adenine nucleotides.  Stimulation of guanylyl cyclases and the resultant accumulation of cGMP regulates complex signaling cascades through immediate downstream effectors, including cGMP-dependent protein kinases, cGMP-regulated phosphodiesterases, and cyclic nucleotide-gated ion channels.  Guanylyl cyclases and cGMP-mediated signaling cascades play a central role in the regulation of diverse (patho)physiol. processes, including vascular smooth muscle motility, intestinal fluid and electrolyte homeostasis, and retinal phototransduction.  Topics addressed in this review include the structure and chromosomal localization of the genes for guanylyl cyclases, structure and function of the members of the guanylyl cyclase family, mol. mechanisms regulating enzymic activity, and mol. sequences coupling ligand binding to catalytic activity.  A brief overview is presented of the downstream events controlled by guanylyl cyclases, including the effectors that are regulated by cGMP and the role that guanylyl cyclases play in cell physiol. and pathophysiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHStLFSGOzzbVg90H21EOLACvtfcHk0lgFyF7SNgvlOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntFCmsbg%253D&md5=0694e83a91440f3fff3c0a2312682b15</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DK.%2BA.%26aulast%3DPitari%26aufirst%3DG.%2BM.%26aulast%3DKazerounian%26aufirst%3DS.%26aulast%3DRuiz-Stewart%26aufirst%3DI.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DSchulz%26aufirst%3DS.%26aulast%3DChepenik%26aufirst%3DK.%2BP.%26aulast%3DWaldman%26aufirst%3DS.%2BA.%26atitle%3DGuanylyl%2520cyclases%2520and%2520signaling%2520by%2520cyclic%2520GMP%26jtitle%3DPharmacol.%2520Rev.%26date%3D2000%26volume%3D52%26spage%3D375%26epage%3D414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ugarte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil-Bea, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Barroso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cedazo-Minguez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Osta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyarzabal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuadrado-Tejedor, M.</span></span> <span> </span><span class="NLM_article-title">Decreased levels of guanosine 3′, 5′-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer’s disease</span>. <i>Neuropathol. Appl. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">471</span>– <span class="NLM_lpage">482</span>, <span class="refDoi"> DOI: 10.1111/nan.12203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1111%2Fnan.12203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25488891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlCgs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2015&pages=471-482&author=A.+Ugarteauthor=F.+Gil-Beaauthor=C.+Garcia-Barrosoauthor=A.+Cedazo-Minguezauthor=M.+J.+Ramirezauthor=R.+Francoauthor=A.+Garcia-Ostaauthor=J.+Oyarzabalauthor=M.+Cuadrado-Tejedor&title=Decreased+levels+of+guanosine+3%E2%80%B2%2C+5%E2%80%B2-monophosphate+%28cGMP%29+in+cerebrospinal+fluid+%28CSF%29+are+associated+with+cognitive+decline+and+amyloid+pathology+in+Alzheimer%E2%80%99s+disease&doi=10.1111%2Fnan.12203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease</span></div><div class="casAuthors">Ugarte, Ana; Gil-Bea, Francisco; Garcia-Barroso, Carolina; Cedazo-Minguez, Angel; Ramirez, M. Javier; Franco, Rafael; Garcia-Osta, Ana; Oyarzabal, Julen; Cuadrado-Tejedor, Mar</div><div class="citationInfo"><span class="NLM_cas:title">Neuropathology and Applied Neurobiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">471-482</span>CODEN:
                <span class="NLM_cas:coden">NANEDL</span>;
        ISSN:<span class="NLM_cas:issn">0305-1846</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : Levels of the cyclic nucleotides guanosine 3', 5'-monophosphate (cGMP) or adenosine 3', 5'-monophosphate (cAMP) that play important roles in memory processes are not characterized in Alzheimer's disease (AD).  The aim of this study was to analyze the levels of these nucleotides in cerebrospinal fluid (CSF) samples from patients diagnosed with clin. and prodromal stages of AD and study the expression level of the enzymes that hydrolyzed them [phosphodiesterases (PDEs)] in the brain of AD patients vs. controls.  Methods : For cGMP and cAMP CSF anal., the cohort (n = 79) included cognitively normal participants (subjective cognitive impairment), individuals with stable mild cognitive impairment or AD converters (sMCI and cMCI), and mild AD patients.  A high throughput liq. chromatog.-tandem mass spectrometry method was used.  Interactions between CSF cGMP or cAMP with mini-mental state examn. (MMSE) score, CSF Aβ(1-42) and CSF p-tau were analyzed.  For PDE4, 5, 9 and 10 expression anal., brains of AD patients vs. controls (n = 7 and n = 8) were used.  Results : cGMP, and not cAMP levels, were significantly lower in the CSF of patients diagnosed with mild AD when compared with nondemented controls.  CSF levels of cGMP showed a significant assocn. with MMSE-diagnosed clin. dementia and with CSF biomarker Aβ42 in AD patients.  Significant increase in PDE5 expression was detected in temporal cortex of AD patients compared with that of age-matched healthy control subjects.  No changes in the expression of others PDEs were detected.  Conclusions : These results support the potential involvement of cGMP in the pathol. and clin. development of AD.  The cGMP redn. in early stages of AD might participate in the aggravation of amyloid pathol. and cognitive decline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDfphh1a73krVg90H21EOLACvtfcHk0ljFAO-_GZZ3Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlCgs7s%253D&md5=4aabb42e396d12b9a74e64bd42abb064</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1111%2Fnan.12203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fnan.12203%26sid%3Dliteratum%253Aachs%26aulast%3DUgarte%26aufirst%3DA.%26aulast%3DGil-Bea%26aufirst%3DF.%26aulast%3DGarcia-Barroso%26aufirst%3DC.%26aulast%3DCedazo-Minguez%26aufirst%3DA.%26aulast%3DRamirez%26aufirst%3DM.%2BJ.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DGarcia-Osta%26aufirst%3DA.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26atitle%3DDecreased%2520levels%2520of%2520guanosine%25203%25E2%2580%25B2%252C%25205%25E2%2580%25B2-monophosphate%2520%2528cGMP%2529%2520in%2520cerebrospinal%2520fluid%2520%2528CSF%2529%2520are%2520associated%2520with%2520cognitive%2520decline%2520and%2520amyloid%2520pathology%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeuropathol.%2520Appl.%2520Neurobiol.%26date%3D2015%26volume%3D41%26spage%3D471%26epage%3D482%26doi%3D10.1111%2Fnan.12203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">García-Barroso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricobaraza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascual-Lucas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unceta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rico, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goicolea, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sallés, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanciego, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyarzabal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuadrado-Tejedor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Osta, A.</span></span> <span> </span><span class="NLM_article-title">Tadalafil crosses the blood–brain barrier and reverses cognitive dysfunction in a mouse model of AD</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">123</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2012.06.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.neuropharm.2012.06.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=22776546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtV2nu77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2013&pages=114-123&author=C.+Garc%C3%ADa-Barrosoauthor=A.+Ricobarazaauthor=M.+Pascual-Lucasauthor=N.+Uncetaauthor=A.+J.+Ricoauthor=M.+A.+Goicoleaauthor=J.+Sall%C3%A9sauthor=J.+L.+Lanciegoauthor=J.+Oyarzabalauthor=R.+Francoauthor=M.+Cuadrado-Tejedorauthor=A.+Garcia-Osta&title=Tadalafil+crosses+the+blood%E2%80%93brain+barrier+and+reverses+cognitive+dysfunction+in+a+mouse+model+of+AD&doi=10.1016%2Fj.neuropharm.2012.06.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD</span></div><div class="casAuthors">Garcia-Barroso, Carolina; Ricobaraza, Ana; Pascual-Lucas, Maria; Unceta, Nora; Rico, Alberto J.; Goicolea, Maria Aranzazu; Salles, Joan; Lanciego, Jose Luis; Oyarzabal, Julen; Franco, Rafael; Cuadrado-Tejedor, Mar; Garcia-Osta, Ana</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">114-123</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Previous studies have demonstrated that cognitive function can be restored in mouse models of Alzheimer's disease (AD) following administration of sildenafil, a specific PDE5 inhibitor (Puzzo et al., 2009; Cuadrado-Tejedor et al.).  Another very potent PDE5 inhibitor with a longer half-life and safe in chronic treatments, tadalafil, may represent a better alternative candidate for AD therapy.  However, tadalafil was proven unable to achieve similar benefits than those of sildenafil in AD animal models (Puzzo et al., 2009).  The lack of efficacy was attributed to inability to cross the blood-brain barrier (BBB).  In this paper we first measured the blood and brain levels of tadalafil to prove that the compd. crosses BBB and that chronic treatment leads to accumulation in the brain of the J20 transgenic mouse model of AD.  We demonstrated the presence of PDE5 mRNA in the brain of the mice and also in the human brain.  After a 10 wk treatment with either of these PDE5 inhibitors, the performance of the J20 mice in the Morris water maze test improved when compared with the transgenic mice that received vehicle.  Biochem. anal. revealed that neither sildenafil nor tadalafil altered the amyloid burden, although both compds. reduced Tau phosphorylation in the mouse hippocampus.  This study provides evidence of the potential benefits of a chronic tadalafil treatment in AD therapy.This article is part of a Special Issue entitled 'Cognitive Enhancers'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfkrxYqIGt7LVg90H21EOLACvtfcHk0lgegDUwQ9YMDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtV2nu77O&md5=aafb7dacec3ffd9d8ef4abc38c08e0f6</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2012.06.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2012.06.052%26sid%3Dliteratum%253Aachs%26aulast%3DGarc%25C3%25ADa-Barroso%26aufirst%3DC.%26aulast%3DRicobaraza%26aufirst%3DA.%26aulast%3DPascual-Lucas%26aufirst%3DM.%26aulast%3DUnceta%26aufirst%3DN.%26aulast%3DRico%26aufirst%3DA.%2BJ.%26aulast%3DGoicolea%26aufirst%3DM.%2BA.%26aulast%3DSall%25C3%25A9s%26aufirst%3DJ.%26aulast%3DLanciego%26aufirst%3DJ.%2BL.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3DGarcia-Osta%26aufirst%3DA.%26atitle%3DTadalafil%2520crosses%2520the%2520blood%25E2%2580%2593brain%2520barrier%2520and%2520reverses%2520cognitive%2520dysfunction%2520in%2520a%2520mouse%2520model%2520of%2520AD%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D64%26spage%3D114%26epage%3D123%26doi%3D10.1016%2Fj.neuropharm.2012.06.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Puzzo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitolo, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trinchese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arancio, O.</span></span> <span> </span><span class="NLM_article-title">Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">6887</span>– <span class="NLM_lpage">6897</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.5291-04.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1523%2FJNEUROSCI.5291-04.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16033898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmslClt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=6887-6897&author=D.+Puzzoauthor=O.+Vitoloauthor=F.+Trincheseauthor=J.+P.+Jacobauthor=A.+Palmeriauthor=O.+Arancio&title=Amyloid-beta+peptide+inhibits+activation+of+the+nitric+oxide%2FcGMP%2FcAMP-responsive+element-binding+protein+pathway+during+hippocampal+synaptic+plasticity&doi=10.1523%2FJNEUROSCI.5291-04.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloid-β peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity</span></div><div class="casAuthors">Puzzo, Daniela; Vitolo, Ottavio; Trinchese, Fabrizio; Jacob, Joel P.; Palmeri, Agostino; Arancio, Ottavio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">6887-6897</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Amyloid-β (Aβ), a peptide thought to play a crucial role in Alzheimer's disease (AD), has many targets that, in turn, activate different 2nd-messenger cascades.  Interestingly, Aβ was found to markedly impair hippocampal long-term potentiation (LTP).  To identify a new pathway that might be responsible for such impairment, the authors analyzed the role of the NO/sol. guanylyl cyclase (sGC)/cGMP/cGMP-dependent protein kinase (cGK)/cAMP-responsive element-binding protein (CREB) cascade because of its involvement in LTP.  The use of the NO donor 2-(N,N-dethylamino)-diazenolate-2-oxide diethylammonium salt (DEA/NO), the sGC stimulator 3-(4-amino-5-cyclopropylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine, or the cGMP-analogs 8-bromo-cGMP and 8-(4-chlorophenylthio)-cGMP reversed the Aβ-induced impairment of CA1-LTP through cGK activation.  Furthermore, these compds. reestablished the enhancement of CREB phosphorylation occurring during LTP in slices exposed to Aβ.  We also found that Aβ blocks the increase in cGMP immunoreactivity occurring immediately after LTP and that DEA/NO counteracts the effect of Aβ.  These results strongly suggest that, when modulating hippocampal synaptic plasticity, Aβ downregulates the NO/cGMP/cGK/CREB pathway; thus, enhancement of the NO/cGMP signaling may provide a novel approach to the treatment of AD and other neurodegenerative diseases with elevated prodn. of Aβ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT_M3WUlYelLVg90H21EOLACvtfcHk0ljgiHsZFZWJlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmslClt78%253D&md5=448717d56147ceb9665d8c1ce8136c98</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.5291-04.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.5291-04.2005%26sid%3Dliteratum%253Aachs%26aulast%3DPuzzo%26aufirst%3DD.%26aulast%3DVitolo%26aufirst%3DO.%26aulast%3DTrinchese%26aufirst%3DF.%26aulast%3DJacob%26aufirst%3DJ.%2BP.%26aulast%3DPalmeri%26aufirst%3DA.%26aulast%3DArancio%26aufirst%3DO.%26atitle%3DAmyloid-beta%2520peptide%2520inhibits%2520activation%2520of%2520the%2520nitric%2520oxide%252FcGMP%252FcAMP-responsive%2520element-binding%2520protein%2520pathway%2520during%2520hippocampal%2520synaptic%2520plasticity%26jtitle%3DJ.%2520Neurosci.%26date%3D2005%26volume%3D25%26spage%3D6887%26epage%3D6897%26doi%3D10.1523%2FJNEUROSCI.5291-04.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Osta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuadrado-Tejedor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Barroso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyarzabal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, R.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterases as therapeutic targets for Alzheimer’s disease</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">832</span>– <span class="NLM_lpage">844</span>, <span class="refDoi"> DOI: 10.1021/cn3000907</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn3000907" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVejs7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=832-844&author=A.+Garcia-Ostaauthor=M.+Cuadrado-Tejedorauthor=C.+Garcia-Barrosoauthor=J.+Oyarzabalauthor=R.+Franco&title=Phosphodiesterases+as+therapeutic+targets+for+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fcn3000907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterases as Therapeutic Targets for Alzheimer's Disease</span></div><div class="casAuthors">Garcia-Osta, Ana; Cuadrado-Tejedor, Mar; Garcia-Barroso, Carolina; Oyarzabal, Julen; Franco, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">832-844</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is the most common form of dementia among the elderly.  In AD patients, memory loss is accompanied by the formation of beta-amyloid plaques and the appearance of tau in a pathol. form.  Given the lack of effective treatments for AD, the development of new management strategies for these patients is crit.  The continued failure to find effective therapies using mols. aimed at addressing the anti-beta amyloid pathol. has led researchers to focus on other non-amyloid-based approaches to restore memory function.  Promising non-amyloid related candidate targets include phosphosdiesterases (PDEs), and indeed, Rolipram, a specific PDE4 inhibitor, was the first compd. found to effectively restore cognitive deficits in animal models of AD.  More recently, PDE5 inhibitors have also been shown to effectively restore memory function.  Accordingly, inhibitors of other members of the PDE family may also improve memory performance in AD and non-AD animal models.  Hence, in this review, we will summarize the data supporting the use of PDE inhibitors as cognitive enhancers and we will discuss the possible mechanisms of action underlying these effects.  We shall also adopt a medicinal chem. perspective that leads us to propose the most promising PDE candidates on the basis of inhibitor selectivity, brain distribution, and mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppeOP4NskdvrVg90H21EOLACvtfcHk0lhC1UyEpMJkhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVejs7nK&md5=53c6dfed22bb240b17132672b13fdcf1</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1021%2Fcn3000907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn3000907%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Osta%26aufirst%3DA.%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3DGarcia-Barroso%26aufirst%3DC.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DFranco%26aufirst%3DR.%26atitle%3DPhosphodiesterases%2520as%2520therapeutic%2520targets%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D832%26epage%3D844%26doi%3D10.1021%2Fcn3000907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benito, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbanke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awasthi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capece, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhardt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro-Sala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarajan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutz, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnsen, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luhrmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, A.</span></span> <span> </span><span class="NLM_article-title">HDAC inhibitor-dependent transcriptome and memory reinstatement in cognitive decline models</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">3572</span>– <span class="NLM_lpage">3584</span>, <span class="refDoi"> DOI: 10.1172/JCI79942</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1172%2FJCI79942" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=26280576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A280%3ADC%252BC287js12iuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=3572-3584&author=E.+Benitoauthor=H.+Urbankeauthor=B.+Ramachandranauthor=J.+Barthauthor=R.+Halderauthor=A.+Awasthiauthor=G.+Jainauthor=V.+Capeceauthor=S.+Burkhardtauthor=M.+Navarro-Salaauthor=S.+Nagarajanauthor=A.+L.+Schutzauthor=S.+A.+Johnsenauthor=S.+Bonnauthor=R.+Luhrmannauthor=C.+Deanauthor=A.+Fischer&title=HDAC+inhibitor-dependent+transcriptome+and+memory+reinstatement+in+cognitive+decline+models&doi=10.1172%2FJCI79942"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitor-dependent transcriptome and memory reinstatement in cognitive decline models</span></div><div class="casAuthors">Benito Eva; Urbanke Hendrik; Ramachandran Binu; Barth Jonas; Halder Rashi; Awasthi Ankit; Jain Gaurav; Capece Vincenzo; Burkhardt Susanne; Navarro-Sala Magdalena; Nagarajan Sankari; Schutz Anna-Lena; Johnsen Steven A; Bonn Stefan; Luhrmann Reinhardt; Dean Camin; Fischer Andre</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3572-84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Aging and increased amyloid burden are major risk factors for cognitive diseases such as Alzheimer's disease (AD).  Effective therapies for these diseases are lacking.  Here, we evaluated mouse models of age-associated memory impairment and amyloid deposition to study transcriptome and cell type-specific epigenome plasticity in the brain and peripheral organs.  We determined that aging and amyloid pathology are associated with inflammation and impaired synaptic function in the hippocampal CA1 region as the result of epigenetic-dependent alterations in gene expression.  In both amyloid and aging models, inflammation was associated with increased gene expression linked to a subset of transcription factors, while plasticity gene deregulation was differentially mediated.  Amyloid pathology impaired histone acetylation and decreased expression of plasticity genes, while aging altered H4K12 acetylation-linked differential splicing at the intron-exon junction in neurons, but not nonneuronal cells.  Furthermore, oral administration of the clinically approved histone deacetylase inhibitor vorinostat not only restored spatial memory, but also exerted antiinflammatory action and reinstated epigenetic balance and transcriptional homeostasis at the level of gene expression and exon usage.  This study provides a systems-level investigation of transcriptome plasticity in the hippocampal CA1 region in aging and AD models and suggests that histone deacetylase inhibitors should be further explored as a cost-effective therapeutic strategy against age-associated cognitive decline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTaDMtpB5WPpwyMywPm6HgQfW6udTcc2eZHX6qXZ9zF1Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287js12iuw%253D%253D&md5=e30caf3ba1aaddf0a149c514d23640b8</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1172%2FJCI79942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI79942%26sid%3Dliteratum%253Aachs%26aulast%3DBenito%26aufirst%3DE.%26aulast%3DUrbanke%26aufirst%3DH.%26aulast%3DRamachandran%26aufirst%3DB.%26aulast%3DBarth%26aufirst%3DJ.%26aulast%3DHalder%26aufirst%3DR.%26aulast%3DAwasthi%26aufirst%3DA.%26aulast%3DJain%26aufirst%3DG.%26aulast%3DCapece%26aufirst%3DV.%26aulast%3DBurkhardt%26aufirst%3DS.%26aulast%3DNavarro-Sala%26aufirst%3DM.%26aulast%3DNagarajan%26aufirst%3DS.%26aulast%3DSchutz%26aufirst%3DA.%2BL.%26aulast%3DJohnsen%26aufirst%3DS.%2BA.%26aulast%3DBonn%26aufirst%3DS.%26aulast%3DLuhrmann%26aufirst%3DR.%26aulast%3DDean%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DA.%26atitle%3DHDAC%2520inhibitor-dependent%2520transcriptome%2520and%2520memory%2520reinstatement%2520in%2520cognitive%2520decline%2520models%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2015%26volume%3D125%26spage%3D3572%26epage%3D3584%26doi%3D10.1172%2FJCI79942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolan, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G. V. W.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 6 interacts with the microtubule-associated protein tau</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">2119</span>– <span class="NLM_lpage">2130</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2008.05564.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1111%2Fj.1471-4159.2008.05564.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=18636984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtV2rt7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2008&pages=2119-2130&author=H.+Dingauthor=P.+J.+Dolanauthor=G.+V.+W.+Johnson&title=Histone+deacetylase+6+interacts+with+the+microtubule-associated+protein+tau&doi=10.1111%2Fj.1471-4159.2008.05564.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 interacts with the microtubule-associated protein tau</span></div><div class="casAuthors">Ding, Huiping; Dolan, Philip J.; Johnson, Gail V. W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2119-2130</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6), a unique cytoplasmic deacetylase, likely plays a role in neurodegeneration by coordinating cell responses to abnormal protein aggregation.  Here, we provide in vitro and in vivo evidence that HDAC6 interacts with tau, a microtubule-assocd. protein that forms neurofibrillary tangles in Alzheimer's disease.  This interaction is mediated by the microtubule-binding domain on tau and the Ser/Glu tetradecapeptide domain on HDAC6.  Treatment with tubacin, a selective inhibitor of tubulin deacetylation activity of HDAC6, did not disrupt HDAC6-tau interaction.  Nonetheless tubacin treatment attenuated site-specific tau phosphorylation, as did shRNA-mediated knockdown of HDAC6.  Proteasome inhibition potentiated HDAC6-tau interactions and facilitated the concn. and co-localization of HDAC6 and tau in a perinuclear aggresome-like compartment, independent of HDAC6 tubulin deacetylase activity.  Furthermore, we obsd. that in Alzheimer's disease brains the protein level of HDAC6 was significantly increased.  These findings establish HDAC6 as a tau-interacting protein and as a potential modulator of tau phosphorylation and accumulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9OtxbhpBU9LVg90H21EOLACvtfcHk0ljt62eInf1zOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtV2rt7fM&md5=cf63da19f8f887459227b620d9a0898b</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2008.05564.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2008.05564.x%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%26aulast%3DDolan%26aufirst%3DP.%2BJ.%26aulast%3DJohnson%26aufirst%3DG.%2BV.%2BW.%26atitle%3DHistone%2520deacetylase%25206%2520interacts%2520with%2520the%2520microtubule-associated%2520protein%2520tau%26jtitle%3DJ.%2520Neurochem.%26date%3D2008%26volume%3D106%26spage%3D2119%26epage%3D2130%26doi%3D10.1111%2Fj.1471-4159.2008.05564.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guan, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggarty, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacometti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannenberg, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieland, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePinho, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaenisch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, L. H.</span></span> <span> </span><span class="NLM_article-title">HDAC2 negatively regulates memory formation and synaptic plasticity</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>459</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1038/nature07925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnature07925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=19424149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsF2ltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=459&publication_year=2009&pages=55-60&author=J.+S.+Guanauthor=S.+J.+Haggartyauthor=E.+Giacomettiauthor=J.+H.+Dannenbergauthor=N.+Josephauthor=J.+Gaoauthor=T.+J.+Nielandauthor=Y.+Zhouauthor=X.+Wangauthor=R.+Mazitschekauthor=J.+E.+Bradnerauthor=R.+A.+DePinhoauthor=R.+Jaenischauthor=L.+H.+Tsai&title=HDAC2+negatively+regulates+memory+formation+and+synaptic+plasticity&doi=10.1038%2Fnature07925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC2 negatively regulates memory formation and synaptic plasticity</span></div><div class="casAuthors">Guan, Ji-Song; Haggarty, Stephen J.; Giacometti, Emanuela; Dannenberg, Jan-Hermen; Joseph, Nadine; Gao, Jun; Nieland, Thomas J. F.; Zhou, Ying; Wang, Xinyu; Mazitschek, Ralph; Bradner, James E.; DePinho, Ronald A.; Jaenisch, Rudolf; Tsai, Li-Huei</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">459</span>
        (<span class="NLM_cas:issue">7243</span>),
    <span class="NLM_cas:pages">55-60</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chromatin modifications, esp. histone-tail acetylation, have been implicated in memory formation.  Increased histone-tail acetylation induced by histone deacetylases inhibitors (HDACis) facilitates learning and memory in wild-type mice as well as in mouse models of neurodegeneration.  Harnessing the therapeutic potential of HDACis requires knowledge of the specific HDAC family member(s) linked to cognitive enhancement.  Here, the authors show that neuron-specific overexpression of HDAC2, but not that of HDAC1, decreased dendritic spine d., synapse no., synaptic plasticity and memory formation.  Conversely, gene Hdac2 deficiency resulted in increased synapse no. and memory facilitation, similar to chronic treatment with HDACis in mice.  Notably, reduced synapse no. and learning impairment of HDAC2-overexpressing mice were ameliorated by chronic treatment with HDACis.  Correspondingly, treatment with HDACis failed to further facilitate memory formation in gene Hdac2-deficient mice.  Furthermore, anal. of promoter occupancy revealed an assocn. of HDAC2 with the promoters of genes implicated in synaptic plasticity and memory formation.  Taken together, these results suggest that HDAC2 functions in modulating synaptic plasticity and long-lasting changes of neural circuits, which in turn neg. regulates learning and memory.  These observations encourage the development and testing of HDAC2-selective inhibitors for human diseases assocd. with memory impairment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0MzAlmmDwLLVg90H21EOLACvtfcHk0liDD58p5efeEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsF2ltro%253D&md5=bbd00accb8b6992f9c109114e8818388</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1038%2Fnature07925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07925%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DJ.%2BS.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DGiacometti%26aufirst%3DE.%26aulast%3DDannenberg%26aufirst%3DJ.%2BH.%26aulast%3DJoseph%26aufirst%3DN.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DNieland%26aufirst%3DT.%2BJ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DDePinho%26aufirst%3DR.%2BA.%26aulast%3DJaenisch%26aufirst%3DR.%26aulast%3DTsai%26aufirst%3DL.%2BH.%26atitle%3DHDAC2%2520negatively%2520regulates%2520memory%2520formation%2520and%2520synaptic%2520plasticity%26jtitle%3DNature%26date%3D2009%26volume%3D459%26spage%3D55%26epage%3D60%26doi%3D10.1038%2Fnature07925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hubbert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guardiola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nixon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, T. P.</span></span> <span> </span><span class="NLM_article-title">HDAC6 is a microtubule-associated deacetylase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>417</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">458</span>, <span class="refDoi"> DOI: 10.1038/417455a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2F417455a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=12024216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvVersr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=455-458&author=C.+Hubbertauthor=A.+Guardiolaauthor=R.+Shaoauthor=Y.+Kawaguchiauthor=A.+Itoauthor=A.+Nixonauthor=M.+Yoshidaauthor=X.+F.+Wangauthor=T.+P.+Yao&title=HDAC6+is+a+microtubule-associated+deacetylase&doi=10.1038%2F417455a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 is a microtubule-associated deacetylase</span></div><div class="casAuthors">Hubbert, Charlotte; Guardiola, Amaris; Shao, Rong; Kawaguchi, Yoshiharu; Ito, Akihiro; Nixon, Andrew; Yoshida, Minoru; Wang, Xiao-Fan; Yao, Tso-Pang</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6887</span>),
    <span class="NLM_cas:pages">455-458</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Reversible acetylation of α-tubulin has been implicated in regulating microtubule stability and function.  The distribution of acetylated α-tubulin is tightly controlled and stereotypic.  Acetylated α-tubulin is most abundant in stable microtubules but is absent from dynamic cellular structures such as neuronal growth cones and the leading edges of fibroblasts.  However, the enzymes responsible for regulating tubulin acetylation and deacetylation are not known.  Here we report that a member of the histone deacetylase family, HDAC6, functions as a tubulin deacetylase.  HDAC6 is localized exclusively in the cytoplasm, where it assocs. with microtubules and localizes with the microtubule motor complex contg. p150glued.  In vivo, the overexpression of HDAC6 leads to a global deacetylation of α-tubulin, whereas a decrease in HDAC6 increases α-tubulin acetylation.  In vitro, purified HDAC6 potently deacetylates α-tubulin in assembled microtubules.  Furthermore, overexpression of HDAC6 promotes chemotactic cell movement, supporting the idea that HDAC6-mediated deacetylation regulates microtubule-dependent cell motility.  Our results show that HDAC6 is the tubulin deacetylase, and provide evidence that reversible acetylation regulates important biol. processes beyond histone metab. and gene transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp76Er3MrWtO7Vg90H21EOLACvtfcHk0liL7O9es42ALw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvVersr4%253D&md5=f18cbb0af388925c606e822358ba3da6</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1038%2F417455a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F417455a%26sid%3Dliteratum%253Aachs%26aulast%3DHubbert%26aufirst%3DC.%26aulast%3DGuardiola%26aufirst%3DA.%26aulast%3DShao%26aufirst%3DR.%26aulast%3DKawaguchi%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DA.%26aulast%3DNixon%26aufirst%3DA.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%2BF.%26aulast%3DYao%26aufirst%3DT.%2BP.%26atitle%3DHDAC6%2520is%2520a%2520microtubule-associated%2520deacetylase%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D455%26epage%3D458%26doi%3D10.1038%2F417455a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cook, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gendron, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlomagno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunmore, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeTure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrucelli, L.</span></span> <span> </span><span class="NLM_article-title">Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2936</span>– <span class="NLM_lpage">2945</span>, <span class="refDoi"> DOI: 10.1093/hmg/dds125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1093%2Fhmg%2Fdds125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=22492994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1ylurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=2936-2945&author=C.+Cookauthor=T.+F.+Gendronauthor=K.+Scheffelauthor=Y.+Carlomagnoauthor=J.+Dunmoreauthor=M.+DeTureauthor=L.+Petrucelli&title=Loss+of+HDAC6%2C+a+novel+CHIP+substrate%2C+alleviates+abnormal+tau+accumulation&doi=10.1093%2Fhmg%2Fdds125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation</span></div><div class="casAuthors">Cook, Casey; Gendron, Tania F.; Scheffel, Kristyn; Carlomagno, Yari; Dunmore, Judy; DeTure, Michael; Petrucelli, Leonard</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2936-2945</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The abnormal accumulation of the microtubule-binding protein tau is assocd. with a no. of neurodegenerative conditions, and correlates with cognitive decline in Alzheimer's disease.  The ubiquitin ligase carboxy terminus of Hsp70-interacting protein (CHIP) and the mol. chaperone Hsp90 are implicated in protein triage decisions involving tau, and have consequently been targeted for therapeutic approaches aimed at decreasing tau burden.  Here, we present evidence that CHIP binds, ubiquitinates and regulates expression of histone deacetylase 6 (HDAC6).  As the deacetylase for Hsp90, HDAC6 modulates Hsp90 function and dets. the favorability of refolding vs. degrdn. of Hsp90 client proteins.  Moreover, we demonstrate that HDAC6 levels pos. correlate with tau burden, while a decrease in HDAC6 activity or expression promotes tau clearance.  Consistent with previous research on Hsp90 clients in cancer, we provide evidence that a loss of HDAC6 activity augments the efficacy of an Hsp90 inhibitor and drives client degrdn., in this case tau.  Therefore, our current findings not only identify HDAC6 as a crit. factor for the regulation of tau levels, but also indicate that a multi-faceted treatment approach could more effectively arrest tau accumulation in disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGxNKFm3ntlrVg90H21EOLACvtfcHk0ljh3VnKSFCCbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1ylurs%253D&md5=dc9f4f7cf50e42bdbbcc46c494877ccd</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fdds125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fdds125%26sid%3Dliteratum%253Aachs%26aulast%3DCook%26aufirst%3DC.%26aulast%3DGendron%26aufirst%3DT.%2BF.%26aulast%3DScheffel%26aufirst%3DK.%26aulast%3DCarlomagno%26aufirst%3DY.%26aulast%3DDunmore%26aufirst%3DJ.%26aulast%3DDeTure%26aufirst%3DM.%26aulast%3DPetrucelli%26aufirst%3DL.%26atitle%3DLoss%2520of%2520HDAC6%252C%2520a%2520novel%2520CHIP%2520substrate%252C%2520alleviates%2520abnormal%2520tau%2520accumulation%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2012%26volume%3D21%26spage%3D2936%26epage%3D2945%26doi%3D10.1093%2Fhmg%2Fdds125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cuadrado-Tejedor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Barroso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Arias, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabal, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Gonzalez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mederos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugarte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segura, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perea, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyarzabal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Osta, A.</span></span> <span> </span><span class="NLM_article-title">A first-in-class small-molecule that acts as a dual inhibitor of HDAC and PDE5 and that rescues hippocampal synaptic impairment in Alzheimer’s disease mice</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">524</span>– <span class="NLM_lpage">539</span>, <span class="refDoi"> DOI: 10.1038/npp.2016.163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnpp.2016.163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=27550730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFOntLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=524-539&author=M.+Cuadrado-Tejedorauthor=C.+Garcia-Barrosoauthor=J.+A.+Sanchez-Ariasauthor=O.+Rabalauthor=M.+Perez-Gonzalezauthor=S.+Mederosauthor=A.+Ugarteauthor=R.+Francoauthor=V.+Seguraauthor=G.+Pereaauthor=J.+Oyarzabalauthor=A.+Garcia-Osta&title=A+first-in-class+small-molecule+that+acts+as+a+dual+inhibitor+of+HDAC+and+PDE5+and+that+rescues+hippocampal+synaptic+impairment+in+Alzheimer%E2%80%99s+disease+mice&doi=10.1038%2Fnpp.2016.163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice</span></div><div class="casAuthors">Cuadrado-Tejedor, Mar; Garcia-Barroso, Carolina; Sanchez-Arias, Juan A.; Rabal, Obdulia; Perez-Gonzalez, Marta; Mederos, Sara; Ugarte, Ana; Franco, Rafael; Segura, Victor; Perea, Gertrudis; Oyarzabal, Julen; Garcia-Osta, Ana</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">524-539</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The targeting of two independent but synergistic enzymic activities, histone deacetylases (HDACs, class I and HDAC6) and phosphodiesterase 5 (PDE5), has recently been validated as a potentially novel therapeutic approach for Alzheimer's disease (AD).  Here we report the discovery of a new first-in-class small-mol. (CM-414) that acts as a dual inhibitor of PDE5 and HDACs.  We have used this compd. as a chem. probe to validate this systems therapeutics strategy, where an increase in the activation of cAMP/cGMP-responsive element-binding protein (CREB) induced by PDE5 inhibition, combined with moderate HDAC class I inhibition, leads to efficient histone acetylation.  This mol. rescued the impaired long-term potentiation evident in hippocampal slices from APP/PS1 mice.  Chronic treatment of Tg2576 mice with CM-414 diminished brain Aβ and tau phosphorylation (pTau) levels, increased the inactive form of GSK3β, reverted the decrease in dendritic spine d. on hippocampal neurons, and reversed their cognitive deficits, at least in part by inducing the expression of genes related to synaptic transmission.  Thus, CM-414 may serve as the starting point to discover balanced dual inhibitors with an optimal efficacy and safety profile for clin. testing on AD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrel_KiPL5177Vg90H21EOLACvtfcHk0ljiiw8GQNfjsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFOntLfP&md5=26482df7c58696a362ca1e73bab12264</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2016.163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2016.163%26sid%3Dliteratum%253Aachs%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3DGarcia-Barroso%26aufirst%3DC.%26aulast%3DSanchez-Arias%26aufirst%3DJ.%2BA.%26aulast%3DRabal%26aufirst%3DO.%26aulast%3DPerez-Gonzalez%26aufirst%3DM.%26aulast%3DMederos%26aufirst%3DS.%26aulast%3DUgarte%26aufirst%3DA.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DSegura%26aufirst%3DV.%26aulast%3DPerea%26aufirst%3DG.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DGarcia-Osta%26aufirst%3DA.%26atitle%3DA%2520first-in-class%2520small-molecule%2520that%2520acts%2520as%2520a%2520dual%2520inhibitor%2520of%2520HDAC%2520and%2520PDE5%2520and%2520that%2520rescues%2520hippocampal%2520synaptic%2520impairment%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520mice%26jtitle%3DNeuropsychopharmacology%26date%3D2017%26volume%3D42%26spage%3D524%26epage%3D539%26doi%3D10.1038%2Fnpp.2016.163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabal, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Arias, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuadrado-Tejedor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Miguel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Gonzalez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Barroso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugarte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estella-Hermoso de Mendoza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espelosin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ursua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haizhong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Osta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyarzabal, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of in vivo chemical probes for treating Alzheimer’s disease: dual phosphodiesterase 5 (PDE5) and class I histone deacetylase selective inhibitors</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1765</span>– <span class="NLM_lpage">1782</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.8b00648</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.8b00648" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVKjtLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1765-1782&author=O.+Rabalauthor=J.+A.+Sanchez-Ariasauthor=M.+Cuadrado-Tejedorauthor=I.+de+Miguelauthor=M.+Perez-Gonzalezauthor=C.+Garcia-Barrosoauthor=A.+Ugarteauthor=A.+Estella-Hermoso+de+Mendozaauthor=E.+Saezauthor=M.+Espelosinauthor=S.+Ursuaauthor=T.+Haizhongauthor=W.+Weiauthor=X.+Mushengauthor=A.+Garcia-Ostaauthor=J.+Oyarzabal&title=Discovery+of+in+vivo+chemical+probes+for+treating+Alzheimer%E2%80%99s+disease%3A+dual+phosphodiesterase+5+%28PDE5%29+and+class+I+histone+deacetylase+selective+inhibitors&doi=10.1021%2Facschemneuro.8b00648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of in Vivo Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective Inhibitors</span></div><div class="casAuthors">Rabal, Obdulia; Sanchez-Arias, Juan A.; Cuadrado-Tejedor, Mar; de Miguel, Irene; Perez-Gonzalez, Marta; Garcia-Barroso, Carolina; Ugarte, Ana; Estella-Hermoso de Mendoza, Ander; Saez, Elena; Espelosin, Maria; Ursua, Susana; Haizhong, Tan; Wei, Wu; Musheng, Xu; Garcia-Osta, Ana; Oyarzabal, Julen</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1765-1782</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In order to det. the contributions of histone deacetylase (HDAC) isoforms to the beneficial effects of dual phosphodiesterase 5 (PDE5) and pan-HDAC inhibitors on in vivo models of Alzheimer's disease (AD), we have designed, synthesized, and tested novel chem. probes with the desired target compd. profile of PDE5 and class I HDAC selective inhibitors.  Compared to previous hydroxamate-based series, these mols. exhibit longer residence times on HDACs.  In this scenario, shorter or longer preincubation times may have a significant impact on the IC50 values of these compds. and therefore on their corresponding selectivity profiles on the different HDAC isoforms.  On the other hand, different chem. series have been explored and, as expected, some pairwise comparisons show a clear impact of the scaffold on biol. responses.  The lead identification process led to compd. I, which shows an adequate ADME-Tox profile and in vivo target engagement (histone acetylation and cAMP/cGMP response element-binding (CREB) phosphorylation) in the central nervous system (CNS), suggesting that this compd. represents an optimized chem. probe; thus, I has been assayed in a mouse model of AD (Tg2576).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpMx-DcLUAMrVg90H21EOLACvtfcHk0lh4BwC-oG7BdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVKjtLvF&md5=d3d13a9121111b166ea69c09106eb3c5</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.8b00648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.8b00648%26sid%3Dliteratum%253Aachs%26aulast%3DRabal%26aufirst%3DO.%26aulast%3DSanchez-Arias%26aufirst%3DJ.%2BA.%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3Dde%2BMiguel%26aufirst%3DI.%26aulast%3DPerez-Gonzalez%26aufirst%3DM.%26aulast%3DGarcia-Barroso%26aufirst%3DC.%26aulast%3DUgarte%26aufirst%3DA.%26aulast%3DEstella-Hermoso%2Bde%2BMendoza%26aufirst%3DA.%26aulast%3DSaez%26aufirst%3DE.%26aulast%3DEspelosin%26aufirst%3DM.%26aulast%3DUrsua%26aufirst%3DS.%26aulast%3DHaizhong%26aufirst%3DT.%26aulast%3DWei%26aufirst%3DW.%26aulast%3DMusheng%26aufirst%3DX.%26aulast%3DGarcia-Osta%26aufirst%3DA.%26aulast%3DOyarzabal%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520in%2520vivo%2520chemical%2520probes%2520for%2520treating%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520dual%2520phosphodiesterase%25205%2520%2528PDE5%2529%2520and%2520class%2520I%2520histone%2520deacetylase%2520selective%2520inhibitors%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2019%26volume%3D10%26spage%3D1765%26epage%3D1782%26doi%3D10.1021%2Facschemneuro.8b00648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabal, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Arias, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuadrado-Tejedor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Miguel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Gonzalez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Barroso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugarte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estella-Hermoso de Mendoza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espelosin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ursua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haizhong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Osta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyarzabal, J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer’s disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">506</span>– <span class="NLM_lpage">524</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.ejmech.2018.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=29549837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslaiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2018&pages=506-524&author=O.+Rabalauthor=J.+A.+Sanchez-Ariasauthor=M.+Cuadrado-Tejedorauthor=I.+de+Miguelauthor=M.+Perez-Gonzalezauthor=C.+Garcia-Barrosoauthor=A.+Ugarteauthor=A.+Estella-Hermoso+de+Mendozaauthor=E.+Saezauthor=M.+Espelosinauthor=S.+Ursuaauthor=T.+Haizhongauthor=W.+Weiauthor=X.+Mushengauthor=A.+Garcia-Ostaauthor=J.+Oyarzabal&title=Design%2C+synthesis%2C+biological+evaluation+and+in+vivo+testing+of+dual+phosphodiesterase+5+%28PDE5%29+and+histone+deacetylase+6+%28HDAC6%29-selective+inhibitors+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.ejmech.2018.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Rabal, Obdulia; Sanchez-Arias, Juan A.; Cuadrado-Tejedor, Mar; de Miguel, Irene; Perez-Gonzalez, Marta; Garcia-Barroso, Carolina; Ugarte, Ana; Estella-Hermoso de Mendoza, Ander; Saez, Elena; Espelosin, Maria; Ursua, Susana; Tan, Haizhong; Wu, Wei; Xu, Musheng; Garcia-Osta, Ana; Oyarzabal, Julen</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">506-524</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The authors have identified chem. probes that act as dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors (>1 log unit difference vs. class I HDACs) to decipher the contribution of HDAC isoforms to the pos. impact of dual-acting PDE5 and HDAC inhibitors on mouse models of Alzheimer's disease (AD) and fine-tune this systems therapeutics approach.  Structure- and knowledge-based approaches led to the design of first-in-class mols. with the desired target compd. profile: dual PDE5 and HDAC6-selective inhibitors.  Compd. 44b (5-[[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl]methyl]thiophene-2-carbohydroxamic acid), which fulfilled the biochem., functional and ADME-Tox profiling requirements and exhibited adequate pharmacokinetic properties, was selected as pharmacol. tool compd. and tested in a mouse model of AD (Tg2576) in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFqq9VoRla3bVg90H21EOLACvtfcHk0ljYtLi5VRUzsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslaiur4%253D&md5=1ced6634343dd8c0913ea3e6be07ff91</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DRabal%26aufirst%3DO.%26aulast%3DSanchez-Arias%26aufirst%3DJ.%2BA.%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3Dde%2BMiguel%26aufirst%3DI.%26aulast%3DPerez-Gonzalez%26aufirst%3DM.%26aulast%3DGarcia-Barroso%26aufirst%3DC.%26aulast%3DUgarte%26aufirst%3DA.%26aulast%3DEstella-Hermoso%2Bde%2BMendoza%26aufirst%3DA.%26aulast%3DSaez%26aufirst%3DE.%26aulast%3DEspelosin%26aufirst%3DM.%26aulast%3DUrsua%26aufirst%3DS.%26aulast%3DHaizhong%26aufirst%3DT.%26aulast%3DWei%26aufirst%3DW.%26aulast%3DMusheng%26aufirst%3DX.%26aulast%3DGarcia-Osta%26aufirst%3DA.%26aulast%3DOyarzabal%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%252C%2520biological%2520evaluation%2520and%2520in%2520vivo%2520testing%2520of%2520dual%2520phosphodiesterase%25205%2520%2528PDE5%2529%2520and%2520histone%2520deacetylase%25206%2520%2528HDAC6%2529-selective%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D150%26spage%3D506%26epage%3D524%26doi%3D10.1016%2Fj.ejmech.2018.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, V. C.</span></span> <span> </span><span class="NLM_article-title">Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. receptor interactions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">908</span>, <span class="refDoi"> DOI: 10.1021/jm020449y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020449y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtl2ku78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=883-908&author=V.+C.+Jordan&title=Antiestrogens+and+selective+estrogen+receptor+modulators+as+multifunctional+medicines.+1.+receptor+interactions&doi=10.1021%2Fjm020449y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 1. Receptor Interactions</span></div><div class="casAuthors">Jordan, V. Craig</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">883-908</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Antiestrogens and selective Estrogen receptor modulators as multifunctional medicines are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYmuDHzDbu5LVg90H21EOLACvtfcHk0lhkyk-bRYDaOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtl2ku78%253D&md5=b86cc4c3c4a4698a51eac9ab69ae9122</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Fjm020449y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020449y%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DAntiestrogens%2520and%2520selective%2520estrogen%2520receptor%2520modulators%2520as%2520multifunctional%2520medicines.%25201.%2520receptor%2520interactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D883%26epage%3D908%26doi%3D10.1021%2Fjm020449y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ulm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponnusamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, R.</span></span> <span> </span><span class="NLM_article-title">Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers</span>. <i>Endocr. Connect.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">R10</span>– <span class="NLM_lpage">R26</span>, <span class="refDoi"> DOI: 10.1530/EC-18-0425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1530%2FEC-18-0425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=30640710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1CgtLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=R10-R26&author=M.+Ulmauthor=A.+V.+Rameshauthor=K.+M.+McNamaraauthor=S.+Ponnusamyauthor=H.+Sasanoauthor=R.+Narayanan&title=Therapeutic+advances+in+hormone-dependent+cancers%3A+focus+on+prostate%2C+breast+and+ovarian+cancers&doi=10.1530%2FEC-18-0425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers</span></div><div class="casAuthors">Ulm, Michael; Ramesh, Arvind V.; McNamara, Keely M.; Ponnusamy, Suriyan; Sasano, Hironobu; Narayanan, Ramesh</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Connections</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">R10-R26</span>CODEN:
                <span class="NLM_cas:coden">ECNOCX</span>;
        ISSN:<span class="NLM_cas:issn">2049-3614</span>.
    
            (<span class="NLM_cas:orgname">Bioscientifica Ltd.</span>)
        </div><div class="casAbstract">A review.  Hormonal cancers affect over 400,000 men and women and contribute collectively to over 100,000 deaths in the United States alone.  Thanks to advances in the understanding of these cancers at the mol. level and to the discovery of several disease-modifying therapeutics, the last decade has seen a plateauing or even a decreasing trend in the no. of deaths from these cancers.  These advanced therapeutics not only effectively slow the growth of hormonal cancers, but also provide an insight on how these cancers become refractory and evolve as an altogether distinct subset.  This review summarizes the current therapeutic trends in hormonal cancers, with focus on prostate, breast and ovarian cancers.  The review discusses the clin. drugs being used now, promising mols. that are going through various stages of development and makes some predictions on how the therapeutic landscape will shift in the next decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ79Ne7WjUi7Vg90H21EOLACvtfcHk0liX8YVIy-bjnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1CgtLrJ&md5=fc90ea2d4be544b19d078dc4c66bc9da</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1530%2FEC-18-0425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252FEC-18-0425%26sid%3Dliteratum%253Aachs%26aulast%3DUlm%26aufirst%3DM.%26aulast%3DRamesh%26aufirst%3DA.%2BV.%26aulast%3DMcNamara%26aufirst%3DK.%2BM.%26aulast%3DPonnusamy%26aufirst%3DS.%26aulast%3DSasano%26aufirst%3DH.%26aulast%3DNarayanan%26aufirst%3DR.%26atitle%3DTherapeutic%2520advances%2520in%2520hormone-dependent%2520cancers%253A%2520focus%2520on%2520prostate%252C%2520breast%2520and%2520ovarian%2520cancers%26jtitle%3DEndocr.%2520Connect.%26date%3D2019%26volume%3D8%26spage%3DR10%26epage%3DR26%26doi%3D10.1530%2FEC-18-0425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, N. E.</span></span> <span> </span><span class="NLM_article-title">Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7025</span>– <span class="NLM_lpage">7029</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=11585728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsVehsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=7025-7029&author=X.+Yangauthor=D.+L.+Phillipsauthor=A.+T.+Fergusonauthor=W.+G.+Nelsonauthor=J.+G.+Hermanauthor=N.+E.+Davidson&title=Synergistic+activation+of+functional+estrogen+receptor+%28ER%29-alpha+by+DNA+methyltransferase+and+histone+deacetylase+inhibition+in+human+ER-alpha-negative+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells</span></div><div class="casAuthors">Yang, Xiaowei; Phillips, Dawn L.; Ferguson, Anne T.; Nelson, William G.; Herman, James G.; Davidson, Nancy E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7025-7029</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Formation of transcriptional repression complexes such as DNA methyltransferase (DNMT) 1/histone deacetylase (HDAC) or methyl-CpG binding protein/HDAC is emerging as an important mechanism in silencing a variety of methylated tissue-specific and imprinted genes.  Our previous studies showed that treatment of estrogen receptor (ER)-α-neg. human breast cancer cells with the DNMT inhibitor 5-aza-2'-deoxycytidine (5-aza-dC) led to ER mRNA and protein re-expression.  Also, the HDAC inhibitor trichostatin A (TSA) could induce ER transcript about 5-fold.  Here we show that 5-aza-dC alone induced ER transcript about 30-40-fold, and the addn. of TSA elevated ER mRNA expression about 10-fold more in the human ER-neg. breast cancer cell lines MDA-MB-231 and MDA-MB-435.  Overall, the combination of 5-aza-dC and TSA induced a 300-400-fold increase in ER transcript.  Restoration of estrogen responsiveness was demonstrated by the ability of the induced ER protein to elicit estrogen response element-regulated reporter activity from an exogenous plasmid as well as induce expression of the ER target gene, progesterone receptor.  The synergistic activation of ER occurs concomitantly with markedly reduced sol. DNMT1 expression and activity, partial demethylation of the ER CpG island, and increased acetylation of histones H3 and H4.  These data suggest that the activities of both DNMT1 and HDAC are key regulators of methylation-mediated ER gene silencing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9cug6ITynn7Vg90H21EOLACvtfcHk0liX8YVIy-bjnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsVehsrs%253D&md5=baf883039fc6660f20412b27f250df70</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%26aulast%3DPhillips%26aufirst%3DD.%2BL.%26aulast%3DFerguson%26aufirst%3DA.%2BT.%26aulast%3DNelson%26aufirst%3DW.%2BG.%26aulast%3DHerman%26aufirst%3DJ.%2BG.%26aulast%3DDavidson%26aufirst%3DN.%2BE.%26atitle%3DSynergistic%2520activation%2520of%2520functional%2520estrogen%2520receptor%2520%2528ER%2529-alpha%2520by%2520DNA%2520methyltransferase%2520and%2520histone%2520deacetylase%2520inhibition%2520in%2520human%2520ER-alpha-negative%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D7025%26epage%3D7029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sabnis, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goloubeva, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chumsri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodie, A. M. H.</span></span> <span> </span><span class="NLM_article-title">Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1893</span>– <span class="NLM_lpage">1903</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-2458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F0008-5472.CAN-10-2458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=21245100" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFCnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=1893-1903&author=G.+J.+Sabnisauthor=O.+Goloubevaauthor=S.+Chumsriauthor=N.+Nguyenauthor=S.+Sukumarauthor=A.+M.+H.+Brodie&title=Functional+activation+of+the+estrogen+receptor-%CE%B1+and+aromatase+by+the+HDAC+inhibitor+entinostat+sensitizes+ER-negative+tumors+to+letrozole&doi=10.1158%2F0008-5472.CAN-10-2458"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Functional Activation of the Estrogen Receptor-α and Aromatase by the HDAC Inhibitor Entinostat Sensitizes ER-Negative Tumors to Letrozole</span></div><div class="casAuthors">Sabnis, Gauri J.; Goloubeva, Olga; Chumsri, Saranya; Nguyen, Nguyen; Sukumar, Saraswati; Brodie, Angela M. H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1893-1903</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Approx. 25% of breast cancers do not express the estrogen receptor-α (ERα) and consequently do not respond to endocrine therapy.  In these tumors, ERα repression is often due to epigenetic modifications such as methylation and histone deacetylation.  For this reason, we investigated the ability of the histone deacetylase inhibitor entinostat (ENT) to trigger reexpression of ERα and aromatase in breast cancer cells, with the notion that this treatment would restore sensitivity to the aromatase inhibitor (AI) letrozole.  ENT treatment of tumor cells increased expression of ERα and aromatase, along with the enzymic activity of aromatase, in a dose-dependent manner both in vitro and in vivo.  Notably, ERα and aromatase upregulation resulted in sensitization of breast cancer cells to estrogen and letrozole.  Tumor growth rate was significantly lower in tumor xenografts following treatment with ENT alone and in combination with letrozole than in control tumors (P > 0.001).  ENT plus letrozole also prevented lung colonization and growth of tumor cells, with a significant redn. (P > 0.03) in both visible and microscopic foci.  Our results show that ENT treatment can be used to restore the letrozole responsiveness of ER-neg. tumors.  More generally, they provide a strong rationale for immediate clin. evaluation of combinations of histone deacetylase and aromatase inhibitors to treat ER-neg. and endocrine-resistant breast cancers.  Cancer Res; 71(5); 1893-903.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzbAv1kqIFk7Vg90H21EOLACvtfcHk0liX8YVIy-bjnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFCnsLc%253D&md5=0c08c05719072e51936174af019b6e62</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2458%26sid%3Dliteratum%253Aachs%26aulast%3DSabnis%26aufirst%3DG.%2BJ.%26aulast%3DGoloubeva%26aufirst%3DO.%26aulast%3DChumsri%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DN.%26aulast%3DSukumar%26aufirst%3DS.%26aulast%3DBrodie%26aufirst%3DA.%2BM.%2BH.%26atitle%3DFunctional%2520activation%2520of%2520the%2520estrogen%2520receptor-%25CE%25B1%2520and%2520aromatase%2520by%2520the%2520HDAC%2520inhibitor%2520entinostat%2520sensitizes%2520ER-negative%2520tumors%2520to%2520letrozole%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D1893%26epage%3D1903%26doi%3D10.1158%2F0008-5472.CAN-10-2458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Restall, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paiman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byron, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dear, A. E.</span></span> <span> </span><span class="NLM_article-title">A novel histone deacetylase inhibitor augments tamoxifen-mediated attenuation of breast carcinoma growth</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">483</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.1002/ijc.24350</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1002%2Fijc.24350" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=19330834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1amurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2009&pages=483-487&author=C.+Restallauthor=J.+Dohertyauthor=H.+B.+Liuauthor=R.+Genoveseauthor=L.+Paimanauthor=K.+A.+Byronauthor=R.+L.+Andersonauthor=A.+E.+Dear&title=A+novel+histone+deacetylase+inhibitor+augments+tamoxifen-mediated+attenuation+of+breast+carcinoma+growth&doi=10.1002%2Fijc.24350"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">A novel histone deacetylase inhibitor augments tamoxifen-mediated attenuation of breast carcinoma growth</span></div><div class="casAuthors">Restall, Christina; Doherty, Judy; Liu, Hong Bin; Genovese, Rosemary; Paiman, Lisa; Byron, Keith A.; Anderson, Robin L.; Dear, Anthony E.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">483-487</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Earlier we generated novel derivs. of the hydroxamate-based histone deacetylase inhibitor (HDACi), Oxamflatin (Ox), which demonstrate considerable HDACi activity.  Here the effects of one such deriv., Metacept-1 (MCT-1), alone or in combination with tamoxifen on mammary tumor growth have been assessed in a syngeneic orthotopic model.  MCT-1 alone resulted in a trend towards inhibition of growth of 4T1.2 mammary tumors.  Since the combination of MCT-1 and tamoxifen up-regulates estrogen receptor expression in 4T1.2 cells in vitro, we tested this combination and found a significant redn. in primary tumor growth over tamoxifen treatment alone.  Taken together, these observations suggest that the novel HDACi MCT-1 may warrant further exploration in the treatment of estrogen receptor pos. breast carcinoma, particularly when used in combination with conventional agents such as tamoxifen.  © 2009 UICC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDB-RoQfaAubVg90H21EOLACvtfcHk0lhoZlpLD1sMhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1amurs%253D&md5=297b7ae54ac249a461485790bf3ca309</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1002%2Fijc.24350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.24350%26sid%3Dliteratum%253Aachs%26aulast%3DRestall%26aufirst%3DC.%26aulast%3DDoherty%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DH.%2BB.%26aulast%3DGenovese%26aufirst%3DR.%26aulast%3DPaiman%26aufirst%3DL.%26aulast%3DByron%26aufirst%3DK.%2BA.%26aulast%3DAnderson%26aufirst%3DR.%2BL.%26aulast%3DDear%26aufirst%3DA.%2BE.%26atitle%3DA%2520novel%2520histone%2520deacetylase%2520inhibitor%2520augments%2520tamoxifen-mediated%2520attenuation%2520of%2520breast%2520carcinoma%2520growth%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2009%26volume%3D125%26spage%3D483%26epage%3D487%26doi%3D10.1002%2Fijc.24350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sabnis, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goloubeva, O. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazi, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodie, A. H.</span></span> <span> </span><span class="NLM_article-title">HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2804</span>– <span class="NLM_lpage">2816</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1158%2F1535-7163.MCT-13-0345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=24092810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVyqsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=2804-2816&author=G.+J.+Sabnisauthor=O.+G.+Goloubevaauthor=A.+A.+Kaziauthor=P.+Shahauthor=A.+H.+Brodie&title=HDAC+inhibitor+entinostat+restores+responsiveness+of+letrozole-resistant+MCF-7Ca+xenografts+to+aromatase+inhibitors+through+modulation+of+Her-2&doi=10.1158%2F1535-7163.MCT-13-0345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC Inhibitor Entinostat Restores Responsiveness of Letrozole-Resistant MCF-7Ca Xenografts to Aromatase Inhibitors through Modulation of Her-2</span></div><div class="casAuthors">Sabnis, Gauri J.; Goloubeva, Olga G.; Kazi, Armina A.; Shah, Preeti; Brodie, Angela H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2804-2816</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We previously showed that in innately resistant tumors, silencing of the estrogen receptor (ER) could be reversed by treatment with a histone deacetylase (HDAC) inhibitor, entinostat.  Tumors were then responsive to aromatase inhibitor (AI) letrozole.  Here, we investigated whether ER in the acquired letrozole-resistant tumors could be restored with entinostat.  Ovariectomized athymic mice were inoculated with MCF-7Ca cells, supplemented with androstenedione (Δ4A), the aromatizable substrate.  When the tumors reached about 300 mm3, the mice were treated with letrozole.  After initial response to letrozole, the tumors eventually became resistant (doubled their initial vol.).  The mice then were grouped to receive letrozole, exemestane (250 μg/d), entinostat (50 μg/d), or the combination of entinostat with letrozole or exemestane for 26 wk.  The growth rates of tumors of mice treated with the combination of entinostat with letrozole or exemestane were significantly slower than with the single agent (P < 0.05).  Anal. of the letrozole-resistant tumors showed entinostat increased ERα expression and aromatase activity but downregulated Her-2, p-Her-2, p-MAPK, and p-Akt.  However, the mechanism of action of entinostat in reversing acquired resistance did not involve epigenetic silencing but rather included posttranslational as well as transcriptional modulation of Her-2.  Entinostat treatment reduced the assocn. of the Her-2 protein with HSP-90, possibly by reducing the stability of Her-2 protein.  In addn., entinostat also reduced Her-2 mRNA levels and its stability.  Our results suggest that the HDAC inhibitor may reverse letrozole resistance in cells and tumors by modulating Her-2 expression and activity.  Mol Cancer Ther; 12(12); 2804-16. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9K4N7QFrXJrVg90H21EOLACvtfcHk0lhoZlpLD1sMhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVyqsrvI&md5=84d2fcd2a1fb0606e350b8bdea39665f</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0345%26sid%3Dliteratum%253Aachs%26aulast%3DSabnis%26aufirst%3DG.%2BJ.%26aulast%3DGoloubeva%26aufirst%3DO.%2BG.%26aulast%3DKazi%26aufirst%3DA.%2BA.%26aulast%3DShah%26aufirst%3DP.%26aulast%3DBrodie%26aufirst%3DA.%2BH.%26atitle%3DHDAC%2520inhibitor%2520entinostat%2520restores%2520responsiveness%2520of%2520letrozole-resistant%2520MCF-7Ca%2520xenografts%2520to%2520aromatase%2520inhibitors%2520through%2520modulation%2520of%2520Her-2%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D2804%26epage%3D2816%26doi%3D10.1158%2F1535-7163.MCT-13-0345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurn, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raha, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacevic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melisko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismail-Khan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moasser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minton, S. E.</span></span> <span> </span><span class="NLM_article-title">A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">1828</span>– <span class="NLM_lpage">1835</span>, <span class="refDoi"> DOI: 10.1038/bjc.2011.156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fbjc.2011.156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=21559012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntV2hsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2011&pages=1828-1835&author=P.+N.+Munsterauthor=K.+T.+Thurnauthor=S.+Thomasauthor=P.+Rahaauthor=M.+Lacevicauthor=A.+Millerauthor=M.+Meliskoauthor=R.+Ismail-Khanauthor=H.+Rugoauthor=M.+Moasserauthor=S.+E.+Minton&title=A+phase+II+study+of+the+histone+deacetylase+inhibitor+vorinostat+combined+with+tamoxifen+for+the+treatment+of+patients+with+hormone+therapy-resistant+breast+cancer&doi=10.1038%2Fbjc.2011.156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer</span></div><div class="casAuthors">Munster, P. N.; Thurn, K. T.; Thomas, S.; Raha, P.; Lacevic, M.; Miller, A.; Melisko, M.; Ismail-Khan, R.; Rugo, H.; Moasser, M.; Minton, S. E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1828-1835</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are crucial components of the estrogen receptor (ER) transcriptional complex.  Preclinically, HDAC inhibitors can reverse tamoxifen/aromatase inhibitor resistance in hormone receptor-pos. breast cancer.  This concept was examd. in a phase II combination trial with correlative end points.  Patients with ER-pos. metastatic breast cancer progressing on endocrine therapy were treated with 400 mg of vorinostat daily for 3 of 4 wk and 20 mg tamoxifen daily, continuously.  Histone acetylation and HDAC2 expression in peripheral blood mononuclear cells were also evaluated.  In all, 43 patients (median age 56 years (31-71)) were treated, 25 (58%) received prior adjuvant tamoxifen, 29 (67%) failed one prior chemotherapy regimen, 42 (98%) progressed after one, and 23 (54%) after two aromatase inhibitors.  The objective response rate by Response Evaluation Criteria in Solid Tumors criteria was 19% and the clin. benefit rate (response or stable disease >24 wk) was 40%.  The median response duration was 10.3 mo (confidence interval: 8.1-12.4).  Histone hyperacetylation and higher baseline HDAC2 levels correlated with response.  The combination of vorinostat and tamoxifen is well tolerated and exhibits encouraging activity in reversing hormone resistance.  Correlative studies suggest that HDAC2 expression is a predictive marker and histone hyperacetylation is a useful pharmacodynamic marker for the efficacy of this combination.  British Journal of Cancer (2011) 104, 1828-1835; doi:10.1038/bjc.2011.156 www.bjcancer.com Published online 10 May 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDPB1YAqSmBLVg90H21EOLACvtfcHk0lhoZlpLD1sMhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntV2hsbg%253D&md5=15e2afd6a1b658f378e4f41ed2b15ef9</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2011.156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2011.156%26sid%3Dliteratum%253Aachs%26aulast%3DMunster%26aufirst%3DP.%2BN.%26aulast%3DThurn%26aufirst%3DK.%2BT.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DRaha%26aufirst%3DP.%26aulast%3DLacevic%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DA.%26aulast%3DMelisko%26aufirst%3DM.%26aulast%3DIsmail-Khan%26aufirst%3DR.%26aulast%3DRugo%26aufirst%3DH.%26aulast%3DMoasser%26aufirst%3DM.%26aulast%3DMinton%26aufirst%3DS.%2BE.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520the%2520histone%2520deacetylase%2520inhibitor%2520vorinostat%2520combined%2520with%2520tamoxifen%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520hormone%2520therapy-resistant%2520breast%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2011%26volume%3D104%26spage%3D1828%26epage%3D1835%26doi%3D10.1038%2Fbjc.2011.156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avraham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avraham, H. K.</span></span> <span> </span><span class="NLM_article-title">Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">358</span>, <span class="refDoi"> DOI: 10.1002/ijc.11403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1002%2Fijc.11403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=14506733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Gns78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2003&pages=353-358&author=H.+Kawaiauthor=H.+Liauthor=S.+Avrahamauthor=S.+Jiangauthor=H.+K.+Avraham&title=Overexpression+of+histone+deacetylase+HDAC1+modulates+breast+cancer+progression+by+negative+regulation+of+estrogen+receptor+alpha&doi=10.1002%2Fijc.11403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor α</span></div><div class="casAuthors">Kawai, Hideki; Li, Huchun; Avraham, Shalom; Jiang, Shuxian; Avraham, Hava Karsenty</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">353-358</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The interaction between 17β-estradiol and estrogen receptor alpha (ER-α) plays an important role in breast carcinogenesis and breast cancer treatment.  ER-α is a crit. growth regulatory gene in breast cancer and its expression level is tightly linked to the prognosis and treatment outcomes of breast cancer patients.  Loss of ER-α expression in breast epithelial cells is crit. for breast cancer progression.  The underlying mol. mechanisms for this loss, however, are poorly defined.  Histone deacetylases (HDACs) are implicated in the alteration of chromatin assembly and tumorigenesis.  We show that histone deacetylase I (HDAC1) interacts with ER-α in vitro and in vivo and suppresses ER-α transcription activity.  The interaction of HDAC1 with ER-α was mediated by the AF-2 and DBD domains of ER-α.  We obsd. an endogenous interaction of HDAC1 with ER-α in breast cancer cells, which was decreased in the presence of estrogen.  Interestingly, overexpression of HDAC1 in stable transfected MCF-7 clones induced loss of ER-α and significantly increased cell proliferation and colony formation, as compared to the control MCF-7 cells, whereas treatment of stable MCF-7 clones with the HDAC specific inhibitor trichostatin A (TSA) induced re-expression of ER-α mRNA and protein.  Our findings strongly suggest that HDAC1 affects breast cancer progression by promoting cellular proliferation in assocn. with a redn. in both ER-α protein expression and transcriptional activity.  Thus, HDAC1 may be a potential target for therapeutic intervention in the treatment of a subset of ER-neg. breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeLCIVDhHWhrVg90H21EOLACvtfcHk0lisoyMtCOSivg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Gns78%253D&md5=c5ae5e91d0e3c1bd55c5b2baebef844c</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1002%2Fijc.11403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.11403%26sid%3Dliteratum%253Aachs%26aulast%3DKawai%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DAvraham%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DAvraham%26aufirst%3DH.%2BK.%26atitle%3DOverexpression%2520of%2520histone%2520deacetylase%2520HDAC1%2520modulates%2520breast%2520cancer%2520progression%2520by%2520negative%2520regulation%2520of%2520estrogen%2520receptor%2520alpha%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2003%26volume%3D107%26spage%3D353%26epage%3D358%26doi%3D10.1002%2Fijc.11403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hodgesgallagher, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kushner, P. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">297</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1007/s10549-006-9459-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1007%2Fs10549-006-9459-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=17186358" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2007&pages=297-309&author=L.+Hodgesgallagherauthor=C.+D.+Valentineauthor=S.+E.+Baderauthor=P.+J.+Kushner&title=Inhibition+of+histone+deacetylase+enhances+the+anti-proliferative+action+of+antiestrogens+on+breast+cancer+cells+and+blocks+tamoxifen-induced+proliferation+of+uterine+cells&doi=10.1007%2Fs10549-006-9459-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1007%2Fs10549-006-9459-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-006-9459-6%26sid%3Dliteratum%253Aachs%26aulast%3DHodgesgallagher%26aufirst%3DL.%26aulast%3DValentine%26aufirst%3DC.%2BD.%26aulast%3DBader%26aufirst%3DS.%2BE.%26aulast%3DKushner%26aufirst%3DP.%2BJ.%26atitle%3DInhibition%2520of%2520histone%2520deacetylase%2520enhances%2520the%2520anti-proliferative%2520action%2520of%2520antiestrogens%2520on%2520breast%2520cancer%2520cells%2520and%2520blocks%2520tamoxifen-induced%2520proliferation%2520of%2520uterine%2520cells%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2007%26volume%3D105%26spage%3D297%26epage%3D309%26doi%3D10.1007%2Fs10549-006-9459-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Margueron, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escande, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaguer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavaillès, V.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens</span>. <i>J. Mol. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">583</span>– <span class="NLM_lpage">594</span>, <span class="refDoi"> DOI: 10.1677/jme.0.0320583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1677%2Fjme.0.0320583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15072561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjslKjtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2004&pages=583-594&author=R.+Margueronauthor=V.+Duongauthor=S.+Bonnetauthor=A.+Escandeauthor=F.+Vignonauthor=P.+Balaguerauthor=V.+Cavaill%C3%A8s&title=Histone+deacetylase+inhibition+and+estrogen+receptor+alpha+levels+modulate+the+transcriptional+activity+of+partial+antiestrogens&doi=10.1677%2Fjme.0.0320583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibition and estrogen receptor α levels modulate the transcriptional activity of partial antiestrogens</span></div><div class="casAuthors">Margueron, R.; Duong, V.; Bonnet, S.; Escande, A.; Vignon, F.; Balaguer, P.; Cavailles, V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Endocrinology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">583-594</span>CODEN:
                <span class="NLM_cas:coden">JMLEEI</span>;
        ISSN:<span class="NLM_cas:issn">0952-5041</span>.
    
            (<span class="NLM_cas:orgname">Society for Endocrinology</span>)
        </div><div class="casAbstract">In this study, the authors have analyzed the effects of histone deacetylase (HDAC) inhibition on estrogen receptor (ER) expression and on its transcriptional activity in response to antiestrogens.  In several breast cancer cell lines, trichostatin A (TSA), a potent HDAC inhibitor, strongly decreases ERα expression in a dose-dependent manner.  This repression is obsd. independently of the presence of ligand and also occurs in ovarian and endometrial cell lines.  In addn., the authors show that in MCF7 cells bearing a stably transfected reporter plasmid (MELN cells), partial antiestrogens such as 4-OH-tamoxifen (OHTam), raloxifen or LY117018, switch to an agonist activity upon HDAC inhibition.  This effect is blocked by the pure antiestrogen ICI182780 and exhibits a half-maximal concn. of OHTam equiv. to its affinity for ERα.  The TSA-dependent decrease of ERα expression is required to induce the agonist switch of OHTam properties as it is lost in cells constitutively expressing exogenous receptors (MELN-ERα or ERβ).  By contrast, the transrepression activity of OHTam is abolished by TSA independently of the decrease of ERα expression.  Interestingly, in MELN-ERα, ICI182780 remains inhibitory suggesting the involvement of HDAC-independent mechanisms.  Finally, in the absence of TSA, transcriptional activity in response to OHTam is significantly raised in MELN cells expressing low levels of ERα after transfection of antisense oligonucleotides.  In conclusion, inhibition of HDAC enzymic activity and modulation of ERα levels tightly control the relative agonist activity of partial antiestrogens on a stably integrated reporter transgene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQTrvnGSsEvbVg90H21EOLACvtfcHk0lisoyMtCOSivg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjslKjtLw%253D&md5=4ba639a4180a390ed67ba7bf4acaeec8</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1677%2Fjme.0.0320583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252Fjme.0.0320583%26sid%3Dliteratum%253Aachs%26aulast%3DMargueron%26aufirst%3DR.%26aulast%3DDuong%26aufirst%3DV.%26aulast%3DBonnet%26aufirst%3DS.%26aulast%3DEscande%26aufirst%3DA.%26aulast%3DVignon%26aufirst%3DF.%26aulast%3DBalaguer%26aufirst%3DP.%26aulast%3DCavaill%25C3%25A8s%26aufirst%3DV.%26atitle%3DHistone%2520deacetylase%2520inhibition%2520and%2520estrogen%2520receptor%2520alpha%2520levels%2520modulate%2520the%2520transcriptional%2520activity%2520of%2520partial%2520antiestrogens%26jtitle%3DJ.%2520Mol.%2520Endocrinol.%26date%3D2004%26volume%3D32%26spage%3D583%26epage%3D594%26doi%3D10.1677%2Fjme.0.0320583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H. B.</span></span> <span> </span><span class="NLM_article-title">Novel bioactive hybrid compounds dual targeting estrogen receptor and histone deacetylase for treatment of breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4550</span>– <span class="NLM_lpage">4572</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00099</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00099" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovVShsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4550-4572&author=C.+Tangauthor=C.+Liauthor=S.+Zhangauthor=Z.+Huauthor=J.+Wuauthor=C.+Dongauthor=J.+Huangauthor=H.+B.+Zhou&title=Novel+bioactive+hybrid+compounds+dual+targeting+estrogen+receptor+and+histone+deacetylase+for+treatment+of+breast+cancer&doi=10.1021%2Facs.jmedchem.5b00099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer</span></div><div class="casAuthors">Tang, Chu; Li, Changhao; Zhang, Silong; Hu, Zhiye; Wu, Jun; Dong, Chune; Huang, Jian; Zhou, Hai-Bing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4550-4572</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A strategy to develop chemotherapeutic agents by combining several active groups into a single mol. as a conjugate that can modulate multiple cellular pathways may produce compds. having higher efficacy compared to that of single-target drugs.  In this article, we describe the synthesis and evaluation of an array of dual-acting ER and histone deacetylase inhibitors.  These novel hybrid compds. combine an indirect antagonism structure motif of ER (OBHS, oxabicycloheptene sulfonate) with the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA).  These OBHS-HDACi conjugates I (R = OH, NHOH; Ar = Ph, 1-naphthyl, 2-naphthyl, 4-MeC6H5, 3-MeC6H5, 2-MeC6H5, 2-MeOC6H5, etc.) exhibited good ER binding affinity and excellent ERα antagonistic activity, and they also exhibited potent inhibitory activities against HDACs.  Compared with the approved drug tamoxifen, these conjugates exhibited higher antitumor potency in ERα-pos. breast cancer cells (MCF-7).  Moreover, these conjugates not only showed selective anticancer activity that was more potent against MCF-7 cells than DU 145 (prostate cancer), but they had no toxicity toward normal cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokzR9bn5jLU7Vg90H21EOLACvtfcHk0lisoyMtCOSivg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovVShsbk%253D&md5=223b9c3c43e1f8f012efcd1771547ee1</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00099%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DH.%2BB.%26atitle%3DNovel%2520bioactive%2520hybrid%2520compounds%2520dual%2520targeting%2520estrogen%2520receptor%2520and%2520histone%2520deacetylase%2520for%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4550%26epage%3D4572%26doi%3D10.1021%2Facs.jmedchem.5b00099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beckett, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huxley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, M.</span></span> <span> </span><span class="NLM_article-title">Recent advances in matrix metalloproteinase inhibitor research</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/1359-6446(96)89115-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2F1359-6446%2896%2989115-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADyaK28XhtFyrsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1996&pages=16-26&author=R.+P.+Beckettauthor=A.+H.+Davidsonauthor=A.+H.+Drummondauthor=P.+Huxleyauthor=M.+Whittaker&title=Recent+advances+in+matrix+metalloproteinase+inhibitor+research&doi=10.1016%2F1359-6446%2896%2989115-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in matrix metalloproteinase inhibitor research</span></div><div class="casAuthors">Beckett, R. Paul; Davidson, Alan H.; Drummond, Alan H.; Huxley, Philip; Whittaker, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-26</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 88 refs. The matrix metalloproteinases (MMPs) are a family of zinc-dependent enzymes that degrade all of the major components of the extracellular matrix.  Over-expression and activation of MMPs have been linked with a range of diseases for which good therapeutic approaches are currently sought, such as arthritis, cancer and multiple sclerosis.  Inhibition of MMPs has therefore become the focus of considerable interest, and potential therapeutic applications continue to grow.  Orally active, broad-spectrum inhibitors have been identified, and some of these are undergoing clin. evaluation.  Structural information on MMP-inhibitor complexes is now available, enabling the structure-based design of selective MMP inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorKdCxN8GmNrVg90H21EOLACvtfcHk0lhDFm1RwfE_Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhtFyrsrY%253D&md5=a92e257fc7f31a93ce7f6c60758f2d3e</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2F1359-6446%2896%2989115-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F1359-6446%252896%252989115-X%26sid%3Dliteratum%253Aachs%26aulast%3DBeckett%26aufirst%3DR.%2BP.%26aulast%3DDavidson%26aufirst%3DA.%2BH.%26aulast%3DDrummond%26aufirst%3DA.%2BH.%26aulast%3DHuxley%26aufirst%3DP.%26aulast%3DWhittaker%26aufirst%3DM.%26atitle%3DRecent%2520advances%2520in%2520matrix%2520metalloproteinase%2520inhibitor%2520research%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D1996%26volume%3D1%26spage%3D16%26epage%3D26%26doi%3D10.1016%2F1359-6446%2896%2989115-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Overall, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleifeld, O.</span></span> <span> </span><span class="NLM_article-title">Tumour microenvironment — opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">227</span>– <span class="NLM_lpage">239</span>, <span class="refDoi"> DOI: 10.1038/nrc1821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnrc1821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=16498445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhslelt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=227-239&author=C.+M.+Overallauthor=O.+Kleifeld&title=Tumour+microenvironment+%E2%80%94+opinion%3A+validating+matrix+metalloproteinases+as+drug+targets+and+anti-targets+for+cancer+therapy&doi=10.1038%2Fnrc1821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Tumour microenvironment - Opinion: Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy</span></div><div class="casAuthors">Overall, Christopher M.; Kleifeld, Oded</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">227-239</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The matrix metalloproteinases (MMPs) mediate homeostasis of the extracellular environment.  They have multiple signaling activities that are commonly altered during tumorigenesis and that might serve as intervention points for anticancer drugs.  However, there are many criteria to consider in validating MMPs as drug targets and for the development of MMP inhibitors.  The inhibition of some MMPs could have pro-tumorigenic effects (making them anti-targets), counterbalancing the benefits of target inhibition.  These effects might partially account for the failure of MMP inhibitors in clin. trials.  What are the major challenges in MMP target validation and MMP-inhibitor-drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc3iBQEggRc7Vg90H21EOLACvtfcHk0lhDFm1RwfE_Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhslelt70%253D&md5=3edfeca153a62c759443d0893a6212e2</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1038%2Fnrc1821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1821%26sid%3Dliteratum%253Aachs%26aulast%3DOverall%26aufirst%3DC.%2BM.%26aulast%3DKleifeld%26aufirst%3DO.%26atitle%3DTumour%2520microenvironment%2520%25E2%2580%2594%2520opinion%253A%2520validating%2520matrix%2520metalloproteinases%2520as%2520drug%2520targets%2520and%2520anti-targets%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D227%26epage%3D239%26doi%3D10.1038%2Fnrc1821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Egeblad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werb, Z.</span></span> <span> </span><span class="NLM_article-title">New functions for the matrix metalloproteinases in cancer progression</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1038/nrc745</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnrc745" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=11990853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1KktL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=161-174&author=M.+Egebladauthor=Z.+Werb&title=New+functions+for+the+matrix+metalloproteinases+in+cancer+progression&doi=10.1038%2Fnrc745"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">New functions for the matrix metalloproteinases in cancer progression</span></div><div class="casAuthors">Egeblad, Mikala; Werb, Zena</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">161-174</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Matrix metalloproteinases (MMPs) have long been assocd. with cancer-cell invasion and metastasis.  This provided the rationale for clin. trials of MMP inhibitors, unfortunately with disappointing results.  We now know, however, that the MMPs have functions other than promotion of invasion, have substrates other than components of the extracellular matrix, and that they function before invasion in the development of cancer.  With this knowledge in hand, can we rethink the use of MMP inhibitors in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtDQGs5M_BzLVg90H21EOLACvtfcHk0lhDFm1RwfE_Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1KktL8%253D&md5=56dd558362155cb25c9adbea4d478aa8</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1038%2Fnrc745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc745%26sid%3Dliteratum%253Aachs%26aulast%3DEgeblad%26aufirst%3DM.%26aulast%3DWerb%26aufirst%3DZ.%26atitle%3DNew%2520functions%2520for%2520the%2520matrix%2520metalloproteinases%2520in%2520cancer%2520progression%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D161%26epage%3D174%26doi%3D10.1038%2Fnrc745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Page-McCaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewald, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werb, Z.</span></span> <span> </span><span class="NLM_article-title">Matrix metalloproteinases and the regulation of tissue remodelling</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1038/nrm2125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnrm2125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=17318226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=221-233&author=A.+Page-McCawauthor=A.+J.+Ewaldauthor=Z.+Werb&title=Matrix+metalloproteinases+and+the+regulation+of+tissue+remodelling&doi=10.1038%2Fnrm2125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Matrix metalloproteinases and the regulation of tissue remodelling</span></div><div class="casAuthors">Page-McCaw, Andrea; Ewald, Andrew J.; Werb, Zena</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">221-233</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Matrix metalloproteinases (MMPs) were discovered because of their role in amphibian metamorphosis, yet they have attracted more attention because of their roles in disease.  Despite intensive scrutiny in vitro, in cell culture and in animal models, the normal physiol. roles of these extracellular proteases have been elusive.  Recent studies in mice and flies point to essential roles of MMPs as mediators of change and phys. adaptation in tissues, whether developmentally regulated, environmentally induced or disease assocd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruFGsYuEMGL7Vg90H21EOLACvtfcHk0lj03jNlbW4oqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrs74%253D&md5=8c3655e653939cd016e2949c6b017e93</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1038%2Fnrm2125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2125%26sid%3Dliteratum%253Aachs%26aulast%3DPage-McCaw%26aufirst%3DA.%26aulast%3DEwald%26aufirst%3DA.%2BJ.%26aulast%3DWerb%26aufirst%3DZ.%26atitle%3DMatrix%2520metalloproteinases%2520and%2520the%2520regulation%2520of%2520tissue%2520remodelling%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2007%26volume%3D8%26spage%3D221%26epage%3D233%26doi%3D10.1038%2Fnrm2125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, T.</span></span> <span> </span><span class="NLM_article-title">Arylsulfonamides and selectivity of matrix metalloproteinase-2: an overview</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">109</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.02.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.ejmech.2017.02.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=28219048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtVelu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=72-109&author=N.+Adhikariauthor=A.+Mukherjeeauthor=A.+Sahaauthor=T.+Jha&title=Arylsulfonamides+and+selectivity+of+matrix+metalloproteinase-2%3A+an+overview&doi=10.1016%2Fj.ejmech.2017.02.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Arylsulfonamides and selectivity of matrix metalloproteinase-2: An overview</span></div><div class="casAuthors">Adhikari, Nilanjan; Mukherjee, Avinaba; Saha, Achintya; Jha, Tarun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">72-109</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Uncontrolled regulation of specific metalloenzymes plays important roles in several diseases like tumor metastasis and inflammation.  Therefore, selective metalloenzyme inhibition may be a potential target for drug design and development.  Matrix metalloproteinase inhibitors (MMPIs) opened up a new horizon as the possible treatment of arthritis, cancer, and emphysema.  However, due to adverse effects and poor pharmacokinetics, first generation MMPIs failed in clin. trials.  Therefore, development of potential and selective MMPIs is still in demand.  Moreover, the flexibility of the enzyme S1' pocket is variable in length and shape making the designing approach more challenging.  In this article, arylsulfonamides have been highlighted as potential and selective MMP-2 inhibitors through structure-activity relationships study.  It may be postulated that sulfonamide moiety may provide better direction to the assocd. aryl group to accommodate the deep hydrophobic S1' pocket.  Tetrahedral geometry of the sulfonyl function may be favorable than planar carboxyl function regarding the interaction between the aryl group and S1' pocket.  Hydroxamates may impart higher inhibition than corresponding carboxylates due to addnl. hydrogen bonding.  Moreover, MMP-2 selectivity is not only dependent on zinc binders but also on the aryl functions directed towards S1 and S2' pockets.  Therefore, this review may help in designing potential and selective MMP-2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphb5pVEplLcbVg90H21EOLACvtfcHk0lhqnaqw2uJXLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtVelu7g%253D&md5=550e8018477cfa802407443195c41d89</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.02.014%26sid%3Dliteratum%253Aachs%26aulast%3DAdhikari%26aufirst%3DN.%26aulast%3DMukherjee%26aufirst%3DA.%26aulast%3DSaha%26aufirst%3DA.%26aulast%3DJha%26aufirst%3DT.%26atitle%3DArylsulfonamides%2520and%2520selectivity%2520of%2520matrix%2520metalloproteinase-2%253A%2520an%2520overview%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D129%26spage%3D72%26epage%3D109%26doi%3D10.1016%2Fj.ejmech.2017.02.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amin, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, T.</span></span> <span> </span><span class="NLM_article-title">Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies?</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2017.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.phrs.2017.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=28501516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVGrs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2017&pages=8-19&author=S.+A.+Aminauthor=N.+Adhikariauthor=T.+Jha&title=Is+dual+inhibition+of+metalloenzymes+HDAC-8+and+MMP-2+a+potential+pharmacological+target+to+combat+hematological+malignancies%3F&doi=10.1016%2Fj.phrs.2017.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies?</span></div><div class="casAuthors">Amin, Sk. Abdul; Adhikari, Nilanjan; Jha, Tarun</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8-19</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">For the last three decades, metalloenzymes such as histone deacetylases (HDACs) and matrix metalloproteinases (MMPs) have been identified in promoting solid as well as hematol. carcinogenesis.  Histone deacetylase 8 (HDAC-8), a class I HDAC enzyme, may serve as 'epigenetic player' that affects in the regulation of transcription factors and alters the structure of chromosome assocd. with tumorigenesis.  It is established that the influence of MMP-2 in invasion, metastasis and angiogenetic events of hematol. malignancies may be suppressed by HDAC inhibitors through reversion-inducing-cysteine-rich protein with kazal motifs (RECK) protein.  Therefore, the isoform-specific HDAC-8 and MMP-2 inhibitors may provide synergistic medicinal benefit in leukemia.  However, a paucity of articles is available on dual acting HDAC-8/MMP-2 inhibitors.  In this circumstance, a lot of works are still necessary to identify novel dual HDAC-8/MMP-2 inhibitors and this review will surely provide an initial idea regarding the utility of designing such type of dual inhibitors.  Here, the importance of MMP-2 and HDAC-8 inhibition in hematol. malignancies are focussed for the first time as per our knowledge along with the structure-activity relationships (SARs) of a handful of mols., some of which were synthesized inhouse, have been highlighted that will inspire more interactions between the medicinal chem. and biol. community to harness their expertise in design and discovery of the better acting dual inhibitors in future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUOVqI4P-EsLVg90H21EOLACvtfcHk0li0CXl3xBJSOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVGrs7w%253D&md5=a3284a3b2836efb3e6d721d4a0d8e713</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2017.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2017.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DAmin%26aufirst%3DS.%2BA.%26aulast%3DAdhikari%26aufirst%3DN.%26aulast%3DJha%26aufirst%3DT.%26atitle%3DIs%2520dual%2520inhibition%2520of%2520metalloenzymes%2520HDAC-8%2520and%2520MMP-2%2520a%2520potential%2520pharmacological%2520target%2520to%2520combat%2520hematological%2520malignancies%253F%26jtitle%3DPharmacol.%2520Res.%26date%3D2017%26volume%3D122%26spage%3D8%26epage%3D19%26doi%3D10.1016%2Fj.phrs.2017.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chakrabarti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehme, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">HDAC8: a multifaceted target for therapeutic interventions</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">492</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2015.04.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.tips.2015.04.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=26013035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlGqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=481-492&author=A.+Chakrabartiauthor=I.+Oehmeauthor=O.+Wittauthor=G.+Oliveiraauthor=W.+Sipplauthor=C.+Romierauthor=R.+J.+Pierceauthor=M.+Jung&title=HDAC8%3A+a+multifaceted+target+for+therapeutic+interventions&doi=10.1016%2Fj.tips.2015.04.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC8: a multifaceted target for therapeutic interventions</span></div><div class="casAuthors">Chakrabarti, Alokta; Oehme, Ina; Witt, Olaf; Oliveira, Guilherme; Sippl, Wolfgang; Romier, Christophe; Pierce, Raymond J.; Jung, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">481-492</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Histone deacetylase 8 (HDAC8) is a class I histone deacetylase implicated as a therapeutic target in various diseases, including cancer, X-linked intellectual disability, and parasitic infections.  It is a structurally well-characterized enzyme that also deacetylates nonhistone proteins.  In cancer, HDAC8 is a major 'epigenetic player' that is linked to deregulated expression or interaction with transcription factors crit. to tumorigenesis.  In the parasite Schistosoma mansoni and in viral infections, HDAC8 is a novel target to subdue infection.  The current challenge remains in the development of potent selective inhibitors that would specifically target HDAC8 with fewer adverse effects compared with pan-HDAC inhibitors.  Here, we review HDAC8 as a drug target and discuss inhibitors with respect to their structural features and therapeutic interventions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPwG01nKtWHLVg90H21EOLACvtfcHk0lhjsqUGno6vQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlGqsL4%253D&md5=c99b5c390930dc17398d15f20127758b</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DChakrabarti%26aufirst%3DA.%26aulast%3DOehme%26aufirst%3DI.%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DOliveira%26aufirst%3DG.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DRomier%26aufirst%3DC.%26aulast%3DPierce%26aufirst%3DR.%2BJ.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DHDAC8%253A%2520a%2520multifaceted%2520target%2520for%2520therapeutic%2520interventions%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D481%26epage%3D492%26doi%3D10.1016%2Fj.tips.2015.04.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chakrabarti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melesina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolbinger, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehme, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1609</span>– <span class="NLM_lpage">1634</span>, <span class="refDoi"> DOI: 10.4155/fmc-2016-0117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.4155%2Ffmc-2016-0117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=27572818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKhsrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=1609-1634&author=A.+Chakrabartiauthor=J.+Melesinaauthor=F.+R.+Kolbingerauthor=I.+Oehmeauthor=J.+Sengerauthor=O.+Wittauthor=W.+Sipplauthor=M.+Jung&title=Targeting+histone+deacetylase+8+as+a+therapeutic+approach+to+cancer+and+neurodegenerative+diseases&doi=10.4155%2Ffmc-2016-0117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases</span></div><div class="casAuthors">Chakrabarti, Alokta; Melesina, Jelena; Kolbinger, Fiona R.; Oehme, Ina; Senger, Johanna; Witt, Olaf; Sippl, Wolfgang; Jung, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1609-1634</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Histone deacetylase 8 (HDAC8), a unique class I zinc-dependent HDAC, is an emerging target in cancer and other diseases.  Its substrate repertoire extends beyond histones to many nonhistone proteins.  Besides being a deacetylase, HDAC8 also mediates signaling via scaffolding functions.  Aberrant expression or deregulated interactions with transcription factors are crit. in HDAC8-dependent cancers.  Many potent HDAC8-selective inhibitors with cellular activity and anticancer effects have been reported.  We present HDAC8 as a druggable target and discuss inhibitors of different chem. scaffolds with cellular effects.  Furthermore, we review HDAC8 activators that revert activity of mutant enzymes.  Isotype-selective HDAC8 targeting in patients with HDAC8-relevant cancers is challenging, however, is promising to avoid adverse side effects as obsd. with pan-HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAgIFjNGH66LVg90H21EOLACvtfcHk0liY_n7W9H-n6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKhsrzF&md5=942984331e8f3c589b9257c17d2a9ec2</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2016-0117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2016-0117%26sid%3Dliteratum%253Aachs%26aulast%3DChakrabarti%26aufirst%3DA.%26aulast%3DMelesina%26aufirst%3DJ.%26aulast%3DKolbinger%26aufirst%3DF.%2BR.%26aulast%3DOehme%26aufirst%3DI.%26aulast%3DSenger%26aufirst%3DJ.%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DTargeting%2520histone%2520deacetylase%25208%2520as%2520a%2520therapeutic%2520approach%2520to%2520cancer%2520and%2520neurodegenerative%2520diseases%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2016%26volume%3D8%26spage%3D1609%26epage%3D1634%26doi%3D10.4155%2Ffmc-2016-0117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellenga, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraaije, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamps, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bont, E. S.</span></span> <span> </span><span class="NLM_article-title">The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia</span>. <i>Crit. Rev. Oncol. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2003.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.critrevonc.2003.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15157658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A280%3ADC%252BD2c3lvFCjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2004&pages=87-100&author=G.+Kleinauthor=E.+Vellengaauthor=M.+W.+Fraaijeauthor=W.+A.+Kampsauthor=E.+S.+de+Bont&title=The+possible+role+of+matrix+metalloproteinase+%28MMP%29-2+and+MMP-9+in+cancer%2C+e.g.+acute+leukemia&doi=10.1016%2Fj.critrevonc.2003.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia</span></div><div class="casAuthors">Klein G; Vellenga E; Fraaije M W; Kamps W A; de Bont E S J M</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-100</span>
        ISSN:<span class="NLM_cas:issn">1040-8428</span>.
    </div><div class="casAbstract">In the past decades, a lot of effort has been put in identifying the role of matrix metalloproteinases (MMPs) in cancer.  The main role of MMPs in angiogenesis, tumor growth and metastasis is degradation of extracellular matrix (ECM) and release and/or activation of growth factors through their degradative activity.  The degradative activity finally results in cancer progression.  MMP-inhibitors (MMPIs) have already been designed and tested, based on the degradative role of MMPs in cancer progression.  First clinical trials with MMPIs have been performed with disappointing results, showing that in order to use MMP-inhibition the mechanisms underlying MMP-expression in cancer have to be further elucidated.  This paper reviews the mechanisms of MMPs on molecular and cellular level and discusses the role for MMPs and MMP-inhibition in cancer with special focus on acute leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHKDAY2m_YX-vW160gIxP_fW6udTcc2ebzT5eJTDuD_Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3lvFCjuw%253D%253D&md5=19112f90fed85d9bd147c1475b1c3c58</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2003.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2003.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DKlein%26aufirst%3DG.%26aulast%3DVellenga%26aufirst%3DE.%26aulast%3DFraaije%26aufirst%3DM.%2BW.%26aulast%3DKamps%26aufirst%3DW.%2BA.%26aulast%3Dde%2BBont%26aufirst%3DE.%2BS.%26atitle%3DThe%2520possible%2520role%2520of%2520matrix%2520metalloproteinase%2520%2528MMP%2529-2%2520and%2520MMP-9%2520in%2520cancer%252C%2520e.g.%2520acute%2520leukemia%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2004%26volume%3D50%26spage%3D87%26epage%3D100%26doi%3D10.1016%2Fj.critrevonc.2003.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, S. H.</span></span> <span> </span><span class="NLM_article-title">HDAC inhibitors and RECK modulate endoplasmic reticulum stress in tumor cells</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">258</span>, <span class="refDoi"> DOI: 10.3390/ijms18020258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.3390%2Fijms18020258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsFCmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=258&author=Y.+Chenauthor=Y.+H.+Tsaiauthor=S.+H.+Tseng&title=HDAC+inhibitors+and+RECK+modulate+endoplasmic+reticulum+stress+in+tumor+cells&doi=10.3390%2Fijms18020258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitors and RECK modulate endoplasmic reticulum stress in tumor cells</span></div><div class="casAuthors">Chen, Yun; Tsai, Ya-Hui; Tseng, Sheng-Hong</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">258/1-258/9</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">In the tumor microenvironment hypoxia and nutrient deprived states can induce endoplasmic reticulum (ER) stress.  If ER stress is not relieved, the tumor cells may become apoptotic.  Therefore, targeting ER homeostasis is a potential strategy for cancer treatment.  Various chemotherapeutic agents including histone deacetylase (HDAC) inhibitors can induce ER stress to cause cell death in cancers.  Some HDAC inhibitors can prevent HDAC from binding to the specificity protein 1-binding site of the promoter of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) and up-regulate RECK expression.  Up-regulation of RECK expression by HDAC inhibitors has been obsd. in various cancer types.  RECK is a tumor and metastasis suppressor gene and is crit. for regulating tumor cell invasiveness and metastasis.  RECK also modulates ER stress via binding to and sequestering glucose-regulated protein 78 protein, so that the transmembrane sensors, such as protein kinase RNA-like ER kinase are released to activate eukaryotic translational initiation factor 2α phosphorylation and enhance ER stress.  Therefore, HDAC inhibitors may directly induce ER stress or indirectly induce this stress by up-regulating RECK in cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX53c53XHhHLVg90H21EOLACvtfcHk0lhrc5E9FIhRGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsFCmtbs%253D&md5=b6487b31b9fe8b9363a3443dc88c4523</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.3390%2Fijms18020258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18020258%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTsai%26aufirst%3DY.%2BH.%26aulast%3DTseng%26aufirst%3DS.%2BH.%26atitle%3DHDAC%2520inhibitors%2520and%2520RECK%2520modulate%2520endoplasmic%2520reticulum%2520stress%2520in%2520tumor%2520cells%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D258%26doi%3D10.3390%2Fijms18020258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, W.-C.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">3069</span>– <span class="NLM_lpage">3072</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=12810630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD3sXks1eitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=3069-3072&author=L.-T.+Liuauthor=H.-C.+Changauthor=L.-C.+Chiangauthor=W.-C.+Hung&title=Histone+deacetylase+inhibitor+up-regulates+RECK+to+inhibit+MMP-2+activation+and+cancer+cell+invasion"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitor Up-Regulates RECK to Inhibit MMP-2 Activation and Cancer Cell Invasion</span></div><div class="casAuthors">Liu, Li-Teh; Chang, Hui-Chiu; Chiang, Lien-Chai; Hung, Wen-Chun</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3069-3072</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors are known to exert antimetastatic and antiangiogenic activity in vitro and in vivo.  RECK is a membrane-anchored glycoprotein that neg. regulates matrix metalloproteinases (MMPs) and inhibits tumor metastasis and angiogenesis.  In this study, we test the possibility that HDAC inhibitor may increase RECK expression to inhibit MMP activation and cancer cell invasion.  Our results showed that trichostatin A (TSA) up-regulated RECK via transcriptional activation in CL-1 human lung cancer cells.  Flow cytometric anal. demonstrated that RECK protein on cell surface was increased after treatment of TSA.  Moreover, up-regulation of RECK expression by TSA attenuated MMP-2 activity.  To explore whether HDAC inhibitor-induced inhibition of MMP-2 activation is indeed mediated via RECK, we used small interference RNA (siRNA) to block RECK expression and found that inhibition of RECK by siRNA abolished the inhibitory effect of TSA on MMP-2 activation.  In addn., TSA suppressed the invasive ability of CL-1 cells.  Taken together, this study reveals a novel mechanism by which HDAC inhibitors suppress tumor invasion and provides a new strategy for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBPNbfE-AnIrVg90H21EOLACvtfcHk0li6aMA13iaknA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXks1eitLk%253D&md5=92b3c13b7eaa1f61d53f5345e2f1f7da</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.-T.%26aulast%3DChang%26aufirst%3DH.-C.%26aulast%3DChiang%26aufirst%3DL.-C.%26aulast%3DHung%26aufirst%3DW.-C.%26atitle%3DHistone%2520deacetylase%2520inhibitor%2520up-regulates%2520RECK%2520to%2520inhibit%2520MMP-2%2520activation%2520and%2520cancer%2520cell%2520invasion%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D3069%26epage%3D3072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takemoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuramae, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, J.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriuchi, T.</span></span> <span> </span><span class="NLM_article-title">Low expression of reversion-inducing cysteine-rich protein with kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">376</span>– <span class="NLM_lpage">383</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2007.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.lungcan.2007.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=17714826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A280%3ADC%252BD2sjmtVanug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2007&pages=376-383&author=N.+Takemotoauthor=M.+Tadaauthor=Y.+Hidaauthor=T.+Asanoauthor=S.+Chengauthor=T.+Kuramaeauthor=J.-I.+Hamadaauthor=M.+Miyamotoauthor=S.+Kondoauthor=T.+Moriuchi&title=Low+expression+of+reversion-inducing+cysteine-rich+protein+with+kazal+motifs+%28RECK%29+indicates+a+shorter+survival+after+resection+in+patients+with+adenocarcinoma+of+the+lung&doi=10.1016%2Fj.lungcan.2007.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Low expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung</span></div><div class="casAuthors">Takemoto Norihiro; Tada Mitsuhiro; Hida Yasuhiro; Asano Toshimichi; Cheng Shaoqiang; Kuramae Tarou; Hamada Jun-Ichi; Miyamoto Masaki; Kondo Satoshi; Moriuchi Tetsuya</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">376-83</span>
        ISSN:<span class="NLM_cas:issn">0169-5002</span>.
    </div><div class="casAbstract">It has been reported that an endogenous matrix metalloproteinase (MMP) inhibitor, reversion-inducing cysteine-rich protein with Kazal motifs (RECK), is able to inhibit tumour angiogenesis, invasion, and metastasis through inhibition of MMP-2, MMP-9, and membrane type-1 (MT1)-MMP (MMP-14) secretion and activity.  In this study, using quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR), we have analysed RECK expression levels in resected non-small-cell lung cancer (NSCLC) tissue and compared these data with the clinicopathological features of these patients to investigate the role of RECK in NSCLC.  We have also analysed the expression of MMP-2, MMP-9, and MMP-14 and compared the data with those for RECK expression.  Tissue samples of primary lung cancers were obtained from a total of 83 patients [46 with adenocarcinomas (ADC) and 37 with squamous cell carcinomas (SCC)] who underwent curative resection.  The samples were taken from 83 tumours and 20 matched normal lung tissue samples as controls.  Expressions of RECK in ADC and SCC were significantly lower than in the control.  In ADC tissue, the expression of RECK was higher in stage IA than in stage IB-IIIA.  There was no such a correlation in SCC.  In ADC, univariate analysis for relapse-free survival using Cox regression analysis identified low RECK expression (p=0.036), low MMP-14 expression (p=0.038), and tumour T2 (p=0.034) as significant negative prognostic predictors.  However, in SCC, none of the clinicopathological factors assessed, including RECK expression, had prognostic value.  In conclusion, our study suggests that suppression of RECK expression is involved in the progression of ADC of the lung and that RECK expression in resected ADC of the lung is a favorable predictor of patients' prognosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT1wVUn54DMxEcLvDNbOD4DfW6udTcc2eYIRqFTzmziq7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjmtVanug%253D%253D&md5=f2943e51bd570acc3037d692f05c3a4b</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2007.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2007.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DTakemoto%26aufirst%3DN.%26aulast%3DTada%26aufirst%3DM.%26aulast%3DHida%26aufirst%3DY.%26aulast%3DAsano%26aufirst%3DT.%26aulast%3DCheng%26aufirst%3DS.%26aulast%3DKuramae%26aufirst%3DT.%26aulast%3DHamada%26aufirst%3DJ.-I.%26aulast%3DMiyamoto%26aufirst%3DM.%26aulast%3DKondo%26aufirst%3DS.%26aulast%3DMoriuchi%26aufirst%3DT.%26atitle%3DLow%2520expression%2520of%2520reversion-inducing%2520cysteine-rich%2520protein%2520with%2520kazal%2520motifs%2520%2528RECK%2529%2520indicates%2520a%2520shorter%2520survival%2520after%2520resection%2520in%2520patients%2520with%2520adenocarcinoma%2520of%2520the%2520lung%26jtitle%3DLung%2520Cancer%26date%3D2007%26volume%3D58%26spage%3D376%26epage%3D383%26doi%3D10.1016%2Fj.lungcan.2007.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span> <span> </span><span class="NLM_article-title">Expression of RECK and MMP-2 in salivary adenoid cystic carcinoma: correlation with tumor progression and patient prognosis</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1549</span>– <span class="NLM_lpage">1555</span>, <span class="refDoi"> DOI: 10.3892/ol.2014.1906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.3892%2Fol.2014.1906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=24765174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1egtbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=1549-1555&author=X.+Zhouauthor=S.+Huangauthor=L.+Jiangauthor=S.+Zhangauthor=W.+Liauthor=Z.+Chenauthor=D.+Zhang&title=Expression+of+RECK+and+MMP-2+in+salivary+adenoid+cystic+carcinoma%3A+correlation+with+tumor+progression+and+patient+prognosis&doi=10.3892%2Fol.2014.1906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of RECK and MMP-2 in salivary adenoid cystic carcinoma: correlation with tumor progression and patient prognosis</span></div><div class="casAuthors">Zhou, Xiaoqing; Huang, Shengyun; Jiang, Licheng; Zhang, Shizhou; Li, Wengang; Chen, Zhanwei; Zhang, Dongsheng</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1549-1555</span>CODEN:
                <span class="NLM_cas:coden">OLNEB5</span>;
        ISSN:<span class="NLM_cas:issn">1792-1074</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Reversion-inducing cysteine-rich protein with Kazal motifs (RECK), a glycosylphosphatidylinositol-anchored glycoprotein, inhibits the enzymic activities of certain matrix metalloproteinases (MMPs).  RECK has been studied in numerous human tumors, but the expression of RECK in salivary adenoid cystic carcinoma (SACC), and its correlation with patient prognosis, has never been investigated thus far.  In the present study, the expression of RECK and MMP-2 was evaluated in two ACC cell lines and in 83 patients with SACC.  The results of quant. polymerase chain reaction and western blot anal. revealed that the ACC-2 and ACC-M cell lines expressed RECK and MMP-2 mRNA and protein.  The immunohistochem. staining in the patients demonstrated that pos. expression of RECK and MMP-2 was obsd. in 21/83 (25.3%) and 69/83 (83.1%) cases, resp., and that RECK expression was significantly assocd. with the tumor-node-metastasis stage, histol. grade and perineural invasion of patients with SACC (P<0.05).  Furthermore, there was a significant assocn. between the pos. expression of RECK and that of MMP-2 (P<0.0001).  Univariate and multivariate analyses confirmed that a lack of RECK expression was an independent and significant factor for the prediction of a poor prognosis.  In conclusion, RECK is a promising prognostic marker and potential therapeutic agent in SACC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEsWU5CQRRI7Vg90H21EOLACvtfcHk0lhtTxxUw3EXfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1egtbjJ&md5=a5e7ff027c7fcbc4a52ccfa9c1ee5f61</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.3892%2Fol.2014.1906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2014.1906%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DD.%26atitle%3DExpression%2520of%2520RECK%2520and%2520MMP-2%2520in%2520salivary%2520adenoid%2520cystic%2520carcinoma%253A%2520correlation%2520with%2520tumor%2520progression%2520and%2520patient%2520prognosis%26jtitle%3DOncol.%2520Lett.%26date%3D2014%26volume%3D7%26spage%3D1549%26epage%3D1555%26doi%3D10.3892%2Fol.2014.1906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, D.</span></span> <span> </span><span class="NLM_article-title">Low expression of RECK indicates a shorter survival for patients with invasive breast cancer</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">1084</span>– <span class="NLM_lpage">1089</span>, <span class="refDoi"> DOI: 10.1111/j.1349-7006.2012.02265.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1111%2Fj.1349-7006.2012.02265.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=22404079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38XnslKhsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2012&pages=1084-1089&author=Y.+Zhangauthor=S.+Chengauthor=G.+Zhangauthor=W.+Maauthor=Y.+Liuauthor=R.+Zhaoauthor=Q.+Zhangauthor=D.+Pang&title=Low+expression+of+RECK+indicates+a+shorter+survival+for+patients+with+invasive+breast+cancer&doi=10.1111%2Fj.1349-7006.2012.02265.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Low expression of RECK indicates a shorter survival for patients with invasive breast cancer</span></div><div class="casAuthors">Zhang, Yue; Cheng, Shaoqiang; Zhang, Guoqiang; Ma, Wenjie; Liu, Yang; Zhao, Rui; Zhang, Qingyuan; Pang, Da</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1084-1089</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Expression cloning was used to initially isolate the reversion-inducing cysteine-rich protein with Kazal motifs (RECK) gene as a suppressor of transformation.  The gene was found to encode a membrane-anchored regulator of MMPs.  Exptl. studies showed that RECK can suppress tumor invasion, metastasis, and angiogenesis.  However, the clin. impact of RECK remains unclear.  To assess the clin. significance of RECK expression in invasive breast cancer, a total of 119 patients with invasive breast cancer were retrospectively examd.  Expression of RECK in tumor tissues was assessed by immunohistochem. staining.  A significant correlation between RECK expression and 5-yr survival rate was documented.  The 5-yr survival rate for patients with strong RECK expression was significantly higher than that for patients with weakly expressing tumors.  Univariate and multivariate analyses confirmed that reduced RECK expression was an independent and significant factor in predicting a poor prognosis.  In conclusion, RECK expression is a significant prognostic factor correlated with long-term survival for patients with invasive breast cancer.  RECK expression is therefore a potentially useful prognostic marker for breast cancer. (Cancer Sci 2012; 103: 1084-1089).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodDVql2M-ImrVg90H21EOLACvtfcHk0lhtTxxUw3EXfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnslKhsLw%253D&md5=6900ce8bd6a7dbb003ceb4d0471cb918</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2012.02265.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2012.02265.x%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DPang%26aufirst%3DD.%26atitle%3DLow%2520expression%2520of%2520RECK%2520indicates%2520a%2520shorter%2520survival%2520for%2520patients%2520with%2520invasive%2520breast%2520cancer%26jtitle%3DCancer%2520Sci.%26date%3D2012%26volume%3D103%26spage%3D1084%26epage%3D1089%26doi%3D10.1111%2Fj.1349-7006.2012.02265.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. M.</span></span> <span> </span><span class="NLM_article-title">Spermidine inhibits MMP-2 via modulation of histone acetyltransferase and histone deacetylase in HDFs</span>. <i>Int. J. Biol. Macromol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1003</span>– <span class="NLM_lpage">1007</span>, <span class="refDoi"> DOI: 10.1016/j.ijbiomac.2012.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.ijbiomac.2012.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=22925630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFCltL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=1003-1007&author=I.+H.+Parkauthor=M.+M.+Kim&title=Spermidine+inhibits+MMP-2+via+modulation+of+histone+acetyltransferase+and+histone+deacetylase+in+HDFs&doi=10.1016%2Fj.ijbiomac.2012.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Spermidine inhibits MMP-2 via modulation of histone acetyltransferase and histone deacetylase in HDFs</span></div><div class="casAuthors">Park, In-Hwan; Kim, Moon-Moo</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biological Macromolecules</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1003-1007</span>CODEN:
                <span class="NLM_cas:coden">IJBMDR</span>;
        ISSN:<span class="NLM_cas:issn">0141-8130</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In recent years, aging has been reported to be regulated by HAT.  In this study, the inhibitory effects of spermidine on the matrix metalloproteinase-2 (MMP-2) activity and expression were investigated in human dermal fibroblasts (HDFs).  It was obsd. that spermidine inhibits MMP-2 activity and expression.  In addn., the expression levels of histone acetyltransferase (HAT), phospho-extracellular-signal related kinase (p-ERK), phospho-c-jun N-terminal kinase (p-JNK), and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) are decreased in the presence of spermidine.  In contrast, the expression levels of histone deacetylase 1 (HDAC1), sirtuin 1 (SIRT1), phospho-p38 (p-p38) are increased by spermidine.  In conclusion, our results suggest that spermidine could have a therapeutic potential in inhibition of metastasis through the inhibitory effects on activity and expression of MMP-2 via regulation of HAT and HDAC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC-HeX-aJ4WbVg90H21EOLACvtfcHk0lhtTxxUw3EXfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFCltL3F&md5=8211e2e91a30222797064c99eb1d18f9</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1016%2Fj.ijbiomac.2012.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijbiomac.2012.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DI.%2BH.%26aulast%3DKim%26aufirst%3DM.%2BM.%26atitle%3DSpermidine%2520inhibits%2520MMP-2%2520via%2520modulation%2520of%2520histone%2520acetyltransferase%2520and%2520histone%2520deacetylase%2520in%2520HDFs%26jtitle%3DInt.%2520J.%2520Biol.%2520Macromol.%26date%3D2012%26volume%3D51%26spage%3D1003%26epage%3D1007%26doi%3D10.1016%2Fj.ijbiomac.2012.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, W. C.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">3069</span>– <span class="NLM_lpage">3072</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=12810630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD3sXks1eitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=3069-3072&author=L.+T.+Liuauthor=H.+C.+Changauthor=L.+C.+Chiangauthor=W.+C.+Hung&title=Histone+deacetylase+inhibitor+up-regulates+RECK+to+inhibit+MMP-2+activation+and+cancer+cell+invasion"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitor Up-Regulates RECK to Inhibit MMP-2 Activation and Cancer Cell Invasion</span></div><div class="casAuthors">Liu, Li-Teh; Chang, Hui-Chiu; Chiang, Lien-Chai; Hung, Wen-Chun</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3069-3072</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors are known to exert antimetastatic and antiangiogenic activity in vitro and in vivo.  RECK is a membrane-anchored glycoprotein that neg. regulates matrix metalloproteinases (MMPs) and inhibits tumor metastasis and angiogenesis.  In this study, we test the possibility that HDAC inhibitor may increase RECK expression to inhibit MMP activation and cancer cell invasion.  Our results showed that trichostatin A (TSA) up-regulated RECK via transcriptional activation in CL-1 human lung cancer cells.  Flow cytometric anal. demonstrated that RECK protein on cell surface was increased after treatment of TSA.  Moreover, up-regulation of RECK expression by TSA attenuated MMP-2 activity.  To explore whether HDAC inhibitor-induced inhibition of MMP-2 activation is indeed mediated via RECK, we used small interference RNA (siRNA) to block RECK expression and found that inhibition of RECK by siRNA abolished the inhibitory effect of TSA on MMP-2 activation.  In addn., TSA suppressed the invasive ability of CL-1 cells.  Taken together, this study reveals a novel mechanism by which HDAC inhibitors suppress tumor invasion and provides a new strategy for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBPNbfE-AnIrVg90H21EOLACvtfcHk0lhtTxxUw3EXfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXks1eitLk%253D&md5=92b3c13b7eaa1f61d53f5345e2f1f7da</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%2BT.%26aulast%3DChang%26aufirst%3DH.%2BC.%26aulast%3DChiang%26aufirst%3DL.%2BC.%26aulast%3DHung%26aufirst%3DW.%2BC.%26atitle%3DHistone%2520deacetylase%2520inhibitor%2520up-regulates%2520RECK%2520to%2520inhibit%2520MMP-2%2520activation%2520and%2520cancer%2520cell%2520invasion%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D3069%26epage%3D3072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span> <span> </span><span class="NLM_article-title">Expression of RECK and MMP-2 in salivary adenoid cystic carcinoma: correlation with tumor progression and patient prognosis</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1549</span>– <span class="NLM_lpage">1555</span>, <span class="refDoi"> DOI: 10.3892/ol.2014.1906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.3892%2Fol.2014.1906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=24765174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1egtbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=1549-1555&author=X.+Zhouauthor=S.+Huangauthor=L.+Jiangauthor=S.+Zhangauthor=W.+Liauthor=Z.+Chenauthor=D.+Zhang&title=Expression+of+RECK+and+MMP-2+in+salivary+adenoid+cystic+carcinoma%3A+correlation+with+tumor+progression+and+patient+prognosis&doi=10.3892%2Fol.2014.1906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of RECK and MMP-2 in salivary adenoid cystic carcinoma: correlation with tumor progression and patient prognosis</span></div><div class="casAuthors">Zhou, Xiaoqing; Huang, Shengyun; Jiang, Licheng; Zhang, Shizhou; Li, Wengang; Chen, Zhanwei; Zhang, Dongsheng</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1549-1555</span>CODEN:
                <span class="NLM_cas:coden">OLNEB5</span>;
        ISSN:<span class="NLM_cas:issn">1792-1074</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Reversion-inducing cysteine-rich protein with Kazal motifs (RECK), a glycosylphosphatidylinositol-anchored glycoprotein, inhibits the enzymic activities of certain matrix metalloproteinases (MMPs).  RECK has been studied in numerous human tumors, but the expression of RECK in salivary adenoid cystic carcinoma (SACC), and its correlation with patient prognosis, has never been investigated thus far.  In the present study, the expression of RECK and MMP-2 was evaluated in two ACC cell lines and in 83 patients with SACC.  The results of quant. polymerase chain reaction and western blot anal. revealed that the ACC-2 and ACC-M cell lines expressed RECK and MMP-2 mRNA and protein.  The immunohistochem. staining in the patients demonstrated that pos. expression of RECK and MMP-2 was obsd. in 21/83 (25.3%) and 69/83 (83.1%) cases, resp., and that RECK expression was significantly assocd. with the tumor-node-metastasis stage, histol. grade and perineural invasion of patients with SACC (P<0.05).  Furthermore, there was a significant assocn. between the pos. expression of RECK and that of MMP-2 (P<0.0001).  Univariate and multivariate analyses confirmed that a lack of RECK expression was an independent and significant factor for the prediction of a poor prognosis.  In conclusion, RECK is a promising prognostic marker and potential therapeutic agent in SACC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEsWU5CQRRI7Vg90H21EOLACvtfcHk0ljWvKqYV8dykQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1egtbjJ&md5=a5e7ff027c7fcbc4a52ccfa9c1ee5f61</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.3892%2Fol.2014.1906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2014.1906%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DD.%26atitle%3DExpression%2520of%2520RECK%2520and%2520MMP-2%2520in%2520salivary%2520adenoid%2520cystic%2520carcinoma%253A%2520correlation%2520with%2520tumor%2520progression%2520and%2520patient%2520prognosis%26jtitle%3DOncol.%2520Lett.%26date%3D2014%26volume%3D7%26spage%3D1549%26epage%3D1555%26doi%3D10.3892%2Fol.2014.1906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karthik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varunkumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravikumar, V.</span></span> <span> </span><span class="NLM_article-title">Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">334</span>, <span class="refDoi"> DOI: 10.1016/j.biopha.2014.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.biopha.2014.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=24485799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Kiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2014&pages=327-334&author=S.+Karthikauthor=R.+Sankarauthor=K.+Varunkumarauthor=V.+Ravikumar&title=Romidepsin+induces+cell+cycle+arrest%2C+apoptosis%2C+histone+hyperacetylation+and+reduces+matrix+metalloproteinases+2+and+9+expression+in+bortezomib+sensitized+non-small+cell+lung+cancer+cells&doi=10.1016%2Fj.biopha.2014.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells</span></div><div class="casAuthors">Karthik, Selvaraju; Sankar, Renu; Varunkumar, Krishnamoorthy; Ravikumar, Vilwanathan</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">327-334</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors have been proven to be effective therapeutic agents to kill cancer cells through inhibiting HDAC activity or altering the structure of chromatin.  We recently reported that chemotherapy by the HDAC inhibitor, romidepsin activates the anti- apoptotic transcription factor NF-κB in A549 non-small cell lung cancer (NSCLC) cells and fails to induce significant levels of apoptosis.  We also demonstrated that NF-κB inhibition with proteasome inhibitor bortezomib enhanced HDAC inhibitor induced mitochondrial injury and sensitize A549 NSCLC cells to apoptosis through the generation of reactive oxygen species.  In this study, we investigate whether combined treatment with romidepsin and bortezomib would induce apoptosis in A549 NSCLC cells by activating cell cycle arrest, enhanced generation of p21 and p53, down-regulation of matrix metalloproteinases (MMPs) 2,9 also altering the acetylation status of histone proteins.  Our data show that combination of romidepsin and bortezomib caused cell cycle arrest at Sub G0-G1 transition, up-regulation of cell cycle protein p21 and tumor suppressor protein p53.  In addn., romidepsin down-regulated the expression of MMP-2,9 and hyperacetylation of histone H3 and H4 in bortezomib sensitized A549 NSCLC cells.  From this study we concluded that romidepsin and bortezomib cooperatively inhibit A549 NSCLC cell proliferation by altering the histone acetylation status, expression of cell cycle regulators and MMPs.  Romidepsin along with bortezomib might be an effective treatment approach for A549 NSCLC cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowFboPEMP8h7Vg90H21EOLACvtfcHk0ljWvKqYV8dykQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Kiuro%253D&md5=e061f1e42888b1a731ee5bf95e3ba803</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2014.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2014.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DKarthik%26aufirst%3DS.%26aulast%3DSankar%26aufirst%3DR.%26aulast%3DVarunkumar%26aufirst%3DK.%26aulast%3DRavikumar%26aufirst%3DV.%26atitle%3DRomidepsin%2520induces%2520cell%2520cycle%2520arrest%252C%2520apoptosis%252C%2520histone%2520hyperacetylation%2520and%2520reduces%2520matrix%2520metalloproteinases%25202%2520and%25209%2520expression%2520in%2520bortezomib%2520sensitized%2520non-small%2520cell%2520lung%2520cancer%2520cells%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2014%26volume%3D68%26spage%3D327%26epage%3D334%26doi%3D10.1016%2Fj.biopha.2014.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Hierarchical virtual screening of the dual MMP-2/HDAC-6 inhibitors from natural products based on pharmacophore models and molecular docking</span>. <i>J. Biomol. Struct. Dyn.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">649</span>– <span class="NLM_lpage">670</span>, <span class="refDoi"> DOI: 10.1080/07391102.2018.1434833</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1080%2F07391102.2018.1434833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=29380672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXislSjt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=649-670&author=Y.+Wangauthor=L.+Yangauthor=J.+Houauthor=Q.+Zouauthor=Q.+Gaoauthor=W.+Yaoauthor=Q.+Yaoauthor=J.+Zhang&title=Hierarchical+virtual+screening+of+the+dual+MMP-2%2FHDAC-6+inhibitors+from+natural+products+based+on+pharmacophore+models+and+molecular+docking&doi=10.1080%2F07391102.2018.1434833"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Hierarchical virtual screening of the dual MMP-2/HDAC-6 inhibitors from natural products based on pharmacophore models and molecular docking</span></div><div class="casAuthors">Wang, Yijun; Yang, Limei; Hou, Jiaying; Zou, Qing; Gao, Qi; Yao, Wenhui; Yao, Qizheng; Zhang, Ji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Structure and Dynamics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">649-670</span>CODEN:
                <span class="NLM_cas:coden">JBSDD6</span>;
        ISSN:<span class="NLM_cas:issn">0739-1102</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The dual-target inhibitors tend to improve the response rate in treating tumors, comparing with the single-target inhibitors.  Matrix metalloproteinase-2 (MMP-2) and histone deacetylase-6 (HDAC-6) are attractive targets for cancer therapy.  In this study, the hierarchical virtual screening of dual MMP-2/HDAC-6 inhibitors from natural products is investigated.  The pharmacophore model of MMP-2 inhibitors is built based on ligands, but the pharmacophore model of HDAC-6 inhibitors is built based on the exptl. crystal structures of multiple receptor-ligand complexes.  The reliability of these two pharmacophore models is validated subsequently.  The hierarchical virtual screening, combining these two different pharmacophore models of MMP-2 and HDAC-6 inhibitors with mol. docking, is carried out to identify the dual MMP-2/HDAC-6 inhibitors from a database of natural products.  The four potential dual MMP-2/HDAC-6 inhibitors of natural products, STOCK1 N-46177, STOCK1 N-52245, STOCK1 N-55477, and STOCK1 N-69706, are found.  The studies of binding modes show that the screened four natural products can simultaneously well bind with the MMP-2 and HDAC-6 active sites by different kinds of interactions, to inhibit the MMP-2 and HDAC-6 activities.  In addn., the ADMET properties of screened four natural products are assessed.  These found dual MMP-2/HDAC-6 inhibitors of natural products could serve as the lead compds. for designing the new dual MMP-2/HDAC-6 inhibitors having higher biol. activities by carrying out structural modifications and optimizations in the future studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj-OBmoj28F7Vg90H21EOLACvtfcHk0ljWvKqYV8dykQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXislSjt7c%253D&md5=7fe92585a5c37b548ff3e569c851214f</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1080%2F07391102.2018.1434833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07391102.2018.1434833%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DQ.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DYao%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DHierarchical%2520virtual%2520screening%2520of%2520the%2520dual%2520MMP-2%252FHDAC-6%2520inhibitors%2520from%2520natural%2520products%2520based%2520on%2520pharmacophore%2520models%2520and%2520molecular%2520docking%26jtitle%3DJ.%2520Biomol.%2520Struct.%2520Dyn.%26date%3D2019%26volume%3D37%26spage%3D649%26epage%3D670%26doi%3D10.1080%2F07391102.2018.1434833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, A. J.</span></span> <span> </span><span class="NLM_article-title">The regulation of multiple p53 stress responses is mediated through MDM2</span>. <i>Genes Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1177/1947601912454734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1177%2F1947601912454734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=23150753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsVSlsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=199-208&author=W.+Huauthor=Z.+Fengauthor=A.+J.+Levine&title=The+regulation+of+multiple+p53+stress+responses+is+mediated+through+MDM2&doi=10.1177%2F1947601912454734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">The regulation of multiple p53 stress responses is mediated through MDM2</span></div><div class="casAuthors">Hu, Wenwei; Feng, Zhaohui; Levine, Arnold J.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">199-208, 10</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  The MDM2 oncogene is a key neg. regulator of the p53 tumor suppressor protein.  MDM2 and p53 form an autoregulatory feedback loop to tightly control the proper cellular responses to various stress signals in order to prevent mutations and tumor formation.  The levels and function of the MDM2 protein, an E3 ubiquitin ligase, are regulated by a wide variety of extracellular and intracellular stress signals through distinct signaling pathways and mechanisms.  These signals regulate the E3 ubiquitin ligase activity of MDM2, the ability of MDM2 to interact with p53 and a no. of other proteins, and the cellular localization of MDM2, which in turn impact significantly upon p53 function.  This review provides an overview of the regulation of MDM2 activities by the signals and factors that regulate the MDM2 protein, including genotoxic stress signals, oncogenic activation, cell cycle transition, ribosomal stress, chronic stress, neurohormones, and microRNAs.  Disruption of the proper regulation of the MDM2-p53 neg. feedback loop impacts significantly upon the frequency of tumorigenesis in a host.  A better understanding of the complex regulation of MDM2 and its impact upon p53 function in cells under different conditions will help to develop novel and more effective strategies for cancer therapy and prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS47PnIALZFrVg90H21EOLACvtfcHk0lgaK1wRLZh9Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsVSlsL4%253D&md5=118063f81d7ae8eb68189bf3a4ddce30</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1177%2F1947601912454734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601912454734%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DW.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DLevine%26aufirst%3DA.%2BJ.%26atitle%3DThe%2520regulation%2520of%2520multiple%2520p53%2520stress%2520responses%2520is%2520mediated%2520through%2520MDM2%26jtitle%3DGenes%2520Cancer%26date%3D2012%26volume%3D3%26spage%3D199%26epage%3D208%26doi%3D10.1177%2F1947601912454734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Small molecules simultaneously inhibiting p53-murine double minute 2 (MDM2) interaction and histone deacetylases (HDACs): discovery of novel multitargeting antitumor agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7245</span>– <span class="NLM_lpage">7260</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00664</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00664" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlykur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7245-7260&author=S.+Heauthor=G.+Dongauthor=S.+Wuauthor=K.+Fangauthor=Z.+Miaoauthor=W.+Wangauthor=C.+Sheng&title=Small+molecules+simultaneously+inhibiting+p53-murine+double+minute+2+%28MDM2%29+interaction+and+histone+deacetylases+%28HDACs%29%3A+discovery+of+novel+multitargeting+antitumor+agents&doi=10.1021%2Facs.jmedchem.8b00664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents</span></div><div class="casAuthors">He, Shipeng; Dong, Guoqiang; Wu, Shanchao; Fang, Kun; Miao, Zhenyuan; Wang, Wei; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7245-7260</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">P53-Murine double minute 2 (MDM2) interaction and histone deacetylases (HDACs) are important targets in antitumor drug development.  Inspired by the synergistic effects between MDM2 and HDACs, the first MDM2/HDACs dual inhibitors were identified, which showed excellent activities against both targets.  In particular, compd. 14d was proven to be a potent and orally active MDM2/HDAC dual inhibitor, whose antitumor mechanisms were validated in cancer cells.  Compd. 14d showed excellent in vivo antitumor potency in the A549 xenograft model, providing a promising lead compd. for the development of novel antitumor agents.  Also, this proof-of-concept study offers a novel and efficient strategy for multitargeting antitumor drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx94Uvm3pP8bVg90H21EOLACvtfcHk0lgaK1wRLZh9Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlykur3L&md5=68871e41ecb786e135b01742e59eec85</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00664%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DFang%26aufirst%3DK.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DSmall%2520molecules%2520simultaneously%2520inhibiting%2520p53-murine%2520double%2520minute%25202%2520%2528MDM2%2529%2520interaction%2520and%2520histone%2520deacetylases%2520%2528HDACs%2529%253A%2520discovery%2520of%2520novel%2520multitargeting%2520antitumor%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7245%26epage%3D7260%26doi%3D10.1021%2Facs.jmedchem.8b00664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haaland, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forthun, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huseby, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gausdal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knappskog, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Micklem, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorens, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruserud, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gjertsen, B. T.</span></span> <span> </span><span class="NLM_article-title">Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">910</span>– <span class="NLM_lpage">917</span>, <span class="refDoi"> DOI: 10.1038/leu.2011.315</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fleu.2011.315" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=22064349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvFemsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=910-917&author=E.+McCormackauthor=I.+Haalandauthor=G.+Venasauthor=R.+B.+Forthunauthor=S.+Husebyauthor=G.+Gausdalauthor=S.+Knappskogauthor=D.+R.+Micklemauthor=J.+B.+Lorensauthor=O.+Bruserudauthor=B.+T.+Gjertsen&title=Synergistic+induction+of+p53+mediated+apoptosis+by+valproic+acid+and+nutlin-3+in+acute+myeloid+leukemia&doi=10.1038%2Fleu.2011.315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia</span></div><div class="casAuthors">McCormack, E.; Haaland, I.; Venas, G.; Forthun, R. B.; Huseby, S.; Gausdal, G.; Knappskog, S.; Micklem, D. R.; Lorens, J. B.; Bruserud, O.; Gjertsen, B. T.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">910-917</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although TP53 mutations are rare in acute myeloid leukemia (AML), wild type p53 function is habitually annulled through overexpression of MDM2 or through various mechanisms including epigenetic silencing by histone deacetylases (HDACs).  We hypothesized that co-inhibition of MDM2 and HDACs, with nutlin-3 and valproic acid (VPA) would additively inhibit growth in leukemic cells expressing wild type TP53 and induce p53-mediated apoptosis.  In vitro studies with the combination demonstrated synergistic induction of apoptosis in AML cell lines and patient cells.  Nutlin-3 and VPA co-treatment resulted in massive induction of p53, acetylated p53 and p53 target genes in comparison with either agent alone, followed by p53 dependent cell death with autophagic features.  In primary AML cells, inhibition of proliferation by the combination therapy correlated with the CD34 expression level of AML blasts.  To evaluate the combination in vivo, we developed an orthotopic, NOD/SCID IL2rγnull xenograft model of MOLM-13 (AML FAB M5a; wild type TP53) expressing firefly luciferase.  Survival anal. and bioluminescent imaging demonstrated the superior in vivo efficacy of the dual inhibition of MDM2 and HDAC in comparison with controls.  Our results suggest the concomitant targeting of MDM2-p53 and HDAC inhibition, may be an effective therapeutic strategy for the treatment of AML.  Leukemia (2012) 26, 910-917; doi:10.1038/leu.2011.315; published online 8 Nov. 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqDcdeQ4hD6rVg90H21EOLACvtfcHk0lgaK1wRLZh9Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvFemsbg%253D&md5=0e9f5076fc4458681edaa04d6231a28f</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1038%2Fleu.2011.315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2011.315%26sid%3Dliteratum%253Aachs%26aulast%3DMcCormack%26aufirst%3DE.%26aulast%3DHaaland%26aufirst%3DI.%26aulast%3DVenas%26aufirst%3DG.%26aulast%3DForthun%26aufirst%3DR.%2BB.%26aulast%3DHuseby%26aufirst%3DS.%26aulast%3DGausdal%26aufirst%3DG.%26aulast%3DKnappskog%26aufirst%3DS.%26aulast%3DMicklem%26aufirst%3DD.%2BR.%26aulast%3DLorens%26aufirst%3DJ.%2BB.%26aulast%3DBruserud%26aufirst%3DO.%26aulast%3DGjertsen%26aufirst%3DB.%2BT.%26atitle%3DSynergistic%2520induction%2520of%2520p53%2520mediated%2520apoptosis%2520by%2520valproic%2520acid%2520and%2520nutlin-3%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26spage%3D910%26epage%3D917%26doi%3D10.1038%2Fleu.2011.315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of peptide boronate derivatives as histone deacetylase (HDAC) and proteasome dual inhibitors for overcoming bortezomib resistance of multiple myeloma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b02161</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b02161" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=Y.+Zhouauthor=X.+Liuauthor=J.+Xueauthor=L.+Liuauthor=T.+Liangauthor=W.+Liauthor=X.+Yangauthor=X.+Houauthor=H.+Fang&title=Discovery+of+peptide+boronate+derivatives+as+histone+deacetylase+%28HDAC%29+and+proteasome+dual+inhibitors+for+overcoming+bortezomib+resistance+of+multiple+myeloma&doi=10.1021%2Facs.jmedchem.9b02161"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b02161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b02161%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DXue%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520peptide%2520boronate%2520derivatives%2520as%2520histone%2520deacetylase%2520%2528HDAC%2529%2520and%2520proteasome%2520dual%2520inhibitors%2520for%2520overcoming%2520bortezomib%2520resistance%2520of%2520multiple%2520myeloma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26doi%3D10.1021%2Facs.jmedchem.9b02161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romanelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stazi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fioravanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwergel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Bello, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomella, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battistelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strippoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripodi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">del Bufalo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rota, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trisciuoglio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valente, S.</span></span> <span> </span><span class="NLM_article-title">Design of first-in-class dual EZH2/HDAC inhibitor: biochemical activity and biological evaluation in cancer cells</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00014</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=A.+Romanelliauthor=G.+Staziauthor=R.+Fioravantiauthor=C.+Zwergelauthor=E.+Di+Belloauthor=S.+Pomellaauthor=C.+Perroneauthor=C.+Battistelliauthor=R.+Strippoliauthor=M.+Tripodiauthor=D.+del+Bufaloauthor=R.+Rotaauthor=D.+Trisciuoglioauthor=A.+Maiauthor=S.+Valente&title=Design+of+first-in-class+dual+EZH2%2FHDAC+inhibitor%3A+biochemical+activity+and+biological+evaluation+in+cancer+cells&doi=10.1021%2Facsmedchemlett.0c00014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00014%26sid%3Dliteratum%253Aachs%26aulast%3DRomanelli%26aufirst%3DA.%26aulast%3DStazi%26aufirst%3DG.%26aulast%3DFioravanti%26aufirst%3DR.%26aulast%3DZwergel%26aufirst%3DC.%26aulast%3DDi%2BBello%26aufirst%3DE.%26aulast%3DPomella%26aufirst%3DS.%26aulast%3DPerrone%26aufirst%3DC.%26aulast%3DBattistelli%26aufirst%3DC.%26aulast%3DStrippoli%26aufirst%3DR.%26aulast%3DTripodi%26aufirst%3DM.%26aulast%3Ddel%2BBufalo%26aufirst%3DD.%26aulast%3DRota%26aufirst%3DR.%26aulast%3DTrisciuoglio%26aufirst%3DD.%26aulast%3DMai%26aufirst%3DA.%26aulast%3DValente%26aufirst%3DS.%26atitle%3DDesign%2520of%2520first-in-class%2520dual%2520EZH2%252FHDAC%2520inhibitor%253A%2520biochemical%2520activity%2520and%2520biological%2520evaluation%2520in%2520cancer%2520cells%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26doi%3D10.1021%2Facsmedchemlett.0c00014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1016%2Fj.ejmech.2015.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=25805446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVWis7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2015&pages=127-135&author=X.+Zhangauthor=Y.+Kongauthor=J.+Zhangauthor=M.+Suauthor=Y.+Zhouauthor=Y.+Zangauthor=J.+Liauthor=Y.+Chenauthor=Y.+Fangauthor=X.+Zhangauthor=W.+Lu&title=Design%2C+synthesis+and+biological+evaluation+of+colchicine+derivatives+as+novel+tubulin+and+histone+deacetylase+dual+inhibitors&doi=10.1016%2Fj.ejmech.2015.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors</span></div><div class="casAuthors">Zhang, Xuan; Kong, Yannan; Zhang, Jie; Su, Mingbo; Zhou, Yubo; Zang, Yi; Li, Jia; Chen, Yi; Fang, Yanfen; Zhang, Xiongwen; Lu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">127-135</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A new class of colchicine derivs. were designed and synthesized as tubulin-HDAC dual inhibitors.  Biol. evaluations of these hybrids included the inhibitory activity of HDAC, tubulin polymn. anal., in vitro cell cycle anal. in HCT-116 cells and cytotoxicity against different cancer cell lines.  Hybrid I behaved as potent HDAC-tubulin dual inhibitor and showed comparable cytotoxicity with colchicine.  Compd. II exhibited powerful tubulin inhibitory activity, moderate anti-HDAC activity and the most potent cytotoxicity (IC50 = 2-105 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6P07-g6WBfbVg90H21EOLACvtfcHk0lhAHsZOFtnUtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVWis7o%253D&md5=e532028d8f03179da99f533eefa62568</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DKong%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DW.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520colchicine%2520derivatives%2520as%2520novel%2520tubulin%2520and%2520histone%2520deacetylase%2520dual%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D95%26spage%3D127%26epage%3D135%26doi%3D10.1016%2Fj.ejmech.2015.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Dual NAMPT/HDAC inhibitors as a new strategy for multitargeting antitumor drug discovery</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00414</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00414" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOqsrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=34-38&author=W.+Chenauthor=G.+Dongauthor=Y.+Wuauthor=W.+Zhangauthor=C.+Miaoauthor=C.+Sheng&title=Dual+NAMPT%2FHDAC+inhibitors+as+a+new+strategy+for+multitargeting+antitumor+drug+discovery&doi=10.1021%2Facsmedchemlett.7b00414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery</span></div><div class="casAuthors">Chen, Wei; Dong, Guoqiang; Wu, Ying; Zhang, Wannian; Miao, Chaoyu; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-38</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel dual nicotinamide phosphoribosyltransferase (NAMPT) and histone deacetylase (HDAC) inhibitors were designed by a pharmacophore fusion approach.  The thiazolocarboxamide inhibitors were highly active for both targets.  In particular, compd. 7f (NAMPT IC50 = 15 nM, HDAC1 IC50 = 2 nM) showed potent in vivo antitumor efficacy in the HCT116 xenograft model.  The study offers a new strategy for multi-target antitumor drug discovery by simultaneously acting on cancer metab. and epigenetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeCOjvPbhLxbVg90H21EOLACvtfcHk0lhAHsZOFtnUtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOqsrjJ&md5=72fc5750e9b6d3b1a0331f1f3a8a3f5c</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00414%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DW.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DMiao%26aufirst%3DC.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DDual%2520NAMPT%252FHDAC%2520inhibitors%2520as%2520a%2520new%2520strategy%2520for%2520multitargeting%2520antitumor%2520drug%2520discovery%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D34%26epage%3D38%26doi%3D10.1021%2Facsmedchemlett.7b00414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 1-(2-Aminophenyl)-3-arylurea derivatives as potential EphA2 and HDAC dual inhibitors</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">1136</span>– <span class="NLM_lpage">1141</span>, <span class="refDoi"> DOI: 10.1248/cpb.c16-00154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1248%2Fcpb.c16-00154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=27477652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFyru7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=1136-1141&author=Y.+Zhuauthor=T.+Ranauthor=X.+Chenauthor=J.+Niuauthor=S.+Zhaoauthor=T.+Luauthor=W.+Tang&title=Synthesis+and+biological+evaluation+of+1-%282-Aminophenyl%29-3-arylurea+derivatives+as+potential+EphA2+and+HDAC+dual+inhibitors&doi=10.1248%2Fcpb.c16-00154"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of 1-(2-aminophenyl)-3-arylurea derivatives as potential EphA2 and HDAC dual inhibitors</span></div><div class="casAuthors">Zhu, Yong; Ran, Ting; Chen, Xin; Niu, Jiaqi; Zhao, Shuang; Lu, Tao; Tang, Weifang</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1136-1141</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">A series of 1-(2-aminophenyl)-3-arylurea novel derivs. were synthesized and evaluated against Ephrin type-A receptor 2 (EphA2) and histone deacetylases (HDACs) kinase.  Most of the compds. exhibited inhibitory activity against EphA2 and HDAC.  The antiproliferative activities were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (thiazolyl blue, tetrazolium blue) against the human cancer cell lines HCT116, K562 and MCF7.  Compds. (I) (R1 = 3-pyridyl, 4-methoxyphenyl) showed the most potent inhibitory activity against EphA2 and HDAC.  However, compd. I (R1 = 4-methoxyphenyl) exhibited higher potency against HCT116 (IC50 = 5.29 μm) and MCF7 (IC50 = 7.42 μm).  1-(2-Aminophenyl)-3-arylurea analogs may serve as new EphA2-HDAC dual inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWik4Z7qFvSLVg90H21EOLACvtfcHk0lg2FO8ZlHBY_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFyru7vM&md5=4bd5f4b4d7cf57e1b713c0a778520e68</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1248%2Fcpb.c16-00154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.c16-00154%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DRan%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DNiu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DTang%26aufirst%3DW.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25201-%25282-Aminophenyl%2529-3-arylurea%2520derivatives%2520as%2520potential%2520EphA2%2520and%2520HDAC%2520dual%2520inhibitors%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2016%26volume%3D64%26spage%3D1136%26epage%3D1141%26doi%3D10.1248%2Fcpb.c16-00154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel indoleamine 2,3-dioxygenase 1 (IDO1) and histone deacetylase (HDAC) dual inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">312</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00487</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00487" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtVWrurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=312-317&author=K.+Fangauthor=G.+Dongauthor=Y.+Liauthor=S.+Heauthor=Y.+Wuauthor=S.+Wuauthor=W.+Wangauthor=C.+Sheng&title=Discovery+of+novel+indoleamine+2%2C3-dioxygenase+1+%28IDO1%29+and+histone+deacetylase+%28HDAC%29+dual+inhibitors&doi=10.1021%2Facsmedchemlett.7b00487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors</span></div><div class="casAuthors">Fang, Kun; Dong, Guoqiang; Li, Yu; He, Shipeng; Wu, Ying; Wu, Shanchao; Wang, Wei; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">312-317</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In order to take advantage of both immunotherapeutic and epigenetic antitumor agents, the first generation of dual indoleamine 2,3-dioxygenase 1 (IDO1) and histone deacetylase (HDAC) inhibitors were designed.  The highly active dual inhibitor 10 showed excellent and balanced activity against both IDO1 (IC50 = 69.0 nM) and HDAC1 (IC50 = 66.5 nM), whose dual targeting mechanisms were validated in cancer cells.  Compd. 10 had good pharmacokinetic profiles as an orally active antitumor agent and significantly reduced the L-kynurenine level in plasma.  In particular, it showed excellent in vivo antitumor efficacy in the murine LLC tumor model with low toxicity.  This proof-of-concept study provided a novel strategy for cancer treatment.  Compd. 10 represents a promising lead compd. for the development of novel antitumor agents and can also be used as a valuable probe to clarify the relationships and mechanisms between cancer immunotherapy and epigenetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEDqXRR2J0zrVg90H21EOLACvtfcHk0liFlzocyBdjwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtVWrurc%253D&md5=c808b75f03d703dc7e66798759457f4a</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00487%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520novel%2520indoleamine%25202%252C3-dioxygenase%25201%2520%2528IDO1%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520dual%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D312%26epage%3D317%26doi%3D10.1021%2Facsmedchemlett.7b00487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nebbioso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voltz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germain, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrosino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bontempo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiavone, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bresciani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Lera, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gronemeyer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altucci, L.</span></span> <span> </span><span class="NLM_article-title">Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1038/nm1161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fnm1161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15619633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A280%3ADC%252BD2M%252FgvFeitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=77-84&author=A.+Nebbiosoauthor=N.+Clarkeauthor=E.+Voltzauthor=E.+Germainauthor=C.+Ambrosinoauthor=P.+Bontempoauthor=R.+Alvarezauthor=E.+M.+Schiavoneauthor=F.+Ferraraauthor=F.+Brescianiauthor=A.+Weiszauthor=A.+R.+de+Leraauthor=H.+Gronemeyerauthor=L.+Altucci&title=Tumor-selective+action+of+HDAC+inhibitors+involves+TRAIL+induction+in+acute+myeloid+leukemia+cells&doi=10.1038%2Fnm1161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells</span></div><div class="casAuthors">Nebbioso Angela; Clarke Nicole; Voltz Emilie; Germain Emmanuelle; Ambrosino Concetta; Bontempo Paola; Alvarez Rosana; Schiavone Ettore M; Ferrara Felicetto; Bresciani Francesco; Weisz Alessandro; de Lera Angel R; Gronemeyer Hinrich; Altucci Lucia</div><div class="citationInfo"><span class="NLM_cas:title">Nature medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-84</span>
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    </div><div class="casAbstract">Chromatin is a dynamic macromolecular structure epigenetically modified to regulate specific gene expression.  Altered chromatin function can lead to aberrant expression of growth regulators and may, ultimately, cause cancer.  That many human diseases have epigenetic etiology has stimulated the development of 'epigenetic' therapies.  Inhibitors of histone deacetylases (HDACIs) induce proliferation arrest, maturation and apoptosis of cancer cells, but not normal cells, in vitro and in vivo, and are currently being tested in clinical trials.  We investigated the mechanism(s) underlying this tumor selectivity.  We report that HDACIs induce, in addition to p21, expression of TRAIL (Apo2L, TNFSF10) by directly activating the TNFSF10 promoter, thereby triggering tumor-selective death signaling in acute myeloid leukemia (AML) cells and the blasts of individuals with AML.  RNA interference revealed that the induction of p21, TRAIL and differentiation are separable activities of HDACIs.  HDACIs induced proliferation arrest, TRAIL-mediated apoptosis and suppression of AML blast clonogenicity irrespective of French-American-British (FAB) classification status, karyotype and immunophenotype.  No apoptosis was seen in normal CD34(+) progenitor cells.  Our results identify TRAIL as a mediator of the anticancer action of HDACIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQQMQxhEeVK8Hqj_yg7twvpfW6udTcc2eagJN4BkCxKdLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M%252FgvFeitg%253D%253D&md5=675e025a119adb957d2ae708419e7216</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1038%2Fnm1161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1161%26sid%3Dliteratum%253Aachs%26aulast%3DNebbioso%26aufirst%3DA.%26aulast%3DClarke%26aufirst%3DN.%26aulast%3DVoltz%26aufirst%3DE.%26aulast%3DGermain%26aufirst%3DE.%26aulast%3DAmbrosino%26aufirst%3DC.%26aulast%3DBontempo%26aufirst%3DP.%26aulast%3DAlvarez%26aufirst%3DR.%26aulast%3DSchiavone%26aufirst%3DE.%2BM.%26aulast%3DFerrara%26aufirst%3DF.%26aulast%3DBresciani%26aufirst%3DF.%26aulast%3DWeisz%26aufirst%3DA.%26aulast%3Dde%2BLera%26aufirst%3DA.%2BR.%26aulast%3DGronemeyer%26aufirst%3DH.%26aulast%3DAltucci%26aufirst%3DL.%26atitle%3DTumor-selective%2520action%2520of%2520HDAC%2520inhibitors%2520involves%2520TRAIL%2520induction%2520in%2520acute%2520myeloid%2520leukemia%2520cells%26jtitle%3DNat.%2520Med.%26date%3D2005%26volume%3D11%26spage%3D77%26epage%3D84%26doi%3D10.1038%2Fnm1161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macfarlane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheat, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, G. M.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">S193</span>– <span class="NLM_lpage">S206</span>, <span class="refDoi"> DOI: 10.1038/sj.cdd.4401535</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=10.1038%2Fsj.cdd.4401535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=15608694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVyqtrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=S193-S206&author=S.+Inoueauthor=M.+Macfarlaneauthor=N.+Harperauthor=L.+M.+Wheatauthor=M.+J.+Dyerauthor=G.+M.+Cohen&title=Histone+deacetylase+inhibitors+potentiate+TNF-related+apoptosis-inducing+ligand+%28TRAIL%29-induced+apoptosis+in+lymphoid+malignancies&doi=10.1038%2Fsj.cdd.4401535"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies</span></div><div class="casAuthors">Inoue, S.; MacFarlane, M.; Harper, N.; Wheat, L. M. C.; Dyer, M. J. S.; Cohen, G. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">Suppl. 2</span>),
    <span class="NLM_cas:pages">S193-S206</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">New therapies are required for chronic lymphocytic leukemia (CLL), an incurable disease characterized by failure of mature lymphocytes to undergo apoptosis.  Activation of cell surface death receptors, such as via TRAIL receptor ligation, may provide a novel therapeutic target for various malignancies.  However, CLL and other lymphoid malignancies are resistant to TRAIL.  The authors report that low concns. of histone deacetylase (HDAC) inhibitors, such as depsipeptide, which alone failed to induce apoptosis, markedly sensitize CLL cells and other primary lymphoid malignancies to TRAIL-induced apoptosis.  These combinations caused little or no toxicity to normal lymphocytes.  HDAC inhibitors sensitized resistant cells to TRAIL-induced apoptosis by facilitating formation of an active death-inducing signaling complex (DISC), leading to the rapid activation of caspase-8.  The facilitated DISC formation also occurred in the absence of TRAIL-R2 upregulation.  Thus, the combination of HDAC inhibitors and TRAIL may be valuable in the treatment of various hemopoietic malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZUbiS50swSLVg90H21EOLACvtfcHk0lhDITEclWi-3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVyqtrnP&md5=70ea27149269ee1a8353686753aea0ac</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1038%2Fsj.cdd.4401535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.cdd.4401535%26sid%3Dliteratum%253Aachs%26aulast%3DInoue%26aufirst%3DS.%26aulast%3DMacfarlane%26aufirst%3DM.%26aulast%3DHarper%26aufirst%3DN.%26aulast%3DWheat%26aufirst%3DL.%2BM.%26aulast%3DDyer%26aufirst%3DM.%2BJ.%26aulast%3DCohen%26aufirst%3DG.%2BM.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520potentiate%2520TNF-related%2520apoptosis-inducing%2520ligand%2520%2528TRAIL%2529-induced%2520apoptosis%2520in%2520lymphoid%2520malignancies%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2004%26volume%3D11%26spage%3DS193%26epage%3DS206%26doi%3D10.1038%2Fsj.cdd.4401535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skok, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zidar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikelj, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilas, J.</span></span> <span> </span><span class="NLM_article-title">Dual inhibitors of human DNA topoisomerase II and other cancer-related targets</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">884</span>– <span class="NLM_lpage">904</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00726</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00726" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFalu7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=884-904&author=Z.+Skokauthor=N.+Zidarauthor=D.+Kikeljauthor=J.+Ilas&title=Dual+inhibitors+of+human+DNA+topoisomerase+II+and+other+cancer-related+targets&doi=10.1021%2Facs.jmedchem.9b00726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets</span></div><div class="casAuthors">Skok, Ziga; Zidar, Nace; Kikelj, Danijel; Ilas, Janez</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">884-904</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Human DNA topoisomerase II is an important target in anticancer therapy.  Despite the clin. success of drugs that target topoisomerase II, the development of resistant cancer cells can limit their clin. efficacy.  To maximize the therapeutic potential of anticancer drugs, combination therapies and multi-target drugs have been suggested in many studies, where the use of multi-target drugs is advantageous from the pharmacokinetics point of view.  There are various different options for the prepn. of dual-target or multiple-target inhibitors, as topoisomerase II is both structurally (e.g., topoisomerase I, Hsp90, kinases) and functionally (e.g., histone deacetylases, proteasome) connected to many validated anticancer targets.  In this article, we discuss the scientific background behind targeting topoisomerase II together with a no. of other targets important in cancer therapy, we review the present status and discuss further options in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_2Nk9XaQ1KbVg90H21EOLACvtfcHk0lhgVCAdQucbsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFalu7nP&md5=2115c6cfef1ab63422f39f07dd9eb708</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00726%26sid%3Dliteratum%253Aachs%26aulast%3DSkok%26aufirst%3DZ.%26aulast%3DZidar%26aufirst%3DN.%26aulast%3DKikelj%26aufirst%3DD.%26aulast%3DIlas%26aufirst%3DJ.%26atitle%3DDual%2520inhibitors%2520of%2520human%2520DNA%2520topoisomerase%2520II%2520and%2520other%2520cancer-related%2520targets%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D884%26epage%3D904%26doi%3D10.1021%2Facs.jmedchem.9b00726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZW1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZW1','PDB','4ZW1'); return false;">PDB: 4ZW1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LXZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LXZ','PDB','4LXZ'); return false;">PDB: 4LXZ</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-17%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00491%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00491" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a8bf45de43cd6","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
